{"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118962","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38308797","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405021","label":"url"}],"paper_title":{"en":"Reducing echocardiographic examination time through routine use of fully automated software: a comparative study of measurement and report creation time","ja":"Reducing echocardiographic examination time through routine use of fully automated software: a comparative study of measurement and report creation time"},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Nomura Yuka"},{"name":"Saijyo Yoshihito"},{"name":"Sata Masataka"},{"name":"Kusunose Kenya"}],"ja":[{"name":"平田 有紀奈"},{"name":"野村 侑香"},{"name":"西條 良仁"},{"name":"佐田 政隆"},{"name":"楠瀬 賢也"}]},"description":{"en":"Manual interpretation of echocardiographic data is time-consuming and operator-dependent. With the advent of artificial intelligence (AI), there is a growing interest in its potential to streamline echocardiographic interpretation and reduce variability. This study aimed to compare the time taken for measurements by AI to that by human experts after converting the acquired dynamic images into DICOM data. Twenty-three consecutive patients were examined by a single operator, with varying image quality and different medical conditions. Echocardiographic parameters were independently evaluated by human expert using the manual method and the fully automated US2.ai software. The automated processes facilitated by the US2.ai software encompass real-time processing of 2D and Doppler data, measurement of clinically important variables (such as LV function and geometry), automated parameter assessment, and report generation with findings and comments aligned with guidelines. We assessed the duration required for echocardiographic measurements and report creation. The AI significantly reduced the measurement time compared to the manual method (159 ± 66 vs. 325 ± 94 s, p < 0.01). In the report creation step, AI was also significantly faster compared to the manual method (71 ± 39 vs. 429 ± 128 s, p < 0.01). The incorporation of AI into echocardiographic analysis led to a 70% reduction in measurement and report creation time compared to manual methods. In cases with fair or poor image quality, AI required more corrections and extended measurement time than in cases of good image quality. Report creation time was longer in cases with increased report complexity due to human confirmation of AI-generated findings. This fully automated software has the potential to serve as an efficient tool for echocardiographic analysis, offering results that enhance clinical workflow by providing rapid, zero-click reports, thereby adding significant value.","ja":"Manual interpretation of echocardiographic data is time-consuming and operator-dependent. With the advent of artificial intelligence (AI), there is a growing interest in its potential to streamline echocardiographic interpretation and reduce variability. This study aimed to compare the time taken for measurements by AI to that by human experts after converting the acquired dynamic images into DICOM data. Twenty-three consecutive patients were examined by a single operator, with varying image quality and different medical conditions. Echocardiographic parameters were independently evaluated by human expert using the manual method and the fully automated US2.ai software. The automated processes facilitated by the US2.ai software encompass real-time processing of 2D and Doppler data, measurement of clinically important variables (such as LV function and geometry), automated parameter assessment, and report generation with findings and comments aligned with guidelines. We assessed the duration required for echocardiographic measurements and report creation. The AI significantly reduced the measurement time compared to the manual method (159 ± 66 vs. 325 ± 94 s, p < 0.01). In the report creation step, AI was also significantly faster compared to the manual method (71 ± 39 vs. 429 ± 128 s, p < 0.01). The incorporation of AI into echocardiographic analysis led to a 70% reduction in measurement and report creation time compared to manual methods. In cases with fair or poor image quality, AI required more corrections and extended measurement time than in cases of good image quality. Report creation time was longer in cases with increased report complexity due to human confirmation of AI-generated findings. This fully automated software has the potential to serve as an efficient tool for echocardiographic analysis, offering results that enhance clinical workflow by providing rapid, zero-click reports, thereby adding significant value."},"publication_date":"2024-02-03","publication_name":{"en":"Journal of Echocardiography","ja":"Journal of Echocardiography"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12574-023-00636-6"],"issn":["1880-344X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118966","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38296266","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405041","label":"url"}],"paper_title":{"en":"Echocardiographic artificial intelligence for pulmonary hypertension classification","ja":"Echocardiographic artificial intelligence for pulmonary hypertension classification"},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Tsuji Takumasa"},{"name":"Kotoku Jun'ichi"},{"name":"Sata Masataka"},{"name":"Kusunose Kenya"}],"ja":[{"name":"平田 有紀奈"},{"name":"Tsuji Takumasa"},{"name":"Kotoku Jun'ichi"},{"name":"佐田 政隆"},{"name":"楠瀬 賢也"}]},"description":{"en":"The classification of pulmonary hypertension (PH) is crucial for determining the appropriate therapeutic strategy. We investigated whether machine learning (ML) algorithms may assist in echocardiographic PH prediction, where current guidelines recommend integrating several different parameters. We obtained physical and echocardiographic data from 885 patients who underwent right heart catheterisation (RHC). Patients were classified into three groups: non-PH, precapillary PH and postcapillary PH, based on values obtained from RHC. Using 24 parameters, we created predictive models employing four different classifiers and selected the one with the highest area under the curve. We then calculated the macro-average classification accuracy for PH on the derivation cohort (n=720) and prospective validation data set (n=165), comparing the results with guideline-based echocardiographic assessment obtained from each cohort. Logistic regression with elastic net regularisation had the highest classification accuracy, with areas under the curves of 0.789, 0.766 and 0.742 for normal, precapillary PH and postcapillary PH, respectively. The ML model demonstrated significantly better predictive accuracy than the guideline-based echocardiographic assessment in the derivation cohort (59.4% vs 51.6%, p<0.01). In the independent validation data set, the ML model's accuracy was comparable to the guideline-based PH classification (59.4% vs 57.8%, p=0.638). This preliminary study suggests promising potential for our ML model in predicting echocardiographic PH. Further research and validation are needed to fully assess its clinical utility in PH diagnosis and treatment decision-making.","ja":"The classification of pulmonary hypertension (PH) is crucial for determining the appropriate therapeutic strategy. We investigated whether machine learning (ML) algorithms may assist in echocardiographic PH prediction, where current guidelines recommend integrating several different parameters. We obtained physical and echocardiographic data from 885 patients who underwent right heart catheterisation (RHC). Patients were classified into three groups: non-PH, precapillary PH and postcapillary PH, based on values obtained from RHC. Using 24 parameters, we created predictive models employing four different classifiers and selected the one with the highest area under the curve. We then calculated the macro-average classification accuracy for PH on the derivation cohort (n=720) and prospective validation data set (n=165), comparing the results with guideline-based echocardiographic assessment obtained from each cohort. Logistic regression with elastic net regularisation had the highest classification accuracy, with areas under the curves of 0.789, 0.766 and 0.742 for normal, precapillary PH and postcapillary PH, respectively. The ML model demonstrated significantly better predictive accuracy than the guideline-based echocardiographic assessment in the derivation cohort (59.4% vs 51.6%, p<0.01). In the independent validation data set, the ML model's accuracy was comparable to the guideline-based PH classification (59.4% vs 57.8%, p=0.638). This preliminary study suggests promising potential for our ML model in predicting echocardiographic PH. Further research and validation are needed to fully assess its clinical utility in PH diagnosis and treatment decision-making."},"publication_date":"2024-01-30","publication_name":{"en":"Heart","ja":"Heart"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/heartjnl-2023-323320"],"issn":["1468-201X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118925","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38246422","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=404698","label":"url"}],"paper_title":{"en":"Pulmonary Pressure-flow responses to exercise in heart failure treated with angiotensin receptor neprilysin inhibitor.","ja":"Pulmonary Pressure-flow responses to exercise in heart failure treated with angiotensin receptor neprilysin inhibitor."},"authors":{"en":[{"name":"Yamaguchi N"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Takahashi Tomonori"},{"name":"Saijo Yoshihito"},{"name":"Kadota Muneyuki"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"},{"name":"Kusunose Kenya"}],"ja":[{"name":"山口 夏美"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"髙橋 智紀"},{"name":"西條 良仁"},{"name":"門田 宗之"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"},{"name":"楠瀬 賢也"}]},"description":{"en":"The role of the angiotensin receptor neprilysin inhibitor (ARNI) in cardiac function, particularly its impact on pulmonary circulation, remains underexplored. Recent studies have described abnormal mean pulmonary artery pressure (mPAP)-cardiac output (CO) responses as having the potential to assess the disease state. The aim of this study was to assess the effects of ARNI on pulmonary circulation in heart failure. We measured echocardiographic parameters post 6-min walk (6 MW) and compared the changes with baseline and follow-up. Our hypothesis was that pulmonary pressure-flow relationship of the pulmonary circulation obtained by 6 MW stress echocardiography would be improved with treatment. We prospectively enrolled 39 heart failure patients and conducted the 6 MW test indoors. Post-6 MW echocardiography measured echocardiographic variables, and CO was derived from electric cardiometry. Individualized ARNI doses were optimized, with follow-up echocardiographic evaluations after 1 year. Left ventricular (LV) volume were significantly reduced (160.7 ± 49.6 ml vs 136.0 ± 54.3 ml, P < 0.001), and LV ejection fraction was significantly improved (37.6 ± 11.3% vs 44.9 ± 11.5%, P < 0.001). Among the 31 patients who underwent 6 MW stress echocardiographic study at baseline and 1 year later, 6 MW distance increased after treatment (380 m vs 430 m, P = 0.003). The ΔmPAP/ΔCO by 6 MW stress decreased with treatment (6.9 mmHg/L/min vs 2.8 mmHg/L/min, P = 0.002). The left atrial volume index was associated with the response group receiving ARNI treatment for pulmonary circulation. Initiation of ARNI was associated with improvement of left ventricular size and LVEF. Additionally, the 6 MW distance increased and the ΔmPAP/ΔCO was improved to within normal range with treatment.","ja":"The role of the angiotensin receptor neprilysin inhibitor (ARNI) in cardiac function, particularly its impact on pulmonary circulation, remains underexplored. Recent studies have described abnormal mean pulmonary artery pressure (mPAP)-cardiac output (CO) responses as having the potential to assess the disease state. The aim of this study was to assess the effects of ARNI on pulmonary circulation in heart failure. We measured echocardiographic parameters post 6-min walk (6 MW) and compared the changes with baseline and follow-up. Our hypothesis was that pulmonary pressure-flow relationship of the pulmonary circulation obtained by 6 MW stress echocardiography would be improved with treatment. We prospectively enrolled 39 heart failure patients and conducted the 6 MW test indoors. Post-6 MW echocardiography measured echocardiographic variables, and CO was derived from electric cardiometry. Individualized ARNI doses were optimized, with follow-up echocardiographic evaluations after 1 year. Left ventricular (LV) volume were significantly reduced (160.7 ± 49.6 ml vs 136.0 ± 54.3 ml, P < 0.001), and LV ejection fraction was significantly improved (37.6 ± 11.3% vs 44.9 ± 11.5%, P < 0.001). Among the 31 patients who underwent 6 MW stress echocardiographic study at baseline and 1 year later, 6 MW distance increased after treatment (380 m vs 430 m, P = 0.003). The ΔmPAP/ΔCO by 6 MW stress decreased with treatment (6.9 mmHg/L/min vs 2.8 mmHg/L/min, P = 0.002). The left atrial volume index was associated with the response group receiving ARNI treatment for pulmonary circulation. Initiation of ARNI was associated with improvement of left ventricular size and LVEF. Additionally, the 6 MW distance increased and the ΔmPAP/ΔCO was improved to within normal range with treatment."},"publication_date":"2024-01-19","publication_name":{"en":"International Journal of Cardiology","ja":"International Journal of Cardiology"},"volume":"Vol.400","starting_page":"131789","ending_page":"131789","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijcard.2024.131789"],"issn":["1874-1754"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118911","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38218772","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=404665","label":"url"}],"paper_title":{"en":"Sex differences in the association between epicardial adipose tissue volume and left atrial volume index","ja":"Sex differences in the association between epicardial adipose tissue volume and left atrial volume index"},"authors":{"en":[{"name":"Yamaguchi S"},{"name":"Maeda M"},{"name":"Oba K"},{"name":"Maimaituxun G"},{"name":"Arasaki O"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Soeki Takeshi"},{"name":"Yamada Hirotsugu"},{"name":"Fukuda Daiju"},{"name":"Masuzaki H"},{"name":"Sata Masataka"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"Yamaguchi S"},{"name":"Maeda M"},{"name":"Oba K"},{"name":"Maimaituxun G"},{"name":"Arasaki O"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"添木 武"},{"name":"山田 博胤"},{"name":"福田 大受"},{"name":"Masuzaki H"},{"name":"佐田 政隆"},{"name":"島袋 充生"}]},"description":{"en":"Sex disparities in the association between epicardial adipose tissue volume (EATV) and cardiovascular disease have been reported. The sex-dependent effects of EATV on left atrial (LA) size have not been elucidated. Consecutive 247 subjects (median 65 [interquartile range 57, 75] years; 67% of men) who underwent multi-detector computed tomography without significant coronary artery disease or moderate to severe valvular disease were divided into two groups: patients with sinus rhythm (SR) or atrial fibrillation (AF). Sex differences in the association between the EATV index (EATVI) (mL/m) and LA volume index (LAVI) in 63 SR (28 men and 35 women) and 184 AF (137 men and 47 women) patients were evaluated using univariate and multivariate regression analyses. In overall that includes both men and women, the relationship between EATVI and LAVI was not significantly correlated for patients with SR and AF. The relationship between EATVI and LAVI differed between men and women in both SR and AF groups. In SR patients, there was a positive relationship between EATVI and LAVI in men, but not in women. In contrast, in patients with AF, a negative relationship was found between EATVI and LAVI in women, whereas no association was found in men. We evaluated sex differences in the association between EATVI and LAVI in patients with either SR or AF, and found a positive relationship in men with SR and a negative relationship in women with AF. This is the first report to evaluate sex differences in the relationship between EATVI and LAVI, suggesting that EAT may play a role, at least in part, in sex differences in the etiology of AF.","ja":"Sex disparities in the association between epicardial adipose tissue volume (EATV) and cardiovascular disease have been reported. The sex-dependent effects of EATV on left atrial (LA) size have not been elucidated. Consecutive 247 subjects (median 65 [interquartile range 57, 75] years; 67% of men) who underwent multi-detector computed tomography without significant coronary artery disease or moderate to severe valvular disease were divided into two groups: patients with sinus rhythm (SR) or atrial fibrillation (AF). Sex differences in the association between the EATV index (EATVI) (mL/m) and LA volume index (LAVI) in 63 SR (28 men and 35 women) and 184 AF (137 men and 47 women) patients were evaluated using univariate and multivariate regression analyses. In overall that includes both men and women, the relationship between EATVI and LAVI was not significantly correlated for patients with SR and AF. The relationship between EATVI and LAVI differed between men and women in both SR and AF groups. In SR patients, there was a positive relationship between EATVI and LAVI in men, but not in women. In contrast, in patients with AF, a negative relationship was found between EATVI and LAVI in women, whereas no association was found in men. We evaluated sex differences in the association between EATVI and LAVI in patients with either SR or AF, and found a positive relationship in men with SR and a negative relationship in women with AF. This is the first report to evaluate sex differences in the relationship between EATVI and LAVI, suggesting that EAT may play a role, at least in part, in sex differences in the etiology of AF."},"publication_date":"2024-01-13","publication_name":{"en":"BMC Cardiovascular Disorders","ja":"BMC Cardiovascular Disorders"},"volume":"Vol.24","number":"No.1","starting_page":"46","ending_page":"46","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12872-023-03569-1"],"issn":["1471-2261"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118910","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38148349","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=404663","label":"url"}],"paper_title":{"en":"Nocturnal blood pressure and left ventricular hypertrophy in patients with diabetes mellitus","ja":"Nocturnal blood pressure and left ventricular hypertrophy in patients with diabetes mellitus"},"authors":{"en":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"Sata Masataka"}],"ja":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"佐田 政隆"}]},"publication_date":"2023-12-26","publication_name":{"en":"Hypertension Research","ja":"Hypertension Research"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41440-023-01562-x"],"issn":["1348-4214"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118909","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38188937","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=404664","label":"url"}],"paper_title":{"en":"Unsupervised cluster analysis reveals different phenotypes in patients after transcatheter aortic valve replacement","ja":"Unsupervised cluster analysis reveals different phenotypes in patients after transcatheter aortic valve replacement"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Tsuji T"},{"name":"Hirata Yukina"},{"name":"Takahashi Tomonori"},{"name":"Sata Masataka"},{"name":"Sato K"},{"name":"Albakaa N"},{"name":"Ishizu T"},{"name":"Kotoku J"},{"name":"Seo Y"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Tsuji T"},{"name":"平田 有紀奈"},{"name":"髙橋 智紀"},{"name":"佐田 政隆"},{"name":"Sato K"},{"name":"Albakaa N"},{"name":"Ishizu T"},{"name":"Kotoku J"},{"name":"Seo Y"}]},"description":{"en":"The aim of this study was to identify phenotypes with potential prognostic significance in aortic stenosis (AS) patients after transcatheter aortic valve replacement (TAVR) through a clustering approach. This multi-centre retrospective study included 1365 patients with severe AS who underwent TAVR between January 2015 and March 2019. Among demographics, laboratory, and echocardiography parameters, 20 variables were selected through dimension reduction and used for unsupervised clustering. Phenotypes and outcomes were compared between clusters. Patients were randomly divided into a derivation cohort ( = 1092: 80%) and a validation cohort ( = 273: 20%). Three clusters with markedly different features were identified. Cluster 1 was associated predominantly with elderly age, a high aortic valve gradient, and left ventricular (LV) hypertrophy; Cluster 2 consisted of preserved LV ejection fraction, larger aortic valve area, and high blood pressure; and Cluster 3 demonstrated tachycardia and low flow/low gradient AS. Adverse outcomes differed significantly among clusters during a median of 2.2 years of follow-up ( < 0.001). After adjustment for clinical and echocardiographic data in a Cox proportional hazards model, Cluster 3 (hazard ratio, 4.18; 95% confidence interval, 1.76-9.94; = 0.001) was associated with increased risk of adverse outcomes. In sequential Cox models, a model based on clinical data and echocardiographic variables ( = 18.4) was improved by Cluster 3 ( = 31.5; = 0.001) in the validation cohort. Unsupervised cluster analysis of patients after TAVR revealed three different groups for assessment of prognosis. This provides a new perspective in the categorization of patients after TAVR that considers comorbidities and extravalvular cardiac dysfunction.","ja":"The aim of this study was to identify phenotypes with potential prognostic significance in aortic stenosis (AS) patients after transcatheter aortic valve replacement (TAVR) through a clustering approach. This multi-centre retrospective study included 1365 patients with severe AS who underwent TAVR between January 2015 and March 2019. Among demographics, laboratory, and echocardiography parameters, 20 variables were selected through dimension reduction and used for unsupervised clustering. Phenotypes and outcomes were compared between clusters. Patients were randomly divided into a derivation cohort ( = 1092: 80%) and a validation cohort ( = 273: 20%). Three clusters with markedly different features were identified. Cluster 1 was associated predominantly with elderly age, a high aortic valve gradient, and left ventricular (LV) hypertrophy; Cluster 2 consisted of preserved LV ejection fraction, larger aortic valve area, and high blood pressure; and Cluster 3 demonstrated tachycardia and low flow/low gradient AS. Adverse outcomes differed significantly among clusters during a median of 2.2 years of follow-up ( < 0.001). After adjustment for clinical and echocardiographic data in a Cox proportional hazards model, Cluster 3 (hazard ratio, 4.18; 95% confidence interval, 1.76-9.94; = 0.001) was associated with increased risk of adverse outcomes. In sequential Cox models, a model based on clinical data and echocardiographic variables ( = 18.4) was improved by Cluster 3 ( = 31.5; = 0.001) in the validation cohort. Unsupervised cluster analysis of patients after TAVR revealed three different groups for assessment of prognosis. This provides a new perspective in the categorization of patients after TAVR that considers comorbidities and extravalvular cardiac dysfunction."},"publication_date":"2023-12-20","publication_name":{"en":"European Heart Journal Open","ja":"European Heart Journal Open"},"volume":"Vol.4","number":"No.1","starting_page":"oead136","ending_page":"oead136","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/ehjopen/oead136"],"issn":["2752-4191"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37940531","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=404801","label":"url"}],"paper_title":{"en":"Lipoprotein (a) is a risk factor of aortic valve calcification in patients with a risk of atherosclerosis","ja":"Lipoprotein (a) is a risk factor of aortic valve calcification in patients with a risk of atherosclerosis"},"authors":{"en":[{"name":"Tserensonom Munkhtsetseg"},{"name":"Yagi Shusuke"},{"name":"Ise Takayuki"},{"name":"Kawabata Yutaka"},{"name":"Kadota Muneyuki"},{"name":"Hara Tomoya"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"Tserensonom Munkhtsetseg"},{"name":"八木 秀介"},{"name":"伊勢 孝之"},{"name":"川端 豊"},{"name":"門田 宗之"},{"name":"原 知也"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Aortic valve calcification (AVC), which causes aortic stenosis (AS), is more common in elderly persons. Controlling for conventional risk variables did not, however, reduce the incidence of AS. Thus, residual risk factors of AS should be identified. We enrolled 513 patients who underwent coronary angiography with computed tomography because of suspicion of coronary artery disease (CAD) or ruling out of CAD before aortic valve replacement. Calcium volume was calculated with a commercially available application. Conventional and lipid-related risk factors including serum levels of Lp(a) were evaluated for all patients. Calcium volume and Lp(a) levels were significantly higher in patients who underwent aortic valve replacement than in those who did not. A single regression analysis showed that the calcium volume was positively associated with age and the Lp(a) levels and negatively associated with the estimated glomerular filtration rate. No statistical significance was observed for other risk factors, including oxidized low-density lipoprotein, omega-3 fatty acids levels. The multiple regression analysis revealed that age (P<0.001), female sex (P<0.05), Lp(a) (P<0.01), and hemoglobin A1c (P<0.01) were determinants of the calcium volume. The area under the curve in receiver operating characteristic analysis of Lp(a) for implementation of AVR was 0.65 at an Lp(a) cut-off level of 16 mg/dL. In conclusion, the serum Lp(a) level is a potent risk factor of AVC in patients with high risk of atherosclerosis. J. Med. Invest. 70 : 450-456, August, 2023.","ja":"Aortic valve calcification (AVC), which causes aortic stenosis (AS), is more common in elderly persons. Controlling for conventional risk variables did not, however, reduce the incidence of AS. Thus, residual risk factors of AS should be identified. We enrolled 513 patients who underwent coronary angiography with computed tomography because of suspicion of coronary artery disease (CAD) or ruling out of CAD before aortic valve replacement. Calcium volume was calculated with a commercially available application. Conventional and lipid-related risk factors including serum levels of Lp(a) were evaluated for all patients. Calcium volume and Lp(a) levels were significantly higher in patients who underwent aortic valve replacement than in those who did not. A single regression analysis showed that the calcium volume was positively associated with age and the Lp(a) levels and negatively associated with the estimated glomerular filtration rate. No statistical significance was observed for other risk factors, including oxidized low-density lipoprotein, omega-3 fatty acids levels. The multiple regression analysis revealed that age (P<0.001), female sex (P<0.05), Lp(a) (P<0.01), and hemoglobin A1c (P<0.01) were determinants of the calcium volume. The area under the curve in receiver operating characteristic analysis of Lp(a) for implementation of AVR was 0.65 at an Lp(a) cut-off level of 16 mg/dL. In conclusion, the serum Lp(a) level is a potent risk factor of AVC in patients with high risk of atherosclerosis. J. Med. Invest. 70 : 450-456, August, 2023."},"publication_date":"2023-12","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.70","number":"No.3.4","starting_page":"450","ending_page":"456","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.70.450"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37947148","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=404798","label":"url"}],"paper_title":{"en":"Innate Immune System Regulated by Stimulator of Interferon Genes, a Cytosolic DNA Sensor, Regulates Endothelial Function","ja":"Innate Immune System Regulated by Stimulator of Interferon Genes, a Cytosolic DNA Sensor, Regulates Endothelial Function"},"authors":{"en":[{"name":"Pham PT"},{"name":"Bavuu Oyunbileg"},{"name":"Kim-Kaneyama JR"},{"name":"Lei XF"},{"name":"Yamamoto T"},{"name":"Otsuka K"},{"name":"Suto Kumiko"},{"name":"Kusunose Kenya"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Barber GN"},{"name":"Sata Masataka"},{"name":"Fukuda Daiju"}],"ja":[{"name":"Pham PT"},{"name":"Oyunbileg Bavuu"},{"name":"Kim-Kaneyama JR"},{"name":"Lei XF"},{"name":"Yamamoto T"},{"name":"Otsuka K"},{"name":"數藤 久美子"},{"name":"楠瀬 賢也"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"Barber GN"},{"name":"佐田 政隆"},{"name":"福田 大受"}]},"description":{"en":"Background Sterile inflammation caused by metabolic disorders impairs endothelial function; however, the underlying mechanism by which hyperglycemia induces inflammation remains obscure. Recent studies have suggested that stimulator of interferon genes (STING), a key cytosolic DNA sensor in the innate immune system, contributes to the pathogenesis of inflammatory diseases. This study examines the role of the STING in endothelial dysfunction in streptozotocin-induced diabetic mice. Methods and Results Injection of streptozotocin promoted the expression of STING and DNA damage markers in the aorta of wild-type mice. Streptozotocin elevated blood glucose and lipid levels in both wild-type and STING-deficient mice, which showed no statistical differences. Genetic deletion of STING ameliorated endothelial dysfunction as determined by the vascular relaxation in response to acetylcholine (<0.001) and increased endothelial nitric oxide synthase phosphorylation in the aorta (<0.05) in STZ-injected mice. Endothelium-independent vascular response to sodium nitroprusside did not differ. Treatment with a direct STING agonist, cyclic GMP-AMP, or mitochondrial DNA increased inflammatory molecule expression (eg, and ) and decreased endothelial nitric oxide synthase phosphorylation in human umbilical vein endothelial cells, partially through the STING pathway. Cyclic GMP-AMP significantly impaired endothelial function of aortic segments obtained from wild-type mice, which was ameliorated in the presence of C-176, a STING inhibitor, or a neutralizing interferon-β antibody. Furthermore, the administration of C-176 ameliorated endothelial dysfunction in STZ-induced diabetic mice (<0.01). Conclusions The DNA damage response regulated by STING impairs endothelial function. STING signaling may be a potential therapeutic target of endothelial dysfunction caused by hyperglycemia.","ja":"Background Sterile inflammation caused by metabolic disorders impairs endothelial function; however, the underlying mechanism by which hyperglycemia induces inflammation remains obscure. Recent studies have suggested that stimulator of interferon genes (STING), a key cytosolic DNA sensor in the innate immune system, contributes to the pathogenesis of inflammatory diseases. This study examines the role of the STING in endothelial dysfunction in streptozotocin-induced diabetic mice. Methods and Results Injection of streptozotocin promoted the expression of STING and DNA damage markers in the aorta of wild-type mice. Streptozotocin elevated blood glucose and lipid levels in both wild-type and STING-deficient mice, which showed no statistical differences. Genetic deletion of STING ameliorated endothelial dysfunction as determined by the vascular relaxation in response to acetylcholine (<0.001) and increased endothelial nitric oxide synthase phosphorylation in the aorta (<0.05) in STZ-injected mice. Endothelium-independent vascular response to sodium nitroprusside did not differ. Treatment with a direct STING agonist, cyclic GMP-AMP, or mitochondrial DNA increased inflammatory molecule expression (eg, and ) and decreased endothelial nitric oxide synthase phosphorylation in human umbilical vein endothelial cells, partially through the STING pathway. Cyclic GMP-AMP significantly impaired endothelial function of aortic segments obtained from wild-type mice, which was ameliorated in the presence of C-176, a STING inhibitor, or a neutralizing interferon-β antibody. Furthermore, the administration of C-176 ameliorated endothelial dysfunction in STZ-induced diabetic mice (<0.01). Conclusions The DNA damage response regulated by STING impairs endothelial function. STING signaling may be a potential therapeutic target of endothelial dysfunction caused by hyperglycemia."},"publication_date":"2023-11-10","publication_name":{"en":"Journal of the American Heart Association","ja":"Journal of the American Heart Association"},"volume":"Vol.12","number":"No.22","starting_page":"e030084","ending_page":"e030084","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/JAHA.123.030084"],"issn":["2047-9980"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118732","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37926523","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=403755","label":"url"}],"paper_title":{"en":"Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment","ja":"Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment"},"authors":{"en":[{"name":"Yamaji T"},{"name":"Harada T"},{"name":"Kajikawa M"},{"name":"Maruhashi T"},{"name":"Kishimoto S"},{"name":"Yusoff FM"},{"name":"Chayama K"},{"name":"Goto C"},{"name":"Nakashima A"},{"name":"Tomiyama H"},{"name":"Takase B"},{"name":"Kohro T,"},{"name":"Suzuki T"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Watanabe K"},{"name":"Takemoto Y,"},{"name":"Hano T"},{"name":"Sata Masataka"},{"name":"Ishibashi Y,"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Yamashina A"},{"name":"Koba S"},{"name":"Higashi Y"}],"ja":[{"name":"Yamaji T"},{"name":"Harada T"},{"name":"Kajikawa M"},{"name":"Maruhashi T"},{"name":"Kishimoto S"},{"name":"Yusoff FM"},{"name":"Chayama K"},{"name":"Goto C"},{"name":"Nakashima A"},{"name":"Tomiyama H"},{"name":"Takase B"},{"name":"Kohro T,"},{"name":"Suzuki T"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Watanabe K"},{"name":"Takemoto Y,"},{"name":"Hano T"},{"name":"佐田 政隆"},{"name":"Ishibashi Y,"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Yamashina A"},{"name":"Koba S"},{"name":"Higashi Y"}]},"description":{"en":"There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins. The subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients. The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL. Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at <150 mg/dL.","ja":"There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins. The subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients. The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL. Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at <150 mg/dL."},"publication_date":"2023-11-03","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.64416"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37734303","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=403236","label":"url"}],"paper_title":{"en":"The Clinical Utility of Noninvasive Forrester Classification in Acute Heart Failure from PREDICT Study","ja":"The Clinical Utility of Noninvasive Forrester Classification in Acute Heart Failure from PREDICT Study"},"authors":{"en":[{"name":"Takahashi Tomonori"},{"name":"Iwano H"},{"name":"Shibayama K"},{"name":"Kitai T"},{"name":"Tanaka H"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"},{"name":"Kusunose Kenya"}],"ja":[{"name":"髙橋 智紀"},{"name":"Iwano H"},{"name":"Shibayama K"},{"name":"Kitai T"},{"name":"Tanaka H"},{"name":"山田 博胤"},{"name":"佐田 政隆"},{"name":"楠瀬 賢也"}]},"description":{"en":"The Forrester classification plays a crucial role in comprehending the underlying pathophysiology of heart failure (HF) and is employed to categorize the severity and predict the outcomes of patients with acute HF. Our objective was to assess the predictive value of the Forrester classification, based on noninvasive hemodynamic measurements obtained through Doppler echocardiography at admission, in forecasting the short-term prognosis posthospitalization of patients with acute HF. Patients were recruited for the Prospect trial to elucidate the utility of EchocarDIography-based Cardiac ouTput in acute heart failure (PREDICT) study, a multicenter, prospective study conducted in Japan. Participants were stratified into 4 profiles using cardiac index (CI) and early mitral filling velocity (E)/early-diastolic mitral annular velocity (e') ratio obtained from Doppler echocardiography upon admission (profile I: CI >2.2, E/e' ≤15, profile II: CI >2.2, E/e' >15, profile III: CI ≤2.2, E/e' ≤15, profile IV: CI ≤2.2, E/e' >15). The primary composite outcome of the study was all-cause mortality or worsening HF during the 14 days of hospitalization. Cox proportional hazards model analysis was employed to identify prognostic factors during the observation period. A total of 270 subjects, with a mean age of 74 ± 14 years and a male proportion of 60%, were enrolled in the study. During the 14-day period of hospitalization, 58 participants (22%) had a composite outcome. Patients with low CI (i.e., profiles III and IV) demonstrated an elevated risk of composite outcome after adjusting for confounding variables, as evidenced by the adjusted hazard ratios of 5.85 (95% confidence interval 1.17 to 29.09, p <0.01, vs profile III) and 6.50 (95% confidence interval 1.53 to 27.68, p <0.01, vs profile IV) in comparison with profile I, respectively. In conclusion, the Forrester classification, derived from noninvasive Doppler echocardiography at admission, may predict early deterioration in patients hospitalized with acute HF.","ja":"The Forrester classification plays a crucial role in comprehending the underlying pathophysiology of heart failure (HF) and is employed to categorize the severity and predict the outcomes of patients with acute HF. Our objective was to assess the predictive value of the Forrester classification, based on noninvasive hemodynamic measurements obtained through Doppler echocardiography at admission, in forecasting the short-term prognosis posthospitalization of patients with acute HF. Patients were recruited for the Prospect trial to elucidate the utility of EchocarDIography-based Cardiac ouTput in acute heart failure (PREDICT) study, a multicenter, prospective study conducted in Japan. Participants were stratified into 4 profiles using cardiac index (CI) and early mitral filling velocity (E)/early-diastolic mitral annular velocity (e') ratio obtained from Doppler echocardiography upon admission (profile I: CI >2.2, E/e' ≤15, profile II: CI >2.2, E/e' >15, profile III: CI ≤2.2, E/e' ≤15, profile IV: CI ≤2.2, E/e' >15). The primary composite outcome of the study was all-cause mortality or worsening HF during the 14 days of hospitalization. Cox proportional hazards model analysis was employed to identify prognostic factors during the observation period. A total of 270 subjects, with a mean age of 74 ± 14 years and a male proportion of 60%, were enrolled in the study. During the 14-day period of hospitalization, 58 participants (22%) had a composite outcome. Patients with low CI (i.e., profiles III and IV) demonstrated an elevated risk of composite outcome after adjusting for confounding variables, as evidenced by the adjusted hazard ratios of 5.85 (95% confidence interval 1.17 to 29.09, p <0.01, vs profile III) and 6.50 (95% confidence interval 1.53 to 27.68, p <0.01, vs profile IV) in comparison with profile I, respectively. In conclusion, the Forrester classification, derived from noninvasive Doppler echocardiography at admission, may predict early deterioration in patients hospitalized with acute HF."},"publication_date":"2023-09-19","publication_name":{"en":"The American Journal of Cardiology","ja":"The American Journal of Cardiology"},"volume":"Vol.207","starting_page":"75","ending_page":"81","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.amjcard.2023.08.119"],"issn":["1879-1913"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37707682","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85170841573&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=403163","label":"url"}],"paper_title":{"en":"Correlation between energy loss index and B-type natriuretic peptide: a vector flow mapping study","ja":"Correlation between energy loss index and B-type natriuretic peptide: a vector flow mapping study"},"authors":{"en":[{"name":"Morita Sanae"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Takahashi Tomonori"},{"name":"Saijo Yoshihito"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"},{"name":"Kusunose Kenya"}],"ja":[{"name":"森田 沙瑛"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"髙橋 智紀"},{"name":"西條 良仁"},{"name":"山田 博胤"},{"name":"佐田 政隆"},{"name":"楠瀬 賢也"}]},"description":{"en":"Vector Flow Mapping (VFM) and Energy Loss (EL) evaluation are emerging echocardiographic techniques that offer detailed insights into cardiac function. This study aimed to explore the relationship between EL parameters and B-type natriuretic peptide (BNP) levels, a well-established marker of heart failure severity. Our study prospectively enrolled 62 patients experiencing shortness of breath and suspected heart failure, who underwent echocardiography and had BNP levels measured between January 2018 and August 2020. Patients were stratified based on BNP levels, and their clinical and echocardiographic characteristics were evaluated. Univariate and multivariate regression analyses were performed to assess the correlation between BNP levels and various echocardiographic variables, including VFM parameters. Patients were stratified into two groups based on their BNP levels: BNP < 200 pg/ml (n = 53) and BNP ≥ 200 pg/ml (n = 9). Patients with BNP ≥ 200 pg/ml presented significantly different clinical and echocardiographic characteristics, such as older age, larger left ventricular mass and volume indices, higher pulmonary artery systolic pressure, higher E/e' ratio, and larger EL parameters. Multivariate regression analysis demonstrated the E/e' ratio and ELA (EL during Atrial contraction phase/A wave ratio as significant determinants of logBNP. Receiver operating characteristic curve analysis showed ELA/A > 36.0 J/m as a significant predictor of high BNP with 89% sensitivity and 85% specificity. ELA/A demonstrated an incremental diagnostic value over elevated left atrial pressure for predicting high BNP (C statistic = 0.98 vs 0.74, P = 0.006). This study provides novel insights into the potential utility of EL parameters as auxiliary indicators of cardiac load, thereby enhancing our understanding of heart failure.","ja":"Vector Flow Mapping (VFM) and Energy Loss (EL) evaluation are emerging echocardiographic techniques that offer detailed insights into cardiac function. This study aimed to explore the relationship between EL parameters and B-type natriuretic peptide (BNP) levels, a well-established marker of heart failure severity. Our study prospectively enrolled 62 patients experiencing shortness of breath and suspected heart failure, who underwent echocardiography and had BNP levels measured between January 2018 and August 2020. Patients were stratified based on BNP levels, and their clinical and echocardiographic characteristics were evaluated. Univariate and multivariate regression analyses were performed to assess the correlation between BNP levels and various echocardiographic variables, including VFM parameters. Patients were stratified into two groups based on their BNP levels: BNP < 200 pg/ml (n = 53) and BNP ≥ 200 pg/ml (n = 9). Patients with BNP ≥ 200 pg/ml presented significantly different clinical and echocardiographic characteristics, such as older age, larger left ventricular mass and volume indices, higher pulmonary artery systolic pressure, higher E/e' ratio, and larger EL parameters. Multivariate regression analysis demonstrated the E/e' ratio and ELA (EL during Atrial contraction phase/A wave ratio as significant determinants of logBNP. Receiver operating characteristic curve analysis showed ELA/A > 36.0 J/m as a significant predictor of high BNP with 89% sensitivity and 85% specificity. ELA/A demonstrated an incremental diagnostic value over elevated left atrial pressure for predicting high BNP (C statistic = 0.98 vs 0.74, P = 0.006). This study provides novel insights into the potential utility of EL parameters as auxiliary indicators of cardiac load, thereby enhancing our understanding of heart failure."},"publication_date":"2023-09-14","publication_name":{"en":"Journal of Echocardiography","ja":"Journal of Echocardiography"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12574-023-00623-x"],"issn":["1880-344X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118556","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37607768","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85168568959&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402794","label":"url"}],"paper_title":{"en":"Reduced reactive hyperemia of the brachial artery in diabetic patients assessed by repeated measurements: The FMD-J B study","ja":"Reduced reactive hyperemia of the brachial artery in diabetic patients assessed by repeated measurements: The FMD-J B study"},"authors":{"en":[{"name":"Masaki N"},{"name":"Adachi T"},{"name":"Tomiyama H"},{"name":"Kohro T"},{"name":"Suzuki T"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Koba S"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"Sata Masataka"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Higashi Y"},{"name":"Yamashina A"},{"name":"Takase B"}],"ja":[{"name":"Masaki N"},{"name":"Adachi T"},{"name":"Tomiyama H"},{"name":"Kohro T"},{"name":"Suzuki T"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Koba S"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"佐田 政隆"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Higashi Y"},{"name":"Yamashina A"},{"name":"Takase B"}]},"description":{"en":"Type 2 diabetes mellitus (T2DM) is a major cause of microvascular dysfunction. However, its effect on blood flow patterns during ischemic demand has not been adequately elucidated. In this study, we investigated the hypothesis that microvascular dysfunction in patients with T2DM manifests as brachial reactive hyperemia (BRH), defined as the ratio of peak blood flow velocities in a brachial artery before and after forearm cuff occlusion. The study enrolled 943 subjects (men, n = 152 [T2DM] and n = 371 [non-T2DM]; women, n = 107 [T2DM] and n = 313 [non-T2DM], respectively) with no history of cardiovascular disease. Semiautomatic measurements were obtained three times at 1.5-year intervals to confirm the reproducibility of factors involved in BRH for each sex. An age-adjusted mixed model demonstrated attenuated BRH in the presence of T2DM in both men (p = 0.022) and women (p = 0.031) throughout the study period. Post hoc analysis showed that the estimated BRH was significantly attenuated in patients with T2DM regardless of sex, except at baseline in women. In multivariate regression analysis, T2DM was a negative predictor of BRH at every measurement in men. For women, BRH was more strongly associated with alcohol consumption. Repeated measurements analysis revealed that T2DM was associated with attenuated postocclusion reactive hyperemia.","ja":"Type 2 diabetes mellitus (T2DM) is a major cause of microvascular dysfunction. However, its effect on blood flow patterns during ischemic demand has not been adequately elucidated. In this study, we investigated the hypothesis that microvascular dysfunction in patients with T2DM manifests as brachial reactive hyperemia (BRH), defined as the ratio of peak blood flow velocities in a brachial artery before and after forearm cuff occlusion. The study enrolled 943 subjects (men, n = 152 [T2DM] and n = 371 [non-T2DM]; women, n = 107 [T2DM] and n = 313 [non-T2DM], respectively) with no history of cardiovascular disease. Semiautomatic measurements were obtained three times at 1.5-year intervals to confirm the reproducibility of factors involved in BRH for each sex. An age-adjusted mixed model demonstrated attenuated BRH in the presence of T2DM in both men (p = 0.022) and women (p = 0.031) throughout the study period. Post hoc analysis showed that the estimated BRH was significantly attenuated in patients with T2DM regardless of sex, except at baseline in women. In multivariate regression analysis, T2DM was a negative predictor of BRH at every measurement in men. For women, BRH was more strongly associated with alcohol consumption. Repeated measurements analysis revealed that T2DM was associated with attenuated postocclusion reactive hyperemia."},"publication_date":"2023-08","publication_name":{"en":"Physiological Reports","ja":"Physiological Reports"},"volume":"Vol.11","number":"No.16","starting_page":"e15786","ending_page":"e15786","languages":["eng"],"referee":true,"identifiers":{"doi":["10.14814/phy2.15786"],"issn":["2051-817X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37507534","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=399230","label":"url"}],"paper_title":{"en":"Not a small frog in a big pond: targeting bradykinin receptor B2 signaling in vascular smooth muscle cells for treatment of hypertension","ja":"Not a small frog in a big pond: targeting bradykinin receptor B2 signaling in vascular smooth muscle cells for treatment of hypertension"},"authors":{"en":[{"name":"Higashikuni Yasutomi"},{"name":"Liu Wenhao"},{"name":"Sata Masataka"}],"ja":[{"name":"Higashikuni Yasutomi"},{"name":"Liu Wenhao"},{"name":"佐田 政隆"}]},"publication_date":"2023-07-28","publication_name":{"en":"Hypertension Research","ja":"Hypertension Research"},"volume":"Vol.46","number":"No.10","starting_page":"2415","ending_page":"2418","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41440-023-01385-w"],"issn":["1348-4214"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37481235","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85166962366&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=399229","label":"url"}],"paper_title":{"en":"Effectiveness of surveillance by echocardiography for Cancer therapeutics-related cardiac dysfunction of patients with breast Cancer","ja":"Effectiveness of surveillance by echocardiography for Cancer therapeutics-related cardiac dysfunction of patients with breast Cancer"},"authors":{"en":[{"name":"Okushi Yuichiro"},{"name":"Saijyo Yoshihito"},{"name":"Yamada Hirotsugu"},{"name":"Toba Hiroaki"},{"name":"Zheng Robert"},{"name":"Seno Hiromitsu"},{"name":"Takahashi Tomonori"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"},{"name":"Kusunose Kenya"}],"ja":[{"name":"大櫛 祐一郎"},{"name":"西條 良仁"},{"name":"山田 博胤"},{"name":"鳥羽 博明"},{"name":"Robert Zheng"},{"name":"瀬野 弘光"},{"name":"髙橋 智紀"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"},{"name":"楠瀬 賢也"}]},"description":{"en":"Cancer therapeutics-related cardiac dysfunction (CTRCD) affect the prognosis of patients with breast cancer. Echocardiographic surveillance of patients treated with anti-human epidermal growth factor receptor type 2 (HER2) antibodies has been recommended, but few reports have provided evidence on patients with breast cancer only. We aimed to evaluate the effectiveness of echocardiographic surveillance for breast cancer patients. We identified 250 patients with breast cancer who were treated with anti-HER2 antibodies from July 2007 to September 2021. We divided 48 patients with echocardiographic surveillance every 3 months into the surveillance group and 202 patients without echocardiographic surveillance into the non-surveillance group. In the surveillance group, patients with a considerable reduction in global longitudinal strain of 15 % were considered for the initiation of cardioprotective drugs. The composite outcome of CTRCD and acute heart failure was the study endpoint. The mean age was 59 ± 12 years. During the follow-up period of 15 months (12-17 months), 12 patients reached the endpoint. The surveillance group had significantly lower incidence of the composite outcome (2.1 % vs. 5.5 %, adjusted odds ratio: 0.28, 95 % confidential intervals: 0.09-0.94; p = 0.039) and higher rates of prescriptions of cardioprotective drugs than the non-surveillance group. The incidence of cardiac complications was significantly lower in the surveillance group than the non-surveillance group, which supports the effectiveness of echocardiographic surveillance in patients with breast cancer.","ja":"Cancer therapeutics-related cardiac dysfunction (CTRCD) affect the prognosis of patients with breast cancer. Echocardiographic surveillance of patients treated with anti-human epidermal growth factor receptor type 2 (HER2) antibodies has been recommended, but few reports have provided evidence on patients with breast cancer only. We aimed to evaluate the effectiveness of echocardiographic surveillance for breast cancer patients. We identified 250 patients with breast cancer who were treated with anti-HER2 antibodies from July 2007 to September 2021. We divided 48 patients with echocardiographic surveillance every 3 months into the surveillance group and 202 patients without echocardiographic surveillance into the non-surveillance group. In the surveillance group, patients with a considerable reduction in global longitudinal strain of 15 % were considered for the initiation of cardioprotective drugs. The composite outcome of CTRCD and acute heart failure was the study endpoint. The mean age was 59 ± 12 years. During the follow-up period of 15 months (12-17 months), 12 patients reached the endpoint. The surveillance group had significantly lower incidence of the composite outcome (2.1 % vs. 5.5 %, adjusted odds ratio: 0.28, 95 % confidential intervals: 0.09-0.94; p = 0.039) and higher rates of prescriptions of cardioprotective drugs than the non-surveillance group. The incidence of cardiac complications was significantly lower in the surveillance group than the non-surveillance group, which supports the effectiveness of echocardiographic surveillance in patients with breast cancer."},"publication_date":"2023-07-20","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.82","number":"No.6","starting_page":"467","ending_page":"472","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2023.07.002"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118456","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37462755","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=399228","label":"url"}],"paper_title":{"en":"Olive mill wastewater and hydroxytyrosol inhibits atherogenesis in apolipoprotein E-deficient mice","ja":"Olive mill wastewater and hydroxytyrosol inhibits atherogenesis in apolipoprotein E-deficient mice"},"authors":{"en":[{"name":"Hara Tomoya"},{"name":"Fukuda Daiju"},{"name":"Ganbaatar Byambasuren"},{"name":"Pham Tran Phuong"},{"name":"Aini Kunduziayi"},{"name":"Rahadian Arief"},{"name":"Suto Kumiko"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"原 知也"},{"name":"福田 大受"},{"name":"Ganbaatar Byambasuren"},{"name":"Pham Tran Phuong"},{"name":"Kunduziayi Aini"},{"name":"Arief Rahadian"},{"name":"數藤 久美子"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"The Mediterranean diet, which is characterized by high consumption of olive oil, prevents cardiovascular disease. Meanwhile, olive mill wastewater (OMWW), which is obtained as a byproduct during olive oil production, contains various promising bioactive components such as water-soluble polyphenols. Hydroxytyrosol (HT), the major polyphenol in OMWW, has anti-oxidative and anti-inflammatory properties; however, the atheroprotective effects of OMWW and HT remain to be fully understood. Here, we investigated the effect of OMWW and HT on atherogenesis. Male 8-week-old apolipoprotein E-deficient mice were fed a western-type diet supplemented with OMWW (0.30%w/w) or HT (0.02%w/w) for 20 weeks. The control group was fed a non-supplemented diet. OMWW and HT attenuated the development of atherosclerosis in the aortic arch as determined by Sudan IV staining (P < 0.01, respectively) without alteration of body weight, plasma lipid levels, and blood pressure. OMWW and HT also decreased the production of oxidative stress (P < 0.01, respectively) and the expression of NADPH oxidase subunits (e.g., NOX2 and p22phox) and inflammatory molecules (e.g. IL-1β and MCP-1) in the aorta. The results of in vitro experiments demonstrated that HT inhibited the expression of these molecules that were stimulated with LPS in RAW264.7 cells, murine macrophage-like cells. OMWW and HT similarly attenuated atherogenesis. HT is a major component of water-soluble polyphenols in OMWW, and it inhibited inflammatory activation of macrophages. Therefore, our results suggest that the atheroprotective effects of OMWW are at least partially attributable to the anti-inflammatory effects of HT.","ja":"The Mediterranean diet, which is characterized by high consumption of olive oil, prevents cardiovascular disease. Meanwhile, olive mill wastewater (OMWW), which is obtained as a byproduct during olive oil production, contains various promising bioactive components such as water-soluble polyphenols. Hydroxytyrosol (HT), the major polyphenol in OMWW, has anti-oxidative and anti-inflammatory properties; however, the atheroprotective effects of OMWW and HT remain to be fully understood. Here, we investigated the effect of OMWW and HT on atherogenesis. Male 8-week-old apolipoprotein E-deficient mice were fed a western-type diet supplemented with OMWW (0.30%w/w) or HT (0.02%w/w) for 20 weeks. The control group was fed a non-supplemented diet. OMWW and HT attenuated the development of atherosclerosis in the aortic arch as determined by Sudan IV staining (P < 0.01, respectively) without alteration of body weight, plasma lipid levels, and blood pressure. OMWW and HT also decreased the production of oxidative stress (P < 0.01, respectively) and the expression of NADPH oxidase subunits (e.g., NOX2 and p22phox) and inflammatory molecules (e.g. IL-1β and MCP-1) in the aorta. The results of in vitro experiments demonstrated that HT inhibited the expression of these molecules that were stimulated with LPS in RAW264.7 cells, murine macrophage-like cells. OMWW and HT similarly attenuated atherogenesis. HT is a major component of water-soluble polyphenols in OMWW, and it inhibited inflammatory activation of macrophages. Therefore, our results suggest that the atheroprotective effects of OMWW are at least partially attributable to the anti-inflammatory effects of HT."},"publication_date":"2023-07-18","publication_name":{"en":"Heart and Vessels","ja":"Heart and Vessels"},"volume":"Vol.38","number":"No.11","starting_page":"1386","ending_page":"1394","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s00380-023-02290-5"],"issn":["1615-2573"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118457","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37461063","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=399224","label":"url"}],"paper_title":{"en":"Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)","ja":"Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)"},"authors":{"en":[{"name":"Tanaka A"},{"name":"Taguchi I"},{"name":"Hisauchi I"},{"name":"Yoshida H"},{"name":"Shimabukuro Michio"},{"name":"Hongo H"},{"name":"Ishikawa T"},{"name":"Kadokami T"},{"name":"Yagi Shusuke"},{"name":"Sata Masataka"},{"name":"Node K"}],"ja":[{"name":"Tanaka A"},{"name":"Taguchi I"},{"name":"Hisauchi I"},{"name":"Yoshida H"},{"name":"島袋 充生"},{"name":"Hongo H"},{"name":"Ishikawa T"},{"name":"Kadokami T"},{"name":"八木 秀介"},{"name":"佐田 政隆"},{"name":"Node K"}]},"description":{"en":"Dotinurad is a newer urate-lowering agent that selectively inhibits urate transporter 1 in the renal proximal tubule and increases urinary urate excretion. Currently, little is known about the clinical efficacies of dotinurad in patients with hyperuricemia and hypertension. The aim of this study was to assess the clinical effects of a selective urate reabsorption inhibitor dotinurad on serum uric acid (SUA) levels and relevant vascular markers in patients with hyperuricemia and treated hypertension. This investigator-initiated, multicenter, prospective, single-arm, open-label, exploratory clinical trial in Japan enrolled patients with hyperuricemia and treated hypertension who received a 24-week dotinurad therapy (a starting dose at 0.5 mg once daily and up-titrated to 2 mg once daily). The primary endpoint was a percentage change in the SUA level from baseline to week 24. The secondary endpoints were cardiovascular and metabolic measurements, including changes in the cardio-ankle vascular index (CAVI) and derivatives of reactive oxygen metabolites (d-ROMs) concentration at week 24. Fifty patients (mean age 70.5 ± 11.0 years, with 76.0% being men, and mean SUA level 8.5 ± 1.2 mg/dL) were included in the analysis. The percentage change from baseline in the SUA level at week 24 was - 35.8% (95% confidence interval [CI] - 39.7% to - 32.0%, P < 0.001), with approximately three quarters of patients achieving an SUA level of ≤ 6.0 mg/dL at week 24. The proportional changes from baseline in the geometric mean of CAVI and d-ROMs at week 24 were 0.96 (95% CI 0.92 to 1.00, P = 0.044) and 0.96 (95% CI 0.92 to 1.00, P = 0.044), respectively. In addition to meaningful SUA-lowering effects, 24 weeks of dotinurad therapy may favorably affect arterial stiffness and oxidative stress markers, suggesting off-target vascular protection of dotinurad. Further research is expected to verify our findings and elucidate the entire off-target effects of dotinurad. Trial registration jRCTs021210013, registration date June 24, 2021.","ja":"Dotinurad is a newer urate-lowering agent that selectively inhibits urate transporter 1 in the renal proximal tubule and increases urinary urate excretion. Currently, little is known about the clinical efficacies of dotinurad in patients with hyperuricemia and hypertension. The aim of this study was to assess the clinical effects of a selective urate reabsorption inhibitor dotinurad on serum uric acid (SUA) levels and relevant vascular markers in patients with hyperuricemia and treated hypertension. This investigator-initiated, multicenter, prospective, single-arm, open-label, exploratory clinical trial in Japan enrolled patients with hyperuricemia and treated hypertension who received a 24-week dotinurad therapy (a starting dose at 0.5 mg once daily and up-titrated to 2 mg once daily). The primary endpoint was a percentage change in the SUA level from baseline to week 24. The secondary endpoints were cardiovascular and metabolic measurements, including changes in the cardio-ankle vascular index (CAVI) and derivatives of reactive oxygen metabolites (d-ROMs) concentration at week 24. Fifty patients (mean age 70.5 ± 11.0 years, with 76.0% being men, and mean SUA level 8.5 ± 1.2 mg/dL) were included in the analysis. The percentage change from baseline in the SUA level at week 24 was - 35.8% (95% confidence interval [CI] - 39.7% to - 32.0%, P < 0.001), with approximately three quarters of patients achieving an SUA level of ≤ 6.0 mg/dL at week 24. The proportional changes from baseline in the geometric mean of CAVI and d-ROMs at week 24 were 0.96 (95% CI 0.92 to 1.00, P = 0.044) and 0.96 (95% CI 0.92 to 1.00, P = 0.044), respectively. In addition to meaningful SUA-lowering effects, 24 weeks of dotinurad therapy may favorably affect arterial stiffness and oxidative stress markers, suggesting off-target vascular protection of dotinurad. Further research is expected to verify our findings and elucidate the entire off-target effects of dotinurad. Trial registration jRCTs021210013, registration date June 24, 2021."},"publication_date":"2023-07-17","publication_name":{"en":"European Journal of Medical Research","ja":"European Journal of Medical Research"},"volume":"Vol.28","number":"No.1","starting_page":"238","ending_page":"238","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s40001-023-01208-1"],"issn":["2047-783X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118375","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37286486","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=398057","label":"url"}],"paper_title":{"en":"Evaluation of the Accuracy of ChatGPT in Answering Clinical Questions on the Japanese Society of Hypertension Guidelines","ja":"Evaluation of the Accuracy of ChatGPT in Answering Clinical Questions on the Japanese Society of Hypertension Guidelines"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Kashima Shuichiro"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"鹿島 修一郎"},{"name":"佐田 政隆"}]},"description":{"en":"To assist healthcare providers in interpreting guidelines, clinical questions (CQ) are often included, but not always, which can make interpretation difficult for non-expert clinicians. We evaluated the ability of ChatGPT to accurately answer CQs on the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Methods and Results: We conducted an observational study using data from JSH 2019. The accuracy rate for CQs and limited evidence-based questions of the guidelines (Qs) were evaluated. ChatGPT demonstrated a higher accuracy rate for CQs than for Qs (80% vs. 36%, P value: 0.005). ChatGPT has the potential to be a valuable tool for clinicians in the management of hypertension.","ja":"To assist healthcare providers in interpreting guidelines, clinical questions (CQ) are often included, but not always, which can make interpretation difficult for non-expert clinicians. We evaluated the ability of ChatGPT to accurately answer CQs on the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Methods and Results: We conducted an observational study using data from JSH 2019. The accuracy rate for CQs and limited evidence-based questions of the guidelines (Qs) were evaluated. ChatGPT demonstrated a higher accuracy rate for CQs than for Qs (80% vs. 36%, P value: 0.005). ChatGPT has the potential to be a valuable tool for clinicians in the management of hypertension."},"publication_date":"2023-06-07","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.87","number":"No.7","starting_page":"1030","ending_page":"1033","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-23-030"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118454","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37460267","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85165601733&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=399070","label":"url"}],"paper_title":{"en":"Artificial intelligence-assisted interpretation of systolic function by echocardiogram","ja":"Artificial intelligence-assisted interpretation of systolic function by echocardiogram"},"authors":{"en":[{"name":"Yamaguchi Natsumi"},{"name":"Kosaka Yoshitaka"},{"name":"Haga Akihiro"},{"name":"Sata Masataka"},{"name":"Kusunose Kenya"}],"ja":[{"name":"山口 夏美"},{"name":"髙坂 佳孝"},{"name":"芳賀 昭弘"},{"name":"佐田 政隆"},{"name":"楠瀬 賢也"}]},"description":{"en":"Precise and reliable echocardiographic assessment of left ventricular ejection fraction (LVEF) is needed for clinical decision-making. Recently, artificial intelligence (AI) models have been developed to estimate LVEF accurately. The aim of this study was to evaluate whether an AI model could estimate an expert read of LVEF and reduce the interinstitutional variability of level 1 readers with the AI-LVEF displayed on the echocardiographic screen. This prospective, multicentre echocardiographic study was conducted by five cardiologists of level 1 echocardiographic skill (minimum level of competency to interpret images) from different hospitals. Protocol 1: Visual LVEFs for the 48 cases were measured without input from the AI-LVEF. Protocol 2: the 48 cases were again shown to all readers with inclusion of AI-LVEF data. To assess the concordance and accuracy with or without AI-LVEF, each visual LVEF measurement was compared with an average of the estimates by five expert readers as a reference. A good correlation was found between AI-LVEF and reference LVEF (r=0.90, p<0.001) from the expert readers. For the classification LVEF, the area under the curve was 0.95 on heart failure with preserved EF and 0.96 on heart failure reduced EF. For the precision, the SD was reduced from 6.1±2.3 to 2.5±0.9 (p<0.001) with AI-LVEF. For the accuracy, the root-mean squared error was improved from 7.5±3.1 to 5.6±3.2 (p=0.004) with AI-LVEF. AI can assist with the interpretation of systolic function on an echocardiogram for level 1 readers from different institutions.","ja":"Precise and reliable echocardiographic assessment of left ventricular ejection fraction (LVEF) is needed for clinical decision-making. Recently, artificial intelligence (AI) models have been developed to estimate LVEF accurately. The aim of this study was to evaluate whether an AI model could estimate an expert read of LVEF and reduce the interinstitutional variability of level 1 readers with the AI-LVEF displayed on the echocardiographic screen. This prospective, multicentre echocardiographic study was conducted by five cardiologists of level 1 echocardiographic skill (minimum level of competency to interpret images) from different hospitals. Protocol 1: Visual LVEFs for the 48 cases were measured without input from the AI-LVEF. Protocol 2: the 48 cases were again shown to all readers with inclusion of AI-LVEF data. To assess the concordance and accuracy with or without AI-LVEF, each visual LVEF measurement was compared with an average of the estimates by five expert readers as a reference. A good correlation was found between AI-LVEF and reference LVEF (r=0.90, p<0.001) from the expert readers. For the classification LVEF, the area under the curve was 0.95 on heart failure with preserved EF and 0.96 on heart failure reduced EF. For the precision, the SD was reduced from 6.1±2.3 to 2.5±0.9 (p<0.001) with AI-LVEF. For the accuracy, the root-mean squared error was improved from 7.5±3.1 to 5.6±3.2 (p=0.004) with AI-LVEF. AI can assist with the interpretation of systolic function on an echocardiogram for level 1 readers from different institutions."},"publication_date":"2023-06","publication_name":{"en":"Open Heart","ja":"Open Heart"},"volume":"Vol.10","number":"No.2","starting_page":"e002287.","ending_page":"e002287.","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/openhrt-2023-002287"],"issn":["2053-3624"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118374","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37245990","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=398056","label":"url"}],"paper_title":{"en":"Intimal Sarcoma of the Pulmonary Artery as an Embolic Cause of Sudden Death","ja":"Intimal Sarcoma of the Pulmonary Artery as an Embolic Cause of Sudden Death"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Hara Tomoya"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"原 知也"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"佐田 政隆"}]},"publication_date":"2023-05-26","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.87","number":"No.7","starting_page":"1036","ending_page":"1036","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-23-0029"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118373","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37273880","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=398055","label":"url"}],"paper_title":{"en":"Deep learning approach for analyzing chest x-rays to predict cardiac events in heart failure","ja":"Deep learning approach for analyzing chest x-rays to predict cardiac events in heart failure"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Hirata Yukina"},{"name":"Yamaguchi Natsumi"},{"name":"Kosaka Y"},{"name":"Tsuji T"},{"name":"Kotoku J"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"平田 有紀奈"},{"name":"山口 夏海"},{"name":"髙坂 佳孝"},{"name":"Tsuji T"},{"name":"Kotoku J"},{"name":"佐田 政隆"}]},"description":{"en":"A deep learning (DL) model based on a chest x-ray was reported to predict elevated pulmonary artery wedge pressure (PAWP) as heart failure (HF). The aim of this study was to (1) investigate the role of probability of elevated PAWP for the prediction of clinical outcomes in association with other parameters, and (2) to evaluate whether probability of elevated PAWP based on DL added prognostic information to other conventional clinical prognostic factors in HF. We evaluated 192 patients hospitalized with HF. We used a previously developed AI model to predict HF and calculated probability of elevated PAWP. Readmission following HF and cardiac mortality were the primary endpoints. Probability of elevated PAWP was associated with diastolic function by echocardiography. During a median follow-up period of 58 months, 57 individuals either died or were readmitted. Probability of elevated PAWP appeared to be associated with worse clinical outcomes. After adjustment for readmission score and laboratory data in a Cox proportional-hazards model, probability of elevated PAWP at pre-discharge was associated with event free survival, independent of elevated left atrial pressure (LAP) based on echocardiographic guidelines ( < 0.001). In sequential Cox models, a model based on clinical data was improved by elevated LAP (= 0.005), and increased further by probability of elevated PAWP (< 0.001). In contrast, the addition of pulmonary congestion interpreted by a doctor did not statistically improve the ability of a model containing clinical variables (compared = 0.086). This study showed the potential of using a DL model on a chest x-ray to predict PAWP and its ability to add prognostic information to other conventional clinical prognostic factors in HF. The results may help to enhance the accuracy of prediction models used to evaluate the risk of clinical outcomes in HF, potentially resulting in more informed clinical decision-making and better care for patients.","ja":"A deep learning (DL) model based on a chest x-ray was reported to predict elevated pulmonary artery wedge pressure (PAWP) as heart failure (HF). The aim of this study was to (1) investigate the role of probability of elevated PAWP for the prediction of clinical outcomes in association with other parameters, and (2) to evaluate whether probability of elevated PAWP based on DL added prognostic information to other conventional clinical prognostic factors in HF. We evaluated 192 patients hospitalized with HF. We used a previously developed AI model to predict HF and calculated probability of elevated PAWP. Readmission following HF and cardiac mortality were the primary endpoints. Probability of elevated PAWP was associated with diastolic function by echocardiography. During a median follow-up period of 58 months, 57 individuals either died or were readmitted. Probability of elevated PAWP appeared to be associated with worse clinical outcomes. After adjustment for readmission score and laboratory data in a Cox proportional-hazards model, probability of elevated PAWP at pre-discharge was associated with event free survival, independent of elevated left atrial pressure (LAP) based on echocardiographic guidelines ( < 0.001). In sequential Cox models, a model based on clinical data was improved by elevated LAP (= 0.005), and increased further by probability of elevated PAWP (< 0.001). In contrast, the addition of pulmonary congestion interpreted by a doctor did not statistically improve the ability of a model containing clinical variables (compared = 0.086). This study showed the potential of using a DL model on a chest x-ray to predict PAWP and its ability to add prognostic information to other conventional clinical prognostic factors in HF. The results may help to enhance the accuracy of prediction models used to evaluate the risk of clinical outcomes in HF, potentially resulting in more informed clinical decision-making and better care for patients."},"publication_date":"2023-05-19","publication_name":{"en":"Frontiers in Cardiovascular Medicine","ja":"Frontiers in Cardiovascular Medicine"},"volume":"Vol.10","starting_page":"1081628","ending_page":"1081628","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fcvm.2023.1081628"],"issn":["2297-055X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118875","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37161392","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85158935839&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396843","label":"url"}],"paper_title":{"en":"Classification of chest X-ray images by incorporation of medical domain knowledge into operation branch networks.","ja":"Classification of chest X-ray images by incorporation of medical domain knowledge into operation branch networks."},"authors":{"en":[{"name":"Tsuji T"},{"name":"Hirata Yukina"},{"name":"Kusunose Kenya"},{"name":"Sata Masataka"},{"name":"Kumagai S"},{"name":"Shiraishi K"},{"name":"Kotoku J"}],"ja":[{"name":"Tsuji T"},{"name":"平田 有紀奈"},{"name":"楠瀬 賢也"},{"name":"佐田 政隆"},{"name":"Kumagai S"},{"name":"Shiraishi K"},{"name":"Kotoku J"}]},"description":{"en":"This study was conducted to alleviate a common difficulty in chest X-ray image diagnosis: The attention region in a convolutional neural network (CNN) does not often match the doctor's point of focus. The method presented herein, which guides the area of attention in CNN to a medically plausible region, can thereby improve diagnostic capabilities. The model is based on an attention branch network, which has excellent interpretability of the classification model. This model has an additional new operation branch that guides the attention region to the lung field and heart in chest X-ray images. We also used three chest X-ray image datasets (Teikyo, Tokushima, and ChestX-ray14) to evaluate the CNN attention area of interest in these fields. Additionally, after devising a quantitative method of evaluating improvement of a CNN's region of interest, we applied it to evaluation of the proposed model. Operation branch networks maintain or improve the area under the curve to a greater degree than conventional CNNs do. Furthermore, the network better emphasizes reasonable anatomical parts in chest X-ray images. The proposed network better emphasizes the reasonable anatomical parts in chest X-ray images. This method can enhance capabilities for image interpretation based on judgment.","ja":"This study was conducted to alleviate a common difficulty in chest X-ray image diagnosis: The attention region in a convolutional neural network (CNN) does not often match the doctor's point of focus. The method presented herein, which guides the area of attention in CNN to a medically plausible region, can thereby improve diagnostic capabilities. The model is based on an attention branch network, which has excellent interpretability of the classification model. This model has an additional new operation branch that guides the attention region to the lung field and heart in chest X-ray images. We also used three chest X-ray image datasets (Teikyo, Tokushima, and ChestX-ray14) to evaluate the CNN attention area of interest in these fields. Additionally, after devising a quantitative method of evaluating improvement of a CNN's region of interest, we applied it to evaluation of the proposed model. Operation branch networks maintain or improve the area under the curve to a greater degree than conventional CNNs do. Furthermore, the network better emphasizes reasonable anatomical parts in chest X-ray images. The proposed network better emphasizes the reasonable anatomical parts in chest X-ray images. This method can enhance capabilities for image interpretation based on judgment."},"publication_date":"2023-05-09","publication_name":{"en":"BMC Medical Imaging","ja":"BMC Medical Imaging"},"volume":"Vol.23","number":"No.1","starting_page":"62","ending_page":"62","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12880-023-01019-0"],"issn":["1471-2342"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118567","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37028805","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396842","label":"url"}],"paper_title":{"en":"Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study","ja":"Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study"},"authors":{"en":[{"name":"Kudo A"},{"name":"Machii N"},{"name":"Ono T"},{"name":"Saito H"},{"name":"Oshiro Y"},{"name":"Takahashi R"},{"name":"Oshiro K"},{"name":"Taneda Y"},{"name":"Higa M"},{"name":"Nakachi K"},{"name":"Yagi Shusuke"},{"name":"Masuzaki H"},{"name":"Sata Masataka"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"Kudo A"},{"name":"Machii N"},{"name":"Ono T"},{"name":"Saito H"},{"name":"Oshiro Y"},{"name":"Takahashi R"},{"name":"Oshiro K"},{"name":"Taneda Y"},{"name":"Higa M"},{"name":"Nakachi K"},{"name":"八木 秀介"},{"name":"Masuzaki H"},{"name":"佐田 政隆"},{"name":"島袋 充生"}]},"description":{"en":"This study aimed to evaluate the impacts of dapagliflozin on 24-hour glucose variability and diabetes-related biochemical variables in Japanese patients with type 2 diabetes who had received basal insulin supported oral therapy (BOT). Changes in mean daily blood glucose level before and after 48-72 hours of add-on or no add-on of dapagliflozin (primary end point) and diabetes-related biochemical variables and major safety variables during the 12 weeks (secondary end point) were evaluated in the multicenter, randomized, two-arm, open-label, parallel-group comparison study. Among 36 participants, 18 were included in the no add-on group and 18 were included in the dapagliflozin add-on group. Age, gender, and body mass index were comparable between the groups. There were no changes in continuous glucose monitoring metrics in the no add-on group. In the dapagliflozin add-on group, mean glucose (183-156 mg/dL, p=0.001), maximum glucose (300-253, p<0.01), and SD glucose (57-45, p<0.05) decreased. Time in range increased (p<0.05), while time above the range decreased in the dapagliflozin add-on group but not in the no add-on group. After 12-week treatment with dapagliflozin add-on, 8-hydroxy-2'-deoxyguanosine (8OHdG), as well as hemoglobin A1c (HbA1c), decreased. This study showed that the mean daily blood glucose and other daily glucose profiles were amended after 48-72 hours of dapagliflozin add-on in Japanese patients with type 2 diabetes who received BOT. The diabetes-related biochemical variables such as HbA1c and urinary 8OHdG were also obtained during the 12 weeks of dapagliflozin add-on without major adverse events. A preferable 24-hour glucose profile in 'time in ranges' and an improvement in reactive oxygen species by dapagliflozin warrant us to evaluate these benefits in larger clinical studies. UMIN000019457.","ja":"This study aimed to evaluate the impacts of dapagliflozin on 24-hour glucose variability and diabetes-related biochemical variables in Japanese patients with type 2 diabetes who had received basal insulin supported oral therapy (BOT). Changes in mean daily blood glucose level before and after 48-72 hours of add-on or no add-on of dapagliflozin (primary end point) and diabetes-related biochemical variables and major safety variables during the 12 weeks (secondary end point) were evaluated in the multicenter, randomized, two-arm, open-label, parallel-group comparison study. Among 36 participants, 18 were included in the no add-on group and 18 were included in the dapagliflozin add-on group. Age, gender, and body mass index were comparable between the groups. There were no changes in continuous glucose monitoring metrics in the no add-on group. In the dapagliflozin add-on group, mean glucose (183-156 mg/dL, p=0.001), maximum glucose (300-253, p<0.01), and SD glucose (57-45, p<0.05) decreased. Time in range increased (p<0.05), while time above the range decreased in the dapagliflozin add-on group but not in the no add-on group. After 12-week treatment with dapagliflozin add-on, 8-hydroxy-2'-deoxyguanosine (8OHdG), as well as hemoglobin A1c (HbA1c), decreased. This study showed that the mean daily blood glucose and other daily glucose profiles were amended after 48-72 hours of dapagliflozin add-on in Japanese patients with type 2 diabetes who received BOT. The diabetes-related biochemical variables such as HbA1c and urinary 8OHdG were also obtained during the 12 weeks of dapagliflozin add-on without major adverse events. A preferable 24-hour glucose profile in 'time in ranges' and an improvement in reactive oxygen species by dapagliflozin warrant us to evaluate these benefits in larger clinical studies. UMIN000019457."},"publication_date":"2023-04","publication_name":{"en":"BMJ Open Diabetes Research & Care","ja":"BMJ Open Diabetes Research & Care"},"volume":"Vol.11","number":"No.2","starting_page":"e003302","ending_page":"e003302","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/bmjdrc-2022-003302"],"issn":["2052-4897"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117912","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36449252","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85143121783&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393335","label":"url"}],"paper_title":{"en":"New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy","ja":"New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy"},"authors":{"en":[{"name":"Matsuda Noritake"},{"name":"Otsuka Hideki"},{"name":"Otani Tamaki"},{"name":"Azane Shota"},{"name":"Kunikane Yamato"},{"name":"Otomi Yoichi"},{"name":"Ueki Yuya"},{"name":"Kubota Masahiro"},{"name":"Amano Masafumi"},{"name":"Yagi Shusuke"},{"name":"Sata Masataka"},{"name":"Harada Masafumi"}],"ja":[{"name":"松田 憲武"},{"name":"大塚 秀樹"},{"name":"大谷 環樹"},{"name":"Azane Shota"},{"name":"Kunikane Yamato"},{"name":"Otomi Yoichi"},{"name":"植木 勇弥"},{"name":"Kubota Masahiro"},{"name":"Amano Masafumi"},{"name":"八木 秀介"},{"name":"佐田 政隆"},{"name":"原田 雅史"}]},"description":{"en":"Amyloid light chain (AL) and transthyretin (ATTR) are the major subtypes of cardiac amyloidosis (CA). Tc-pyrophosphate (PYP) scintigraphy is used to differentiate ATTR from other CA subtypes. We adapted the standardized uptake value (SUV) for Tc-PYP and proposed two quantitative indices, amyloid deposition volume (AmyDV) and total amyloid uptake (TAU). This study aimed to evaluate the utility of these quantitative indices in differentiating ATTR from non-ATTRs. Before the SUV measurement, the Becquerel calibration factor (BCF) of Tc was obtained by a phantom experiment. Thirty-two patients who had undergone hybrid SPECT/CT imaging 3 h after injection of Tc-PYP (370 MBq) were studied. CT attenuation correction for image reconstruction was applied in all. We calculated SUV, AmyDV, and TAU using a quantitative analysis software program for bone SPECT (GI-BONE) and analyzed AmyDV using two methods: threshold method (set 40%); and constant value method (average SUV of ribs). We assessed the diagnostic ability of heart-to-contralateral lung (H/CL) ratio, SUV, AmyDV, and TAU to differentiate ATTR from non-ATTR using receiver operating characteristic (ROC) analysis. Statistically significant differences in all quantitative indices were observed between ATTR and non-ATTR. The area under the curve of each quantitative index for discriminating between ATTR and non-ATTR were as follows: H/CL, 0.997; SUV, 0.953; SUV (M1), 0.964; SUV (M2), 0.969; AmyDV (M1), 0.875; AmyDV (M2), 0.974; and TAU, 0.974. The AmyDV (M2) had higher diagnostic ability than AmyDV (M1). Thus, TAU was calculated as AmyDV (M2) × SUV (M2). In the ROC curve, SUV, AmyDV, and TAU had almost the same diagnostic ability as H/CL in distinguishing ATTR from non-ATTRs. We propose two novel 3D-based quantitative parameters (AmyDV and TAU) that have almost equal ability to discriminate ATTR from non-ATTR.","ja":"Amyloid light chain (AL) and transthyretin (ATTR) are the major subtypes of cardiac amyloidosis (CA). Tc-pyrophosphate (PYP) scintigraphy is used to differentiate ATTR from other CA subtypes. We adapted the standardized uptake value (SUV) for Tc-PYP and proposed two quantitative indices, amyloid deposition volume (AmyDV) and total amyloid uptake (TAU). This study aimed to evaluate the utility of these quantitative indices in differentiating ATTR from non-ATTRs. Before the SUV measurement, the Becquerel calibration factor (BCF) of Tc was obtained by a phantom experiment. Thirty-two patients who had undergone hybrid SPECT/CT imaging 3 h after injection of Tc-PYP (370 MBq) were studied. CT attenuation correction for image reconstruction was applied in all. We calculated SUV, AmyDV, and TAU using a quantitative analysis software program for bone SPECT (GI-BONE) and analyzed AmyDV using two methods: threshold method (set 40%); and constant value method (average SUV of ribs). We assessed the diagnostic ability of heart-to-contralateral lung (H/CL) ratio, SUV, AmyDV, and TAU to differentiate ATTR from non-ATTR using receiver operating characteristic (ROC) analysis. Statistically significant differences in all quantitative indices were observed between ATTR and non-ATTR. The area under the curve of each quantitative index for discriminating between ATTR and non-ATTR were as follows: H/CL, 0.997; SUV, 0.953; SUV (M1), 0.964; SUV (M2), 0.969; AmyDV (M1), 0.875; AmyDV (M2), 0.974; and TAU, 0.974. The AmyDV (M2) had higher diagnostic ability than AmyDV (M1). Thus, TAU was calculated as AmyDV (M2) × SUV (M2). In the ROC curve, SUV, AmyDV, and TAU had almost the same diagnostic ability as H/CL in distinguishing ATTR from non-ATTRs. We propose two novel 3D-based quantitative parameters (AmyDV and TAU) that have almost equal ability to discriminate ATTR from non-ATTR."},"publication_date":"2023-04","publication_name":{"en":"Japanese Journal of Radiology","ja":"Japanese Journal of Radiology"},"volume":"Vol.41","number":"No.4","starting_page":"428","ending_page":"436","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s11604-022-01364-0"],"issn":["1867-108X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117567","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36195252","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392385","label":"url"}],"paper_title":{"en":"Emerging roles of Protease-Activated Receptors in Cardiometabolic Disorders","ja":"Emerging roles of Protease-Activated Receptors in Cardiometabolic Disorders"},"authors":{"en":[{"name":"Hara Tomoya"},{"name":"Sata Masataka"},{"name":"Fukuda Daiju"}],"ja":[{"name":"原 知也"},{"name":"佐田 政隆"},{"name":"福田 大受"}]},"description":{"en":"Cardiometabolic disorders, including obesity-related insulin resistance and atherosclerosis, share sterile chronic inflammation as a major cause; however, the precise underlying mechanisms of chronic inflammation in cardiometabolic disorders are not fully understood. Accumulating evidence suggests that several coagulation proteases, including thrombin and activated factor X (FXa), play an important role not only in the coagulation cascade but also in the proinflammatory responses through protease-activated receptors (PARs) in many cell types. Four members of the PAR family have been cloned (PAR 1-4). For instance, thrombin activates PAR-1, PAR-3, and PAR-4. FXa activates both PAR-1 and PAR-2, while it has no effect on PAR-3 or PAR-4. Previous studies demonstrated that PAR-1 and PAR-2 activated by thrombin or FXa promote gene expression of inflammatory molecules mainly via the NF-κB and ERK1/2 pathways. In obese adipose tissue and atherosclerotic vascular tissue, various stresses increase the expression of tissue factor and procoagulant activity. Recent studies indicated that the activation of PARs in adipocytes and vascular cells by coagulation proteases promotes inflammation in these tissues, which leads to the development of cardiometabolic diseases. This review briefly summarizes the role of PARs and coagulation proteases in the pathogenesis of inflammatory diseases and describes recent findings (including ours) on the potential participation of this system in the development of cardiometabolic disorders. New insights into PARs may ensure a better understanding of cardiometabolic disorders and suggest new therapeutic options for these major health threats.","ja":"Cardiometabolic disorders, including obesity-related insulin resistance and atherosclerosis, share sterile chronic inflammation as a major cause; however, the precise underlying mechanisms of chronic inflammation in cardiometabolic disorders are not fully understood. Accumulating evidence suggests that several coagulation proteases, including thrombin and activated factor X (FXa), play an important role not only in the coagulation cascade but also in the proinflammatory responses through protease-activated receptors (PARs) in many cell types. Four members of the PAR family have been cloned (PAR 1-4). For instance, thrombin activates PAR-1, PAR-3, and PAR-4. FXa activates both PAR-1 and PAR-2, while it has no effect on PAR-3 or PAR-4. Previous studies demonstrated that PAR-1 and PAR-2 activated by thrombin or FXa promote gene expression of inflammatory molecules mainly via the NF-κB and ERK1/2 pathways. In obese adipose tissue and atherosclerotic vascular tissue, various stresses increase the expression of tissue factor and procoagulant activity. Recent studies indicated that the activation of PARs in adipocytes and vascular cells by coagulation proteases promotes inflammation in these tissues, which leads to the development of cardiometabolic diseases. This review briefly summarizes the role of PARs and coagulation proteases in the pathogenesis of inflammatory diseases and describes recent findings (including ours) on the potential participation of this system in the development of cardiometabolic disorders. New insights into PARs may ensure a better understanding of cardiometabolic disorders and suggest new therapeutic options for these major health threats."},"publication_date":"2023-04","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.81","number":"No.4","starting_page":"337","ending_page":"346","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2022.09.013"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118932","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37006797","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=395125","label":"url"}],"paper_title":{"en":"Endomyocardial biopsy-proven fulminant lymphocytic myocarditis presenting with mid-apical ballooning","ja":"Endomyocardial biopsy-proven fulminant lymphocytic myocarditis presenting with mid-apical ballooning"},"authors":{"en":[{"name":"Miyamoto Ryota"},{"name":"Ise Takayuki"},{"name":"Yoshida Tomoya"},{"name":"Sata Masataka"}],"ja":[{"name":"宮本 亮太"},{"name":"伊勢 孝之"},{"name":"?田 知哉"},{"name":"佐田 政隆"}]},"publication_date":"2023-03-15","publication_name":{"en":"European Heart Journal. Case Reports","ja":"European Heart Journal. Case Reports"},"volume":"Vol.7","number":"No.3","starting_page":"ytad123","ending_page":"ytad123","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/ehjcr/ytad123"],"issn":["2514-2119"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118275","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36357528","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=394017","label":"url"}],"paper_title":{"en":"Isoproterenol loading transesophageal echocardiography in atrial fibrillation","ja":"Isoproterenol loading transesophageal echocardiography in atrial fibrillation"},"authors":{"en":[{"name":"Takahashi Tomonori"},{"name":"Kusunose Kenya"},{"name":"Hayashi S"},{"name":"Zheng Robert"},{"name":"Yamaguchi Natsumi"},{"name":"Morita Sae"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Saijyo Yoshihito"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"髙橋 智紀"},{"name":"楠瀬 賢也"},{"name":"Hayashi S"},{"name":"Robert Zheng"},{"name":"山口 夏美"},{"name":"森田 沙瑛"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"In patients with sludge or severe spontaneous echo contrast (SEC) in the left atrial appendage (LAA), cases with isoproterenol loading transesophageal echocardiography (ISP-TEE) have been reported to identify the presence of thrombus in the LAA. This study aimed to assess the validity and hemodynamic changes of ISP-TEE in the LAA. We prospectively enrolled patients with atrial fibrillation (AF) who underwent ISP-TEE. The degree of sludge/SEC was categorized as being either absent (grade 0), mild SEC (grade 1), moderate SEC (grade 2), severe SEC or sludge (grade 3). The hemodynamic evaluation was performed by measuring LAA flow velocity, LAA tissue Doppler imaging (LAA-TDI) velocity, and pulmonary vein systolic forward flow velocity (PVS). In total, 35 patients (mean age 71 ± 7 years; 71% male) underwent ISP-TEE. Among 35 patients, 30 patients had grade 3 or 2 SEC, 5 patients had grade 1 SEC. After ISP loading, 23 patients (66% of all patients) showed improved sludge/SEC and one patient was diagnosed with thrombus in the LAA. There were 25 patients with grade 1 SEC, or no SEC (classified as Group1), 10 patients had residual sludge or grade 2 to 3 SEC (classified as Group2) after ISP administration. LAA flow, LAA-TDI, and PVS velocities were significantly higher in group 1 than in group 2 after ISP administration. There was no complication during the examination and after 24 h and 3 months. ISP infusion may be a potential tool to recognize LAA thrombus under the sludge/SEC during TEE in AF.","ja":"In patients with sludge or severe spontaneous echo contrast (SEC) in the left atrial appendage (LAA), cases with isoproterenol loading transesophageal echocardiography (ISP-TEE) have been reported to identify the presence of thrombus in the LAA. This study aimed to assess the validity and hemodynamic changes of ISP-TEE in the LAA. We prospectively enrolled patients with atrial fibrillation (AF) who underwent ISP-TEE. The degree of sludge/SEC was categorized as being either absent (grade 0), mild SEC (grade 1), moderate SEC (grade 2), severe SEC or sludge (grade 3). The hemodynamic evaluation was performed by measuring LAA flow velocity, LAA tissue Doppler imaging (LAA-TDI) velocity, and pulmonary vein systolic forward flow velocity (PVS). In total, 35 patients (mean age 71 ± 7 years; 71% male) underwent ISP-TEE. Among 35 patients, 30 patients had grade 3 or 2 SEC, 5 patients had grade 1 SEC. After ISP loading, 23 patients (66% of all patients) showed improved sludge/SEC and one patient was diagnosed with thrombus in the LAA. There were 25 patients with grade 1 SEC, or no SEC (classified as Group1), 10 patients had residual sludge or grade 2 to 3 SEC (classified as Group2) after ISP administration. LAA flow, LAA-TDI, and PVS velocities were significantly higher in group 1 than in group 2 after ISP administration. There was no complication during the examination and after 24 h and 3 months. ISP infusion may be a potential tool to recognize LAA thrombus under the sludge/SEC during TEE in AF."},"publication_date":"2023-03","publication_name":{"en":"The International Journal of Cardiovascular Imaging","ja":"The International Journal of Cardiovascular Imaging"},"volume":"Vol.39","number":"No.3","starting_page":"511","ending_page":"518","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10554-022-02749-y"],"issn":["1875-8312"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117974","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36308299","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=394010","label":"url"}],"paper_title":{"en":"Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial","ja":"Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial"},"authors":{"en":[{"name":"Tanaka A,"},{"name":"Sata Masataka"},{"name":"Okada Y"},{"name":"Teragawa H"},{"name":"Eguchi K"},{"name":"Shimabukuro Michio"},{"name":"Taguchi I"},{"name":"Matsunaga K"},{"name":"Kanzaki Y"},{"name":"Yoshida H"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Kitakaze M"},{"name":"Murohara T"},{"name":"Node K"}],"ja":[{"name":"Tanaka A,"},{"name":"佐田 政隆"},{"name":"Okada Y"},{"name":"Teragawa H"},{"name":"Eguchi K"},{"name":"島袋 充生"},{"name":"Taguchi I"},{"name":"Matsunaga K"},{"name":"Kanzaki Y"},{"name":"Yoshida H"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Kitakaze M"},{"name":"Murohara T"},{"name":"Node K"}]},"description":{"en":"To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients. In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0-10.0% (42-86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, and 464 patients (median age 68 years, female 31.7%, median type 2 diabetes duration 8 years, median HbA1c 7.3%) were included in the analyses. For the primary endpoint, the changes in the mean CCA-IMT from baseline to 24 months were 0.0013 [95% confidence interval (CI), -0.0155-0.0182] mm and 0.0015 (95% CI, -0.0155-0.0184) mm in the ipragliflozin and control groups, respectively, with an estimated group difference (ipragliflozin-control) of -0.0001 mm (95% CI, -0.0191-0.0189; P = 0.989). A group difference in HbA1c change at 24 months was also non-significant between the treatment groups [-0.1% (95% CI, -0.2-0.1); P = 0.359]. Twenty-four months of ipragliflozin treatment did not affect carotid IMT status in patients with type 2 diabetes recruited in the PROTECT study, relative to the non-SGLT2 inhibitor-use standard care for type 2 diabetes.","ja":"To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients. In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0-10.0% (42-86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, and 464 patients (median age 68 years, female 31.7%, median type 2 diabetes duration 8 years, median HbA1c 7.3%) were included in the analyses. For the primary endpoint, the changes in the mean CCA-IMT from baseline to 24 months were 0.0013 [95% confidence interval (CI), -0.0155-0.0182] mm and 0.0015 (95% CI, -0.0155-0.0184) mm in the ipragliflozin and control groups, respectively, with an estimated group difference (ipragliflozin-control) of -0.0001 mm (95% CI, -0.0191-0.0189; P = 0.989). A group difference in HbA1c change at 24 months was also non-significant between the treatment groups [-0.1% (95% CI, -0.2-0.1); P = 0.359]. Twenty-four months of ipragliflozin treatment did not affect carotid IMT status in patients with type 2 diabetes recruited in the PROTECT study, relative to the non-SGLT2 inhibitor-use standard care for type 2 diabetes."},"publication_date":"2023-02-02","publication_name":{"en":"European Heart Journal. Cardiovascular Pharmacotherapy","ja":"European Heart Journal. Cardiovascular Pharmacotherapy"},"volume":"Vol.9","number":"No.2","starting_page":"165","ending_page":"172","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/ehjcvp/pvac059"],"issn":["2055-6845"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117970","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36440584","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393998","label":"url"}],"paper_title":{"en":"NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload","ja":"NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload"},"authors":{"en":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"Numata G"},{"name":"Tanaka K"},{"name":"Fukuda Daiju"},{"name":"Tanaka Y"},{"name":"Hirata Y"},{"name":"Imamura T"},{"name":"Takimoto E"},{"name":"Komuro I"},{"name":"Sata Masataka"}],"ja":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"Numata G"},{"name":"Tanaka K"},{"name":"福田 大受"},{"name":"Tanaka Y"},{"name":"Hirata Y"},{"name":"Imamura T"},{"name":"Takimoto E"},{"name":"Komuro I"},{"name":"佐田 政隆"}]},"description":{"en":"Mechanical stress on the heart, such as high blood pressure, initiates inflammation and causes hypertrophic heart disease. However, the regulatory mechanism of inflammation and its role in the stressed heart remain unclear. IL-1β (interleukin-1β) is a proinflammatory cytokine that causes cardiac hypertrophy and heart failure. Here, we show that neural signals activate the NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing 3) inflammasome for IL-1β production to induce adaptive hypertrophy in the stressed heart. C57BL/6 mice, knockout mouse strains for NLRP3 and P2RX7 (P2X purinoceptor 7), and adrenergic neuron-specific knockout mice for SLC17A9, a secretory vesicle protein responsible for the storage and release of ATP, were used for analysis. Pressure overload was induced by transverse aortic constriction. Various animal models were used, including pharmacological treatment with apyrase, lipopolysaccharide, 2'(3')--(4-benzoylbenzoyl)-ATP, MCC950, anti-IL-1β antibodies, clonidine, pseudoephedrine, isoproterenol, and bisoprolol, left stellate ganglionectomy, and ablation of cardiac afferent nerves with capsaicin. Cardiac function and morphology, gene expression, myocardial IL-1β and caspase-1 activity, and extracellular ATP level were assessed. In vitro experiments were performed using primary cardiomyocytes and fibroblasts from rat neonates and human microvascular endothelial cell line. Cell surface area and proliferation were assessed. Genetic disruption of NLRP3 resulted in significant loss of IL-1β production, cardiac hypertrophy, and contractile function during pressure overload. A bone marrow transplantation experiment revealed an essential role of NLRP3 in cardiac nonimmune cells in myocardial IL-1β production and cardiac phenotype. Pharmacological depletion of extracellular ATP or genetic disruption of the P2X7 receptor suppressed myocardial NLRP3 inflammasome activity during pressure overload, indicating an important role of ATP/P2X7 axis in cardiac inflammation and hypertrophy. Extracellular ATP induced hypertrophic changes of cardiac cells in an NLRP3- and IL-1β-dependent manner in vitro. Manipulation of the sympathetic nervous system suggested sympathetic efferent nerves as the main source of extracellular ATP. Depletion of ATP release from sympathetic efferent nerves, ablation of cardiac afferent nerves, or a lipophilic β-blocker reduced cardiac extracellular ATP level, and inhibited NLRP3 inflammasome activation, IL-1β production, and adaptive cardiac hypertrophy during pressure overload. Cardiac inflammation and hypertrophy are regulated by heart-brain interaction. Controlling neural signals might be important for the treatment of hypertensive heart disease.","ja":"Mechanical stress on the heart, such as high blood pressure, initiates inflammation and causes hypertrophic heart disease. However, the regulatory mechanism of inflammation and its role in the stressed heart remain unclear. IL-1β (interleukin-1β) is a proinflammatory cytokine that causes cardiac hypertrophy and heart failure. Here, we show that neural signals activate the NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing 3) inflammasome for IL-1β production to induce adaptive hypertrophy in the stressed heart. C57BL/6 mice, knockout mouse strains for NLRP3 and P2RX7 (P2X purinoceptor 7), and adrenergic neuron-specific knockout mice for SLC17A9, a secretory vesicle protein responsible for the storage and release of ATP, were used for analysis. Pressure overload was induced by transverse aortic constriction. Various animal models were used, including pharmacological treatment with apyrase, lipopolysaccharide, 2'(3')--(4-benzoylbenzoyl)-ATP, MCC950, anti-IL-1β antibodies, clonidine, pseudoephedrine, isoproterenol, and bisoprolol, left stellate ganglionectomy, and ablation of cardiac afferent nerves with capsaicin. Cardiac function and morphology, gene expression, myocardial IL-1β and caspase-1 activity, and extracellular ATP level were assessed. In vitro experiments were performed using primary cardiomyocytes and fibroblasts from rat neonates and human microvascular endothelial cell line. Cell surface area and proliferation were assessed. Genetic disruption of NLRP3 resulted in significant loss of IL-1β production, cardiac hypertrophy, and contractile function during pressure overload. A bone marrow transplantation experiment revealed an essential role of NLRP3 in cardiac nonimmune cells in myocardial IL-1β production and cardiac phenotype. Pharmacological depletion of extracellular ATP or genetic disruption of the P2X7 receptor suppressed myocardial NLRP3 inflammasome activity during pressure overload, indicating an important role of ATP/P2X7 axis in cardiac inflammation and hypertrophy. Extracellular ATP induced hypertrophic changes of cardiac cells in an NLRP3- and IL-1β-dependent manner in vitro. Manipulation of the sympathetic nervous system suggested sympathetic efferent nerves as the main source of extracellular ATP. Depletion of ATP release from sympathetic efferent nerves, ablation of cardiac afferent nerves, or a lipophilic β-blocker reduced cardiac extracellular ATP level, and inhibited NLRP3 inflammasome activation, IL-1β production, and adaptive cardiac hypertrophy during pressure overload. Cardiac inflammation and hypertrophy are regulated by heart-brain interaction. Controlling neural signals might be important for the treatment of hypertensive heart disease."},"publication_date":"2023-01-24","publication_name":{"en":"Circulation","ja":"Circulation"},"volume":"Vol.147","number":"No.4","starting_page":"338","ending_page":"355","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/CIRCULATIONAHA.122.060860"],"issn":["1524-4539"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117602","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36244741","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392542","label":"url"}],"paper_title":{"en":"Association of Microluminal Structures Assessed by Optical Coherence Tomography With Local Inflammation in Adjacent Epicardial Adipose Tissue and Coronary Plaque Characteristics in Fresh Cadavers","ja":"Association of Microluminal Structures Assessed by Optical Coherence Tomography With Local Inflammation in Adjacent Epicardial Adipose Tissue and Coronary Plaque Characteristics in Fresh Cadavers"},"authors":{"en":[{"name":"Kawabata Yutaka"},{"name":"Wakatsuki Tetsuzo"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Ito Hiroyuki"},{"name":"Matsuura Tomomi"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Tsuruo Y"},{"name":"Sata Masataka"}],"ja":[{"name":"川端 豊"},{"name":"若槻 哲三"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"伊藤 浩敬"},{"name":"松浦 朋美"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"Tsuruo Y"},{"name":"佐田 政隆"}]},"description":{"en":"Coronary intraplaque microluminal structures (MS) are associated with plaque vulnerability, and the inward progression of vascular inflammation from the adventitia towards the media and intima has also been demonstrated. Therefore, in the present study we investigated the relationships among MS, local inflammation in adjacent epicardial adipose tissue (EAT), and coronary plaque characteristics.Methods and Results: Optical coherence tomography (OCT) revealed MS in the left anterior descending coronary artery in 10 fresh cadaveric hearts. We sampled 30 lesions and subdivided them based on the presence of MS: MS (+) group (n=19) and MS (-) group (n=11). We measured inflammatory molecule levels in the adjacent EAT and percentage lipid volume assessed by integrated backscatter intravascular ultrasound in each lesion. The expression levels of vascular endothelial growth factor B and C-C motif chemokine ligand 2 were significantly higher in the MS (+) group than in the MS (-) group (0.9±0.7 vs. 0.2±0.2 arbitrary units (AU), P=0.04 and 1.5±0.5 vs. 0.6±0.7 AU, P=0.02, respectively). Percentage lipid volume was significantly higher in the MS (+) group than in the MS (-) group (38.7±16.5 vs. 23.7±10.9%, P=0.03). Intraplaque MS observed on OCT were associated with lipid-rich plaques and local inflammation in the adjacent EAT. Collectively, these results suggest that local inflammation in the EAT is associated with coronary plaque vulnerability via MS.","ja":"Coronary intraplaque microluminal structures (MS) are associated with plaque vulnerability, and the inward progression of vascular inflammation from the adventitia towards the media and intima has also been demonstrated. Therefore, in the present study we investigated the relationships among MS, local inflammation in adjacent epicardial adipose tissue (EAT), and coronary plaque characteristics.Methods and Results: Optical coherence tomography (OCT) revealed MS in the left anterior descending coronary artery in 10 fresh cadaveric hearts. We sampled 30 lesions and subdivided them based on the presence of MS: MS (+) group (n=19) and MS (-) group (n=11). We measured inflammatory molecule levels in the adjacent EAT and percentage lipid volume assessed by integrated backscatter intravascular ultrasound in each lesion. The expression levels of vascular endothelial growth factor B and C-C motif chemokine ligand 2 were significantly higher in the MS (+) group than in the MS (-) group (0.9±0.7 vs. 0.2±0.2 arbitrary units (AU), P=0.04 and 1.5±0.5 vs. 0.6±0.7 AU, P=0.02, respectively). Percentage lipid volume was significantly higher in the MS (+) group than in the MS (-) group (38.7±16.5 vs. 23.7±10.9%, P=0.03). Intraplaque MS observed on OCT were associated with lipid-rich plaques and local inflammation in the adjacent EAT. Collectively, these results suggest that local inflammation in the EAT is associated with coronary plaque vulnerability via MS."},"publication_date":"2023","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.87","number":"No.2","starting_page":"329","ending_page":"335","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-22-0299"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35562627","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392915","label":"url"}],"paper_title":{"en":"Association between cardiovascular risk factors and left ventricular strain distribution in patients without previous cardiovascular disease","ja":"Association between cardiovascular risk factors and left ventricular strain distribution in patients without previous cardiovascular disease"},"authors":{"en":[{"name":"Takahashi Tomonori"},{"name":"Kusunose Kenya"},{"name":"Zheng Robert"},{"name":"Yamaguchi Natsumi"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Saijyo Yoshihito"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"髙橋 智紀"},{"name":"楠瀬 賢也"},{"name":"Robert Zheng"},{"name":"山口 夏美"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Some cardiovascular (CV) risk factors, such as hypertension and diabetes mellitus, have been reported to reduce left ventricular (LV) longitudinal strain (LS) even in patients with preserved LV ejection fraction. We hypothesized that multiple CV risk factors might cause changes in myocardial strain. Our study aimed to assess the association between multiple CV risk factors and strain in patients without previous CV disease (CVD). We retrospectively evaluated 137 patients without CVD, who underwent echocardiography at our institution between May 2017 and February 2020. They were divided into four groups based on the number of risk factors (group 0: no risk factor, group 1: one risk factor, group 2: two risk factors, and groups 3: three or four risk factors). Risk factors were hypertension, dyslipidemia, diabetes mellitus, and chronic kidney disease. Absolute values of global LS (GLS) and relative apical LS ratio (RALSR) defined using the equation: average apical LS/(average basal LS + average mid LS) and was used as a marker of strain distribution. Out of 137 patients, group 0 had 35 patients, group 1 had 35 patients, group 2 had 32 patients, and group 3 had 35 patients. GLS was 22.4 ± 2.0%, 21.7 ± 2.1%, 21.3 ± 1.8%, 20.7 ± 2.2%, and RALSR was 0.64 ± 0.06, 0.66 ± 0.06, 0.68 ± 0.08, 0.69 ± 0.07 in groups 0-3, respectively. The one-way ANOVA detected significant differences between groups in GLS (p = 0.005) and RALSR (p = 0.037), respectively. Group 3 had a significantly lower GLS and higher RALSR than group 0 (p < 0.05). In patients without previous CVD, LS decreased especially from the basal segment as the number of cardiovascular risks increased. The segmental LS may be markers of occult LV dysfunction in patients with CV risk factors.","ja":"Some cardiovascular (CV) risk factors, such as hypertension and diabetes mellitus, have been reported to reduce left ventricular (LV) longitudinal strain (LS) even in patients with preserved LV ejection fraction. We hypothesized that multiple CV risk factors might cause changes in myocardial strain. Our study aimed to assess the association between multiple CV risk factors and strain in patients without previous CV disease (CVD). We retrospectively evaluated 137 patients without CVD, who underwent echocardiography at our institution between May 2017 and February 2020. They were divided into four groups based on the number of risk factors (group 0: no risk factor, group 1: one risk factor, group 2: two risk factors, and groups 3: three or four risk factors). Risk factors were hypertension, dyslipidemia, diabetes mellitus, and chronic kidney disease. Absolute values of global LS (GLS) and relative apical LS ratio (RALSR) defined using the equation: average apical LS/(average basal LS + average mid LS) and was used as a marker of strain distribution. Out of 137 patients, group 0 had 35 patients, group 1 had 35 patients, group 2 had 32 patients, and group 3 had 35 patients. GLS was 22.4 ± 2.0%, 21.7 ± 2.1%, 21.3 ± 1.8%, 20.7 ± 2.2%, and RALSR was 0.64 ± 0.06, 0.66 ± 0.06, 0.68 ± 0.08, 0.69 ± 0.07 in groups 0-3, respectively. The one-way ANOVA detected significant differences between groups in GLS (p = 0.005) and RALSR (p = 0.037), respectively. Group 3 had a significantly lower GLS and higher RALSR than group 0 (p < 0.05). In patients without previous CVD, LS decreased especially from the basal segment as the number of cardiovascular risks increased. The segmental LS may be markers of occult LV dysfunction in patients with CV risk factors."},"publication_date":"2022-12","publication_name":{"en":"Journal of Echocardiography","ja":"Journal of Echocardiography"},"volume":"Vol.20","number":"No.4","starting_page":"208","ending_page":"215","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12574-022-00576-7"],"issn":["1880-344X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117489","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36114704","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=392132","label":"url"}],"paper_title":{"en":"Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial","ja":"Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial"},"authors":{"en":[{"name":"Tanaka Atsushi"},{"name":"Imai Takumi"},{"name":"Shimabukuro Michio"},{"name":"Nakamura Ikuko"},{"name":"Matsunaga Kazuo"},{"name":"Ozaki Yukio"},{"name":"Minamino Tohru"},{"name":"Sata Masataka"},{"name":"Node Koichi"}],"ja":[{"name":"Tanaka Atsushi"},{"name":"Imai Takumi"},{"name":"Shimabukuro Michio"},{"name":"Nakamura Ikuko"},{"name":"Matsunaga Kazuo"},{"name":"Ozaki Yukio"},{"name":"Minamino Tohru"},{"name":"佐田 政隆"},{"name":"Node Koichi"}]},"description":{"en":"Clinical evidence is lacking about the influence of sodium-glucose cotransporter 2 inhibitors on white blood cell (WBC) counts, a commonly used and widely available marker of inflammation. The aim of the present analysis was to assess the effect of canagliflozin relative to glimepiride on WBC counts. This was a post-hoc subanalysis of the CANDLE trial (Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial; UMIN000017669), an investigator-initiated, multicenter, open-label, randomized, controlled trial. A total of 233 patients with type 2 diabetes and concomitant heart failure were randomly assigned to either canagliflozin (n = 113) or glimepiride (n = 120) treatment for 24 weeks. Overall, patient baseline characteristics were as follows: mean ± standard deviation age, 68.6 ± 10.1 years; hemoglobin A1c, 7.0 ± 0.9%; left ventricular ejection fraction, 56.7 ± 14.4%; and median N-terminal pro-brain natriuretic peptide, 252 pg/mL (interquartile range 96-563 pg/mL). The mean baseline WBC counts were 6704 cells/μL (95% confidence interval 6,362-7,047) in the canagliflozin group and 6322 cells/μL (95% confidence interval 5,991-6,654) in the glimepiride group. There were no significant differences between treatment groups in terms of changes in WBC counts from baseline to weeks 4 and 12. In contrast, a group difference (canagliflozin minus glimepiride) from baseline to week 24 was significant (mean difference - 456 cells/μL [95% confidence interval -774 to -139, P = 0.005]). Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure.","ja":"Clinical evidence is lacking about the influence of sodium-glucose cotransporter 2 inhibitors on white blood cell (WBC) counts, a commonly used and widely available marker of inflammation. The aim of the present analysis was to assess the effect of canagliflozin relative to glimepiride on WBC counts. This was a post-hoc subanalysis of the CANDLE trial (Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial; UMIN000017669), an investigator-initiated, multicenter, open-label, randomized, controlled trial. A total of 233 patients with type 2 diabetes and concomitant heart failure were randomly assigned to either canagliflozin (n = 113) or glimepiride (n = 120) treatment for 24 weeks. Overall, patient baseline characteristics were as follows: mean ± standard deviation age, 68.6 ± 10.1 years; hemoglobin A1c, 7.0 ± 0.9%; left ventricular ejection fraction, 56.7 ± 14.4%; and median N-terminal pro-brain natriuretic peptide, 252 pg/mL (interquartile range 96-563 pg/mL). The mean baseline WBC counts were 6704 cells/μL (95% confidence interval 6,362-7,047) in the canagliflozin group and 6322 cells/μL (95% confidence interval 5,991-6,654) in the glimepiride group. There were no significant differences between treatment groups in terms of changes in WBC counts from baseline to weeks 4 and 12. In contrast, a group difference (canagliflozin minus glimepiride) from baseline to week 24 was significant (mean difference - 456 cells/μL [95% confidence interval -774 to -139, P = 0.005]). Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure."},"publication_date":"2022-09-16","publication_name":{"en":"Journal of Diabetes Investigation","ja":"Journal of Diabetes Investigation"},"volume":"Vol.13","number":"No.12","starting_page":"1990","ending_page":"1999","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/jdi.13899"],"issn":["2040-1124"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117375","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35961594","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=389452","label":"url"}],"paper_title":{"en":"Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet.","ja":"Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet."},"authors":{"en":[{"name":"Bavuu O"},{"name":"Fukuda Daiju"},{"name":"Ganbaatar B"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"Bavuu Oyunbileg"},{"name":"福田 大受"},{"name":"GANBAATAR BYAMBASUREN"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Esaxerenone is a novel, non-steroidal selective mineralocorticoid receptor (Csige et al.) blocker. MR activation plays a crucial role in the development of cardiovascular and metabolic diseases. In this study, we investigated the effects of esaxerenone on various metabolic parameters in mice. Esaxerenone (3 mg/kg/day) was orally administered to high-fat diet (HFD)-fed male C57BL/6 mice. Mice fed a normal diet (ND) served as controls. Glucose and insulin tolerance, plasma lipid levels, and transaminase levels were assessed as metabolic parameters. Macrophage accumulation in the adipose tissue was evaluated using histological analysis. 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes were used for in vitro experiments. Gene expression and insulin signaling were examined using quantitative RT-PCR and western blotting, respectively. HFD successfully induced insulin resistance compared with that in ND. Esaxerenone ameliorated insulin resistance (P < 0.05) without altering other metabolic parameters, such as the lipid profile. Esaxerenone administration tended to decrease plasma transaminase levels compared with those in the non-treated group. In the adipose tissue, esaxerenone decreased macrophage accumulation (P < 0.05) and increased the expression levels of adiponectin and PPARγ. Aldosterone significantly decreased the expression levels of PPARγ and adiponectin in 3T3-L1 adipocytes. Furthermore, aldosterone attenuated insulin-induced Akt phosphorylation in 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes in a dose-dependent manner (P < 0.01). These effects were ameliorated by pretreatment with esaxerenone. Esaxerenone ameliorated insulin resistance in HFD-fed mice. Reduction of inflammation and improvement in insulin signaling may underlie the beneficial effects of esaxerenone.","ja":"Esaxerenone is a novel, non-steroidal selective mineralocorticoid receptor (Csige et al.) blocker. MR activation plays a crucial role in the development of cardiovascular and metabolic diseases. In this study, we investigated the effects of esaxerenone on various metabolic parameters in mice. Esaxerenone (3 mg/kg/day) was orally administered to high-fat diet (HFD)-fed male C57BL/6 mice. Mice fed a normal diet (ND) served as controls. Glucose and insulin tolerance, plasma lipid levels, and transaminase levels were assessed as metabolic parameters. Macrophage accumulation in the adipose tissue was evaluated using histological analysis. 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes were used for in vitro experiments. Gene expression and insulin signaling were examined using quantitative RT-PCR and western blotting, respectively. HFD successfully induced insulin resistance compared with that in ND. Esaxerenone ameliorated insulin resistance (P < 0.05) without altering other metabolic parameters, such as the lipid profile. Esaxerenone administration tended to decrease plasma transaminase levels compared with those in the non-treated group. In the adipose tissue, esaxerenone decreased macrophage accumulation (P < 0.05) and increased the expression levels of adiponectin and PPARγ. Aldosterone significantly decreased the expression levels of PPARγ and adiponectin in 3T3-L1 adipocytes. Furthermore, aldosterone attenuated insulin-induced Akt phosphorylation in 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes in a dose-dependent manner (P < 0.01). These effects were ameliorated by pretreatment with esaxerenone. Esaxerenone ameliorated insulin resistance in HFD-fed mice. Reduction of inflammation and improvement in insulin signaling may underlie the beneficial effects of esaxerenone."},"publication_date":"2022-09-15","publication_name":{"en":"European Journal of Pharmacology","ja":"European Journal of Pharmacology"},"starting_page":"175190","ending_page":"175190","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ejphar.2022.175190"],"issn":["1879-0712"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118561","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36176986","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402889","label":"url"}],"paper_title":{"en":"Expanding role of deoxyribonucleic acid-sensing mechanism in the development of lifestyle-related diseases","ja":"Expanding role of deoxyribonucleic acid-sensing mechanism in the development of lifestyle-related diseases"},"authors":{"en":[{"name":"Nishimoto Sachiko"},{"name":"Sata Masataka"},{"name":"Fukuda Daiju"}],"ja":[{"name":"西本 幸子"},{"name":"佐田 政隆"},{"name":"福田 大受"}]},"description":{"en":"In lifestyle-related diseases, such as cardiovascular, metabolic, respiratory, and kidney diseases, chronic inflammation plays a causal role in their pathogenesis; however, underlying mechanisms of sterile chronic inflammation are not well-understood. Previous studies have confirmed the damage of cells in these organs in the presence of various risk factors such as diabetes, dyslipidemia, and cigarette smoking, releasing various endogenous ligands for pattern recognition receptors. These studies suggested that nucleic acids released from damaged tissues accumulate in these tissues, acting as an endogenous ligand. Undamaged DNA is an integral factor for the sustenance of life, whereas, DNA fragments, especially those from pathogens, are potent activators of the inflammatory response. Recent studies have indicated that inflammatory responses such as the production of type I interferon (IFN) induced by DNA-sensing mechanisms which contributes to self-defense system in innate immunity participates in the progression of inflammatory diseases by the recognition of nucleic acids derived from the host, including mitochondrial DNA (mtDNA). The body possesses several types of DNA sensors. Toll-like receptor 9 (TLR9) recognizes DNA fragments in the endosomes. In addition, the binding of DNA fragments in the cytosol activates cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS), resulting in the synthesis of the second messenger cyclic GMP-AMP (cGAMP). The binding of cGAMP to stimulator of interferon genes (STING) activates NF-κB and TBK-1 signaling and consequently the production of many inflammatory cytokines including IFNs. Numerous previous studies have demonstrated the role of DNA sensors in self-defense through the recognition of DNA fragments derived from pathogens. Beyond the canonical role of TLR9 and cGAS-STING, this review describes the role of these DNA-sensing mechanism in the inflammatory responses caused by endogenous DNA fragments, and in the pathogenesis of lifestyle-related diseases.","ja":"In lifestyle-related diseases, such as cardiovascular, metabolic, respiratory, and kidney diseases, chronic inflammation plays a causal role in their pathogenesis; however, underlying mechanisms of sterile chronic inflammation are not well-understood. Previous studies have confirmed the damage of cells in these organs in the presence of various risk factors such as diabetes, dyslipidemia, and cigarette smoking, releasing various endogenous ligands for pattern recognition receptors. These studies suggested that nucleic acids released from damaged tissues accumulate in these tissues, acting as an endogenous ligand. Undamaged DNA is an integral factor for the sustenance of life, whereas, DNA fragments, especially those from pathogens, are potent activators of the inflammatory response. Recent studies have indicated that inflammatory responses such as the production of type I interferon (IFN) induced by DNA-sensing mechanisms which contributes to self-defense system in innate immunity participates in the progression of inflammatory diseases by the recognition of nucleic acids derived from the host, including mitochondrial DNA (mtDNA). The body possesses several types of DNA sensors. Toll-like receptor 9 (TLR9) recognizes DNA fragments in the endosomes. In addition, the binding of DNA fragments in the cytosol activates cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS), resulting in the synthesis of the second messenger cyclic GMP-AMP (cGAMP). The binding of cGAMP to stimulator of interferon genes (STING) activates NF-κB and TBK-1 signaling and consequently the production of many inflammatory cytokines including IFNs. Numerous previous studies have demonstrated the role of DNA sensors in self-defense through the recognition of DNA fragments derived from pathogens. Beyond the canonical role of TLR9 and cGAS-STING, this review describes the role of these DNA-sensing mechanism in the inflammatory responses caused by endogenous DNA fragments, and in the pathogenesis of lifestyle-related diseases."},"publication_date":"2022-09-13","publication_name":{"en":"Frontiers in Cardiovascular Medicine","ja":"Frontiers in Cardiovascular Medicine"},"volume":"Vol.9","starting_page":"881181","ending_page":"881181","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fcvm.2022.881181"],"issn":["2297-055X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118008","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36017722","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391649","label":"url"}],"paper_title":{"en":"Clinical course and decision-making in heart failure by preload stress echocardiography: a preliminary study","ja":"Clinical course and decision-making in heart failure by preload stress echocardiography: a preliminary study"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Saijo Y"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"西條 良仁"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Abnormal left ventricular diastolic response to preload stress can be an early marker of heart failure (HF). The aim of this study was to assess clinical course in patients with HF with preserved ejection fraction (HFpEF) who underwent preload stress echocardiography. In the subgroup analysis, we assessed the prognosis of patients with unstable signs during preload stress classified by treatment strategies. We prospectively conducted preload stress echocardiographic studies between January 2006 and December 2013 in 211 patients with HFpEF. Fifty-eight patients had abnormal diastolic reserve during preload stress (unstable impaired relaxation: unstable IR). Of 58 patients with unstable IR, 19 patients were assigned to additional therapy by increased or additional therapy and 39 patients were assigned to standard therapy. Composite outcomes were prespecified as the primary endpoint of death and hospitalization for deteriorating HF. During a median period of 6.9 years, 19 patients (33%) reached the composite outcome. Unstable group with standard therapy had significantly shorter event-free survival than stable group. Patients with uptitration of therapy had longer event-free survival than those with standard therapy group after adjustment of laboratory data (hazard ratio, 0.20, 95% confidence interval, 0.05-0.90; P = 0.036); the 10 year event-free survival in patients with and without uptitration of therapy was 93% and 51%, respectively (P = 0.023). Patients with unstable sign had significantly shorter event-free survival than patients with stable sign. After additional therapy, the prognosis of patients with unstable signs improved. This technique may impact decision-making for improving their prognosis.","ja":"Abnormal left ventricular diastolic response to preload stress can be an early marker of heart failure (HF). The aim of this study was to assess clinical course in patients with HF with preserved ejection fraction (HFpEF) who underwent preload stress echocardiography. In the subgroup analysis, we assessed the prognosis of patients with unstable signs during preload stress classified by treatment strategies. We prospectively conducted preload stress echocardiographic studies between January 2006 and December 2013 in 211 patients with HFpEF. Fifty-eight patients had abnormal diastolic reserve during preload stress (unstable impaired relaxation: unstable IR). Of 58 patients with unstable IR, 19 patients were assigned to additional therapy by increased or additional therapy and 39 patients were assigned to standard therapy. Composite outcomes were prespecified as the primary endpoint of death and hospitalization for deteriorating HF. During a median period of 6.9 years, 19 patients (33%) reached the composite outcome. Unstable group with standard therapy had significantly shorter event-free survival than stable group. Patients with uptitration of therapy had longer event-free survival than those with standard therapy group after adjustment of laboratory data (hazard ratio, 0.20, 95% confidence interval, 0.05-0.90; P = 0.036); the 10 year event-free survival in patients with and without uptitration of therapy was 93% and 51%, respectively (P = 0.023). Patients with unstable sign had significantly shorter event-free survival than patients with stable sign. After additional therapy, the prognosis of patients with unstable signs improved. This technique may impact decision-making for improving their prognosis."},"publication_date":"2022-08-26","publication_name":{"en":"ESC Heart Failure","ja":"ESC Heart Failure"},"volume":"Vol.9","number":"No.6","starting_page":"4020","ending_page":"4029","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/ehf2.14127"],"issn":["2055-5822"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117809","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35871575","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387783","label":"url"}],"paper_title":{"en":"Effect of Novel Stratified Lipid Risk by \"LDL-Window\" and Flow-Mediated Dilation on the Prognosis of Coronary Artery Disease Using the FMD-J Study A Data","ja":"Effect of Novel Stratified Lipid Risk by \"LDL-Window\" and Flow-Mediated Dilation on the Prognosis of Coronary Artery Disease Using the FMD-J Study A Data"},"authors":{"en":[{"name":"Abe S"},{"name":"Haruyama Y"},{"name":"Kobashi G"},{"name":"Toyoda S"},{"name":"Inoue T"},{"name":"Tomiyama H"},{"name":"Ishizu T"},{"name":"Kohro T"},{"name":"Higashi Y"},{"name":"Takase B"},{"name":"Suzuki T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Koba S"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"Sata Masataka"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Yamashina A"}],"ja":[{"name":"Abe S"},{"name":"Haruyama Y"},{"name":"Kobashi G"},{"name":"Toyoda S"},{"name":"Inoue T"},{"name":"Tomiyama H"},{"name":"Ishizu T"},{"name":"Kohro T"},{"name":"Higashi Y"},{"name":"Takase B"},{"name":"Suzuki T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Koba S"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"佐田 政隆"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Yamashina A"}]},"description":{"en":"Elevated levels of triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) are regarded as a residual lipid risk in low-density lipoprotein cholesterol (LDL-C)-lowering therapy. This study investigated the association between lipid risk stratified by TG and non-HDL-C and the prognosis of patients with coronary artery disease (CAD), and the association between stratified lipid risk and flow-mediated dilatation (FMD) index.Methods and Results: The 624 CAD patients enrolled in flow-mediated dilation (FMD)-J study A were divided into 4 groups: low-risk group (n=413) with TG <150 mg/dL and non-HDL-C <170 mg/dL; hyper-TG group (n=180) with TG 150 mg/dL and non-HDL-C <170 mg/dL; hyper-non-HDL group (n=12) with TG <150 mg/dL and non-HDL-C 170 mg/dL; and high-risk group (n=19) with TG 150 mg/dL and non-HDL-C 170 mg/dL. Comparison of the groups showed the cumulative incidence of a 3-point major adverse cardiovascular event (MACE) was different and highest in the high-risk group in all the patients (P=0.009), and in patients with a FMD index 7.0% (P=0.021), but not in those with a FMD index <7.0%. Multivariable regression analysis showed that high lipid risk (P=0.019) and FMD <7.0% (P=0.040) were independently correlated with the incidence of a 3-point MACE. Novel stratification of lipid risk, simply using TG and non-HDL-C levels, combined with FMD measurement, is useful for predicting cardiovascular outcomes in patients with CAD.","ja":"Elevated levels of triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) are regarded as a residual lipid risk in low-density lipoprotein cholesterol (LDL-C)-lowering therapy. This study investigated the association between lipid risk stratified by TG and non-HDL-C and the prognosis of patients with coronary artery disease (CAD), and the association between stratified lipid risk and flow-mediated dilatation (FMD) index.Methods and Results: The 624 CAD patients enrolled in flow-mediated dilation (FMD)-J study A were divided into 4 groups: low-risk group (n=413) with TG <150 mg/dL and non-HDL-C <170 mg/dL; hyper-TG group (n=180) with TG 150 mg/dL and non-HDL-C <170 mg/dL; hyper-non-HDL group (n=12) with TG <150 mg/dL and non-HDL-C 170 mg/dL; and high-risk group (n=19) with TG 150 mg/dL and non-HDL-C 170 mg/dL. Comparison of the groups showed the cumulative incidence of a 3-point major adverse cardiovascular event (MACE) was different and highest in the high-risk group in all the patients (P=0.009), and in patients with a FMD index 7.0% (P=0.021), but not in those with a FMD index <7.0%. Multivariable regression analysis showed that high lipid risk (P=0.019) and FMD <7.0% (P=0.040) were independently correlated with the incidence of a 3-point MACE. Novel stratification of lipid risk, simply using TG and non-HDL-C levels, combined with FMD measurement, is useful for predicting cardiovascular outcomes in patients with CAD."},"publication_date":"2022-08-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.86","number":"No.9","starting_page":"1444","ending_page":"1454","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-21-1068"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117802","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35884961","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387782","label":"url"}],"paper_title":{"en":"Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial","ja":"Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial"},"authors":{"en":[{"name":"Sezai A"},{"name":"Tanaka A"},{"name":"Imai T"},{"name":"Kida K"},{"name":"Sekino H"},{"name":"Murohara T"},{"name":"Sata Masataka"},{"name":"Suzuki N"},{"name":"Node K"}],"ja":[{"name":"Sezai A"},{"name":"Tanaka A"},{"name":"Imai T"},{"name":"Kida K"},{"name":"Sekino H"},{"name":"Murohara T"},{"name":"佐田 政隆"},{"name":"Suzuki N"},{"name":"Node K"}]},"description":{"en":"We present results of a 24-week comparative study of the effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin vs. the sulfonylurea glimepiride, by baseline body mass index (BMI), in patients with type 2 diabetes and chronic heart failure. We conducted a post hoc analysis of the CANDLE trial. This subanalysis evaluated NT-proBNP, BMI, and other laboratory parameters, according to the subgroups stratified by BMI ≥ 25 kg/m vs. BMI < 25 kg/m. A group ratio of proportional changes in the geometric means of NT-proBNP was 0.99 ( = 0.940) for the subgroup with BMI ≥ 25 kg/m and 0.85 ( = 0.075) for the subgroup with BMI < 25 kg/m, respectively. When baseline BMI was modeled as a continuous variable, results for patients with BMI < 30 kg/m showed a slightly smaller increase in NT-proBNP in the canagliflozin group vs. the glimepiride group ( = 0.295); that difference was not seen among patients with BMI ≥30 kg/m ( = 0.948). Irrespective of obesity, the canagliflozin group was associated with significant reduction in BMI compared to the glimepiride group. There was no significant difference in the effects of canagliflozin, relative to glimepiride, on NT-proBNP concentrations irrespective of baseline obesity. UMIN clinical trial registration number: UMIN000017669.","ja":"We present results of a 24-week comparative study of the effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin vs. the sulfonylurea glimepiride, by baseline body mass index (BMI), in patients with type 2 diabetes and chronic heart failure. We conducted a post hoc analysis of the CANDLE trial. This subanalysis evaluated NT-proBNP, BMI, and other laboratory parameters, according to the subgroups stratified by BMI ≥ 25 kg/m vs. BMI < 25 kg/m. A group ratio of proportional changes in the geometric means of NT-proBNP was 0.99 ( = 0.940) for the subgroup with BMI ≥ 25 kg/m and 0.85 ( = 0.075) for the subgroup with BMI < 25 kg/m, respectively. When baseline BMI was modeled as a continuous variable, results for patients with BMI < 30 kg/m showed a slightly smaller increase in NT-proBNP in the canagliflozin group vs. the glimepiride group ( = 0.295); that difference was not seen among patients with BMI ≥30 kg/m ( = 0.948). Irrespective of obesity, the canagliflozin group was associated with significant reduction in BMI compared to the glimepiride group. There was no significant difference in the effects of canagliflozin, relative to glimepiride, on NT-proBNP concentrations irrespective of baseline obesity. UMIN clinical trial registration number: UMIN000017669."},"publication_date":"2022-07-09","publication_name":{"en":"Biomedicines","ja":"Biomedicines"},"volume":"Vol.10","number":"No.7","starting_page":"1656","ending_page":"1656","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/biomedicines10071656"],"issn":["2227-9059"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117321","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34853214","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383575","label":"url"}],"paper_title":{"en":"Give a Leg Up: Screening for Peripheral Artery Disease after Acute Myocardial Infarction","ja":"Give a Leg Up: Screening for Peripheral Artery Disease after Acute Myocardial Infarction"},"authors":{"en":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"Sata Masataka"}],"ja":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"佐田 政隆"}]},"publication_date":"2022-07-01","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.29","number":"No.7","starting_page":"989","ending_page":"991","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.ED186"],"issn":["1340-3478"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117234","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85127324683&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386326","label":"url"}],"paper_title":{"en":"Drug-coated balloon angioplasty for severe pulmonary vein stenosis resulting from cryoballoon ablation for atrial fibrillation","ja":"Drug-coated balloon angioplasty for severe pulmonary vein stenosis resulting from cryoballoon ablation for atrial fibrillation"},"authors":{"en":[{"name":"Yamaguchi Koji"},{"name":"Wakatsuki Tetsuzo"},{"name":"Matsuura Tomomi"},{"name":"Matsumoto Kazuhisa"},{"name":"Kawabata Yutaka"},{"name":"Kadota Muneyuki"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"山口 浩司"},{"name":"若槻 哲三"},{"name":"松浦 朋美"},{"name":"松本 和久"},{"name":"川端 豊"},{"name":"門田 宗之"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"publication_date":"2022-07","publication_name":{"en":"Journal of Cardiology Cases","ja":"Journal of Cardiology Cases"},"volume":"Vol.26","starting_page":"35","ending_page":"38","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jccase.2022.02.009"],"issn":["1878-5409"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34927214","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383570","label":"url"}],"paper_title":{"en":"Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism","ja":"Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism"},"authors":{"en":[{"name":"Okushi Y"},{"name":"Kusunose Kenya"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"大櫛 祐一郎"},{"name":"楠瀬 賢也"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician's discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose. We aimed to compare the mortality associated with the use of rivaroxaban, edoxaban, and apixaban in clinical practice. We identified 38,245 patients with first hospitalization for VTE from the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). We classified patients into three groups by DOAC (rivaroxaban and edoxaban group, rivaroxaban and apixaban group, and edoxaban and apixaban group) and compared the in-hospital mortality and bleeding risk by propensity score (PS) matching in each group. After PS matching, patients with rivaroxaban use had significantly lower total in-hospital mortality (1.2% vs. 2.1%; odds ratio [OR] 0.55, p = 0.012) and in-hospital mortality within 21 days (0.4% vs. 1.0%; OR 0.41, p = 0.020) and 28 days (0.7% vs. 1.3%; OR 0.53, p = 0.042) than patients with apixaban use. In the subanalysis, significant differences were only observed in patients younger than 80 years of age, patients with pulmonary embolism, and patients without heart failure. There was no significant difference in in-hospital mortality in the other groups and in the rate of bleeding events among the three groups. On PS-matched analysis, there was a difference in in-hospital mortality, especially in the rivaroxaban and apixaban group. Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE.","ja":"The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician's discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose. We aimed to compare the mortality associated with the use of rivaroxaban, edoxaban, and apixaban in clinical practice. We identified 38,245 patients with first hospitalization for VTE from the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). We classified patients into three groups by DOAC (rivaroxaban and edoxaban group, rivaroxaban and apixaban group, and edoxaban and apixaban group) and compared the in-hospital mortality and bleeding risk by propensity score (PS) matching in each group. After PS matching, patients with rivaroxaban use had significantly lower total in-hospital mortality (1.2% vs. 2.1%; odds ratio [OR] 0.55, p = 0.012) and in-hospital mortality within 21 days (0.4% vs. 1.0%; OR 0.41, p = 0.020) and 28 days (0.7% vs. 1.3%; OR 0.53, p = 0.042) than patients with apixaban use. In the subanalysis, significant differences were only observed in patients younger than 80 years of age, patients with pulmonary embolism, and patients without heart failure. There was no significant difference in in-hospital mortality in the other groups and in the rate of bleeding events among the three groups. On PS-matched analysis, there was a difference in in-hospital mortality, especially in the rivaroxaban and apixaban group. Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE."},"publication_date":"2022-07","publication_name":{"en":"American Journal of Cardiovascular Drugs","ja":"American Journal of Cardiovascular Drugs"},"volume":"Vol.22","number":"No.4","starting_page":"407","ending_page":"416","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s40256-021-00514-5"],"issn":["1179-187X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117225","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35783826","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386256","label":"url"}],"paper_title":{"en":"Deep Learning for Detection of Exercise-Induced Pulmonary Hypertension Using Chest X-Ray Images","ja":"Deep Learning for Detection of Exercise-Induced Pulmonary Hypertension Using Chest X-Ray Images"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Hirata Yukina"},{"name":"Yamaguchi Natsumi"},{"name":"Kosaka Y"},{"name":"Tsuji T"},{"name":"Kotoku J"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"平田 有紀奈"},{"name":"山口 夏美"},{"name":"髙坂 佳孝"},{"name":"Tsuji T"},{"name":"Kotoku J"},{"name":"佐田 政隆"}]},"description":{"en":"Stress echocardiography is an emerging tool used to detect exercise-induced pulmonary hypertension (EIPH). However, facilities that can perform stress echocardiography are limited by issues such as cost and equipment. We evaluated the usefulness of a deep learning (DL) approach based on a chest X-ray (CXR) to predict EIPH in 6-min walk stress echocardiography. The study enrolled 142 patients with scleroderma or mixed connective tissue disease with scleroderma features who performed a 6-min walk stress echocardiographic test. EIPH was defined by abnormal cardiac output (CO) responses that involved an increase in mean pulmonary artery pressure (mPAP). We used the previously developed AI model to predict PH and calculated PH probability in this cohort. EIPH defined as ΔmPAP/ΔCO >3.3 and exercise mPAP >25 mmHg was observed in 52 patients, while non-EIPH was observed in 90 patients. The patients with EIPH had a higher mPAP at rest than those without EIPH. The probability of PH based on the DL model was significantly higher in patients with EIPH than in those without EIPH. Multivariate analysis showed that gender, mean PAP at rest, and the probability of PH based on the DL model were independent predictors of EIPH. A model based on baseline parameters (age, gender, and mPAP at rest) was improved by adding the probability of PH predicted by the DL model (AUC: from 0.65 to 0.74; = 0.046). Applying the DL model based on a CXR may have a potential for detection of EIPH in the clinical setting.","ja":"Stress echocardiography is an emerging tool used to detect exercise-induced pulmonary hypertension (EIPH). However, facilities that can perform stress echocardiography are limited by issues such as cost and equipment. We evaluated the usefulness of a deep learning (DL) approach based on a chest X-ray (CXR) to predict EIPH in 6-min walk stress echocardiography. The study enrolled 142 patients with scleroderma or mixed connective tissue disease with scleroderma features who performed a 6-min walk stress echocardiographic test. EIPH was defined by abnormal cardiac output (CO) responses that involved an increase in mean pulmonary artery pressure (mPAP). We used the previously developed AI model to predict PH and calculated PH probability in this cohort. EIPH defined as ΔmPAP/ΔCO >3.3 and exercise mPAP >25 mmHg was observed in 52 patients, while non-EIPH was observed in 90 patients. The patients with EIPH had a higher mPAP at rest than those without EIPH. The probability of PH based on the DL model was significantly higher in patients with EIPH than in those without EIPH. Multivariate analysis showed that gender, mean PAP at rest, and the probability of PH based on the DL model were independent predictors of EIPH. A model based on baseline parameters (age, gender, and mPAP at rest) was improved by adding the probability of PH predicted by the DL model (AUC: from 0.65 to 0.74; = 0.046). Applying the DL model based on a CXR may have a potential for detection of EIPH in the clinical setting."},"publication_date":"2022-06-15","publication_name":{"en":"Frontiers in Cardiovascular Medicine","ja":"Frontiers in Cardiovascular Medicine"},"volume":"Vol.9","starting_page":"891703","ending_page":"891703","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fcvm.2022.891703"],"issn":["2297-055X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35365797","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384946","label":"url"}],"paper_title":{"en":"Linking RNA dynamics to heart disease: the lncRNA/miRNA/mRNA axis in myocardial ischemia-reperfusion injury","ja":"Linking RNA dynamics to heart disease: the lncRNA/miRNA/mRNA axis in myocardial ischemia-reperfusion injury"},"authors":{"en":[{"name":"Liu W"},{"name":"Higashikuni Y"},{"name":"Sata Masataka"}],"ja":[{"name":"Liu W"},{"name":"Higashikuni Y"},{"name":"佐田 政隆"}]},"publication_date":"2022-06","publication_name":{"en":"Hypertension Research","ja":"Hypertension Research"},"volume":"Vol.45","number":"No.6","starting_page":"1067","ending_page":"1069","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41440-022-00905-4"],"issn":["1348-4214"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118012","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34670901","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382775","label":"url"}],"paper_title":{"en":"Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood.","ja":"Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood."},"authors":{"en":[{"name":"Mitsui Yasuhiro"},{"name":"Yagi Mai"},{"name":"Muraki Sho"},{"name":"Matsuura Tomomi"},{"name":"Bando Yoshimi"},{"name":"Fujimoto Shota"},{"name":"Kitamura Shinji"},{"name":"Okamoto Koichi"},{"name":"Muguruma Naoki"},{"name":"Sata Masataka"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"三井 康裕"},{"name":"Yagi Mai"},{"name":"村木 翔"},{"name":"松浦 朋美"},{"name":"坂東 良美"},{"name":"藤本 将太"},{"name":"北村 晋志"},{"name":"岡本 耕一"},{"name":"六車 直樹"},{"name":"佐田 政隆"},{"name":"高山 哲治"}]},"publication_date":"2022-05-15","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"volume":"Vol.61","number":"No.10","starting_page":"1491","ending_page":"1495","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.8313-21"],"issn":["0918-2918"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117213","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35283367","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384745","label":"url"}],"paper_title":{"en":"Impact of Tweeting Summaries by the Japanese Circulation Society Official Account on Article Viewership - Pilot Trial","ja":"Impact of Tweeting Summaries by the Japanese Circulation Society Official Account on Article Viewership - Pilot Trial"},"authors":{"en":[{"name":"Mizuno A"},{"name":"Kusunose Kenya"},{"name":"Kishi T"},{"name":"Rewley J"},{"name":"Matsumoto C"},{"name":"Sahashi Y"},{"name":"Ishida M"},{"name":"Sanada S"},{"name":"Fukuda M"},{"name":"Sugimoto T"},{"name":"Hirano M"},{"name":"Yoneoka D"},{"name":"Sata Masataka"},{"name":"Anzai T"},{"name":"Node K"}],"ja":[{"name":"Mizuno A"},{"name":"楠瀬 賢也"},{"name":"Kishi T"},{"name":"Rewley J"},{"name":"Matsumoto C"},{"name":"Sahashi Y"},{"name":"Ishida M"},{"name":"Sanada S"},{"name":"Fukuda M"},{"name":"Sugimoto T"},{"name":"Hirano M"},{"name":"Yoneoka D"},{"name":"佐田 政隆"},{"name":"Anzai T"},{"name":"Node K"}]},"description":{"en":"The impact of promotional tweets from the official journal account (forCirculation JournalandCirculation Reports) on article viewership has not been thoroughly evaluated.Methods and Results:We retrospectively collected journal viewership data forCirculation JournalandCirculation Reportsfrom March 2021 to August 2021. We compared viewership between articles with (n=15) and without (n=250) tweets. After 1 : 4 propensity score matching (15 tweeted articles and 60 non-tweeted matched controls), journal viewership metrics within 7 days of the tweeting date (and the hypothetical tweeting date), was larger in tweeted articles than non-tweeted articles (median [interquartile range] Abstract page views 89 [60-104] vs. 18 [8-41]). This pilot study suggests a positive relationship between journal-posted promotional tweets and article viewership.","ja":"The impact of promotional tweets from the official journal account (forCirculation JournalandCirculation Reports) on article viewership has not been thoroughly evaluated.Methods and Results:We retrospectively collected journal viewership data forCirculation JournalandCirculation Reportsfrom March 2021 to August 2021. We compared viewership between articles with (n=15) and without (n=250) tweets. After 1 : 4 propensity score matching (15 tweeted articles and 60 non-tweeted matched controls), journal viewership metrics within 7 days of the tweeting date (and the hypothetical tweeting date), was larger in tweeted articles than non-tweeted articles (median [interquartile range] Abstract page views 89 [60-104] vs. 18 [8-41]). This pilot study suggests a positive relationship between journal-posted promotional tweets and article viewership."},"publication_date":"2022-03-12","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.86","number":"No.4","starting_page":"715","ending_page":"720","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-21-0944"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116996","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34248111","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384441","label":"url"}],"paper_title":{"en":"Emerging Roles of the Innate Immune System Regulated by DNA Sensors in the Development of Vascular and Metabolic Diseases","ja":"Emerging Roles of the Innate Immune System Regulated by DNA Sensors in the Development of Vascular and Metabolic Diseases"},"authors":{"en":[{"name":"Fukuda Daiju"},{"name":"Pham PT"},{"name":"Sata Masataka"}],"ja":[{"name":"福田 大受"},{"name":"Pham PT"},{"name":"佐田 政隆"}]},"description":{"en":"Sterile chronic inflammation causes cardiometabolic disorders; however, the mechanisms are not fully understood. Previous studies have demonstrated the degradation of cells/tissues in the vasculature and metabolic organs in lifestyle-associated diseases, such as diabetes and hyperlipidemia, suggesting the release and/or accumulation of nucleic acids from damaged cells. DNA is indispensable for life; however, DNA fragments, especially those from pathogens, strongly induce inflammation by the activation of DNA sensors. Growing evidence suggests that DNA-sensing mechanisms, which are normally involved in self-defense against pathogens as the innate immune system, are associated with the progression of inflammatory diseases in response to endogenous DNA fragments. There are several types of DNA sensors in our bodies. Toll-like receptor 9 (TLR9)-one of the most studied DNA sensors-recognizes DNA fragments in endosome. In addition, stimulator of interferon genes (STING), which has recently been extensively investigated, recognizes cyclic GMP-AMP (cGAMP) generated from DNA fragments in the cytosol. Both TLR9 and STING are known to play pivotal roles in host defense as the innate immune system. However, recent studies have indicated that the activation of these DNA sensors in immune cells, such as macrophages, promotes inflammation leading to the development of vascular and metabolic diseases associated with lifestyle. In this review, we discuss recent advances in determining the roles of DNA sensors in these disease contexts. Revealing a novel mechanism of sterile chronic inflammation regulated by DNA sensors might facilitate clinical interventions for these health conditions.","ja":"Sterile chronic inflammation causes cardiometabolic disorders; however, the mechanisms are not fully understood. Previous studies have demonstrated the degradation of cells/tissues in the vasculature and metabolic organs in lifestyle-associated diseases, such as diabetes and hyperlipidemia, suggesting the release and/or accumulation of nucleic acids from damaged cells. DNA is indispensable for life; however, DNA fragments, especially those from pathogens, strongly induce inflammation by the activation of DNA sensors. Growing evidence suggests that DNA-sensing mechanisms, which are normally involved in self-defense against pathogens as the innate immune system, are associated with the progression of inflammatory diseases in response to endogenous DNA fragments. There are several types of DNA sensors in our bodies. Toll-like receptor 9 (TLR9)-one of the most studied DNA sensors-recognizes DNA fragments in endosome. In addition, stimulator of interferon genes (STING), which has recently been extensively investigated, recognizes cyclic GMP-AMP (cGAMP) generated from DNA fragments in the cytosol. Both TLR9 and STING are known to play pivotal roles in host defense as the innate immune system. However, recent studies have indicated that the activation of these DNA sensors in immune cells, such as macrophages, promotes inflammation leading to the development of vascular and metabolic diseases associated with lifestyle. In this review, we discuss recent advances in determining the roles of DNA sensors in these disease contexts. Revealing a novel mechanism of sterile chronic inflammation regulated by DNA sensors might facilitate clinical interventions for these health conditions."},"publication_date":"2022-03-01","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.29","number":"No.3","starting_page":"297","ending_page":"307","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.RV17059"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116382","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34231099","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376717","label":"url"}],"paper_title":{"en":"Evaluation of the input site and characteristics of the antegrade fast pathway based on three-dimensional bi-atrial stimulus-ventricle mapping","ja":"Evaluation of the input site and characteristics of the antegrade fast pathway based on three-dimensional bi-atrial stimulus-ventricle mapping"},"authors":{"en":[{"name":"Matsumoto Kazuhisa"},{"name":"Tobiume Takeshi"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Wakatsuki Tetsuzo"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"松本 和久"},{"name":"飛梅 威"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"若槻 哲三"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"Previous studies examined the right atrial (RA) input site of the antegrade fast pathway (AFp) (AFpI). However, the left atrial (LA) input to the atrioventricular (AV) node has not been extensively evaluated. In this study, we created three-dimensional (3-D) bi-atrial stimulus-ventricle (St-V) maps and analyzed the input site and characteristics of the AFp in both the RA and LA. Forty-four patients diagnosed with atrial fibrillation or WPW syndrome were included in this study. Three-dimensional bi-atrial St-V mapping was performed using an electroanatomical mapping system. Sites exhibiting the minimal St-V interval (MinSt-V) were defined as AFpIs and were classified into seven segments, four in the RA (F, S, M, and I) and three in the LA (M1, M2, and M3). By combining the MinSt-V in the RA and LA, the AFpIs were classified into three types: RA, LA, and bi-atrial (BA) types. The clinical and electrophysiological characteristics were compared. AFpIs were most frequently observed at site S in the RA (34%) and M2 in the LA (50%), and the BA type was the most common (57%). AFpIs in the LA were recognized in 75% of the patients. There were no clinical or electrophysiological indicators for predicting AFpI sites. Three-dimensional bi-atrial St-V maps could classify AFpIs in both the RA and LA. AFpIs in the LA were frequently recognized. There were no significant clinical or electrophysiological indicators for predicting AFpI sites, and 3-D bi-atrial St-V mapping was the only method to reveal the precise AFp input site.","ja":"Previous studies examined the right atrial (RA) input site of the antegrade fast pathway (AFp) (AFpI). However, the left atrial (LA) input to the atrioventricular (AV) node has not been extensively evaluated. In this study, we created three-dimensional (3-D) bi-atrial stimulus-ventricle (St-V) maps and analyzed the input site and characteristics of the AFp in both the RA and LA. Forty-four patients diagnosed with atrial fibrillation or WPW syndrome were included in this study. Three-dimensional bi-atrial St-V mapping was performed using an electroanatomical mapping system. Sites exhibiting the minimal St-V interval (MinSt-V) were defined as AFpIs and were classified into seven segments, four in the RA (F, S, M, and I) and three in the LA (M1, M2, and M3). By combining the MinSt-V in the RA and LA, the AFpIs were classified into three types: RA, LA, and bi-atrial (BA) types. The clinical and electrophysiological characteristics were compared. AFpIs were most frequently observed at site S in the RA (34%) and M2 in the LA (50%), and the BA type was the most common (57%). AFpIs in the LA were recognized in 75% of the patients. There were no clinical or electrophysiological indicators for predicting AFpI sites. Three-dimensional bi-atrial St-V maps could classify AFpIs in both the RA and LA. AFpIs in the LA were frequently recognized. There were no significant clinical or electrophysiological indicators for predicting AFpI sites, and 3-D bi-atrial St-V mapping was the only method to reveal the precise AFp input site."},"publication_date":"2022-03","publication_name":{"en":"Journal of Interventional Cardiac Electrophysiology","ja":"Journal of Interventional Cardiac Electrophysiology"},"volume":"Vol.63","number":"No.2","starting_page":"417","ending_page":"424","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10840-021-01026-7"],"issn":["1572-8595"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35095031","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85125252399&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384440","label":"url"}],"paper_title":{"en":"JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease","ja":"JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease"},"authors":{"en":[{"name":"Nakamura Masato"},{"name":"Yaku Hitoshi"},{"name":"Ako Junya"},{"name":"Arai Hirokuni"},{"name":"Asai Tohru"},{"name":"Chikamori Taishiro"},{"name":"Daida Hiroyuki"},{"name":"Doi Kiyoshi"},{"name":"Fukui Toshihiro"},{"name":"Ito Toshiaki"},{"name":"Kadota Kazushige"},{"name":"Kobayashi Junjiro"},{"name":"Komiya Tatsuhiko"},{"name":"Kozuma Ken"},{"name":"Nakagawa Yoshihisa"},{"name":"Nakao Koichi"},{"name":"Niinami Hiroshi"},{"name":"Ohno Takayuki"},{"name":"Ozaki Yukio"},{"name":"Sata Masataka"},{"name":"Takanashi Shuichiro"},{"name":"Takemura Hirofumi"},{"name":"Ueno Takafumi"},{"name":"Yasuda Satoshi"},{"name":"Yokoyama Hitoshi"},{"name":"Fujita Tomoyuki"},{"name":"Kasai Tokuo"},{"name":"Kohsaka Shun"},{"name":"Kubo Takashi"},{"name":"Manabe Susumu"},{"name":"Matsumoto Naoya"},{"name":"Miyagawa Shigeru"},{"name":"Mizuno Tomohiro"},{"name":"Motomura Noboru"},{"name":"Numata Satoshi"},{"name":"Nakajima Hiroyuki"},{"name":"Oda Hirotaka"},{"name":"Otake Hiromasa"},{"name":"Otsuka Fumiyuki"},{"name":"Sasaki Ken-Ichiro"},{"name":"Shimada Kazunori"},{"name":"Shimokawa Tomoki"},{"name":"Shinke Toshiro"},{"name":"Suzuki Tomoaki"},{"name":"Takahashi Masao"},{"name":"Tanaka Nobuhiro"},{"name":"Tsuneyoshi Hiroshi"},{"name":"Tojo Taiki"},{"name":"Une Dai"},{"name":"Wakasa Satoru"},{"name":"Yamaguchi Koji"},{"name":"Akasaka Takashi"},{"name":"Hirayama Atsushi"},{"name":"Kimura Kazuo"},{"name":"Kimura Takeshi"},{"name":"Matsui Yoshiro"},{"name":"Miyazaki Shunichi"},{"name":"Okamura Yoshitaka"},{"name":"Ono Minoru"},{"name":"Shiomi Hiroki"},{"name":"Tanemoto Kazuo"}],"ja":[{"name":"Nakamura Masato"},{"name":"Yaku Hitoshi"},{"name":"Ako Junya"},{"name":"Arai Hirokuni"},{"name":"Asai Tohru"},{"name":"Chikamori Taishiro"},{"name":"Daida Hiroyuki"},{"name":"Doi Kiyoshi"},{"name":"Fukui Toshihiro"},{"name":"Ito Toshiaki"},{"name":"Kadota Kazushige"},{"name":"Kobayashi Junjiro"},{"name":"Komiya Tatsuhiko"},{"name":"Kozuma Ken"},{"name":"Nakagawa Yoshihisa"},{"name":"Nakao Koichi"},{"name":"Niinami Hiroshi"},{"name":"Ohno Takayuki"},{"name":"Ozaki Yukio"},{"name":"佐田 政隆"},{"name":"Takanashi Shuichiro"},{"name":"Takemura Hirofumi"},{"name":"Ueno Takafumi"},{"name":"Yasuda Satoshi"},{"name":"Yokoyama Hitoshi"},{"name":"Fujita Tomoyuki"},{"name":"Kasai Tokuo"},{"name":"Kohsaka Shun"},{"name":"Kubo Takashi"},{"name":"Manabe Susumu"},{"name":"Matsumoto Naoya"},{"name":"Miyagawa Shigeru"},{"name":"Mizuno Tomohiro"},{"name":"Motomura Noboru"},{"name":"Numata Satoshi"},{"name":"Nakajima Hiroyuki"},{"name":"Oda Hirotaka"},{"name":"Otake Hiromasa"},{"name":"Otsuka Fumiyuki"},{"name":"Sasaki Ken-Ichiro"},{"name":"Shimada Kazunori"},{"name":"Shimokawa Tomoki"},{"name":"Shinke Toshiro"},{"name":"Suzuki Tomoaki"},{"name":"Takahashi Masao"},{"name":"Tanaka Nobuhiro"},{"name":"Tsuneyoshi Hiroshi"},{"name":"Tojo Taiki"},{"name":"Une Dai"},{"name":"Wakasa Satoru"},{"name":"山口 浩司"},{"name":"Akasaka Takashi"},{"name":"Hirayama Atsushi"},{"name":"Kimura Kazuo"},{"name":"Kimura Takeshi"},{"name":"Matsui Yoshiro"},{"name":"Miyazaki Shunichi"},{"name":"Okamura Yoshitaka"},{"name":"Ono Minoru"},{"name":"Shiomi Hiroki"},{"name":"Tanemoto Kazuo"}]},"publication_date":"2022-02-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.86","number":"No.3","starting_page":"477","ending_page":"588","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-20-1282"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34322777","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85111531757&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378018","label":"url"}],"paper_title":{"en":"How to standardize the measurement of left ventricular ejection fraction","ja":"How to standardize the measurement of left ventricular ejection fraction"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Zheng Robert"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Robert Zheng"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2022-01-28","publication_name":{"en":"Journal of Medical Ultrasonics","ja":"Journal of Medical Ultrasonics"},"volume":"Vol.49","number":"No.1","starting_page":"35","ending_page":"43","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10396-021-01116-z"],"issn":["1613-2254"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116989","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35042505","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85123015852&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384034","label":"url"}],"paper_title":{"en":"Clinical clerkship students' preferences and satisfaction regarding online lectures during the COVID-19 pandemic","ja":"Clinical clerkship students' preferences and satisfaction regarding online lectures during the COVID-19 pandemic"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Kusunose Kenya"},{"name":"Kadota Muneyuki"},{"name":"Kawabata Yutaka"},{"name":"Matsuura Tomomi"},{"name":"Soga Tomohiro"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Kawahito Shinji"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"楠瀬 賢也"},{"name":"門田 宗之"},{"name":"川端 豊"},{"name":"松浦 朋美"},{"name":"曽我 朋宏"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"川人 伸次"},{"name":"佐田 政隆"}]},"description":{"en":"The COVID-19 pandemic has caused an unprecedented disruption in medical education. Students and lecturers had to adapt to online education. The current study aimed to investigate the level of satisfaction and future preference for online lectures among clinical clerkship students and elucidated the factors that affect these outcomes. We selected a sample of 114 medical students undergoing clinical clerkship during the COVID-19 pandemic. We conducted onsite lectures before the pandemic and online lectures after the outbreak. A survey was conducted, and the sample included students and 17 lecturers. The average scores of total satisfaction and future preference related to online lectures were computed. Students' scores on total satisfaction with online lectures and their future preference were higher than those for onsite lectures. Scores on the ease of debating dimension were low and those on accessibility of lectures in online lectures were higher than those in onsite lectures. There was no difference between the two groups in the scores on the comprehensibility and ease of asking questions dimensions. Results of the multiple regression analysis revealed that accessibility determined total satisfaction, and future preference was determined by comprehensibility as well as accessibility. Contrary to students' future preferences, lecturers favored onsite lectures to online ones. Online lectures are an acceptable mode of teaching during the COVID-19 pandemic for students undergoing clinical clerkship. Online lectures are expected to become more pervasive to avoid the spread of COVID-19.","ja":"The COVID-19 pandemic has caused an unprecedented disruption in medical education. Students and lecturers had to adapt to online education. The current study aimed to investigate the level of satisfaction and future preference for online lectures among clinical clerkship students and elucidated the factors that affect these outcomes. We selected a sample of 114 medical students undergoing clinical clerkship during the COVID-19 pandemic. We conducted onsite lectures before the pandemic and online lectures after the outbreak. A survey was conducted, and the sample included students and 17 lecturers. The average scores of total satisfaction and future preference related to online lectures were computed. Students' scores on total satisfaction with online lectures and their future preference were higher than those for onsite lectures. Scores on the ease of debating dimension were low and those on accessibility of lectures in online lectures were higher than those in onsite lectures. There was no difference between the two groups in the scores on the comprehensibility and ease of asking questions dimensions. Results of the multiple regression analysis revealed that accessibility determined total satisfaction, and future preference was determined by comprehensibility as well as accessibility. Contrary to students' future preferences, lecturers favored onsite lectures to online ones. Online lectures are an acceptable mode of teaching during the COVID-19 pandemic for students undergoing clinical clerkship. Online lectures are expected to become more pervasive to avoid the spread of COVID-19."},"publication_date":"2022-01-18","publication_name":{"en":"BMC Medical Education","ja":"BMC Medical Education"},"volume":"Vol.22","number":"No.1","starting_page":"43","ending_page":"43","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12909-021-03096-7"],"issn":["1472-6920"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116987","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35063270","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383987","label":"url"}],"paper_title":{"en":"Effects of Radiofrequency Catheter Ablation on Cardiac Reserve Using Preload Stress Echocardiography in Paroxysmal and Persistent Atrial Fibrillation","ja":"Effects of Radiofrequency Catheter Ablation on Cardiac Reserve Using Preload Stress Echocardiography in Paroxysmal and Persistent Atrial Fibrillation"},"authors":{"en":[{"name":"Ishii Nao"},{"name":"Kusunose Kenya"},{"name":"Shono A"},{"name":"Matsumoto K"},{"name":"Nishio Susumu"},{"name":"Yamaguchi Natsumi"},{"name":"Hirata Yukina"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"石井 なお"},{"name":"楠瀬 賢也"},{"name":"Shono A"},{"name":"Matsumoto K"},{"name":"西尾 進"},{"name":"山口 夏美"},{"name":"平田 有紀奈"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"The effects of catheter ablation on exercise tolerance and quality of life in patients with atrial fibrillation (AF) have been reported. We assessed cardiac function in more detail using the leg positive pressure (LPP) technique and found that contractile reserve is particularly important in relation to exercise tolerance and prognosis. In this study, we used the LPP technique to examine changes in contractile reserve immediately after ablation and 6 months later. We prospectively enrolled patients who underwent catheter ablation for AF at 2 institutes. We performed LPP stress echocardiography 2 to 3 days after (FU-1) and 6 months after (FU-2) ablation to examine changes in cardiac function indexes. The primary end point was improvement in contractile reserve. Ultimately, 109 patients (mean age 67.4 ± 9.6 years; 70% men) underwent 2 sessions of LPP stress echocardiography. The median CHADS-VAS score was 2 (interquartile range 13). From FU-1 to FU-2, the change in the stroke volume index after the LPP maneuver increased in patients with paroxysmal and persistent AF with low CHADS-VAS scores (both p <0.05). Regardless of AF subtype, contractile reserve at FU-2 improved in patients with low CHADS-VAS scores compared with that at FU-1. In contrast, patients with high CHADS-VAS scores had no change. In conclusion, patients with AF with a low CHADS-VAS score had improved contractile reserve after ablation, whereas patients with high scores did not show any improvement. Aggressive interventions in patients with high scores may lead to better management after catheter ablation.","ja":"The effects of catheter ablation on exercise tolerance and quality of life in patients with atrial fibrillation (AF) have been reported. We assessed cardiac function in more detail using the leg positive pressure (LPP) technique and found that contractile reserve is particularly important in relation to exercise tolerance and prognosis. In this study, we used the LPP technique to examine changes in contractile reserve immediately after ablation and 6 months later. We prospectively enrolled patients who underwent catheter ablation for AF at 2 institutes. We performed LPP stress echocardiography 2 to 3 days after (FU-1) and 6 months after (FU-2) ablation to examine changes in cardiac function indexes. The primary end point was improvement in contractile reserve. Ultimately, 109 patients (mean age 67.4 ± 9.6 years; 70% men) underwent 2 sessions of LPP stress echocardiography. The median CHADS-VAS score was 2 (interquartile range 13). From FU-1 to FU-2, the change in the stroke volume index after the LPP maneuver increased in patients with paroxysmal and persistent AF with low CHADS-VAS scores (both p <0.05). Regardless of AF subtype, contractile reserve at FU-2 improved in patients with low CHADS-VAS scores compared with that at FU-1. In contrast, patients with high CHADS-VAS scores had no change. In conclusion, patients with AF with a low CHADS-VAS score had improved contractile reserve after ablation, whereas patients with high scores did not show any improvement. Aggressive interventions in patients with high scores may lead to better management after catheter ablation."},"publication_date":"2022-01-18","publication_name":{"en":"The American Journal of Cardiology","ja":"The American Journal of Cardiology"},"volume":"Vol.168","starting_page":"71","ending_page":"77","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.amjcard.2021.12.026"],"issn":["1879-1913"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116992","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34657137","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383571","label":"url"}],"paper_title":{"en":"Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study","ja":"Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yoshida H"},{"name":"Tanaka A"},{"name":"Teragawa H"},{"name":"Akasaki Y"},{"name":"Fukumoto Y"},{"name":"Eguchi K"},{"name":"Kamiya H"},{"name":"Kario K"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"},{"name":"Node K"},{"name":"Matsuhisa Munehide"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Yoshida H"},{"name":"Tanaka A"},{"name":"Teragawa H"},{"name":"Akasaki Y"},{"name":"Fukumoto Y"},{"name":"Eguchi K"},{"name":"Kamiya H"},{"name":"Kario K"},{"name":"山田 博胤"},{"name":"佐田 政隆"},{"name":"Node K"},{"name":"松久 宗英"}]},"publication_date":"2022-01","publication_name":{"en":"Hypertension Research","ja":"Hypertension Research"},"volume":"Vol.45","number":"No.1","starting_page":"106","ending_page":"115","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41440-021-00752-9"],"issn":["1348-4214"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://repo.lib.tokushima-u.ac.jp/117131","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117131","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050855201331782272/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388651","label":"url"}],"paper_title":{"en":"徳島県循環器病対策推進計画","ja":"徳島県循環器病対策推進計画"},"authors":{"en":[{"name":"Sata Masataka"}],"ja":[{"name":"佐田 政隆"}]},"description":{"en":"Cerebrovascular diseases including stroke and cardiovascular diseases are the leading causes of death in Japan, which together account for 23.2% of the total number of deaths in 2018. The major causes of the need for long-term care in Japan are also cerebrovascular disease(16.1%)and cardiovascular disease(4.5%), which together account for more than one-fifth of the total. Medical expenses for both cerebrovascular and cardiovascular disease account for ≈20% of the total, which is the highest by injury/illness classification. The Cerebrovascular and Cardiovascular Disease Control Act, of Japanese national law, was promulgated by a legislative act on December 14, 2018, and enacted on December 1, 2019. On the basis of the Cerebrovascular and Cardiovascular Disease Control Act, the Ministry of Health, Labour and Welfare, Japan, published the Japanese National Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Disease on October 27, 2020. It has indicated both problems in the current situation and individual measures to address the problems. The Japanese National Plan includes 3 major measures : spreading awareness of prevention measures and accurate information on cerebrovascular and cardiovascular disease ; enhancing service provision systems related to health, medical care, and welfare services ; and promoting research on cerebrovascular and cardiovascular disease. The 2 main goals of the Japanese National Plan are to extend healthy life expectancy by 3 years by 2040 compared with 2016 and to decrease age-adjusted mortality of cerebrovascular and cardiovascular disease. The average life expectancy and healthy life expectancy for both men and women increased by 0.67 to 1.72 years from 2010 to 2016 in Japan. In 2016, the unhealthy period which is defined as differences between healthy life expectancy(men, 72.14 years ; women, 74.49 years)and average life expectancy(men, 80.98 years ; women, 87.14 years)was large : ≈8.8 years for men and ≈12.4 years for women. Therefore, extending healthy life expectancy is a primary goal of the Japanese National Plan. Based on this national plan, the Tokushima Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Diseases is developed through the meetings of the Tokushima Council for Promotion of Measures Against Cerebrovascular and Cardiovascular Diseases, parliamentary associated meetings, and public comments. The council is composed of patients with cerebrovascular or cardiovascular disease ; those engaged in emergency services and health, medical, or welfare services ; and those with academic experience. Here, we describe outline of the Tokushima Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Disease.","ja":"Cerebrovascular diseases including stroke and cardiovascular diseases are the leading causes of death in Japan, which together account for 23.2% of the total number of deaths in 2018. The major causes of the need for long-term care in Japan are also cerebrovascular disease(16.1%)and cardiovascular disease(4.5%), which together account for more than one-fifth of the total. Medical expenses for both cerebrovascular and cardiovascular disease account for ≈20% of the total, which is the highest by injury/illness classification. The Cerebrovascular and Cardiovascular Disease Control Act, of Japanese national law, was promulgated by a legislative act on December 14, 2018, and enacted on December 1, 2019. On the basis of the Cerebrovascular and Cardiovascular Disease Control Act, the Ministry of Health, Labour and Welfare, Japan, published the Japanese National Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Disease on October 27, 2020. It has indicated both problems in the current situation and individual measures to address the problems. The Japanese National Plan includes 3 major measures : spreading awareness of prevention measures and accurate information on cerebrovascular and cardiovascular disease ; enhancing service provision systems related to health, medical care, and welfare services ; and promoting research on cerebrovascular and cardiovascular disease. The 2 main goals of the Japanese National Plan are to extend healthy life expectancy by 3 years by 2040 compared with 2016 and to decrease age-adjusted mortality of cerebrovascular and cardiovascular disease. The average life expectancy and healthy life expectancy for both men and women increased by 0.67 to 1.72 years from 2010 to 2016 in Japan. In 2016, the unhealthy period which is defined as differences between healthy life expectancy(men, 72.14 years ; women, 74.49 years)and average life expectancy(men, 80.98 years ; women, 87.14 years)was large : ≈8.8 years for men and ≈12.4 years for women. Therefore, extending healthy life expectancy is a primary goal of the Japanese National Plan. Based on this national plan, the Tokushima Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Diseases is developed through the meetings of the Tokushima Council for Promotion of Measures Against Cerebrovascular and Cardiovascular Diseases, parliamentary associated meetings, and public comments. The council is composed of patients with cerebrovascular or cardiovascular disease ; those engaged in emergency services and health, medical, or welfare services ; and those with academic experience. Here, we describe outline of the Tokushima Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Disease."},"publication_date":"2021-12-25","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.77","number":"No.5,6","starting_page":"199","ending_page":"206","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116054","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33775978","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=377688","label":"url"}],"paper_title":{"en":"Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.","ja":"Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice."},"authors":{"en":[{"name":"Suto Kumiko"},{"name":"Fukuda Daiju"},{"name":"Shinohara Masakazu"},{"name":"Ganbaatar Byambasuren"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Hirata Ken-Ichi"},{"name":"Sata Masataka"}],"ja":[{"name":"數藤 久美子"},{"name":"福田 大受"},{"name":"Shinohara Masakazu"},{"name":"GANBAATAR BYAMBASUREN"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"Hirata Ken-Ichi"},{"name":"佐田 政隆"}]},"description":{"en":"Various pathological processes related to diabetes cause endothelial dysfunction. Eicosanoids derived from arachidonic acid (AA) have roles in vascular regulation. Fibrates have recently been shown to attenuate vascular complications in diabetics. Here we examined the effects of pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, on plasma eicosanoid levels and endothelial function in diabetic mice. Diabetes was induced in 7-week-old male wild-type mice by a single injection of streptozotocin (150 mg/kg). Pemafibrate (0.3 mg/kg/day) was administered orally for 3 weeks. Untreated mice received vehicle. Circulating levels of eicosanoids and free fatty acids were measured using both gas and liquid chromatography-mass spectrometry. Endothelium-dependent and endothelium-independent vascular responses to acetylcholine and sodium nitroprusside, respectively, were analyzed. Pemafibrate reduced both triglyceride and non-high-density lipoprotein -cholesterol levels (P<0.01), without affecting body weight. It also decreased circulating levels of AA (P<0.001), thromboxane B (P<0.001), prostaglandin E, leukotriene B (P<0.05), and 5-hydroxyeicosatetraenoic acid (P<0.001), all of which were elevated by the induction of diabetes. In contrast, the plasma levels of 15-deoxy-Δ-prostaglandin J, which declined following diabetes induction, remained unaffected by pemafibrate treatment. In diabetic mice, pemafibrate decreased palmitic acid (PA) and stearic acid concentrations (P<0.05). Diabetes induction impaired endothelial function, whereas pemafibrate ameliorated it (P<0.001). The results of ex vivo experiments indicated that eicosanoids or PA impaired endothelial function. Pemafibrate diminished the levels of vasoconstrictive eicosanoids and free fatty acids accompanied by a reduction of triglyceride. These effects may be associated with the improvement of endothelial function by pemafibrate in diabetic mice.","ja":"Various pathological processes related to diabetes cause endothelial dysfunction. Eicosanoids derived from arachidonic acid (AA) have roles in vascular regulation. Fibrates have recently been shown to attenuate vascular complications in diabetics. Here we examined the effects of pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, on plasma eicosanoid levels and endothelial function in diabetic mice. Diabetes was induced in 7-week-old male wild-type mice by a single injection of streptozotocin (150 mg/kg). Pemafibrate (0.3 mg/kg/day) was administered orally for 3 weeks. Untreated mice received vehicle. Circulating levels of eicosanoids and free fatty acids were measured using both gas and liquid chromatography-mass spectrometry. Endothelium-dependent and endothelium-independent vascular responses to acetylcholine and sodium nitroprusside, respectively, were analyzed. Pemafibrate reduced both triglyceride and non-high-density lipoprotein -cholesterol levels (P<0.01), without affecting body weight. It also decreased circulating levels of AA (P<0.001), thromboxane B (P<0.001), prostaglandin E, leukotriene B (P<0.05), and 5-hydroxyeicosatetraenoic acid (P<0.001), all of which were elevated by the induction of diabetes. In contrast, the plasma levels of 15-deoxy-Δ-prostaglandin J, which declined following diabetes induction, remained unaffected by pemafibrate treatment. In diabetic mice, pemafibrate decreased palmitic acid (PA) and stearic acid concentrations (P<0.05). Diabetes induction impaired endothelial function, whereas pemafibrate ameliorated it (P<0.001). The results of ex vivo experiments indicated that eicosanoids or PA impaired endothelial function. Pemafibrate diminished the levels of vasoconstrictive eicosanoids and free fatty acids accompanied by a reduction of triglyceride. These effects may be associated with the improvement of endothelial function by pemafibrate in diabetic mice."},"publication_date":"2021-12-01","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.28","number":"No.12","starting_page":"1349","ending_page":"1360","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.61101"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116725","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33678753","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374771","label":"url"}],"paper_title":{"en":"Sirt7 Deficiency Attenuates Neointimal Formation Following Vascular Injury by Modulating Vascular Smooth Muscle Cell Proliferation","ja":"Sirt7 Deficiency Attenuates Neointimal Formation Following Vascular Injury by Modulating Vascular Smooth Muscle Cell Proliferation"},"authors":{"en":[{"name":"Kimura Yuichi"},{"name":"Izumiya Yasuhiro"},{"name":"Araki Satoshi"},{"name":"Yamamura Satoru"},{"name":"Hanatani Shinsuke"},{"name":"Onoue Yoshiro"},{"name":"Ishida Toshifumi"},{"name":"Arima Yuichiro"},{"name":"Nakamura Taishi"},{"name":"Yamamoto Eiichiro"},{"name":"Senokuchi Takafumi"},{"name":"Yoshizawa Tatsuya"},{"name":"Sata Masataka"},{"name":"Kim-Mitsuyama Shokei"},{"name":"Nakagata Naomi"},{"name":"Bober Eva"},{"name":"Braun Thomas"},{"name":"Kaikita Koichi"},{"name":"Yamagata Kazuya"},{"name":"Tsujita Kenichi"}],"ja":[{"name":"Kimura Yuichi"},{"name":"Izumiya Yasuhiro"},{"name":"Araki Satoshi"},{"name":"Yamamura Satoru"},{"name":"Hanatani Shinsuke"},{"name":"Onoue Yoshiro"},{"name":"Ishida Toshifumi"},{"name":"Arima Yuichiro"},{"name":"Nakamura Taishi"},{"name":"Yamamoto Eiichiro"},{"name":"Senokuchi Takafumi"},{"name":"Yoshizawa Tatsuya"},{"name":"佐田 政隆"},{"name":"Kim-Mitsuyama Shokei"},{"name":"Nakagata Naomi"},{"name":"Bober Eva"},{"name":"Braun Thomas"},{"name":"Kaikita Koichi"},{"name":"Yamagata Kazuya"},{"name":"Tsujita Kenichi"}]},"description":{"en":"Sirt7 is a recently identified sirtuin and has important roles in various pathological conditions, including cancer progression and metabolic disorders. It has previously been reported that Sirt7 is a key molecule in acute myocardial wound healing and pressure overload-induced cardiac hypertrophy. In this study, the role of Sirt7 in neointimal formation after vascular injury is investigated.Methods and Results:Systemic (Sirt7) and smooth muscle cell-specific Sirt7-deficient mice were subjected to femoral artery wire injury. Primary vascular smooth muscle cells (VSMCs) were isolated from the aorta of wild type (WT) and Sirt7mice and their capacity for cell proliferation and migration was compared. Sirt7 expression was increased in vascular tissue at the sites of injury. Sirt7mice demonstrated significant reduction in neointimal formation compared to WT mice. In vitro, Sirt7 deficiency attenuated the proliferation of serum-induced VSMCs. Serum stimulation-induced upregulation of cyclins and cyclin-dependent-kinase 2 (CDK2) was significantly attenuated in VSMCs of Sirt7compared with WT mice. These changes were accompanied by enhanced expression of the microRNA 290-295 cluster, the translational negative regulator of CDK2, in VSMCs of Sirt7mice. It was confirmed that smooth muscle cell-specific Sirt7-deficient mice showed significant reduction in neointima compared with control mice. Sirt7 deficiency attenuates neointimal formation after vascular injury. Given the predominant role in vascular neointimal formation, Sirt7 is a potentially suitable target for treatment of vascular diseases.","ja":"Sirt7 is a recently identified sirtuin and has important roles in various pathological conditions, including cancer progression and metabolic disorders. It has previously been reported that Sirt7 is a key molecule in acute myocardial wound healing and pressure overload-induced cardiac hypertrophy. In this study, the role of Sirt7 in neointimal formation after vascular injury is investigated.Methods and Results:Systemic (Sirt7) and smooth muscle cell-specific Sirt7-deficient mice were subjected to femoral artery wire injury. Primary vascular smooth muscle cells (VSMCs) were isolated from the aorta of wild type (WT) and Sirt7mice and their capacity for cell proliferation and migration was compared. Sirt7 expression was increased in vascular tissue at the sites of injury. Sirt7mice demonstrated significant reduction in neointimal formation compared to WT mice. In vitro, Sirt7 deficiency attenuated the proliferation of serum-induced VSMCs. Serum stimulation-induced upregulation of cyclins and cyclin-dependent-kinase 2 (CDK2) was significantly attenuated in VSMCs of Sirt7compared with WT mice. These changes were accompanied by enhanced expression of the microRNA 290-295 cluster, the translational negative regulator of CDK2, in VSMCs of Sirt7mice. It was confirmed that smooth muscle cell-specific Sirt7-deficient mice showed significant reduction in neointima compared with control mice. Sirt7 deficiency attenuates neointimal formation after vascular injury. Given the predominant role in vascular neointimal formation, Sirt7 is a potentially suitable target for treatment of vascular diseases."},"publication_date":"2021-11-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.85","number":"No.12","starting_page":"2232","ending_page":"2240","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-20-0936"],"issn":["1346-9843"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34129950","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376471","label":"url"}],"paper_title":{"en":"Clinical Utility of Overlap Time for Incomplete Relaxation to Predict Cardiac Events in Heart Failure: Incomplete relaxation in heart failure","ja":"Clinical Utility of Overlap Time for Incomplete Relaxation to Predict Cardiac Events in Heart Failure: Incomplete relaxation in heart failure"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Arase Miharu"},{"name":"Zheng Robert"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"荒瀬 美晴"},{"name":"Robert Zheng"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"The overlap time of transmitral flow can be a novel marker of subclinical left ventricular (LV) dysfunction for predicting adverse events in heart failure (HF). We aimed to 1) investigate the role of overlap time of E-A wave in association with clinical parameters, and 2) evaluate whether the overlap time could add prognostic information with respect to other conventional clinical prognosticators in HF. We prospectively evaluated 153 patients hospitalized with HF (mean age 68±15 years; 63% male). The primary endpoint was readmission following HF and cardiac death. During a median period of 25 months, 43 patients were either readmitted or died. Overlap time appeared to be associated with worse outcomes. After adjustment for readmission score and ratio of diastolic filling period and cardiac cycle length in a Cox proportional-hazards model, overlap time was associated with event free survival, independent of elevated left atrial pressure (LAP) based on guidelines. When overlap time was added to the model based on clinical variables and elevated LAP, the C-statistic significantly improves from 0.70 (95% CI: 0.63-0.77) to 0.77 (95% CI: 0.69-0.83, compared P=0.035). This preliminary study suggested that prolonged overlap time may have potential for predicting readmission and cardiac mortality risk assessment in HF.","ja":"The overlap time of transmitral flow can be a novel marker of subclinical left ventricular (LV) dysfunction for predicting adverse events in heart failure (HF). We aimed to 1) investigate the role of overlap time of E-A wave in association with clinical parameters, and 2) evaluate whether the overlap time could add prognostic information with respect to other conventional clinical prognosticators in HF. We prospectively evaluated 153 patients hospitalized with HF (mean age 68±15 years; 63% male). The primary endpoint was readmission following HF and cardiac death. During a median period of 25 months, 43 patients were either readmitted or died. Overlap time appeared to be associated with worse outcomes. After adjustment for readmission score and ratio of diastolic filling period and cardiac cycle length in a Cox proportional-hazards model, overlap time was associated with event free survival, independent of elevated left atrial pressure (LAP) based on guidelines. When overlap time was added to the model based on clinical variables and elevated LAP, the C-statistic significantly improves from 0.70 (95% CI: 0.63-0.77) to 0.77 (95% CI: 0.69-0.83, compared P=0.035). This preliminary study suggested that prolonged overlap time may have potential for predicting readmission and cardiac mortality risk assessment in HF."},"publication_date":"2021-11-12","publication_name":{"en":"Journal of Cardiac Failure","ja":"Journal of Cardiac Failure"},"volume":"Vol.27","number":"No.11","starting_page":"1222","ending_page":"1230","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.cardfail.2021.05.018"],"issn":["1532-8414"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116739","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34769508","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383129","label":"url"}],"paper_title":{"en":"Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications","ja":"Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications"},"authors":{"en":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"Obana T"},{"name":"Sata Masataka"}],"ja":[{"name":"Higashikuni Y"},{"name":"Liu W"},{"name":"Obana T"},{"name":"佐田 政隆"}]},"description":{"en":"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic with a great impact on social and economic activities, as well as public health. In most patients, the symptoms of COVID-19 are a high-grade fever and a dry cough, and spontaneously resolve within ten days. However, in severe cases, COVID-19 leads to atypical bilateral interstitial pneumonia, acute respiratory distress syndrome, and systemic thromboembolism, resulting in multiple organ failure with high mortality and morbidity. SARS-CoV-2 has immune evasion mechanisms, including inhibition of interferon signaling and suppression of T cell and B cell responses. SARS-CoV-2 infection directly and indirectly causes dysregulated immune responses, platelet hyperactivation, and endothelial dysfunction, which interact with each other and are exacerbated by cardiovascular risk factors. In this review, we summarize current knowledge on the pathogenic basis of thromboinflammation and endothelial injury in COVID-19. We highlight the distinct contributions of dysregulated immune responses, platelet hyperactivation, and endothelial dysfunction to the pathogenesis of COVID-19. In addition, we discuss potential therapeutic strategies targeting these mechanisms.","ja":"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic with a great impact on social and economic activities, as well as public health. In most patients, the symptoms of COVID-19 are a high-grade fever and a dry cough, and spontaneously resolve within ten days. However, in severe cases, COVID-19 leads to atypical bilateral interstitial pneumonia, acute respiratory distress syndrome, and systemic thromboembolism, resulting in multiple organ failure with high mortality and morbidity. SARS-CoV-2 has immune evasion mechanisms, including inhibition of interferon signaling and suppression of T cell and B cell responses. SARS-CoV-2 infection directly and indirectly causes dysregulated immune responses, platelet hyperactivation, and endothelial dysfunction, which interact with each other and are exacerbated by cardiovascular risk factors. In this review, we summarize current knowledge on the pathogenic basis of thromboinflammation and endothelial injury in COVID-19. We highlight the distinct contributions of dysregulated immune responses, platelet hyperactivation, and endothelial dysfunction to the pathogenesis of COVID-19. In addition, we discuss potential therapeutic strategies targeting these mechanisms."},"publication_date":"2021-11-08","publication_name":{"en":"International Journal of Molecular Sciences","ja":"International Journal of Molecular Sciences"},"volume":"Vol.22","number":"No.21","starting_page":"12081","ending_page":"12081","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/ijms222112081"],"issn":["1422-0067"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116972","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34810277","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85120377378&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383572","label":"url"}],"paper_title":{"en":"Impact of cancer on short-term in-hospital mortality after primary acute myocardial infarction","ja":"Impact of cancer on short-term in-hospital mortality after primary acute myocardial infarction"},"authors":{"en":[{"name":"Zheng Robert"},{"name":"Kusunose Kenya"},{"name":"Okushi Y"},{"name":"Okayama Y"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"Robert Zheng"},{"name":"楠瀬 賢也"},{"name":"大櫛 祐一郎"},{"name":"Okayama Y"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"publication_date":"2021-11","publication_name":{"en":"Open Heart","ja":"Open Heart"},"volume":"Vol.8","number":"No.2","starting_page":"e00186","ending_page":"e00186","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/openhrt-2021-001860"],"issn":["2053-3624"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34119401","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382429","label":"url"}],"paper_title":{"en":"Predictive value of left atrial function for latent paroxysmal atrial fibrillation as the cause of embolic stroke of undetermined source","ja":"Predictive value of left atrial function for latent paroxysmal atrial fibrillation as the cause of embolic stroke of undetermined source"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Takahashi Hironori"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Zheng Robert"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimada Kenji"},{"name":"Kanematsu Yasuhisa"},{"name":"Takagi Yasushi"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"高橋 寛典"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"Robert Zheng"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島田 健司"},{"name":"兼松 康久"},{"name":"髙木 康志"},{"name":"佐田 政隆"}]},"description":{"en":"In patients with embolic stroke of undetermined source (ESUS), paroxysmal atrial fibrillation (AF) is often diagnosed, however, the risk of paroxysmal AF in ESUS has not been well described. Several studies have suggested a linkage between left atrial (LA) functional parameters and risk of AF in stroke patients. The aim of this study was to assess the role of LA functional parameters as predictors of latent paroxysmal AF in ESUS on admission. Between January 2015 and December 2019, consecutive stroke patients with suspected ESUS at admission were prospectively included in this study. They were under hospital electrocardiographic monitoring for detection of new-onset AF. Various echocardiographic parameters including left atrial strain were assessed for association with new-onset AF. We gathered 1082 consecutive patients with ischemic stroke. After exclusions, 121 patients with suspected ESUS at admission formed the study cohort. New-onset AF was detected in 46 (38%) patients during hospital electrocardiographic monitoring (median follow-up: 18 days). LA pump and reservoir strains were significantly and independently associated with new-onset AF. Receiver operating characteristic analysis for the association with new-onset AF showed that the areas under the curve (AUCs) of clinical parameters plus one of each strain (LA pump strain: AUC: 0.86±0.04 and LA reservoir strain: AUC: 0.76±0.05) models were significantly better than plus LA volume index (AUC: 0.68±0.04, compared p-values <0.05). LA strain was significantly associated with new development of AF. Patients with impaired LA function at admission should be carefully monitored to find AF.","ja":"In patients with embolic stroke of undetermined source (ESUS), paroxysmal atrial fibrillation (AF) is often diagnosed, however, the risk of paroxysmal AF in ESUS has not been well described. Several studies have suggested a linkage between left atrial (LA) functional parameters and risk of AF in stroke patients. The aim of this study was to assess the role of LA functional parameters as predictors of latent paroxysmal AF in ESUS on admission. Between January 2015 and December 2019, consecutive stroke patients with suspected ESUS at admission were prospectively included in this study. They were under hospital electrocardiographic monitoring for detection of new-onset AF. Various echocardiographic parameters including left atrial strain were assessed for association with new-onset AF. We gathered 1082 consecutive patients with ischemic stroke. After exclusions, 121 patients with suspected ESUS at admission formed the study cohort. New-onset AF was detected in 46 (38%) patients during hospital electrocardiographic monitoring (median follow-up: 18 days). LA pump and reservoir strains were significantly and independently associated with new-onset AF. Receiver operating characteristic analysis for the association with new-onset AF showed that the areas under the curve (AUCs) of clinical parameters plus one of each strain (LA pump strain: AUC: 0.86±0.04 and LA reservoir strain: AUC: 0.76±0.05) models were significantly better than plus LA volume index (AUC: 0.68±0.04, compared p-values <0.05). LA strain was significantly associated with new development of AF. Patients with impaired LA function at admission should be carefully monitored to find AF."},"publication_date":"2021-11","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.78","number":"No.5","starting_page":"355","ending_page":"361","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2021.05.005"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116689","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33775867","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85114290883&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382161","label":"url"}],"paper_title":{"en":"Long-chain monounsaturated fatty acids improve endothelial function with altering microbial flora","ja":"Long-chain monounsaturated fatty acids improve endothelial function with altering microbial flora"},"authors":{"en":[{"name":"Tsutsumi Rie"},{"name":"Yamasaki Yuki"},{"name":"Takeo Jiro"},{"name":"Miyahara Hiroko"},{"name":"Sebe Mayu"},{"name":"Bando Masahiro"},{"name":"Tanba Yousuke"},{"name":"Mishima Yuna"},{"name":"Takeji Kana"},{"name":"Ueshima Nanako"},{"name":"Kuroda Masashi"},{"name":"Masumoto Saeko"},{"name":"Harada Nagakatsu"},{"name":"Fukuda Daiju"},{"name":"Yoshimoto Ryoko"},{"name":"Yasuo M. Tsutsumi ."},{"name":"Aihara Ken-ichi"},{"name":"Sata Masataka"},{"name":"Sakaue Hiroshi"}],"ja":[{"name":"堤 理恵"},{"name":"山﨑 幸"},{"name":"Takeo Jiro"},{"name":"Miyahara Hiroko"},{"name":"瀬部 真由"},{"name":"板東 正浩"},{"name":"Tanba Yousuke"},{"name":"Mishima Yuna"},{"name":"Takeji Kana"},{"name":"Ueshima Nanako"},{"name":"黒田 雅士"},{"name":"升本 早枝子"},{"name":"原田 永勝"},{"name":"福田 大受"},{"name":"Yoshimoto Ryoko"},{"name":"Yasuo M. Tsutsumi ."},{"name":"粟飯原 賢一"},{"name":"佐田 政隆"},{"name":"阪上 浩"}]},"description":{"en":"Fish oil-derived long-chain monounsaturated fatty acids (LCMUFAs) with a carbon chain length longer than 18 units ameliorate cardiovascular risk in mice. In this study, we investigated whether LCMUFAs could improve endothelial functions in mice and humans. In a double-blind, randomized, placebo-controlled, parallel-group, multi-center study, healthy subjects were randomly assigned to either an LCMUFA oil (saury oil) or a control oil (olive and tuna oils) group. Sixty subjects were enrolled and administrated each oil for 4 weeks. For the animal study, ApoE mice were fed a Western diet supplemented with 3% of either gadoleic acid (C20:1) or cetoleic acid (C22:1) for 12 weeks. Participants from the LCMUFA group showed improvements in endothelial function and a lower trimethylamine-N-oxide level, which is a predictor of coronary artery disease. C20:1 and C22:1 oils significantly improved atherosclerotic lesions and plasma levels of several inflammatory cytokines, including IL-6 and TNF-α. These beneficial effects were consistent with an improvement in the gut microbiota environment, as evident from the decreased ratio of Firmicutes and/ or Bacteroidetes, increase in the abundance of Akkermansia, and upregulation of short-chain fatty acid (SCFA)-induced glucagon-like peptide-1 (GLP-1) expression and serum GLP-1 level. These data suggest that LCMUFAs alter the microbiota environment that stimulate the production of SCFAs, resulting in the induction of GLP-1 secretion. Fish oil-derived long-chain monounsaturated fatty acids might thus help to protect against cardiovascular disease.","ja":"Fish oil-derived long-chain monounsaturated fatty acids (LCMUFAs) with a carbon chain length longer than 18 units ameliorate cardiovascular risk in mice. In this study, we investigated whether LCMUFAs could improve endothelial functions in mice and humans. In a double-blind, randomized, placebo-controlled, parallel-group, multi-center study, healthy subjects were randomly assigned to either an LCMUFA oil (saury oil) or a control oil (olive and tuna oils) group. Sixty subjects were enrolled and administrated each oil for 4 weeks. For the animal study, ApoE mice were fed a Western diet supplemented with 3% of either gadoleic acid (C20:1) or cetoleic acid (C22:1) for 12 weeks. Participants from the LCMUFA group showed improvements in endothelial function and a lower trimethylamine-N-oxide level, which is a predictor of coronary artery disease. C20:1 and C22:1 oils significantly improved atherosclerotic lesions and plasma levels of several inflammatory cytokines, including IL-6 and TNF-α. These beneficial effects were consistent with an improvement in the gut microbiota environment, as evident from the decreased ratio of Firmicutes and/ or Bacteroidetes, increase in the abundance of Akkermansia, and upregulation of short-chain fatty acid (SCFA)-induced glucagon-like peptide-1 (GLP-1) expression and serum GLP-1 level. These data suggest that LCMUFAs alter the microbiota environment that stimulate the production of SCFAs, resulting in the induction of GLP-1 secretion. Fish oil-derived long-chain monounsaturated fatty acids might thus help to protect against cardiovascular disease."},"publication_date":"2021-11","publication_name":{"en":"Translational Research : The Journal of Laboratory and Clinical Medicine","ja":"Translational Research : The Journal of Laboratory and Clinical Medicine"},"volume":"Vol.237","starting_page":"16","ending_page":"30","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.trsl.2021.03.016"],"issn":["1878-1810"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117323","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34677193","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85116636823&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387220","label":"url"}],"paper_title":{"en":"Use of Echocardiography and Heart Failure In-Hospital Mortality from Registry Data in Japan.","ja":"Use of Echocardiography and Heart Failure In-Hospital Mortality from Registry Data in Japan."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Okushi Yuichiro"},{"name":"Okayama Yoshihiro"},{"name":"Zheng Robert"},{"name":"Nakai Michikazu"},{"name":"Sumita Yoko"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Okushi Yuichiro"},{"name":"Okayama Yoshihiro"},{"name":"Zheng Robert"},{"name":"Nakai Michikazu"},{"name":"Sumita Yoko"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Echocardiography requires a high degree of skill on the part of the examiner, and the skill may be more improved in larger volume centers. This study investigated trends and outcomes associated with the use and volume of echocardiographic exams from a real-world registry database of heart failure (HF) hospitalizations. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). A first analysis was performed to assess the trend of echocardiographic examinations between 2012 and 2016. A secondary analysis was performed to assess whether echocardiographic use was associated with in-hospital mortality in 2015. During this period, the use of echocardiography grew at an average annual rate of 6%. Patients with echocardiography had declining rates of hospital mortality, and these trends were associated with high hospitalization costs. In the 2015 sample, a total of 52,832 echocardiograms were examined, corresponding to 65.6% of all HF hospital admissions for that year. We found that the use and volume of echocardiography exams were associated with significantly lower odds of all-cause hospital mortality in heart failure (adjusted odds ratio (OR): 0.48 for use of echocardiography and 0.78 for the third tertile; both < 0.001). The use of echocardiography was associated with decreased odds of hospital mortality in HF. The volumes of echocardiographic examinations were also associated with hospital mortality.","ja":"Echocardiography requires a high degree of skill on the part of the examiner, and the skill may be more improved in larger volume centers. This study investigated trends and outcomes associated with the use and volume of echocardiographic exams from a real-world registry database of heart failure (HF) hospitalizations. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). A first analysis was performed to assess the trend of echocardiographic examinations between 2012 and 2016. A secondary analysis was performed to assess whether echocardiographic use was associated with in-hospital mortality in 2015. During this period, the use of echocardiography grew at an average annual rate of 6%. Patients with echocardiography had declining rates of hospital mortality, and these trends were associated with high hospitalization costs. In the 2015 sample, a total of 52,832 echocardiograms were examined, corresponding to 65.6% of all HF hospital admissions for that year. We found that the use and volume of echocardiography exams were associated with significantly lower odds of all-cause hospital mortality in heart failure (adjusted odds ratio (OR): 0.48 for use of echocardiography and 0.78 for the third tertile; both < 0.001). The use of echocardiography was associated with decreased odds of hospital mortality in HF. The volumes of echocardiographic examinations were also associated with hospital mortality."},"publication_date":"2021-09-30","publication_name":{"en":"Journal of Cardiovascular Development and Disease","ja":"Journal of Cardiovascular Development and Disease"},"volume":"Vol.8","number":"No.10","starting_page":"124","ending_page":"124","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/jcdd8100124"],"issn":["2308-3425"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118014","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33867390","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375108","label":"url"}],"paper_title":{"en":"Infective Endocarditis from Furuncle with Meningitis Complication Caused by Methicillin-resistant Staphylococcus aureus","ja":"Infective Endocarditis from Furuncle with Meningitis Complication Caused by Methicillin-resistant Staphylococcus aureus"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Takahashi T"},{"name":"Murakami K"},{"name":"Azuma M"},{"name":"Sugano M"},{"name":"Miyamoto R"},{"name":"Niki M"},{"name":"Yamada Hirotsugu"},{"name":"Kawabata Yutaka"},{"name":"Akihiro Tani"},{"name":"Fukuda Daiju"},{"name":"Kadota Muneyuki"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Tobiume Takeshi"},{"name":"Matsuura Tomomi"},{"name":"Yamaguchi Koji"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Hata H"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Takahashi T"},{"name":"Murakami K"},{"name":"Azuma M"},{"name":"Sugano M"},{"name":"Miyamoto R"},{"name":"Niki M"},{"name":"山田 博胤"},{"name":"川端 豊"},{"name":"谷 彰浩"},{"name":"福田 大受"},{"name":"門田 宗之"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"飛梅 威"},{"name":"松浦 朋美"},{"name":"山口 浩司"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"Hata H"},{"name":"佐田 政隆"}]},"publication_date":"2021-09-15","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"volume":"Vol.60","number":"No.20","starting_page":"3251","ending_page":"3255","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.6902-20"],"issn":["0918-2918"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116720","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34521417","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85115075981&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382160","label":"url"}],"paper_title":{"en":"Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial","ja":"Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Imai T"},{"name":"Tanaka A"},{"name":"Dohi K"},{"name":"Shiina K"},{"name":"Yamada T"},{"name":"Kida K"},{"name":"Eguchi K"},{"name":"Teragawa H"},{"name":"Takeishi Y"},{"name":"Ohte N"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"},{"name":"Node K"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Imai T"},{"name":"Tanaka A"},{"name":"Dohi K"},{"name":"Shiina K"},{"name":"Yamada T"},{"name":"Kida K"},{"name":"Eguchi K"},{"name":"Teragawa H"},{"name":"Takeishi Y"},{"name":"Ohte N"},{"name":"山田 博胤"},{"name":"佐田 政隆"},{"name":"Node K"}]},"description":{"en":"Identification of the effective subtypes of treatment for heart failure (HF) is an essential topic for optimizing treatment of the disorder. We hypothesized that the beneficial effect of SGLT2 inhibitors (SGLT2i) on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) might depend on baseline diastolic function. To elucidate the effects of SGLT2i in type 2 diabetes mellitus (T2DM) and chronic HF we investigated, as a post-hoc sub-study of the CANDLE trial, the effects of canagliflozin on NT-proBNP levels from baseline to 24 weeks, with the data stratified by left ventricular (LV) diastolic function at baseline. Patients (n = 233) in the CANDLE trial were assigned randomly to either an add-on canagliflozin (n = 113) or glimepiride treatment groups (n = 120). The primary endpoint was a comparison between the two groups of the changes from baseline to 24 weeks in NT-pro BNP levels, stratified according to baseline ventricular diastolic function. The change in the geometric mean of NT-proBNP level from baseline to 24 weeks was 0.98 (95% CI 0.89-1.08) in the canagliflozin group and 1.07 (95% CI 0.97-1.18) in the glimepiride group. The ratio of change with canagliflozin/glimepiride was 0.93 (95% CI 0.82-1.05). Responder analyses were used to investigate the response of an improvement in NT-proBNP levels. Although the subgroup analyses for septal annular velocity (SEP-e') showed no marked heterogeneity in treatment effect, the subgroup with an SEP-e' < 4.7 cm/s indicated there was an association with lower NT-proBNP levels in the canagliflozin group compared with that in the glimepiride group (ratio of change with canagliflozin/glimepiride (0.83, 95% CI 0.66-1.04). In the subgroup with a lower LV diastolic function, canagliflozin showed a trend of reduced NT-pro BNP levels compared to that observed with glimepiride. This study suggests that the beneficial effects of canagliflozin treatment may be different in subgroups classified by the severity of LV diastolic dysfunction.","ja":"Identification of the effective subtypes of treatment for heart failure (HF) is an essential topic for optimizing treatment of the disorder. We hypothesized that the beneficial effect of SGLT2 inhibitors (SGLT2i) on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) might depend on baseline diastolic function. To elucidate the effects of SGLT2i in type 2 diabetes mellitus (T2DM) and chronic HF we investigated, as a post-hoc sub-study of the CANDLE trial, the effects of canagliflozin on NT-proBNP levels from baseline to 24 weeks, with the data stratified by left ventricular (LV) diastolic function at baseline. Patients (n = 233) in the CANDLE trial were assigned randomly to either an add-on canagliflozin (n = 113) or glimepiride treatment groups (n = 120). The primary endpoint was a comparison between the two groups of the changes from baseline to 24 weeks in NT-pro BNP levels, stratified according to baseline ventricular diastolic function. The change in the geometric mean of NT-proBNP level from baseline to 24 weeks was 0.98 (95% CI 0.89-1.08) in the canagliflozin group and 1.07 (95% CI 0.97-1.18) in the glimepiride group. The ratio of change with canagliflozin/glimepiride was 0.93 (95% CI 0.82-1.05). Responder analyses were used to investigate the response of an improvement in NT-proBNP levels. Although the subgroup analyses for septal annular velocity (SEP-e') showed no marked heterogeneity in treatment effect, the subgroup with an SEP-e' < 4.7 cm/s indicated there was an association with lower NT-proBNP levels in the canagliflozin group compared with that in the glimepiride group (ratio of change with canagliflozin/glimepiride (0.83, 95% CI 0.66-1.04). In the subgroup with a lower LV diastolic function, canagliflozin showed a trend of reduced NT-pro BNP levels compared to that observed with glimepiride. This study suggests that the beneficial effects of canagliflozin treatment may be different in subgroups classified by the severity of LV diastolic dysfunction."},"publication_date":"2021-09-14","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.20","number":"No.1","starting_page":"186","ending_page":"186","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-021-01380-w"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33852960","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=381777","label":"url"}],"paper_title":{"en":"Left Atrial Strain Associated with Functional Recovery in Patients Receiving Optimal Treatment for Heart Failure","ja":"Left Atrial Strain Associated with Functional Recovery in Patients Receiving Optimal Treatment for Heart Failure"},"authors":{"en":[{"name":"Torii Yuta"},{"name":"Kusunose Kenya"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"鳥居 裕太"},{"name":"楠瀬 賢也"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Heart failure with recovered ejection fraction (HFrecEF) has been reported in several previous studies to have a better prognosis than heart failure with reduced ejection fraction (HFrEF). However, the factors associated with HFrecEF have not been identified. The aim of this study was to test the hypothesis that left atrial (LA) strain could help identify patients with recovered ejection fraction (EF) among those with heart failure (HF) with low EF on admission. One hundred consecutive patients hospitalized for the first time for new-onset HF were enrolled. Patients were clinically diagnosed with HFrEF on admission (left ventricular EF < 40%) and received optimal treatment for HF. Twenty-eight patients improved to HFrecEF during 6 months of follow-up. Regarding clinical background, there were significantly more women and a lower rate of atrial fibrillation in the HFrecEF group than in the HFrEF group. In a multivariate logistic regression analysis, LA strain was an independent predictor of HFrecEF, even after adjustment for gender and left ventricular EF (odds ratio: 4.06; 95% CI: 2.04-8.07; P < .001). A cutoff value of 10.8% for LA strain showed high sensitivity (96%) and specificity (82%) in identifying HFrecEF in patients with HF presenting with low EF on admission. During a follow-up period of 24 ± 13 months, 31 patients (31%) had cardiovascular death or readmission for HF. Patients with reduced LA strain (<10.8%) had significantly shorter event-free survival than those with preserved LA strain (P = .02). LA strain is a useful indicator for predicting HFrecEF and should be considered as a routine measurement in patients with HFrEF on admission.","ja":"Heart failure with recovered ejection fraction (HFrecEF) has been reported in several previous studies to have a better prognosis than heart failure with reduced ejection fraction (HFrEF). However, the factors associated with HFrecEF have not been identified. The aim of this study was to test the hypothesis that left atrial (LA) strain could help identify patients with recovered ejection fraction (EF) among those with heart failure (HF) with low EF on admission. One hundred consecutive patients hospitalized for the first time for new-onset HF were enrolled. Patients were clinically diagnosed with HFrEF on admission (left ventricular EF < 40%) and received optimal treatment for HF. Twenty-eight patients improved to HFrecEF during 6 months of follow-up. Regarding clinical background, there were significantly more women and a lower rate of atrial fibrillation in the HFrecEF group than in the HFrEF group. In a multivariate logistic regression analysis, LA strain was an independent predictor of HFrecEF, even after adjustment for gender and left ventricular EF (odds ratio: 4.06; 95% CI: 2.04-8.07; P < .001). A cutoff value of 10.8% for LA strain showed high sensitivity (96%) and specificity (82%) in identifying HFrecEF in patients with HF presenting with low EF on admission. During a follow-up period of 24 ± 13 months, 31 patients (31%) had cardiovascular death or readmission for HF. Patients with reduced LA strain (<10.8%) had significantly shorter event-free survival than those with preserved LA strain (P = .02). LA strain is a useful indicator for predicting HFrecEF and should be considered as a routine measurement in patients with HFrEF on admission."},"publication_date":"2021-09","publication_name":{"en":"Journal of the American Society of Echocardiography","ja":"Journal of the American Society of Echocardiography"},"volume":"Vol.34","number":"No.9","starting_page":"966","ending_page":"975","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.echo.2021.03.016"],"issn":["1097-6795"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://repo.lib.tokushima-u.ac.jp/117048","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390007750045919616/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387575","label":"url"}],"paper_title":{"en":"The Utility of a Combination of 99mTc-MIBI Washout Imaging and Cardiac Magnetic Resonance Imaging in the Evaluation of Cardiomyopathy","ja":"The Utility of a Combination of 99mTc-MIBI Washout Imaging and Cardiac Magnetic Resonance Imaging in the Evaluation of Cardiomyopathy"},"authors":{"en":[{"name":"Yamanaka Moriaki"},{"name":"Takao Shoichiro"},{"name":"Otsuka Hideki"},{"name":"Otomi Youichi"},{"name":"Irahara Saho"},{"name":"Kunikane Yamato"},{"name":"Takashi Satoru"},{"name":"Yamamoto Airi"},{"name":"Sata Masataka"},{"name":"Harada Masafumi"}],"ja":[{"name":"山中 森晶"},{"name":"髙尾 正一郎"},{"name":"大塚 秀樹"},{"name":"音見 暢一"},{"name":"苛原 早保"},{"name":"国金 大和"},{"name":"Takashi Satoru"},{"name":"Yamamoto Airi"},{"name":"佐田 政隆"},{"name":"原田 雅史"}]},"description":{"en":"Background: In cardiomyopathy, 99mTc-MIBI washout can reflect mitochondrial dysfunction and late gadolinium enhancement (LGE) on cardiac magnetic imaging (MRI) is associated with tissue fibrosis. We sought to determine the relationship between 99mTc-MIBI uptake, 99mTc-MIBI washout, and LGE on MRI in patients with cardiomyopathy. Methods: Twenty-one patients underwent rest myocardial perfusion scintigraphy at 45 minutes (early) and 4 hours (delayed) after intravenous 99mTc-MIBI administration and cardiac MRI. We assessed myocardial perfusion, 99mTc-MIBI washout, and LGE. We divided the left ventricle (LV) wall into 16 segments using a polar map. Then, we classified each segment into 5 groups according to 99mTc-MIBI uptake in early-rest images and washout. Additionally, we created a contingency table based on LGE presence/absence in the groups. Results: We evaluated 336 segments in 21 patients. 99mTc-MIBI uptake was decreased in 168 segments in the early-rest 99mTc-MIBI images. 99mTc-MIBI washout was observed in 108 segments with either normal perfusion or reduced perfusion in the early-rest 99mTc-MIBI images. LGE was positive in 104 segments. A contingency table analysis with Fisher窶冱 exact test showed that LGE was observed significantly more frequently in the segments with decreased 99mTc-MIBI uptake (p < 0.001). In segments without a decreased 99mTc-MIBI uptake, there was a significant correlation between increased 99mTc-MIBI washout and the presence of LGE (p = 0.033). Conclusions: In cardiomyopathy, the mitochondrial dysfunction in the early stage is shown as 99mTc-MIBI washout, and fibrotic changes in the myocardium in advanced stages are shown as LGE on cardiac MRI. The severity of myocardial damage and the clinical stage of cardiomyopathy can be evaluated using multimodal imaging.","ja":"Background: In cardiomyopathy, 99mTc-MIBI washout can reflect mitochondrial dysfunction and late gadolinium enhancement (LGE) on cardiac magnetic imaging (MRI) is associated with tissue fibrosis. We sought to determine the relationship between 99mTc-MIBI uptake, 99mTc-MIBI washout, and LGE on MRI in patients with cardiomyopathy. Methods: Twenty-one patients underwent rest myocardial perfusion scintigraphy at 45 minutes (early) and 4 hours (delayed) after intravenous 99mTc-MIBI administration and cardiac MRI. We assessed myocardial perfusion, 99mTc-MIBI washout, and LGE. We divided the left ventricle (LV) wall into 16 segments using a polar map. Then, we classified each segment into 5 groups according to 99mTc-MIBI uptake in early-rest images and washout. Additionally, we created a contingency table based on LGE presence/absence in the groups. Results: We evaluated 336 segments in 21 patients. 99mTc-MIBI uptake was decreased in 168 segments in the early-rest 99mTc-MIBI images. 99mTc-MIBI washout was observed in 108 segments with either normal perfusion or reduced perfusion in the early-rest 99mTc-MIBI images. LGE was positive in 104 segments. A contingency table analysis with Fisher窶冱 exact test showed that LGE was observed significantly more frequently in the segments with decreased 99mTc-MIBI uptake (p < 0.001). In segments without a decreased 99mTc-MIBI uptake, there was a significant correlation between increased 99mTc-MIBI washout and the presence of LGE (p = 0.033). Conclusions: In cardiomyopathy, the mitochondrial dysfunction in the early stage is shown as 99mTc-MIBI washout, and fibrotic changes in the myocardium in advanced stages are shown as LGE on cardiac MRI. The severity of myocardial damage and the clinical stage of cardiomyopathy can be evaluated using multimodal imaging."},"publication_date":"2021-08","publication_name":{"en":"Annals of Nuclear Cardiology","ja":"Annals of Nuclear Cardiology"},"volume":"Vol.7","number":"No.1","starting_page":"8","ending_page":"16","languages":["eng"],"referee":true,"identifiers":{"doi":["10.17996/anc.21-00124"],"issn":["2424-1741"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34513940","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387222","label":"url"}],"paper_title":{"en":"Deep Learning Analysis of Echocardiographic Images to Predict Positive Genotype in Patients With Hypertrophic Cardiomyopathy.","ja":"Deep Learning Analysis of Echocardiographic Images to Predict Positive Genotype in Patients With Hypertrophic Cardiomyopathy."},"authors":{"en":[{"name":"Morita X. Sae"},{"name":"Kusunose Kenya"},{"name":"Haga Akihiro"},{"name":"Sata Masataka"},{"name":"Hasegawa Kohei"},{"name":"Raita Yoshihiko"},{"name":"Reilly P. Muredach"},{"name":"Fifer A. Michael"},{"name":"Maurer S. Mathew"},{"name":"Shimada J. Yuichi"}],"ja":[{"name":"Morita X. Sae"},{"name":"楠瀬 賢也"},{"name":"芳賀 昭弘"},{"name":"佐田 政隆"},{"name":"Hasegawa Kohei"},{"name":"Raita Yoshihiko"},{"name":"Reilly P. Muredach"},{"name":"Fifer A. Michael"},{"name":"Maurer S. Mathew"},{"name":"Shimada J. Yuichi"}]},"description":{"en":"Genetic testing provides valuable insights into family screening strategies, diagnosis, and prognosis in patients with hypertrophic cardiomyopathy (HCM). On the other hand, genetic testing carries socio-economical and psychological burdens. It is therefore important to identify patients with HCM who are more likely to have positive genotype. However, conventional prediction models based on clinical and echocardiographic parameters offer only modest accuracy and are subject to intra- and inter-observer variability. We therefore hypothesized that deep convolutional neural network (DCNN, a type of deep learning) analysis of echocardiographic images improves the predictive accuracy of positive genotype in patients with HCM. In each case, we obtained parasternal short- and long-axis as well as apical 2-, 3-, 4-, and 5-chamber views. We employed DCNN algorithm to predict positive genotype based on the input echocardiographic images. We performed 5-fold cross-validations. We used 2 reference models-the Mayo HCM Genotype Predictor score (Mayo score) and the Toronto HCM Genotype score (Toronto score). We compared the area under the receiver-operating-characteristic curve (AUC) between a combined model using the reference model plus DCNN-derived probability and the reference model. We calculated the -value by performing 1,000 bootstrapping. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). In addition, we examined the net reclassification improvement. We included 99 adults with HCM who underwent genetic testing. Overall, 45 patients (45%) had positive genotype. The new model combining Mayo score and DCNN-derived probability significantly outperformed Mayo score (AUC 0.86 [95% CI 0.79-0.93] vs. 0.72 [0.61-0.82]; < 0.001). Similarly, the new model combining Toronto score and DCNN-derived probability exhibited a higher AUC compared to Toronto score alone (AUC 0.84 [0.76-0.92] vs. 0.75 [0.65-0.85]; = 0.03). An improvement in the sensitivity, specificity, PPV, and NPV was also achieved, along with significant net reclassification improvement. In conclusion, compared to the conventional models, our new model combining the conventional and DCNN-derived models demonstrated superior accuracy to predict positive genotype in patients with HCM.","ja":"Genetic testing provides valuable insights into family screening strategies, diagnosis, and prognosis in patients with hypertrophic cardiomyopathy (HCM). On the other hand, genetic testing carries socio-economical and psychological burdens. It is therefore important to identify patients with HCM who are more likely to have positive genotype. However, conventional prediction models based on clinical and echocardiographic parameters offer only modest accuracy and are subject to intra- and inter-observer variability. We therefore hypothesized that deep convolutional neural network (DCNN, a type of deep learning) analysis of echocardiographic images improves the predictive accuracy of positive genotype in patients with HCM. In each case, we obtained parasternal short- and long-axis as well as apical 2-, 3-, 4-, and 5-chamber views. We employed DCNN algorithm to predict positive genotype based on the input echocardiographic images. We performed 5-fold cross-validations. We used 2 reference models-the Mayo HCM Genotype Predictor score (Mayo score) and the Toronto HCM Genotype score (Toronto score). We compared the area under the receiver-operating-characteristic curve (AUC) between a combined model using the reference model plus DCNN-derived probability and the reference model. We calculated the -value by performing 1,000 bootstrapping. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). In addition, we examined the net reclassification improvement. We included 99 adults with HCM who underwent genetic testing. Overall, 45 patients (45%) had positive genotype. The new model combining Mayo score and DCNN-derived probability significantly outperformed Mayo score (AUC 0.86 [95% CI 0.79-0.93] vs. 0.72 [0.61-0.82]; < 0.001). Similarly, the new model combining Toronto score and DCNN-derived probability exhibited a higher AUC compared to Toronto score alone (AUC 0.84 [0.76-0.92] vs. 0.75 [0.65-0.85]; = 0.03). An improvement in the sensitivity, specificity, PPV, and NPV was also achieved, along with significant net reclassification improvement. In conclusion, compared to the conventional models, our new model combining the conventional and DCNN-derived models demonstrated superior accuracy to predict positive genotype in patients with HCM."},"publication_date":"2021-08-27","publication_name":{"en":"Frontiers in Cardiovascular Medicine","ja":"Frontiers in Cardiovascular Medicine"},"volume":"Vol.8","starting_page":"669860","ending_page":"669860","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fcvm.2021.669860"],"issn":["2297-055X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116065","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33746155","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85111576585&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=381775","label":"url"}],"paper_title":{"en":"Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation","ja":"Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation"},"authors":{"en":[{"name":"Matsuura Tomomi"},{"name":"Soeki Takeshi"},{"name":"Fukuda Daiju"},{"name":"Uematsu Etsuko"},{"name":"Tobiume Takeshi"},{"name":"Hara Tomoya"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"松浦 朋美"},{"name":"添木 武"},{"name":"福田 大受"},{"name":"Uematsu Etsuko"},{"name":"飛梅 威"},{"name":"原 知也"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Activated factor X (FXa), which contributes to chronic inflammation via protease-activated receptor 2 (PAR2), might play an important role in atrial fibrillation (AF) arrhythmogenesis. This study aimed to assess whether PAR2 signaling contributes to AF arrhythmogenesis and whether rivaroxaban ameliorates atrial inflammation and prevents AF.Methods and Results:In Study 1, PAR2 deficient (PAR2-/-) and wild-type mice were infused with angiotensin II (Ang II) or a vehicle via an osmotic minipump for 2 weeks. In Study 2, spontaneously hypertensive rats (SHRs) were treated with rivaroxaban, warfarin, or vehicle for 2 weeks after 8 h of right atrial rapid pacing. The AF inducibility and atrial remodeling in both studies were examined. Ang II-treated PAR2-/- mice had a lower incidence of AF and less mRNA expression of collagen1 and collagen3 in the atrium compared to wild-type mice treated with Ang II. Rivaroxaban significantly reduced AF inducibility compared with warfarin or vehicle. In SHRs treated with a vehicle, rapid atrial pacing promoted gene expression of inflammatory and fibrosis-related biomarkers in the atrium. Rivaroxaban, but not warfarin, significantly reduced expression levels of these genes. The FXa-PAR2 signaling pathway might contribute to AF arrhythmogenesis associated with atrial inflammation. A direct FXa inhibitor, rivaroxaban, could prevent atrial inflammation and reduce AF inducibility, probably by inhibiting the pro-inflammatory activation.","ja":"Activated factor X (FXa), which contributes to chronic inflammation via protease-activated receptor 2 (PAR2), might play an important role in atrial fibrillation (AF) arrhythmogenesis. This study aimed to assess whether PAR2 signaling contributes to AF arrhythmogenesis and whether rivaroxaban ameliorates atrial inflammation and prevents AF.Methods and Results:In Study 1, PAR2 deficient (PAR2-/-) and wild-type mice were infused with angiotensin II (Ang II) or a vehicle via an osmotic minipump for 2 weeks. In Study 2, spontaneously hypertensive rats (SHRs) were treated with rivaroxaban, warfarin, or vehicle for 2 weeks after 8 h of right atrial rapid pacing. The AF inducibility and atrial remodeling in both studies were examined. Ang II-treated PAR2-/- mice had a lower incidence of AF and less mRNA expression of collagen1 and collagen3 in the atrium compared to wild-type mice treated with Ang II. Rivaroxaban significantly reduced AF inducibility compared with warfarin or vehicle. In SHRs treated with a vehicle, rapid atrial pacing promoted gene expression of inflammatory and fibrosis-related biomarkers in the atrium. Rivaroxaban, but not warfarin, significantly reduced expression levels of these genes. The FXa-PAR2 signaling pathway might contribute to AF arrhythmogenesis associated with atrial inflammation. A direct FXa inhibitor, rivaroxaban, could prevent atrial inflammation and reduce AF inducibility, probably by inhibiting the pro-inflammatory activation."},"publication_date":"2021-07-21","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.85","number":"No.8","starting_page":"1383","ending_page":"1391","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-20-1006"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34226923","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85120384111&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376699","label":"url"}],"paper_title":{"en":"STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases","ja":"STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases"},"authors":{"en":[{"name":"Phuong Tran Pham"},{"name":"Fukuda Daiju"},{"name":"Nishimoto Sachiko"},{"name":"Kim-Kaneyama JR"},{"name":"Lei XF"},{"name":"Takahashi Yutaka"},{"name":"Sato Tomohito"},{"name":"Tanaka Kimie"},{"name":"Suto Kumiko"},{"name":"Kawabata Yutaka"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimada Kenji"},{"name":"Kanematsu Yasuhisa"},{"name":"Takagi Yasushi"},{"name":"Shimabukuro Michio"},{"name":"Setou Mitsutoshi"},{"name":"Barber N Glen"},{"name":"Sata Masataka"}],"ja":[{"name":"Pham Tran Phuong"},{"name":"福田 大受"},{"name":"西本 幸子"},{"name":"Kim-Kaneyama JR"},{"name":"Lei XF"},{"name":"Takahashi Yutaka"},{"name":"Sato Tomohito"},{"name":"Tanaka Kimie"},{"name":"數藤 久美子"},{"name":"川端 豊"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島田 健司"},{"name":"兼松 康久"},{"name":"髙木 康志"},{"name":"島袋 充生"},{"name":"Setou Mitsutoshi"},{"name":"Barber N Glen"},{"name":"佐田 政隆"}]},"description":{"en":"Lifestyle-related diseases promote atherosclerosis, a chronic inflammatory disease; however, the molecular mechanism remains largely unknown. Endogenous DNA fragments released under over-nutrient condition provoke sterile inflammation through the recognition by DNA sensors. Here, we investigated the role of stimulator of interferon genes (STING), a cytosolic DNA sensor, in atherogenesis. Apolipoprotein E-deficient (Apoe-/-) mice fed a western-type diet (WTD), a hypercholesterolaemic mouse model, showed higher STING expression and markers for DNA damage such as γH2AX, p53, and single-stranded DNA (ssDNA) accumulation in macrophages in the aorta compared with wild-type (WT) mice. The level of cGAMP, a STING agonist, in the aorta was higher in Apoe-/- mice. Genetic deletion of Sting in Apoe-/- mice reduced atherosclerotic lesions in the aortic arch, lipid, and macrophage accumulation in plaques, and inflammatory molecule expression in the aorta compared with the control. Pharmacological blockade of STING using a specific inhibitor, C-176, ameliorated atherogenesis in Apoe-/- mice. In contrast, bone marrow-specific STING expression in Apoe-/- mice stimulated atherogenesis. Expression or deletion of STING did not affect metabolic parameters and blood pressure. In vitro studies revealed that STING activation by cGAMP or mitochondrial DNA accelerated inflammatory molecule expression (e.g. TNF-α or IFN-β) in mouse and human macrophages. Activation of nuclear factor-κB and TANK binding kinase 1 was involved in STING-associated vascular inflammation and macrophage activation. Furthermore, human atherosclerotic lesions in the carotid arteries expressed STING and cGAMP. Stimulator of interferon genes stimulates pro-inflammatory activation of macrophages, leading to the development of atherosclerosis. Stimulator of interferon genes signalling may serve as a potential therapeutic target for atherosclerosis.","ja":"Lifestyle-related diseases promote atherosclerosis, a chronic inflammatory disease; however, the molecular mechanism remains largely unknown. Endogenous DNA fragments released under over-nutrient condition provoke sterile inflammation through the recognition by DNA sensors. Here, we investigated the role of stimulator of interferon genes (STING), a cytosolic DNA sensor, in atherogenesis. Apolipoprotein E-deficient (Apoe-/-) mice fed a western-type diet (WTD), a hypercholesterolaemic mouse model, showed higher STING expression and markers for DNA damage such as γH2AX, p53, and single-stranded DNA (ssDNA) accumulation in macrophages in the aorta compared with wild-type (WT) mice. The level of cGAMP, a STING agonist, in the aorta was higher in Apoe-/- mice. Genetic deletion of Sting in Apoe-/- mice reduced atherosclerotic lesions in the aortic arch, lipid, and macrophage accumulation in plaques, and inflammatory molecule expression in the aorta compared with the control. Pharmacological blockade of STING using a specific inhibitor, C-176, ameliorated atherogenesis in Apoe-/- mice. In contrast, bone marrow-specific STING expression in Apoe-/- mice stimulated atherogenesis. Expression or deletion of STING did not affect metabolic parameters and blood pressure. In vitro studies revealed that STING activation by cGAMP or mitochondrial DNA accelerated inflammatory molecule expression (e.g. TNF-α or IFN-β) in mouse and human macrophages. Activation of nuclear factor-κB and TANK binding kinase 1 was involved in STING-associated vascular inflammation and macrophage activation. Furthermore, human atherosclerotic lesions in the carotid arteries expressed STING and cGAMP. Stimulator of interferon genes stimulates pro-inflammatory activation of macrophages, leading to the development of atherosclerosis. Stimulator of interferon genes signalling may serve as a potential therapeutic target for atherosclerosis."},"publication_date":"2021-07-06","publication_name":{"en":"European Heart Journal","ja":"European Heart Journal"},"volume":"Vol.42","number":"No.42","starting_page":"4336","ending_page":"4348","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/eurheartj/ehab249"],"issn":["1522-9645"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116449","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32879149","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371088","label":"url"}],"paper_title":{"en":"Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice","ja":"Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice"},"authors":{"en":[{"name":"Ganbaatar B"},{"name":"Fukuda Daiju"},{"name":"Shinohara M"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Hirata KI"},{"name":"Sata Masataka"}],"ja":[{"name":"GANBAATAR BYAMBASUREN"},{"name":"福田 大受"},{"name":"Shinohara M"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"Hirata KI"},{"name":"佐田 政隆"}]},"description":{"en":"The bioactive lipid, sphingosine-1-phosphate (S1P), has various roles in the physiology and pathophysiology of many diseases. There are five S1P receptors; however, the role of each S1P receptor in atherogenesis is still obscure. Here we investigated the contribution of S1P receptor 2 (S1P2) to atherogenesis by using a specific S1P2 antagonist, ONO-5430514, in apolipoprotein E-deficient (Apoe) mice. Apoe mice fed with a western-type diet (WTD) received ONO-5430514 (30 mg/kg/day) or vehicle. To examine the effect on atherogenesis, Sudan IV staining, histological analysis, qPCR, and vascular reactivity assay was performed. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. WTD-fed Apoe mice had significantly higher S1P2 expression in the aorta compared with wild-type mice. S1P2 antagonist treatment for 20 weeks reduced atherosclerotic lesion development (p<0.05). S1P2 antagonist treatment for 8 weeks ameliorated endothelial dysfunction (p<0.05) accompanied with significant reduction of lipid deposition, macrophage accumulation, and inflammatory molecule expression in the aorta compared with vehicle. S1P2 antagonist attenuated the phosphorylation of JNK in the abdominal aorta compared with vehicle (p<0.05). In HUVEC, S1P promoted inflammatory molecule expression such as MCP-1 and VCAM-1 p<0.001), which was attenuated by S1P2 antagonist or a JNK inhibitor (p<0.01). S1P2 antagonist also inhibited S1P-induced JNK phosphorylation in HUVEC (p<0.05). Our results suggested that an S1P2 antagonist attenuates endothelial dysfunction and prevents atherogenesis. S1P2, which promotes inflammatory activation of endothelial cells, might be a therapeutic target for atherosclerosis.","ja":"The bioactive lipid, sphingosine-1-phosphate (S1P), has various roles in the physiology and pathophysiology of many diseases. There are five S1P receptors; however, the role of each S1P receptor in atherogenesis is still obscure. Here we investigated the contribution of S1P receptor 2 (S1P2) to atherogenesis by using a specific S1P2 antagonist, ONO-5430514, in apolipoprotein E-deficient (Apoe) mice. Apoe mice fed with a western-type diet (WTD) received ONO-5430514 (30 mg/kg/day) or vehicle. To examine the effect on atherogenesis, Sudan IV staining, histological analysis, qPCR, and vascular reactivity assay was performed. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. WTD-fed Apoe mice had significantly higher S1P2 expression in the aorta compared with wild-type mice. S1P2 antagonist treatment for 20 weeks reduced atherosclerotic lesion development (p<0.05). S1P2 antagonist treatment for 8 weeks ameliorated endothelial dysfunction (p<0.05) accompanied with significant reduction of lipid deposition, macrophage accumulation, and inflammatory molecule expression in the aorta compared with vehicle. S1P2 antagonist attenuated the phosphorylation of JNK in the abdominal aorta compared with vehicle (p<0.05). In HUVEC, S1P promoted inflammatory molecule expression such as MCP-1 and VCAM-1 p<0.001), which was attenuated by S1P2 antagonist or a JNK inhibitor (p<0.01). S1P2 antagonist also inhibited S1P-induced JNK phosphorylation in HUVEC (p<0.05). Our results suggested that an S1P2 antagonist attenuates endothelial dysfunction and prevents atherogenesis. S1P2, which promotes inflammatory activation of endothelial cells, might be a therapeutic target for atherosclerosis."},"publication_date":"2021-06-01","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.28","number":"No.6","starting_page":"630","ending_page":"642","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.54916"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116140","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34027673","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375885","label":"url"}],"paper_title":{"en":"Acute Hospital Mortality of Venous Thromboembolism in Patients With Cancer From Registry Data","ja":"Acute Hospital Mortality of Venous Thromboembolism in Patients With Cancer From Registry Data"},"authors":{"en":[{"name":"Okushi Y"},{"name":"Kusunose Kenya"},{"name":"Okayama Y"},{"name":"Zheng Robert"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"大櫛 祐一郎"},{"name":"楠瀬 賢也"},{"name":"Okayama Y"},{"name":"Robert Zheng"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Background The prognosis of patients with cancer-venous thromboembolism (VTE) is not well known because of a lack of registry data. Moreover, there is also no knowledge on how specific types are related to prognosis. We sought to evaluate the clinical characteristics and outcomes of patients with cancer-associated VTE, compared with a matched cohort without cancer using real-world registry data of VTE. Methods and Results This study was based on the Diagnosis Procedure Combination database in the JROAD-DPC (Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination). Of 5 106 151 total patients included in JROAD-DPC, we identified 49 580 patients who were first hospitalized with VTE from April 2012 to March 2017. Propensity score was estimated with a logistic regression model, with cancer as the dependent variable and 18 clinically relevant covariates. After propensity matching, there were 25 148 patients with VTE with or without cancer. On propensity score-matched analysis with 25 148 patients with VTE, patients with cancer had higher total in-hospital mortality within 7 days (1.3% versus 1.1%, odds ratio [OR], 1.66; 95% CI, 1.31-2.11; <0.0001), 14 days (2.5% versus 1.5%, OR, 2.07; 95% CI, 1.72-2.49; <0.0001), and 30 days (4.8% versus 2.0%, OR, 2.85; 95% CI, 2.45-3.31; <0.0001). On analysis for each type of cancer, in-hospital mortality in 11 types of cancer was significantly high, especially pancreas (OR, 12.96; 95% CI, 6.41-26.20), biliary tract (OR, 8.67; 95% CI, 3.00-25.03), and liver (OR, 7.31; 95% CI, 3.05-17.50). Conclusions Patients with cancer had a higher in-hospital acute mortality for VTE than those without cancer, especially in pancreatic, biliary tract, and liver cancers.","ja":"Background The prognosis of patients with cancer-venous thromboembolism (VTE) is not well known because of a lack of registry data. Moreover, there is also no knowledge on how specific types are related to prognosis. We sought to evaluate the clinical characteristics and outcomes of patients with cancer-associated VTE, compared with a matched cohort without cancer using real-world registry data of VTE. Methods and Results This study was based on the Diagnosis Procedure Combination database in the JROAD-DPC (Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination). Of 5 106 151 total patients included in JROAD-DPC, we identified 49 580 patients who were first hospitalized with VTE from April 2012 to March 2017. Propensity score was estimated with a logistic regression model, with cancer as the dependent variable and 18 clinically relevant covariates. After propensity matching, there were 25 148 patients with VTE with or without cancer. On propensity score-matched analysis with 25 148 patients with VTE, patients with cancer had higher total in-hospital mortality within 7 days (1.3% versus 1.1%, odds ratio [OR], 1.66; 95% CI, 1.31-2.11; <0.0001), 14 days (2.5% versus 1.5%, OR, 2.07; 95% CI, 1.72-2.49; <0.0001), and 30 days (4.8% versus 2.0%, OR, 2.85; 95% CI, 2.45-3.31; <0.0001). On analysis for each type of cancer, in-hospital mortality in 11 types of cancer was significantly high, especially pancreas (OR, 12.96; 95% CI, 6.41-26.20), biliary tract (OR, 8.67; 95% CI, 3.00-25.03), and liver (OR, 7.31; 95% CI, 3.05-17.50). Conclusions Patients with cancer had a higher in-hospital acute mortality for VTE than those without cancer, especially in pancreatic, biliary tract, and liver cancers."},"publication_date":"2021-05-22","publication_name":{"en":"Journal of the American Heart Association","ja":"Journal of the American Heart Association"},"volume":"Vol.10","number":"No.11","starting_page":"e019373","ending_page":"e019373","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/JAHA.120.019373"],"issn":["2047-9980"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85098957691&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373239","label":"url"}],"paper_title":{"en":"Quantification of Carotid Plaque Histology Using iPlaque Software","ja":"Quantification of Carotid Plaque Histology Using iPlaque Software"},"authors":{"en":[{"name":"Ogata T"},{"name":"Shimada H"},{"name":"Inoue T"},{"name":"Takeshita S"},{"name":"Tsuboi Y"},{"name":"Uesugi N"},{"name":"Fujiwara M"},{"name":"Sata Masataka"},{"name":"Yamada Hirotsugu"}],"ja":[{"name":"Ogata T"},{"name":"Shimada H"},{"name":"Inoue T"},{"name":"Takeshita S"},{"name":"Tsuboi Y"},{"name":"Uesugi N"},{"name":"Fujiwara M"},{"name":"佐田 政隆"},{"name":"山田 博胤"}]},"publication_date":"2021-04","publication_name":{"en":"Ultrasound in Medicine & Biology","ja":"Ultrasound in Medicine & Biology"},"volume":"Vol.47","number":"No.4","starting_page":"928","ending_page":"931","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ultrasmedbio.2020.12.002"],"issn":["0301-5629"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116335","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374772","label":"url"}],"paper_title":{"en":"Frontiers of inflammatory disease research: inflammation in cardiovascular-cerebral diseases","ja":"Frontiers of inflammatory disease research: inflammation in cardiovascular-cerebral diseases"},"authors":{"en":[{"name":"Fukuda Daiju"},{"name":"Sata Masataka"}],"ja":[{"name":"福田 大受"},{"name":"佐田 政隆"}]},"publication_date":"2021-03-29","publication_name":{"en":"Inflammation and Regeneration","ja":"Inflammation and Regeneration"},"volume":"Vol.41","number":"No.1","starting_page":"10","ending_page":"10","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s41232-021-00160-z"],"issn":["1880-8190"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33609716","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85108436549&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374030","label":"url"}],"paper_title":{"en":"Deep Learning for Detection of Elevated Pulmonary Artery Wedge Pressure using Standard Chest X-Ray","ja":"Deep Learning for Detection of Elevated Pulmonary Artery Wedge Pressure using Standard Chest X-Ray"},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Kusunose Kenya"},{"name":"Tsuji Takumasa"},{"name":"Fujimori Kohei"},{"name":"Kotoku Jun'ichi"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"楠瀬 賢也"},{"name":"Tsuji Takumasa"},{"name":"Fujimori Kohei"},{"name":"Kotoku Jun'ichi"},{"name":"佐田 政隆"}]},"description":{"en":"To accurately diagnose and control heart failure (HF), it is important to carry out a simple assessment of elevated pulmonary arterial wedge pressure (PAWP). The aim of this study was to develop and validate an objective method for detecting elevated PAWP by applying deep learning (DL) to a chest x-ray (CXR). We enrolled 1013 consecutive patients with a right-heart catheter between October 2009 and February 2020. We developed a convolutional neural network to identify patients with elevated PAWP (> 18 mm Hg) as the actual value of PAWP to be used in the dataset for training. In the prospective validation dataset used to detect elevated PAWP, the area under the receiver operating characteristic curve (AUC) was calculated using the DL model that evaluated the CXR. In the prospective validation dataset, the AUC of the DL model with CXR was not significantly different from the AUC produced by brain natriuretic peptide (BNP) and the echocardiographic left-ventricular diastolic dysfunction (DD) algorithm (DL model: 0.77 vs BNP: 0.77 vs DD algorithm: 0.70; respectively; P = NS for all comparisons); it was, however, significantly higher than the AUC of the cardiothoracic ratio (DL model vs cardiothoracic ratio [CTR]: 0.66, P = 0.044). The model based on 3 parameters (BNP, DD algorithm, and CTR) was improved by adding the DL model (AUC: from 0.80 to 0.86; P = 0.041). Applying the DL model based on a CXR (a classical, universal, and low-cost test) is useful for screening for elevated PAWP.","ja":"To accurately diagnose and control heart failure (HF), it is important to carry out a simple assessment of elevated pulmonary arterial wedge pressure (PAWP). The aim of this study was to develop and validate an objective method for detecting elevated PAWP by applying deep learning (DL) to a chest x-ray (CXR). We enrolled 1013 consecutive patients with a right-heart catheter between October 2009 and February 2020. We developed a convolutional neural network to identify patients with elevated PAWP (> 18 mm Hg) as the actual value of PAWP to be used in the dataset for training. In the prospective validation dataset used to detect elevated PAWP, the area under the receiver operating characteristic curve (AUC) was calculated using the DL model that evaluated the CXR. In the prospective validation dataset, the AUC of the DL model with CXR was not significantly different from the AUC produced by brain natriuretic peptide (BNP) and the echocardiographic left-ventricular diastolic dysfunction (DD) algorithm (DL model: 0.77 vs BNP: 0.77 vs DD algorithm: 0.70; respectively; P = NS for all comparisons); it was, however, significantly higher than the AUC of the cardiothoracic ratio (DL model vs cardiothoracic ratio [CTR]: 0.66, P = 0.044). The model based on 3 parameters (BNP, DD algorithm, and CTR) was improved by adding the DL model (AUC: from 0.80 to 0.86; P = 0.041). Applying the DL model based on a CXR (a classical, universal, and low-cost test) is useful for screening for elevated PAWP."},"publication_date":"2021-02-18","publication_name":{"en":"The Canadian Journal of Cardiology","ja":"The Canadian Journal of Cardiology"},"volume":"Vol.37","number":"No.8","starting_page":"1198","ending_page":"1206","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.cjca.2021.02.007"],"issn":["1916-7075"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://dx.doi.org/10.1136/openhrt-2020-001559","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116465","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374028","label":"url"}],"paper_title":{"en":"Cardiac reserve by 6-minute walk stress echocardiography in systemic sclerosis.","ja":"Cardiac reserve by 6-minute walk stress echocardiography in systemic sclerosis."},"authors":{"en":[{"name":"Arase Miharu"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi N"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Okushi Y"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"荒瀬 美晴"},{"name":"楠瀬 賢也"},{"name":"山口 夏美"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"大櫛 祐一郎"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"publication_date":"2021-02","publication_name":{"en":"Open Heart","ja":"Open Heart"},"volume":"Vol.8","number":"No.1","starting_page":"e001559","ending_page":"e001559","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/openhrt-2020-001559"],"issn":["2053-3624"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116464","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33498709","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85099832739&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373474","label":"url"}],"paper_title":{"en":"Association between Vitamin D and Heart Failure Mortality in 10,974 Hospitalized Individuals.","ja":"Association between Vitamin D and Heart Failure Mortality in 10,974 Hospitalized Individuals."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Okushi Y"},{"name":"Okayama Y"},{"name":"Zheng Robert"},{"name":"Abe M"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"大櫛 祐一郎"},{"name":"Okayama Y"},{"name":"Robert Zheng"},{"name":"Abe M"},{"name":"Nakai M"},{"name":"Sumita Y"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"A broad range of chronic conditions, including heart failure (HF), have been associated with vitamin D deficiency. Existing clinical trials involving vitamin D supplementation in chronic HF patients have been inconclusive. We sought to evaluate the outcomes of patients with vitamin D supplementation, compared with a matched cohort using real-world big data of HF hospitalization. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). After exclusion criteria, we identified 93,692 patients who were first hospitalized with HF between April 2012 and March 2017 (mean age was 79 ± 12 years, and 52.2% were male). Propensity score (PS) was estimated with logistic regression model, with vitamin D supplementation as the dependent variable and clinically relevant covariates. On PS-matched analysis with 10,974 patients, patients with vitamin D supplementation had lower total in-hospital mortality (6.5 vs. 9.4%, odds ratio: 0.67, < 0.001) and in-hospital mortality within 7 days and 30 days (0.9 vs. 2.5%, OR, 0.34, and 3.8 vs. 6.5%, OR: 0.56, both < 0.001). In the sub-group analysis, mortalities in patients with age < 75, diabetes, dyslipidemia, atrial arrhythmia, cancer, renin-angiotensin system blocker, and β-blocker were not affected by vitamin D supplementation. Patients with vitamin D supplementation had a lower in-hospital mortality for HF than patients without vitamin D supplementation in the propensity matched cohort. The identification of specific clinical characteristics in patients benefitting from vitamin D may be useful for determining targets of future randomized control trials.","ja":"A broad range of chronic conditions, including heart failure (HF), have been associated with vitamin D deficiency. Existing clinical trials involving vitamin D supplementation in chronic HF patients have been inconclusive. We sought to evaluate the outcomes of patients with vitamin D supplementation, compared with a matched cohort using real-world big data of HF hospitalization. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). After exclusion criteria, we identified 93,692 patients who were first hospitalized with HF between April 2012 and March 2017 (mean age was 79 ± 12 years, and 52.2% were male). Propensity score (PS) was estimated with logistic regression model, with vitamin D supplementation as the dependent variable and clinically relevant covariates. On PS-matched analysis with 10,974 patients, patients with vitamin D supplementation had lower total in-hospital mortality (6.5 vs. 9.4%, odds ratio: 0.67, < 0.001) and in-hospital mortality within 7 days and 30 days (0.9 vs. 2.5%, OR, 0.34, and 3.8 vs. 6.5%, OR: 0.56, both < 0.001). In the sub-group analysis, mortalities in patients with age < 75, diabetes, dyslipidemia, atrial arrhythmia, cancer, renin-angiotensin system blocker, and β-blocker were not affected by vitamin D supplementation. Patients with vitamin D supplementation had a lower in-hospital mortality for HF than patients without vitamin D supplementation in the propensity matched cohort. The identification of specific clinical characteristics in patients benefitting from vitamin D may be useful for determining targets of future randomized control trials."},"publication_date":"2021-01-23","publication_name":{"en":"Nutrients","ja":"Nutrients"},"volume":"Vol.13","number":"No.2","starting_page":"335","ending_page":"335","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/nu13020335"],"issn":["2072-6643"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://doi.org/10.3389/fcvm.2020.607825","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33521062","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373473","label":"url"}],"paper_title":{"en":"Deleterious Effects of Epicardial Adipose Tissue Volume on Global Longitudinal Strain in Patients With Preserved Left Ventricular Ejection Fraction","ja":"Deleterious Effects of Epicardial Adipose Tissue Volume on Global Longitudinal Strain in Patients With Preserved Left Ventricular Ejection Fraction"},"authors":{"en":[{"name":"Maimaituxun Gulinu"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Torii Yuta"},{"name":"Yamada Nao"},{"name":"Soeki Takeshi"},{"name":"Masuzaki H"},{"name":"Sata Masataka"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"Gulinu Maimaituxun"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"鳥居 裕太"},{"name":"山田 なお"},{"name":"添木 武"},{"name":"Masuzaki H"},{"name":"佐田 政隆"},{"name":"島袋 充生"}]},"publication_date":"2021-01-15","publication_name":{"en":"Frontiers in Cardiovascular Medicine","ja":"Frontiers in Cardiovascular Medicine"},"volume":"Vol.7","starting_page":"607825","ending_page":"607825","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fcvm.2020.607825"],"issn":["2297-055X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_5914-20/_article","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116336","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33456037","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=373298","label":"url"}],"paper_title":{"en":"An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration","ja":"An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration"},"authors":{"en":[{"name":"Tanaka Hironori"},{"name":"Saijyo Yoshihito"},{"name":"Tomonari Tetsu"},{"name":"Tanaka Takahiro"},{"name":"Taniguchi Tatsuya"},{"name":"Yagi Shusuke"},{"name":"Okamoto Koichi"},{"name":"Miyamoto Hiroshi"},{"name":"Sogabe Masahiro"},{"name":"Sato Yasushi"},{"name":"Muguruma Naoki"},{"name":"Tsuneyama Koichi"},{"name":"Sata Masataka"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"田中 宏典"},{"name":"西條 良仁"},{"name":"友成 哲"},{"name":"田中 貴大"},{"name":"谷口 達哉"},{"name":"八木 秀介"},{"name":"岡本 耕一"},{"name":"宮本 弘志"},{"name":"曽我部 正弘"},{"name":"佐藤 康史"},{"name":"六車 直樹"},{"name":"常山 幸一"},{"name":"佐田 政隆"},{"name":"高山 哲治"}]},"description":{"en":"A 42-year-old woman visited our hospital due to syncope. Contrast-enhanced CT revealed portosystemic shunt, portal vein hypoplasia, and multiple liver nodules. The histological examination of a liver biopsy specimen exhibited portal vein hypoplasia and revealed that the liver tumor was positive for glutamine synthetase. The patient was therefore diagnosed with congenital extrahepatic portosystemic shunt type II, and with focal nodular hyperplasia (FNH)-like nodules. She had the complication of severe portopulmonary hypertension and underwent complete shunt closure by balloon-occluded retrograde transvenous obliteration (B-RTO). The intrahepatic portal vein was well developed at 1 year after B-RTO, and multiple liver nodules completely regressed. Her pulmonary hypertension also improved.","ja":"A 42-year-old woman visited our hospital due to syncope. Contrast-enhanced CT revealed portosystemic shunt, portal vein hypoplasia, and multiple liver nodules. The histological examination of a liver biopsy specimen exhibited portal vein hypoplasia and revealed that the liver tumor was positive for glutamine synthetase. The patient was therefore diagnosed with congenital extrahepatic portosystemic shunt type II, and with focal nodular hyperplasia (FNH)-like nodules. She had the complication of severe portopulmonary hypertension and underwent complete shunt closure by balloon-occluded retrograde transvenous obliteration (B-RTO). The intrahepatic portal vein was well developed at 1 year after B-RTO, and multiple liver nodules completely regressed. Her pulmonary hypertension also improved."},"publication_date":"2021-01-15","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"volume":"Vol.60","number":"No.12","starting_page":"1839","ending_page":"1845","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.5914-20"],"issn":["1349-7235"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116019","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33994469","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=377691","label":"url"}],"paper_title":{"en":"Congenital Hypogonadotropic Hypogonadism with Early-Onset Coronary Artery Disease.","ja":"Congenital Hypogonadotropic Hypogonadism with Early-Onset Coronary Artery Disease."},"authors":{"en":[{"name":"Takashima Akira"},{"name":"Yagi Shusuke"},{"name":"Yamaguchi Koji"},{"name":"Kurahashi Kiyoe"},{"name":"Kojima Yuko"},{"name":"Zheng Robert"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yoshida Sumiko"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Aihara Ken-ichi"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"Takashima Akira"},{"name":"八木 秀介"},{"name":"山口 浩司"},{"name":"倉橋 清衛"},{"name":"Kojima Yuko"},{"name":"Zheng Robert"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"吉田 守美子"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"粟飯原 賢一"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"The patient with congenital hypogonadotropic hypogonadism (HH) shows low serum levels of androgen, which is a group of sex hormones including testosterone, caused by the decreased gonadotropin release in the hypothalamus. Recent reports showed androgens exert protective effects against insulin resistance or atherosclerotic diseases, such as diabetes mellitus or coronary artery disease. However, whether the juvenile hypogonadism affects the diabetes or cardiovascular disease is unclear. We report a case of a middle-aged man with congenital HH who had severe coronary artery disease complicated with metabolic disorders. J. Med. Invest. 68 : 189-191, February, 2021.","ja":"The patient with congenital hypogonadotropic hypogonadism (HH) shows low serum levels of androgen, which is a group of sex hormones including testosterone, caused by the decreased gonadotropin release in the hypothalamus. Recent reports showed androgens exert protective effects against insulin resistance or atherosclerotic diseases, such as diabetes mellitus or coronary artery disease. However, whether the juvenile hypogonadism affects the diabetes or cardiovascular disease is unclear. We report a case of a middle-aged man with congenital HH who had severe coronary artery disease complicated with metabolic disorders. J. Med. Invest. 68 : 189-191, February, 2021."},"publication_date":"2021","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.68","number":"No.1.2","starting_page":"189","ending_page":"191","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.68.189"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115937","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33489354","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85098701678&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375888","label":"url"}],"paper_title":{"en":"Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients","ja":"Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients"},"authors":{"en":[{"name":"Kawabata Yutaka"},{"name":"Soeki Takeshi"},{"name":"Ito Hiroyuki"},{"name":"Matsuura Tomomi"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Kitani M"},{"name":"Kawano K"},{"name":"Taketani Y"},{"name":"Sata Masataka"}],"ja":[{"name":"川端 豊"},{"name":"添木 武"},{"name":"伊藤 浩敬"},{"name":"松浦 朋美"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"Kitani M"},{"name":"Kawano K"},{"name":"Taketani Y"},{"name":"佐田 政隆"}]},"publication_date":"2020-12-25","publication_name":{"en":"International Journal of Hypertension","ja":"International Journal of Hypertension"},"starting_page":"6653851","ending_page":"6653851","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1155/2020/6653851"],"issn":["2090-0384"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116343","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33664895","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85099515348&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375707","label":"url"}],"paper_title":{"en":"Antegrade slow pathway mapping of typical atrioventricular nodal reentrant tachycardia based on direct slow pathway capture","ja":"Antegrade slow pathway mapping of typical atrioventricular nodal reentrant tachycardia based on direct slow pathway capture"},"authors":{"en":[{"name":"Tobiume Takeshi"},{"name":"Kato R"},{"name":"Matsuura Tomomi"},{"name":"Matsumoto Kazuhisa"},{"name":"Hara M"},{"name":"Takamori N"},{"name":"Taketani Y"},{"name":"Okwa K"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"},{"name":"Matsumoto K"}],"ja":[{"name":"飛梅 威"},{"name":"Kato R"},{"name":"松浦 朋美"},{"name":"松本 和久"},{"name":"Hara M"},{"name":"Takamori N"},{"name":"Taketani Y"},{"name":"Okwa K"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"添木 武"},{"name":"佐田 政隆"},{"name":"Matsumoto K"}]},"publication_date":"2020-12-24","publication_name":{"en":"Journal of Arrhythmia","ja":"Journal of Arrhythmia"},"volume":"Vol.37","number":"No.1","starting_page":"128","ending_page":"139","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/joa3.12484"],"issn":["1880-4276"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116291","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33268604","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85099089624&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=372765","label":"url"}],"paper_title":{"en":"Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis - An Update on Recent Findings","ja":"Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis - An Update on Recent Findings"},"authors":{"en":[{"name":"Tanaka K"},{"name":"Fukuda Daiju"},{"name":"Sata Masataka"}],"ja":[{"name":"Tanaka K"},{"name":"福田 大受"},{"name":"佐田 政隆"}]},"description":{"en":"Adipose tissue serves not only as an energy store or a mechanical cushion, but also as an endocrine organ. Recent evidence revealed that perivascular adipose tissue is involved in vascular homeostasis and pathophysiology of adjacent arteries by producing various adipokines. Epicardial adipose tissue (EAT) is located between the surface of the heart and the visceral layer of the pericardium and surrounds the coronary arteries. Many clinical studies suggest that an increase in EAT volume is associated with coronary artery disease. It has been reported that exercise and some antidiabetic drugs can reduce EAT volume. In this review, we outline recent findings on the roles of EAT in the pathogenesis of coronary atherosclerosis.","ja":"Adipose tissue serves not only as an energy store or a mechanical cushion, but also as an endocrine organ. Recent evidence revealed that perivascular adipose tissue is involved in vascular homeostasis and pathophysiology of adjacent arteries by producing various adipokines. Epicardial adipose tissue (EAT) is located between the surface of the heart and the visceral layer of the pericardium and surrounds the coronary arteries. Many clinical studies suggest that an increase in EAT volume is associated with coronary artery disease. It has been reported that exercise and some antidiabetic drugs can reduce EAT volume. In this review, we outline recent findings on the roles of EAT in the pathogenesis of coronary atherosclerosis."},"publication_date":"2020-12-01","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.85","number":"No.1","starting_page":"2","ending_page":"8","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-20-0935"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117214","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33250455","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85099105428&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=372579","label":"url"}],"paper_title":{"en":"Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes - A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society","ja":"Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes - A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society"},"authors":{"en":[{"name":"Araki Eiichi"},{"name":"Tanaka Atsushi"},{"name":"Inagaki Nobuya"},{"name":"Ito Hiroshi"},{"name":"Ueki Kohjiro"},{"name":"Murohara Toyoaki"},{"name":"Imai Kenjiro"},{"name":"Sata Masataka"},{"name":"Sugiyama Takehiro"},{"name":"Ishii Hideki"},{"name":"Yamane Shunsuke"},{"name":"Kadowaki Takashi"},{"name":"Komuro Issei"},{"name":"Node Koichi"}],"ja":[{"name":"Araki Eiichi"},{"name":"Tanaka Atsushi"},{"name":"Inagaki Nobuya"},{"name":"Ito Hiroshi"},{"name":"Ueki Kohjiro"},{"name":"Murohara Toyoaki"},{"name":"Imai Kenjiro"},{"name":"佐田 政隆"},{"name":"Sugiyama Takehiro"},{"name":"Ishii Hideki"},{"name":"Yamane Shunsuke"},{"name":"Kadowaki Takashi"},{"name":"Komuro Issei"},{"name":"Node Koichi"}]},"publication_date":"2020-11-30","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.12","number":"No.1","starting_page":"1","ending_page":"51","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-20-0865"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115491","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33203947","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=372449","label":"url"}],"paper_title":{"en":"Deep learning to predict elevated pulmonary artery pressure in patients with suspected pulmonary hypertension using standard chest X ray","ja":"Deep learning to predict elevated pulmonary artery pressure in patients with suspected pulmonary hypertension using standard chest X ray"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Hirata Yukina"},{"name":"Tsuji T"},{"name":"Kotoku J"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"平田 有紀奈"},{"name":"Tsuji T"},{"name":"Kotoku J"},{"name":"佐田 政隆"}]},"description":{"en":"Accurate diagnosis of pulmonary hypertension (PH) is crucial to ensure that patients receive timely treatment. We hypothesized that application of artificial intelligence (AI) to the chest X-ray (CXR) could identify elevated pulmonary artery pressure (PAP) and stratify the risk of heart failure hospitalization with PH. We retrospectively enrolled a total of 900 consecutive patients with suspected PH. We trained a convolutional neural network to identify patients with elevated PAP (> 20 mmHg) as the actual value of PAP. The endpoints in this study were admission or occurrence of heart failure with elevated PAP. In an independent evaluation set for detection of elevated PAP, the area under curve (AUC) by the AI algorithm was significantly higher than the AUC by measurements of CXR images and human observers (0.71 vs. 0.60 and vs. 0.63, all p < 0.05). In patients with AI predicted PH had 2-times the risk of heart failure with PH compared with those without AI predicted PH. This preliminary work suggests that applying AI to the CXR in high risk groups has limited performance when used alone in identifying elevated PAP. We believe that this report can serve as an impetus for a future large study.","ja":"Accurate diagnosis of pulmonary hypertension (PH) is crucial to ensure that patients receive timely treatment. We hypothesized that application of artificial intelligence (AI) to the chest X-ray (CXR) could identify elevated pulmonary artery pressure (PAP) and stratify the risk of heart failure hospitalization with PH. We retrospectively enrolled a total of 900 consecutive patients with suspected PH. We trained a convolutional neural network to identify patients with elevated PAP (> 20 mmHg) as the actual value of PAP. The endpoints in this study were admission or occurrence of heart failure with elevated PAP. In an independent evaluation set for detection of elevated PAP, the area under curve (AUC) by the AI algorithm was significantly higher than the AUC by measurements of CXR images and human observers (0.71 vs. 0.60 and vs. 0.63, all p < 0.05). In patients with AI predicted PH had 2-times the risk of heart failure with PH compared with those without AI predicted PH. This preliminary work suggests that applying AI to the CXR in high risk groups has limited performance when used alone in identifying elevated PAP. We believe that this report can serve as an impetus for a future large study."},"publication_date":"2020-11-17","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"Vol.10","number":"No.1","starting_page":"19311","ending_page":"19311","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41598-020-76359-w"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32209616","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378138","label":"url"}],"paper_title":{"en":"Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction","ja":"Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction"},"authors":{"en":[{"name":"Saijyo Yoshihito"},{"name":"Kusunose Kenya"},{"name":"Okushi Y"},{"name":"Yamada Hirotsugu"},{"name":"Toba Hiroaki"},{"name":"Sata Masataka"}],"ja":[{"name":"西條 良仁"},{"name":"楠瀬 賢也"},{"name":"大櫛 祐一郎"},{"name":"山田 博胤"},{"name":"鳥羽 博明"},{"name":"佐田 政隆"}]},"description":{"en":"The aim of our study was to assess the association between risk of cancer-therapy-related cardiac dysfunction (CTRCD) after first follow-up and the difference in echocardiographic measures from baseline to follow-up. We retrospectively enrolled 87 consecutive patients (58±14 years, 55 women) who received anthracycline and underwent echocardiographic examinations both before (baseline) and after initial anthracycline administration (first follow-up). We measured absolute values of global longitudinal strain (GLS), apical longitudinal strain (LS), mid-LS and basal-LS at baseline and first follow-up, and per cent changes (Δ) of these parameters were calculated. Among 61 patients who underwent further echocardiographic examinations (second follow-up, third follow-up, etc), we assessed the association between regional left ventricular (LV) systolic dysfunction from baseline to follow-up and development of CTRCD, defined as LV ejection fraction (LVEF) under 53% and more absolute decrease of 10% from baseline, after first follow-up. LVEF (65%±4% vs 63±4%, p=0.004), GLS (23.2%±2.6% vs 22.2±2.4%, p=0.005) and basal-LS (21.9%±2.5% vs 19.9±2.4%, p<0.001) at first follow-up significantly decreased compared with baseline. Among the 61 patients who had further follow-up echocardiographic examinations, 13% developed CTRCD. In the Cox-hazard model, worse Δbasal-LS was significantly associated with CTRCD. By Kaplan-Meier analysis, patients with Δbasal-LS decrease of more than the median value (-9.7%) had significantly worse event-free survival than those with a smaller decrease (p=0.015). Basal-LS significantly decreased prior to development of CTRCD, and worse basal-LS was associated with development of CTRCD in patients receiving anthracycline chemotherapy.","ja":"The aim of our study was to assess the association between risk of cancer-therapy-related cardiac dysfunction (CTRCD) after first follow-up and the difference in echocardiographic measures from baseline to follow-up. We retrospectively enrolled 87 consecutive patients (58±14 years, 55 women) who received anthracycline and underwent echocardiographic examinations both before (baseline) and after initial anthracycline administration (first follow-up). We measured absolute values of global longitudinal strain (GLS), apical longitudinal strain (LS), mid-LS and basal-LS at baseline and first follow-up, and per cent changes (Δ) of these parameters were calculated. Among 61 patients who underwent further echocardiographic examinations (second follow-up, third follow-up, etc), we assessed the association between regional left ventricular (LV) systolic dysfunction from baseline to follow-up and development of CTRCD, defined as LV ejection fraction (LVEF) under 53% and more absolute decrease of 10% from baseline, after first follow-up. LVEF (65%±4% vs 63±4%, p=0.004), GLS (23.2%±2.6% vs 22.2±2.4%, p=0.005) and basal-LS (21.9%±2.5% vs 19.9±2.4%, p<0.001) at first follow-up significantly decreased compared with baseline. Among the 61 patients who had further follow-up echocardiographic examinations, 13% developed CTRCD. In the Cox-hazard model, worse Δbasal-LS was significantly associated with CTRCD. By Kaplan-Meier analysis, patients with Δbasal-LS decrease of more than the median value (-9.7%) had significantly worse event-free survival than those with a smaller decrease (p=0.015). Basal-LS significantly decreased prior to development of CTRCD, and worse basal-LS was associated with development of CTRCD in patients receiving anthracycline chemotherapy."},"publication_date":"2020-11","publication_name":{"en":"Heart","ja":"Heart"},"volume":"Vol.106","number":"No.22","starting_page":"1752","ending_page":"1758","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/heartjnl-2019-316339"],"issn":["1468-201X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32879152","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=371089","label":"url"}],"paper_title":{"en":"Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study","ja":"Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study"},"authors":{"en":[{"name":"Tanabe N"},{"name":"Fukuda K"},{"name":"Matsubara H"},{"name":"Nakanishi N"},{"name":"Tahara N"},{"name":"Ikeda S"},{"name":"Kishi T"},{"name":"Satoh T"},{"name":"Hirata KI"},{"name":"Inoue T"},{"name":"Kimura H"},{"name":"Okano Y"},{"name":"Okazaki O"},{"name":"Sata Masataka"},{"name":"Tsujino I"},{"name":"Ueno S"},{"name":"Yamada N"},{"name":"Yao A"},{"name":"Kuriyama T"}],"ja":[{"name":"Tanabe N"},{"name":"Fukuda K"},{"name":"Matsubara H"},{"name":"Nakanishi N"},{"name":"Tahara N"},{"name":"Ikeda S"},{"name":"Kishi T"},{"name":"Satoh T"},{"name":"Hirata KI"},{"name":"Inoue T"},{"name":"Kimura H"},{"name":"Okano Y"},{"name":"Okazaki O"},{"name":"佐田 政隆"},{"name":"Tsujino I"},{"name":"Ueno S"},{"name":"Yamada N"},{"name":"Yao A"},{"name":"Kuriyama T"}]},"description":{"en":"Selexipag is an oral prostacyclin receptor (IP receptor) agonist with a non-prostanoid structure. This study examined its efficacy and safety in Japanese patients with non-operated or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).Methods and Results:This Phase II study was a randomized, double-blind, placebo-controlled parallel-group comparison. The primary endpoint was a change in pulmonary vascular resistance (PVR) from baseline to week 17. The main analysis involved a per-protocol set group of 28 subjects. The change in PVR (mean±SD) after 17 weeks of treatment in the selexipag group was -104±191 dyn·s/cm, whereas that in the placebo group was 26±180 dyn·s/cm. Thus, the treatment effect after 17 weeks of selexipag treatment was calculated as -130±189 dyn·s/cm(P=0.1553). Although the primary endpoint was not met, for the group not concomitantly using a pulmonary vasodilator the PVR in the selexipag group was significantly decreased compared with placebo group (P=0.0364). The selexipag group also showed improvement in total pulmonary resistance and cardiac index. Selexipag treatment improved pulmonary hemodynamics in Japanese patients with CTEPH, but PVR did not show a significant difference between the selexipag and placebo groups. (Trial registration: JAPIC Clinical Trials Information [JapicCTI-111667]).","ja":"Selexipag is an oral prostacyclin receptor (IP receptor) agonist with a non-prostanoid structure. This study examined its efficacy and safety in Japanese patients with non-operated or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).Methods and Results:This Phase II study was a randomized, double-blind, placebo-controlled parallel-group comparison. The primary endpoint was a change in pulmonary vascular resistance (PVR) from baseline to week 17. The main analysis involved a per-protocol set group of 28 subjects. The change in PVR (mean±SD) after 17 weeks of treatment in the selexipag group was -104±191 dyn·s/cm, whereas that in the placebo group was 26±180 dyn·s/cm. Thus, the treatment effect after 17 weeks of selexipag treatment was calculated as -130±189 dyn·s/cm(P=0.1553). Although the primary endpoint was not met, for the group not concomitantly using a pulmonary vasodilator the PVR in the selexipag group was significantly decreased compared with placebo group (P=0.0364). The selexipag group also showed improvement in total pulmonary resistance and cardiac index. Selexipag treatment improved pulmonary hemodynamics in Japanese patients with CTEPH, but PVR did not show a significant difference between the selexipag and placebo groups. (Trial registration: JAPIC Clinical Trials Information [JapicCTI-111667])."},"publication_date":"2020-09-03","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.84","number":"No.10","starting_page":"1866","ending_page":"1874","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-20-0438"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114190","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31487533","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85072539026&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359365","label":"url"}],"paper_title":{"en":"Association between Right Ventricular Contractile Function and Cardiac Events in Isolated Post-capillary and Combined Pre- and Post-capillary Pulmonary Hypertension","ja":"Association between Right Ventricular Contractile Function and Cardiac Events in Isolated Post-capillary and Combined Pre- and Post-capillary Pulmonary Hypertension"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yamada nao"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Saijoh Yoshihito"},{"name":"Hirata Yukina"},{"name":"Torii Yuta"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"山田 なお"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"西條 良仁"},{"name":"平田 有紀奈"},{"name":"鳥居 裕太"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Recent studies have shown that patients with combined pre- and postcapillary pulmonary hypertension (CpcPH) had worse outcomes than those with isolated postcapillary pulmonary hypertension (IpcPH). However, the prognostic factors including right ventricular (RV) function have not been well documented. The aim of this study was to assess the differentiation of PH phenotypes, using echocardiography, and the association between RV longitudinal strain and cardiac events. We prospectively recruited consecutive patients who had undergone right heart catheterization. The primary endpoint was cardiovascular death or readmission due to heart failure. We included 137 patients with Group 2 PH. A RV longitudinal strain of 17% was sensitive (85%) and specific (70%) to determine the CpcPH. During a median period of 31 months, 43 patients experienced the primary endpoint during follow-up. In a multivariate analysis, RV longitudinal strain was associated with the primary endpoint in both CpcPH and IpcPH (HR: 0.84, P = 0.003; HR: 0.86, P = 0.001). Lower RV longitudinal strain was independently associated with worse outcomes in CpcPH and IpcPH. RV longitudinal strain may play a prognostic role in PH phenotypes.","ja":"Recent studies have shown that patients with combined pre- and postcapillary pulmonary hypertension (CpcPH) had worse outcomes than those with isolated postcapillary pulmonary hypertension (IpcPH). However, the prognostic factors including right ventricular (RV) function have not been well documented. The aim of this study was to assess the differentiation of PH phenotypes, using echocardiography, and the association between RV longitudinal strain and cardiac events. We prospectively recruited consecutive patients who had undergone right heart catheterization. The primary endpoint was cardiovascular death or readmission due to heart failure. We included 137 patients with Group 2 PH. A RV longitudinal strain of 17% was sensitive (85%) and specific (70%) to determine the CpcPH. During a median period of 31 months, 43 patients experienced the primary endpoint during follow-up. In a multivariate analysis, RV longitudinal strain was associated with the primary endpoint in both CpcPH and IpcPH (HR: 0.84, P = 0.003; HR: 0.86, P = 0.001). Lower RV longitudinal strain was independently associated with worse outcomes in CpcPH and IpcPH. RV longitudinal strain may play a prognostic role in PH phenotypes."},"publication_date":"2020-09-02","publication_name":{"en":"Journal of Cardiac Failure","ja":"Journal of Cardiac Failure"},"volume":"Vol.26","number":"No.1","starting_page":"43","ending_page":"51","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.cardfail.2019.08.021"],"issn":["1532-8414"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://ci.nii.ac.jp/naid/130007887358/","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390848250135697408/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=377175","label":"url"}],"paper_title":{"en":"Comparison of Global Longitudinal Strain Measurement Among Recent Version Echocardiographic Machines and Vendor Independent Strain Analysis Software","ja":"最新の心エコー図診断装置および装置非依存性ストレイン解析ソフトウェアを用いたGlobal Longitudinal Strain計測の装置間差に関する検討"},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Kusunose Kenya"},{"name":"Fujita Yukina"},{"name":"Arase Miharu"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"楠瀬 賢也"},{"name":"藤田 幸那"},{"name":"荒瀬 美晴"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"description":{"en":"
Purpose: Global longitudinal strain (GLS) assessed using the two-dimensional (2D) speckle tracking method is considered to be an accurate and reproducible measurement method for assessing the LV contractility. However, the measurement variability across different ultrasonography machines has been discussed. This study aimed to determine whether the measurement variability among newer echocardiographic machines is lower than that reported in previous studies.
Subjects and Methods: We enrolled 34 healthy volunteers. Apical images were acquired using three types of latest ultrasonography machines at the Tokushima University Hospital. The GLS values were assessed and compared using the latest version of the vendor-specific software and one vendor-independent software packages (EchoInsight ver. 2.2.6.2230, Epsilon).
Results and Discussion: The upgraded vendor-specific software showed good correlation in GLS [GE vs. Philips (r=0.678, p<0.001, Bias 1.1%, 2SD ±2.9%), GE vs. Canon (r=0.690, p<0.001, Bias 0.4%, 2SD ±2.5%), Philips vs. Canon (r=0.551, p<0.001, Bias 1.5%, 2SD ±3.2%)]. The GLS measured using vendor-independent software provided greater degree of correlation than that with each software alone.
Conclusion: The measurement variability of GLS between devices was superior than that reported previously. Moreover, the GLS measured using the images acquired using each device with EchoInsight showed good inter-device correlation.
","ja":"目的:左室長軸方向ストレイン(GLS)は,正確で再現性の良い左室機能評価の指標とされているが,超音波診断装置間でのばらつきは未だ議論がある.本研究では,最新の超音波診断装置を用いることにより,GLSの装置間差が軽減しているという仮説を検証することを目的とした.
対象と方法: 34名の健康なボランティアの測定を行った.心尖部の画像は,徳島大学病院超音波センターに導入された最新の超音波装置を使用して取得した.GLSの測定はそれぞれの装置に搭載されているソフトウェアおよび,装置非依存性ストレイン解析ソフトウェアであるEchoInsightを用いて測定し,比較した.
結果と考察:各装置間でGLSに良好な相関が得られた(GE vs. Philips[r=0.678, p<0.001, Bias 1.1%, 2SD ±2.9%],GE vs. Canon[r=0.690, p<0.001, Bias 0.4%, 2SD ±2.5%],Philips vs. Canon[r=0.551, p<0.001, Bias 1.5%, 2SD ±3.2%]).EchoInsightを用いた場合,各装置で計測したGLSよりも相関関係は良好であった.
結語:GLSの装置間差は過去の報告と比較して改善していた.さらにEchoInsightを用いて計測したGLSは,良好な相関関係を認めた.
"},"publication_date":"2020-08","publication_name":{"en":"Japanese Journal of Medical Ultrasound Technology","ja":"超音波検査技術"},"volume":"Vol.45","number":"No.4","starting_page":"405","ending_page":"413","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.11272/jss.316"],"issn":["1881-4506"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32684602","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85088879684&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=370334","label":"url"}],"paper_title":{"en":"Association between Sarcopenia/Lower Muscle Mass and Short-Term Regression of Deep Vein Thrombosis Using Direct Oral Anticoagulants","ja":"Association between Sarcopenia/Lower Muscle Mass and Short-Term Regression of Deep Vein Thrombosis Using Direct Oral Anticoagulants"},"authors":{"en":[{"name":"Torii Yuta"},{"name":"Kusunose Kenya"},{"name":"Zheng Robert"},{"name":"Yamada Hirotsugu"},{"name":"Amano Rie"},{"name":"Matsumoto Rikizo"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Yamada Nao"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Okayama Yoshihiro"},{"name":"Sata Masataka"}],"ja":[{"name":"鳥居 裕太"},{"name":"楠瀬 賢也"},{"name":"Robert Zheng"},{"name":"山田 博胤"},{"name":"Amano Rie"},{"name":"Matsumoto Rikizo"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"山田 なお"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"Okayama Yoshihiro"},{"name":"佐田 政隆"}]},"description":{"en":"Advanced age, obesity, and muscle weakness are independent factors in the onset of deep vein thrombosis (DVT). Recently, an association between sarcopenia and DVT has been reported. We hypothesized that sarcopenia related factors, observed by ultrasonography, are associated with the regression effect on the thrombus following anticoagulation therapy. The present study focused on gastrocnemius muscle (GCM) thickness and the GCM's internal echogenic brightness. We examined the association with DVT regression following direct oral anticoagulants (DOACs) treatment.The prospective cohort study period was between October 2017 and August 2018. We enrolled 46 patients diagnosed with DVT by ultrasonography, who were aged >60 years old and treated with DOACs. Sarcopenia was evaluated using the Asian Working Group for Sarcopenia flowchart. The average DOACs treatment period was 94 days, and 29 patients exhibited thrombus regression. On univariate logistic regression analysis, sarcopenia, average GCM diameter index, and gastrocnemius integrated backscatter index were significantly associated with thrombus regression. In a multivariate model, only the average GCM diameter index correlated with thrombus regression.The average GCM diameter index is associated with DVT regression treated with DOACs. Considering the GCM diameter during DVT treatment can be a marker to make a decision for the treatment of DVT.","ja":"Advanced age, obesity, and muscle weakness are independent factors in the onset of deep vein thrombosis (DVT). Recently, an association between sarcopenia and DVT has been reported. We hypothesized that sarcopenia related factors, observed by ultrasonography, are associated with the regression effect on the thrombus following anticoagulation therapy. The present study focused on gastrocnemius muscle (GCM) thickness and the GCM's internal echogenic brightness. We examined the association with DVT regression following direct oral anticoagulants (DOACs) treatment.The prospective cohort study period was between October 2017 and August 2018. We enrolled 46 patients diagnosed with DVT by ultrasonography, who were aged >60 years old and treated with DOACs. Sarcopenia was evaluated using the Asian Working Group for Sarcopenia flowchart. The average DOACs treatment period was 94 days, and 29 patients exhibited thrombus regression. On univariate logistic regression analysis, sarcopenia, average GCM diameter index, and gastrocnemius integrated backscatter index were significantly associated with thrombus regression. In a multivariate model, only the average GCM diameter index correlated with thrombus regression.The average GCM diameter index is associated with DVT regression treated with DOACs. Considering the GCM diameter during DVT treatment can be a marker to make a decision for the treatment of DVT."},"publication_date":"2020-07-30","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.61","number":"No.4","starting_page":"787","ending_page":"794","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.20-032"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115917","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32714475","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=370335","label":"url"}],"paper_title":{"en":"Emerging roles of Toll-like receptor 9 in cardiometabolic disorders","ja":"Emerging roles of Toll-like receptor 9 in cardiometabolic disorders"},"authors":{"en":[{"name":"Nishimoto S"},{"name":"Fukuda Daiju"},{"name":"Sata Masataka"}],"ja":[{"name":"Nishimoto S"},{"name":"福田 大受"},{"name":"佐田 政隆"}]},"description":{"en":"Growing evidence suggests that damage-associated molecule patterns (DAMPs) and their receptors, pattern recognition receptors (PRRs), are associated with the progression of cardiometabolic disorders, including obesity-related insulin resistance and atherosclerosis. Cardiometabolic disorders share sterile chronic inflammation as a major cause; however, the exact mechanisms are still obscure. Toll-like receptor 9 (TLR9), one of the nucleic acid-sensing TLRs, recognizes DNA fragments derived from pathogens and contributes to self-defense by activation of the innate immune system. In addition, previous studies demonstrated that TLR9 recognizes DNA fragments released from host cells, accelerating sterile inflammation, which is associated with inflammatory diseases such as autoimmune diseases. In obese adipose tissue and atherosclerotic vascular tissue, various stresses release DNA fragments and/or nuclear proteins as DAMPs from degenerated adipocytes and vascular cells. Recent studies indicated that the activation of TLR9 in immune cells including macrophages and dendritic cells by recognition of these DAMPs promotes inflammation in these tissues, which causes cardiometabolic disorders. This review discusses recent advances in understanding the role of sterile inflammation associated with TLR9 and its endogenous ligands in cardiometabolic disorders. New insights into innate immunity may provide better understanding of cardiometabolic disorders and new therapeutic options for these major health threats in recent decades.","ja":"Growing evidence suggests that damage-associated molecule patterns (DAMPs) and their receptors, pattern recognition receptors (PRRs), are associated with the progression of cardiometabolic disorders, including obesity-related insulin resistance and atherosclerosis. Cardiometabolic disorders share sterile chronic inflammation as a major cause; however, the exact mechanisms are still obscure. Toll-like receptor 9 (TLR9), one of the nucleic acid-sensing TLRs, recognizes DNA fragments derived from pathogens and contributes to self-defense by activation of the innate immune system. In addition, previous studies demonstrated that TLR9 recognizes DNA fragments released from host cells, accelerating sterile inflammation, which is associated with inflammatory diseases such as autoimmune diseases. In obese adipose tissue and atherosclerotic vascular tissue, various stresses release DNA fragments and/or nuclear proteins as DAMPs from degenerated adipocytes and vascular cells. Recent studies indicated that the activation of TLR9 in immune cells including macrophages and dendritic cells by recognition of these DAMPs promotes inflammation in these tissues, which causes cardiometabolic disorders. This review discusses recent advances in understanding the role of sterile inflammation associated with TLR9 and its endogenous ligands in cardiometabolic disorders. New insights into innate immunity may provide better understanding of cardiometabolic disorders and new therapeutic options for these major health threats in recent decades."},"publication_date":"2020-07-21","publication_name":{"en":"Inflammation and Regeneration","ja":"Inflammation and Regeneration"},"volume":"Vol.40","starting_page":"18","ending_page":"18","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s41232-020-00118-7"],"issn":["1880-9693"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31566217","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85086792785&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366519","label":"url"}],"paper_title":{"en":"Deterioration of Biventricular Strain Is an Early Marker of Cardiac Involvement in Confirmed Sarcoidosis","ja":"Deterioration of Biventricular Strain Is an Early Marker of Cardiac Involvement in Confirmed Sarcoidosis"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Fujiwara M"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Saijo Y"},{"name":"Yamada N"},{"name":"Hirata Yukina"},{"name":"Torii Yuta"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Fujiwara M"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"西條 良仁"},{"name":"山田 なお"},{"name":"平田 有紀奈"},{"name":"鳥居 裕太"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Risk assessment of developing cardiac involvement in systemic sarcoidosis can be challenging because of limited data. Recently, attention has been given to left ventricular and right ventricular (LV and RV) involvement in cardiac sarcoidosis (CS) and its prevalence, relevance, and prognostic value. The aim of this study was to assess the role of biventricular strain to predict prognosis in confirmed sarcoidosis patients. LV and RV longitudinal strains (LSs) were evaluated by 2D speckle tracking in 139 consecutive confirmed sarcoidosis patients without other pre-existing structural heart diseases, and 52 age- and gender-matched control subjects. The primary endpoint was CS-related events (cardiac death or development of cardiac involvement). Sarcoidosis without cardiac involvement had significantly lower LV and RV free wall LS compared with control subjects. Basal LS had a higher area under the curve for differentiation of sarcoidosis in patients without cardiac involvement compared to control (cut-off value: -18% with 89% sensitivity and 69% specificity). During a median period of 50 months, the occurrence of CS-related events was observed in 20 patients. In a multivariate analysis, basal LV LS and RV free wall LS were associated with the events [hazard ratio (HR) 0.72, P < 0.001 and HR: 0.83, P = 0.006, respectively]. Patients with impaired biventricular function had significantly shorter event-free survival than those with preserved biventricular function (P < 0.001). Deterioration of biventricular strain was associated with CS-related events. This information might be useful for clinical evaluation and follow-up in sarcoidosis.","ja":"Risk assessment of developing cardiac involvement in systemic sarcoidosis can be challenging because of limited data. Recently, attention has been given to left ventricular and right ventricular (LV and RV) involvement in cardiac sarcoidosis (CS) and its prevalence, relevance, and prognostic value. The aim of this study was to assess the role of biventricular strain to predict prognosis in confirmed sarcoidosis patients. LV and RV longitudinal strains (LSs) were evaluated by 2D speckle tracking in 139 consecutive confirmed sarcoidosis patients without other pre-existing structural heart diseases, and 52 age- and gender-matched control subjects. The primary endpoint was CS-related events (cardiac death or development of cardiac involvement). Sarcoidosis without cardiac involvement had significantly lower LV and RV free wall LS compared with control subjects. Basal LS had a higher area under the curve for differentiation of sarcoidosis in patients without cardiac involvement compared to control (cut-off value: -18% with 89% sensitivity and 69% specificity). During a median period of 50 months, the occurrence of CS-related events was observed in 20 patients. In a multivariate analysis, basal LV LS and RV free wall LS were associated with the events [hazard ratio (HR) 0.72, P < 0.001 and HR: 0.83, P = 0.006, respectively]. Patients with impaired biventricular function had significantly shorter event-free survival than those with preserved biventricular function (P < 0.001). Deterioration of biventricular strain was associated with CS-related events. This information might be useful for clinical evaluation and follow-up in sarcoidosis."},"publication_date":"2020-07-01","publication_name":{"en":"European Heart Journal Cardiovascular Imaging","ja":"European Heart Journal Cardiovascular Imaging"},"volume":"Vol.21","number":"No.7","starting_page":"796","ending_page":"804","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/ehjci/jez235"],"issn":["2047-2412"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32457429","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85086387455&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366518","label":"url"}],"paper_title":{"en":"Usefulness of the SAGE Score to Predict Elevated Values of Brachial-Ankle Pulse Wave Velocity in Japanese Subjects With Hypertension","ja":"Usefulness of the SAGE Score to Predict Elevated Values of Brachial-Ankle Pulse Wave Velocity in Japanese Subjects With Hypertension"},"authors":{"en":[{"name":"Tomiyama Hirofumi"},{"name":"Vlachopoulos Charalambos"},{"name":"Xaplanteris Panagiotis"},{"name":"Nakano Hiroki"},{"name":"Shiina Kazuki"},{"name":"Ishizu Tomoko"},{"name":"Kohro Takahide"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Tanaka Atsushi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ohkuma Toshiaki"},{"name":"Ninomiya Toshiharu"},{"name":"Chikamori Taishiro"},{"name":"Yamashina Akira"},{"name":"Ueda Shin-Ichiro"}],"ja":[{"name":"Tomiyama Hirofumi"},{"name":"Vlachopoulos Charalambos"},{"name":"Xaplanteris Panagiotis"},{"name":"Nakano Hiroki"},{"name":"Shiina Kazuki"},{"name":"Ishizu Tomoko"},{"name":"Kohro Takahide"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Tanaka Atsushi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ohkuma Toshiaki"},{"name":"Ninomiya Toshiharu"},{"name":"Chikamori Taishiro"},{"name":"Yamashina Akira"},{"name":"Ueda Shin-Ichiro"}]},"description":{"en":"The score based on the office systolic blood pressure, age, fasting blood glucose level, and estimated glomerular filtration rate (SAGE score) has been proposed as a useful marker to identify elevated values of carotid-femoral pulse wave velocity (PWV). The present cross-sectional study was conducted to examine whether the SAGE score is also a useful marker to identify subjects with elevated brachial-ankle PWV values in Japanese subjects with hypertension. We measured the brachial-ankle PWV and calculated the SAGE score in a total of 1019 employees of a Japanese company with hypertension and 817 subjects with hypertension derived from a multicenter study cohort. The analyses in this study were based on data from these two study groups as well as on a composite population of the two (n = 1836). The receiver operating characteristic curve analysis showed that the area under the curve to identify subjects with brachial-ankle PWV values of 1800 cm/s was over 0.70 in each of the three study groups. Even after adjustments, a SAGE score 7 had a significant odds ratio for identifying subjects with brachial-ankle PWV values 1800 cm/s in the 1836 study subjects from the composite occupational and multicenter study cohort (odds ratio = 2.1, 95% confidence interval = 1.4-3.0, P < 0.01). Thus, in Japanese subjects with hypertension, the SAGE score may be a useful marker for identifying subjects with elevated brachial-ankle PWV values.","ja":"The score based on the office systolic blood pressure, age, fasting blood glucose level, and estimated glomerular filtration rate (SAGE score) has been proposed as a useful marker to identify elevated values of carotid-femoral pulse wave velocity (PWV). The present cross-sectional study was conducted to examine whether the SAGE score is also a useful marker to identify subjects with elevated brachial-ankle PWV values in Japanese subjects with hypertension. We measured the brachial-ankle PWV and calculated the SAGE score in a total of 1019 employees of a Japanese company with hypertension and 817 subjects with hypertension derived from a multicenter study cohort. The analyses in this study were based on data from these two study groups as well as on a composite population of the two (n = 1836). The receiver operating characteristic curve analysis showed that the area under the curve to identify subjects with brachial-ankle PWV values of 1800 cm/s was over 0.70 in each of the three study groups. Even after adjustments, a SAGE score 7 had a significant odds ratio for identifying subjects with brachial-ankle PWV values 1800 cm/s in the 1836 study subjects from the composite occupational and multicenter study cohort (odds ratio = 2.1, 95% confidence interval = 1.4-3.0, P < 0.01). Thus, in Japanese subjects with hypertension, the SAGE score may be a useful marker for identifying subjects with elevated brachial-ankle PWV values."},"publication_date":"2020-05-26","publication_name":{"en":"Hypertension Research","ja":"Hypertension Research"},"volume":"Vol.43","number":"No.11","starting_page":"1284","ending_page":"1294","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41440-020-0472-7"],"issn":["1348-4214"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114196","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31103590","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85070068493&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363957","label":"url"}],"paper_title":{"en":"A Deep Learning Approach for Assessment of Regional Wall Motion Abnormality From Echocardiographic Images","ja":"A Deep Learning Approach for Assessment of Regional Wall Motion Abnormality From Echocardiographic Images"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Abe Takashi"},{"name":"Haga Akihiro"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Harada Masafumi"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"阿部 考志"},{"name":"芳賀 昭弘"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"原田 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"This study investigated whether a deep convolutional neural network (DCNN) could provide improved detection of regional wall motion abnormalities (RWMAs) and differentiate among groups of coronary infarction territories from conventional 2-dimensional echocardiographic images compared with that of cardiologists, sonographers, and resident readers. An effective intervention for reduction of misreading of RWMAs is needed. The hypothesis was that a DCNN trained using echocardiographic images would provide improved detection of RWMAs in the clinical setting. A total of 300 patients with a history of myocardial infarction were enrolled. From this cohort, 3 groups of 100 patients each had infarctions of the left anterior descending (LAD) artery, the left circumflex (LCX) branch, and the right coronary artery (RCA). A total of 100 age-matched control patients with normal wall motion were selected from a database. Each case contained cardiac ultrasonographs from short-axis views at end-diastolic, mid-systolic, and end-systolic phases. After the DCNN underwent 100 steps of training, diagnostic accuracies were calculated from the test set. Independently, 10 versions of the same model were trained, and ensemble predictions were performed using those versions. For detection of the presence of WMAs, the area under the receiver-operating characteristic curve (AUC) produced by the deep learning algorithm was similar to that produced by the cardiologists and sonographer readers (0.99 vs. 0.98, respectively; p = 0.15) and significantly higher than the AUC result of the resident readers (0.99 vs. 0.90, respectively; p = 0.002). For detection of territories of WMAs, the AUC by the deep learning algorithm was similar to the AUC by the cardiologist and sonographer readers (0.97 vs. 0.95, respectively; p = 0.61) and significantly higher than the AUC by resident readers (0.97 vs. 0.83, respectively; p = 0.003). From a validation group at an independent site (n = 40), the AUC by the deep learning algorithm was 0.90. The present results support the possibility of using DCNN for automated diagnosis of RWMAs in the field of echocardiography.","ja":"This study investigated whether a deep convolutional neural network (DCNN) could provide improved detection of regional wall motion abnormalities (RWMAs) and differentiate among groups of coronary infarction territories from conventional 2-dimensional echocardiographic images compared with that of cardiologists, sonographers, and resident readers. An effective intervention for reduction of misreading of RWMAs is needed. The hypothesis was that a DCNN trained using echocardiographic images would provide improved detection of RWMAs in the clinical setting. A total of 300 patients with a history of myocardial infarction were enrolled. From this cohort, 3 groups of 100 patients each had infarctions of the left anterior descending (LAD) artery, the left circumflex (LCX) branch, and the right coronary artery (RCA). A total of 100 age-matched control patients with normal wall motion were selected from a database. Each case contained cardiac ultrasonographs from short-axis views at end-diastolic, mid-systolic, and end-systolic phases. After the DCNN underwent 100 steps of training, diagnostic accuracies were calculated from the test set. Independently, 10 versions of the same model were trained, and ensemble predictions were performed using those versions. For detection of the presence of WMAs, the area under the receiver-operating characteristic curve (AUC) produced by the deep learning algorithm was similar to that produced by the cardiologists and sonographer readers (0.99 vs. 0.98, respectively; p = 0.15) and significantly higher than the AUC result of the resident readers (0.99 vs. 0.90, respectively; p = 0.002). For detection of territories of WMAs, the AUC by the deep learning algorithm was similar to the AUC by the cardiologist and sonographer readers (0.97 vs. 0.95, respectively; p = 0.61) and significantly higher than the AUC by resident readers (0.97 vs. 0.83, respectively; p = 0.003). From a validation group at an independent site (n = 40), the AUC by the deep learning algorithm was 0.90. The present results support the possibility of using DCNN for automated diagnosis of RWMAs in the field of echocardiography."},"publication_date":"2020-05-15","publication_name":{"en":"JACC. Cardiovascular Imaging","ja":"JACC. Cardiovascular Imaging"},"volume":"Vol.13","number":"No.2","starting_page":"374","ending_page":"381","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jcmg.2019.02.024"],"issn":["1876-7591"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115096","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32349193","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85083984977&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366094","label":"url"}],"paper_title":{"en":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)","ja":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)"},"authors":{"en":[{"name":"Tanaka A"},{"name":"Hisauchi I"},{"name":"Taguchi I"},{"name":"Sezai A"},{"name":"Toyoda S"},{"name":"Tomiyama H"},{"name":"Sata Masataka"},{"name":"Ueda S"},{"name":"Oyama JI"},{"name":"Kitakaze M"},{"name":"Murohara T"},{"name":"Node K"}],"ja":[{"name":"Tanaka A"},{"name":"Hisauchi I"},{"name":"Taguchi I"},{"name":"Sezai A"},{"name":"Toyoda S"},{"name":"Tomiyama H"},{"name":"佐田 政隆"},{"name":"Ueda S"},{"name":"Oyama JI"},{"name":"Kitakaze M"},{"name":"Murohara T"},{"name":"Node K"}]},"publication_date":"2020-04-29","publication_name":{"en":"ESC Heart Failure","ja":"ESC Heart Failure"},"volume":"Vol.7","number":"No.4","starting_page":"1585","ending_page":"159","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/ehf2.12707"],"issn":["2055-5822"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115024","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32344829","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85083901945&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366093","label":"url"}],"paper_title":{"en":"Clinically Feasible and Accurate View Classification of Echocardiographic Images Using Deep Learning","ja":"Clinically Feasible and Accurate View Classification of Echocardiographic Images Using Deep Learning"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Haga Akihiro"},{"name":"Inoue Mizuki"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"芳賀 昭弘"},{"name":"井上 瑞妃"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"description":{"en":"A proper echocardiographic study requires several video clips recorded from different acquisition angles for observation of the complex cardiac anatomy. However, these video clips are not necessarily labeled in a database. Identification of the acquired view becomes the first step of analyzing an echocardiogram. Currently, there is no consensus whether the mislabeled samples can be used to create a feasible clinical prediction model of ejection fraction (EF). The aim of this study was to test two types of input methods for the classification of images, and to test the accuracy of the prediction model for EF in a learning database containing mislabeled images that were not checked by observers. We enrolled 340 patients with five standard views (long axis, short axis, 3-chamber view, 4-chamber view and 2-chamber view) and 10 images in a cycle, used for training a convolutional neural network to classify views (total 17,000 labeled images). All DICOM images were rigidly registered and rescaled into a reference image to fit the size of echocardiographic images. We employed 5-fold cross validation to examine model performance. We tested models trained by two types of data, averaged images and 10 selected images. Our best model (from 10 selected images) classified video views with 98.1% overall test accuracy in the independent cohort. In our view classification model, 1.9% of the images were mislabeled. To determine if this 98.1% accuracy was acceptable for creating the clinical prediction model using echocardiographic data, we tested the prediction model for EF using learning data with a 1.9% error rate. The accuracy of the prediction model for EF was warranted, even with training data containing 1.9% mislabeled images. The CNN algorithm can classify images into five standard views in a clinical setting. Our results suggest that this approach may provide a clinically feasible accuracy level of view classification for the analysis of echocardiographic data.","ja":"A proper echocardiographic study requires several video clips recorded from different acquisition angles for observation of the complex cardiac anatomy. However, these video clips are not necessarily labeled in a database. Identification of the acquired view becomes the first step of analyzing an echocardiogram. Currently, there is no consensus whether the mislabeled samples can be used to create a feasible clinical prediction model of ejection fraction (EF). The aim of this study was to test two types of input methods for the classification of images, and to test the accuracy of the prediction model for EF in a learning database containing mislabeled images that were not checked by observers. We enrolled 340 patients with five standard views (long axis, short axis, 3-chamber view, 4-chamber view and 2-chamber view) and 10 images in a cycle, used for training a convolutional neural network to classify views (total 17,000 labeled images). All DICOM images were rigidly registered and rescaled into a reference image to fit the size of echocardiographic images. We employed 5-fold cross validation to examine model performance. We tested models trained by two types of data, averaged images and 10 selected images. Our best model (from 10 selected images) classified video views with 98.1% overall test accuracy in the independent cohort. In our view classification model, 1.9% of the images were mislabeled. To determine if this 98.1% accuracy was acceptable for creating the clinical prediction model using echocardiographic data, we tested the prediction model for EF using learning data with a 1.9% error rate. The accuracy of the prediction model for EF was warranted, even with training data containing 1.9% mislabeled images. The CNN algorithm can classify images into five standard views in a clinical setting. Our results suggest that this approach may provide a clinically feasible accuracy level of view classification for the analysis of echocardiographic data."},"publication_date":"2020-04-25","publication_name":{"en":"Biomolecules","ja":"Biomolecules"},"volume":"Vol.10","number":"No.5","starting_page":"E665","ending_page":"E665","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/biom10050665"],"issn":["2218-273X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116640","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32281556","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85083919450&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366091","label":"url"}],"paper_title":{"en":"Atherosclerotic Coronary Plaque Is Associated With Adventitial Vasa Vasorum and Local Inflammation in Adjacent Epicardial Adipose Tissue in Fresh Cadavers","ja":"Atherosclerotic Coronary Plaque Is Associated With Adventitial Vasa Vasorum and Local Inflammation in Adjacent Epicardial Adipose Tissue in Fresh Cadavers"},"authors":{"en":[{"name":"Ito Hiroyuki"},{"name":"Wakatsuki Tetsuzo"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Kawabata Yutaka"},{"name":"Matsuura Tomomi"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Tsuruo Yoshihiro"},{"name":"Sata Masataka"}],"ja":[{"name":"伊藤 浩敬"},{"name":"若槻 哲三"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"川端 豊"},{"name":"松浦 朋美"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"鶴尾 吉宏"},{"name":"佐田 政隆"}]},"publication_date":"2020-04-24","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.84","number":"No.5","starting_page":"769","ending_page":"775","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-19-0914"],"issn":["1346-9843"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115247","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32320401","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85083949564&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366092","label":"url"}],"paper_title":{"en":"Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial","ja":"Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial"},"authors":{"en":[{"name":"Tanaka A"},{"name":"Taguchi I"},{"name":"Teragawa H"},{"name":"Ishizaka N"},{"name":"Kanzaki Y"},{"name":"Tomiyama H"},{"name":"Sata Masataka"},{"name":"Sezai A"},{"name":"Eguchi K"},{"name":"Kato T"},{"name":"Toyoda S"},{"name":"Ishibashi R"},{"name":"Kario K"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Maemura K"},{"name":"Higashi Y"},{"name":"Yamada H"},{"name":"Ohishi M"},{"name":"Yokote K"},{"name":"Murohara T"},{"name":"Oyama JI"},{"name":"Node K"}],"ja":[{"name":"Tanaka A"},{"name":"Taguchi I"},{"name":"Teragawa H"},{"name":"Ishizaka N"},{"name":"Kanzaki Y"},{"name":"Tomiyama H"},{"name":"佐田 政隆"},{"name":"Sezai A"},{"name":"Eguchi K"},{"name":"Kato T"},{"name":"Toyoda S"},{"name":"Ishibashi R"},{"name":"Kario K"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Maemura K"},{"name":"Higashi Y"},{"name":"Yamada H"},{"name":"Ohishi M"},{"name":"Yokote K"},{"name":"Murohara T"},{"name":"Oyama JI"},{"name":"Node K"}]},"description":{"en":"An elevated level of serum uric acid (SUA) is associated with an increased risk of cardiovascular disease. Pharmacological intervention with urate-lowering agents, such as the conventional purine analogue xanthine oxidase (XO) inhibitor, allopurinol, has been used widely for a long period of time in clinical practice to reduce SUA levels. Febuxostat, a novel non-purine selective inhibitor of XO, has higher potency for inhibition of XO activity and greater urate-lowering efficacy than conventional allopurinol. However, clinical evidence regarding the effects of febuxostat on atherosclerosis is lacking. The purpose of the study was to test whether treatment with febuxostat delays carotid intima-media thickness (IMT) progression in patients with asymptomatic hyperuricemia. The study was a multicenter, prospective, randomized, open-label, blinded-endpoint clinical trial undertaken at 48 sites throughout Japan between May 2014 and August 2018. Adults with both asymptomatic hyperuricemia (SUA >7.0 mg/dL) and maximum IMT of the common carotid artery (CCA) ≥1.1 mm at screening were allocated equally using a central web system to receive either dose-titrated febuxostat (10-60 mg daily) or as a control-arm, non-pharmacological lifestyle modification for hyperuricemia, such as a healthy diet and exercise therapy. Of the 514 enrolled participants, 31 were excluded from the analysis, with the remaining 483 people (mean age 69.1 years [standard deviation 10.4 years], female 19.7%) included in the primary analysis (febuxostat group, 239; control group, 244), based on a modified intention-to-treat principal. The carotid IMT images were recorded by a single sonographer at each site and read in a treatment-blinded manner by a single analyzer at a central core laboratory. The primary endpoint was the percentage change from baseline to 24 months in mean IMT of the CCA, determined by analysis of covariance using the allocation adjustment factors (age, gender, history of type 2 diabetes, baseline SUA, and baseline maximum IMT of the CCA) as the covariates. Key secondary endpoints included changes in other carotid ultrasonographic parameters and SUA and the incidence of clinical events. The mean values (± standard deviation) of CCA-IMT were 0.825 mm ± 0.173 mm in the febuxostat group and 0.832 mm ± 0.175 mm in the control group (mean between-group difference [febuxostat - control], -0.007 mm [95% confidence interval (CI) -0.039 mm to 0.024 mm; P = 0.65]) at baseline; 0.832 mm ± 0.182 mm in the febuxostat group and 0.848 mm ± 0.176 mm in the control group (mean between-group difference, -0.016 mm [95% CI -0.051 mm to 0.019 mm; P = 0.37]) at 24 months. Compared with the control group, febuxostat had no significant effect on the primary endpoint (mean percentage change 1.2% [95% CI -0.6% to 3.0%] in the febuxostat group (n = 207) versus 1.4% [95% CI -0.5% to 3.3%] in the control group (n = 193); mean between-group difference, -0.2% [95% CI -2.3% to 1.9%; P = 0.83]). Febuxostat also had no effect on the other carotid ultrasonographic parameters. The mean baseline values of SUA were comparable between the two groups (febuxostat, 7.76 mg/dL ± 0.98 mg/dL versus control, 7.73 mg/dL ± 1.04 mg/dL; mean between-group difference, 0.03 mg/dL [95% CI -0.15 mg/dL to 0.21 mg/dL; P = 0.75]). The mean value of SUA at 24 months was significantly lower in the febuxostat group than in the control group (febuxostat, 4.66 mg/dL ± 1.27 mg/dL versus control, 7.28 mg/dL ± 1.27 mg/dL; mean between-group difference, -2.62 mg/dL [95% CI -2.86 mg/dL to -2.38 mg/dL; P < 0.001]). Episodes of gout arthritis occurred only in the control group (4 patients [1.6%]). There were three deaths in the febuxostat group and seven in the control group during follow-up. A limitation of the study was the study design, as it was not a placebo-controlled trial, had a relatively small sample size and a short intervention period, and only enrolled Japanese patients with asymptomatic hyperuricemia. In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment did not delay carotid atherosclerosis progression, compared with non-pharmacological care. These findings do not support the use of febuxostat for delaying carotid atherosclerosis in this population. University Hospital Medical Information Network Clinical Trial Registry UMIN000012911.","ja":"An elevated level of serum uric acid (SUA) is associated with an increased risk of cardiovascular disease. Pharmacological intervention with urate-lowering agents, such as the conventional purine analogue xanthine oxidase (XO) inhibitor, allopurinol, has been used widely for a long period of time in clinical practice to reduce SUA levels. Febuxostat, a novel non-purine selective inhibitor of XO, has higher potency for inhibition of XO activity and greater urate-lowering efficacy than conventional allopurinol. However, clinical evidence regarding the effects of febuxostat on atherosclerosis is lacking. The purpose of the study was to test whether treatment with febuxostat delays carotid intima-media thickness (IMT) progression in patients with asymptomatic hyperuricemia. The study was a multicenter, prospective, randomized, open-label, blinded-endpoint clinical trial undertaken at 48 sites throughout Japan between May 2014 and August 2018. Adults with both asymptomatic hyperuricemia (SUA >7.0 mg/dL) and maximum IMT of the common carotid artery (CCA) ≥1.1 mm at screening were allocated equally using a central web system to receive either dose-titrated febuxostat (10-60 mg daily) or as a control-arm, non-pharmacological lifestyle modification for hyperuricemia, such as a healthy diet and exercise therapy. Of the 514 enrolled participants, 31 were excluded from the analysis, with the remaining 483 people (mean age 69.1 years [standard deviation 10.4 years], female 19.7%) included in the primary analysis (febuxostat group, 239; control group, 244), based on a modified intention-to-treat principal. The carotid IMT images were recorded by a single sonographer at each site and read in a treatment-blinded manner by a single analyzer at a central core laboratory. The primary endpoint was the percentage change from baseline to 24 months in mean IMT of the CCA, determined by analysis of covariance using the allocation adjustment factors (age, gender, history of type 2 diabetes, baseline SUA, and baseline maximum IMT of the CCA) as the covariates. Key secondary endpoints included changes in other carotid ultrasonographic parameters and SUA and the incidence of clinical events. The mean values (± standard deviation) of CCA-IMT were 0.825 mm ± 0.173 mm in the febuxostat group and 0.832 mm ± 0.175 mm in the control group (mean between-group difference [febuxostat - control], -0.007 mm [95% confidence interval (CI) -0.039 mm to 0.024 mm; P = 0.65]) at baseline; 0.832 mm ± 0.182 mm in the febuxostat group and 0.848 mm ± 0.176 mm in the control group (mean between-group difference, -0.016 mm [95% CI -0.051 mm to 0.019 mm; P = 0.37]) at 24 months. Compared with the control group, febuxostat had no significant effect on the primary endpoint (mean percentage change 1.2% [95% CI -0.6% to 3.0%] in the febuxostat group (n = 207) versus 1.4% [95% CI -0.5% to 3.3%] in the control group (n = 193); mean between-group difference, -0.2% [95% CI -2.3% to 1.9%; P = 0.83]). Febuxostat also had no effect on the other carotid ultrasonographic parameters. The mean baseline values of SUA were comparable between the two groups (febuxostat, 7.76 mg/dL ± 0.98 mg/dL versus control, 7.73 mg/dL ± 1.04 mg/dL; mean between-group difference, 0.03 mg/dL [95% CI -0.15 mg/dL to 0.21 mg/dL; P = 0.75]). The mean value of SUA at 24 months was significantly lower in the febuxostat group than in the control group (febuxostat, 4.66 mg/dL ± 1.27 mg/dL versus control, 7.28 mg/dL ± 1.27 mg/dL; mean between-group difference, -2.62 mg/dL [95% CI -2.86 mg/dL to -2.38 mg/dL; P < 0.001]). Episodes of gout arthritis occurred only in the control group (4 patients [1.6%]). There were three deaths in the febuxostat group and seven in the control group during follow-up. A limitation of the study was the study design, as it was not a placebo-controlled trial, had a relatively small sample size and a short intervention period, and only enrolled Japanese patients with asymptomatic hyperuricemia. In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment did not delay carotid atherosclerosis progression, compared with non-pharmacological care. These findings do not support the use of febuxostat for delaying carotid atherosclerosis in this population. University Hospital Medical Information Network Clinical Trial Registry UMIN000012911."},"publication_date":"2020-04-22","publication_name":{"en":"PLoS Medicine","ja":"PLoS Medicine"},"volume":"Vol.17","number":"No.4","starting_page":"e1003095","ending_page":"e1003095","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pmed.1003095"],"issn":["1549-1676"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32114052","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85080985939&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366061","label":"url"}],"paper_title":{"en":"Empagliflozin Ameliorates Endothelial Dysfunction and Suppresses Atherogenesis in Diabetic Apolipoprotein E-deficient Mice","ja":"Empagliflozin Ameliorates Endothelial Dysfunction and Suppresses Atherogenesis in Diabetic Apolipoprotein E-deficient Mice"},"authors":{"en":[{"name":"Ganbaatar B"},{"name":"Fukuda Daiju"},{"name":"Shinohara M"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Hirata KI"},{"name":"Sata Masataka"}],"ja":[{"name":"GANBAATAR BYAMBASUREN"},{"name":"福田 大受"},{"name":"Shinohara M"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"Hirata KI"},{"name":"佐田 政隆"}]},"description":{"en":"Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE) mice. Male streptozotocin (STZ) - induced diabetic ApoE mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E and thromboxane B (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-α in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.","ja":"Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE) mice. Male streptozotocin (STZ) - induced diabetic ApoE mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E and thromboxane B (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-α in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially."},"publication_date":"2020-04-15","publication_name":{"en":"European Journal of Pharmacology","ja":"European Journal of Pharmacology"},"volume":"Vol.15","number":"No.875","starting_page":"173040","ending_page":"173040","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ejphar.2020.173040"],"issn":["1879-0712"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32152482","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85081661351&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366064","label":"url"}],"paper_title":{"en":"Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A","ja":"Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A"},"authors":{"en":[{"name":"Maruhashi T"},{"name":"Soga J"},{"name":"Fujimura N"},{"name":"Idei N"},{"name":"Mikami S"},{"name":"Iwamoto Y"},{"name":"Iwamoto A"},{"name":"Kajikawa M"},{"name":"Matsumoto T"},{"name":"Oda N"},{"name":"Kishimoto S"},{"name":"Matsui S"},{"name":"Hashimoto H"},{"name":"Takaeko Y"},{"name":"Yamaji T"},{"name":"Harada T"},{"name":"Han Y"},{"name":"Aibara Y"},{"name":"Mohamad Yusoff F"},{"name":"Hidaka T"},{"name":"Kihara Y"},{"name":"Chayama K"},{"name":"Noma K"},{"name":"Nakashima A"},{"name":"Goto C"},{"name":"Tomiyama H"},{"name":"Takase B"},{"name":"Kohro T"},{"name":"Suzuki T"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Koba S"},{"name":"Watanabe K"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"Sata Masataka"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Ikeda H"},{"name":"Yamashina A"},{"name":"Higashi Y"}],"ja":[{"name":"Maruhashi T"},{"name":"Soga J"},{"name":"Fujimura N"},{"name":"Idei N"},{"name":"Mikami S"},{"name":"Iwamoto Y"},{"name":"Iwamoto A"},{"name":"Kajikawa M"},{"name":"Matsumoto T"},{"name":"Oda N"},{"name":"Kishimoto S"},{"name":"Matsui S"},{"name":"Hashimoto H"},{"name":"Takaeko Y"},{"name":"Yamaji T"},{"name":"Harada T"},{"name":"Han Y"},{"name":"Aibara Y"},{"name":"Mohamad Yusoff F"},{"name":"Hidaka T"},{"name":"Kihara Y"},{"name":"Chayama K"},{"name":"Noma K"},{"name":"Nakashima A"},{"name":"Goto C"},{"name":"Tomiyama H"},{"name":"Takase B"},{"name":"Kohro T"},{"name":"Suzuki T"},{"name":"Ishizu T"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Koba S"},{"name":"Watanabe K"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"佐田 政隆"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Ikeda H"},{"name":"Yamashina A"},{"name":"Higashi Y"}]},"description":{"en":"The usefulness of brachial-ankle pulse wave velocity (baPWV), an index of arterial stiffness, is not fully known for the management of treated hypertensive patients with a history of coronary artery disease (CAD) who have blood pressure less than 130/80 mmHg, a recommended blood pressure target in the updated major hypertension guidelines. We analyzed data for 447 treated hypertensive patients with CAD enrolled in FMD-J Study A for assessment of the predictive value of baPWV for future cardiovascular events. The primary outcome was a composite of coronary events, stroke, heart failure, and sudden death. During a median follow-up period of 47.6 months, the primary outcome occurred in 64 patients. Blood pressure less than 130/80 mmHg was significantly associated with a lower risk of the composite outcome independent of other cardiovascular risk factors in treated hypertensive patients with CAD (hazard ratio, 0.59; 95% confidence interval (CI), 0.35-0.99; P = 0.04). In treated hypertensive patients with CAD who had blood pressure less than 130/80 mmHg, baPWV above the cutoff value of 1731 cm/s, derived from receiver-operator characteristic curve analysis for the composite outcome was significantly associated with a higher risk of the composite outcome independent of conventional risk factors (hazard ratio, 2.83; 95% CI, 1.02-7.91; P = 0.04). baPWV was an independent predictor of cardiovascular events in treated hypertensive patients with CAD who had blood pressure less than 130/80 mmHg, for whom measurement of baPWV is recommended for cardiovascular risk assessment.","ja":"The usefulness of brachial-ankle pulse wave velocity (baPWV), an index of arterial stiffness, is not fully known for the management of treated hypertensive patients with a history of coronary artery disease (CAD) who have blood pressure less than 130/80 mmHg, a recommended blood pressure target in the updated major hypertension guidelines. We analyzed data for 447 treated hypertensive patients with CAD enrolled in FMD-J Study A for assessment of the predictive value of baPWV for future cardiovascular events. The primary outcome was a composite of coronary events, stroke, heart failure, and sudden death. During a median follow-up period of 47.6 months, the primary outcome occurred in 64 patients. Blood pressure less than 130/80 mmHg was significantly associated with a lower risk of the composite outcome independent of other cardiovascular risk factors in treated hypertensive patients with CAD (hazard ratio, 0.59; 95% confidence interval (CI), 0.35-0.99; P = 0.04). In treated hypertensive patients with CAD who had blood pressure less than 130/80 mmHg, baPWV above the cutoff value of 1731 cm/s, derived from receiver-operator characteristic curve analysis for the composite outcome was significantly associated with a higher risk of the composite outcome independent of conventional risk factors (hazard ratio, 2.83; 95% CI, 1.02-7.91; P = 0.04). baPWV was an independent predictor of cardiovascular events in treated hypertensive patients with CAD who had blood pressure less than 130/80 mmHg, for whom measurement of baPWV is recommended for cardiovascular risk assessment."},"publication_date":"2020-03-09","publication_name":{"en":"Hypertension Research","ja":"Hypertension Research"},"volume":"Vol.43","number":"No.8","starting_page":"781","ending_page":"790","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41440-020-0420-6"],"issn":["1348-4214"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113232","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30810909","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85062643604&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350373","label":"url"}],"paper_title":{"en":"Sequential speckle tracking imaging to detect early stage of cancer therapeutics-related cardiac dysfunction in a patient with breast cancer","ja":"Sequential speckle tracking imaging to detect early stage of cancer therapeutics-related cardiac dysfunction in a patient with breast cancer"},"authors":{"en":[{"name":"Saijo Yoshihito"},{"name":"Kusunose Kenya"},{"name":"Yamada Nao"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Sata Masataka"}],"ja":[{"name":"Saijo Yoshihito"},{"name":"楠瀬 賢也"},{"name":"Yamada Nao"},{"name":"山田 博胤"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"佐田 政隆"}]},"publication_date":"2020-02-27","publication_name":{"en":"Journal of Echocardiography","ja":"Journal of Echocardiography"},"volume":"Vol.18","number":"No.2","starting_page":"134","ending_page":"135","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12574-019-00423-2"],"issn":["1880-344X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115927","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32101838","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366059","label":"url"}],"paper_title":{"en":"Biodegradable Extremely-Small-Diameter Vascular Graft Made of Silk Fibroin can be Implanted in Mice","ja":"Biodegradable Extremely-Small-Diameter Vascular Graft Made of Silk Fibroin can be Implanted in Mice"},"authors":{"en":[{"name":"Tanaka K"},{"name":"Fukuda Daiju"},{"name":"Higashikuni Y"},{"name":"Hirata Y"},{"name":"Komuro I"},{"name":"Saotome T"},{"name":"Yamashita Y"},{"name":"Asakura T"},{"name":"Sata Masataka"}],"ja":[{"name":"Tanaka K"},{"name":"福田 大受"},{"name":"Higashikuni Y"},{"name":"Hirata Y"},{"name":"Komuro I"},{"name":"Saotome T"},{"name":"Yamashita Y"},{"name":"Asakura T"},{"name":"佐田 政隆"}]},"description":{"en":"Synthetic vascular grafts are widely used in surgical revascularization, mainly for medium- to large-sized vessels. However, synthetic grafts smaller than 6 mm in diameter are associated with a high incidence of thrombosis. In this study, we evaluated silk fibroin, a major protein of silk, with high biocompatibility and biodegradability, as a useful material for extremely-small-diameter vascular grafts. A small-sized (0.9 mm inner diameter) graft was braided from a silk fibroin thread. The right carotid arteries of 8- to 14-week-old male C57BL/6 mice were cut at the midpoint, and fibroin grafts (5- to 7-mm in length) were transplanted using a cuff technique with polyimide cuffs. The grafts were harvested at different time points and analyzed histologically. CD31+ endothelial cells had already started to proliferate at 2 weeks after implantation. At 4 weeks, neointima had formed with α-smooth muscle actin+ cells, and the luminal surface was covered with CD31+endothelial cells. Mac3+ macrophages were accumulated in the grafts. Graft patency was confirmed at up to 6 months after implantation. This mouse model of arterial graft implantation enables us to analyze the remodeling process and biocompatibility of extremely-small-diameter vascular grafts. Biodegradable silk fibroin might be applicable for further researches using genetically modified mice.","ja":"Synthetic vascular grafts are widely used in surgical revascularization, mainly for medium- to large-sized vessels. However, synthetic grafts smaller than 6 mm in diameter are associated with a high incidence of thrombosis. In this study, we evaluated silk fibroin, a major protein of silk, with high biocompatibility and biodegradability, as a useful material for extremely-small-diameter vascular grafts. A small-sized (0.9 mm inner diameter) graft was braided from a silk fibroin thread. The right carotid arteries of 8- to 14-week-old male C57BL/6 mice were cut at the midpoint, and fibroin grafts (5- to 7-mm in length) were transplanted using a cuff technique with polyimide cuffs. The grafts were harvested at different time points and analyzed histologically. CD31+ endothelial cells had already started to proliferate at 2 weeks after implantation. At 4 weeks, neointima had formed with α-smooth muscle actin+ cells, and the luminal surface was covered with CD31+endothelial cells. Mac3+ macrophages were accumulated in the grafts. Graft patency was confirmed at up to 6 months after implantation. This mouse model of arterial graft implantation enables us to analyze the remodeling process and biocompatibility of extremely-small-diameter vascular grafts. Biodegradable silk fibroin might be applicable for further researches using genetically modified mice."},"publication_date":"2020-02-26","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.27","starting_page":"1299","ending_page":"1309","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.52720"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115926","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32101837","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390286426514028416/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366058","label":"url"}],"paper_title":{"en":"Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice","ja":"Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice"},"authors":{"en":[{"name":"Rahadian Arief"},{"name":"Fukuda Daiju"},{"name":"Salim HM"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"Arief Rahadian"},{"name":"福田 大受"},{"name":"Salim HM"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"Recent studies have demonstrated that selective sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, although their mechanism remains obscure. We examined the effect of canagliflozin, an SGLT2i, on atherogenesis and investigated its underlying mechanism. Canagliflozin (30 mg/kg/day) was administered by gavage to streptozotocin-induced diabetic apolipoprotein E-deficient (ApoE) mice. Sudan IV staining was performed at the aortic arch. Immunostaining, quantitative RT-PCR, and vascular reactivity assay were performed using the aorta. In vitro experiments using human umbilical vein endothelial cells (HUVECs) were also performed. Canagliflozin decreased blood glucose (P<0.001) and total cholesterol (P<0.05) levels. Sudan IV staining showed that 12-week canagliflozin treatment decreased atherosclerotic lesions (P<0.05). Further, 8-week canagliflozin treatment ameliorated endothelial dysfunction, as determined by acetylcholine-induced vasodilation (P<0.05), and significantly reduced the expressions of inflammatory molecules such as ICAM-1 and VCAM-1 in the aorta at the RNA and protein levels. Canagliflozin also reduced the expressions of NADPH oxidase subunits such as NOX2 and p22phox in the aorta and reduced urinary excretion of 8-OHdG, suggesting a reduction in oxidative stress. Methylglyoxal, a precursor of advanced glycation end products, increased the expressions of ICAM-1 and p22phox in HUVECs (P<0.05, both). Methylglyoxal also decreased the phosphorylation of eNOS and Akt but increased the phosphorylation of eNOS and p38 MAPK in HUVECs. Canagliflozin prevents endothelial dysfunction and atherogenesis in diabetic ApoE mice. Anti-inflammatory and antioxidative potential due to reduced glucose toxicity to endothelial cells might be its underlying mechanisms.","ja":"Recent studies have demonstrated that selective sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, although their mechanism remains obscure. We examined the effect of canagliflozin, an SGLT2i, on atherogenesis and investigated its underlying mechanism. Canagliflozin (30 mg/kg/day) was administered by gavage to streptozotocin-induced diabetic apolipoprotein E-deficient (ApoE) mice. Sudan IV staining was performed at the aortic arch. Immunostaining, quantitative RT-PCR, and vascular reactivity assay were performed using the aorta. In vitro experiments using human umbilical vein endothelial cells (HUVECs) were also performed. Canagliflozin decreased blood glucose (P<0.001) and total cholesterol (P<0.05) levels. Sudan IV staining showed that 12-week canagliflozin treatment decreased atherosclerotic lesions (P<0.05). Further, 8-week canagliflozin treatment ameliorated endothelial dysfunction, as determined by acetylcholine-induced vasodilation (P<0.05), and significantly reduced the expressions of inflammatory molecules such as ICAM-1 and VCAM-1 in the aorta at the RNA and protein levels. Canagliflozin also reduced the expressions of NADPH oxidase subunits such as NOX2 and p22phox in the aorta and reduced urinary excretion of 8-OHdG, suggesting a reduction in oxidative stress. Methylglyoxal, a precursor of advanced glycation end products, increased the expressions of ICAM-1 and p22phox in HUVECs (P<0.05, both). Methylglyoxal also decreased the phosphorylation of eNOS and Akt but increased the phosphorylation of eNOS and p38 MAPK in HUVECs. Canagliflozin prevents endothelial dysfunction and atherogenesis in diabetic ApoE mice. Anti-inflammatory and antioxidative potential due to reduced glucose toxicity to endothelial cells might be its underlying mechanisms."},"publication_date":"2020-02-26","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.27","number":"No.11","starting_page":"1141","ending_page":"1151","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.52100"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32111541","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85080044447&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363963","label":"url"}],"paper_title":{"en":"Deep Learning for Assessment of Left Ventricular Ejection Fraction from Echocardiographic Images","ja":"Deep Learning for Assessment of Left Ventricular Ejection Fraction from Echocardiographic Images"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Haga Akihiro"},{"name":"Yamaguchi Natsumi"},{"name":"Abe Takashi"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Harada Masafumi"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"芳賀 昭弘"},{"name":"Yamaguchi Natsumi"},{"name":"阿部 考志"},{"name":"Fukuda Daiju"},{"name":"山田 博胤"},{"name":"原田 雅史"},{"name":"佐田 政隆"}]},"publication_date":"2020-02-25","publication_name":{"en":"Journal of the American Society of Echocardiography","ja":"Journal of the American Society of Echocardiography"},"volume":"Vol.33","number":"No.5","starting_page":"632","ending_page":"635","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.echo.2020.01.009"],"issn":["1097-6795"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33693230","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=374770","label":"url"}],"paper_title":{"en":"Diastolic Mitral Regurgitation on Color M-Mode Echocardiography in a Patient With Complete Atrioventricular Block.","ja":"Diastolic Mitral Regurgitation on Color M-Mode Echocardiography in a Patient With Complete Atrioventricular Block."},"authors":{"en":[{"name":"Tani Akihiro"},{"name":"Kusunose Kenya"},{"name":"Mastumoto Kazuhisa"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"谷 彰浩"},{"name":"楠瀬 賢也"},{"name":"松本 和久"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2020-02-20","publication_name":{"en":"Circulation Reports","ja":"Circulation Reports"},"volume":"Vol.2","number":"No.3","starting_page":"207","ending_page":"208","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circrep.CR-20-0002"],"issn":["2434-0790"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115257","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32117043","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85079782281&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366062","label":"url"}],"paper_title":{"en":"Levels of Adiponectin Expression in Peri-Renal and Subcutaneous Adipose Tissue and Its Determinants in Human Biopsied Samples","ja":"Levels of Adiponectin Expression in Peri-Renal and Subcutaneous Adipose Tissue and Its Determinants in Human Biopsied Samples"},"authors":{"en":[{"name":"Maimaituxun Gulinu"},{"name":"Fukuda Daiju"},{"name":"Izaki Hirofumi"},{"name":"Hirata Y"},{"name":"Kanayama HO"},{"name":"Masuzaki H"},{"name":"Sata Masataka"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"Gulinu Maimaituxun"},{"name":"福田 大受"},{"name":"井崎 博文"},{"name":"Hirata Y"},{"name":"Kanayama HO"},{"name":"Masuzaki H"},{"name":"佐田 政隆"},{"name":"島袋 充生"}]},"publication_date":"2020-02-06","publication_name":{"en":"Frontiers in Endocrinology","ja":"Frontiers in Endocrinology"},"number":"No.10","starting_page":"897","ending_page":"897","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fendo.2019.00897"],"issn":["1664-2392"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=377174","label":"url"}],"paper_title":{"en":"Validation of Epicardial Adipose Tissue Thickness by Echocardiography for Predicting Coronary Artery Disease: a Multicenter Study","ja":"冠動脈疾患の予測における心外膜下脂肪厚計測の有用性について:多施設共同研究"},"authors":{"en":[{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"原田 修"},{"name":"宮里 尚美"},{"name":"原國 督"},{"name":"Kusunose Kenya"},{"name":"伊藤 敦彦"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"原田 修"},{"name":"宮里 尚美"},{"name":"原國 督"},{"name":"楠瀬 賢也"},{"name":"伊藤 敦彦"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2020-02","publication_name":{"en":"Japanese Journal of Medical Ultrasound Technology","ja":"超音波検査技術"},"volume":"Vol.45","number":"No.1","starting_page":"11","ending_page":"20","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.11272/jss.302"],"issn":["1881-4514"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31956209","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85079208017&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363021","label":"url"}],"paper_title":{"en":"Association of Local Epicardial Adipose Tissue Depots and Left Ventricular Diastolic Performance in Patients With Preserved Left Ventricular Ejection Fraction","ja":"Association of Local Epicardial Adipose Tissue Depots and Left Ventricular Diastolic Performance in Patients With Preserved Left Ventricular Ejection Fraction"},"authors":{"en":[{"name":"Gulinu Maimaituxun"},{"name":"Yamada Hirotsugu"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yukina Hirata"},{"name":"Susumu Nishio"},{"name":"Soeki Takeshi"},{"name":"Hiroaki Masuzaki"},{"name":"Sata Masataka"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"Gulinu Maimaituxun"},{"name":"山田 博胤"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"Yukina Hirata"},{"name":"Susumu Nishio"},{"name":"添木 武"},{"name":"Hiroaki Masuzaki"},{"name":"佐田 政隆"},{"name":"島袋 充生"}]},"publication_date":"2020-01-24","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.84","number":"No.2","starting_page":"203","ending_page":"216","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-19-0793"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114774","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31910779","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85077720595&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363023","label":"url"}],"paper_title":{"en":"Diagnostic Criteria of FlowMediated Vasodilation for Normal Endothelial Function and NitroglycerinInduced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery","ja":"Diagnostic Criteria of FlowMediated Vasodilation for Normal Endothelial Function and NitroglycerinInduced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery"},"authors":{"en":[{"name":"Maruhashi Tatsuya"},{"name":"Kajikawa Masato"},{"name":"Kishimoto Shinji"},{"name":"Hashimoto Haruki"},{"name":"Takaeko Yuji"},{"name":"Yamaji Takayuki"},{"name":"Harada Takahiro"},{"name":"Han Yiming"},{"name":"Aibara Yoshiki"},{"name":"Yusoff Mohamad Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}],"ja":[{"name":"Maruhashi Tatsuya"},{"name":"Kajikawa Masato"},{"name":"Kishimoto Shinji"},{"name":"Hashimoto Haruki"},{"name":"Takaeko Yuji"},{"name":"Yamaji Takayuki"},{"name":"Harada Takahiro"},{"name":"Han Yiming"},{"name":"Aibara Yoshiki"},{"name":"Yusoff Mohamad Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}]},"description":{"en":"Background Diagnostic criteria of flow-mediated vasodilation (FMD), an index of endothelial function, and nitroglycerin-induced vasodilation (NID), an index of vascular smooth muscle function, of the brachial artery have not been established. The purpose of this study was to propose diagnostic criteria of FMD and NID for normal endothelial function and normal vascular smooth muscle function. Methods and Results We investigated the cutoff values of FMD and NID in subjects with (risk group) and those without cardiovascular risk factors or cardiovascular diseases (no-risk group) in 7277 Japanese subjects (mean age 51.4±10.8 years) from the Flow-Mediated Dilation Japan study and the Flow-Mediated Dilatation Japan Registry study for analysis of the cutoff value of FMD and in 1764 Japanese subjects (62.2±16.1 years) from the registry of Hiroshima University Hospital for analysis of the cutoff value of NID. Receiver-operator characteristic curve analysis of FMD to discriminate subjects in the no-risk group from patients in the risk group showed that the optimal cutoff value of FMD to diagnose subjects in the no-risk group was 7.1%. Receiver-operator characteristic curve analysis of NID to discriminate subjects in the no-risk group from patients in the risk group showed that the optimal cutoff value of NID to diagnose subjects in the no-risk group was 15.6%. Conclusions We propose that the cutoff value for normal endothelial function assessed by FMD of the brachial artery is 7.1% and that the cutoff value for normal vascular smooth muscle function assessed by NID of the brachial artery is 15.6% in Japanese subjects. Clinical Trial Registration www.umin.ac.jp Unique identifiers: UMIN000012950, UMIN000012951, UMIN000012952, and UMIN000003409.","ja":"Background Diagnostic criteria of flow-mediated vasodilation (FMD), an index of endothelial function, and nitroglycerin-induced vasodilation (NID), an index of vascular smooth muscle function, of the brachial artery have not been established. The purpose of this study was to propose diagnostic criteria of FMD and NID for normal endothelial function and normal vascular smooth muscle function. Methods and Results We investigated the cutoff values of FMD and NID in subjects with (risk group) and those without cardiovascular risk factors or cardiovascular diseases (no-risk group) in 7277 Japanese subjects (mean age 51.4±10.8 years) from the Flow-Mediated Dilation Japan study and the Flow-Mediated Dilatation Japan Registry study for analysis of the cutoff value of FMD and in 1764 Japanese subjects (62.2±16.1 years) from the registry of Hiroshima University Hospital for analysis of the cutoff value of NID. Receiver-operator characteristic curve analysis of FMD to discriminate subjects in the no-risk group from patients in the risk group showed that the optimal cutoff value of FMD to diagnose subjects in the no-risk group was 7.1%. Receiver-operator characteristic curve analysis of NID to discriminate subjects in the no-risk group from patients in the risk group showed that the optimal cutoff value of NID to diagnose subjects in the no-risk group was 15.6%. Conclusions We propose that the cutoff value for normal endothelial function assessed by FMD of the brachial artery is 7.1% and that the cutoff value for normal vascular smooth muscle function assessed by NID of the brachial artery is 15.6% in Japanese subjects. Clinical Trial Registration www.umin.ac.jp Unique identifiers: UMIN000012950, UMIN000012951, UMIN000012952, and UMIN000003409."},"publication_date":"2020-01-21","publication_name":{"en":"Journal of the American Heart Association","ja":"Journal of the American Heart Association"},"volume":"Vol.9","number":"No.8","starting_page":"e013915","ending_page":"e013915","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/JAHA.119.013915"],"issn":["2047-9980"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114211","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31759113","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360968","label":"url"}],"paper_title":{"en":"Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice","ja":"Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice"},"authors":{"en":[{"name":"Rahadian Arief"},{"name":"Fukuda Daiju"},{"name":"Salim HM"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Arief Rahadian"},{"name":"福田 大受"},{"name":"Hotimah Masdan Salim"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Diabetic patients have coagulation abnormalities, in which thrombin plays a key role. Whereas accumulating evidence suggests that it also contributes to the development of vascular dysfunction through the activation of protease-activated receptors (PARs). Here we investigated whether the blockade of thrombin attenuates endothelial dysfunction in diabetic mice. Induction of diabetes by streptozotocin (STZ) increased the expression of PAR1, PAR3, and PAR4 in the aorta. STZ-induced diabetic mice showed impairment of endothelial function, while the administration of dabigatran etexilate, a direct thrombin inhibitor, significantly attenuated endothelial dysfunction in diabetic mice with no alteration of metabolic parameters including blood glucose level. Dabigatran did not affect endothelium-independent vasodilation. Dabigatran decreased the expression of inflammatory molecules (e.g., MCP-1 and ICAM-1) in the aorta of diabetic mice. Thrombin increased the expression of these inflammatory molecules and the phosphorylation of IκBα, and decreased the phosphorylation of eNOS in human umbilical endothelial cells (HUVEC). Thrombin significantly impaired the endothelium-dependent vascular response of aortic rings obtained from wild-type mice. Inhibition of NF-κB attenuated thrombin-induced inflammatory molecule expression in HUVEC and ameliorated thrombin-induced endothelial dysfunction in aortic rings. Dabigatran attenuated the development of diabetes-induced endothelial dysfunction. Thrombin signaling may serve as a potential therapeutic target in diabetic condition.","ja":"Diabetic patients have coagulation abnormalities, in which thrombin plays a key role. Whereas accumulating evidence suggests that it also contributes to the development of vascular dysfunction through the activation of protease-activated receptors (PARs). Here we investigated whether the blockade of thrombin attenuates endothelial dysfunction in diabetic mice. Induction of diabetes by streptozotocin (STZ) increased the expression of PAR1, PAR3, and PAR4 in the aorta. STZ-induced diabetic mice showed impairment of endothelial function, while the administration of dabigatran etexilate, a direct thrombin inhibitor, significantly attenuated endothelial dysfunction in diabetic mice with no alteration of metabolic parameters including blood glucose level. Dabigatran did not affect endothelium-independent vasodilation. Dabigatran decreased the expression of inflammatory molecules (e.g., MCP-1 and ICAM-1) in the aorta of diabetic mice. Thrombin increased the expression of these inflammatory molecules and the phosphorylation of IκBα, and decreased the phosphorylation of eNOS in human umbilical endothelial cells (HUVEC). Thrombin significantly impaired the endothelium-dependent vascular response of aortic rings obtained from wild-type mice. Inhibition of NF-κB attenuated thrombin-induced inflammatory molecule expression in HUVEC and ameliorated thrombin-induced endothelial dysfunction in aortic rings. Dabigatran attenuated the development of diabetes-induced endothelial dysfunction. Thrombin signaling may serve as a potential therapeutic target in diabetic condition."},"publication_date":"2020-01","publication_name":{"en":"Vascular Pharmacology","ja":"Vascular Pharmacology"},"volume":"Vol.124","starting_page":"106632","ending_page":"106632","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.vph.2019.106632"],"issn":["1879-3649"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114645","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32378595","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85084219030&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366095","label":"url"}],"paper_title":{"en":"Classification of physical activity in patients with heart failure categorized as New York Heart Association class I or II","ja":"Classification of physical activity in patients with heart failure categorized as New York Heart Association class I or II"},"authors":{"en":[{"name":"Doi Sayuri"},{"name":"Tamura A"},{"name":"Minagawa Takako"},{"name":"Osaka A"},{"name":"Sata Masataka"}],"ja":[{"name":"土井 さゆり"},{"name":"Tamura A"},{"name":"南川 貴子"},{"name":"Osaka A"},{"name":"佐田 政隆"}]},"description":{"en":"This study aimed that we were classification of physical activity in patients with heart failure categorized as New York Heart Association (NYHA) class I or II. We were a survey using a researcher- administered questionnaire, SF-8, the Specific Activity Scale (SAS), and the Scale to Measure Self-Care Behavior of Patients with Heart Disease. We included 70 patients who were treated in the Department of Cardiovascular Medicine at Hospital A. Regarding patient characteristics and clinical information after the cluster analysis, there were significant differences in the NYHA class (p = 0.001), BNP level (p = 0.012), self-management of medication adherence (p = 0.000), and exercise habits (p = 0.005). We summarized characteristics of each group as follows : Group A showed high tolerance to physical activity and near-perfect self-management; Group B showed moderate tolerance to physical activity but was not willing to commit to daily exercise and self-management; and Group C showed low tolerance to physical activity and often requested others to handle medication management. We needed that tolerance to physical activity and proposals for tailored instruction according to patient conditions, and needed that instructions tailored to the characteristics of heart failure patients in groups A-C. J. Med. Invest. 67 : 124-133, February, 2020.","ja":"This study aimed that we were classification of physical activity in patients with heart failure categorized as New York Heart Association (NYHA) class I or II. We were a survey using a researcher- administered questionnaire, SF-8, the Specific Activity Scale (SAS), and the Scale to Measure Self-Care Behavior of Patients with Heart Disease. We included 70 patients who were treated in the Department of Cardiovascular Medicine at Hospital A. Regarding patient characteristics and clinical information after the cluster analysis, there were significant differences in the NYHA class (p = 0.001), BNP level (p = 0.012), self-management of medication adherence (p = 0.000), and exercise habits (p = 0.005). We summarized characteristics of each group as follows : Group A showed high tolerance to physical activity and near-perfect self-management; Group B showed moderate tolerance to physical activity but was not willing to commit to daily exercise and self-management; and Group C showed low tolerance to physical activity and often requested others to handle medication management. We needed that tolerance to physical activity and proposals for tailored instruction according to patient conditions, and needed that instructions tailored to the characteristics of heart failure patients in groups A-C. J. Med. Invest. 67 : 124-133, February, 2020."},"publication_date":"2020","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.67","number":"No.1.2","starting_page":"124","ending_page":"133","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.67.124"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114188","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31822217","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=361983","label":"url"}],"paper_title":{"en":"Brachial-Ankle Pulse Wave Velocity Versus Its Stiffness Index β-Transformed Value as Risk Marker for Cardiovascular Disease","ja":"Brachial-Ankle Pulse Wave Velocity Versus Its Stiffness Index β-Transformed Value as Risk Marker for Cardiovascular Disease"},"authors":{"en":[{"name":"Hirofumi Tomiyama"},{"name":"Toshiaki Ohkuma"},{"name":"Toshiharu Ninomiya"},{"name":"Hiroki Nakano"},{"name":"Chisa Matsumoto"},{"name":"Alberto Avolio"},{"name":"Takahide Kohro"},{"name":"Yukihito Higashi"},{"name":"Tetsuya Maruhashi"},{"name":"Bonpei Takase"},{"name":"Toru Suzuki"},{"name":"Tomoko Ishizu"},{"name":"Shinichiro Ueta"},{"name":"Tsutomu Yamazaki"},{"name":"Tomoo Furumoto"},{"name":"Kazuomi Kario"},{"name":"Teruo Inoue"},{"name":"Shinji Koba"},{"name":"Yasuhiko Takemoto"},{"name":"Takuzo Hano"},{"name":"Sata Masataka"},{"name":"Yutaka Ishibashi"},{"name":"Koichi Node"},{"name":"Koji Maemura"},{"name":"Yusuke Ohya"},{"name":"Taiji Furukawa"},{"name":"Hiroshi Ito"},{"name":"Taishiro Chikamori"},{"name":"Akira Yamashina"}],"ja":[{"name":"Hirofumi Tomiyama"},{"name":"Toshiaki Ohkuma"},{"name":"Toshiharu Ninomiya"},{"name":"Hiroki Nakano"},{"name":"Chisa Matsumoto"},{"name":"Alberto Avolio"},{"name":"Takahide Kohro"},{"name":"Yukihito Higashi"},{"name":"Tetsuya Maruhashi"},{"name":"Bonpei Takase"},{"name":"Toru Suzuki"},{"name":"Tomoko Ishizu"},{"name":"Shinichiro Ueta"},{"name":"Tsutomu Yamazaki"},{"name":"Tomoo Furumoto"},{"name":"Kazuomi Kario"},{"name":"Teruo Inoue"},{"name":"Shinji Koba"},{"name":"Yasuhiko Takemoto"},{"name":"Takuzo Hano"},{"name":"佐田 政隆"},{"name":"Yutaka Ishibashi"},{"name":"Koichi Node"},{"name":"Koji Maemura"},{"name":"Yusuke Ohya"},{"name":"Taiji Furukawa"},{"name":"Hiroshi Ito"},{"name":"Taishiro Chikamori"},{"name":"Akira Yamashina"}]},"description":{"en":"Background The difference in the predictive ability of the brachial-ankle pulse wave velocity (baPWV) and its stiffness index β-transformed value (β-baPWV, ie, baPWV adjusted for the pulse pressure) for the development of pathophysiological abnormalities related to cardiovascular disease or future occurrence of cardiovascular disease was examined. Methods and Results In study 1, a 7-year prospective observational study in cohorts of 3274 men and 3490 men, the area under the curve in the receiver operator characteristic curve analysis was higher for baPWV than for β-baPWV for predicting the development of hypertension (0.73, 95% CI=0.70 to 0.75 versus 0.59, 95% CI=0.56 to 0.62; <0.01) and/or the development of retinopathy (0.78, 95% CI=0.73 to 0.82 versus 0.66, 95% CI=0.60 to 0.71; <0.01) by the end of the study period. During study 2, a 3-year observation period on 511 patients with coronary artery disease, 72 cardiovascular events were confirmed. The C statistics of both markers for predicting the development of cardiovascular events were similar. Conclusions Stiffness index β transformation of the baPWV may attenuate the significance of the baPWV as a risk marker for development of pathophysiological abnormalities related to cardiovascular disease in male subjects.","ja":"Background The difference in the predictive ability of the brachial-ankle pulse wave velocity (baPWV) and its stiffness index β-transformed value (β-baPWV, ie, baPWV adjusted for the pulse pressure) for the development of pathophysiological abnormalities related to cardiovascular disease or future occurrence of cardiovascular disease was examined. Methods and Results In study 1, a 7-year prospective observational study in cohorts of 3274 men and 3490 men, the area under the curve in the receiver operator characteristic curve analysis was higher for baPWV than for β-baPWV for predicting the development of hypertension (0.73, 95% CI=0.70 to 0.75 versus 0.59, 95% CI=0.56 to 0.62; <0.01) and/or the development of retinopathy (0.78, 95% CI=0.73 to 0.82 versus 0.66, 95% CI=0.60 to 0.71; <0.01) by the end of the study period. During study 2, a 3-year observation period on 511 patients with coronary artery disease, 72 cardiovascular events were confirmed. The C statistics of both markers for predicting the development of cardiovascular events were similar. Conclusions Stiffness index β transformation of the baPWV may attenuate the significance of the baPWV as a risk marker for development of pathophysiological abnormalities related to cardiovascular disease in male subjects."},"publication_date":"2019-12-17","publication_name":{"en":"Journal of the American Heart Association","ja":"Journal of the American Heart Association"},"volume":"Vol.8","number":"No.24","starting_page":"e013004","ending_page":"e013004","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/JAHA.119.013004"],"issn":["2047-9980"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114212","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31735774","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85075961168&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360967","label":"url"}],"paper_title":{"en":"Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice","ja":"Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice"},"authors":{"en":[{"name":"Aini K"},{"name":"Fukuda Daiju"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"Hirata Yukina"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"AINI KUNDUZIAYI"},{"name":"福田 大受"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"平田 有紀奈"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel antidiabetic agents with possible vascular protection effects. Endothelial dysfunction is an initiation step in atherogenesis. The purpose of this study was to investigate whether vildagliptin (Vilda) attenuates the development of endothelial dysfunction and atherosclerotic lesions in nondiabetic apolipoprotein E-deficient (ApoE) mice. Eight-week-old nondiabetic ApoE mice fed a Western-type diet received Vilda (50 mg/kg/day) for 20 weeks or 8 weeks. After 20 weeks of treatment, Vilda administration reduced atherogenesis in the aortic arch as determined by en face Sudan IV staining compared with the vehicle group (P < 0.05). Vilda also reduced lipid accumulation (P < 0.05) and vascular cell adhesion molecule-1 (VCAM-1) expression (P < 0.05) and tended to decrease macrophage infiltration (P = 0.05) into atherosclerotic plaques compared with vehicle. After 8 weeks of treatment, endothelium-dependent vascular reactivity was examined. Vilda administration significantly attenuated the impairment of endothelial function in nondiabetic ApoE mice compared with the vehicle group (P < 0.05). Vilda treatment did not alter metabolic parameters, including blood glucose level, in both study protocols. To investigate the mechanism, aortic segments obtained from wild-type mice were incubated with exendin-4 (Ex-4), a glucagon-like peptide-1 (GLP-1) analog, in the presence or absence of lipopolysaccharide (LPS). Ex-4 attenuated the impairment of endothelium-dependent vasodilation induced by LPS (P < 0.01). Furthermore, Ex-4 promoted phosphorylation of eNOS at Ser1177 which was decreased by LPS in human umbilical endothelial cells (P < 0.05). Vilda inhibited the development of endothelial dysfunction and prevented atherogenesis in nondiabetic ApoE mice. Our results suggested that GLP-1-dependent amelioration of endothelial dysfunction is associated with the atheroprotective effects of Vilda.","ja":"Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel antidiabetic agents with possible vascular protection effects. Endothelial dysfunction is an initiation step in atherogenesis. The purpose of this study was to investigate whether vildagliptin (Vilda) attenuates the development of endothelial dysfunction and atherosclerotic lesions in nondiabetic apolipoprotein E-deficient (ApoE) mice. Eight-week-old nondiabetic ApoE mice fed a Western-type diet received Vilda (50 mg/kg/day) for 20 weeks or 8 weeks. After 20 weeks of treatment, Vilda administration reduced atherogenesis in the aortic arch as determined by en face Sudan IV staining compared with the vehicle group (P < 0.05). Vilda also reduced lipid accumulation (P < 0.05) and vascular cell adhesion molecule-1 (VCAM-1) expression (P < 0.05) and tended to decrease macrophage infiltration (P = 0.05) into atherosclerotic plaques compared with vehicle. After 8 weeks of treatment, endothelium-dependent vascular reactivity was examined. Vilda administration significantly attenuated the impairment of endothelial function in nondiabetic ApoE mice compared with the vehicle group (P < 0.05). Vilda treatment did not alter metabolic parameters, including blood glucose level, in both study protocols. To investigate the mechanism, aortic segments obtained from wild-type mice were incubated with exendin-4 (Ex-4), a glucagon-like peptide-1 (GLP-1) analog, in the presence or absence of lipopolysaccharide (LPS). Ex-4 attenuated the impairment of endothelium-dependent vasodilation induced by LPS (P < 0.01). Furthermore, Ex-4 promoted phosphorylation of eNOS at Ser1177 which was decreased by LPS in human umbilical endothelial cells (P < 0.05). Vilda inhibited the development of endothelial dysfunction and prevented atherogenesis in nondiabetic ApoE mice. Our results suggested that GLP-1-dependent amelioration of endothelial dysfunction is associated with the atheroprotective effects of Vilda."},"publication_date":"2019-11-15","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.60","number":"No.6","starting_page":"1421","ending_page":"1429","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.19-117"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114189","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31611537","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360390","label":"url"}],"paper_title":{"en":"Association of Echocardiography Before Major Elective Non-Cardiac Surgery With Improved Postoperative Outcomes - Possible Implications for Patient Care.","ja":"Association of Echocardiography Before Major Elective Non-Cardiac Surgery With Improved Postoperative Outcomes - Possible Implications for Patient Care."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Torii Yuta"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Saijoh Yoshihito"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"鳥居 裕太"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Whether preoperative echocardiography improves postoperative outcomes is not well established, so we examined the value of echocardiographic assessment on the onset of postoperative heart failure (HF), and determining which patients benefitted most from undergoing echocardiography prior to major elective non-cardiac surgery.Methods and Results:We identified all patients aged 50 years and older who had major elective non-cardiac surgery, and excluded patients with previously identified severe cardiovascular disease. The primary endpoint was the onset of HF during hospitalization. A total of 806 patients were included in the analysis. During hospitalization, 49 patients (6%) reached the primary endpoint. Within the matched cohort, preoperative echocardiography was associated with a statistically significant decrease in postoperative HF (hazard ratio: 0.46, P=0.01). In subgroup analyses, age, sex, body surface area, hypertension, diabetes mellitus, prior HF, surgical type, chronic kidney disease, pulmonary disease, and malignancy influenced the association of echocardiography with postoperative HF. The use of echocardiography in elderly patients with certain risk factors was associated with improved postoperative outcomes. The basis for this finding remains to be determined; particularly whether echocardiography is simply a marker of a population with better outcomes or whether it leads to better management that improves outcomes.","ja":"Whether preoperative echocardiography improves postoperative outcomes is not well established, so we examined the value of echocardiographic assessment on the onset of postoperative heart failure (HF), and determining which patients benefitted most from undergoing echocardiography prior to major elective non-cardiac surgery.Methods and Results:We identified all patients aged 50 years and older who had major elective non-cardiac surgery, and excluded patients with previously identified severe cardiovascular disease. The primary endpoint was the onset of HF during hospitalization. A total of 806 patients were included in the analysis. During hospitalization, 49 patients (6%) reached the primary endpoint. Within the matched cohort, preoperative echocardiography was associated with a statistically significant decrease in postoperative HF (hazard ratio: 0.46, P=0.01). In subgroup analyses, age, sex, body surface area, hypertension, diabetes mellitus, prior HF, surgical type, chronic kidney disease, pulmonary disease, and malignancy influenced the association of echocardiography with postoperative HF. The use of echocardiography in elderly patients with certain risk factors was associated with improved postoperative outcomes. The basis for this finding remains to be determined; particularly whether echocardiography is simply a marker of a population with better outcomes or whether it leads to better management that improves outcomes."},"publication_date":"2019-10-12","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.83","number":"No.12","starting_page":"2512","ending_page":"2519","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-19-0663"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.jstage.jst.go.jp/article/naika/108/8/108_1607/_pdf","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390848250135223424/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=358170","label":"url"}],"paper_title":{"en":"Recent Advance in Atherosclerosis Research","ja":"医学と医療の最前線 動脈硬化研究の最近の進歩"},"authors":{"en":[{"name":"田中 君枝"},{"name":"平田 陽一郎"},{"name":"Fukuda Daiju"},{"name":"Sata Masataka"}],"ja":[{"name":"田中 君枝"},{"name":"平田 陽一郎"},{"name":"福田 大受"},{"name":"佐田 政隆"}]},"publication_date":"2019-08-10","publication_name":{"en":"The Journal of the Japanese Society of Internal Medicine","ja":"日本内科学会雑誌"},"volume":"Vol.108","number":"No.10","starting_page":"1607","ending_page":"1615","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.2169/naika.108.1607"],"issn":["1883-2083"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114191","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31422131","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359366","label":"url"}],"paper_title":{"en":"Pulmonary Artery Hypertension-Specific Therapy Improves Exercise Tolerance and Outcomes in Exercise-Induced Pulmonary Hypertension","ja":"Pulmonary Artery Hypertension-Specific Therapy Improves Exercise Tolerance and Outcomes in Exercise-Induced Pulmonary Hypertension"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Saijoh Yoshihito"},{"name":"Torii Yuta"},{"name":"Yamada nao"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"西條 良仁"},{"name":"鳥居 裕太"},{"name":"山田 なお"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"publication_date":"2019-08-08","publication_name":{"en":"JACC. Cardiovascular Imaging","ja":"JACC. Cardiovascular Imaging"},"volume":"Vol.12","number":"No.12","starting_page":"2576","ending_page":"2579","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jcmg.2019.07.002"],"issn":["1876-7591"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114192","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31371788","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354810","label":"url"}],"paper_title":{"en":"Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice","ja":"Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice"},"authors":{"en":[{"name":"Pham PT"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Pham PT"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Activated factor X (FXa) plays a central role in the coagulation cascade, while it also mediates vascular function through activation of protease-activated receptors (PARs). Here, we examined whether inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in streptozotocin (STZ)-induced diabetic mice. Induction of diabetes increased the expression of a major FXa receptor, PAR2, in the aorta (P < 0.05). Administration of rivaroxaban (10 mg/kg/day) to diabetic wild-type (WT) mice for 3 weeks attenuated endothelial dysfunction as determined by acetylcholine-dependent vasodilation compared with the control (P < 0.001), without alteration of blood glucose level. Rivaroxaban promoted eNOS phosphorylation in the aorta (P < 0.001). Induction of diabetes to PAR2-deficient (PAR2) mice did not affect endothelial function and eNOS phosphorylation in the aorta compared with non-diabetic PAR2 mice. FXa or a PAR2 agonist significantly impaired endothelial function in aortic rings obtained from WT mice, but not in those from PAR2 mice. FXa promoted JNK phosphorylation (P < 0.01) and reduced eNOS phosphorylation (P < 0.05) in human coronary artery endothelial cells (HCAEC). FXa-induced endothelial dysfunction in aortic rings (P < 0.001) and eNOS phosphorylation (P < 0.05) in HCAEC were partially ameliorated by a JNK inhibitor. Rivaroxaban ameliorated diabetes-induced endothelial dysfunction. Our results suggest that FXa or PAR2 is a potential therapeutic target.","ja":"Activated factor X (FXa) plays a central role in the coagulation cascade, while it also mediates vascular function through activation of protease-activated receptors (PARs). Here, we examined whether inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in streptozotocin (STZ)-induced diabetic mice. Induction of diabetes increased the expression of a major FXa receptor, PAR2, in the aorta (P < 0.05). Administration of rivaroxaban (10 mg/kg/day) to diabetic wild-type (WT) mice for 3 weeks attenuated endothelial dysfunction as determined by acetylcholine-dependent vasodilation compared with the control (P < 0.001), without alteration of blood glucose level. Rivaroxaban promoted eNOS phosphorylation in the aorta (P < 0.001). Induction of diabetes to PAR2-deficient (PAR2) mice did not affect endothelial function and eNOS phosphorylation in the aorta compared with non-diabetic PAR2 mice. FXa or a PAR2 agonist significantly impaired endothelial function in aortic rings obtained from WT mice, but not in those from PAR2 mice. FXa promoted JNK phosphorylation (P < 0.01) and reduced eNOS phosphorylation (P < 0.05) in human coronary artery endothelial cells (HCAEC). FXa-induced endothelial dysfunction in aortic rings (P < 0.001) and eNOS phosphorylation (P < 0.05) in HCAEC were partially ameliorated by a JNK inhibitor. Rivaroxaban ameliorated diabetes-induced endothelial dysfunction. Our results suggest that FXa or PAR2 is a potential therapeutic target."},"publication_date":"2019-08-01","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"Vol.9","number":"No.1","starting_page":"11206","ending_page":"11206","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41598-019-47474-0"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114193","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31378421","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85069976367&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354806","label":"url"}],"paper_title":{"en":"Updated Left Ventricular Diastolic Function Recommendations and Cardiovascular Events in Patients with Heart Failure Hospitalization","ja":"Updated Left Ventricular Diastolic Function Recommendations and Cardiovascular Events in Patients with Heart Failure Hospitalization"},"authors":{"en":[{"name":"Torii Yuta"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Rie Amano"},{"name":"Masami Yamao"},{"name":"Robert Zheng"},{"name":"Saijoh Yoshihito"},{"name":"Yamada nao"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"鳥居 裕太"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"天野 里江"},{"name":"山尾 雅美"},{"name":"Robert Zheng"},{"name":"西條 良仁"},{"name":"山田 なお"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Evaluation of diastolic dysfunction is crucial in determining elevated left atrial pressure. However, a validation of the long-term prognostic value of the newly proposed algorithm updated in 2016 has not been performed. The aim of the present study was to investigate the relative value of the updated 2016 diastolic dysfunction grading system for the incidence of readmission in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Two hundred thirty-two patients hospitalized with HF were retrospectively evaluated. Subjects were divided into two subgroups: those with HFrEF (n = 127) and those with HFpEF (n = 105). Readmission risk scores were calculated using the Yale Center for Outcomes Research and Evaluation HF, LACE index, and HOSPITAL scores. The primary end point was readmission following HF and cardiac death. Over a period of 24 months, 86 patients were either readmitted or died. Multivariate Cox analysis was performed on both the HFrEF and HFpEF groups. In the HFrEF group, both the 2009 and 2016 algorithms had superior incremental value for the association of the primary end point to several readmission risk scores. In the HFpEF group, only the 2016 algorithm led to significant improvement in association with the primary end point. The 2016 algorithm had incremental value over several readmission risk scores alone. The recommendations of the 2016 algorithm can be useful for readmission and cardiac mortality risk assessment in patients with HFrEF and HFpEF. The use of echocardiography to estimate elevated left atrial pressure appears to identify a higher risk group and may allow a more tailored approach to therapy.","ja":"Evaluation of diastolic dysfunction is crucial in determining elevated left atrial pressure. However, a validation of the long-term prognostic value of the newly proposed algorithm updated in 2016 has not been performed. The aim of the present study was to investigate the relative value of the updated 2016 diastolic dysfunction grading system for the incidence of readmission in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Two hundred thirty-two patients hospitalized with HF were retrospectively evaluated. Subjects were divided into two subgroups: those with HFrEF (n = 127) and those with HFpEF (n = 105). Readmission risk scores were calculated using the Yale Center for Outcomes Research and Evaluation HF, LACE index, and HOSPITAL scores. The primary end point was readmission following HF and cardiac death. Over a period of 24 months, 86 patients were either readmitted or died. Multivariate Cox analysis was performed on both the HFrEF and HFpEF groups. In the HFrEF group, both the 2009 and 2016 algorithms had superior incremental value for the association of the primary end point to several readmission risk scores. In the HFpEF group, only the 2016 algorithm led to significant improvement in association with the primary end point. The 2016 algorithm had incremental value over several readmission risk scores alone. The recommendations of the 2016 algorithm can be useful for readmission and cardiac mortality risk assessment in patients with HFrEF and HFpEF. The use of echocardiography to estimate elevated left atrial pressure appears to identify a higher risk group and may allow a more tailored approach to therapy."},"publication_date":"2019-08-01","publication_name":{"en":"Journal of the American Society of Echocardiography","ja":"Journal of the American Society of Echocardiography"},"volume":"Vol.32","number":"No.10","starting_page":"1286","ending_page":"1297","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.echo.2019.06.006"],"issn":["1097-6795"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114195","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31308448","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85069056464&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354819","label":"url"}],"paper_title":{"en":"Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study","ja":"Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study"},"authors":{"en":[{"name":"Kajikawa M"},{"name":"Maruhashi T"},{"name":"Hidaka T"},{"name":"Matsui S"},{"name":"Hashimoto H"},{"name":"Takaeko Y"},{"name":"Nakano Y"},{"name":"Kurisu S"},{"name":"Kihara Y"},{"name":"Yusoff FM"},{"name":"Kishimoto S"},{"name":"Chayama K"},{"name":"Goto C"},{"name":"Noma K"},{"name":"Nakashima A"},{"name":"Hiro T"},{"name":"Hirayama A"},{"name":"Shiina K"},{"name":"Tomiyama H"},{"name":"Yagi Shusuke"},{"name":"Rie Amano"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"},{"name":"Higashi Y"}],"ja":[{"name":"Kajikawa M"},{"name":"Maruhashi T"},{"name":"Hidaka T"},{"name":"Matsui S"},{"name":"Hashimoto H"},{"name":"Takaeko Y"},{"name":"Nakano Y"},{"name":"Kurisu S"},{"name":"Kihara Y"},{"name":"Yusoff FM"},{"name":"Kishimoto S"},{"name":"Chayama K"},{"name":"Goto C"},{"name":"Noma K"},{"name":"Nakashima A"},{"name":"Hiro T"},{"name":"Hirayama A"},{"name":"Shiina K"},{"name":"Tomiyama H"},{"name":"八木 秀介"},{"name":"天野 里江"},{"name":"山田 博胤"},{"name":"佐田 政隆"},{"name":"Higashi Y"}]},"description":{"en":"The dipeptidyl peptidase-4 inhibitor saxagliptin is a widely used antihyperglycemic agent in patients with type 2 diabetes. The purpose of this study was to evaluate the effects of saxagliptin on endothelial function in patients with type 2 diabetes. This was a prospective, multicenter, interventional study. A total of 34 patients with type 2 diabetes were enrolled at four university hospitals in Japan. Treatment of patients was initially started with saxagliptin at a dose of 5 mg daily. Assessment of endothelial function assessed by flow-mediated vasodilation (FMD) and measurement of stromal cell-derived factor-1α (SDF-1α) were conducted at baseline and at 3 months after treatment with saxagliptin. A total of 31 patients with type 2 diabetes were included in the analysis. Saxagliptin significantly increased FMD from 3.1 ± 3.1% to 4.2 ± 2.4% (P = 0.032) and significantly decreased total cholesterol from 190 ± 24 mg/dL to 181 ± 25 mg/dL (P = 0.002), glucose from 160 ± 53 mg/dL to 133 ± 25 mg/dL (P < 0.001), HbA1c from 7.5 ± 0.6% to 7.0 ± 0.6% (P < 0.001), urine albumin-to-creatinine ratio from 63.8 ± 134.2 mg/g to 40.9 ± 83.0 mg/g (P = 0.043), and total SDF-1α from 2108 ± 243 pg/mL to 1284 ± 345 pg/mL (P < 0.001). These findings suggest that saxagliptin is effective for improving endothelial function.","ja":"The dipeptidyl peptidase-4 inhibitor saxagliptin is a widely used antihyperglycemic agent in patients with type 2 diabetes. The purpose of this study was to evaluate the effects of saxagliptin on endothelial function in patients with type 2 diabetes. This was a prospective, multicenter, interventional study. A total of 34 patients with type 2 diabetes were enrolled at four university hospitals in Japan. Treatment of patients was initially started with saxagliptin at a dose of 5 mg daily. Assessment of endothelial function assessed by flow-mediated vasodilation (FMD) and measurement of stromal cell-derived factor-1α (SDF-1α) were conducted at baseline and at 3 months after treatment with saxagliptin. A total of 31 patients with type 2 diabetes were included in the analysis. Saxagliptin significantly increased FMD from 3.1 ± 3.1% to 4.2 ± 2.4% (P = 0.032) and significantly decreased total cholesterol from 190 ± 24 mg/dL to 181 ± 25 mg/dL (P = 0.002), glucose from 160 ± 53 mg/dL to 133 ± 25 mg/dL (P < 0.001), HbA1c from 7.5 ± 0.6% to 7.0 ± 0.6% (P < 0.001), urine albumin-to-creatinine ratio from 63.8 ± 134.2 mg/g to 40.9 ± 83.0 mg/g (P = 0.043), and total SDF-1α from 2108 ± 243 pg/mL to 1284 ± 345 pg/mL (P < 0.001). These findings suggest that saxagliptin is effective for improving endothelial function."},"publication_date":"2019-07-15","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"Vol.9","number":"No.1","starting_page":"10206","ending_page":"10206","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41598-019-46726-3"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113864","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050001338827789056/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=358780","label":"url"}],"paper_title":{"en":"A case of subacute thyroiditis associated with complete occlusion of right coronary artery","ja":"A case of subacute thyroiditis associated with complete occlusion of right coronary artery"},"authors":{"en":[{"name":"Nakanishi Akinori"},{"name":"Shunto Jouji"},{"name":"Shunto Reiko"},{"name":"Sata Masataka"},{"name":"Bando Hiroshi"}],"ja":[{"name":"Nakanishi Akinori"},{"name":"Shunto Jouji"},{"name":"Shunto Reiko"},{"name":"佐田 政隆"},{"name":"Bando Hiroshi"}]},"publication_date":"2019-07","publication_name":{"en":"Journal of Diabetes, Metabolic Disorders & Control","ja":"Journal of Diabetes, Metabolic Disorders & Control"},"volume":"Vol.6","number":"No.3","starting_page":"54","ending_page":"58","languages":["eng"],"referee":true,"identifiers":{"doi":["10.15406/jdmdc.2019.06.00183"],"issn":["2374-6947"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114194","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31257314","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85070102118&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=363956","label":"url"}],"paper_title":{"en":"Utilization of Artificial Intelligence in Echocardiography","ja":"Utilization of Artificial Intelligence in Echocardiography"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Haga Akihiro"},{"name":"Abe Takashi"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"芳賀 昭弘"},{"name":"阿部 考志"},{"name":"佐田 政隆"}]},"description":{"en":"Echocardiography has a central role in the diagnosis and management of cardiovascular disease. Precise and reliable echocardiographic assessment is required for clinical decision-making. Even if the development of new technologies (3-dimentional echocardiography, speckle-tracking, semi-automated analysis, etc.), the final decision on analysis is strongly dependent on operator experience. Diagnostic errors are a major unresolved problem. Moreover, not only can cardiologists differ from one another in image interpretation, but also the same observer may come to different findings when a reading is repeated. Daily high workloads in clinical practice may lead to this error, and all cardiologists require precise perception in this field. Artificial intelligence (AI) has the potential to improve analysis and interpretation of medical images to a new stage compared with previous algorithms. From our comprehensive review, we believe AI has the potential to improve accuracy of diagnosis, clinical management, and patient care. Although there are several concerns about the required large dataset and \"black box\" algorithm, AI can provide satisfactory results in this field. In the future, it will be necessary for cardiologists to adapt their daily practice to incorporate AI in this new stage of echocardiography.","ja":"Echocardiography has a central role in the diagnosis and management of cardiovascular disease. Precise and reliable echocardiographic assessment is required for clinical decision-making. Even if the development of new technologies (3-dimentional echocardiography, speckle-tracking, semi-automated analysis, etc.), the final decision on analysis is strongly dependent on operator experience. Diagnostic errors are a major unresolved problem. Moreover, not only can cardiologists differ from one another in image interpretation, but also the same observer may come to different findings when a reading is repeated. Daily high workloads in clinical practice may lead to this error, and all cardiologists require precise perception in this field. Artificial intelligence (AI) has the potential to improve analysis and interpretation of medical images to a new stage compared with previous algorithms. From our comprehensive review, we believe AI has the potential to improve accuracy of diagnosis, clinical management, and patient care. Although there are several concerns about the required large dataset and \"black box\" algorithm, AI can provide satisfactory results in this field. In the future, it will be necessary for cardiologists to adapt their daily practice to incorporate AI in this new stage of echocardiography."},"publication_date":"2019-06-29","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.83","number":"No.8","starting_page":"1623","ending_page":"1629","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-19-0420"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113417","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31178488","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85072509638&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352653","label":"url"}],"paper_title":{"en":"Long-surviving Anomalous Origin of the Right Pulmonary Artery from the Ascending Aorta Complicated with Pulmonary Arteriovenous Fistula","ja":"Long-surviving Anomalous Origin of the Right Pulmonary Artery from the Ascending Aorta Complicated with Pulmonary Arteriovenous Fistula"},"authors":{"en":[{"name":"Ueno Rie"},{"name":"Yagi Shusuke"},{"name":"Bando Mika"},{"name":"Sata Masataka"}],"ja":[{"name":"上野 理絵"},{"name":"八木 秀介"},{"name":"坂東 美佳"},{"name":"佐田 政隆"}]},"publication_date":"2019-06-07","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"volume":"Vol.58","number":"No.18","starting_page":"2749","ending_page":"2750","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.2455-18"],"issn":["1349-7235"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113219","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30393271","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85066748188&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347233","label":"url"}],"paper_title":{"en":"Simultaneous Pulmonary Arterial and Venous Round Structures in Pulmonary Aspergillosis.","ja":"Simultaneous Pulmonary Arterial and Venous Round Structures in Pulmonary Aspergillosis."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Yamazaki Hiromu"},{"name":"Nishio Susumu"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"山﨑 宙"},{"name":"西尾 進"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2019-05","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.83","number":"No.6","starting_page":"1416","ending_page":"1416","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-18-0898"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113231","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30905257","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85063712345&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350365","label":"url"}],"paper_title":{"en":"Toll-Like Receptor 9 Plays a Pivotal Role in Angiotensin II-Induced Atherosclerosis","ja":"Toll-Like Receptor 9 Plays a Pivotal Role in Angiotensin II-Induced Atherosclerosis"},"authors":{"en":[{"name":"Fukuda Daiju"},{"name":"Nishimoto Sachiko"},{"name":"Aini Kunduziayi"},{"name":"Tanaka Atsushi"},{"name":"Nishiguchi Tsuyoshi"},{"name":"Kim-Kaneyama Joo-Ri"},{"name":"Lei Xiao-Feng"},{"name":"Masuda Kiyoshi"},{"name":"Naruto Takuya"},{"name":"Tanaka Kimie"},{"name":"Higashikuni Yasutomi"},{"name":"Hirata Yoichiro"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Imoto Issei"},{"name":"Akasaka Takashi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"福田 大受"},{"name":"Nishimoto Sachiko"},{"name":"Aini Kunduziayi"},{"name":"Tanaka Atsushi"},{"name":"Nishiguchi Tsuyoshi"},{"name":"Kim-Kaneyama Joo-Ri"},{"name":"Lei Xiao-Feng"},{"name":"Masuda Kiyoshi"},{"name":"Naruto Takuya"},{"name":"Tanaka Kimie"},{"name":"Higashikuni Yasutomi"},{"name":"Hirata Yoichiro"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"Imoto Issei"},{"name":"Akasaka Takashi"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Background Toll-like receptor ( TLR ) 9 recognizes bacterial DNA , activating innate immunity, whereas it also provokes inflammation in response to fragmented DNA released from mammalian cells. We investigated whether TLR 9 contributes to the development of vascular inflammation and atherogenesis using apolipoprotein E-deficient ( Apoe ) mice. Methods and Results Tlr9-deficient Apoe ( Tlr9 Apoe ) mice and Apoe mice on a Western-type diet received subcutaneous angiotensin II infusion (1000 ng/kg per minute) for 28 days. Angiotensin II increased the plasma level of double-stranded DNA, an endogenous ligand of TLR 9, in these mice. Genetic deletion or pharmacologic blockade of TLR 9 in angiotensin II-infused Apoe mice attenuated atherogenesis in the aortic arch ( P<0.05), reduced the accumulation of lipid and macrophages in atherosclerotic plaques, and decreased RNA expression of inflammatory molecules in the aorta with no alteration of metabolic parameters. On the other hand, restoration of TLR 9 in bone marrow in Tlr9 Apoe mice promoted atherogenesis in the aortic arch ( P<0.05). A TLR 9 agonist markedly promoted proinflammatory activation of Apoe macrophages, partially through p38 mitogen-activated protein kinase signaling. In addition, genomic DNA extracted from macrophages promoted inflammatory molecule expression more effectively in Apoe macrophages than in Tlr9 Apoe macrophages. Furthermore, in humans, circulating double-stranded DNA in the coronary artery positively correlated with inflammatory features of coronary plaques determined by optical coherence tomography in patients with acute myocardial infarction ( P<0.05). Conclusions TLR 9 plays a pivotal role in the development of vascular inflammation and atherogenesis through proinflammatory activation of macrophages. TLR 9 may serve as a potential therapeutic target for atherosclerosis.","ja":"Background Toll-like receptor ( TLR ) 9 recognizes bacterial DNA , activating innate immunity, whereas it also provokes inflammation in response to fragmented DNA released from mammalian cells. We investigated whether TLR 9 contributes to the development of vascular inflammation and atherogenesis using apolipoprotein E-deficient ( Apoe ) mice. Methods and Results Tlr9-deficient Apoe ( Tlr9 Apoe ) mice and Apoe mice on a Western-type diet received subcutaneous angiotensin II infusion (1000 ng/kg per minute) for 28 days. Angiotensin II increased the plasma level of double-stranded DNA, an endogenous ligand of TLR 9, in these mice. Genetic deletion or pharmacologic blockade of TLR 9 in angiotensin II-infused Apoe mice attenuated atherogenesis in the aortic arch ( P<0.05), reduced the accumulation of lipid and macrophages in atherosclerotic plaques, and decreased RNA expression of inflammatory molecules in the aorta with no alteration of metabolic parameters. On the other hand, restoration of TLR 9 in bone marrow in Tlr9 Apoe mice promoted atherogenesis in the aortic arch ( P<0.05). A TLR 9 agonist markedly promoted proinflammatory activation of Apoe macrophages, partially through p38 mitogen-activated protein kinase signaling. In addition, genomic DNA extracted from macrophages promoted inflammatory molecule expression more effectively in Apoe macrophages than in Tlr9 Apoe macrophages. Furthermore, in humans, circulating double-stranded DNA in the coronary artery positively correlated with inflammatory features of coronary plaques determined by optical coherence tomography in patients with acute myocardial infarction ( P<0.05). Conclusions TLR 9 plays a pivotal role in the development of vascular inflammation and atherogenesis through proinflammatory activation of macrophages. TLR 9 may serve as a potential therapeutic target for atherosclerosis."},"publication_date":"2019-04-02","publication_name":{"en":"Journal of the American Heart Association","ja":"Journal of the American Heart Association"},"volume":"Vol.8","number":"No.7","starting_page":"e010860","ending_page":"e010860","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/JAHA.118.010860"],"issn":["2047-9980"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113069","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30470971","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85057125051&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352652","label":"url"}],"paper_title":{"en":"Left atrial functional response after a marathon in healthy amateur volunteers","ja":"Left atrial functional response after a marathon in healthy amateur volunteers"},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Morita Sae"},{"name":"Torii Yuta"},{"name":"Nishio Susumu"},{"name":"Zheng Robert"},{"name":"Saijo Yoshihito"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"森田 沙瑛"},{"name":"鳥居 裕太"},{"name":"西尾 進"},{"name":"Robert Zheng"},{"name":"西條 良仁"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"Middle-aged marathon runners have an increased risk of developing atrial fibrillation (AF). A previous study described that repetitive marathon running was associated with left atrial (LA) dysfunction. However, whether this change is common in marathon runners and which runners are at risk of LA dysfunction remain unknown. The purpose of this study was to determine which factors could predict LA dysfunction. We prospectively examined 12 healthy amateur volunteers (9 males, 31 ± 8 years old) who participated in a full marathon. All echocardiographic measurements and speckle-tracking echocardiography were performed before and after the marathon. The endpoint was defined as reduced LA reservoir strain 1 day after the marathon (non-responder group). Seven participants were in the non-responder group. Age (35 ± 9 vs. 26 ± 2 years, p = 0.020), augmentation index (76 ± 12 vs. 55 ± 8, p = 0.002), and diastolic blood pressures (83 ± 11 vs. 70 ± 7 mmHg, p = 0.021) in the non-responder group were significantly higher compared with the responder group. In multivariate linear regression analysis, only the augmentation index was an independent predictor of reduced LA reservoir function after the marathon (β = - 0.646, p = 0.023). The augmentation index was a predictive marker for reduction in LA reservoir function after a marathon in healthy amateur volunteers.","ja":"Middle-aged marathon runners have an increased risk of developing atrial fibrillation (AF). A previous study described that repetitive marathon running was associated with left atrial (LA) dysfunction. However, whether this change is common in marathon runners and which runners are at risk of LA dysfunction remain unknown. The purpose of this study was to determine which factors could predict LA dysfunction. We prospectively examined 12 healthy amateur volunteers (9 males, 31 ± 8 years old) who participated in a full marathon. All echocardiographic measurements and speckle-tracking echocardiography were performed before and after the marathon. The endpoint was defined as reduced LA reservoir strain 1 day after the marathon (non-responder group). Seven participants were in the non-responder group. Age (35 ± 9 vs. 26 ± 2 years, p = 0.020), augmentation index (76 ± 12 vs. 55 ± 8, p = 0.002), and diastolic blood pressures (83 ± 11 vs. 70 ± 7 mmHg, p = 0.021) in the non-responder group were significantly higher compared with the responder group. In multivariate linear regression analysis, only the augmentation index was an independent predictor of reduced LA reservoir function after the marathon (β = - 0.646, p = 0.023). The augmentation index was a predictive marker for reduction in LA reservoir function after a marathon in healthy amateur volunteers."},"publication_date":"2019-04","publication_name":{"en":"The International Journal of Cardiovascular Imaging","ja":"The International Journal of Cardiovascular Imaging"},"volume":"Vol.35","number":"No.4","starting_page":"633","ending_page":"643","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10554-018-1502-2"],"issn":["1875-8312"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114197","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30918221","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85065217320&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350371","label":"url"}],"paper_title":{"en":"Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Disease - Post Hoc Analysis of the FMD-J Study A.","ja":"Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Disease - Post Hoc Analysis of the FMD-J Study A."},"authors":{"en":[{"name":"Kajikawa M"},{"name":"Maruhashi T,"},{"name":"Kishimoto S,"},{"name":"Matsui S"},{"name":"Hashimoto H"},{"name":"Takaeko Y"},{"name":"Yusoff FM"},{"name":"Kihara Y"},{"name":"Chayama K"},{"name":"Goto C"},{"name":"Noma K"},{"name":"Nakashima A"},{"name":"Tomiyama H,"},{"name":"Takase B"},{"name":"Kohro T"},{"name":"Suzuki T"},{"name":"Ishizu T,"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Koba S"},{"name":"Watanabe K"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"Sata Masataka"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Ikeda H"},{"name":"Yamashina A"},{"name":"Higashi Y"}],"ja":[{"name":"Kajikawa M"},{"name":"Maruhashi T,"},{"name":"Kishimoto S,"},{"name":"Matsui S"},{"name":"Hashimoto H"},{"name":"Takaeko Y"},{"name":"Yusoff FM"},{"name":"Kihara Y"},{"name":"Chayama K"},{"name":"Goto C"},{"name":"Noma K"},{"name":"Nakashima A"},{"name":"Tomiyama H,"},{"name":"Takase B"},{"name":"Kohro T"},{"name":"Suzuki T"},{"name":"Ishizu T,"},{"name":"Ueda S"},{"name":"Yamazaki T"},{"name":"Furumoto T"},{"name":"Kario K"},{"name":"Inoue T"},{"name":"Koba S"},{"name":"Watanabe K"},{"name":"Takemoto Y"},{"name":"Hano T"},{"name":"佐田 政隆"},{"name":"Ishibashi Y"},{"name":"Node K"},{"name":"Maemura K"},{"name":"Ohya Y"},{"name":"Furukawa T"},{"name":"Ito H"},{"name":"Ikeda H"},{"name":"Yamashina A"},{"name":"Higashi Y"}]},"description":{"en":"Circulating triglyceride (TG) levels are a current focus as a residual risk for cardiovascular (CV) events. We evaluated the relationship between circulating TG levels and future CV events in patients with coronary artery disease (CAD) who were treated with conventional therapy. Methods and Results: We analyzed data for 652 patients who were enrolled in the FMD-J Study A. We investigated the associations between serum TG levels and first major CV events (death from CV cause, nonfatal acute coronary syndrome (ACS), nonfatal stroke, and CAD) for a 3-year follow-up period. Patients were divided into 4 groups based on serum TG level: low-normal (<100 mg/dL), high-normal (100-149 mg/dL), borderline hypertriglyceridemia (150-199 mg/dL), and moderate hypertriglyceridemia (≥200 mg/dL). During a median follow-up period of 46.6 months, 14 patients died (9 from CV causes), 16 had nonfatal ACS, 6 had nonfatal stroke, and 54 had CAD. The Kaplan-Meier curves for first major CV event among the 4 groups were significantly different (P=0.04). After adjustment for various confounders, serum TG level ≥100 mg/dL were significantly associated with an increased risk of first major CV events compared with serum TG level <100 mg/dL. Serum TG level may be a surrogate marker for predicting CV events in patients with CAD.","ja":"Circulating triglyceride (TG) levels are a current focus as a residual risk for cardiovascular (CV) events. We evaluated the relationship between circulating TG levels and future CV events in patients with coronary artery disease (CAD) who were treated with conventional therapy. Methods and Results: We analyzed data for 652 patients who were enrolled in the FMD-J Study A. We investigated the associations between serum TG levels and first major CV events (death from CV cause, nonfatal acute coronary syndrome (ACS), nonfatal stroke, and CAD) for a 3-year follow-up period. Patients were divided into 4 groups based on serum TG level: low-normal (<100 mg/dL), high-normal (100-149 mg/dL), borderline hypertriglyceridemia (150-199 mg/dL), and moderate hypertriglyceridemia (≥200 mg/dL). During a median follow-up period of 46.6 months, 14 patients died (9 from CV causes), 16 had nonfatal ACS, 6 had nonfatal stroke, and 54 had CAD. The Kaplan-Meier curves for first major CV event among the 4 groups were significantly different (P=0.04). After adjustment for various confounders, serum TG level ≥100 mg/dL were significantly associated with an increased risk of first major CV events compared with serum TG level <100 mg/dL. Serum TG level may be a surrogate marker for predicting CV events in patients with CAD."},"publication_date":"2019-03-26","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.83","number":"No.5","starting_page":"1064","ending_page":"1071","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-18-1082"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113220","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30135329","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85062425735&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345559","label":"url"}],"paper_title":{"en":"Association of Decreased Docosahexaenoic Acid Level After Statin Therapy and Low Eicosapentaenoic Acid Level with In-Stent Restenosis in Patients with Acute Coronary Syndrome","ja":"Association of Decreased Docosahexaenoic Acid Level After Statin Therapy and Low Eicosapentaenoic Acid Level with In-Stent Restenosis in Patients with Acute Coronary Syndrome"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Kondo Daisuke"},{"name":"Ise Takayuki"},{"name":"Fukuda Daiju"},{"name":"Yamaguchi Koji"},{"name":"Wakatsuki Tetsuzo"},{"name":"Kawabata Yutaka"},{"name":"Ito Hiroyuki"},{"name":"Saijo Yoshihito"},{"name":"Seno Hiromitsu"},{"name":"Sutou Kumiko"},{"name":"Ueno Rie"},{"name":"Todoroki Takafumi"},{"name":"Kusunose Kenya"},{"name":"Matsuura Tomomi"},{"name":"Tobiume Takeshi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Aihara Ken-ichi"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Kondo Daisuke"},{"name":"伊勢 孝之"},{"name":"福田 大受"},{"name":"山口 浩司"},{"name":"若槻 哲三"},{"name":"川端 豊"},{"name":"伊藤 浩敬"},{"name":"西條 良仁"},{"name":"瀬野 弘光"},{"name":"數藤 久美子"},{"name":"上野 理絵"},{"name":"轟 貴史"},{"name":"楠瀬 賢也"},{"name":"松浦 朋美"},{"name":"飛梅 威"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"粟飯原 賢一"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"It is speculated that statin therapy modulates the synthesis of polyunsaturated fatty acids (PUFA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). However, the data available on the effects of statin therapy on the serum levels of PUFA and the subsequent impact on in-stent restenosis (ISR) in patients with acute coronary syndrome (ACS) are limited. A total of 120 ACS patients who received emergent coronary stent implantation, follow-up coronary angiography to evaluate ISR, and new statin therapy were enrolled. We measured the serum levels of the PUFA and lipids at the onset of ACS and at the follow-up coronary angiography. The follow-up coronary angiography revealed 38 ISR cases. New statin therapy significantly reduced the serum levels of DHA and low-density lipoprotein cholesterol (LDL-C), while it did not affect EPA level. Single regression analysis revealed that a decreased serum level of LDL-C was associated with decreased DHA level. The multiple logistic regression analysis revealed that the decreased DHA level after statin therapy and low serum level of EPA on admission were determinants of prevalence of ISR. Statin therapy decreased the serum level of DHA with a parallel reduction in LDL-C level in patients with ACS. Decreased DHA level after statin therapy and low EPA level on admission are risk factors for ISR, indicating that in patients with ACS, decreased serum levels of DHA may be a residual target for the prevention of ISR.","ja":"It is speculated that statin therapy modulates the synthesis of polyunsaturated fatty acids (PUFA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). However, the data available on the effects of statin therapy on the serum levels of PUFA and the subsequent impact on in-stent restenosis (ISR) in patients with acute coronary syndrome (ACS) are limited. A total of 120 ACS patients who received emergent coronary stent implantation, follow-up coronary angiography to evaluate ISR, and new statin therapy were enrolled. We measured the serum levels of the PUFA and lipids at the onset of ACS and at the follow-up coronary angiography. The follow-up coronary angiography revealed 38 ISR cases. New statin therapy significantly reduced the serum levels of DHA and low-density lipoprotein cholesterol (LDL-C), while it did not affect EPA level. Single regression analysis revealed that a decreased serum level of LDL-C was associated with decreased DHA level. The multiple logistic regression analysis revealed that the decreased DHA level after statin therapy and low serum level of EPA on admission were determinants of prevalence of ISR. Statin therapy decreased the serum level of DHA with a parallel reduction in LDL-C level in patients with ACS. Decreased DHA level after statin therapy and low EPA level on admission are risk factors for ISR, indicating that in patients with ACS, decreased serum levels of DHA may be a residual target for the prevention of ISR."},"publication_date":"2019-03-01","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.26","number":"No.3","starting_page":"272","ending_page":"281","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.44735"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113230","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30509509","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85057486666&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350359","label":"url"}],"paper_title":{"en":"Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON","ja":"Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON"},"authors":{"en":[{"name":"Teramoto Tamio"},{"name":"Kiyosue Arihiro"},{"name":"Ishigaki Yasushi"},{"name":"Harada-Shiba Mariko"},{"name":"Kawabata Yumiko"},{"name":"Ozaki Asuka"},{"name":"Baccara-Dinet T. Marie"},{"name":"Sata Masataka"}],"ja":[{"name":"Teramoto Tamio"},{"name":"Kiyosue Arihiro"},{"name":"Ishigaki Yasushi"},{"name":"Harada-Shiba Mariko"},{"name":"Kawabata Yumiko"},{"name":"Ozaki Asuka"},{"name":"Baccara-Dinet T. Marie"},{"name":"佐田 政隆"}]},"description":{"en":"Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, given every 2 weeks (Q2W), significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in Japanese hypercholesterolemic patients on background statin. We evaluated alirocumab 150mg every 4 weeks (Q4W) in patients on lowest-dose statin or non-statin lipid-lowering therapy (LLT). ODYSSEY NIPPON was a double-blind study conducted in Japanese patients with LDL-C ≥100mg/dL (heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia with coronary heart disease) or ≥120mg/dL (non-familial hypercholesterolemia, Japan Atherosclerosis Society category III) on atorvastatin 5mg/day or non-statin LLT. Patients were randomized (1:1:1) to subcutaneous alirocumab 150mg Q4W, alirocumab 150mg Q2W, or placebo for the 12-week double-blind treatment period (DBTP), followed by a 52-week open-label treatment period (OLTP). At entry into the OLTP, patients received alirocumab 150mg Q4W, with possible up-titration to 150mg Q2W at Week 24. Least-square mean percent change in LDL-C from baseline at Week 12 (primary efficacy endpoint) was -43.8% for alirocumab Q4W, -70.1% for Q2W, and -4.3% for placebo. During the OLTP, mean LDL-C change from baseline was -45.1% at Week 20, with a further reduction at Week 36, with achieved levels maintained to Week 64. Percent of patients with ≥1 adverse event (DBTP) was 51.9% with alirocumab Q4W, 47.2% with Q2W, and 46.4% with placebo. Most common adverse events were infections and infestations (25.9%, 22.6%, 17.9%, respectively), gastrointestinal disorders (13.0%, 9.4%, 12.5%), nervous system disorders (5.6%, 7.5%, 10.7%), and general disorders and administration-site conditions (3.7%, 11.3%, 5.4%). Hypercholesterolemic Japanese patients who tolerate only lowest-strength dose statin or non-statin LLT can achieve robust LDL-C reduction with alirocumab 150mg Q4W, in addition to their current LLT. Alirocumab 150mg Q4W dosing was efficacious and generally well tolerated without new safety concerns. (ClinicalTrials.gov number: NCT02584504).","ja":"Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, given every 2 weeks (Q2W), significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in Japanese hypercholesterolemic patients on background statin. We evaluated alirocumab 150mg every 4 weeks (Q4W) in patients on lowest-dose statin or non-statin lipid-lowering therapy (LLT). ODYSSEY NIPPON was a double-blind study conducted in Japanese patients with LDL-C ≥100mg/dL (heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia with coronary heart disease) or ≥120mg/dL (non-familial hypercholesterolemia, Japan Atherosclerosis Society category III) on atorvastatin 5mg/day or non-statin LLT. Patients were randomized (1:1:1) to subcutaneous alirocumab 150mg Q4W, alirocumab 150mg Q2W, or placebo for the 12-week double-blind treatment period (DBTP), followed by a 52-week open-label treatment period (OLTP). At entry into the OLTP, patients received alirocumab 150mg Q4W, with possible up-titration to 150mg Q2W at Week 24. Least-square mean percent change in LDL-C from baseline at Week 12 (primary efficacy endpoint) was -43.8% for alirocumab Q4W, -70.1% for Q2W, and -4.3% for placebo. During the OLTP, mean LDL-C change from baseline was -45.1% at Week 20, with a further reduction at Week 36, with achieved levels maintained to Week 64. Percent of patients with ≥1 adverse event (DBTP) was 51.9% with alirocumab Q4W, 47.2% with Q2W, and 46.4% with placebo. Most common adverse events were infections and infestations (25.9%, 22.6%, 17.9%, respectively), gastrointestinal disorders (13.0%, 9.4%, 12.5%), nervous system disorders (5.6%, 7.5%, 10.7%), and general disorders and administration-site conditions (3.7%, 11.3%, 5.4%). Hypercholesterolemic Japanese patients who tolerate only lowest-strength dose statin or non-statin LLT can achieve robust LDL-C reduction with alirocumab 150mg Q4W, in addition to their current LLT. Alirocumab 150mg Q4W dosing was efficacious and generally well tolerated without new safety concerns. (ClinicalTrials.gov number: NCT02584504)."},"publication_date":"2019-03","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.73","number":"No.3","starting_page":"218","ending_page":"227","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2018.10.004"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113350","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30756346","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85061449967&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350374","label":"url"}],"paper_title":{"en":"Noninvasive assessment of left-ventricular diastolic electromechanical coupling in hypertensive heart disease,","ja":"Noninvasive assessment of left-ventricular diastolic electromechanical coupling in hypertensive heart disease,"},"authors":{"en":[{"name":"Saito Yuko"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Saito Ken"},{"name":"Sata Masataka"}],"ja":[{"name":"Saito Yuko"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"Saito Ken"},{"name":"佐田 政隆"}]},"description":{"en":"There is a need to stratify patients who may develop heart failure because of the current \"heart failure pandemic\". We hypothesized that noninvasive assessment of diastolic electromechanical coupling by electrocardiography and Doppler echocardiography may be clinically useful for risk stratification of hypertensive patients who may develop heart failure. We measured the time from the peak to end of the T wave (TpTe) as an electrophysiological parameter, and peak early diastolic mitral flow (E) and lateral annular (e') velocities as mechanical parameters in 109 patients with hypertension. Relationships between these parameters and their association with the prognosis were evaluated. The e' was inversely correlated with TpTe (p < 0.001) and QTc (p < 0.014), whereas E/e' was positively correlated with TpTe (p < 0.001) and QTc (p < 0.001). The TpTe predicted patients with E/e' > 12. There were 24 cardiovascular events during follow-up (57 ± 20 months), and Kaplan-Meier analysis showed that outcome was worse (p = 0.003) in patients with higher E/e' than lower E/e'; however, there was no difference between patients with longer TpTe (≧72 ms) and shorter TpTe (< 72 ms). The correlation of TpTe with e' and E/e' in hypertensive patients suggests that these parameters reflect diastolic ventricular electromechanical coupling. The E/e' predicted outcome, and an elevated E/e' should be suspected when TpTe is prolonged (> 72 ms). Noninvasive evaluation of diastolic electromechanical coupling is clinically useful in patients with hypertension for predicting their outcome.","ja":"There is a need to stratify patients who may develop heart failure because of the current \"heart failure pandemic\". We hypothesized that noninvasive assessment of diastolic electromechanical coupling by electrocardiography and Doppler echocardiography may be clinically useful for risk stratification of hypertensive patients who may develop heart failure. We measured the time from the peak to end of the T wave (TpTe) as an electrophysiological parameter, and peak early diastolic mitral flow (E) and lateral annular (e') velocities as mechanical parameters in 109 patients with hypertension. Relationships between these parameters and their association with the prognosis were evaluated. The e' was inversely correlated with TpTe (p < 0.001) and QTc (p < 0.014), whereas E/e' was positively correlated with TpTe (p < 0.001) and QTc (p < 0.001). The TpTe predicted patients with E/e' > 12. There were 24 cardiovascular events during follow-up (57 ± 20 months), and Kaplan-Meier analysis showed that outcome was worse (p = 0.003) in patients with higher E/e' than lower E/e'; however, there was no difference between patients with longer TpTe (≧72 ms) and shorter TpTe (< 72 ms). The correlation of TpTe with e' and E/e' in hypertensive patients suggests that these parameters reflect diastolic ventricular electromechanical coupling. The E/e' predicted outcome, and an elevated E/e' should be suspected when TpTe is prolonged (> 72 ms). Noninvasive evaluation of diastolic electromechanical coupling is clinically useful in patients with hypertension for predicting their outcome."},"publication_date":"2019-02-12","publication_name":{"en":"Journal of Echocardiography","ja":"Journal of Echocardiography"},"volume":"Vol.17","number":"No.4","starting_page":"206","ending_page":"212","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12574-019-00421-4"],"issn":["1880-344X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113325","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31064959","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351690","label":"url"}],"paper_title":{"en":"Measurement of hemodynamics immediately after vaginal delivery in healthy pregnant women by electrical cardiometry.","ja":"Measurement of hemodynamics immediately after vaginal delivery in healthy pregnant women by electrical cardiometry."},"authors":{"en":[{"name":"Yoshida Atsuko"},{"name":"Kaji Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Yonetani Naoto"},{"name":"Sogawa Eishi"},{"name":"Yamao Masami"},{"name":"Maeda Kazuhisa"},{"name":"Sata Masataka"},{"name":"Irahara Minoru"}],"ja":[{"name":"吉田 あつ子"},{"name":"加地 剛"},{"name":"山田 博胤"},{"name":"米谷 直人"},{"name":"祖川 英至"},{"name":"Yamao Masami"},{"name":"前田 和寿"},{"name":"佐田 政隆"},{"name":"苛原 稔"}]},"description":{"en":"Few reports have focused on hemodynamics around delivery in pregnant women because of the difficulty of continuous and noninvasive measurement. Electrical cardiometry allows noninvasive continuous monitoring of hemodynamics and has recently been used in non-pregnant subjects. We compared the use of electrical cardiometry versus transthoracic echocardiography in healthy pregnant women and evaluated hemodynamics immediately after vaginal delivery. In Study 1, electrical cardiometry and transthoracic echocardiography were used to measure cardiac output in 20 pregnant women with threatened premature delivery. A significant correlation was found between the two methods, with electrical cardiometry showing the higher cardiac output. In Study 2, heart rate, stroke volume, and cardiac output were continuously measured in 15 women during vaginal delivery up to 2 h postpartum. Cardiac output increased markedly because of an increased heart rate and stroke volume at the time of newborn delivery. The heart rate then immediately returned to baseline, while cardiac output remained elevated for at least 2 h after delivery because of a sustained high stroke volume. Electrical cardiometry was as readily available as transthoracic echocardiography for evaluating hemodynamics and allowed for continuous measurement during labor. High intrapartum cardiac output was sustained for at least 2 h after vaginal delivery. J. Med. Invest. 66 : 75-80, February, 2019.","ja":"Few reports have focused on hemodynamics around delivery in pregnant women because of the difficulty of continuous and noninvasive measurement. Electrical cardiometry allows noninvasive continuous monitoring of hemodynamics and has recently been used in non-pregnant subjects. We compared the use of electrical cardiometry versus transthoracic echocardiography in healthy pregnant women and evaluated hemodynamics immediately after vaginal delivery. In Study 1, electrical cardiometry and transthoracic echocardiography were used to measure cardiac output in 20 pregnant women with threatened premature delivery. A significant correlation was found between the two methods, with electrical cardiometry showing the higher cardiac output. In Study 2, heart rate, stroke volume, and cardiac output were continuously measured in 15 women during vaginal delivery up to 2 h postpartum. Cardiac output increased markedly because of an increased heart rate and stroke volume at the time of newborn delivery. The heart rate then immediately returned to baseline, while cardiac output remained elevated for at least 2 h after delivery because of a sustained high stroke volume. Electrical cardiometry was as readily available as transthoracic echocardiography for evaluating hemodynamics and allowed for continuous measurement during labor. High intrapartum cardiac output was sustained for at least 2 h after vaginal delivery. J. Med. Invest. 66 : 75-80, February, 2019."},"publication_date":"2019-02","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.66","number":"No.1.2","starting_page":"75","ending_page":"80","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.66.75"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114198","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30635311","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85059843315&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350361","label":"url"}],"paper_title":{"en":"Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome","ja":"Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Nishiyama Seiichi"},{"name":"Abe Toshio"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Nishiyama Seiichi"},{"name":"Abe Toshio"},{"name":"佐田 政隆"}]},"description":{"en":"Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thromboembolic events including venous thromboembolism (VTE) in association with the presence of antiphospholipid antibodies. The standard treatment of VTE historically consists of anticoagulation therapy with warfarin, a vitamin K antagonist. Recently, direct oral anticoagulants, including rivaroxaban have become available for the treatment of VTE. However, the choice of anticoagulant, and the duration of anticoagulation in patients with APS has not been determined yet due to lack of evidence. Here, we report a case of recurrent venous thrombosis after discontinuation of rivaroxaban therapy and avoiding sedentary lifestyle in a patient with APS. We suggest that indefinite anticoagulation therapy might be needed even in low-risk APS cases.","ja":"Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thromboembolic events including venous thromboembolism (VTE) in association with the presence of antiphospholipid antibodies. The standard treatment of VTE historically consists of anticoagulation therapy with warfarin, a vitamin K antagonist. Recently, direct oral anticoagulants, including rivaroxaban have become available for the treatment of VTE. However, the choice of anticoagulant, and the duration of anticoagulation in patients with APS has not been determined yet due to lack of evidence. Here, we report a case of recurrent venous thrombosis after discontinuation of rivaroxaban therapy and avoiding sedentary lifestyle in a patient with APS. We suggest that indefinite anticoagulation therapy might be needed even in low-risk APS cases."},"publication_date":"2019-01-10","publication_name":{"en":"BMJ Case Reports","ja":"BMJ Case Reports"},"volume":"Vol.12","number":"No.1","starting_page":"e227663","ending_page":"e227663","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/bcr-2018-227663"],"issn":["1757-790X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://ci.nii.ac.jp/naid/120006552371/","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112988","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050001338015711104/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=362414","label":"url"}],"paper_title":{"en":"A successful case of catheter ablation against ventricular tachycardia storm due to old myocardial infarction in a patient with aortic valve replacement","ja":"大動脈弁人工弁(機械弁)置換術後遠隔期に生じたOMI-VT stormに対し経心房中隔的に施行したカテーテルアブレーションが著効した1例"},"authors":{"en":[{"name":"Takahashi Mina"},{"name":"Tobiume Takeshi"},{"name":"Matsumoto Kazuhisa"},{"name":"Matsuura Tomomi"},{"name":"Soeki Takeshi"},{"name":"藤本 裕太"},{"name":"原田 貴文"},{"name":"Robahto Zengu"},{"name":"數藤 久美子"},{"name":"西條 良仁"},{"name":"上野 理絵"},{"name":"Kawabata Yutaka"},{"name":"Bando Mika"},{"name":"Yamada nao"},{"name":"Ito Hiroyuki"},{"name":"轟 貴史"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"高橋 未奈"},{"name":"飛梅 威"},{"name":"松本 和久"},{"name":"松浦 朋美"},{"name":"添木 武"},{"name":"藤本 裕太"},{"name":"原田 貴文"},{"name":"Zheng Robert"},{"name":"數藤 久美子"},{"name":"西條 良仁"},{"name":"上野 理絵"},{"name":"川端 豊"},{"name":"坂東 美佳"},{"name":"山田 なお"},{"name":"伊藤 浩敬"},{"name":"轟 貴史"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"A 68-year-old woman with VT storm and frequent appropriate ICD therapy was referred for catheter ablation. Her past history was notable for aortic valve replacement by mechanical valve due to infectious endocarditis 17 years prior to presentation and left ventricular apical old myocardial infarction with unknown onset. At 67 years old, She admitted to the prior hospital due to ventricular tachycardia with LBBB and superior axis at heart rate of 210 per minutes. Administration of amiodarone and magnesium sulfate was ineffective and cardioversion of 200J was successfully terminated the tachycardia. Intra-cardiac defibrillator was implanted and the administration of amiodarone and mexiletine was started. 5 months after, she admitted to the hospital due to the frequent appropriate shock against the same ventricular tachycardia. Administration of lidocaine, sotalol, pilsicainide, and magnesium sulfate could not control the tachycardia and she was referred to our hospital for catheter ablation. During the first session, ventricular tachycardia was easily induced and electroanatomical mapping was performed both during tachycardia and during sinus rhythm. Late diastolic potential preceding the onset of QRS wave by 45ms was detected at the infero-septal side of the apical aneurysm. 7 5s of the RF energy application at this site could terminate the tachycardia and thereafter no ventricular tachycardia was induced. But after dose-reduction or cessation of some anti-arrhythmic drugs, ventricular tachycardia was recurred and second session was performed. This time, no ventricular tachycardia was induced, then we performed isthmus transection and core isolation against the apical aneurysm. Thereafter no ventricular tachycardia was occurred in spite of dose-reduction or cessation of some anti-arrhythmic drugs.","ja":"A 68-year-old woman with VT storm and frequent appropriate ICD therapy was referred for catheter ablation. Her past history was notable for aortic valve replacement by mechanical valve due to infectious endocarditis 17 years prior to presentation and left ventricular apical old myocardial infarction with unknown onset. At 67 years old, She admitted to the prior hospital due to ventricular tachycardia with LBBB and superior axis at heart rate of 210 per minutes. Administration of amiodarone and magnesium sulfate was ineffective and cardioversion of 200J was successfully terminated the tachycardia. Intra-cardiac defibrillator was implanted and the administration of amiodarone and mexiletine was started. 5 months after, she admitted to the hospital due to the frequent appropriate shock against the same ventricular tachycardia. Administration of lidocaine, sotalol, pilsicainide, and magnesium sulfate could not control the tachycardia and she was referred to our hospital for catheter ablation. During the first session, ventricular tachycardia was easily induced and electroanatomical mapping was performed both during tachycardia and during sinus rhythm. Late diastolic potential preceding the onset of QRS wave by 45ms was detected at the infero-septal side of the apical aneurysm. 7 5s of the RF energy application at this site could terminate the tachycardia and thereafter no ventricular tachycardia was induced. But after dose-reduction or cessation of some anti-arrhythmic drugs, ventricular tachycardia was recurred and second session was performed. This time, no ventricular tachycardia was induced, then we performed isthmus transection and core isolation against the apical aneurysm. Thereafter no ventricular tachycardia was occurred in spite of dose-reduction or cessation of some anti-arrhythmic drugs."},"publication_date":"2019","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.74","number":"No.56","starting_page":"201","ending_page":"208","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390845713087095296/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=362413","label":"url"}],"paper_title":{"en":"超音波検査を用いた心外膜下脂肪厚の検査者間誤差の検討","ja":"超音波検査を用いた心外膜下脂肪厚の検査者間誤差の検討"},"authors":{"en":[{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"原田 修"},{"name":"宮里 尚美"},{"name":"原 國督"},{"name":"Kusunose Kenya"},{"name":"伊藤 敦彦"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"原田 修"},{"name":"宮里 尚美"},{"name":"原 國督"},{"name":"楠瀬 賢也"},{"name":"伊藤 敦彦"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2019","publication_name":{"en":"Japanese Journal of Medical Ultrasound Technology","ja":"超音波検査技術"},"volume":"Vol.44","number":"No.4","starting_page":"456","ending_page":"463","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.11272/jss.290"],"issn":["1881-4514"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390845713087255168/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=362412","label":"url"}],"paper_title":{"en":"糖尿病性腎症の各病期における超音波指標の比較","ja":"糖尿病性腎症の各病期における超音波指標の比較"},"authors":{"en":[{"name":"松本 力三"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"湯浅 麻美"},{"name":"Torii Yuta"},{"name":"天野 里江"},{"name":"山尾 雅美"},{"name":"Arase Miharu"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"松本 力三"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"湯浅 麻美"},{"name":"鳥居 裕太"},{"name":"天野 里江"},{"name":"山尾 雅美"},{"name":"荒瀬 美晴"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2019","publication_name":{"en":"Japanese Journal of Medical Ultrasound Technology","ja":"超音波検査技術"},"volume":"Vol.44","number":"No.4","starting_page":"447","ending_page":"455","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.11272/jss.288"],"issn":["1881-4514"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114167","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31656303","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85074142443&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360965","label":"url"}],"paper_title":{"en":"Osteolytic primary bone lymphoma in the multiple bones","ja":"Osteolytic primary bone lymphoma in the multiple bones"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Zheng Robert"},{"name":"Nishiyama Seiichi"},{"name":"Kawabata Yutaka"},{"name":"Ise Takayuki"},{"name":"Sugiura Kosuke"},{"name":"Yoshinari Haruhiko"},{"name":"Nishisho Toshihiko"},{"name":"Bando Yoshimi"},{"name":"Kagawa Kumiko"},{"name":"Fukuda Daiju"},{"name":"Soga Tomohiro"},{"name":"Saijoh Yoshihito"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Kawahito Shinji"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Robert Zheng"},{"name":"Nishiyama Seiichi"},{"name":"川端 豊"},{"name":"伊勢 孝之"},{"name":"Sugiura Kosuke"},{"name":"Yoshinari Haruhiko"},{"name":"Nishisho Toshihiko"},{"name":"Bando Yoshimi"},{"name":"Kagawa Kumiko"},{"name":"福田 大受"},{"name":"Soga Tomohiro"},{"name":"西條 良仁"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"川人 伸次"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"Primary non-Hodgkin bone lymphoma (PBL) can involve solitary or multiple destructive bone lesions such as those of the femur or pelvis humerus, and some cases have osteolytic lesions. PBL is a rare disease in adults. Thus, PBL is rarely considered a differential diagnosis of the osteolytic tumor. In addition, PBL can be underdiagnosed because patients do not experience symptoms or show objective abnormalities in the early stage. Here, we reported an elderly patient with PBL in multiple bones, including the cranial and femoral bones that were fractured due to falling. J. Med. Invest. 66 : 347-350, August, 2019.","ja":"Primary non-Hodgkin bone lymphoma (PBL) can involve solitary or multiple destructive bone lesions such as those of the femur or pelvis humerus, and some cases have osteolytic lesions. PBL is a rare disease in adults. Thus, PBL is rarely considered a differential diagnosis of the osteolytic tumor. In addition, PBL can be underdiagnosed because patients do not experience symptoms or show objective abnormalities in the early stage. Here, we reported an elderly patient with PBL in multiple bones, including the cranial and femoral bones that were fractured due to falling. J. Med. Invest. 66 : 347-350, August, 2019."},"publication_date":"2019","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.66","number":"No.3,4","starting_page":"347","ending_page":"350","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.66.347"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114166","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31656302","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=360962","label":"url"}],"paper_title":{"en":"Adult onset of Immunoglobulin A vasculitis - A case report,","ja":"Adult onset of Immunoglobulin A vasculitis - A case report,"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Endo Itsuro"},{"name":"Murakami Taichi"},{"name":"Hida Tetsuya"},{"name":"Yamamoto Yousuke"},{"name":"Soga Tomohiro"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Kawahito Shinji"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"遠藤 逸朗"},{"name":"Murakami Taichi"},{"name":"Hida Tetsuya"},{"name":"Yamamoto Yousuke"},{"name":"Soga Tomohiro"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"川人 伸次"},{"name":"佐田 政隆"}]},"description":{"en":"Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, primarily occurs during childhood between the ages of 3 and 15 years and is the most common form of systemic vasculitis in children ; its occurrence in adults has been rarely reported. Such low incidence could be attributable to either under-diagnosis or misdiagnosis. Thus, not only pediatricians but also physicians should be able to diagnose IgAV accurately to manage the patients appropriately and avoid its associated complications. In addition, treatment of adult onset IgAV with renal involvement has not been fully established yet. We describe here a case of adult onset IgAV complicated by proteinuria and pharyngitis, which was cured by no specific treatment. J. Med. Invest. 66 : 344-346, August, 2019.","ja":"Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, primarily occurs during childhood between the ages of 3 and 15 years and is the most common form of systemic vasculitis in children ; its occurrence in adults has been rarely reported. Such low incidence could be attributable to either under-diagnosis or misdiagnosis. Thus, not only pediatricians but also physicians should be able to diagnose IgAV accurately to manage the patients appropriately and avoid its associated complications. In addition, treatment of adult onset IgAV with renal involvement has not been fully established yet. We describe here a case of adult onset IgAV complicated by proteinuria and pharyngitis, which was cured by no specific treatment. J. Med. Invest. 66 : 344-346, August, 2019."},"publication_date":"2019","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.66","number":"No.3,4","starting_page":"344","ending_page":"346","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.66.344"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113418","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31064935","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85065794702&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352124","label":"url"}],"paper_title":{"en":"Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency","ja":"Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Kagawa Kumiko"},{"name":"Fujimoto Eiki"},{"name":"Sata Masataka"},{"name":"Saijoh Yoshihito"}],"ja":[{"name":"八木 秀介"},{"name":"賀川 久美子"},{"name":"藤本 鋭貴"},{"name":"佐田 政隆"},{"name":"西條 良仁"}]},"description":{"en":"Protein S (PS) deficiency is an inherited thrombophilia associated with an increased risk of venous thromboembolism (VTE). In Japan, unfractionated heparin followed by warfarin has been historically applied for the treatment of VTE. Recent evidence showed that direct oral anticoagulants (DOACs) were non-inferior to standard therapy with warfarin, with significantly less bleeding in patients with VTE. However, it is unknown whether DOACs are effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report a case of recurrent venous thrombosis during edoxaban therapy in a patient with protein S deficiency, which was successfully treated using high-dose apixaban therapy. J.Med. Invest. 66 : 182-184, February, 2019.","ja":"Protein S (PS) deficiency is an inherited thrombophilia associated with an increased risk of venous thromboembolism (VTE). In Japan, unfractionated heparin followed by warfarin has been historically applied for the treatment of VTE. Recent evidence showed that direct oral anticoagulants (DOACs) were non-inferior to standard therapy with warfarin, with significantly less bleeding in patients with VTE. However, it is unknown whether DOACs are effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report a case of recurrent venous thrombosis during edoxaban therapy in a patient with protein S deficiency, which was successfully treated using high-dose apixaban therapy. J.Med. Invest. 66 : 182-184, February, 2019."},"publication_date":"2019","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.66","number":"No.1,2","starting_page":"182","ending_page":"184","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.66.182"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113420","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31064936","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85065772885&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352123","label":"url"}],"paper_title":{"en":"Lambda-like J wave due to acute myocardial infarction of the diagonal branch","ja":"Lambda-like J wave due to acute myocardial infarction of the diagonal branch"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Ueno Rie"},{"name":"Sutou Kumiko"},{"name":"Wakatsuki Tetsuzo"},{"name":"Yamaguchi Koji"},{"name":"Saijo Yoshihito"},{"name":"Hara Tomoya"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Bando Mika"},{"name":"Matsuura Tomomi"},{"name":"Tobiume Takeshi"},{"name":"Yamada Hirotsugu"},{"name":"Fukuda Daiju"},{"name":"Soeki Takeshi"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"上野 理絵"},{"name":"數藤 久美子"},{"name":"若槻 哲三"},{"name":"山口 浩司"},{"name":"西條 良仁"},{"name":"原 貴文"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"坂東 美佳"},{"name":"松浦 朋美"},{"name":"飛梅 威"},{"name":"山田 博胤"},{"name":"福田 大受"},{"name":"添木 武"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"The culprit lesion of acute myocardial infarction could be predicted by electrocardiogram findings. However, we experienced some cases with coronary angiographic finding in the area of ST-T elevation that was different from that predicted. The lambda-like J wave could be caused by ischemia although the mechanism has not been fully elucidated. We report a case of acute myocardial infarction that showed discrepancy between ST-T elevation with lambda-like ischemic J wave in a broad area and coronary angiographical finding of diagonal branch occlusion. J. Med. Invest. 66 : 185-187, February, 2019.","ja":"The culprit lesion of acute myocardial infarction could be predicted by electrocardiogram findings. However, we experienced some cases with coronary angiographic finding in the area of ST-T elevation that was different from that predicted. The lambda-like J wave could be caused by ischemia although the mechanism has not been fully elucidated. We report a case of acute myocardial infarction that showed discrepancy between ST-T elevation with lambda-like ischemic J wave in a broad area and coronary angiographical finding of diagonal branch occlusion. J. Med. Invest. 66 : 185-187, February, 2019."},"publication_date":"2019","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.66","number":"No.1,2","starting_page":"185","ending_page":"187","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.66.185"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113475","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31064944","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85065788300&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352122","label":"url"}],"paper_title":{"en":"Spontaneous arteriovenous fistula of the superficial temporal artery","ja":"Spontaneous arteriovenous fistula of the superficial temporal artery"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Saijo Yoshihito"},{"name":"Matsuda Taku"},{"name":"Kanematsu Yasuhisa"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"西條 良仁"},{"name":"Matsuda Taku"},{"name":"兼松 康久"},{"name":"佐田 政隆"}]},"description":{"en":"An arteriovenous fistula of the superficial temporal artery (STA) is a direct and abnormal communication between the STA, feeding artery, and superficial temporal vein, draining veins that bypass the capillary network. Several cases of trauma-induced or iatrogenic-induced arteriovenous fistula (AVF) of the STA have been reported ; however, spontaneous AVF of the STA not associated with trauma or medical treatment are extremely rare. Herein, we present a case of spontaneous AVF of the STA diagnosed in old age. J. Med. Invest. 66 : 209-210, February, 2019.","ja":"An arteriovenous fistula of the superficial temporal artery (STA) is a direct and abnormal communication between the STA, feeding artery, and superficial temporal vein, draining veins that bypass the capillary network. Several cases of trauma-induced or iatrogenic-induced arteriovenous fistula (AVF) of the STA have been reported ; however, spontaneous AVF of the STA not associated with trauma or medical treatment are extremely rare. Herein, we present a case of spontaneous AVF of the STA diagnosed in old age. J. Med. Invest. 66 : 209-210, February, 2019."},"publication_date":"2019","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.66","number":"No.1,2","starting_page":"209","ending_page":"210","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.66.209"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113476","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31064945","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85065766564&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352121","label":"url"}],"paper_title":{"en":"Rupture of pes anserine bursa in a patient with pes anserine pain syndrome due to osteoarthritis","ja":"Rupture of pes anserine bursa in a patient with pes anserine pain syndrome due to osteoarthritis"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"佐田 政隆"}]},"description":{"en":"Pes anserinus pain syndrome is a common, clinically defined condition that is characterized by pain around the medial knee and tenderness over the upper medial tibia. The anserine bursa could be the site of proliferative and inflammatory conditions due to knee osteoarthritis, leading to pain and fluid retention. However, rupture of the pes anserinus is rare. Herein, we present a case of rupture of the pes anserine bursa in a patient with pes anserine pain syndrome and osteoarthritis. Physicians should consider rupture of the pes anserine bursa as a differential diagnosis of acute unilateral lower leg swelling. J. Med. Invest. 66 : 211-212, February, 2019.","ja":"Pes anserinus pain syndrome is a common, clinically defined condition that is characterized by pain around the medial knee and tenderness over the upper medial tibia. The anserine bursa could be the site of proliferative and inflammatory conditions due to knee osteoarthritis, leading to pain and fluid retention. However, rupture of the pes anserinus is rare. Herein, we present a case of rupture of the pes anserine bursa in a patient with pes anserine pain syndrome and osteoarthritis. Physicians should consider rupture of the pes anserine bursa as a differential diagnosis of acute unilateral lower leg swelling. J. Med. Invest. 66 : 211-212, February, 2019."},"publication_date":"2019","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.66","number":"No.1,2","starting_page":"211","ending_page":"212","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.66.211"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113228","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30619056","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350356","label":"url"}],"paper_title":{"en":"Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies: A Cohort Study.","ja":"Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies: A Cohort Study."},"authors":{"en":[{"name":"Izumi Yuishin"},{"name":"Miyamoto Ryosuke"},{"name":"Fujita Koji"},{"name":"Yamamoto Yuki"},{"name":"Yamada Hirotsugu"},{"name":"Matsubara Tomoyasu"},{"name":"Unai Yuki"},{"name":"Tsukamoto Ai"},{"name":"Takamatsu Naoko"},{"name":"Nodera Hiroyuki"},{"name":"Hayashi Shinya"},{"name":"Oda Masaya"},{"name":"Mori Atsuko"},{"name":"Nishida Yoshihiko"},{"name":"Watanabe Shunsuke"},{"name":"Ogawa Hirohisa"},{"name":"Uehara Hisanori"},{"name":"Murayama Shigeo"},{"name":"Sata Masataka"},{"name":"Kaji Ryuji"}],"ja":[{"name":"和泉 唯信"},{"name":"宮本 亮介"},{"name":"藤田 浩司"},{"name":"Yamamoto Yuki"},{"name":"山田 博胤"},{"name":"Matsubara Tomoyasu"},{"name":"Unai Yuki"},{"name":"Tsukamoto Ai"},{"name":"Takamatsu Naoko"},{"name":"野寺 裕之"},{"name":"Hayashi Shinya"},{"name":"Oda Masaya"},{"name":"Mori Atsuko"},{"name":"Nishida Yoshihiko"},{"name":"Watanabe Shunsuke"},{"name":"小川 博久"},{"name":"上原 久典"},{"name":"Murayama Shigeo"},{"name":"佐田 政隆"},{"name":"梶 龍兒"}]},"description":{"en":"Takotsubo syndrome (TTS) is an acute cardiac syndrome characterized by regional left ventricular dysfunction with a peculiar circumferential pattern, which typically results in apical ballooning. Evidence indicates a pivotal role of catecholamines in TTS, and researchers have discussed multiple hypotheses on the etiology, including multivessel coronary spasm, myocardial stunning, excessive transient ventricular afterload, and cardiac sympathetic overactivity with local noradrenaline spillover. Although central nervous system disorders, such as stroke and epilepsy, are known to trigger TTS, the incidence and clinical features of TTS in neurodegenerative disorders are poorly understood. Here, we retrospectively examined TTS cases in a single-center cohort composed of 250 patients with amyotrophic lateral sclerosis (ALS) and 870 patients with synucleinopathies [582 patients with Parkinson's disease (PD), 125 patients with dementia with Lewy bodies (DLB), and 163 patients with multiple system atrophy (MSA)] and identified 4 (1.6%, including 2 women) cases with ALS and no cases with synucleinopathies. Two ALS patients underwent autopsy and the pathological findings were compatible with the chronological changes identified in catecholamine-induced cardiomyopathy. A literature review identified 16 TTS cases with ALS, 1 case each with PD and DLB, and no cases with MSA. When current and previous TTS cases with ALS were concatenated: 55% (11/20) were female; 35% (7/20) had a bulbar-onset and 45% (9/20) had a limb-onset; the mean age of TTS onset was 63.3 ± 9.0 years and the mean interval time from ALS onset to TTS development was 4.9 ± 3.0 years; no (0/16) patients developed TTS within 12 months after ALS onset; 50% (10/20) underwent artificial ventilations; the mortality was 17% (3/18); and most cases had precipitating factors, and TTS development was associated with gastrostomy, tracheostomy, or infections in 45% (9/20) of the patients. This study demonstrated that ALS is a considerable predisposing factor of TTS and that synucleinopathies rarely cause TTS. The distinct TTS incidence between ALS and synucleinopathies may be due to cardiac sympathetic overactivity in ALS and may also be affected by cardiac sympathetic denervation in synucleinopathies. Moreover, the etiology of TTS in ALS may be reasonably explained by the two-hit theory.","ja":"Takotsubo syndrome (TTS) is an acute cardiac syndrome characterized by regional left ventricular dysfunction with a peculiar circumferential pattern, which typically results in apical ballooning. Evidence indicates a pivotal role of catecholamines in TTS, and researchers have discussed multiple hypotheses on the etiology, including multivessel coronary spasm, myocardial stunning, excessive transient ventricular afterload, and cardiac sympathetic overactivity with local noradrenaline spillover. Although central nervous system disorders, such as stroke and epilepsy, are known to trigger TTS, the incidence and clinical features of TTS in neurodegenerative disorders are poorly understood. Here, we retrospectively examined TTS cases in a single-center cohort composed of 250 patients with amyotrophic lateral sclerosis (ALS) and 870 patients with synucleinopathies [582 patients with Parkinson's disease (PD), 125 patients with dementia with Lewy bodies (DLB), and 163 patients with multiple system atrophy (MSA)] and identified 4 (1.6%, including 2 women) cases with ALS and no cases with synucleinopathies. Two ALS patients underwent autopsy and the pathological findings were compatible with the chronological changes identified in catecholamine-induced cardiomyopathy. A literature review identified 16 TTS cases with ALS, 1 case each with PD and DLB, and no cases with MSA. When current and previous TTS cases with ALS were concatenated: 55% (11/20) were female; 35% (7/20) had a bulbar-onset and 45% (9/20) had a limb-onset; the mean age of TTS onset was 63.3 ± 9.0 years and the mean interval time from ALS onset to TTS development was 4.9 ± 3.0 years; no (0/16) patients developed TTS within 12 months after ALS onset; 50% (10/20) underwent artificial ventilations; the mortality was 17% (3/18); and most cases had precipitating factors, and TTS development was associated with gastrostomy, tracheostomy, or infections in 45% (9/20) of the patients. This study demonstrated that ALS is a considerable predisposing factor of TTS and that synucleinopathies rarely cause TTS. The distinct TTS incidence between ALS and synucleinopathies may be due to cardiac sympathetic overactivity in ALS and may also be affected by cardiac sympathetic denervation in synucleinopathies. Moreover, the etiology of TTS in ALS may be reasonably explained by the two-hit theory."},"publication_date":"2018-12-13","publication_name":{"en":"Frontiers in Neurology","ja":"Frontiers in Neurology"},"volume":"Vol.9","starting_page":"1099","ending_page":"1099","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fneur.2018.01099"],"issn":["1664-2295"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113226","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30460242","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350355","label":"url"}],"paper_title":{"en":"Activation of Toll-Like Receptor 9 Impairs Blood Flow Recovery After Hind-Limb Ischemia","ja":"Activation of Toll-Like Receptor 9 Impairs Blood Flow Recovery After Hind-Limb Ischemia"},"authors":{"en":[{"name":"Nishimoto Sachiko"},{"name":"Aini Kunduziayi"},{"name":"Fukuda Daiju"},{"name":"Higashikuni Yasutomi"},{"name":"Tanaka Kimie"},{"name":"Hirata Yoichiro"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Nishimoto Sachiko"},{"name":"Aini Kunduziayi"},{"name":"福田 大受"},{"name":"Higashikuni Yasutomi"},{"name":"Tanaka Kimie"},{"name":"Hirata Yoichiro"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Peripheral artery disease causes significant functional disability and results in impaired quality of life. Ischemic tissue injury releases various endogenous ligands for Toll-like receptors (TLRs), suggesting the involvement of TLRs in blood flow recovery. However, the role of TLR9, which was originally known as a sensor for bacterial DNA, remains unknown. This study investigated the role of TLR9 in blood flow recovery in the ischemic limb using a mouse hind-limb ischemia model. Unilateral femoral artery ligation was performed in TLR9-deficient () mice and wild-type mice. In wild-type mice, femoral artery ligation significantly increased mRNA expression of TLR9 in the ischemic limb ( < 0.001) and plasma levels of cell-free DNA (cfDNA) as determined by single-stranded DNA (ssDNA) ( < 0.05) and double-stranded DNA (dsDNA) ( < 0.01), which are endogenous ligands for TLR9, compared with the sham-operated group. Laser Doppler perfusion imaging demonstrated significantly improved ratio of blood flow in the ischemic to non-ischemic limb in mice compared with wild-type mice at 2 weeks after ligation ( < 0.05). mice showed increased capillary density and reduced macrophage infiltration in ischemic limb. Genetic deletion of TLR9 reduced the expression of TNF-α, and attenuated NF-κB activation in ischemic muscle compared with wild-type mice ( < 0.05, respectively) at 3 days after the surgery. ODN1826, a synthetic agonistic oligonucleotide for TLR9, or plasma obtained from mice with ischemic muscle promoted the expression of TNF-α in wild-type macrophages ( < 0.05), but not in macrophages. ODN1826 also activated NF-κB signaling as determined by the degradation of IκBα in wild-type macrophages ( < 0.05), but not in macrophages. In vitro experiments using human umbilical vein endothelial cells demonstrated that TNF-α, or conditioned medium obtained from wild-type macrophages treated with ODN1826 accelerated cell death as determined by MTS assay ( < 0.05 and < 0.01, respectively). Our results suggest that ischemic muscle releases cfDNA, which activates TLR9 and enhances inflammation, leading to impairment of blood flow recovery in the ischemic limb. cfDNA-TLR9 signaling may serve as a potential therapeutic target in ischemic limb disease.","ja":"Peripheral artery disease causes significant functional disability and results in impaired quality of life. Ischemic tissue injury releases various endogenous ligands for Toll-like receptors (TLRs), suggesting the involvement of TLRs in blood flow recovery. However, the role of TLR9, which was originally known as a sensor for bacterial DNA, remains unknown. This study investigated the role of TLR9 in blood flow recovery in the ischemic limb using a mouse hind-limb ischemia model. Unilateral femoral artery ligation was performed in TLR9-deficient () mice and wild-type mice. In wild-type mice, femoral artery ligation significantly increased mRNA expression of TLR9 in the ischemic limb ( < 0.001) and plasma levels of cell-free DNA (cfDNA) as determined by single-stranded DNA (ssDNA) ( < 0.05) and double-stranded DNA (dsDNA) ( < 0.01), which are endogenous ligands for TLR9, compared with the sham-operated group. Laser Doppler perfusion imaging demonstrated significantly improved ratio of blood flow in the ischemic to non-ischemic limb in mice compared with wild-type mice at 2 weeks after ligation ( < 0.05). mice showed increased capillary density and reduced macrophage infiltration in ischemic limb. Genetic deletion of TLR9 reduced the expression of TNF-α, and attenuated NF-κB activation in ischemic muscle compared with wild-type mice ( < 0.05, respectively) at 3 days after the surgery. ODN1826, a synthetic agonistic oligonucleotide for TLR9, or plasma obtained from mice with ischemic muscle promoted the expression of TNF-α in wild-type macrophages ( < 0.05), but not in macrophages. ODN1826 also activated NF-κB signaling as determined by the degradation of IκBα in wild-type macrophages ( < 0.05), but not in macrophages. In vitro experiments using human umbilical vein endothelial cells demonstrated that TNF-α, or conditioned medium obtained from wild-type macrophages treated with ODN1826 accelerated cell death as determined by MTS assay ( < 0.05 and < 0.01, respectively). Our results suggest that ischemic muscle releases cfDNA, which activates TLR9 and enhances inflammation, leading to impairment of blood flow recovery in the ischemic limb. cfDNA-TLR9 signaling may serve as a potential therapeutic target in ischemic limb disease."},"publication_date":"2018-10-16","publication_name":{"en":"Frontiers in Cardiovascular Medicine","ja":"Frontiers in Cardiovascular Medicine"},"volume":"Vol.5","starting_page":"144","ending_page":"144","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fcvm.2018.00144"],"issn":["2297-055X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30321103","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85055024782&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=347173","label":"url"}],"paper_title":{"en":"Inhibition of Atherosclerotic Plaque Development by Oral Administration of α-Glucosyl Hesperidin and Water-Dispersible Hesperetin in Apolipoprotein E Knockout Mice.","ja":"Inhibition of Atherosclerotic Plaque Development by Oral Administration of α-Glucosyl Hesperidin and Water-Dispersible Hesperetin in Apolipoprotein E Knockout Mice."},"authors":{"en":[{"name":"Sugasawa Noriko"},{"name":"Katagi Ayako"},{"name":"Kurobe Hirotsugu"},{"name":"Nakayama Taisuke"},{"name":"Nishio Chika"},{"name":"Takumi Hiroko"},{"name":"Higashiguchi Fumiharu"},{"name":"Aihara Ken-ichi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"},{"name":"Kitagawa Tetsuya"}],"ja":[{"name":"Sugasawa Noriko"},{"name":"Katagi Ayako"},{"name":"Kurobe Hirotsugu"},{"name":"Nakayama Taisuke"},{"name":"Nishio Chika"},{"name":"Takumi Hiroko"},{"name":"Higashiguchi Fumiharu"},{"name":"Aihara Ken-ichi"},{"name":"島袋 充生"},{"name":"佐田 政隆"},{"name":"Kitagawa Tetsuya"}]},"description":{"en":"Hesperidin, an abundant flavonoid in citrus fruit, and its aglycone, hesperetin, have been reported to possess various physiological activities, including antioxidant, anti-inflammatory, hypolipidemic, and antihypertensive activities. In this study, we investigated whether α-glucosyl hesperidin and water-dispersible hesperetin have protective effects on atherosclerotic progression in apolipoprotein E knockout (Apo-E KO) mice. Ten-week-old male Apo-E KO mice were randomly assigned a regular high-fat diet, a high-fat diet with 0.5% α-glucosyl hesperidin, or a high-fat diet with 0.1% water-dispersible hesperetin for 12 weeks. Measurement of plasma total cholesterol levels, histological staining of aortic root, and immunohistochemistry for macrophages were performed to evaluate atherosclerotic plaque formation. Vascular reactivity of mouse aortic rings was also measured. Both α-glucosyl hesperidin and water-dispersible hesperetin reduced plasma total cholesterol level. They also reduced plaque formation area, adipose deposition, and macrophage infiltration into atherosclerotic lesion. Vascular-endothelium-dependent relaxation in response to acetylcholine was improved in both experimental diet groups compared to the high-fat diet group. Our study suggests that both α-glucosyl hesperidin and water-dispersible hesperetin exert protective effects on atherosclerotic progression in Apo-E KO mice because they exhibit hypolipidemic activity, reduce inflammation through macrophages, and prevent endothelial dysfunction.","ja":"Hesperidin, an abundant flavonoid in citrus fruit, and its aglycone, hesperetin, have been reported to possess various physiological activities, including antioxidant, anti-inflammatory, hypolipidemic, and antihypertensive activities. In this study, we investigated whether α-glucosyl hesperidin and water-dispersible hesperetin have protective effects on atherosclerotic progression in apolipoprotein E knockout (Apo-E KO) mice. Ten-week-old male Apo-E KO mice were randomly assigned a regular high-fat diet, a high-fat diet with 0.5% α-glucosyl hesperidin, or a high-fat diet with 0.1% water-dispersible hesperetin for 12 weeks. Measurement of plasma total cholesterol levels, histological staining of aortic root, and immunohistochemistry for macrophages were performed to evaluate atherosclerotic plaque formation. Vascular reactivity of mouse aortic rings was also measured. Both α-glucosyl hesperidin and water-dispersible hesperetin reduced plasma total cholesterol level. They also reduced plaque formation area, adipose deposition, and macrophage infiltration into atherosclerotic lesion. Vascular-endothelium-dependent relaxation in response to acetylcholine was improved in both experimental diet groups compared to the high-fat diet group. Our study suggests that both α-glucosyl hesperidin and water-dispersible hesperetin exert protective effects on atherosclerotic progression in Apo-E KO mice because they exhibit hypolipidemic activity, reduce inflammation through macrophages, and prevent endothelial dysfunction."},"publication_date":"2018-10-15","publication_name":{"en":"Journal of the American College of Nutrition","ja":"Journal of the American College of Nutrition"},"starting_page":"1","ending_page":"8","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1080/07315724.2018.1468831"],"issn":["1541-1087"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114199","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30185691","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85054095916&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345628","label":"url"}],"paper_title":{"en":"Epicardial Fat and Pericardial Fat Surrounding the Heart Have Different Characteristics.","ja":"Epicardial Fat and Pericardial Fat Surrounding the Heart Have Different Characteristics."},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2018-09-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.82","number":"No.10","starting_page":"2475","ending_page":"2476","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-18-0923"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30244845","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85053732191&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=346399","label":"url"}],"paper_title":{"en":"Usefulness of Epicardial Adipose Tissue Volume to Predict Recurrent Atrial Fibrillation After Radiofrequency Catheter Ablation","ja":"Usefulness of Epicardial Adipose Tissue Volume to Predict Recurrent Atrial Fibrillation After Radiofrequency Catheter Ablation"},"authors":{"en":[{"name":"Maeda Minetaka"},{"name":"Oba Kageyuki"},{"name":"Yamaguchi Satoshi"},{"name":"Arasaki Osamu"},{"name":"Sata Masataka"},{"name":"Masuzaki Hiroaki"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"Maeda Minetaka"},{"name":"Oba Kageyuki"},{"name":"Yamaguchi Satoshi"},{"name":"Arasaki Osamu"},{"name":"佐田 政隆"},{"name":"Masuzaki Hiroaki"},{"name":"島袋 充生"}]},"description":{"en":"Although increasing evidence suggests that epicardial adipose tissue volume (EATV) is associated with post-ablation atrial fibrillation (AF), ranges of EATV predictive of post-ablation recurrence of AF remain unclear. In this study, we evaluated: (1) relationships between EATV and characteristics of AF, (2) impact of EATV on recurrent AF after radiofrequency ablation; , and (3) cut-off point for recurrent AF using a receiver operating characteristic curve. In 218 consecutive symptomatic patients undergoing who underwent ablation for AF (143 paroxysmal AF; 78 persistent AF), the EATV index (EATVI: EATV/body surface area, mL/m) was measured using 320-row multidetector computed tomography. The high EATV group showed specific cardiometabolic derangements as well as left atrial dilatation and left ventricular dysfunction. Multivariate regression analysis showed that the EATVI was an independent predictor of recurrent AF after catheter ablation. High EATV (EATVI 85 mL/m) or EATVI cutoff 116 mL/m can predict recurrent AF after catheter ablation, independent of other risk factors. In conclusion, EATVI was an independent predictor of recurrent AF after catheter ablation; a high EATV tertile or EATVI cutoff may be useful for prediction of recurrent AF after catheter ablation. Future studies should determine the utility of the EATVI in the clinical setting of AF ablation.","ja":"Although increasing evidence suggests that epicardial adipose tissue volume (EATV) is associated with post-ablation atrial fibrillation (AF), ranges of EATV predictive of post-ablation recurrence of AF remain unclear. In this study, we evaluated: (1) relationships between EATV and characteristics of AF, (2) impact of EATV on recurrent AF after radiofrequency ablation; , and (3) cut-off point for recurrent AF using a receiver operating characteristic curve. In 218 consecutive symptomatic patients undergoing who underwent ablation for AF (143 paroxysmal AF; 78 persistent AF), the EATV index (EATVI: EATV/body surface area, mL/m) was measured using 320-row multidetector computed tomography. The high EATV group showed specific cardiometabolic derangements as well as left atrial dilatation and left ventricular dysfunction. Multivariate regression analysis showed that the EATVI was an independent predictor of recurrent AF after catheter ablation. High EATV (EATVI 85 mL/m) or EATVI cutoff 116 mL/m can predict recurrent AF after catheter ablation, independent of other risk factors. In conclusion, EATVI was an independent predictor of recurrent AF after catheter ablation; a high EATV tertile or EATVI cutoff may be useful for prediction of recurrent AF after catheter ablation. Future studies should determine the utility of the EATVI in the clinical setting of AF ablation."},"publication_date":"2018-09-21","publication_name":{"en":"The American Journal of Cardiology","ja":"The American Journal of Cardiology"},"volume":"Vol.122","number":"No.10","starting_page":"1694","ending_page":"1700","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.amjcard.2018.08.005"],"issn":["0002-9149"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114202","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=346564","label":"url"}],"paper_title":{"en":"Possible Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis.","ja":"Possible Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis."},"authors":{"en":[{"name":"Tanaka Kimie"},{"name":"Sata Masataka"}],"ja":[{"name":"Tanaka Kimie"},{"name":"佐田 政隆"}]},"publication_date":"2018-08","publication_name":{"en":"Annals of Nuclear Cardiology","ja":"Annals of Nuclear Cardiology"},"volume":"Vol.4","number":"No.1","starting_page":"5","ending_page":"10","languages":["eng"],"referee":true,"identifiers":{"doi":["10.17996/anc.18-00079"],"issn":["2424-1741"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114201","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29902700","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=340033","label":"url"}],"paper_title":{"en":"Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice.","ja":"Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice."},"authors":{"en":[{"name":"Ganbaatar B"},{"name":"Fukuda Daiju"},{"name":"Salim HM"},{"name":"Nishimoto Sachiko"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"Hirata Y"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"GANBAATAR BYAMBASUREN"},{"name":"福田 大受"},{"name":"Salim HM"},{"name":"西本 幸子"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"Hirata Y"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"Ticagrelor reduces cardiovascular events in patients with acute coronary syndrome (ACS). Recent studies demonstrated the expression of P2Y12 on vascular cells including endothelial cells, as well as platelets, and suggested its contribution to atherogenesis. We investigated whether ticagrelor attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein E-deficient (apoe) mice. Eight-week-old male apoe mice were fed a western-type diet (WTD) supplemented with 0.1% ticagrelor (approximately 120 mg/kg/day). Non-treated animals on WTD served as control. Atherosclerotic lesions were examined by en-face Sudan IV staining, histological analyses, quantitative RT-PCR analysis, and western blotting. Endothelial function was analyzed by acetylcholine-dependent vasodilation using aortic rings. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. Ticagrelor treatment for 20 weeks attenuated atherosclerotic lesion progression in the aortic arch compared with control (p < 0.05). Ticagrelor administration for 8 weeks attenuated endothelial dysfunction (p < 0.01). Ticagrelor reduced the expression of inflammatory molecules such as vascular cell adhesion molecule-1, macrophage accumulation, and lipid deposition. Ticagrelor decreased the phosphorylation of JNK in the aorta compared with control (p < 0.05). Ticagrelor and a JNK inhibitor ameliorated impairment of endothelium-dependent vasodilation by adenosine diphosphate (ADP) in wild-type mouse aortic segments. Furthermore, ticagrelor inhibited the expression of inflammatory molecules which were promoted by ADP in HUVEC (p < 0.001). Ticagrelor also inhibited ADP-induced JNK activation in HUVEC (p < 0.05). Ticagrelor attenuated vascular dysfunction and atherogenesis through the inhibition of inflammatory activation of endothelial cells. These effects might be a potential mechanism by which ticagrelor decreases cardiovascular events in patients with ACS.","ja":"Ticagrelor reduces cardiovascular events in patients with acute coronary syndrome (ACS). Recent studies demonstrated the expression of P2Y12 on vascular cells including endothelial cells, as well as platelets, and suggested its contribution to atherogenesis. We investigated whether ticagrelor attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein E-deficient (apoe) mice. Eight-week-old male apoe mice were fed a western-type diet (WTD) supplemented with 0.1% ticagrelor (approximately 120 mg/kg/day). Non-treated animals on WTD served as control. Atherosclerotic lesions were examined by en-face Sudan IV staining, histological analyses, quantitative RT-PCR analysis, and western blotting. Endothelial function was analyzed by acetylcholine-dependent vasodilation using aortic rings. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. Ticagrelor treatment for 20 weeks attenuated atherosclerotic lesion progression in the aortic arch compared with control (p < 0.05). Ticagrelor administration for 8 weeks attenuated endothelial dysfunction (p < 0.01). Ticagrelor reduced the expression of inflammatory molecules such as vascular cell adhesion molecule-1, macrophage accumulation, and lipid deposition. Ticagrelor decreased the phosphorylation of JNK in the aorta compared with control (p < 0.05). Ticagrelor and a JNK inhibitor ameliorated impairment of endothelium-dependent vasodilation by adenosine diphosphate (ADP) in wild-type mouse aortic segments. Furthermore, ticagrelor inhibited the expression of inflammatory molecules which were promoted by ADP in HUVEC (p < 0.001). Ticagrelor also inhibited ADP-induced JNK activation in HUVEC (p < 0.05). Ticagrelor attenuated vascular dysfunction and atherogenesis through the inhibition of inflammatory activation of endothelial cells. These effects might be a potential mechanism by which ticagrelor decreases cardiovascular events in patients with ACS."},"publication_date":"2018-08","publication_name":{"en":"Atherosclerosis","ja":"Atherosclerosis"},"volume":"Vol.275","starting_page":"124","ending_page":"132","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.atherosclerosis.2018.05.053"],"issn":["1879-1484"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112877","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30005132","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85054773574&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=340466","label":"url"}],"paper_title":{"en":"A clinical application of preload stress echocardiography for predicting future hemodynamic worsening in patients with early-stage heart failure.","ja":"A clinical application of preload stress echocardiography for predicting future hemodynamic worsening in patients with early-stage heart failure."},"authors":{"en":[{"name":"Saijo Yoshihito"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Bando Mika"},{"name":"Nishio Susumu"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Seno Hiromitsu"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"西條 良仁"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"坂東 美佳"},{"name":"西尾 進"},{"name":"鳥居 裕太"},{"name":"平田 有紀奈"},{"name":"瀬野 弘光"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"To improve the prognosis of patients with heart failure, risk stratification in their early stage is important. We assessed whether the change in transmitral flow (TMF) velocity pattern during preload augmentation can predict future hemodynamic worsening in early-stage heart failure patients with impaired relaxation TMF pattern. We designed a prospective cohort study that included 155 consecutive patients with impaired relaxation (IR) pattern at rest. Preload stress echocardiography was achieved using leg-positive pressure (LPP), and changes in TMF pattern during the LPP was observed during baseline echocardiographic examination. The patients whose TMF pattern developed to pseudonormal (PN) pattern throughout the study period were classified into the change to PN group, and patients whose TMF pattern stayed in IR pattern were classified into the stay in IR group. The median follow-up period was 17 months. The average age was 68 ± 11 years old, and 97 patients (63%) were male. Among 155 patients, 27 were classified into the change to PN group. A Cox proportional hazard analysis confirmed that the change in the peak atrial systolic TMF velocity during the LPP (ΔA, hazard ratio = 0.58 per 1SD; 95% CI = 0.39-0.88, P = 0.010) was the powerful independent predictor of change into PN pattern. Kaplan-Meier analysis revealed that the patients with ΔA -7 cm/s had more likely to develop into PN pattern than patients with ΔA > -7 cm/s (P = 0.001). Evaluation of a response in TMF during the LPP might provide an incremental diagnostic value to detect future overt heart failure in patients with early-stage heart failure.","ja":"To improve the prognosis of patients with heart failure, risk stratification in their early stage is important. We assessed whether the change in transmitral flow (TMF) velocity pattern during preload augmentation can predict future hemodynamic worsening in early-stage heart failure patients with impaired relaxation TMF pattern. We designed a prospective cohort study that included 155 consecutive patients with impaired relaxation (IR) pattern at rest. Preload stress echocardiography was achieved using leg-positive pressure (LPP), and changes in TMF pattern during the LPP was observed during baseline echocardiographic examination. The patients whose TMF pattern developed to pseudonormal (PN) pattern throughout the study period were classified into the change to PN group, and patients whose TMF pattern stayed in IR pattern were classified into the stay in IR group. The median follow-up period was 17 months. The average age was 68 ± 11 years old, and 97 patients (63%) were male. Among 155 patients, 27 were classified into the change to PN group. A Cox proportional hazard analysis confirmed that the change in the peak atrial systolic TMF velocity during the LPP (ΔA, hazard ratio = 0.58 per 1SD; 95% CI = 0.39-0.88, P = 0.010) was the powerful independent predictor of change into PN pattern. Kaplan-Meier analysis revealed that the patients with ΔA -7 cm/s had more likely to develop into PN pattern than patients with ΔA > -7 cm/s (P = 0.001). Evaluation of a response in TMF during the LPP might provide an incremental diagnostic value to detect future overt heart failure in patients with early-stage heart failure."},"publication_date":"2018-07-13","publication_name":{"en":"Echocardiography","ja":"Echocardiography"},"volume":"Vol.35","number":"No.10","starting_page":"1587","ending_page":"1595","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/echo.14098"],"issn":["1540-8175"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113035","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30005558","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85050474129&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=350354","label":"url"}],"paper_title":{"en":"Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease FMD-J (Flow-Mediated Dilation Japan) Study","ja":"Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease FMD-J (Flow-Mediated Dilation Japan) Study"},"authors":{"en":[{"name":"Maruhashi Tatsuya"},{"name":"Soga Junko"},{"name":"Fujimura Noritaka"},{"name":"Idei Naomi"},{"name":"Mikami Shinsuke"},{"name":"Iwamoto Yumiko"},{"name":"Iwamoto Akimichi"},{"name":"Kajikawa Masato"},{"name":"Matsumoto Takeshi"},{"name":"Oda Nozomu"},{"name":"Kishimoto Shinji"},{"name":"Matsui Shogo"},{"name":"Hashimoto Haruki"},{"name":"Aibara Yoshiki"},{"name":"Mohamad Yusoff Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Noma Kensuke"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}],"ja":[{"name":"Maruhashi Tatsuya"},{"name":"Soga Junko"},{"name":"Fujimura Noritaka"},{"name":"Idei Naomi"},{"name":"Mikami Shinsuke"},{"name":"Iwamoto Yumiko"},{"name":"Iwamoto Akimichi"},{"name":"Kajikawa Masato"},{"name":"Matsumoto Takeshi"},{"name":"Oda Nozomu"},{"name":"Kishimoto Shinji"},{"name":"Matsui Shogo"},{"name":"Hashimoto Haruki"},{"name":"Aibara Yoshiki"},{"name":"Mohamad Yusoff Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Noma Kensuke"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}]},"description":{"en":"The usefulness of vascular function tests for management of patients with a history of coronary artery disease is not fully known. We measured flow-mediated vasodilation (FMD) and brachial-ankle pulse wave velocity (baPWV) in 462 patients with coronary artery disease for assessment of the predictive value of FMD and baPWV for future cardiovascular events in a prospective multicenter observational study. The first primary outcome was coronary events, and the second primary outcome was a composite of coronary events, stroke, heart failure, and sudden death. During a median follow-up period of 49.2 months, the first primary outcome occurred in 56 patients and the second primary outcome occurred in 66 patients. FMD above the cutoff value of 7.1%, derived from receiver-operator curve analyses for the first and second primary outcomes, was significantly associated with lower risk of the first (hazard ratio, 0.27; 95% confidence interval, 0.06-0.74; =0.008) and second (hazard ratio, 0.32; 95% confidence interval, 0.09-0.79; =0.01) primary outcomes. baPWV above the cutoff value of 1731 cm/s was significantly associated with higher risk of the first (hazard ratio, 1.86; 95% confidence interval, 1.01-3.44; =0.04) and second (hazard ratio, 2.19; 95% confidence interval, 1.23-3.90; =0.008) primary outcomes. Among 4 groups stratified according to the combination of cutoff values of FMD and baPWV, stepwise increases in the calculated risk ratio for the first and second primary outcomes were observed. In patients with coronary artery disease, both FMD and baPWV were significant predictors of cardiovascular events. The combination of FMD and baPWV provided further cardiovascular risk stratification. URL: www.umin.ac.jp. Unique identifier: UMIN000012950.","ja":"The usefulness of vascular function tests for management of patients with a history of coronary artery disease is not fully known. We measured flow-mediated vasodilation (FMD) and brachial-ankle pulse wave velocity (baPWV) in 462 patients with coronary artery disease for assessment of the predictive value of FMD and baPWV for future cardiovascular events in a prospective multicenter observational study. The first primary outcome was coronary events, and the second primary outcome was a composite of coronary events, stroke, heart failure, and sudden death. During a median follow-up period of 49.2 months, the first primary outcome occurred in 56 patients and the second primary outcome occurred in 66 patients. FMD above the cutoff value of 7.1%, derived from receiver-operator curve analyses for the first and second primary outcomes, was significantly associated with lower risk of the first (hazard ratio, 0.27; 95% confidence interval, 0.06-0.74; =0.008) and second (hazard ratio, 0.32; 95% confidence interval, 0.09-0.79; =0.01) primary outcomes. baPWV above the cutoff value of 1731 cm/s was significantly associated with higher risk of the first (hazard ratio, 1.86; 95% confidence interval, 1.01-3.44; =0.04) and second (hazard ratio, 2.19; 95% confidence interval, 1.23-3.90; =0.008) primary outcomes. Among 4 groups stratified according to the combination of cutoff values of FMD and baPWV, stepwise increases in the calculated risk ratio for the first and second primary outcomes were observed. In patients with coronary artery disease, both FMD and baPWV were significant predictors of cardiovascular events. The combination of FMD and baPWV provided further cardiovascular risk stratification. URL: www.umin.ac.jp. Unique identifier: UMIN000012950."},"publication_date":"2018-07-12","publication_name":{"en":"Journal of the American Heart Association","ja":"Journal of the American Heart Association"},"volume":"Vol.7","starting_page":"14","ending_page":"14","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/JAHA.118.008588"],"issn":["2047-9980"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114204","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30146462","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85052061274&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345560","label":"url"}],"paper_title":{"en":"Right Ventricular Function and Beneficial Effects of Cardiac Rehabilitation in Patients With Systolic Chronic Heart Failure.","ja":"Right Ventricular Function and Beneficial Effects of Cardiac Rehabilitation in Patients With Systolic Chronic Heart Failure."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Seno Hiromitsu"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Saijo Y"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"瀬野 弘光"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"鳥居 裕太"},{"name":"平田 有紀奈"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"It has been recognized that a comprehensive cardiac rehabilitation (CR) program improves mortality in patients with chronic heart failure. On the other hand, the magnitude of the improvement in exercise capacity after CR differs among individuals. The aim of this study was to assess the echocardiographic determinants of responders to CR using preload stress echocardiography. We prospectively enrolled 58 chronic heart failure patients with reduced left ventricular ejection fraction (aged 62 ± 11 years; 69% male; left ventricular ejection fraction 43% ± 7%) who had received optimized medical treatment in a CR program for 5 months. We performed preload echocardiographic studies using leg positive pressure (LPP) to assess the echocardiographic parameters during preload augmentation. We defined 41 patients as a development cohort to assess the predictive value of echocardiographic variables. Next, we validated results in the remaining 17 patients as a validation cohort. In the development cohort, significant improvement in peak oxygen uptake (VO) (>10%) after CR was observed in 58% patients. In a multivariable logistic regression model, the significant predictor of improvement in exercise capacity was right ventricular (RV) strain during LPP (odds ratio: 3.96 per 1 standard deviation; P = 0.01). An RV strain value of -16% during LPP had a good sensitivity of 0.79 and a specificity of 0.71 to identify patients with improvement in peak VO. In the validation cohort, an optimal cutoff value of RV strain value was the same (area under the curve: 0.77, sensitivity: 0.78, specificity: 0.65). RV strain during LPP may be an echocardiographic parameter for assessing beneficial effects of CR.","ja":"It has been recognized that a comprehensive cardiac rehabilitation (CR) program improves mortality in patients with chronic heart failure. On the other hand, the magnitude of the improvement in exercise capacity after CR differs among individuals. The aim of this study was to assess the echocardiographic determinants of responders to CR using preload stress echocardiography. We prospectively enrolled 58 chronic heart failure patients with reduced left ventricular ejection fraction (aged 62 ± 11 years; 69% male; left ventricular ejection fraction 43% ± 7%) who had received optimized medical treatment in a CR program for 5 months. We performed preload echocardiographic studies using leg positive pressure (LPP) to assess the echocardiographic parameters during preload augmentation. We defined 41 patients as a development cohort to assess the predictive value of echocardiographic variables. Next, we validated results in the remaining 17 patients as a validation cohort. In the development cohort, significant improvement in peak oxygen uptake (VO) (>10%) after CR was observed in 58% patients. In a multivariable logistic regression model, the significant predictor of improvement in exercise capacity was right ventricular (RV) strain during LPP (odds ratio: 3.96 per 1 standard deviation; P = 0.01). An RV strain value of -16% during LPP had a good sensitivity of 0.79 and a specificity of 0.71 to identify patients with improvement in peak VO. In the validation cohort, an optimal cutoff value of RV strain value was the same (area under the curve: 0.77, sensitivity: 0.78, specificity: 0.65). RV strain during LPP may be an echocardiographic parameter for assessing beneficial effects of CR."},"publication_date":"2018-06-07","publication_name":{"en":"The Canadian Journal of Cardiology","ja":"The Canadian Journal of Cardiology"},"volume":"Vol.34","number":"No.10","starting_page":"1307","ending_page":"1315","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.cjca.2018.06.003"],"issn":["1916-7075"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29895425","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85048476487&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=340032","label":"url"}],"paper_title":{"en":"Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension.","ja":"Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension."},"authors":{"en":[{"name":"Tanaka Atsushi"},{"name":"Kawaguchi Atsushi"},{"name":"Tomiyama Hirofumi"},{"name":"Ishizu Tomoko"},{"name":"Matsumoto Chisa"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Yamashina Akira"},{"name":"Node Koichi"}],"ja":[{"name":"Tanaka Atsushi"},{"name":"Kawaguchi Atsushi"},{"name":"Tomiyama Hirofumi"},{"name":"Ishizu Tomoko"},{"name":"Matsumoto Chisa"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Yamashina Akira"},{"name":"Node Koichi"}]},"description":{"en":"The endothelial dysfunction-arterial stiffness-atherosclerosis continuum plays an important pathophysiological role in hypertension. The aim of this study was to investigate the cross-sectional association between serum uric acid (SUA) and vascular markers related to this continuum, and to assess the longitudinal association between SUA and endothelial function that represents the initial step of the continuum. We evaluated the baseline associations between SUA levels and vascular markers that included flow-mediated vasodilatation (FMD), brachial-ankle pulse wave velocity (baPWV), and common carotid artery intima-media thickness (CCA-IMT) in 648 subjects receiving antihypertensive treatment. The longitudinal association between baseline SUA levels and FMD measured at 1.5 and 3 yr of follow-up was also investigated. At baseline, modest, but significant correlations were observed between SUA and FMD in females (r = -0.171), baPWV in males with SUA >368.78 μmol/L (r = -0.122) and in females with a SUA level 362.83 μmol/L (r = 0.217), mean CCA-IMT in females with a SUA level 333.09 μmol/L (r = 0.139), and max CCA-IMT in females with SUA level 333.09 μmol/L (r = 0.138). A longitudinal association between SUA and FMD was less observed in males. In females, the baseline SUA was associated significantly with FMD values at 1.5 yr (r = -0.211), and SUA levels >237.92 μmol/L were associated significantly and independently with FMD values at 3 yr (r = -0.166). Lower SUA levels were associated with better vascular markers of the continuum, especially in females. Furthermore, we observed a longitudinal association between SUA and endothelial function, suggesting SUA level may be a potential marker of the continuum in hypertension.","ja":"The endothelial dysfunction-arterial stiffness-atherosclerosis continuum plays an important pathophysiological role in hypertension. The aim of this study was to investigate the cross-sectional association between serum uric acid (SUA) and vascular markers related to this continuum, and to assess the longitudinal association between SUA and endothelial function that represents the initial step of the continuum. We evaluated the baseline associations between SUA levels and vascular markers that included flow-mediated vasodilatation (FMD), brachial-ankle pulse wave velocity (baPWV), and common carotid artery intima-media thickness (CCA-IMT) in 648 subjects receiving antihypertensive treatment. The longitudinal association between baseline SUA levels and FMD measured at 1.5 and 3 yr of follow-up was also investigated. At baseline, modest, but significant correlations were observed between SUA and FMD in females (r = -0.171), baPWV in males with SUA >368.78 μmol/L (r = -0.122) and in females with a SUA level 362.83 μmol/L (r = 0.217), mean CCA-IMT in females with a SUA level 333.09 μmol/L (r = 0.139), and max CCA-IMT in females with SUA level 333.09 μmol/L (r = 0.138). A longitudinal association between SUA and FMD was less observed in males. In females, the baseline SUA was associated significantly with FMD values at 1.5 yr (r = -0.211), and SUA levels >237.92 μmol/L were associated significantly and independently with FMD values at 3 yr (r = -0.166). Lower SUA levels were associated with better vascular markers of the continuum, especially in females. Furthermore, we observed a longitudinal association between SUA and endothelial function, suggesting SUA level may be a potential marker of the continuum in hypertension."},"publication_date":"2018-06-06","publication_name":{"en":"International Journal of Cardiology","ja":"International Journal of Cardiology"},"volume":"Vol.272","starting_page":"308","ending_page":"313","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijcard.2018.06.017"],"issn":["1874-1754"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113221","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29848884","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85052204332&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339739","label":"url"}],"paper_title":{"en":"Clinical, Electrocardiographic, and Echocardiographic Parameter Combination Predicts the Onset of Atrial Fibrillation.","ja":"Clinical, Electrocardiographic, and Echocardiographic Parameter Combination Predicts the Onset of Atrial Fibrillation."},"authors":{"en":[{"name":"Soeki Takeshi"},{"name":"Matsuura Tomomi"},{"name":"Tobiume Takeshi"},{"name":"Bando Sachiko"},{"name":"Kazuhisa Matsumoto"},{"name":"Nagano Hiromi"},{"name":"Uematsu Etsuko"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"添木 武"},{"name":"松浦 朋美"},{"name":"飛梅 威"},{"name":"坂東 佐知子"},{"name":"松本 和久"},{"name":"Nagano Hiromi"},{"name":"Uematsu Etsuko"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"The ability to identify risk markers for new-onset atrial fibrillation (AF) is critical to the development of preventive strategies, but it remains unknown whether a combination of clinical, electrocardiographic, and echocardiographic parameters predicts the onset of AF. In the present study, we evaluated the predictive value of a combined score that includes these parameters.Methods and Results:We retrospectively studied 1,040 patients without AF who underwent both echocardiography and 24-h Holter electrocardiography between May 2005 and December 2010. During a median follow-up period of 68.4 months (IQR, 49.9-93.3 months), we investigated the incidence of new-onset AF. Of the 1,040 patients, 103 (9.9%) developed AF. Patients who developed AF were older than patients who did not. Total heart beats, premature atrial contraction (PAC) count, maximum RR interval, and frequency of sinus pause quantified on 24-h electrocardiography were associated with new-onset AF. LA diameter (LAD) on echocardiography was also associated with the development of AF. On multivariate Cox analysis, age 58 years, PAC count 80 beats/day, maximum RR interval 1.64 s, and LAD 4.5 cm were independently associated with the development of AF. The incidence rate of new-onset AF significantly increased as the combined score (i.e., the sum of the risk score determined using hazard ratios) increased. A combined score that includes age, PAC count, maximum RR interval, and LAD could help characterize the risk of new-onset AF.","ja":"The ability to identify risk markers for new-onset atrial fibrillation (AF) is critical to the development of preventive strategies, but it remains unknown whether a combination of clinical, electrocardiographic, and echocardiographic parameters predicts the onset of AF. In the present study, we evaluated the predictive value of a combined score that includes these parameters.Methods and Results:We retrospectively studied 1,040 patients without AF who underwent both echocardiography and 24-h Holter electrocardiography between May 2005 and December 2010. During a median follow-up period of 68.4 months (IQR, 49.9-93.3 months), we investigated the incidence of new-onset AF. Of the 1,040 patients, 103 (9.9%) developed AF. Patients who developed AF were older than patients who did not. Total heart beats, premature atrial contraction (PAC) count, maximum RR interval, and frequency of sinus pause quantified on 24-h electrocardiography were associated with new-onset AF. LA diameter (LAD) on echocardiography was also associated with the development of AF. On multivariate Cox analysis, age 58 years, PAC count 80 beats/day, maximum RR interval 1.64 s, and LAD 4.5 cm were independently associated with the development of AF. The incidence rate of new-onset AF significantly increased as the combined score (i.e., the sum of the risk score determined using hazard ratios) increased. A combined score that includes age, PAC count, maximum RR interval, and LAD could help characterize the risk of new-onset AF."},"publication_date":"2018-05-30","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.82","number":"No.9","starting_page":"2253","ending_page":"2258","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-17-0758"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113224","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29806623","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85049036945&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339670","label":"url"}],"paper_title":{"en":"Effect of the Epicardial Adipose Tissue Volume on the Prevalence of Paroxysmal and Persistent Atrial Fibrillation.","ja":"Effect of the Epicardial Adipose Tissue Volume on the Prevalence of Paroxysmal and Persistent Atrial Fibrillation."},"authors":{"en":[{"name":"Oba Kageyuki"},{"name":"Maeda Minetaka"},{"name":"Maimaituxun Gulinu"},{"name":"Yamaguchi Satoshi"},{"name":"Arasaki Osamu"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Yukina Hirata"},{"name":"Nishio Susumu"},{"name":"Iwase Takashi"},{"name":"Takao Shoichiro"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Harada Masafumi"},{"name":"Masuzaki Hiroaki"},{"name":"Sata Masataka"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"Oba Kageyuki"},{"name":"Maeda Minetaka"},{"name":"Gulinu Maimaituxun"},{"name":"Yamaguchi Satoshi"},{"name":"Arasaki Osamu"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"平田 有紀奈"},{"name":"西尾 進"},{"name":"岩瀬 俊"},{"name":"髙尾 正一郎"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"原田 雅史"},{"name":"Masuzaki Hiroaki"},{"name":"佐田 政隆"},{"name":"島袋 充生"}]},"description":{"en":"Although increasing evidence suggests that epicardial adipose tissue volume (EATV) is associated with atrial fibrillation (AF), it is controversial whether there is a dose-response relationship of increasing EATV along the continuum of AF. We evaluated the effect of the EATV on the prevalence of paroxysmal AF (PAF) and persistent AF (PeAF) and the relationships with cardiac structure and functional remodeling.Methods and Results:Subjects who underwent multidetector computed tomography (MDCT) coronary angiography because of symptoms suggestive of coronary artery disease were divided into sinus rhythm (SR) (n=112), PAF (n=133), and PeAF (n=71) groups. The EATV index (EATV/body surface area, mL/m) was strongly associated with the prevalence of PAF and PeAF on the model adjusted for known AF risk factors. The effect of the EATV index on the prevalence of PeAF, but not on that of PAF, was modified by the left atrial (LA) dimension, suggesting that extension of the LA dimension is related to EATV expansion in PeAF. The cutoff value of the EATV index for the prevalence was higher in PeAF than in PAF (64 vs. 55 mL/m, P<0.01). The EATV index is associated with the prevalence of PAF and PeAF, and its cutoff values are predictive for PAF and PeAF development independently of other AF risk factors.","ja":"Although increasing evidence suggests that epicardial adipose tissue volume (EATV) is associated with atrial fibrillation (AF), it is controversial whether there is a dose-response relationship of increasing EATV along the continuum of AF. We evaluated the effect of the EATV on the prevalence of paroxysmal AF (PAF) and persistent AF (PeAF) and the relationships with cardiac structure and functional remodeling.Methods and Results:Subjects who underwent multidetector computed tomography (MDCT) coronary angiography because of symptoms suggestive of coronary artery disease were divided into sinus rhythm (SR) (n=112), PAF (n=133), and PeAF (n=71) groups. The EATV index (EATV/body surface area, mL/m) was strongly associated with the prevalence of PAF and PeAF on the model adjusted for known AF risk factors. The effect of the EATV index on the prevalence of PeAF, but not on that of PAF, was modified by the left atrial (LA) dimension, suggesting that extension of the LA dimension is related to EATV expansion in PeAF. The cutoff value of the EATV index for the prevalence was higher in PeAF than in PAF (64 vs. 55 mL/m, P<0.01). The EATV index is associated with the prevalence of PAF and PeAF, and its cutoff values are predictive for PAF and PeAF development independently of other AF risk factors."},"publication_date":"2018-05-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.82","number":"No.7","starting_page":"1778","ending_page":"1787","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-18-0021"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113222","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29709994","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85050588123&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339442","label":"url"}],"paper_title":{"en":"Prognostic Value of Frailty and Diastolic Dysfunction in Elderly Patients.","ja":"Prognostic Value of Frailty and Diastolic Dysfunction in Elderly Patients."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Okushi Y"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Saijo Y"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Okushi Y"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"鳥居 裕太"},{"name":"平田 有紀奈"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"High prevalence of frailty and of diastolic dysfunction (DD) in heart failure and high mortality in frail adults have been noted. We characterized frailty by quantifying differences on echocardiography, and assessed the added prognostic utility of frailty and DD grade in an elderly population. One hundred and ninety-one patients 65 years who had at least 1 cardiovascular risk factor were prospectively recruited for clinically indicated echocardiography at the present institute. Weight loss, exhaustion, and deficits in physical activity, gait speed, and handgrip strength were used to categorize patients as frail (3 features), intermediately frail (1 or 2 features), or non-frail (0 features). DD grade 2 was defined as severe. Frailty was associated with larger left atrial volume, smaller stroke volume, and worse DD grade after adjustment for age. In a period of 14 months, 29 patients (15%) had cardiovascular events. The addition of frailty score and severe DD significantly improved the prognostic power of a model containing male gender (model 1, male gender, χ=6.4; model 2, model 1 plus frailty score, χ=16.7, P=0.004; model 3, model 2 plus severe DD, χ=25.5, P=0.015). Both frailty and DD grade were significantly associated with future cardiovascular events in an elderly population with preserved ejection fraction and 1 risk factor of cardiovascular disease.","ja":"High prevalence of frailty and of diastolic dysfunction (DD) in heart failure and high mortality in frail adults have been noted. We characterized frailty by quantifying differences on echocardiography, and assessed the added prognostic utility of frailty and DD grade in an elderly population. One hundred and ninety-one patients 65 years who had at least 1 cardiovascular risk factor were prospectively recruited for clinically indicated echocardiography at the present institute. Weight loss, exhaustion, and deficits in physical activity, gait speed, and handgrip strength were used to categorize patients as frail (3 features), intermediately frail (1 or 2 features), or non-frail (0 features). DD grade 2 was defined as severe. Frailty was associated with larger left atrial volume, smaller stroke volume, and worse DD grade after adjustment for age. In a period of 14 months, 29 patients (15%) had cardiovascular events. The addition of frailty score and severe DD significantly improved the prognostic power of a model containing male gender (model 1, male gender, χ=6.4; model 2, model 1 plus frailty score, χ=16.7, P=0.004; model 3, model 2 plus severe DD, χ=25.5, P=0.015). Both frailty and DD grade were significantly associated with future cardiovascular events in an elderly population with preserved ejection fraction and 1 risk factor of cardiovascular disease."},"publication_date":"2018-04-28","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.82","number":"No.8","starting_page":"2103","ending_page":"2110","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-18-0017"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112891","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29700120","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85055611443&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339441","label":"url"}],"paper_title":{"en":"Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.","ja":"Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice."},"authors":{"en":[{"name":"Hara Tomoya"},{"name":"Phuong Tran Pham"},{"name":"Fukuda Daiju"},{"name":"Yamaguchi Koji"},{"name":"Murata Chie"},{"name":"Nishimoto Sachiko"},{"name":"Yagi Shusuke"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Takeshi Soeki"},{"name":"Wakatsuki Tetsuzo"},{"name":"Imoto Issei"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Hara Tomoya"},{"name":"Phuong Tran Pham"},{"name":"福田 大受"},{"name":"山口 浩司"},{"name":"Murata Chie"},{"name":"Nishimoto Sachiko"},{"name":"八木 秀介"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"Takeshi Soeki"},{"name":"若槻 哲三"},{"name":"Imoto Issei"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"-The coagulation system is closely linked with vascular inflammation, although the underlying mechanisms are still obscure. Recent studies show that protease-activated receptor (PAR)-2, a major receptor of activated factor X (FXa), are expressed in both vascular cells and leukocytes, suggesting that PAR-2 may contribute to the pathogenesis of inflammatory diseases. Here we investigated the role of PAR-2 in vascular inflammation and atherogenesis. -We generated apolipoprotein E-deficient ( ) mice lacking systemic PAR-2 expression ( ). mice which lack or express PAR-2 only in bone-marrow (BM) cells were also generated by BM transplantation. Atherosclerotic lesions were investigated after 20 weeks on a western-type diet (WTD) by histological analyses, quantitative RT-PCR, and western blotting. In vitro experiments using BM-derived macrophages were performed to confirm pro-inflammatory roles of PAR-2. The association between plasma FXa level and the severity of coronary atherosclerosis was also examined in humans who underwent coronary intervention. - mice showed reduced atherosclerotic lesions in the aortic arch (<0.05) along with features of stabilized atherosclerotic plaques such as less lipid deposition (<0.05), collagen loss (<0.01), macrophage accumulation (<0.05), and inflammatory molecule expression (<0.05) compared with mice. Systemic PAR2 deletion in mice significantly decreased the expression of inflammatory molecules in the aorta. The results of BM transplantation experiments demonstrated that PAR-2 in hematopoietic cells contributed to atherogenesis in mice. PAR-2 deletion did not alter metabolic parameters. In vitro experiments demonstrated that FXa or a specific peptide agonist of PAR-2 significantly increased expression of inflammatory molecules and lipid uptake in BM-derived macrophages from wild-type mice compared with those from PAR-2-deficient mice. Activation of NF- κB signaling was involved in PAR-2-associated vascular inflammation and macrophage activation. In humans who underwent coronary intervention, plasma FXa level independently correlated with the severity of coronary atherosclerosis as determined by Gensini score (<0.05) and plaque volume (<0.01). -PAR-2 signaling activates macrophages and promotes vascular inflammation, increasing atherosclerosis in mice. This signaling pathway may also participate in atherogenesis in humans.","ja":"-The coagulation system is closely linked with vascular inflammation, although the underlying mechanisms are still obscure. Recent studies show that protease-activated receptor (PAR)-2, a major receptor of activated factor X (FXa), are expressed in both vascular cells and leukocytes, suggesting that PAR-2 may contribute to the pathogenesis of inflammatory diseases. Here we investigated the role of PAR-2 in vascular inflammation and atherogenesis. -We generated apolipoprotein E-deficient ( ) mice lacking systemic PAR-2 expression ( ). mice which lack or express PAR-2 only in bone-marrow (BM) cells were also generated by BM transplantation. Atherosclerotic lesions were investigated after 20 weeks on a western-type diet (WTD) by histological analyses, quantitative RT-PCR, and western blotting. In vitro experiments using BM-derived macrophages were performed to confirm pro-inflammatory roles of PAR-2. The association between plasma FXa level and the severity of coronary atherosclerosis was also examined in humans who underwent coronary intervention. - mice showed reduced atherosclerotic lesions in the aortic arch (<0.05) along with features of stabilized atherosclerotic plaques such as less lipid deposition (<0.05), collagen loss (<0.01), macrophage accumulation (<0.05), and inflammatory molecule expression (<0.05) compared with mice. Systemic PAR2 deletion in mice significantly decreased the expression of inflammatory molecules in the aorta. The results of BM transplantation experiments demonstrated that PAR-2 in hematopoietic cells contributed to atherogenesis in mice. PAR-2 deletion did not alter metabolic parameters. In vitro experiments demonstrated that FXa or a specific peptide agonist of PAR-2 significantly increased expression of inflammatory molecules and lipid uptake in BM-derived macrophages from wild-type mice compared with those from PAR-2-deficient mice. Activation of NF- κB signaling was involved in PAR-2-associated vascular inflammation and macrophage activation. In humans who underwent coronary intervention, plasma FXa level independently correlated with the severity of coronary atherosclerosis as determined by Gensini score (<0.05) and plaque volume (<0.01). -PAR-2 signaling activates macrophages and promotes vascular inflammation, increasing atherosclerosis in mice. This signaling pathway may also participate in atherogenesis in humans."},"publication_date":"2018-04-26","publication_name":{"en":"Circulation","ja":"Circulation"},"volume":"Vol.138","number":"No.16","starting_page":"1706","ending_page":"1719","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/CIRCULATIONAHA.118.033544"],"issn":["1524-4539"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112879","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29563352","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85045965929&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339436","label":"url"}],"paper_title":{"en":"Local Thickness of Epicardial Adipose Tissue Surrounding the Left Anterior Descending Artery Is a Simple Predictor of Coronary Artery Disease - New Prediction Model in Combination With Framingham Risk Score.","ja":"Local Thickness of Epicardial Adipose Tissue Surrounding the Left Anterior Descending Artery Is a Simple Predictor of Coronary Artery Disease - New Prediction Model in Combination With Framingham Risk Score."},"authors":{"en":[{"name":"Maimaituxun Gulinu"},{"name":"Shimabukuro Michio"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Hirata Yukina"},{"name":"Iwase Takashi"},{"name":"Takao Shoichiro"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Harada Masafumi"},{"name":"Sata Masataka"}],"ja":[{"name":"Gulinu Maimaituxun"},{"name":"島袋 充生"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"平田 有紀奈"},{"name":"Iwase Takashi"},{"name":"髙尾 正一郎"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"Harada Masafumi"},{"name":"佐田 政隆"}]},"description":{"en":"Compared with global cardiac adiposity, the local accumulation of fat surrounding coronary arteries might have a more direct impact on coronary artery disease (CAD). Here, we compared the local epicardial adipose tissue (EAT) thickness and global cardiac adiposity volumes for predicting CAD.Methods and Results:A total of 197 consecutive subjects underwent 320-slice multi-detector computed tomography coronary angiography and were segregated into CAD (1 coronary artery branch stenosis 50%) and non-CAD groups. EAT thickness was measured at the right coronary artery (EAT), the left anterior descending artery (EAT), and the left circumflex artery (EAT). Although EATand EATwere similar between the 2 groups, EATwas larger in the CAD group than in the non-CAD group (5.45±2.16 mm vs. 6.86±2.19 mm, P<0.001). EAT, after correcting for confounding factors, was strongly associated with CAD (r=0.276, P<0.001) and Gensini score (r=0.239, P<0.001). On multiple regression analysis, Framingham risk score combined with EATwas a strong predictor of CAD (adjusted R=0.121; P<0.001). The local fat thickness surrounding the LAD is a simple and useful surrogate marker for estimating the presence, severity, and extent of CAD, independent of classical cardiovascular risk factors.","ja":"Compared with global cardiac adiposity, the local accumulation of fat surrounding coronary arteries might have a more direct impact on coronary artery disease (CAD). Here, we compared the local epicardial adipose tissue (EAT) thickness and global cardiac adiposity volumes for predicting CAD.Methods and Results:A total of 197 consecutive subjects underwent 320-slice multi-detector computed tomography coronary angiography and were segregated into CAD (1 coronary artery branch stenosis 50%) and non-CAD groups. EAT thickness was measured at the right coronary artery (EAT), the left anterior descending artery (EAT), and the left circumflex artery (EAT). Although EATand EATwere similar between the 2 groups, EATwas larger in the CAD group than in the non-CAD group (5.45±2.16 mm vs. 6.86±2.19 mm, P<0.001). EAT, after correcting for confounding factors, was strongly associated with CAD (r=0.276, P<0.001) and Gensini score (r=0.239, P<0.001). On multiple regression analysis, Framingham risk score combined with EATwas a strong predictor of CAD (adjusted R=0.121; P<0.001). The local fat thickness surrounding the LAD is a simple and useful surrogate marker for estimating the presence, severity, and extent of CAD, independent of classical cardiovascular risk factors."},"publication_date":"2018-04-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.82","number":"No.5","starting_page":"1369","ending_page":"1378","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-17-1289"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://search.jamas.or.jp/link/ui/S525350043","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=344784","label":"url"}],"paper_title":{"en":"Calcified Amorphous Tumorに対し腫瘍摘出術を行った一例","ja":"Calcified Amorphous Tumorに対し腫瘍摘出術を行った一例"},"authors":{"en":[{"name":"清水 郁子"},{"name":"瀬野 弘光"},{"name":"Yamaguchi Koji"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"},{"name":"Iwase Takashi"},{"name":"Kurobe Hirotsugu"},{"name":"Kitagawa Tetsuya"}],"ja":[{"name":"清水 郁子"},{"name":"瀬野 弘光"},{"name":"山口 浩司"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"添木 武"},{"name":"佐田 政隆"},{"name":"岩瀬 俊"},{"name":"黒部 裕嗣"},{"name":"北川 哲也"}]},"publication_date":"2018-04","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.74","number":"No.1-2","starting_page":"84","ending_page":"84","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114206","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29526958","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390001288050194688/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339434","label":"url"}],"paper_title":{"en":"An Occluded Hooklet of an Embedded Inferior Vena Cava Filter","ja":"An Occluded Hooklet of an Embedded Inferior Vena Cava Filter"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Yamamoto Y."},{"name":"Nishiyama S."},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Yamamoto Y."},{"name":"Nishiyama S."},{"name":"佐田 政隆"}]},"publication_date":"2018-03-09","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"volume":"Vol.57","number":"No.15","starting_page":"2275","ending_page":"2276","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.0505-17"],"issn":["1349-7235"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115151","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29174285","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85035071196&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336475","label":"url"}],"paper_title":{"en":"Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension.","ja":"Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension."},"authors":{"en":[{"name":"Tomiyama H,"},{"name":"Ishizu T, ."},{"name":"Kohro T,"},{"name":"Matsumoto C,"},{"name":"Higashi Y,"},{"name":"Takase B,"},{"name":"Suzuki T,"},{"name":"Ueda S, ."},{"name":"Yamazaki T,"},{"name":"Furumoto T,"},{"name":"Kario K,"},{"name":"Inoue T,"},{"name":"Koba S,"},{"name":"Takemoto Y,"},{"name":"Hano T,"},{"name":"Sata Masataka"},{"name":"Sata M,"},{"name":"Ishibashi Y,"},{"name":"Node K,"},{"name":"Maemura K,"},{"name":"Ohya Y,"},{"name":"Furukawa T,"},{"name":"Ito H,"},{"name":"Yamashina A"}],"ja":[{"name":"Tomiyama H,"},{"name":"Ishizu T, ."},{"name":"Kohro T,"},{"name":"Matsumoto C,"},{"name":"Higashi Y,"},{"name":"Takase B,"},{"name":"Suzuki T,"},{"name":"Ueda S, ."},{"name":"Yamazaki T,"},{"name":"Furumoto T,"},{"name":"Kario K,"},{"name":"Inoue T,"},{"name":"Koba S,"},{"name":"Takemoto Y,"},{"name":"Hano T,"},{"name":"佐田 政隆"},{"name":"Sata M,"},{"name":"Ishibashi Y,"},{"name":"Node K,"},{"name":"Maemura K,"},{"name":"Ohya Y,"},{"name":"Furukawa T,"},{"name":"Ito H,"},{"name":"Yamashina A"}]},"description":{"en":"To examine the longitudinal mutual association between endothelial dysfunction and arterial stiffness, and also to determine which of the two variables was more closely associated with the progression of subclinical organ damage. The brachial-ankle pulse wave velocity (baPWV), carotid intima-media thickness (CIMT), estimated glomerular filtration rate, microalbuminuria and flow-mediated vasodilatation of the brachial artery (FMD) were measured three times at 1.5-year intervals in 674 Japanese patients receiving antihypertensive treatment. The change of the baPWV during the study period was larger in the subjects with baseline FMD values in the lowest tertile as compared to those with baseline FMD values in the highest tertile. The change of the CIMT was smaller in the subjects with baseline baPWV values in the lowest tertile than in those with baseline baPWV values in the highest tertile. After the adjustment, the FMD value at the baseline was inversely associated with the baPWV at the end of the study period (beta=-0.07, p=0.01), although, the reverse association was not significant. The baPWV, but not the FMD value, at the baseline was associated with the CIMT (beta=0.06, p=0.04) measured at the end of the study period. In hypertension, endothelial dysfunction was associated with the progression of arterial stiffness, although the reverse association was not confirmed. The increased arterial stiffness rather than endothelial dysfunction may be more closely associated with the progression of atherosclerotic vascular damage, and the endothelial dysfunction-arterial stiffness-atherosclerosis continuum may be important in hypertension.","ja":"To examine the longitudinal mutual association between endothelial dysfunction and arterial stiffness, and also to determine which of the two variables was more closely associated with the progression of subclinical organ damage. The brachial-ankle pulse wave velocity (baPWV), carotid intima-media thickness (CIMT), estimated glomerular filtration rate, microalbuminuria and flow-mediated vasodilatation of the brachial artery (FMD) were measured three times at 1.5-year intervals in 674 Japanese patients receiving antihypertensive treatment. The change of the baPWV during the study period was larger in the subjects with baseline FMD values in the lowest tertile as compared to those with baseline FMD values in the highest tertile. The change of the CIMT was smaller in the subjects with baseline baPWV values in the lowest tertile than in those with baseline baPWV values in the highest tertile. After the adjustment, the FMD value at the baseline was inversely associated with the baPWV at the end of the study period (beta=-0.07, p=0.01), although, the reverse association was not significant. The baPWV, but not the FMD value, at the baseline was associated with the CIMT (beta=0.06, p=0.04) measured at the end of the study period. In hypertension, endothelial dysfunction was associated with the progression of arterial stiffness, although the reverse association was not confirmed. The increased arterial stiffness rather than endothelial dysfunction may be more closely associated with the progression of atherosclerotic vascular damage, and the endothelial dysfunction-arterial stiffness-atherosclerosis continuum may be important in hypertension."},"publication_date":"2018-02-15","publication_name":{"en":"International Journal of Cardiology","ja":"International Journal of Cardiology"},"volume":"Vol.15","number":"No.253","starting_page":"161","ending_page":"166","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijcard.2017.11.022"],"issn":["1874-1754"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114208","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29487532","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85041922780&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336779","label":"url"}],"paper_title":{"en":"Roles of Perivascular Adipose Tissue in the Pathogenesis of Atherosclerosis.","ja":"Roles of Perivascular Adipose Tissue in the Pathogenesis of Atherosclerosis."},"authors":{"en":[{"name":"Tanaka K,"},{"name":"Sata Masataka"}],"ja":[{"name":"Tanaka K,"},{"name":"佐田 政隆"}]},"description":{"en":"Traditionally, it is believed that white adipose tissues serve as energy storage, heat insulation, and mechanical cushion, whereas non-shivering thermogenesis occurs in brown adipose tissue. Recent evidence revealed that adipose tissue secretes many types of cytokines, called as adipocytokines, which modulate glucose metabolism, lipid profile, appetite, fibrinolysis, blood pressure, and inflammation. Most of the arteries are surrounded by perivascular adipose tissue (PVAT). PVAT has been thought to be simply a structurally supportive tissue for vasculature. However, recent studies showed that PVAT influences vasodilation and vasocontraction, suggesting that PVAT regulates vascular tone and diameter. Adipocytokines secreted from PVAT appear to have direct access to the adjacent arterial wall by diffusion or via vasa vasorum. In fact, PVAT around atherosclerotic lesions and mechanically-injured arteries displayed inflammatory cytokine profiles, suggesting that PVAT functions to promote vascular lesion formation. Many clinical studies revealed that increased accumulation of epicardial adipose tissue (EAT), which surrounds coronary arteries, is associated with coronary artery disease. In this review article, we will summarize recent findings about potential roles of PVAT in the pathogenesis of atherosclerosis, particularly focusing on a series of basic and clinical studies from our laboratory.","ja":"Traditionally, it is believed that white adipose tissues serve as energy storage, heat insulation, and mechanical cushion, whereas non-shivering thermogenesis occurs in brown adipose tissue. Recent evidence revealed that adipose tissue secretes many types of cytokines, called as adipocytokines, which modulate glucose metabolism, lipid profile, appetite, fibrinolysis, blood pressure, and inflammation. Most of the arteries are surrounded by perivascular adipose tissue (PVAT). PVAT has been thought to be simply a structurally supportive tissue for vasculature. However, recent studies showed that PVAT influences vasodilation and vasocontraction, suggesting that PVAT regulates vascular tone and diameter. Adipocytokines secreted from PVAT appear to have direct access to the adjacent arterial wall by diffusion or via vasa vasorum. In fact, PVAT around atherosclerotic lesions and mechanically-injured arteries displayed inflammatory cytokine profiles, suggesting that PVAT functions to promote vascular lesion formation. Many clinical studies revealed that increased accumulation of epicardial adipose tissue (EAT), which surrounds coronary arteries, is associated with coronary artery disease. In this review article, we will summarize recent findings about potential roles of PVAT in the pathogenesis of atherosclerosis, particularly focusing on a series of basic and clinical studies from our laboratory."},"publication_date":"2018-02-13","publication_name":{"en":"Frontiers in Physiology","ja":"Frontiers in Physiology"},"volume":"Vol.9","number":"No.3","starting_page":"3","ending_page":"3","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fphys.2018.00003"],"issn":["1664-042X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114209","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29269019","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85039155853&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=335854","label":"url"}],"paper_title":{"en":"Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury.","ja":"Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury."},"authors":{"en":[{"name":"Hara Tomoya"},{"name":"Fukuda Daiju"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"Hirata Yukina"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"原 知也"},{"name":"福田 大受"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"平田 有紀奈"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Accumulating evidence suggests that activated factor X (FXa), a key coagulation factor, plays an important role in the development of vascular inflammation through activation of many cell types. Here, we investigated whether pharmacological blockade of FXa attenuates neointima formation after wire-mediated vascular injury. Transluminal femoral artery injury was induced in C57BL/6 mice by inserting a straight wire. Rivaroxaban (5mg/kg/day), a direct FXa inhibitor, was administered from one week before surgery until killed. At four weeks after surgery, rivaroxaban significantly attenuated neointima formation in the injured arteries compared with control (P<0.01). Plasma lipid levels and blood pressure were similar between the rivaroxaban-treated group and non-treated group. Quantitative RT-PCR analyses demonstrated that rivaroxaban reduced the expression of inflammatory molecules (e.g., IL-1β and TNF-α) in injured arteries at seven days after surgery (P<0.05, respectively). In vitro experiments using mouse peritoneal macrophages demonstrated that FXa increased the expression of inflammatory molecules (e.g., IL-1β and TNF-α), which was blocked in the presence of rivaroxaban (P<0.05). Also, in vitro experiments using rat vascular smooth muscle cells (VSMC) demonstrated that FXa promoted both proliferation and migration of this cell type (P<0.05), which were blocked in the presence of rivaroxaban. Inhibition of FXa by rivaroxaban attenuates neointima formation after wire-mediated vascular injury through inhibition of inflammatory activation of macrophages and VSMC.","ja":"Accumulating evidence suggests that activated factor X (FXa), a key coagulation factor, plays an important role in the development of vascular inflammation through activation of many cell types. Here, we investigated whether pharmacological blockade of FXa attenuates neointima formation after wire-mediated vascular injury. Transluminal femoral artery injury was induced in C57BL/6 mice by inserting a straight wire. Rivaroxaban (5mg/kg/day), a direct FXa inhibitor, was administered from one week before surgery until killed. At four weeks after surgery, rivaroxaban significantly attenuated neointima formation in the injured arteries compared with control (P<0.01). Plasma lipid levels and blood pressure were similar between the rivaroxaban-treated group and non-treated group. Quantitative RT-PCR analyses demonstrated that rivaroxaban reduced the expression of inflammatory molecules (e.g., IL-1β and TNF-α) in injured arteries at seven days after surgery (P<0.05, respectively). In vitro experiments using mouse peritoneal macrophages demonstrated that FXa increased the expression of inflammatory molecules (e.g., IL-1β and TNF-α), which was blocked in the presence of rivaroxaban (P<0.05). Also, in vitro experiments using rat vascular smooth muscle cells (VSMC) demonstrated that FXa promoted both proliferation and migration of this cell type (P<0.05), which were blocked in the presence of rivaroxaban. Inhibition of FXa by rivaroxaban attenuates neointima formation after wire-mediated vascular injury through inhibition of inflammatory activation of macrophages and VSMC."},"publication_date":"2018-02-05","publication_name":{"en":"European Journal of Pharmacology","ja":"European Journal of Pharmacology"},"volume":"Vol.5","number":"No.820","starting_page":"222","ending_page":"228","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ejphar.2017.12.037"],"issn":["1879-0712"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114210","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29388159","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85045145878&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339428","label":"url"}],"paper_title":{"en":"Provocation of clinically significant left ventricular outflow tract obstruction by postural change in patients with sigmoid septum.","ja":"Provocation of clinically significant left ventricular outflow tract obstruction by postural change in patients with sigmoid septum."},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Nishio Susumu"},{"name":"Torii Yuta"},{"name":"Horike Yuki"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"西尾 進"},{"name":"鳥居 裕太"},{"name":"堀家 由貴"},{"name":"佐田 政隆"}]},"publication_date":"2018-01","publication_name":{"en":"Journal of Echocardiography","ja":"Journal of Echocardiography"},"volume":"Vol.16","number":"No.4","starting_page":"173","ending_page":"174","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12574-018-0372-x"],"issn":["1880-344X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/110959","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28830651","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85027682866&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341714","label":"url"}],"paper_title":{"en":"Development and validation of optimal cut-off value in inter-arm systolic blood pressure difference for prediction of cardiovascular events","ja":"Development and validation of optimal cut-off value in inter-arm systolic blood pressure difference for prediction of cardiovascular events"},"authors":{"en":[{"name":"Hirono Akira"},{"name":"Kusunose Kenya"},{"name":"Kageyama Norihito"},{"name":"Sumitomo Masayuki"},{"name":"Abe Masahiro"},{"name":"Fujinaga Hiroyuki"},{"name":"Sata Masataka"}],"ja":[{"name":"廣野 明"},{"name":"楠瀬 賢也"},{"name":"Kageyama Norihito"},{"name":"Sumitomo Masayuki"},{"name":"Abe Masahiro"},{"name":"Fujinaga Hiroyuki"},{"name":"佐田 政隆"}]},"description":{"en":"An inter-arm systolic blood pressure difference (IAD) is associated with cardiovascular disease. The aim of this study was to develop and validate the optimal cut-off value of IAD as a predictor of major adverse cardiac events in patients with arteriosclerosis risk factors. From 2009 to 2014, 1076 patients who had at least one cardiovascular risk factor were included in the analysis. We defined 700 randomly selected patients as a development cohort to confirm that IAD was the predictor of cardiovascular events and to determine optimal cut-off value of IAD. Next, we validated outcomes in the remaining 376 patients as a validation cohort. The blood pressure (BP) of both arms measurements were done simultaneously using the ankle-brachial blood pressure index (ABI) form of automatic device. The primary endpoint was the cardiovascular event and secondary endpoint was the all-cause mortality. During a median period of 2.8 years, 143 patients reached the primary endpoint in the development cohort. In the multivariate Cox proportional hazards analysis, IAD was the strong predictor of cardiovascular events (hazard ratio: 1.03, 95% confidence interval: 1.01-1.05, p=0.005). The receiver operating characteristic curve revealed that 5mmHg was the optimal cut-off point of IAD to predict cardiovascular events (p<0.001). In the validation cohort, the presence of a large IAD (IAD ≥5mmHg) was significantly associated with the primary endpoint (p=0.021). IAD is significantly associated with future cardiovascular events in patients with arteriosclerosis risk factors. The optimal cut-off value of IAD is 5mmHg.","ja":"An inter-arm systolic blood pressure difference (IAD) is associated with cardiovascular disease. The aim of this study was to develop and validate the optimal cut-off value of IAD as a predictor of major adverse cardiac events in patients with arteriosclerosis risk factors. From 2009 to 2014, 1076 patients who had at least one cardiovascular risk factor were included in the analysis. We defined 700 randomly selected patients as a development cohort to confirm that IAD was the predictor of cardiovascular events and to determine optimal cut-off value of IAD. Next, we validated outcomes in the remaining 376 patients as a validation cohort. The blood pressure (BP) of both arms measurements were done simultaneously using the ankle-brachial blood pressure index (ABI) form of automatic device. The primary endpoint was the cardiovascular event and secondary endpoint was the all-cause mortality. During a median period of 2.8 years, 143 patients reached the primary endpoint in the development cohort. In the multivariate Cox proportional hazards analysis, IAD was the strong predictor of cardiovascular events (hazard ratio: 1.03, 95% confidence interval: 1.01-1.05, p=0.005). The receiver operating characteristic curve revealed that 5mmHg was the optimal cut-off point of IAD to predict cardiovascular events (p<0.001). In the validation cohort, the presence of a large IAD (IAD ≥5mmHg) was significantly associated with the primary endpoint (p=0.021). IAD is significantly associated with future cardiovascular events in patients with arteriosclerosis risk factors. The optimal cut-off value of IAD is 5mmHg."},"publication_date":"2018-01","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.71","number":"No.20","starting_page":"24","ending_page":"30","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2017.06.010"],"issn":["0914-5087"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353342","label":"url"}],"paper_title":{"en":"時効型インスリン療法中の2型糖尿病患者におけるダパグリフロジンの血糖日内変動に及ぼす効果","ja":"時効型インスリン療法中の2型糖尿病患者におけるダパグリフロジンの血糖日内変動に及ぼす効果"},"authors":{"en":[{"name":"工藤 萌宏"},{"name":"待井 典剛"},{"name":"小野 利夫"},{"name":"大城 義人"},{"name":"高橋 隆"},{"name":"種田 嘉信"},{"name":"比嘉 盛丈"},{"name":"Yagi Shusuke"},{"name":"仲地 健"},{"name":"小林 淳"},{"name":"及川 雅啓"},{"name":"Yamada Hirotsugu"},{"name":"竹石 恭知"},{"name":"Sata Masataka"},{"name":"Shimabukuro Michio"}],"ja":[{"name":"工藤 萌宏"},{"name":"待井 典剛"},{"name":"小野 利夫"},{"name":"大城 義人"},{"name":"高橋 隆"},{"name":"種田 嘉信"},{"name":"比嘉 盛丈"},{"name":"八木 秀介"},{"name":"仲地 健"},{"name":"小林 淳"},{"name":"及川 雅啓"},{"name":"山田 博胤"},{"name":"竹石 恭知"},{"name":"佐田 政隆"},{"name":"島袋 充生"}]},"publication_date":"2018","publication_name":{"en":"Journal of Japan Society for the Study of Obesity","ja":"肥満研究"},"volume":"Vol.24","number":"No.Suppl","starting_page":"222","ending_page":"222","languages":["jpn"],"referee":true,"identifiers":{"issn":["1343-229X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29212965","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85042510747&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336431","label":"url"}],"paper_title":{"en":"Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.","ja":"Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome."},"authors":{"en":[{"name":"Hibi Kiyoshi"},{"name":"Sonoda Shinjo"},{"name":"Kawasaki Masanori"},{"name":"Otsuji Yutaka"},{"name":"Murohara Toyoaki"},{"name":"Ishii Hideki"},{"name":"Sato Katsuhiko"},{"name":"Koshida Ryoji"},{"name":"Ozaki Yukio"},{"name":"Sata Masataka"},{"name":"Morino Yoshihiro"},{"name":"Miyamoto Tadashi"},{"name":"Amano Tetsuya"},{"name":"Morita Satoshi"},{"name":"Kozuma Ken"},{"name":"Kimura Kazuo"},{"name":"Fujiwara Hisayoshi"}],"ja":[{"name":"Hibi Kiyoshi"},{"name":"Sonoda Shinjo"},{"name":"Kawasaki Masanori"},{"name":"Otsuji Yutaka"},{"name":"Murohara Toyoaki"},{"name":"Ishii Hideki"},{"name":"Sato Katsuhiko"},{"name":"Koshida Ryoji"},{"name":"Ozaki Yukio"},{"name":"佐田 政隆"},{"name":"Morino Yoshihiro"},{"name":"Miyamoto Tadashi"},{"name":"Amano Tetsuya"},{"name":"Morita Satoshi"},{"name":"Kozuma Ken"},{"name":"Kimura Kazuo"},{"name":"Fujiwara Hisayoshi"}]},"description":{"en":"The results of previous clinical trials on the effects of ezetimibe-statin combination therapy on atherosclerosis are inconsistent, and the anti-atherosclerotic effect of ezetimibe remains controversial.Methods and Results:We conducted a prospective, randomized open-label study at 10 centers. One hundred and twenty-eight statin-naïve patients with acute coronary syndrome (ACS) undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention were randomized to receive either 2 mg/day pitavastatin plus 10 mg/day ezetimibe, or 2 mg/day pitavastatin. One hundred and 3 patients had evaluable IVUS of non-culprit coronary lesions at baseline and at follow-up. The primary endpoint was the percentage change in non-culprit coronary plaque volume (PV) and lipid PV on integrated backscatter IVUS. Mean low-density lipoprotein cholesterol was reduced from 123 mg/dL to 64 mg/dL in the combination therapy group (n=50) and 126 mg/dL to 87 mg/dL in the statin alone group (n=53; between-group difference, 16.9%, P<0.0001). The percent change in PV was -5.1% in the combination therapy group and -6.2% in the statin alone group (P=0.66), although both groups had reduction of PV compared with baseline (both P<0.01). The percent change in lipid PV did not differ between the groups (4.3 vs. -3.0%, P=0.37). In statin-naïve patients with ACS, combined therapy with ezetimibe and statin did not result in a significant change in coronary plaque regression or tissue component compared with statin alone. [Clinical Trial Registration: www.clinicaltrials.gov (NCT00549926)].","ja":"The results of previous clinical trials on the effects of ezetimibe-statin combination therapy on atherosclerosis are inconsistent, and the anti-atherosclerotic effect of ezetimibe remains controversial.Methods and Results:We conducted a prospective, randomized open-label study at 10 centers. One hundred and twenty-eight statin-naïve patients with acute coronary syndrome (ACS) undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention were randomized to receive either 2 mg/day pitavastatin plus 10 mg/day ezetimibe, or 2 mg/day pitavastatin. One hundred and 3 patients had evaluable IVUS of non-culprit coronary lesions at baseline and at follow-up. The primary endpoint was the percentage change in non-culprit coronary plaque volume (PV) and lipid PV on integrated backscatter IVUS. Mean low-density lipoprotein cholesterol was reduced from 123 mg/dL to 64 mg/dL in the combination therapy group (n=50) and 126 mg/dL to 87 mg/dL in the statin alone group (n=53; between-group difference, 16.9%, P<0.0001). The percent change in PV was -5.1% in the combination therapy group and -6.2% in the statin alone group (P=0.66), although both groups had reduction of PV compared with baseline (both P<0.01). The percent change in lipid PV did not differ between the groups (4.3 vs. -3.0%, P=0.37). In statin-naïve patients with ACS, combined therapy with ezetimibe and statin did not result in a significant change in coronary plaque regression or tissue component compared with statin alone. [Clinical Trial Registration: www.clinicaltrials.gov (NCT00549926)]."},"publication_date":"2017-12-07","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.82","number":"No.3","starting_page":"757","ending_page":"766","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-17-0598"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29177991","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85035015467&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336474","label":"url"}],"paper_title":{"en":"Correction to: Treatment with the PPARγ Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats.","ja":"Correction to: Treatment with the PPARγ Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats."},"authors":{"en":[{"name":"Kinouchi Tomoya"},{"name":"Kitazato T. Keiko"},{"name":"Shimada Kenji"},{"name":"Yagi Kenji"},{"name":"Tada Yoshiteru"},{"name":"Matsushita Nobuhisa"},{"name":"Kurashiki Yoshitaka"},{"name":"Satomi Junichiro"},{"name":"Sata Masataka"},{"name":"Nagahiro Shinji"}],"ja":[{"name":"Kinouchi Tomoya"},{"name":"Kitazato T. Keiko"},{"name":"Shimada Kenji"},{"name":"Yagi Kenji"},{"name":"多田 恵曜"},{"name":"Matsushita Nobuhisa"},{"name":"Kurashiki Yoshitaka"},{"name":"Satomi Junichiro"},{"name":"佐田 政隆"},{"name":"Nagahiro Shinji"}]},"description":{"en":"In the original publication of the article, the second author (Keiko T. Kitazato) was missing.","ja":"In the original publication of the article, the second author (Keiko T. Kitazato) was missing."},"publication_date":"2017-11-26","publication_name":{"en":"Translational Stroke Research","ja":"Translational Stroke Research"},"volume":"Vol.9","number":"No.3","starting_page":"317","ending_page":"317","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12975-017-0589-4"],"issn":["1868-4483"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29195110","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85035801160&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339420","label":"url"}],"paper_title":{"en":"Brachial artery diameter as a marker for cardiovascular risk assessment: FMD-J study.","ja":"Brachial artery diameter as a marker for cardiovascular risk assessment: FMD-J study."},"authors":{"en":[{"name":"Maruhashi Tatsuya"},{"name":"Soga Junko"},{"name":"Fujimura Noritaka"},{"name":"Idei Naomi"},{"name":"Mikami Shinsuke"},{"name":"Iwamoto Yumiko"},{"name":"Iwamoto Akimichi"},{"name":"Kajikawa Masato"},{"name":"Matsumoto Takeshi"},{"name":"Oda Nozomu"},{"name":"Kishimoto Shinji"},{"name":"Matsui Shogo"},{"name":"Hashimoto Haruki"},{"name":"Aibara Yoshiki"},{"name":"Yusoff Mohamad Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Noma Kensuke"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}],"ja":[{"name":"Maruhashi Tatsuya"},{"name":"Soga Junko"},{"name":"Fujimura Noritaka"},{"name":"Idei Naomi"},{"name":"Mikami Shinsuke"},{"name":"Iwamoto Yumiko"},{"name":"Iwamoto Akimichi"},{"name":"Kajikawa Masato"},{"name":"Matsumoto Takeshi"},{"name":"Oda Nozomu"},{"name":"Kishimoto Shinji"},{"name":"Matsui Shogo"},{"name":"Hashimoto Haruki"},{"name":"Aibara Yoshiki"},{"name":"Yusoff Mohamad Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Noma Kensuke"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}]},"description":{"en":"Baseline brachial artery (BBA) diameter has been reported to be a potential confounding factor of flow-mediated vasodilation (FMD). The purpose of this study was to evaluate the relationships between BBA diameter and cardiovascular risk factors and compare the diagnostic accuracy of BBA diameter in subjects without cardiovascular risk factors and patients with cardiovascular disease (CVD) with that of FMD. We measured BBA diameter and FMD in 5695 male subjects. In addition, we retrospectively investigated the incidence of cardiovascular events using another population sample consisting of 440 male subjects, to compare the accuracy of BBA diameter with that of FMD in predicting cardiovascular events. BBA diameter and FMD significantly correlated with age, body mass index, systolic blood pressure, diastolic blood pressure, triglycerides, high-density lipoprotein cholesterol, and glucose as well as Framingham risk score. The prevalence of cardiovascular risk factors and CVD increased with the increase in BBA diameter and FMD. Area under the curve (AUC) value of the receiver operating characteristic (ROC) curve for BBA diameter to diagnose subjects without cardiovascular risk factors (0.59 vs. 0.62, p = 0.001) or patients with CVD (0.58 vs. 0.64, p < 0.001) was significantly lower than that for FMD. In the retrospective study, the AUC value of the ROC curve for BBA diameter to predict first major cardiovascular events was significantly lower than that of FMD (0.50 vs. 0.62, p = 0.03). In men, BBA diameter was inferior to FMD for assessment of cardiovascular risk.","ja":"Baseline brachial artery (BBA) diameter has been reported to be a potential confounding factor of flow-mediated vasodilation (FMD). The purpose of this study was to evaluate the relationships between BBA diameter and cardiovascular risk factors and compare the diagnostic accuracy of BBA diameter in subjects without cardiovascular risk factors and patients with cardiovascular disease (CVD) with that of FMD. We measured BBA diameter and FMD in 5695 male subjects. In addition, we retrospectively investigated the incidence of cardiovascular events using another population sample consisting of 440 male subjects, to compare the accuracy of BBA diameter with that of FMD in predicting cardiovascular events. BBA diameter and FMD significantly correlated with age, body mass index, systolic blood pressure, diastolic blood pressure, triglycerides, high-density lipoprotein cholesterol, and glucose as well as Framingham risk score. The prevalence of cardiovascular risk factors and CVD increased with the increase in BBA diameter and FMD. Area under the curve (AUC) value of the receiver operating characteristic (ROC) curve for BBA diameter to diagnose subjects without cardiovascular risk factors (0.59 vs. 0.62, p = 0.001) or patients with CVD (0.58 vs. 0.64, p < 0.001) was significantly lower than that for FMD. In the retrospective study, the AUC value of the ROC curve for BBA diameter to predict first major cardiovascular events was significantly lower than that of FMD (0.50 vs. 0.62, p = 0.03). In men, BBA diameter was inferior to FMD for assessment of cardiovascular risk."},"publication_date":"2017-11-22","publication_name":{"en":"Atherosclerosis","ja":"Atherosclerosis"},"volume":"Vol.268","starting_page":"92","ending_page":"98","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.atherosclerosis.2017.11.022"],"issn":["1879-1484"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115816","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29110250","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85033492212&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336476","label":"url"}],"paper_title":{"en":"Treatment with the PPAR Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats.","ja":"Treatment with the PPAR Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats."},"authors":{"en":[{"name":"Kinouchi Tomoya"},{"name":"Kitazato T. Keiko"},{"name":"Shimada Kenji"},{"name":"Yagi Kenji"},{"name":"Tada Yoshiteru"},{"name":"Matsushita Nobuhisa"},{"name":"Kurashiki Yoshitaka"},{"name":"Satomi Junichiro"},{"name":"Sata Masataka"},{"name":"Nagahiro Shinji"}],"ja":[{"name":"Kinouchi Tomoya"},{"name":"Kitazato T. Keiko"},{"name":"Shimada Kenji"},{"name":"Yagi Kenji"},{"name":"Tada Yoshiteru"},{"name":"Matsushita Nobuhisa"},{"name":"倉敷 佳孝"},{"name":"Satomi Junichiro"},{"name":"佐田 政隆"},{"name":"永廣 信治"}]},"description":{"en":"Neurogenesis is essential for a good post-stroke outcome. Exogenous stem cells are currently being tested to promote neurogenesis after stroke. Elsewhere, we demonstrated that treatment with the PPARγ agonist pioglitazone (PGZ) before cerebral ischemia induction reduced brain damage and activated survival-related genes in ovariectomized (OVX) rats. Here, we tested our hypothesis that post-ischemia treatment with PGZ inhibits brain damage and contributes to neurogenesis via activated stem cells. Bone marrow (BM) cells of 7-week-old Wistar female rats were replaced with BM cells from green fluorescent protein-transgenic (GFP) rats. Three weeks later, they were ovariectomized (OVX/GFP rats). We subjected 7-week-old Wistar male and 13-week-old OVX/GFP rats to 90-min cerebral ischemia. Male and OVX/GFP rats were divided into two groups, one was treated with PGZ (2.5 mg/kg/day) and the other served as the vehicle control (VC). In both male and OVX/GFP rats, post-ischemia treatment with PGZ reduced neurological deficits and the infarct volume. In male rats, PGZ decreased the mRNA level of IL-6 and M1-like macrophages after 24 h. In OVX/GFP rats, PGZ augmented the proliferation of resident stem cells in the subventricular zone (SVZ) and the recruitment of GFP stem cells on days 7-14. Both types of proliferated stem cells migrated from the SVZ into the peri-infarct area. There, they differentiated into mature neurons, glia, and blood vessels in association with activated Akt, MAP2, and VEGF. Post-ischemia treatment with PGZ may offer a new avenue for stroke treatment through contribution to neuroprotection and neurogenesis.","ja":"Neurogenesis is essential for a good post-stroke outcome. Exogenous stem cells are currently being tested to promote neurogenesis after stroke. Elsewhere, we demonstrated that treatment with the PPARγ agonist pioglitazone (PGZ) before cerebral ischemia induction reduced brain damage and activated survival-related genes in ovariectomized (OVX) rats. Here, we tested our hypothesis that post-ischemia treatment with PGZ inhibits brain damage and contributes to neurogenesis via activated stem cells. Bone marrow (BM) cells of 7-week-old Wistar female rats were replaced with BM cells from green fluorescent protein-transgenic (GFP) rats. Three weeks later, they were ovariectomized (OVX/GFP rats). We subjected 7-week-old Wistar male and 13-week-old OVX/GFP rats to 90-min cerebral ischemia. Male and OVX/GFP rats were divided into two groups, one was treated with PGZ (2.5 mg/kg/day) and the other served as the vehicle control (VC). In both male and OVX/GFP rats, post-ischemia treatment with PGZ reduced neurological deficits and the infarct volume. In male rats, PGZ decreased the mRNA level of IL-6 and M1-like macrophages after 24 h. In OVX/GFP rats, PGZ augmented the proliferation of resident stem cells in the subventricular zone (SVZ) and the recruitment of GFP stem cells on days 7-14. Both types of proliferated stem cells migrated from the SVZ into the peri-infarct area. There, they differentiated into mature neurons, glia, and blood vessels in association with activated Akt, MAP2, and VEGF. Post-ischemia treatment with PGZ may offer a new avenue for stroke treatment through contribution to neuroprotection and neurogenesis."},"publication_date":"2017-11-06","publication_name":{"en":"Translational Stroke Research","ja":"Translational Stroke Research"},"volume":"Vol.9","number":"No.3","starting_page":"306","ending_page":"316","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12975-017-0577-8"],"issn":["1868-601X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29100817","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85032912457&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336477","label":"url"}],"paper_title":{"en":"Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels","ja":"Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels"},"authors":{"en":[{"name":"Yamazaki Hiromu"},{"name":"Yagi Shusuke"},{"name":"Torii Yuta"},{"name":"Amano Rie"},{"name":"Oomichi Yasuyuki"},{"name":"Sangawa Teruaki"},{"name":"Fukuda Daiju"},{"name":"Kadota Muneyuki"},{"name":"Ise Takayuki"},{"name":"Ueno Rie"},{"name":"Hara Tomoya"},{"name":"Kusunose Kenya"},{"name":"Matsuura Tomomi"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"山﨑 宙"},{"name":"八木 秀介"},{"name":"Torii Yuta"},{"name":"Amano Rie"},{"name":"Oomichi Yasuyuki"},{"name":"Sangawa Teruaki"},{"name":"福田 大受"},{"name":"門田 宗之"},{"name":"伊勢 孝之"},{"name":"Ueno Rie"},{"name":"原 知也"},{"name":"楠瀬 賢也"},{"name":"松浦 朋美"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"It is well known that warfarin inhibits the synthesis of vitamin K-dependent anticoagulants, including thrombin, protein C and S, and factor Xa, leading, paradoxically, to an initial hypercoagulable state. Edoxaban, a direct inhibitor of activated factor X is widely used for the treatment of acute venous thromboembolism (VTE). However, the effect of edoxaban on circulating coagulation factors, in patients with acute VTE, remains unknown. We enrolled 57 patients with acute VTE with/without pulmonary embolism treated with edoxaban (n=37) or warfarin (n=20) in a clinical setting. Before treatment and 2 weeks after treatment, we evaluated thrombotic burden using ultrasound or computed tomography angiography. We also evaluated thrombin generation, represented by prothrombin fragment F1+2; thrombus degradation, represented by D-dimer; and levels of anticoagulants, including protein C, protein S, and antithrombin III. Both edoxaban and warfarin treatment improved thrombotic burden and decreased prothrombin fragment F1+2, and D-dimer. Edoxaban treatment preserved protein C and protein S levels. In contrast, warfarin decreased protein C and protein S levels. Neither treatment affected antithrombin III. Edoxaban improves VTE while preserving protein C and protein S levels, thereby indicating that edoxaban improves thrombotic burden while maintaining levels of anticoagulants.","ja":"It is well known that warfarin inhibits the synthesis of vitamin K-dependent anticoagulants, including thrombin, protein C and S, and factor Xa, leading, paradoxically, to an initial hypercoagulable state. Edoxaban, a direct inhibitor of activated factor X is widely used for the treatment of acute venous thromboembolism (VTE). However, the effect of edoxaban on circulating coagulation factors, in patients with acute VTE, remains unknown. We enrolled 57 patients with acute VTE with/without pulmonary embolism treated with edoxaban (n=37) or warfarin (n=20) in a clinical setting. Before treatment and 2 weeks after treatment, we evaluated thrombotic burden using ultrasound or computed tomography angiography. We also evaluated thrombin generation, represented by prothrombin fragment F1+2; thrombus degradation, represented by D-dimer; and levels of anticoagulants, including protein C, protein S, and antithrombin III. Both edoxaban and warfarin treatment improved thrombotic burden and decreased prothrombin fragment F1+2, and D-dimer. Edoxaban treatment preserved protein C and protein S levels. In contrast, warfarin decreased protein C and protein S levels. Neither treatment affected antithrombin III. Edoxaban improves VTE while preserving protein C and protein S levels, thereby indicating that edoxaban improves thrombotic burden while maintaining levels of anticoagulants."},"publication_date":"2017-11-01","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.71","number":"No.3","starting_page":"305","ending_page":"309","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2017.09.009"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29185199","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85035102977&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339415","label":"url"}],"paper_title":{"en":"Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.","ja":"Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Aihara Ken-ichi"},{"name":"Kondo Takeshi"},{"name":"Kurahashi Kiyoe"},{"name":"Yoshida Sumiko"},{"name":"Endo Itsuro"},{"name":"Fukuda Daiju"},{"name":"Nakaya Yutaka"},{"name":"Suwaki Kin-Ichiro"},{"name":"Takeji Takashi"},{"name":"Wada Toshihiro"},{"name":"Salim Hotimah Masdan"},{"name":"Hama Saori"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Matsuhisa Munehide"},{"name":"Shimabukuro Michio"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"粟飯原 賢一"},{"name":"近藤 剛史"},{"name":"倉橋 清衛"},{"name":"吉田 守美子"},{"name":"遠藤 逸朗"},{"name":"福田 大受"},{"name":"中屋 豊"},{"name":"Suwaki Kin-Ichiro"},{"name":"Takeji Takashi"},{"name":"Wada Toshihiro"},{"name":"Salim Hotimah Masdan"},{"name":"Hama Saori"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"松久 宗英"},{"name":"島袋 充生"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment.","ja":"Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment."},"publication_date":"2017-11","publication_name":{"en":"Advances in Therapy","ja":"Advances in Therapy"},"volume":"Vol.35","number":"No.1","starting_page":"124","ending_page":"134","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12325-017-0639-z"],"issn":["1865-8652"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28966307","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390282680202467328/","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85032215381&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336481","label":"url"}],"paper_title":{"en":"Low Serum Levels of Eicosapentaenoic Acid and Docosahexaenoic Acid are Risk Factors for Cardiogenic Syncope in Patients with Brugada Syndrome","ja":"Low Serum Levels of Eicosapentaenoic Acid and Docosahexaenoic Acid are Risk Factors for Cardiogenic Syncope in Patients with Brugada Syndrome"},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-Ichi"},{"name":"Fukuda Daiju"},{"name":"Ise Takayuki"},{"name":"Kadota Muneyuki"},{"name":"Bando Sachiko"},{"name":"Matsuura Tomomi"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"添木 武"},{"name":"Aihara Ken-Ichi"},{"name":"福田 大受"},{"name":"伊勢 孝之"},{"name":"Kadota Muneyuki"},{"name":"Bando Sachiko"},{"name":"松浦 朋美"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"The n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have antiarrhythmic effects, possibly via modulation of the cardiac ion channels. Nevertheless, it is unknown whether low serum levels of n-3 PUFAs are risk factors for ventricular fibrillation in patients with Brugada syndrome (BrS). We retrospectively reviewed data from 62 men with BrS and evaluated their serum levels of EPA and DHA, and the risk factors for sudden cardiac death, including a history of cardiogenic syncope. Nineteen patients had a history of cardiogenic syncope, and their EPA and DHA levels were significantly lower than those of the patients without syncope. Multivariate logistic regression analysis revealed that low EPA and DHA levels were associated with the incidence of syncope. The receiver-operator characteristic curve showed the area under the curves of EPA and DHA for history of syncope were 0.84 and 0.72, respectively. In conclusion, low levels of EPA and DHA are risk factors for cardiogenic syncope in patients with BrS, which suggests that n-3 PUFAs play important roles in preventing ventricular fibrillation in BrS.","ja":"The n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have antiarrhythmic effects, possibly via modulation of the cardiac ion channels. Nevertheless, it is unknown whether low serum levels of n-3 PUFAs are risk factors for ventricular fibrillation in patients with Brugada syndrome (BrS). We retrospectively reviewed data from 62 men with BrS and evaluated their serum levels of EPA and DHA, and the risk factors for sudden cardiac death, including a history of cardiogenic syncope. Nineteen patients had a history of cardiogenic syncope, and their EPA and DHA levels were significantly lower than those of the patients without syncope. Multivariate logistic regression analysis revealed that low EPA and DHA levels were associated with the incidence of syncope. The receiver-operator characteristic curve showed the area under the curves of EPA and DHA for history of syncope were 0.84 and 0.72, respectively. In conclusion, low levels of EPA and DHA are risk factors for cardiogenic syncope in patients with BrS, which suggests that n-3 PUFAs play important roles in preventing ventricular fibrillation in BrS."},"publication_date":"2017-10-21","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.58","number":"No.5","starting_page":"720","ending_page":"723","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.16-278"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/110111","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28966316","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85032221042&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336480","label":"url"}],"paper_title":{"en":"Improved Exercise Capacity After Cardiac Rehabilitation Is Associated with Reduced Visceral Fat in Patients with Chronic Heart Failure.","ja":"Improved Exercise Capacity After Cardiac Rehabilitation Is Associated with Reduced Visceral Fat in Patients with Chronic Heart Failure."},"authors":{"en":[{"name":"Takagawa Yuriko"},{"name":"Yagi Shusuke"},{"name":"Ise Takayuki"},{"name":"Ishii Ayumi"},{"name":"Nishikawa Koji"},{"name":"Fukuda Daiju"},{"name":"Kusunose Kenya"},{"name":"Matsuura Tomomi"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Katoh Shinsuke"},{"name":"Aihara Ken-ichi"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"高川 由利子"},{"name":"八木 秀介"},{"name":"伊勢 孝之"},{"name":"Ishii Ayumi"},{"name":"Nishikawa Koji"},{"name":"福田 大受"},{"name":"楠瀬 賢也"},{"name":"松浦 朋美"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"Katoh Shinsuke"},{"name":"Aihara Ken-ichi"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"Participation in a comprehensive cardiac rehabilitation (CR) program has been shown to reduce mortality and improve exercise capacity and symptoms in patients with chronic heart failure (CHF). Reduced exercise capacity leads to a concomitant reduction of skeletal muscle mass and accumulation of body fat. However, it is currently unknown whether CR reduces visceral adipose tissue (VAT) and/or subcutaneous abdominal adipose tissue (SAT) in patients with CHF. In addition, the body composition associated with improved exercise capacity after CR in patients with CHF has not been previously studied. Nineteen CHF patients who were categorized as NYHA functional class II or III and had received optimal medical treatment including a CR program for 5 months were enrolled in this study. The CR program significantly increased peak VO and reduced B-type natriuretic peptide. In addition, fat and body composition analysis showed reductions in the visceral fat tissue (VAT) area, subcutaneous abdominal adipose tissue (SAT) area, body weight, and total fat weight after CR. There were no changes in total water weight and total muscle weight. Single regression analysis revealed that the amelioration of reduced exercise capacity seen after CR is associated with reduced VAT area but not with SAT area or body weight. In conclusion, CR reduces VAT and improves exercise capacity in patients with CHF. This suggests that reducing VAT is important for CR to be most effective in the treatment of CHF.","ja":"Participation in a comprehensive cardiac rehabilitation (CR) program has been shown to reduce mortality and improve exercise capacity and symptoms in patients with chronic heart failure (CHF). Reduced exercise capacity leads to a concomitant reduction of skeletal muscle mass and accumulation of body fat. However, it is currently unknown whether CR reduces visceral adipose tissue (VAT) and/or subcutaneous abdominal adipose tissue (SAT) in patients with CHF. In addition, the body composition associated with improved exercise capacity after CR in patients with CHF has not been previously studied. Nineteen CHF patients who were categorized as NYHA functional class II or III and had received optimal medical treatment including a CR program for 5 months were enrolled in this study. The CR program significantly increased peak VO and reduced B-type natriuretic peptide. In addition, fat and body composition analysis showed reductions in the visceral fat tissue (VAT) area, subcutaneous abdominal adipose tissue (SAT) area, body weight, and total fat weight after CR. There were no changes in total water weight and total muscle weight. Single regression analysis revealed that the amelioration of reduced exercise capacity seen after CR is associated with reduced VAT area but not with SAT area or body weight. In conclusion, CR reduces VAT and improves exercise capacity in patients with CHF. This suggests that reducing VAT is important for CR to be most effective in the treatment of CHF."},"publication_date":"2017-10-21","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.58","number":"No.5","starting_page":"746","ending_page":"751","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.16-454"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114544","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29034006","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85030465923&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336478","label":"url"}],"paper_title":{"en":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus.","ja":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Hirata Yukina"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Fukuda Daiju"},{"name":"Hotimah Masdan Salim"},{"name":"Maimaituxun G,"},{"name":"Nishio Susumu"},{"name":"Takagawa Yuriko"},{"name":"Hama Saori"},{"name":"Matsuura Tomomi"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Aihara Ken-ichi"},{"name":"Akaike Masashi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"平田 有紀奈"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"福田 大受"},{"name":"Hotimah Masdan Salim"},{"name":"Gulinu Maimaituxun"},{"name":"西尾 進"},{"name":"高川 由利子"},{"name":"Hama Saori"},{"name":"松浦 朋美"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"Aihara Ken-ichi"},{"name":"赤池 雅史"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).","ja":"It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327)."},"publication_date":"2017-10-04","publication_name":{"en":"Diabetology & Metabolic Syndrome","ja":"Diabetology & Metabolic Syndrome"},"volume":"Vol.9","starting_page":"78","ending_page":"78","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s13098-017-0275-4"],"issn":["1758-5996"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115484","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28835582","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85030703516&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336482","label":"url"}],"paper_title":{"en":"n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease.","ja":"n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Aihara KI,"},{"name":"Akaike Masashi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"Aihara KI,"},{"name":"赤池 雅史"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"The adoption of the Western-style diet, with decreased fish intake and lack of exercise, has increased the prevalence of cardiovascular disease (CVD) in Japan. Statin treatment has been established to reduce the risk of cardiovascular events; however, 60%-70% of these events occur despite its use. Thus, the residual risk for CVD should be identified and resolved to reduce further cardiovascular events. The serum levels of n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid and docosahexaenoic acid, are reportedly associated with an increased incidence of cardiovascular events and mortality, whereas the addition of n-3 PUFA treatment to the statin treatment decreases cardiovascular events. Similar to statins, n-3 PUFAs have pleiotropic effects in addition to lipid-modifying effects. Pre-clinical and clinical studies have shown that n-3 PUFAs prevent cardiovascular events by ameliorating endothelial function and attenuating lipid accumulation, vascular inflammation, and macrophage recruitment, thereby causing coronary plaque development and rupture. Taken together, n-3 PUFAs are comprehensively able to attenuate the atherogenic response. Therefore, n-3 PUFA intake is recommended to prevent cardiovascular events, particularly in patients with multiple cardiovascular risk factors.","ja":"The adoption of the Western-style diet, with decreased fish intake and lack of exercise, has increased the prevalence of cardiovascular disease (CVD) in Japan. Statin treatment has been established to reduce the risk of cardiovascular events; however, 60%-70% of these events occur despite its use. Thus, the residual risk for CVD should be identified and resolved to reduce further cardiovascular events. The serum levels of n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid and docosahexaenoic acid, are reportedly associated with an increased incidence of cardiovascular events and mortality, whereas the addition of n-3 PUFA treatment to the statin treatment decreases cardiovascular events. Similar to statins, n-3 PUFAs have pleiotropic effects in addition to lipid-modifying effects. Pre-clinical and clinical studies have shown that n-3 PUFAs prevent cardiovascular events by ameliorating endothelial function and attenuating lipid accumulation, vascular inflammation, and macrophage recruitment, thereby causing coronary plaque development and rupture. Taken together, n-3 PUFAs are comprehensively able to attenuate the atherogenic response. Therefore, n-3 PUFA intake is recommended to prevent cardiovascular events, particularly in patients with multiple cardiovascular risk factors."},"publication_date":"2017-10-01","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.24","number":"No.10","starting_page":"999","ending_page":"1010","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.RV17013"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29021259","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85031850278&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336479","label":"url"}],"paper_title":{"en":"Preload Stress Echocardiography Predicts Outcomes in Patients With Preserved Ejection FractionandLow-GradientAorticStenosis","ja":"Preload Stress Echocardiography Predicts Outcomes in Patients With Preserved Ejection FractionandLow-GradientAorticStenosis"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Seno Hiromitsu"},{"name":"Saijo Yoshihito"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"鳥居 裕太"},{"name":"平田 有紀奈"},{"name":"瀬野 弘光"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"The projected aortic valve area (AVA) at a normal transvalvular flow rate using dobutamine is helpful to determine the actual severity of aortic stenosis (AS) and to predict risk of adverse events in low-gradient AS cases with unclear surgical indication. Our study aimed to identify the independent and incremental value of preload stress echocardiography-derived AVA to predict outcomes in patients with preserved ejection fraction and low-gradient AS. We prospectively performed echocardiographic studies in 79 patients with low-gradient AS (age, 77±7 years; 30% men) with preload stress echocardiography using leg positive pressure. AVA was calculated using AVA and transvalvular flow rate at baseline and during leg positive pressure. The primary end point was the decision for aortic valve surgery or cardiac death. During a median period of 19 months, 23 patients had the decision for aortic valve surgery, and none died during follow-up. In a stepwise multivariable analysis, indexed AVA (AVAi; hazard ratio, 2.00 per 0.1 cm/m decrease; 95% confidence interval, 1.36-2.96; <0.001) was associated with the primary end point. Using a receiver operating characteristic curve analysis, the best cutoff value of AVAi for predicting cardiac events was <0.72 cm/m. By incorporating AVAi into AVAi at baseline, continuous net reclassification index for cardiac events was 0.48 (=0.04). In patients with low-gradient AS, indexed AVA derived from preload stress echocardiography can be useful to predict risk of adverse events. The present article should be considered as a proof of concept study, and we think that larger multicenter studies are warranted.","ja":"The projected aortic valve area (AVA) at a normal transvalvular flow rate using dobutamine is helpful to determine the actual severity of aortic stenosis (AS) and to predict risk of adverse events in low-gradient AS cases with unclear surgical indication. Our study aimed to identify the independent and incremental value of preload stress echocardiography-derived AVA to predict outcomes in patients with preserved ejection fraction and low-gradient AS. We prospectively performed echocardiographic studies in 79 patients with low-gradient AS (age, 77±7 years; 30% men) with preload stress echocardiography using leg positive pressure. AVA was calculated using AVA and transvalvular flow rate at baseline and during leg positive pressure. The primary end point was the decision for aortic valve surgery or cardiac death. During a median period of 19 months, 23 patients had the decision for aortic valve surgery, and none died during follow-up. In a stepwise multivariable analysis, indexed AVA (AVAi; hazard ratio, 2.00 per 0.1 cm/m decrease; 95% confidence interval, 1.36-2.96; <0.001) was associated with the primary end point. Using a receiver operating characteristic curve analysis, the best cutoff value of AVAi for predicting cardiac events was <0.72 cm/m. By incorporating AVAi into AVAi at baseline, continuous net reclassification index for cardiac events was 0.48 (=0.04). In patients with low-gradient AS, indexed AVA derived from preload stress echocardiography can be useful to predict risk of adverse events. The present article should be considered as a proof of concept study, and we think that larger multicenter studies are warranted."},"publication_date":"2017-10","publication_name":{"en":"Circulation. Cardiovascular Imaging","ja":"Circulation. Cardiovascular Imaging"},"volume":"Vol.10","number":"No.10","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/CIRCIMAGING.117.006690"],"issn":["1942-0080"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/110928","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28843368","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=333251","label":"url"}],"paper_title":{"en":"Echocardiographic Epicardial Adipose Tissue Thickness Is Associated with Symptomatic Coronary Vasospasm during Provocative Testing.","ja":"Echocardiographic Epicardial Adipose Tissue Thickness Is Associated with Symptomatic Coronary Vasospasm during Provocative Testing."},"authors":{"en":[{"name":"Nishio Susumu"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Hirata Yukina"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"西尾 進"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"平田 有紀奈"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Epicardial adipose tissue (EAT) is the ectopic visceral fat surrounding the heart, which plays an important role in atherosclerosis of the coronary arteries via endothelial damage. Several studies have also suggested that vasospasm with angina (VSA) causes endothelial dysfunction in the coronary arteries. The aim of this study was to evaluate the thickness of EAT in the anterior interventricular groove (EAT-AIG) using echocardiography in patients who had no obstructive coronary artery disease and were suspected of having VSA. Sixty-five patients who underwent intracoronary acetylcholine provocation testing for clinical indications were prospectively enrolled. VSA was diagnosed by coronary artery stenosis increase of >90% and the presentation of chest pain with ischemic changes on electrocardiography. Subjects were divided into two groups, with and without significant coronary spasm (VSA group, 30 patients; non-VSA group, 35 patients), consistent with acetylcholine provocation testing. EAT-AIG thickness was significantly greater in the VSA group than in the non-VSA group (8.2 2.7 vs 6.1 2.5 mm, P = .002). By receiver operating characteristic analysis, EAT-AIG thickness had a high C statistic (area under the curve = 0.81, P < .001) after adjustment for conventional risk factors (smoking, diabetes mellitus, and dyslipidemia). EAT-AIG thickness had incremental diagnostic value over other conventional risk factors (area under the curve = 0.81 vs 0.64, P for comparison = .020). EAT-AIG thickness, which is noninvasively and easily measured using transthoracic echocardiography, can be one of multiple clinical variables associated with VSA.","ja":"Epicardial adipose tissue (EAT) is the ectopic visceral fat surrounding the heart, which plays an important role in atherosclerosis of the coronary arteries via endothelial damage. Several studies have also suggested that vasospasm with angina (VSA) causes endothelial dysfunction in the coronary arteries. The aim of this study was to evaluate the thickness of EAT in the anterior interventricular groove (EAT-AIG) using echocardiography in patients who had no obstructive coronary artery disease and were suspected of having VSA. Sixty-five patients who underwent intracoronary acetylcholine provocation testing for clinical indications were prospectively enrolled. VSA was diagnosed by coronary artery stenosis increase of >90% and the presentation of chest pain with ischemic changes on electrocardiography. Subjects were divided into two groups, with and without significant coronary spasm (VSA group, 30 patients; non-VSA group, 35 patients), consistent with acetylcholine provocation testing. EAT-AIG thickness was significantly greater in the VSA group than in the non-VSA group (8.2 2.7 vs 6.1 2.5 mm, P = .002). By receiver operating characteristic analysis, EAT-AIG thickness had a high C statistic (area under the curve = 0.81, P < .001) after adjustment for conventional risk factors (smoking, diabetes mellitus, and dyslipidemia). EAT-AIG thickness had incremental diagnostic value over other conventional risk factors (area under the curve = 0.81 vs 0.64, P for comparison = .020). EAT-AIG thickness, which is noninvasively and easily measured using transthoracic echocardiography, can be one of multiple clinical variables associated with VSA."},"publication_date":"2017-08-23","publication_name":{"en":"Journal of the American Society of Echocardiography","ja":"Journal of the American Society of Echocardiography"},"volume":"Vol.30","number":"No.10","starting_page":"1021","ending_page":"1027","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.echo.2017.06.024"],"issn":["1097-6795"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28808069","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85030614940&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341593","label":"url"}],"paper_title":{"en":"Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level: FMD-J Study (Flow-Mediated Dilation Japan)","ja":"Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level: FMD-J Study (Flow-Mediated Dilation Japan)"},"authors":{"en":[{"name":"Maruhashi Tatsuya"},{"name":"Soga Junko"},{"name":"Fujimura Noritaka"},{"name":"Idei Naomi"},{"name":"Mikami Shinsuke"},{"name":"Iwamoto Yumiko"},{"name":"Iwamoto Akimichi"},{"name":"Kajikawa Masato"},{"name":"Matsumoto Takeshi"},{"name":"Oda Nozomu"},{"name":"Kishimoto Shinji"},{"name":"Matsui Shogo"},{"name":"Hashimoto Haruki"},{"name":"Aibara Yoshiki"},{"name":"Yusoff Binti Mohamad Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Noma Kensuke"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}],"ja":[{"name":"Maruhashi Tatsuya"},{"name":"Soga Junko"},{"name":"Fujimura Noritaka"},{"name":"Idei Naomi"},{"name":"Mikami Shinsuke"},{"name":"Iwamoto Yumiko"},{"name":"Iwamoto Akimichi"},{"name":"Kajikawa Masato"},{"name":"Matsumoto Takeshi"},{"name":"Oda Nozomu"},{"name":"Kishimoto Shinji"},{"name":"Matsui Shogo"},{"name":"Hashimoto Haruki"},{"name":"Aibara Yoshiki"},{"name":"Yusoff Binti Mohamad Farina"},{"name":"Hidaka Takayuki"},{"name":"Kihara Yasuki"},{"name":"Chayama Kazuaki"},{"name":"Noma Kensuke"},{"name":"Nakashima Ayumu"},{"name":"Goto Chikara"},{"name":"Tomiyama Hirofumi"},{"name":"Takase Bonpei"},{"name":"Kohro Takahide"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"},{"name":"Higashi Yukihito"}]},"description":{"en":"Hypertension is associated with endothelial dysfunction. Blood pressure significantly correlates with endothelial function in antihypertensive drug-naive subjects. The purpose of this study was to determine whether treatment status affects the relationship between blood pressure and endothelial function. We measured flow-mediated vasodilation (FMD) in 2297 subjects, including 1822 antihypertensive drug-naive subjects and 475 treated hypertensive patients. FMD significantly decreased in relation to increase in systolic blood pressure (8.2±3.1% in subjects with systolic blood pressure of <120 mm Hg, 7.5±2.8% for 120-129 mm Hg, 7.1±2.8% for 130-139 mm Hg, and 6.7±2.6% for ≥140 mm Hg; <0.001). Systolic blood pressure was independently associated with FMD in untreated subjects. In contrast, there was no significant relationship between systolic blood pressure and FMD in treated hypertensive patients (4.6±3.1% in treated hypertensives with systolic blood pressure of <120 mm Hg, 4.8±2.7% for 120-129 mm Hg, 4.9±2.8% for 130-139 mm Hg, and 4.5±2.3% for ≥140 mm Hg; =0.77). Propensity score matching analysis revealed that the prevalence of endothelial dysfunction defined as FMD of less than the division point for the lowest tertile, and the middle tertile of FMD was significantly higher in treated hypertensive patients than in untreated subjects in all systolic blood pressure categories. Endothelial function assessed by FMD was impaired regardless of the level of blood pressure achieved by antihypertensive drug treatment in hypertensive patients.","ja":"Hypertension is associated with endothelial dysfunction. Blood pressure significantly correlates with endothelial function in antihypertensive drug-naive subjects. The purpose of this study was to determine whether treatment status affects the relationship between blood pressure and endothelial function. We measured flow-mediated vasodilation (FMD) in 2297 subjects, including 1822 antihypertensive drug-naive subjects and 475 treated hypertensive patients. FMD significantly decreased in relation to increase in systolic blood pressure (8.2±3.1% in subjects with systolic blood pressure of <120 mm Hg, 7.5±2.8% for 120-129 mm Hg, 7.1±2.8% for 130-139 mm Hg, and 6.7±2.6% for ≥140 mm Hg; <0.001). Systolic blood pressure was independently associated with FMD in untreated subjects. In contrast, there was no significant relationship between systolic blood pressure and FMD in treated hypertensive patients (4.6±3.1% in treated hypertensives with systolic blood pressure of <120 mm Hg, 4.8±2.7% for 120-129 mm Hg, 4.9±2.8% for 130-139 mm Hg, and 4.5±2.3% for ≥140 mm Hg; =0.77). Propensity score matching analysis revealed that the prevalence of endothelial dysfunction defined as FMD of less than the division point for the lowest tertile, and the middle tertile of FMD was significantly higher in treated hypertensive patients than in untreated subjects in all systolic blood pressure categories. Endothelial function assessed by FMD was impaired regardless of the level of blood pressure achieved by antihypertensive drug treatment in hypertensive patients."},"publication_date":"2017-08-14","publication_name":{"en":"Hypertension","ja":"Hypertension"},"volume":"Vol.70","number":"No.4","starting_page":"790","ending_page":"797","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/HYPERTENSIONAHA.117.09612"],"issn":["1524-4563"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28808846","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=333255","label":"url"}],"paper_title":{"en":"Age-related changes in morphology of left atrial appendage in patients with atrial fibrillation.","ja":"Age-related changes in morphology of left atrial appendage in patients with atrial fibrillation."},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Shimizu Rikuto"},{"name":"Torii Yuta"},{"name":"Nishio Susumu"},{"name":"Saijo Yoshihito"},{"name":"Takao Shoichiro"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"平田 有紀奈"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"Shimizu Rikuto"},{"name":"鳥居 裕太"},{"name":"西尾 進"},{"name":"西條 良仁"},{"name":"髙尾 正一郎"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"The purpose of this study was to evaluate the relationship between age and frequency of left atrial appendage (LAA) morphology in patients with atrial fibrillation (AF) compared with sinus rhythm (SR). We enrolled 145 AF patients, and 199 SR patients for the control group without any cardiovascular disease. LAA volume index (LAAVi) and morphology were assessed by electrocardiogram-gated computed tomography angiography. LAA morphology was classified into \"chicken wing\" or \"non-chicken wing\" according to the previously described classification. There was no significant trend in frequency of non-chicken wing morphology among ages in the SR group (p = 0.36 for trend), whereas the frequency was negatively related to age in the AF group (p = 0.002 for trend). In multivariable logistic regression, age > 65 (odds ratio [OR] 0.42, p = 0.002) and duration of AF (OR 0.53, p = 0.010) and LAAVi (OR 0.62, p = 0.017) were independent factors of non-chicken wing LAA morphology in the AF group. LAA morphology is affected by age, especially in patients with AF. When we utilize non-chicken wing LAA morphology as a stroke risk factor in patients with AF, we should pay attention to their age.","ja":"The purpose of this study was to evaluate the relationship between age and frequency of left atrial appendage (LAA) morphology in patients with atrial fibrillation (AF) compared with sinus rhythm (SR). We enrolled 145 AF patients, and 199 SR patients for the control group without any cardiovascular disease. LAA volume index (LAAVi) and morphology were assessed by electrocardiogram-gated computed tomography angiography. LAA morphology was classified into \"chicken wing\" or \"non-chicken wing\" according to the previously described classification. There was no significant trend in frequency of non-chicken wing morphology among ages in the SR group (p = 0.36 for trend), whereas the frequency was negatively related to age in the AF group (p = 0.002 for trend). In multivariable logistic regression, age > 65 (odds ratio [OR] 0.42, p = 0.002) and duration of AF (OR 0.53, p = 0.010) and LAAVi (OR 0.62, p = 0.017) were independent factors of non-chicken wing LAA morphology in the AF group. LAA morphology is affected by age, especially in patients with AF. When we utilize non-chicken wing LAA morphology as a stroke risk factor in patients with AF, we should pay attention to their age."},"publication_date":"2017-08-14","publication_name":{"en":"The International Journal of Cardiovascular Imaging","ja":"The International Journal of Cardiovascular Imaging"},"volume":"Vol.34","number":"No.2","starting_page":"321","ending_page":"328","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10554-017-1232-x"],"issn":["1875-8312"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28779371","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85026840711&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=327843","label":"url"}],"paper_title":{"en":"Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?","ja":"Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?"},"authors":{"en":[{"name":"Asakura Masanori"},{"name":"Kim Jiyoong"},{"name":"Asanuma Hiroshi"},{"name":"Hamasaki Toshimitsu"},{"name":"Tsukahara Kengo"},{"name":"Higashino Yorihiko"},{"name":"Ishikawa Tetsuya"},{"name":"Nakama Yasuharu"},{"name":"Koba Shinji"},{"name":"Maruyama Yasuyuki"},{"name":"Tsujimoto Mitsuru"},{"name":"Himeno Hideo"},{"name":"Ohkusa Takanori"},{"name":"Fujino Susumu"},{"name":"Shimizu Makoto"},{"name":"Endo Tsutomu"},{"name":"Yoda Shunichi"},{"name":"Muroya Takahiro"},{"name":"Murohara Toyoaki"},{"name":"Ohte Nobuyuki"},{"name":"Suzuki Hiroshi"},{"name":"Kohno Tohru"},{"name":"Fukui Kazuki"},{"name":"Shiono Takaaki"},{"name":"Takase Hiroyuki"},{"name":"Uzui Hiroyasu"},{"name":"Nagai Yoshiyuki"},{"name":"Hashimoto Yuji"},{"name":"Ikeda Shuntaro"},{"name":"Mizuno Sumio"},{"name":"Tamita Koichi"},{"name":"Fujita Masashi"},{"name":"Satake Kazuo"},{"name":"Kinoshita Yoshihiko"},{"name":"Nunohiro Tatsuya"},{"name":"Sakagami Satoru"},{"name":"Higaki Jitsuo"},{"name":"Morii Isao"},{"name":"Sawada Reimin"},{"name":"Hiasa Yoshikazu"},{"name":"Shigemasa Tomohiko"},{"name":"Nakahama Makoto"},{"name":"Sata Masataka"},{"name":"Doi Osamu"},{"name":"Ueda Tetsuro"},{"name":"Yamada Takahisa"},{"name":"Yamanouchi Takayoshi"},{"name":"Yamaguchi Hajime"},{"name":"Morita Yukiko"},{"name":"Hayashi Hideki"},{"name":"Kitakaze Masafumi"}],"ja":[{"name":"Asakura Masanori"},{"name":"Kim Jiyoong"},{"name":"Asanuma Hiroshi"},{"name":"Hamasaki Toshimitsu"},{"name":"Tsukahara Kengo"},{"name":"Higashino Yorihiko"},{"name":"Ishikawa Tetsuya"},{"name":"Nakama Yasuharu"},{"name":"Koba Shinji"},{"name":"Maruyama Yasuyuki"},{"name":"Tsujimoto Mitsuru"},{"name":"Himeno Hideo"},{"name":"Ohkusa Takanori"},{"name":"Fujino Susumu"},{"name":"Shimizu Makoto"},{"name":"Endo Tsutomu"},{"name":"Yoda Shunichi"},{"name":"Muroya Takahiro"},{"name":"Murohara Toyoaki"},{"name":"Ohte Nobuyuki"},{"name":"Suzuki Hiroshi"},{"name":"Kohno Tohru"},{"name":"Fukui Kazuki"},{"name":"Shiono Takaaki"},{"name":"Takase Hiroyuki"},{"name":"Uzui Hiroyasu"},{"name":"Nagai Yoshiyuki"},{"name":"Hashimoto Yuji"},{"name":"Ikeda Shuntaro"},{"name":"Mizuno Sumio"},{"name":"Tamita Koichi"},{"name":"Fujita Masashi"},{"name":"Satake Kazuo"},{"name":"Kinoshita Yoshihiko"},{"name":"Nunohiro Tatsuya"},{"name":"Sakagami Satoru"},{"name":"Higaki Jitsuo"},{"name":"Morii Isao"},{"name":"Sawada Reimin"},{"name":"Hiasa Yoshikazu"},{"name":"Shigemasa Tomohiko"},{"name":"Nakahama Makoto"},{"name":"佐田 政隆"},{"name":"Doi Osamu"},{"name":"Ueda Tetsuro"},{"name":"Yamada Takahisa"},{"name":"Yamanouchi Takayoshi"},{"name":"Yamaguchi Hajime"},{"name":"Morita Yukiko"},{"name":"Hayashi Hideki"},{"name":"Kitakaze Masafumi"}]},"description":{"en":"We evaluated the effects of an alpha-glucosidase inhibitor, voglibose, on cardiovascular events in patients with a previous myocardial infarction (MI) and impaired glucose tolerance (IGT). This prospective, randomized, open, blinded-endpoint study was conducted in 112 hospitals and clinics in Japan in 3000 subjects with both previous MI and IGT receiving voglibose (0.6 mg/day, n = 424) or no drugs (n = 435) for 2 years. The Data and Safety Monitoring Board (DSMB) recommended discontinuation of the study in June 2012 after an interim analysis when the outcomes of 859 subjects were obtained. The primary endpoint was cardiovascular events including cardiovascular death, nonfatal MI, nonfatal unstable angina, nonfatal stroke, and percutaneous coronary intervention/coronary artery bypass graft. Secondary endpoints included individual components of the primary endpoint in addition to all-cause mortality and hospitalization due to heart failure. The age, ratio of males, and HbA1C were 65 vs. 65 years, 86 vs. 87%, and 5.6 vs. 5.5% in the groups with and without voglibose, respectively. Voglibose improved IGT; however, Kaplan-Meier analysis showed no significant between-group difference with respect to cardiovascular events [12.5% with voglibose vs. 10.1% without voglibose for the primary endpoint (95% confidence interval, 0.82-1.86)]; there were no significant differences in secondary endpoints. Although voglibose effectively treated IGT, no additional benefits for cardiovascular events in patients with previous MI and IGT were observed. Voglibose may not be a contributing therapy to the secondary prevention in patients with MI and IGT. Clinicaltrials.gov number: NCT00212017.","ja":"We evaluated the effects of an alpha-glucosidase inhibitor, voglibose, on cardiovascular events in patients with a previous myocardial infarction (MI) and impaired glucose tolerance (IGT). This prospective, randomized, open, blinded-endpoint study was conducted in 112 hospitals and clinics in Japan in 3000 subjects with both previous MI and IGT receiving voglibose (0.6 mg/day, n = 424) or no drugs (n = 435) for 2 years. The Data and Safety Monitoring Board (DSMB) recommended discontinuation of the study in June 2012 after an interim analysis when the outcomes of 859 subjects were obtained. The primary endpoint was cardiovascular events including cardiovascular death, nonfatal MI, nonfatal unstable angina, nonfatal stroke, and percutaneous coronary intervention/coronary artery bypass graft. Secondary endpoints included individual components of the primary endpoint in addition to all-cause mortality and hospitalization due to heart failure. The age, ratio of males, and HbA1C were 65 vs. 65 years, 86 vs. 87%, and 5.6 vs. 5.5% in the groups with and without voglibose, respectively. Voglibose improved IGT; however, Kaplan-Meier analysis showed no significant between-group difference with respect to cardiovascular events [12.5% with voglibose vs. 10.1% without voglibose for the primary endpoint (95% confidence interval, 0.82-1.86)]; there were no significant differences in secondary endpoints. Although voglibose effectively treated IGT, no additional benefits for cardiovascular events in patients with previous MI and IGT were observed. Voglibose may not be a contributing therapy to the secondary prevention in patients with MI and IGT. Clinicaltrials.gov number: NCT00212017."},"publication_date":"2017-08-04","publication_name":{"en":"Cardiovascular Drugs and Therapy","ja":"Cardiovascular Drugs and Therapy"},"volume":"Vol.31","number":"No.4","starting_page":"401","ending_page":"411","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10557-017-6740-3"],"issn":["1573-7241"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28701678","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85026825932&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=327194","label":"url"}],"paper_title":{"en":"Paget-Schroetter Syndrome in a Baseball Pitcher.","ja":"Paget-Schroetter Syndrome in a Baseball Pitcher."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Mitsugi Minoru"},{"name":"Sanagawa Teruaki"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Mitsugi Minoru"},{"name":"Sanagawa Teruaki"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"Paget-Schroetter syndrome (PSS) is thrombosis of the deep veins draining the upper extremity due to anatomic abnormalities of the thoracic outlet that cause subclavian compression and subsequent thrombosis, leading to thrombus formation in the subclavian vein. Vigorous arm activity in sports is a known risk factor. Here, we report a case of Paget-Schroetter syndrome in a 31-year-old male non-professional baseball pitcher.","ja":"Paget-Schroetter syndrome (PSS) is thrombosis of the deep veins draining the upper extremity due to anatomic abnormalities of the thoracic outlet that cause subclavian compression and subsequent thrombosis, leading to thrombus formation in the subclavian vein. Vigorous arm activity in sports is a known risk factor. Here, we report a case of Paget-Schroetter syndrome in a 31-year-old male non-professional baseball pitcher."},"publication_date":"2017-08-03","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.58","number":"No.4","starting_page":"637","ending_page":"640","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.16-447"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114527","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28623954","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85027879484&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=327197","label":"url"}],"paper_title":{"en":"Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.","ja":"Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale."},"authors":{"en":[{"name":"Teramoto Tamio"},{"name":"Kondo Akira"},{"name":"Kiyosue Arihiro"},{"name":"Harada-Shiba Mariko"},{"name":"Ishigaki Yasushi"},{"name":"Tobita Kimimasa"},{"name":"Kawabata Yumiko"},{"name":"Ozaki Asuka"},{"name":"Baccara-Dinet T. Marie"},{"name":"Sata Masataka"}],"ja":[{"name":"Teramoto Tamio"},{"name":"Kondo Akira"},{"name":"Kiyosue Arihiro"},{"name":"Harada-Shiba Mariko"},{"name":"Ishigaki Yasushi"},{"name":"Tobita Kimimasa"},{"name":"Kawabata Yumiko"},{"name":"Ozaki Asuka"},{"name":"Baccara-Dinet T. Marie"},{"name":"佐田 政隆"}]},"description":{"en":"Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), which can produce substantial and sustained reductions of low-density lipoprotein cholesterol (LDL-C). The randomized, double-blind, placebo-controlled, parallel-group, phase 3 ODYSSEY NIPPON study will explore alirocumab 150 mg every 4 weeks (Q4W) in 163 Japanese patients with hypercholesterolemia who are on the lowest-strength dose of atorvastatin (5 mg/day) or are receiving a non-statin lipid-lowering therapy (LLT) (fenofibrate, bezafibrate, ezetimibe, or diet therapy alone). Hypercholesterolemia is defined as LDL-C ≥ 100 mg/dL (2.6 mmol/L) in patients with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia with a history of documented coronary heart disease, or ≥120 mg/dL (3.1 mmol/L) in patients with non-familial hypercholesterolemia classified as primary prevention category III (i.e. high-risk patients). During the 12-week double-blind treatment period, patients will be randomized (1:1:1) to receive alirocumab subcutaneously (SC) 150 mg Q4W alternating with placebo for alirocumab Q4W, or alirocumab 150 mg SC every 2 weeks (Q2W), or SC placebo Q2W. The primary efficacy endpoint is the percentage change in calculated LDL-C from baseline to week 12. The long-term safety and tolerability of alirocumab will also be investigated. The ODYSSEY NIPPON study will provide insights into the efficacy and safety of alirocumab 150 mg Q4W or 150 mg Q2W among Japanese patients with hypercholesterolemia who are on the lowest-strength dose of atorvastatin, or are receiving a non-statin LLT (including diet therapy alone). ClinicalTrials.gov number: NCT02584504.","ja":"Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), which can produce substantial and sustained reductions of low-density lipoprotein cholesterol (LDL-C). The randomized, double-blind, placebo-controlled, parallel-group, phase 3 ODYSSEY NIPPON study will explore alirocumab 150 mg every 4 weeks (Q4W) in 163 Japanese patients with hypercholesterolemia who are on the lowest-strength dose of atorvastatin (5 mg/day) or are receiving a non-statin lipid-lowering therapy (LLT) (fenofibrate, bezafibrate, ezetimibe, or diet therapy alone). Hypercholesterolemia is defined as LDL-C ≥ 100 mg/dL (2.6 mmol/L) in patients with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia with a history of documented coronary heart disease, or ≥120 mg/dL (3.1 mmol/L) in patients with non-familial hypercholesterolemia classified as primary prevention category III (i.e. high-risk patients). During the 12-week double-blind treatment period, patients will be randomized (1:1:1) to receive alirocumab subcutaneously (SC) 150 mg Q4W alternating with placebo for alirocumab Q4W, or alirocumab 150 mg SC every 2 weeks (Q2W), or SC placebo Q2W. The primary efficacy endpoint is the percentage change in calculated LDL-C from baseline to week 12. The long-term safety and tolerability of alirocumab will also be investigated. The ODYSSEY NIPPON study will provide insights into the efficacy and safety of alirocumab 150 mg Q4W or 150 mg Q2W among Japanese patients with hypercholesterolemia who are on the lowest-strength dose of atorvastatin, or are receiving a non-statin LLT (including diet therapy alone). ClinicalTrials.gov number: NCT02584504."},"publication_date":"2017-07-17","publication_name":{"en":"Lipids in Health and Disease","ja":"Lipids in Health and Disease"},"volume":"Vol.16","number":"No.1","starting_page":"121","ending_page":"121","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12944-017-0513-7"],"issn":["1476-511X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28532772","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325746","label":"url"}],"paper_title":{"en":"Echocardiographic Predictors for Worsening of Six-Minute Walk Distances in Patients With Systemic Sclerosis (Scleroderma)","ja":"Echocardiographic Predictors for Worsening of Six-Minute Walk Distances in Patients With Systemic Sclerosis (Scleroderma)"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Seno Hiromitsu"},{"name":"Saijo Y"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"平田 有紀奈"},{"name":"瀬野 弘光"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Change in 6-minute walk distance (6MWD) has been used as a clinical marker in pulmonary hypertension. Determinants and worsening of 6MWD remain a matter of debate because nonpulmonary factors have an impact on the 6MWD. We hypothesized that future reduction of 6MWD in patients with systemic sclerosis (SSc) was more closely associated with cardiac dysfunction. We prospectively performed standard clinical and echocardiographic evaluations in SSc patients with the 6-minute walk test at enrollment. Features associated with the 6MWD were sought in a multiple linear regression analysis and compared using standardized . Worsening of the 6MWD was defined as a 15% reduction and served as the primary outcome. Eighty-one patients were included. In the multivariate analysis, baseline 6MWD was related to SSc severity score ( = -0.250, p = 0.024), left atrial volume index ( = -0.222, p = 0.046), right ventricular fractional area change ( = 0.252, p = 0.025), and the ratio of mean pulmonary artery pressure and cardiac output ( = -0.31, p = 0.002). During follow-up, 20 patients reached the primary outcome. In sequential Cox models, a model based on right ventricular fractional area change at baseline (chi-square 4.8) was improved by left atrial volume index (chi-square 10.3, p = 0.007). In conclusion, determinants and worsening of 6MWD are explained by cardiac factors. When using the 6MWD as a clinical marker in pulmonary hypertension patients, their left ventricular diastolic function and right ventricular systolic function should be taken into consideration.","ja":"Change in 6-minute walk distance (6MWD) has been used as a clinical marker in pulmonary hypertension. Determinants and worsening of 6MWD remain a matter of debate because nonpulmonary factors have an impact on the 6MWD. We hypothesized that future reduction of 6MWD in patients with systemic sclerosis (SSc) was more closely associated with cardiac dysfunction. We prospectively performed standard clinical and echocardiographic evaluations in SSc patients with the 6-minute walk test at enrollment. Features associated with the 6MWD were sought in a multiple linear regression analysis and compared using standardized . Worsening of the 6MWD was defined as a 15% reduction and served as the primary outcome. Eighty-one patients were included. In the multivariate analysis, baseline 6MWD was related to SSc severity score ( = -0.250, p = 0.024), left atrial volume index ( = -0.222, p = 0.046), right ventricular fractional area change ( = 0.252, p = 0.025), and the ratio of mean pulmonary artery pressure and cardiac output ( = -0.31, p = 0.002). During follow-up, 20 patients reached the primary outcome. In sequential Cox models, a model based on right ventricular fractional area change at baseline (chi-square 4.8) was improved by left atrial volume index (chi-square 10.3, p = 0.007). In conclusion, determinants and worsening of 6MWD are explained by cardiac factors. When using the 6MWD as a clinical marker in pulmonary hypertension patients, their left ventricular diastolic function and right ventricular systolic function should be taken into consideration."},"publication_date":"2017-07-15","publication_name":{"en":"The American Journal of Cardiology","ja":"The American Journal of Cardiology"},"volume":"Vol.120","number":"No.2","starting_page":"315","ending_page":"321","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.amjcard.2017.04.024"],"issn":["1879-1913"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28734918","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85025467938&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=327192","label":"url"}],"paper_title":{"en":"RV Myocardial Strain During Pre-Load Augmentation Is Associated With Exercise Capacity in Patients With Chronic HF","ja":"RV Myocardial Strain During Pre-Load Augmentation Is Associated With Exercise Capacity in Patients With Chronic HF"},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Ishii Ayumi"},{"name":"Hirata Yukina"},{"name":"Seno Hiromitsu"},{"name":"Saijo Yoshihito"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"西尾 進"},{"name":"Ishii Ayumi"},{"name":"平田 有紀奈"},{"name":"瀬野 弘光"},{"name":"西條 良仁"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"The aim of this study was to assess the relationship between right ventricular (RV) function during pre-load augmentation and exercise tolerance. Peak oxygen uptake (VO2) is a strong predictor of mortality in chronic heart failure. Cardiac function during pre-load augmentation is an important part of the phenomenon in the evaluation of exercise capacity. We prospectively performed echocardiographic studies in 68 chronic heart failure patients with cardiopulmonary exercise testing (mean age 60 ± 12 years; 69% male). After resting evaluations, echocardiographic parameters were repeated during leg positive pressure (LPP). Exercise capacity was assessed by peak VO2 in all patients (left ventricular ejection fraction: 43 ± 15%). Patients with severely reduced exercise capacity (peak VO2 <14 ml/kg/min) had significantly lower stroke volume index, left ventricular global longitudinal strain and RV strain and higher filling pressure (E/e' and pulmonary arterial systolic pressure) than the remainder. Stroke volume index ( = 0.49), global longitudinal strain ( = -0.61), E/e' ( = -0.32), pulmonary arterial systolic pressure ( = -0.57), and RV strain ( = -0.66) during LPP were independently correlated to peak VO2 (all p < 0.01). RV strain during LPP was the most powerful predictor in identifying patients with severely reduced exercise capacity (cut off value: -17%; sensitivity: 81%; specificity: 88%; areas under the curve: 0.88; p < 0.001) compared with other variables including resting parameters. RV strain during pre-load augmentation correlated independently to peak VO2 and was a powerful predictor in identifying patients with severely reduced exercise capacity.","ja":"The aim of this study was to assess the relationship between right ventricular (RV) function during pre-load augmentation and exercise tolerance. Peak oxygen uptake (VO2) is a strong predictor of mortality in chronic heart failure. Cardiac function during pre-load augmentation is an important part of the phenomenon in the evaluation of exercise capacity. We prospectively performed echocardiographic studies in 68 chronic heart failure patients with cardiopulmonary exercise testing (mean age 60 ± 12 years; 69% male). After resting evaluations, echocardiographic parameters were repeated during leg positive pressure (LPP). Exercise capacity was assessed by peak VO2 in all patients (left ventricular ejection fraction: 43 ± 15%). Patients with severely reduced exercise capacity (peak VO2 <14 ml/kg/min) had significantly lower stroke volume index, left ventricular global longitudinal strain and RV strain and higher filling pressure (E/e' and pulmonary arterial systolic pressure) than the remainder. Stroke volume index ( = 0.49), global longitudinal strain ( = -0.61), E/e' ( = -0.32), pulmonary arterial systolic pressure ( = -0.57), and RV strain ( = -0.66) during LPP were independently correlated to peak VO2 (all p < 0.01). RV strain during LPP was the most powerful predictor in identifying patients with severely reduced exercise capacity (cut off value: -17%; sensitivity: 81%; specificity: 88%; areas under the curve: 0.88; p < 0.001) compared with other variables including resting parameters. RV strain during pre-load augmentation correlated independently to peak VO2 and was a powerful predictor in identifying patients with severely reduced exercise capacity."},"publication_date":"2017-07-13","publication_name":{"en":"JACC. Cardiovascular Imaging","ja":"JACC. Cardiovascular Imaging"},"volume":"Vol.10","number":"No.10","starting_page":"1240","ending_page":"1249","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jcmg.2017.03.022"],"issn":["1876-7591"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28690284","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85035216086&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=327195","label":"url"}],"paper_title":{"en":"Association Between Waist-to-Height Ratio and Endothelial Dysfunction in Patients With Morbidity A Report From the FMD-J Study","ja":"Association Between Waist-to-Height Ratio and Endothelial Dysfunction in Patients With Morbidity A Report From the FMD-J Study"},"authors":{"en":[{"name":"Tokushige Akihiro"},{"name":"Ueda Shinichiro"},{"name":"Tomiyama Hirofumi"},{"name":"Ohishi Mituru"},{"name":"Kohro Takahide"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Yamashina Akira"}],"ja":[{"name":"Tokushige Akihiro"},{"name":"Ueda Shinichiro"},{"name":"Tomiyama Hirofumi"},{"name":"Ohishi Mituru"},{"name":"Kohro Takahide"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Yamashina Akira"}]},"description":{"en":"Waist circumference (WC), waist-to-height ratio (WHtR) and body mass index (BMI) are known as easy anthropometric markers of abnormal obesity and screening tools for predicting cardiovascular outcomes, but which indices are best is unclear. We therefore investigated the superiority and association between each index and low flow-mediated dilatation (FMD) as a surrogate marker for cardiovascular outcomes in patients with morbidity in a large Japanese prospective cohort.Methods and Results:A total of 1,645 Japanese patients who had coronary artery disease and hypertension or diabetes mellitus were enrolled, and 1,087 of them were analyzed. The high-WHtR group (≥0.5) showed greater morbidity and increased inflammation in association with atherosclerosis compared with the low-WHtR group. High WHtR and advanced age were identified as predictors of low FMD (odds ratio (OR) 1.39, 95% confidence interval (CI) 1.02-1.88, P=0.037 and OR 1.55, 95% CI 1.19-2.01, P=0.001, respectively). However, WC was not associated with that risk in either sex (male: OR 1.37, 95% CI 0.97-1.93, P=0.076; female: OR 1.08, 95% CI 0.68-1.73, P=0.74), and no association was evident between high BMI and low FMD (OR 0.92, 95% CI 0.71-1.19, P=0.54). WHtR offers a superior predictor of decreased FMD than other anthropometric indices, and progression of arteriosclerosis might be detected more sensitively. Further study is needed to investigate the relationship between cardiovascular mortality and WHtR.","ja":"Waist circumference (WC), waist-to-height ratio (WHtR) and body mass index (BMI) are known as easy anthropometric markers of abnormal obesity and screening tools for predicting cardiovascular outcomes, but which indices are best is unclear. We therefore investigated the superiority and association between each index and low flow-mediated dilatation (FMD) as a surrogate marker for cardiovascular outcomes in patients with morbidity in a large Japanese prospective cohort.Methods and Results:A total of 1,645 Japanese patients who had coronary artery disease and hypertension or diabetes mellitus were enrolled, and 1,087 of them were analyzed. The high-WHtR group (≥0.5) showed greater morbidity and increased inflammation in association with atherosclerosis compared with the low-WHtR group. High WHtR and advanced age were identified as predictors of low FMD (odds ratio (OR) 1.39, 95% confidence interval (CI) 1.02-1.88, P=0.037 and OR 1.55, 95% CI 1.19-2.01, P=0.001, respectively). However, WC was not associated with that risk in either sex (male: OR 1.37, 95% CI 0.97-1.93, P=0.076; female: OR 1.08, 95% CI 0.68-1.73, P=0.74), and no association was evident between high BMI and low FMD (OR 0.92, 95% CI 0.71-1.19, P=0.54). WHtR offers a superior predictor of decreased FMD than other anthropometric indices, and progression of arteriosclerosis might be detected more sensitively. Further study is needed to investigate the relationship between cardiovascular mortality and WHtR."},"publication_date":"2017-07-07","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.81","number":"No.12","starting_page":"1911","ending_page":"1918","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-17-0211"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114510","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28683829","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85022075532&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325813","label":"url"}],"paper_title":{"en":"α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.","ja":"α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study."},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Tanaka Atsushi"},{"name":"Sata Masataka"},{"name":"Dai Kazuoki"},{"name":"Sibata Yoshisato"},{"name":"Inoue Yohei"},{"name":"Ikenaga Hiroki"},{"name":"Kishimoto Shinji"},{"name":"Ogasawara Kozue"},{"name":"Takashima Akira"},{"name":"Niki Toshiyuki"},{"name":"Arasaki Osamu"},{"name":"Oshiro Koichi"},{"name":"Mori Yutaka"},{"name":"Ishihara Masaharu"},{"name":"Nobe Koichi"}],"ja":[{"name":"島袋 充生"},{"name":"Tanaka Atsushi"},{"name":"佐田 政隆"},{"name":"Dai Kazuoki"},{"name":"Sibata Yoshisato"},{"name":"Inoue Yohei"},{"name":"Ikenaga Hiroki"},{"name":"Kishimoto Shinji"},{"name":"Ogasawara Kozue"},{"name":"Takashima Akira"},{"name":"Niki Toshiyuki"},{"name":"Arasaki Osamu"},{"name":"Oshiro Koichi"},{"name":"Mori Yutaka"},{"name":"Ishihara Masaharu"},{"name":"Nobe Koichi"}]},"description":{"en":"Little is known about clinical associations between glucose fluctuations including hypoglycemia, heart rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute phase of acute coronary syndrome (ACS). This pilot study aimed to evaluate the short-term effects of glucose fluctuations on HRV and SNS activity in type 2 diabetes mellitus (T2DM) patients with recent ACS. We also examined the effect of suppressing glucose fluctuations with miglitol on these variables. This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group comparative study included 39 T2DM patients with recent ACS, who were randomly assigned to either a miglitol group (n = 19) or a control group (n = 20). After initial 24-h Holter electrocardiogram (ECG) (Day 1), miglitol was commenced and another 24-h Holter ECG (Day 2) was recorded. In addition, continuous glucose monitoring (CGM) was performed throughout the Holter ECG. Although frequent episodes of subclinical hypoglycemia (≤4.44 mmo/L) during CGM were observed on Day 1 in the both groups (35% of patients in the control group and 31% in the miglitol group), glucose fluctuations were decreased and the minimum glucose level was increased with substantial reduction in the episodes of subclinical hypoglycemia to 7.7% in the miglitol group on Day 2. Holter ECG showed that the mean and maximum heart rate and mean LF/HF were increased on Day 2 in the control group, and these increases were attenuated by miglitol. When divided 24-h time periods into day-time (0700-1800 h), night-time (1800-0000 h), and bed-time (0000-0700 h), we found increased SNS activity during day-time, increased maximum heart rate during night-time, and glucose fluctuations during bed-time, which were attenuated by miglitol treatment. In T2DM patients with recent ACS, glucose fluctuations with subclinical hypoglycemia were associated with alterations of HRV and SNS activity, which were mitigated by miglitol, suggesting that these pathological relationships may be a residual therapeutic target in such patients. Trial registration Unique Trial Number, UMIN000005874 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006929 ).","ja":"Little is known about clinical associations between glucose fluctuations including hypoglycemia, heart rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute phase of acute coronary syndrome (ACS). This pilot study aimed to evaluate the short-term effects of glucose fluctuations on HRV and SNS activity in type 2 diabetes mellitus (T2DM) patients with recent ACS. We also examined the effect of suppressing glucose fluctuations with miglitol on these variables. This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group comparative study included 39 T2DM patients with recent ACS, who were randomly assigned to either a miglitol group (n = 19) or a control group (n = 20). After initial 24-h Holter electrocardiogram (ECG) (Day 1), miglitol was commenced and another 24-h Holter ECG (Day 2) was recorded. In addition, continuous glucose monitoring (CGM) was performed throughout the Holter ECG. Although frequent episodes of subclinical hypoglycemia (≤4.44 mmo/L) during CGM were observed on Day 1 in the both groups (35% of patients in the control group and 31% in the miglitol group), glucose fluctuations were decreased and the minimum glucose level was increased with substantial reduction in the episodes of subclinical hypoglycemia to 7.7% in the miglitol group on Day 2. Holter ECG showed that the mean and maximum heart rate and mean LF/HF were increased on Day 2 in the control group, and these increases were attenuated by miglitol. When divided 24-h time periods into day-time (0700-1800 h), night-time (1800-0000 h), and bed-time (0000-0700 h), we found increased SNS activity during day-time, increased maximum heart rate during night-time, and glucose fluctuations during bed-time, which were attenuated by miglitol treatment. In T2DM patients with recent ACS, glucose fluctuations with subclinical hypoglycemia were associated with alterations of HRV and SNS activity, which were mitigated by miglitol, suggesting that these pathological relationships may be a residual therapeutic target in such patients. Trial registration Unique Trial Number, UMIN000005874 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006929 )."},"publication_date":"2017-07-06","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.16","number":"No.1","starting_page":"86","ending_page":"86","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-017-0571-1"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28367861","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85030104785&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=323587","label":"url"}],"paper_title":{"en":"Intracardiac echocardiography-guided biopsy of a lipomatous cardiac tumor arising from the interatrial septum.","ja":"Intracardiac echocardiography-guided biopsy of a lipomatous cardiac tumor arising from the interatrial septum."},"authors":{"en":[{"name":"Takashima Akira"},{"name":"Ogata Tatsuro"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"髙島 啓"},{"name":"Ogata Tatsuro"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"publication_date":"2017-06-17","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.81","number":"No.10","starting_page":"1553","ending_page":"1555","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-17-0138"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112321","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28594865","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85020391442&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325812","label":"url"}],"paper_title":{"en":"Gender-linked impact of epicardial adipose tissue volume in patients who underwent coronary artery bypass graft surgery or non-coronary valve surgery","ja":"Gender-linked impact of epicardial adipose tissue volume in patients who underwent coronary artery bypass graft surgery or non-coronary valve surgery"},"authors":{"en":[{"name":"Gulinu Maimaituxun"},{"name":"Shimabukuro Michio"},{"name":"Salim Masdan Hotimah"},{"name":"Tabata Minoru"},{"name":"Yuji Daisuke"},{"name":"Morimoto Yoshihisa"},{"name":"Akasaka Takeshi"},{"name":"Matsuura Tomomi"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Sugimoto Takaki"},{"name":"Tanaka Masashi"},{"name":"Takanashi Shuichiro"},{"name":"Sata Masataka"}],"ja":[{"name":"Gulinu Maimaituxun"},{"name":"島袋 充生"},{"name":"Hotimah Masdan Salim"},{"name":"Tabata Minoru"},{"name":"Yuji Daisuke"},{"name":"Morimoto Yoshihisa"},{"name":"Akasaka Takeshi"},{"name":"松浦 朋美"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"Sugimoto Takaki"},{"name":"Tanaka Masashi"},{"name":"Takanashi Shuichiro"},{"name":"佐田 政隆"}]},"description":{"en":"Traditional and non-traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) are different between men and women. Gender-linked impact of epicardial adipose tissue volume (EATV) in patients undergoing coronary artery bypass grafting (CABG) remains unknown. Gender-linked impact of EATV, abdominal fat distribution and other traditional ASCVD risk factors were compared in 172 patients (men: 115; women: 57) who underwent CABG or non-coronary valvular surgery (non-CABG). In men, EATV, EATV index (EATV/body surface area) and the markers of adiposity such as body mass index, waist circumference and visceral fat area were higher in the CABG group than in the non-CABG group. Traditional ASCVD risk factors were also prevalent in the CABG group. In women, EATV and EATV index were higher in the CABG group, but other adiposity markers were comparable between CABG and non-CABG groups. Multivariate logistic regression analysis showed that in men, CABG was determined by EATV Index and other ASCVD risk factors including hypertension, dyslipidemia, adiponectin, high sensitive C-reactive protein (hsCRP) and type 2 diabetes mellitus (Corrected R2 = 0.262, p < 0.0001), while in women, type 2 diabetes mellitus is a single strong predictor for CABG, excluding EATV Index (Corrected R2 = 0.266, p = 0.005). Our study found that multiple risk factors, including epicardial adipose tissue volume and traditional ASCVD factors are determinants for CABG in men, but type 2 diabetes mellitus was the sole determinant in women. Gender-specific disparities in risk factors of CABG prompt us to evaluate new diagnostic and treatment strategies and to seek underlying mechanisms.","ja":"Traditional and non-traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) are different between men and women. Gender-linked impact of epicardial adipose tissue volume (EATV) in patients undergoing coronary artery bypass grafting (CABG) remains unknown. Gender-linked impact of EATV, abdominal fat distribution and other traditional ASCVD risk factors were compared in 172 patients (men: 115; women: 57) who underwent CABG or non-coronary valvular surgery (non-CABG). In men, EATV, EATV index (EATV/body surface area) and the markers of adiposity such as body mass index, waist circumference and visceral fat area were higher in the CABG group than in the non-CABG group. Traditional ASCVD risk factors were also prevalent in the CABG group. In women, EATV and EATV index were higher in the CABG group, but other adiposity markers were comparable between CABG and non-CABG groups. Multivariate logistic regression analysis showed that in men, CABG was determined by EATV Index and other ASCVD risk factors including hypertension, dyslipidemia, adiponectin, high sensitive C-reactive protein (hsCRP) and type 2 diabetes mellitus (Corrected R2 = 0.262, p < 0.0001), while in women, type 2 diabetes mellitus is a single strong predictor for CABG, excluding EATV Index (Corrected R2 = 0.266, p = 0.005). Our study found that multiple risk factors, including epicardial adipose tissue volume and traditional ASCVD factors are determinants for CABG in men, but type 2 diabetes mellitus was the sole determinant in women. Gender-specific disparities in risk factors of CABG prompt us to evaluate new diagnostic and treatment strategies and to seek underlying mechanisms."},"publication_date":"2017-06-08","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"Vol.12","number":"No.6","starting_page":"e0177170","ending_page":"e0177170","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0177170"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112318","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28570595","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325806","label":"url"}],"paper_title":{"en":"Plasma brain natriuretic peptide levels are elevated in patients with cancer","ja":"Plasma brain natriuretic peptide levels are elevated in patients with cancer"},"authors":{"en":[{"name":"Bando S"},{"name":"Soeki Takeshi"},{"name":"Matsuura Tomomi"},{"name":"Tobiume Takeshi"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Muguruma Naoki"},{"name":"Takayama Tetsuji"},{"name":"Kishimoto I"},{"name":"Kangawa Kenji"},{"name":"Sata Masataka"}],"ja":[{"name":"坂東 左知子"},{"name":"添木 武"},{"name":"松浦 朋美"},{"name":"飛梅 威"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"六車 直樹"},{"name":"高山 哲治"},{"name":"Kishimoto I"},{"name":"寒川 賢治"},{"name":"佐田 政隆"}]},"description":{"en":"Natriuretic peptides have been proposed as biomarkers of cardiovascular disease, especially heart failure. Brain natriuretic peptide (BNP) has also been shown to be upregulated at the transcriptional and translational levels by pro-inflammatory cytokines in cardiac myocytes. Although we often measure plasma BNP levels in cancer patients, it remains unknown whether cancer-related inflammation affects the plasma BNP levels. We investigated the relationship between the BNP and human cancers. We retrospectively studied 2,923 patients in whom the plasma BNP levels and serum C-reactive protein (CRP) were measured and echocardiography was performed. Patients with clinically evident heart failure (NYHA II or higher), heart disease requiring medical treatment or surgery, renal dysfunction, and inflammatory disease were excluded. There were 234 patients in the final analysis. Blood sampling was performed before surgery and chemotherapy. In addition, we evaluated the relationship between the inflammation and plasma BNP levels in mouse models of colon cancer. Of the 234 patients, 80 were diagnosed with cancer. Both the plasma BNP and serum CRP levels were significantly higher in cancer patients than those without. There were no significant differences in the echocardiographic parameters. There was a significant positive correlation between the plasma BNP and serum CRP levels in cancer patients (r = 0.360, P<0.01) but not in those without. In cancer patients, only the CRP correlated with the BNP independent of the age, creatinine level, hypertension, and body mass index. In addition, in nude mice with subcutaneous colon cancer, the plasma BNP level was elevated compared with that in non-cancer mice, and there was a significant relationship between the plasma BNP and serum levels of the inflammatory markers. In cancer patients, as well as colon cancer model mice, the plasma BNP levels were elevated, possibly due to cancer-related inflammation. The effect of cancer on the BNP levels should be considered when using BNP as an indicator of heart failure in cancer patients.","ja":"Natriuretic peptides have been proposed as biomarkers of cardiovascular disease, especially heart failure. Brain natriuretic peptide (BNP) has also been shown to be upregulated at the transcriptional and translational levels by pro-inflammatory cytokines in cardiac myocytes. Although we often measure plasma BNP levels in cancer patients, it remains unknown whether cancer-related inflammation affects the plasma BNP levels. We investigated the relationship between the BNP and human cancers. We retrospectively studied 2,923 patients in whom the plasma BNP levels and serum C-reactive protein (CRP) were measured and echocardiography was performed. Patients with clinically evident heart failure (NYHA II or higher), heart disease requiring medical treatment or surgery, renal dysfunction, and inflammatory disease were excluded. There were 234 patients in the final analysis. Blood sampling was performed before surgery and chemotherapy. In addition, we evaluated the relationship between the inflammation and plasma BNP levels in mouse models of colon cancer. Of the 234 patients, 80 were diagnosed with cancer. Both the plasma BNP and serum CRP levels were significantly higher in cancer patients than those without. There were no significant differences in the echocardiographic parameters. There was a significant positive correlation between the plasma BNP and serum CRP levels in cancer patients (r = 0.360, P<0.01) but not in those without. In cancer patients, only the CRP correlated with the BNP independent of the age, creatinine level, hypertension, and body mass index. In addition, in nude mice with subcutaneous colon cancer, the plasma BNP level was elevated compared with that in non-cancer mice, and there was a significant relationship between the plasma BNP and serum levels of the inflammatory markers. In cancer patients, as well as colon cancer model mice, the plasma BNP levels were elevated, possibly due to cancer-related inflammation. The effect of cancer on the BNP levels should be considered when using BNP as an indicator of heart failure in cancer patients."},"publication_date":"2017-06-01","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"Vol.12","number":"No.6","starting_page":"e0178607","ending_page":"e0178607","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0178607"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28347868","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85016431523&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=323588","label":"url"}],"paper_title":{"en":"Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.","ja":"Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice."},"authors":{"en":[{"name":"Hotimah Masdan Salim"},{"name":"Fukuda Daiju"},{"name":"Higashikuni Yasutomi"},{"name":"Tanaka Kimie"},{"name":"Hirata Yoichiro"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Hotimah Masdan Salim"},{"name":"福田 大受"},{"name":"Higashikuni Yasutomi"},{"name":"Tanaka Kimie"},{"name":"Hirata Yoichiro"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Dipeptidyl peptidase-4 (DPP-4) inhibitors have various cellular effects that are associated with vascular protection. Here, we examined whether teneligliptin alters the pro-inflammatory phenotype of perivascular adipose tissue (PVAT) and inhibits atherogenesis. Teneligliptin (60mg/kg/day) was administered orally to apolipoprotein-E-deficient (ApoE(-/-)) mice for 20weeks. Teneligliptin significantly inhibited the development of atherosclerosis in the aortic arch compared with vehicle (P<0.05), without alteration of blood glucose level or blood pressure. Histological analyses demonstrated that teneligliptin decreased lipid deposition and MCP-1 expression (P<0.05, respectively), and tended to decrease macrophage accumulation in atherosclerotic plaques. The results of quantitative RT-PCR analysis demonstrated that teneligliptin reduced the expression of inflammatory molecules such as TNF- and MCP-1 in the abdominal aorta. Furthermore, teneligliptin reduced the expression of a macrophage marker and Nox-4, a major NADPH oxidase subunit in adipocytes, in PVAT around the aortic arch. Administration of teneligliptin for 8weeks ameliorated endothelium-dependent vasodilation and reduced oxidative stress as determined by urinary 8-OHdG excretion (P<0.05) compared with vehicle. In vitro experiments demonstrated that exendin-4 (Ex-4), a GLP-1 analog, decreased the expression of inflammatory molecules in RAW264.7 cells. Also, Ex-4 decreased Nox4 expression in 3T3-L1 adipocytes. Teneligliptin inhibited atherogenesis with attenuation of the inflammatory phenotype in PVAT. A GLP-1 analog suppressed pro-inflammatory activation of macrophages and adipocytes. Suppression of the pro-inflammatory phenotype of PVAT might contribute, at least partially, to the cardioprotective effects of teneligliptin.","ja":"Dipeptidyl peptidase-4 (DPP-4) inhibitors have various cellular effects that are associated with vascular protection. Here, we examined whether teneligliptin alters the pro-inflammatory phenotype of perivascular adipose tissue (PVAT) and inhibits atherogenesis. Teneligliptin (60mg/kg/day) was administered orally to apolipoprotein-E-deficient (ApoE(-/-)) mice for 20weeks. Teneligliptin significantly inhibited the development of atherosclerosis in the aortic arch compared with vehicle (P<0.05), without alteration of blood glucose level or blood pressure. Histological analyses demonstrated that teneligliptin decreased lipid deposition and MCP-1 expression (P<0.05, respectively), and tended to decrease macrophage accumulation in atherosclerotic plaques. The results of quantitative RT-PCR analysis demonstrated that teneligliptin reduced the expression of inflammatory molecules such as TNF- and MCP-1 in the abdominal aorta. Furthermore, teneligliptin reduced the expression of a macrophage marker and Nox-4, a major NADPH oxidase subunit in adipocytes, in PVAT around the aortic arch. Administration of teneligliptin for 8weeks ameliorated endothelium-dependent vasodilation and reduced oxidative stress as determined by urinary 8-OHdG excretion (P<0.05) compared with vehicle. In vitro experiments demonstrated that exendin-4 (Ex-4), a GLP-1 analog, decreased the expression of inflammatory molecules in RAW264.7 cells. Also, Ex-4 decreased Nox4 expression in 3T3-L1 adipocytes. Teneligliptin inhibited atherogenesis with attenuation of the inflammatory phenotype in PVAT. A GLP-1 analog suppressed pro-inflammatory activation of macrophages and adipocytes. Suppression of the pro-inflammatory phenotype of PVAT might contribute, at least partially, to the cardioprotective effects of teneligliptin."},"publication_date":"2017-05-27","publication_name":{"en":"Vascular Pharmacology","ja":"Vascular Pharmacology"},"volume":"Vol.96-98","number":"No.16","starting_page":"19","ending_page":"25","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.vph.2017.03.003"],"issn":["1879-3649"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114509","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28490337","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325815","label":"url"}],"paper_title":{"en":"Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.","ja":"Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study."},"authors":{"en":[{"name":"Yamada Hirotsugu"},{"name":"Tanaka Atsushi"},{"name":"Kusunose Kenya"},{"name":"Amano Rie"},{"name":"Matsuhisa Munehide"},{"name":"Daida Hiroyuki"},{"name":"Ito Masaaki"},{"name":"Tsutsui Hiroyuki"},{"name":"Nanasato Mamoru"},{"name":"Kamiya Haruo"},{"name":"Bando Yasuko K"},{"name":"Odawara Masato"},{"name":"Yoshida Hisako"},{"name":"Murohara Toyoaki"},{"name":"Sata Masataka"},{"name":"Node Koichi"}],"ja":[{"name":"山田 博胤"},{"name":"Tanaka Atsushi"},{"name":"楠瀬 賢也"},{"name":"Amano Rie"},{"name":"松久 宗英"},{"name":"Daida Hiroyuki"},{"name":"Ito Masaaki"},{"name":"Tsutsui Hiroyuki"},{"name":"Nanasato Mamoru"},{"name":"Kamiya Haruo"},{"name":"Bando Yasuko K"},{"name":"Odawara Masato"},{"name":"Yoshida Hisako"},{"name":"Murohara Toyoaki"},{"name":"佐田 政隆"},{"name":"Node Koichi"}]},"description":{"en":"Diabetes is associated closely with an increased risk of cardiovascular events, including diastolic dysfunction and heart failure that leads to a shortening of life expectancy. It is therefore extremely valuable to evaluate the impact of antidiabetic agents on cardiac function. However, the influence of dipeptidyl peptidase 4 inhibitors on cardiac function is controversial and a major matter of clinical concern. We therefore evaluated the effect of sitagliptin on echocardiographic parameters of diastolic function in patients with type 2 diabetes as a sub-analysis of the PROLOGUE study.","ja":"Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24 months attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e') independent of other clinical variables such as blood pressure and glycemic control. Trial registration UMIN000004490 (University Hospital Medical Information Network Clinical Trials). https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005356 ; registered November 1, 2010."},"publication_date":"2017-05-11","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.16","number":"No.1","starting_page":"63","ending_page":"63","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-017-0546-2"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/111083","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28373630","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=323302","label":"url"}],"paper_title":{"en":"A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury.","ja":"A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury."},"authors":{"en":[{"name":"Nakaya Yutaka"},{"name":"Fukuda Daiju"},{"name":"Oyamada Takashi"},{"name":"Ogawa Kazuo"},{"name":"Harada Nagakatsu"},{"name":"Nakagami Hironori"},{"name":"Morishita Ryuichi"},{"name":"Sata Masataka"},{"name":"Sakaue Hiroshi"}],"ja":[{"name":"中屋 豊"},{"name":"福田 大受"},{"name":"Oyamada Takashi"},{"name":"Ogawa Kazuo"},{"name":"原田 永勝"},{"name":"Nakagami Hironori"},{"name":"Morishita Ryuichi"},{"name":"佐田 政隆"},{"name":"阪上 浩"}]},"description":{"en":"Although Lp(a) have been thought to be a cardiovascular risk factor, it is unclear whether lowering Lp(a) levels reduces the risk of cardiovascular diseases. No pharmacological agents which selectively reduce serum Lp(a) levels, and Lp(a) is present in primate but absent in common laboratory animals such as mice and pigs. In the present study we used transgenic mice of human Lp(a) and tested effect a novel Lp(a) lowering drug D-47 on neointima formation after vascular injury. D-47 successfully decreased plasma levels of Lp(a) and possibly inhibited neointima formation in Lp(a) transgenic mice. The results indicate that we can modulate plasma Lp(a) levels by pharmacologic agents and inhibit atherogenic properties of Lp(a) by reducing plasma levels of Lp(a). J. Med. Invest. 64: 64-67, February, 2017.","ja":"Although Lp(a) have been thought to be a cardiovascular risk factor, it is unclear whether lowering Lp(a) levels reduces the risk of cardiovascular diseases. No pharmacological agents which selectively reduce serum Lp(a) levels, and Lp(a) is present in primate but absent in common laboratory animals such as mice and pigs. In the present study we used transgenic mice of human Lp(a) and tested effect a novel Lp(a) lowering drug D-47 on neointima formation after vascular injury. D-47 successfully decreased plasma levels of Lp(a) and possibly inhibited neointima formation in Lp(a) transgenic mice. The results indicate that we can modulate plasma Lp(a) levels by pharmacologic agents and inhibit atherogenic properties of Lp(a) by reducing plasma levels of Lp(a). J. Med. Invest. 64: 64-67, February, 2017."},"publication_date":"2017-02","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.64","number":"No.1, 2","starting_page":"64","ending_page":"67","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.64.64"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27665160","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84994494325&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=310517","label":"url"}],"paper_title":{"en":"Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF.","ja":"Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Torii Yuta"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Seno Hiromitsu"},{"name":"Saijo Yoshihito"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Torii Yuta"},{"name":"山田 博胤"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Seno Hiromitsu"},{"name":"Saijo Yoshihito"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"Objectives: The aim of this study was to assess the time course of presumptive TIC and the predictors of LV functional recovery in such patients.Background: Tachycardia-induced cardiomyopathy (TIC) is a potentially reversible cardiomyopathy with effective treatment of the tachyarrhythmia. However, cases without improvement of left ventricular (LV) systolic function were found occasionally. The diagnosis of TIC can be challenging, and the role of echocardiographic imaging in the prediction of LV functional recovery is limited.Methods: LV segmental longitudinal strains (LS) were evaluated by 2-dimensional speckle tracking in 71 consecutive patients (65±16 years; 61% men) with tachyarrhythmia and reduced LV ejection fraction (EF) without any other known cardiovascular disease, and 30 age and gender matched control subjects. Relative apical LS ratio (RALSR) was defined using the equation: average apical LS / (average basal LS + average mid LS) as a marker of strain distribution.Results: Compared to control subjects, patients with tachyarrhythmia had significantly lower global LS. Improvement in LVEF within 6 months after treatment of index arrhythmia was observed in 41 patients, and LVEF did not improve in 30 patients. In univariate analysis, lower LVEF at baseline (hazard ratio: HR: 0.59 per 1SD, p=0.04) and higher RALSR (HR: 11.2 per 1SD, p <0.001) were associated with no recovery in LVEF during follow-up. In a multivariate logistic regression model, the significant predictor of LV systolic functional recovery was RALSR (HR: 22.9 per 1SD, p=0.001). A RALSR of 0.61 was sensitive (71%) and specific (90%) in differentiating LV systolic functional recovery (area under the curve: 0.88).Conclusions: The RALSR was associated with LV systolic functional recovery. This information might be useful for clinical evaluation and follow-up in patients with reduced LVEF.","ja":"Objectives: The aim of this study was to assess the time course of presumptive TIC and the predictors of LV functional recovery in such patients.Background: Tachycardia-induced cardiomyopathy (TIC) is a potentially reversible cardiomyopathy with effective treatment of the tachyarrhythmia. However, cases without improvement of left ventricular (LV) systolic function were found occasionally. The diagnosis of TIC can be challenging, and the role of echocardiographic imaging in the prediction of LV functional recovery is limited.Methods: LV segmental longitudinal strains (LS) were evaluated by 2-dimensional speckle tracking in 71 consecutive patients (65±16 years; 61% men) with tachyarrhythmia and reduced LV ejection fraction (EF) without any other known cardiovascular disease, and 30 age and gender matched control subjects. Relative apical LS ratio (RALSR) was defined using the equation: average apical LS / (average basal LS + average mid LS) as a marker of strain distribution.Results: Compared to control subjects, patients with tachyarrhythmia had significantly lower global LS. Improvement in LVEF within 6 months after treatment of index arrhythmia was observed in 41 patients, and LVEF did not improve in 30 patients. In univariate analysis, lower LVEF at baseline (hazard ratio: HR: 0.59 per 1SD, p=0.04) and higher RALSR (HR: 11.2 per 1SD, p <0.001) were associated with no recovery in LVEF during follow-up. In a multivariate logistic regression model, the significant predictor of LV systolic functional recovery was RALSR (HR: 22.9 per 1SD, p=0.001). A RALSR of 0.61 was sensitive (71%) and specific (90%) in differentiating LV systolic functional recovery (area under the curve: 0.88).Conclusions: The RALSR was associated with LV systolic functional recovery. This information might be useful for clinical evaluation and follow-up in patients with reduced LVEF."},"publication_date":"2017-02","publication_name":{"en":"JACC. Cardiovascular Imaging","ja":"JACC. Cardiovascular Imaging"},"volume":"Vol.10","number":"No.2","starting_page":"118","ending_page":"126","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jcmg.2016.03.019"],"issn":["1876-7591"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353329","label":"url"}],"paper_title":{"en":"超音波検査が診断に有用であった右5指動静脈奇形の1例","ja":"超音波検査が診断に有用であった右5指動静脈奇形の1例"},"authors":{"en":[{"name":"鳥居 裕太"},{"name":"西尾 進"},{"name":"松本 力三"},{"name":"平田 有紀奈"},{"name":"天野 里江"},{"name":"山尾 雅美"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"鳥居 裕太"},{"name":"西尾 進"},{"name":"松本 力三"},{"name":"平田 有紀奈"},{"name":"天野 里江"},{"name":"山尾 雅美"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2017","publication_name":{"en":"Japanese Journal of Medical Ultrasound Technology","ja":"超音波検査技術"},"volume":"Vol.42","number":"No.6","starting_page":"726","ending_page":"726","languages":["jpn"],"referee":true,"identifiers":{"issn":["1881-4506"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339811","label":"url"}],"paper_title":{"en":"巻頭総説 冠動脈硬化における心外膜脂肪の役割 血管","ja":"巻頭総説 冠動脈硬化における心外膜脂肪の役割 血管"},"authors":{"en":[{"name":"Sata Masataka"}],"ja":[{"name":"佐田 政隆"}]},"publication_date":"2017","publication_name":{"en":"日本心脈管作動物質学会","ja":"日本心脈管作動物質学会"},"volume":"Vol.40","number":"No.4","languages":["jpn"],"referee":true,"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27839692","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320454","label":"url"}],"paper_title":{"en":"A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients.","ja":"A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients."},"authors":{"en":[{"name":"Sai K"},{"name":"Kajinami K"},{"name":"Akao H"},{"name":"Iwadare M"},{"name":"Sato-Ishida R"},{"name":"Kawai Y"},{"name":"Takeda K"},{"name":"Tanimoto T"},{"name":"Yamano T"},{"name":"Akasaka T"},{"name":"Ishida T"},{"name":"Hirata K"},{"name":"Saku K"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"},{"name":"Ueno M"},{"name":"Miyazaki S"},{"name":"Shiraki A"},{"name":"Oyama J"},{"name":"Node K"},{"name":"Sugamura K"},{"name":"Ogawa H"},{"name":"Kurose K"},{"name":"Maekawa K"},{"name":"Matsuzawa Y"},{"name":"Imatoh T"},{"name":"Hasegawa R"},{"name":"Japanese Pharmacogenomics Data Science Consortium"},{"name":"Saito Y"}],"ja":[{"name":"Sai K"},{"name":"Kajinami K"},{"name":"Akao H"},{"name":"Iwadare M"},{"name":"Sato-Ishida R"},{"name":"Kawai Y"},{"name":"Takeda K"},{"name":"Tanimoto T"},{"name":"Yamano T"},{"name":"Akasaka T"},{"name":"Ishida T"},{"name":"Hirata K"},{"name":"Saku K"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"佐田 政隆"},{"name":"Ueno M"},{"name":"Miyazaki S"},{"name":"Shiraki A"},{"name":"Oyama J"},{"name":"Node K"},{"name":"Sugamura K"},{"name":"Ogawa H"},{"name":"Kurose K"},{"name":"Maekawa K"},{"name":"Matsuzawa Y"},{"name":"Imatoh T"},{"name":"Hasegawa R"},{"name":"Japanese Pharmacogenomics Data Science Consortium"},{"name":"Saito Y"}]},"publication_date":"2016-12","publication_name":{"en":"Drug Metabolism and Pharmacokinetics","ja":"Drug Metabolism and Pharmacokinetics"},"volume":"Vol.31","number":"No.6","starting_page":"467","ending_page":"470","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.dmpk.2016.09.002"],"issn":["1347-4367"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114508","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27809848","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84994050554&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=321211","label":"url"}],"paper_title":{"en":"Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.","ja":"Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study."},"authors":{"en":[{"name":"Tomiyama Hirofumi"},{"name":"Miwa Takashi"},{"name":"Kan Kenshi"},{"name":"Matsuhisa Munehide"},{"name":"Kamiya Haruo"},{"name":"Nanasato Mamoru"},{"name":"Kitano Tomoki"},{"name":"Sano Hiroaki"},{"name":"Ohno Jun"},{"name":"Iida Masato"},{"name":"Sata Masataka"},{"name":"Yamada Hirotsugu"},{"name":"Maemura Koji"},{"name":"Tanaka Atsushi"},{"name":"Murohara Toyoaki"},{"name":"Node Koichi"}],"ja":[{"name":"Tomiyama Hirofumi"},{"name":"Miwa Takashi"},{"name":"Kan Kenshi"},{"name":"松久 宗英"},{"name":"Kamiya Haruo"},{"name":"Nanasato Mamoru"},{"name":"Kitano Tomoki"},{"name":"Sano Hiroaki"},{"name":"Ohno Jun"},{"name":"Iida Masato"},{"name":"佐田 政隆"},{"name":"山田 博胤"},{"name":"Maemura Koji"},{"name":"Tanaka Atsushi"},{"name":"Murohara Toyoaki"},{"name":"Node Koichi"}]},"description":{"en":"No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl peptidase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness. In the PROLOGUE study, the study participants were either allocated to add-on sitagliptin treatment or to continued treatment with conventional anti-diabetic agents. Among the 463 participants of the PROLOGUE study, we succeeded in measuring the brachial-ankle pulse wave velocity (baPWV) at least two times during the 2-year study period in 96 subjects. The changes in the baPWV during the study period were similar between the both groups (i.e., with/without staglipitin), overall. On the other hand, when the study subjects were divided into two groups according to the glycemic control status during the study period {good glycemic control group (GC) = hemoglobin (Hb)A1c <7.0 at both 12 and 24 months after the treatment randomization; poor glycemic control group (PC) = HbA1c ≥7.0 at either 12 months, 24 months, or both}, the 2-year increase of the baPWV was marginally significantly larger in the PC group (144 ± 235 cm/s) as compared to that the GC group (-10 ± 282 cm/s) (p = 0.036). While the present study could not confirm the beneficial effect of sitagliptin per se on the arterial stiffness, the results suggested that good glycemic control appears to be beneficial for delaying the annual progression of the arterial stiffness. Trial registration University Hospital Medical Information Network Clinical Trials Registry UMIN000004490.","ja":"No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl peptidase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness. In the PROLOGUE study, the study participants were either allocated to add-on sitagliptin treatment or to continued treatment with conventional anti-diabetic agents. Among the 463 participants of the PROLOGUE study, we succeeded in measuring the brachial-ankle pulse wave velocity (baPWV) at least two times during the 2-year study period in 96 subjects. The changes in the baPWV during the study period were similar between the both groups (i.e., with/without staglipitin), overall. On the other hand, when the study subjects were divided into two groups according to the glycemic control status during the study period {good glycemic control group (GC) = hemoglobin (Hb)A1c <7.0 at both 12 and 24 months after the treatment randomization; poor glycemic control group (PC) = HbA1c ≥7.0 at either 12 months, 24 months, or both}, the 2-year increase of the baPWV was marginally significantly larger in the PC group (144 ± 235 cm/s) as compared to that the GC group (-10 ± 282 cm/s) (p = 0.036). While the present study could not confirm the beneficial effect of sitagliptin per se on the arterial stiffness, the results suggested that good glycemic control appears to be beneficial for delaying the annual progression of the arterial stiffness. Trial registration University Hospital Medical Information Network Clinical Trials Registry UMIN000004490."},"publication_date":"2016-11-03","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.15","number":"No.1","starting_page":"150","ending_page":"150","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-016-0472-8"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114485","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27833913","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320836","label":"url"}],"paper_title":{"en":"Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse.","ja":"Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse."},"authors":{"en":[{"name":"Salim HM"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Salim HM"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Endothelial dysfunction caused by increased oxidative stress is a critical initiator of macro- and micro-vascular disease development in diabetic patients. Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. The aim of this study was to examine whether ipragliflozin attenuates endothelial dysfunction in diabetic mice.METHODS: Eight-week-old male C57BL/6 mice were treated with streptozotocin (150mg/kg) by a single intraperitoneal injection to induce diabetes mellitus. At 3days of injection, ipragliflozin (3mg/kg/day) was administered via gavage for 3weeks. Vascular function was assessed by isometric tension recording. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. RNA and protein expression were examined by quantitative RT-PCR (qPCR) and western blot, respectively. Oxidative stress was determined by measuring urine 8-hydroxy-2'-deoxyguanosine (8-OHdG) level.RESULTS: Ipragliflozin administration significantly reduced blood glucose level (P<0.001) and attenuated the impairment of endothelial function in diabetic mice, as determined by acetylcholine-dependent vasodilation (P<0.001). Ipragliflozin did not alter metabolic parameters, such as body weight and food intake. Ipragliflozin administration ameliorated impaired phosphorylation of Akt and eNOSSer1177 in the abdominal aorta and reduced reactive oxygen species generation as determined by urinary excretion of 8-OHdG in diabetic mice. Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P<0.05). In in vitro studies, incubation with methylglyoxal, one of the advanced glycation end products, significantly impaired phosphorylation of Akt and eNOSSer1177 (P<0.01) and increased the expression of MCP-1, VCAM-1, and ICAM-1 in HUVEC.CONCLUSION: Ipragliflozin improved hyperglycemia and prevented the development of endothelial dysfunction under a hyperglycemic state, at least partially by attenuation of oxidative stress.","ja":"BACKGROUND: Endothelial dysfunction caused by increased oxidative stress is a critical initiator of macro- and micro-vascular disease development in diabetic patients. Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. The aim of this study was to examine whether ipragliflozin attenuates endothelial dysfunction in diabetic mice.METHODS: Eight-week-old male C57BL/6 mice were treated with streptozotocin (150mg/kg) by a single intraperitoneal injection to induce diabetes mellitus. At 3days of injection, ipragliflozin (3mg/kg/day) was administered via gavage for 3weeks. Vascular function was assessed by isometric tension recording. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. RNA and protein expression were examined by quantitative RT-PCR (qPCR) and western blot, respectively. Oxidative stress was determined by measuring urine 8-hydroxy-2'-deoxyguanosine (8-OHdG) level.RESULTS: Ipragliflozin administration significantly reduced blood glucose level (P<0.001) and attenuated the impairment of endothelial function in diabetic mice, as determined by acetylcholine-dependent vasodilation (P<0.001). Ipragliflozin did not alter metabolic parameters, such as body weight and food intake. Ipragliflozin administration ameliorated impaired phosphorylation of Akt and eNOSSer1177 in the abdominal aorta and reduced reactive oxygen species generation as determined by urinary excretion of 8-OHdG in diabetic mice. Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P<0.05). In in vitro studies, incubation with methylglyoxal, one of the advanced glycation end products, significantly impaired phosphorylation of Akt and eNOSSer1177 (P<0.01) and increased the expression of MCP-1, VCAM-1, and ICAM-1 in HUVEC.CONCLUSION: Ipragliflozin improved hyperglycemia and prevented the development of endothelial dysfunction under a hyperglycemic state, at least partially by attenuation of oxidative stress."},"publication_date":"2016-10-26","publication_name":{"en":"Frontiers in Cardiovascular Medicine","ja":"Frontiers in Cardiovascular Medicine"},"volume":"Vol.3","starting_page":"43","ending_page":"43","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fcvm.2016.00043"],"issn":["2297-055X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27628220","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84992462594&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=319241","label":"url"}],"paper_title":{"en":"Purulent pericarditis accompanying pericardial abscess induced by nocardia in an immunocompromised patient.","ja":"Purulent pericarditis accompanying pericardial abscess induced by nocardia in an immunocompromised patient."},"authors":{"en":[{"name":"Takashima A"},{"name":"Yagi Shusuke"},{"name":"Yamaguchi Koji"},{"name":"Watanabe S"},{"name":"Yamamoto N"},{"name":"Ito H"},{"name":"Kadota M"},{"name":"Hara T"},{"name":"Yamazaki H"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Tobiume Takeshi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"Takashima A"},{"name":"八木 秀介"},{"name":"山口 浩司"},{"name":"Watanabe S"},{"name":"Yamamoto N"},{"name":"Ito H"},{"name":"Kadota M"},{"name":"Hara T"},{"name":"Yamazaki H"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"飛梅 威"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"publication_date":"2016-10-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.80","number":"No.11","starting_page":"2409","ending_page":"2411","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-16-0531"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27744130","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84991678518&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320945","label":"url"}],"paper_title":{"en":"Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation.","ja":"Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation."},"authors":{"en":[{"name":"Takashima A"},{"name":"Fukuda Daiju"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"Hirata Y"},{"name":"Nishimoto S"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Taketani Yutaka"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Takashima A"},{"name":"福田 大受"},{"name":"Tanaka K"},{"name":"Higashikuni Y"},{"name":"Hirata Y"},{"name":"Nishimoto S"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"竹谷 豊"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND AND AIMS: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are major components of n-3 polyunsaturated fatty acids (n-3 PUFAs) which inhibit atherogenesis, although few studies have examined the effects of the combination of EPA and DHA on atherogenesis. The aim of this study was to investigate whether DHA has additional anti-atherosclerotic effects when combined with EPA.METHODS: Male 8-week-old apolipoprotein E-deficient (Apoe-/-) mice were fed a western-type diet supplemented with different amounts of EPA and DHA; EPA (2.5%, w/w), low-dose EPA + DHA (2.5%, w/w), or high-dose EPA + DHA (5%, w/w) for 20 weeks. The control group was fed a western-type diet containing no n-3 PUFA. Histological and gene expression analysis were performed in atherosclerotic lesions in the aorta. To address the mechanisms, RAW264.7 cells were used.RESULTS: All n-3 PUFA treatments significantly attenuated the development and destabilization of atherosclerotic plaques compared with the control. The anti-atherosclerotic effects were enhanced in the high-dose EPA + DHA group (p < 0.001), whereas the pure EPA group and low-dose EPA + DHA group showed similar results. EPA and DHA additively attenuated the expression of inflammatory molecules in RAW264.7 cells stimulated with LPS. DHA or EPA + DHA suppressed LPS-induced toll-like receptor 4 (TLR4) expression in lipid rafts on RAW264.7 cells (p < 0.05). Lipid raft disruption by methyl--cyclodextrin suppressed mRNA expression of inflammatory molecules in LPS-stimulated macrophages.CONCLUSION: n-3 PUFAs suppressed atherogenesis. DHA combined with EPA had additional anti-inflammatory effects and inhibited atherogenesis in Apoe-/- mice. The reduction of TLR4 expression in lipid rafts in macrophages by DHA might be involved in this mechanism, at least partially.","ja":"BACKGROUND AND AIMS: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are major components of n-3 polyunsaturated fatty acids (n-3 PUFAs) which inhibit atherogenesis, although few studies have examined the effects of the combination of EPA and DHA on atherogenesis. The aim of this study was to investigate whether DHA has additional anti-atherosclerotic effects when combined with EPA.METHODS: Male 8-week-old apolipoprotein E-deficient (Apoe-/-) mice were fed a western-type diet supplemented with different amounts of EPA and DHA; EPA (2.5%, w/w), low-dose EPA + DHA (2.5%, w/w), or high-dose EPA + DHA (5%, w/w) for 20 weeks. The control group was fed a western-type diet containing no n-3 PUFA. Histological and gene expression analysis were performed in atherosclerotic lesions in the aorta. To address the mechanisms, RAW264.7 cells were used.RESULTS: All n-3 PUFA treatments significantly attenuated the development and destabilization of atherosclerotic plaques compared with the control. The anti-atherosclerotic effects were enhanced in the high-dose EPA + DHA group (p < 0.001), whereas the pure EPA group and low-dose EPA + DHA group showed similar results. EPA and DHA additively attenuated the expression of inflammatory molecules in RAW264.7 cells stimulated with LPS. DHA or EPA + DHA suppressed LPS-induced toll-like receptor 4 (TLR4) expression in lipid rafts on RAW264.7 cells (p < 0.05). Lipid raft disruption by methyl--cyclodextrin suppressed mRNA expression of inflammatory molecules in LPS-stimulated macrophages.CONCLUSION: n-3 PUFAs suppressed atherogenesis. DHA combined with EPA had additional anti-inflammatory effects and inhibited atherogenesis in Apoe-/- mice. The reduction of TLR4 expression in lipid rafts in macrophages by DHA might be involved in this mechanism, at least partially."},"publication_date":"2016-10-05","publication_name":{"en":"Atherosclerosis","ja":"Atherosclerosis"},"volume":"Vol.254","starting_page":"142","ending_page":"150","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.atherosclerosis.2016.10.002"],"issn":["1879-1484"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390001205281332224/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=326050","label":"url"}],"paper_title":{"en":"解剖学的異常を認めない膝窩動脈捕捉症候群の1例","ja":"解剖学的異常を認めない膝窩動脈捕捉症候群の1例"},"authors":{"en":[{"name":"鳥居 裕太"},{"name":"西尾 進"},{"name":"玉井 佑里恵"},{"name":"山崎 宙"},{"name":"Takao Shoichiro"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Wakatsuki Tetsuzo"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"鳥居 裕太"},{"name":"西尾 進"},{"name":"玉井 佑里恵"},{"name":"山崎 宙"},{"name":"髙尾 正一郎"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"若槻 哲三"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2016-10","publication_name":{"en":"Japanese Journal of Medical Ultrasound Technology","ja":"超音波検査技術"},"volume":"Vol.41","number":"No.5","starting_page":"513","ending_page":"520","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.11272/jss.41.513"],"issn":["1881-4506"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27273599","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85027917138&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=313865","label":"url"}],"paper_title":{"en":"Long-chain monounsaturated fatty acid-rich fish oil attenuates the development of atherosclerosis in mouse models.","ja":"Long-chain monounsaturated fatty acid-rich fish oil attenuates the development of atherosclerosis in mouse models."},"authors":{"en":[{"name":"Yang Zhi-Hong"},{"name":"Bando Masahiro"},{"name":"Sakurai Toshihiro"},{"name":"Chen Ye"},{"name":"Emma-Okon Beatrice"},{"name":"Wilhite Bree"},{"name":"Fukuda Daiju"},{"name":"Vaisman Boris"},{"name":"Pryor Milton"},{"name":"Wakabayashi Yoshiyuki"},{"name":"Sampson Maureen"},{"name":"Yu Zu-Xi"},{"name":"Sakurai Akiko"},{"name":"Zarzour Abdalrahman"},{"name":"Miyahara Hiroko"},{"name":"Takeo Jiro"},{"name":"Sakaue Hiroshi"},{"name":"Sata Masataka"},{"name":"Remaley T. Alan"}],"ja":[{"name":"Yang Zhi-Hong"},{"name":"板東 正浩"},{"name":"Sakurai Toshihiro"},{"name":"Chen Ye"},{"name":"Emma-Okon Beatrice"},{"name":"Wilhite Bree"},{"name":"福田 大受"},{"name":"Vaisman Boris"},{"name":"Pryor Milton"},{"name":"Wakabayashi Yoshiyuki"},{"name":"Sampson Maureen"},{"name":"Yu Zu-Xi"},{"name":"Sakurai Akiko"},{"name":"Zarzour Abdalrahman"},{"name":"Miyahara Hiroko"},{"name":"Takeo Jiro"},{"name":"阪上 浩"},{"name":"佐田 政隆"},{"name":"Remaley T. Alan"}]},"description":{"en":"SCOPE: Fish oil-derived long-chain monounsaturated fatty acids (LCMUFA) containing chain lengths longer than 18 were previously shown to improve cardiovascular disease risk factors in mice. However, it is not known if LCMUFA also exerts anti-atherogenic effects. The main objective of the present study was to investigate the effect of LCMUFA on the development of atherosclerosis in mouse models.METHODS AND RESULTS: LDLR-KO mice were fed Western diet supplemented with 2% (w/w) of either LCMUFA concentrate, olive oil, or not (control) for 12 wk. LCMUFA, but not olive oil, significantly suppressed the development of atherosclerotic lesions and several plasma inflammatory cytokine levels, although there were no major differences in plasma lipids between the three groups. At higher doses 5% (w/w) LCMUFA supplementation was observed to reduce pro-atherogenic plasma lipoproteins and to also reduce atherosclerosis in ApoE-KO mice fed a Western diet. RNA sequencing and subsequent qPCR analyses revealed that LCMUFA upregulated PPAR signaling pathways in liver. In cell culture studies, apoB-depleted plasma from LDLR-K mice fed LCMUFA showed greater cholesterol efflux from macrophage-like THP-1 cells and ABCA1-overexpressing BHK cells.CONCLUSION: Our research showed for the first time that LCMUFA consumption protects against diet-induced atherosclerosis, possibly by upregulating the PPAR signaling pathway.","ja":"SCOPE: Fish oil-derived long-chain monounsaturated fatty acids (LCMUFA) containing chain lengths longer than 18 were previously shown to improve cardiovascular disease risk factors in mice. However, it is not known if LCMUFA also exerts anti-atherogenic effects. The main objective of the present study was to investigate the effect of LCMUFA on the development of atherosclerosis in mouse models.METHODS AND RESULTS: LDLR-KO mice were fed Western diet supplemented with 2% (w/w) of either LCMUFA concentrate, olive oil, or not (control) for 12 wk. LCMUFA, but not olive oil, significantly suppressed the development of atherosclerotic lesions and several plasma inflammatory cytokine levels, although there were no major differences in plasma lipids between the three groups. At higher doses 5% (w/w) LCMUFA supplementation was observed to reduce pro-atherogenic plasma lipoproteins and to also reduce atherosclerosis in ApoE-KO mice fed a Western diet. RNA sequencing and subsequent qPCR analyses revealed that LCMUFA upregulated PPAR signaling pathways in liver. In cell culture studies, apoB-depleted plasma from LDLR-K mice fed LCMUFA showed greater cholesterol efflux from macrophage-like THP-1 cells and ABCA1-overexpressing BHK cells.CONCLUSION: Our research showed for the first time that LCMUFA consumption protects against diet-induced atherosclerosis, possibly by upregulating the PPAR signaling pathway."},"publication_date":"2016-10","publication_name":{"en":"Molecular Nutrition & Food Research","ja":"Molecular Nutrition & Food Research"},"volume":"Vol.60","number":"No.10","starting_page":"2208","ending_page":"2218","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/mnfr.201600142"],"issn":["1613-4125"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114511","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27624168","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84992361845&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=344831","label":"url"}],"paper_title":{"en":"Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.","ja":"Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study."},"authors":{"en":[{"name":"Maruhashi Tatsuya"},{"name":"Higashi Yukihito"},{"name":"Kihara Yasuki"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"},{"name":"Ueda Shinichiro"},{"name":"Odawara Masato"},{"name":"Terauchi Yasuo"},{"name":"Dai Kazuoki"},{"name":"Ohno Jun"},{"name":"Iida Masato"},{"name":"Sano Hiroaki"},{"name":"Tomiyama Hirofumi"},{"name":"Inoue Teruo"},{"name":"Tanaka Atsushi"},{"name":"Murohara Toyoaki"},{"name":"Node Koichi"}],"ja":[{"name":"Maruhashi Tatsuya"},{"name":"Higashi Yukihito"},{"name":"Kihara Yasuki"},{"name":"山田 博胤"},{"name":"佐田 政隆"},{"name":"Ueda Shinichiro"},{"name":"Odawara Masato"},{"name":"Terauchi Yasuo"},{"name":"Dai Kazuoki"},{"name":"Ohno Jun"},{"name":"Iida Masato"},{"name":"Sano Hiroaki"},{"name":"Tomiyama Hirofumi"},{"name":"Inoue Teruo"},{"name":"Tanaka Atsushi"},{"name":"Murohara Toyoaki"},{"name":"Node Koichi"}]},"description":{"en":"As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment. HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 0.4 vs. 6.6 0.3 and 6.6 0.4 % in the sitagliptin group; 7.0 0.6 vs. 6.6 0.7 and 6.6 0.7 % in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 2.6 vs. 4.4 2.1 and 4.4 2.3 %, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 2.4 % at baseline to 5.2 1.9 % after 12 months and 5.1 2.2 % after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively). Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. University hospital Medical Information Network (UMIN) Center: ID UMIN000004490.","ja":"As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment. HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 0.4 vs. 6.6 0.3 and 6.6 0.4 % in the sitagliptin group; 7.0 0.6 vs. 6.6 0.7 and 6.6 0.7 % in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 2.6 vs. 4.4 2.1 and 4.4 2.3 %, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 2.4 % at baseline to 5.2 1.9 % after 12 months and 5.1 2.2 % after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively). Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. University hospital Medical Information Network (UMIN) Center: ID UMIN000004490."},"publication_date":"2016-09-13","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.15","number":"No.1","starting_page":"134","ending_page":"134","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-016-0438-x"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114507","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27619983","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320476","label":"url"}],"paper_title":{"en":"Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.","ja":"Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study."},"authors":{"en":[{"name":"Tanaka A"},{"name":"Murohara T"},{"name":"Taguchi I"},{"name":"Eguchi K"},{"name":"Suzuki M"},{"name":"Kitakaze M"},{"name":"Sato Y"},{"name":"Ishizu T"},{"name":"Higashi Y"},{"name":"Yamada Hirotsugu"},{"name":"Nanasato M"},{"name":"Shimabukuro Michio"},{"name":"Teragawa H"},{"name":"Ueda S"},{"name":"Kodera S"},{"name":"Matsuhisa Munehide"},{"name":"Kadokami T"},{"name":"Kario K"},{"name":"Nishio Y"},{"name":"Inoue T"},{"name":"Maemura K"},{"name":"Oyama J"},{"name":"Ohishi M"},{"name":"Sata Masataka"},{"name":"Tomiyama H"},{"name":"Node K"},{"name":"PROTECT Study Investigators"}],"ja":[{"name":"Tanaka A"},{"name":"Murohara T"},{"name":"Taguchi I"},{"name":"Eguchi K"},{"name":"Suzuki M"},{"name":"Kitakaze M"},{"name":"Sato Y"},{"name":"Ishizu T"},{"name":"Higashi Y"},{"name":"山田 博胤"},{"name":"Nanasato M"},{"name":"島袋 充生"},{"name":"Teragawa H"},{"name":"Ueda S"},{"name":"Kodera S"},{"name":"松久 宗英"},{"name":"Kadokami T"},{"name":"Kario K"},{"name":"Nishio Y"},{"name":"Inoue T"},{"name":"Maemura K"},{"name":"Oyama J"},{"name":"Ohishi M"},{"name":"佐田 政隆"},{"name":"Tomiyama H"},{"name":"Node K"},{"name":"PROTECT Study Investigators"}]},"description":{"en":"BACKGROUND: Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy. In addition to appropriate glycemic control, multi-factorial intervention for a wide range of risk factors, such as hypertension and dyslipidemia, is crucial for management of diabetes. A recent cardiovascular outcome trial in diabetes patients with higher cardiovascular risk demonstrated that a SGLT2 inhibitor markedly reduced mortality, but not macro-vascular events. However, to date there is no clinical evidence regarding the therapeutic effects of SGLT2 inhibitors on arteriosclerosis. The ongoing PROTECT trial was designed to assess whether the SGLT2 inhibitors, ipragliflozin, prevented progression of carotid intima-media thickness in Japanese patients with type 2 diabetes mellitus.METHODS: A total of 480 participants with type 2 diabetes mellitus with a HbA1c between 6 and 10 % despite receiving diet/exercise therapy and/or standard anti-diabetic agents for at least 3 months, will be randomized systematically (1:1) into either ipragliflozin or control (continuation of conventional therapy) groups. After randomization, ipragliflozin (50-100 mg once daily) will be added on to the background therapy in participants assigned to the ipragliflozin group. The primary endpoint of the study is the change in mean intima-media thickness of the common carotid artery from baseline to 24 months. Images of carotid intima-media thickness will be analyzed at a central core laboratory in a blinded manner. The key secondary endpoints include the change from baseline in other parameters of carotid intima-media thickness, various metabolic parameters, and renal function. Other cardiovascular functional tests are also planned for several sub-studies.DISCUSSION: The PROTECT study is the first to assess the preventive effect of ipragliflozin on progression of carotid atherosclerosis using carotid intima-media thickness as a surrogate marker. The study has potential to clarify the protective effects of ipragliflozin on atherosclerosis. Trial registration Unique Trial Number, UMIN000018440 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021348 ).","ja":"BACKGROUND: Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy. In addition to appropriate glycemic control, multi-factorial intervention for a wide range of risk factors, such as hypertension and dyslipidemia, is crucial for management of diabetes. A recent cardiovascular outcome trial in diabetes patients with higher cardiovascular risk demonstrated that a SGLT2 inhibitor markedly reduced mortality, but not macro-vascular events. However, to date there is no clinical evidence regarding the therapeutic effects of SGLT2 inhibitors on arteriosclerosis. The ongoing PROTECT trial was designed to assess whether the SGLT2 inhibitors, ipragliflozin, prevented progression of carotid intima-media thickness in Japanese patients with type 2 diabetes mellitus.METHODS: A total of 480 participants with type 2 diabetes mellitus with a HbA1c between 6 and 10 % despite receiving diet/exercise therapy and/or standard anti-diabetic agents for at least 3 months, will be randomized systematically (1:1) into either ipragliflozin or control (continuation of conventional therapy) groups. After randomization, ipragliflozin (50-100 mg once daily) will be added on to the background therapy in participants assigned to the ipragliflozin group. The primary endpoint of the study is the change in mean intima-media thickness of the common carotid artery from baseline to 24 months. Images of carotid intima-media thickness will be analyzed at a central core laboratory in a blinded manner. The key secondary endpoints include the change from baseline in other parameters of carotid intima-media thickness, various metabolic parameters, and renal function. Other cardiovascular functional tests are also planned for several sub-studies.DISCUSSION: The PROTECT study is the first to assess the preventive effect of ipragliflozin on progression of carotid atherosclerosis using carotid intima-media thickness as a surrogate marker. The study has potential to clarify the protective effects of ipragliflozin on atherosclerosis. Trial registration Unique Trial Number, UMIN000018440 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021348 )."},"publication_date":"2016-09-13","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.15","number":"No.1","starting_page":"133","ending_page":"133","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-016-0449-7"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324067","label":"url"}],"paper_title":{"en":"糖転移ヘスペリジン/分散ヘスペレチンの動脈硬化病巣進展に対する抑制効果についての検討","ja":"糖転移ヘスペリジン/分散ヘスペレチンの動脈硬化病巣進展に対する抑制効果についての検討"},"authors":{"en":[{"name":"菅澤 典子"},{"name":"Nishio Chika"},{"name":"中山 泰介"},{"name":"Kurobe Hirotsugu"},{"name":"宅見 央子"},{"name":"東口 文治"},{"name":"Aihara Ken-ichi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"},{"name":"Kitagawa Tetsuya"}],"ja":[{"name":"菅澤 典子"},{"name":"西雄 千佳"},{"name":"中山 泰介"},{"name":"黒部 裕嗣"},{"name":"宅見 央子"},{"name":"東口 文治"},{"name":"粟飯原 賢一"},{"name":"島袋 充生"},{"name":"佐田 政隆"},{"name":"北川 哲也"}]},"publication_date":"2016-09","publication_name":{"en":"The Journal of Metabolism and Clinical Nutrition","ja":"日本病態栄養学会誌"},"volume":"Vol.19","number":"No.3","starting_page":"351","ending_page":"360","languages":["jpn"],"referee":true,"identifiers":{"issn":["1345-8167"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26829053","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305871","label":"url"}],"paper_title":{"en":"ALKR1275Q perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.","ja":"ALKR1275Q perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN."},"authors":{"en":[{"name":"Ueda T"},{"name":"Nakata Y"},{"name":"Yamasaki N"},{"name":"Oda H"},{"name":"Sentani K"},{"name":"Kanai A"},{"name":"Onishi N"},{"name":"Ikeda K"},{"name":"Sera Y"},{"name":"Honda Z"},{"name":"Tanaka K"},{"name":"Sata Masataka"},{"name":"Ogawa S"},{"name":"Yasui W"},{"name":"Saya H"},{"name":"Takita J"},{"name":"Honda H"}],"ja":[{"name":"Ueda T"},{"name":"Nakata Y"},{"name":"Yamasaki N"},{"name":"Oda H"},{"name":"Sentani K"},{"name":"Kanai A"},{"name":"Onishi N"},{"name":"Ikeda K"},{"name":"Sera Y"},{"name":"Honda Z"},{"name":"Tanaka K"},{"name":"佐田 政隆"},{"name":"Ogawa S"},{"name":"Yasui W"},{"name":"Saya H"},{"name":"Takita J"},{"name":"Honda H"}]},"description":{"en":"Overexpression of MYCN is a hallmark of neuroblastoma (NB). ALK(R1275Q), an activating mutation of ALK (anaplastic lymphoma kinase), has been found in sporadic and familial NB patients. In this report, we demonstrated that ALK(R1275Q) knock-in, MYCN transgenic compound mice developed NB with complete penetrance. Transcriptome analysis revealed that ALK(R1275Q) globally downregulated the expression of extracellular matrix (ECM)- and basement membrane (BM)-associated genes in both primary neuronal cells and NB tumors. Accordingly, ALK(R1275Q)/MYCN tumors exhibited reduced expression of ECM/BM-related proteins as compared with MYCN tumors. In addition, on MYCN transduction, ALK(R1275Q)-expressing neuronal cells exhibited increased migratory and invasive activities. Consistently, enhanced invasion and metastasis were demonstrated in ALK(R1275Q)/MYCN mice. These results collectively indicate that ALK(R1275Q) confers a malignant potential on neuronal cells that overexpress MYCN by impairing normal ECM/BM integrity and enhancing tumor growth and dissemination. Moreover, we found that crizotinib, an ALK inhibitor, almost completely inhibited the growth of ALK(R1275Q)/MYCN tumors in an allograft model. Our findings provided insights into the cooperative mechanism of the mutated ALK and overexpressed MYCN in the pathogenesis of NB and demonstrated the effectiveness of crizotinib on ALK(R1275Q)-positive tumors.","ja":"Overexpression of MYCN is a hallmark of neuroblastoma (NB). ALK(R1275Q), an activating mutation of ALK (anaplastic lymphoma kinase), has been found in sporadic and familial NB patients. In this report, we demonstrated that ALK(R1275Q) knock-in, MYCN transgenic compound mice developed NB with complete penetrance. Transcriptome analysis revealed that ALK(R1275Q) globally downregulated the expression of extracellular matrix (ECM)- and basement membrane (BM)-associated genes in both primary neuronal cells and NB tumors. Accordingly, ALK(R1275Q)/MYCN tumors exhibited reduced expression of ECM/BM-related proteins as compared with MYCN tumors. In addition, on MYCN transduction, ALK(R1275Q)-expressing neuronal cells exhibited increased migratory and invasive activities. Consistently, enhanced invasion and metastasis were demonstrated in ALK(R1275Q)/MYCN mice. These results collectively indicate that ALK(R1275Q) confers a malignant potential on neuronal cells that overexpress MYCN by impairing normal ECM/BM integrity and enhancing tumor growth and dissemination. Moreover, we found that crizotinib, an ALK inhibitor, almost completely inhibited the growth of ALK(R1275Q)/MYCN tumors in an allograft model. Our findings provided insights into the cooperative mechanism of the mutated ALK and overexpressed MYCN in the pathogenesis of NB and demonstrated the effectiveness of crizotinib on ALK(R1275Q)-positive tumors."},"publication_date":"2016-08-25","publication_name":{"en":"Oncogene","ja":"Oncogene"},"volume":"Vol.35","number":"No.34","starting_page":"4447","ending_page":"4458","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/onc.2015.519"],"issn":["1476-5594"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109694","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27357439","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84979587993&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=309204","label":"url"}],"paper_title":{"en":"Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin.","ja":"Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin."},"authors":{"en":[{"name":"Kadota M"},{"name":"Ise Takayuki"},{"name":"Yagi Shusuke"},{"name":"Iwase Takashi"},{"name":"Akaike Masashi"},{"name":"Ueno R"},{"name":"Kawabata Y"},{"name":"Hara T"},{"name":"Ogasawara K"},{"name":"Bando Mika"},{"name":"Bando S"},{"name":"Matsuura Tomomi"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"Kadota M"},{"name":"伊勢 孝之"},{"name":"八木 秀介"},{"name":"岩瀬 俊"},{"name":"赤池 雅史"},{"name":"Ueno R"},{"name":"Kawabata Y"},{"name":"Hara T"},{"name":"Ogasawara K"},{"name":"坂東 美佳"},{"name":"Bando S"},{"name":"松浦 朋美"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"The renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP) regulate body fluids. Although conventional diuretics have been used for treating heart failure, they activate RAAS and exacerbate renal function. Tolvaptan, a newly developed vasopressin-2 receptor antagonist, elicits aquaresis and improves volume overload in heart failure patients, however, the predictors of tolvaptan effectiveness and the influence on the RAAS and renal function according to tolvaptan therapy are not established. We evaluated 26 chronic heart failure patients receiving therapy with 15 mg/day tolvaptan and examined their laboratory and urinary data before and after tolvaptan therapy. A response to tolvaptan was defined as a body weight decrease by more than 2 kg in a week and a urine volume increase by 500 mL/ day compared with that before tolvaptan administration. Body weight, urine volume, and brain natriuretic peptide levels significantly improved (P < 0.05), without any worsening of renal function represented by serum creatinine, sodium, and potassium. Moreover, no significant changes were observed in the plasma renin activity and plasma aldosterone concentration (PAC). In the responder group, urine osmolality before tolvaptan administration was significantly higher (P < 0.05) but declined significantly after tolvaptan administration (P < 0.05). The AVP/PAC ratio before administration was positively correlated with the efficacy of tolvaptan. Tolvaptan treatment could prevent RAAS activation in chronic heart failure patients. Moreover, monitoring the AVP/PAC ratio may be useful in predicting the tolvaptan response.","ja":"The renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP) regulate body fluids. Although conventional diuretics have been used for treating heart failure, they activate RAAS and exacerbate renal function. Tolvaptan, a newly developed vasopressin-2 receptor antagonist, elicits aquaresis and improves volume overload in heart failure patients, however, the predictors of tolvaptan effectiveness and the influence on the RAAS and renal function according to tolvaptan therapy are not established. We evaluated 26 chronic heart failure patients receiving therapy with 15 mg/day tolvaptan and examined their laboratory and urinary data before and after tolvaptan therapy. A response to tolvaptan was defined as a body weight decrease by more than 2 kg in a week and a urine volume increase by 500 mL/ day compared with that before tolvaptan administration. Body weight, urine volume, and brain natriuretic peptide levels significantly improved (P < 0.05), without any worsening of renal function represented by serum creatinine, sodium, and potassium. Moreover, no significant changes were observed in the plasma renin activity and plasma aldosterone concentration (PAC). In the responder group, urine osmolality before tolvaptan administration was significantly higher (P < 0.05) but declined significantly after tolvaptan administration (P < 0.05). The AVP/PAC ratio before administration was positively correlated with the efficacy of tolvaptan. Tolvaptan treatment could prevent RAAS activation in chronic heart failure patients. Moreover, monitoring the AVP/PAC ratio may be useful in predicting the tolvaptan response."},"publication_date":"2016-07-27","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.57","number":"No.4","starting_page":"461","ending_page":"465","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.15-491"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27086574","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84982113330&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=309517","label":"url"}],"paper_title":{"en":"Depot- and gender-specific expression of NLRP3 inflammasome and toll-like receptors in adipose tissue of cancer patients.","ja":"Depot- and gender-specific expression of NLRP3 inflammasome and toll-like receptors in adipose tissue of cancer patients."},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Sato H"},{"name":"Izaki Hirofumi"},{"name":"Fukuda Daiju"},{"name":"Uematsu E"},{"name":"Hirata Y"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Sakaue Hiroshi"},{"name":"Kanayama Hiro-omi"},{"name":"Masuzaki H"},{"name":"Sata Masataka"}],"ja":[{"name":"島袋 充生"},{"name":"Sato H"},{"name":"井崎 博文"},{"name":"福田 大受"},{"name":"Uematsu E"},{"name":"Hirata Y"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"阪上 浩"},{"name":"金山 博臣"},{"name":"Masuzaki H"},{"name":"佐田 政隆"}]},"publication_date":"2016-07-08","publication_name":{"en":"BioFactors","ja":"BioFactors"},"volume":"Vol.42","number":"No.4","starting_page":"397","ending_page":"406","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/biof.1287"],"issn":["1872-8081"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320021","label":"url"}],"paper_title":{"en":"表在エコー図検査と心エコー図検査のコラボレーションにより感染性心内膜炎が迅速に診断できた僧帽弁逸脱症の1例:Staphylococcus warneriによる自己弁への感染性心内膜炎","ja":"表在エコー図検査と心エコー図検査のコラボレーションにより感染性心内膜炎が迅速に診断できた僧帽弁逸脱症の1例:Staphylococcus warneriによる自己弁への感染性心内膜炎"},"authors":{"en":[{"name":"Yamada Hirotsugu"},{"name":"田中 秀和"},{"name":"宮原 俊介"},{"name":"尾形 竜郎"},{"name":"Kusunose Kenya"},{"name":"西尾 進"},{"name":"鳥居 裕太"},{"name":"平田 有紀奈"},{"name":"大北 裕"},{"name":"Sata Masataka"}],"ja":[{"name":"山田 博胤"},{"name":"田中 秀和"},{"name":"宮原 俊介"},{"name":"尾形 竜郎"},{"name":"楠瀬 賢也"},{"name":"西尾 進"},{"name":"鳥居 裕太"},{"name":"平田 有紀奈"},{"name":"大北 裕"},{"name":"佐田 政隆"}]},"description":{"en":"症例は,46歳男性,循環器内科医師,主訴は左足関節内果部と上腕の疼痛である.僧帽弁逸脱症による僧帽弁逆流と発作性心房細動の既往がある.足関節の疼痛は蜂窩織炎を疑って,血液検査と表在エコー図検査を行った.疼痛部は皮下浮腫が著明であったが,軟部組織の血流シグナルが乏しく,後脛骨動脈の血管壁を主体とした炎症と,同動脈の閉塞が確認された.一方,左手関節近位の尺骨動脈は逆行性血流を示しており,左尺骨動脈分岐部直後で閉塞していた.これらの所見から多発性血管閉塞性動脈炎と診断し,その原因究明のために直ちに心エコー図検査を施行した.その結果,僧帽弁に可動性を有する棍棒状の異常構造物を認め,僧帽弁逆流は高度に増悪しており,感染性心内膜炎と診断された.頭部MRI検査で異常を認めなかったため,外科的加療(疣腫摘除術,僧帽弁形成術,左房縫縮術,左心耳閉鎖術,Maze手術)が行われた.血液培養は陰性であったが,摘出した疣腫の培養からStaphylococcus warneriが同定された.Staphylococcus warneriは皮膚常在菌であり,本病原体による自己弁の感染性心内膜炎は報告が少ない.術後の経過は良好であり,抗生剤を6週間静脈投与した後に社会復帰した.患者が循環器内科医であり,自身の足関節および上腕の疼痛を契機に,表在エコー図検査と心エコー図検査を用いることで,感染性心内膜炎を迅速に診断した稀有な症例であり,かつ,感染性心内膜炎の起炎菌としては稀なStaphylococcus warneriが同定されたので,文献的な考察を加えて報告する.","ja":"症例は,46歳男性,循環器内科医師,主訴は左足関節内果部と上腕の疼痛である.僧帽弁逸脱症による僧帽弁逆流と発作性心房細動の既往がある.足関節の疼痛は蜂窩織炎を疑って,血液検査と表在エコー図検査を行った.疼痛部は皮下浮腫が著明であったが,軟部組織の血流シグナルが乏しく,後脛骨動脈の血管壁を主体とした炎症と,同動脈の閉塞が確認された.一方,左手関節近位の尺骨動脈は逆行性血流を示しており,左尺骨動脈分岐部直後で閉塞していた.これらの所見から多発性血管閉塞性動脈炎と診断し,その原因究明のために直ちに心エコー図検査を施行した.その結果,僧帽弁に可動性を有する棍棒状の異常構造物を認め,僧帽弁逆流は高度に増悪しており,感染性心内膜炎と診断された.頭部MRI検査で異常を認めなかったため,外科的加療(疣腫摘除術,僧帽弁形成術,左房縫縮術,左心耳閉鎖術,Maze手術)が行われた.血液培養は陰性であったが,摘出した疣腫の培養からStaphylococcus warneriが同定された.Staphylococcus warneriは皮膚常在菌であり,本病原体による自己弁の感染性心内膜炎は報告が少ない.術後の経過は良好であり,抗生剤を6週間静脈投与した後に社会復帰した.患者が循環器内科医であり,自身の足関節および上腕の疼痛を契機に,表在エコー図検査と心エコー図検査を用いることで,感染性心内膜炎を迅速に診断した稀有な症例であり,かつ,感染性心内膜炎の起炎菌としては稀なStaphylococcus warneriが同定されたので,文献的な考察を加えて報告する."},"publication_date":"2016-07","publication_name":{"en":"Japanese Journal of Medical Ultrasonics","ja":"超音波医学"},"volume":"Vol.43","number":"No.4","starting_page":"581","ending_page":"586","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.3179/jjmu.JJMU.A.63"],"issn":["1881-9311"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114321","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27351380","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=312697","label":"url"}],"paper_title":{"en":"The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.","ja":"The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial."},"authors":{"en":[{"name":"Oyama J"},{"name":"Murohara T"},{"name":"Kitakaze M"},{"name":"Ishizu T"},{"name":"Sato Y"},{"name":"Kitagawa K"},{"name":"Kamiya H"},{"name":"Ajioka M"},{"name":"Ishiara M"},{"name":"Dai K"},{"name":"Nanasato M"},{"name":"Sata Masataka"},{"name":"Maemura K"},{"name":"Tomiyama H"},{"name":"Higashi Y"},{"name":"Kaku K"},{"name":"Yamada Hirotsugu"},{"name":"Matsuhisa Munehide"},{"name":"Yamashita K"},{"name":"Bando YK"},{"name":"Kashihara N"},{"name":"Ueda S"},{"name":"Inoue T"},{"name":"Node K"},{"name":"PROLOGUE Study Investigators"}],"ja":[{"name":"Oyama J"},{"name":"Murohara T"},{"name":"Kitakaze M"},{"name":"Ishizu T"},{"name":"Sato Y"},{"name":"Kitagawa K"},{"name":"Kamiya H"},{"name":"Ajioka M"},{"name":"Ishiara M"},{"name":"Dai K"},{"name":"Nanasato M"},{"name":"佐田 政隆"},{"name":"Maemura K"},{"name":"Tomiyama H"},{"name":"Higashi Y"},{"name":"Kaku K"},{"name":"山田 博胤"},{"name":"松久 宗英"},{"name":"Yamashita K"},{"name":"Bando YK"},{"name":"Kashihara N"},{"name":"Ueda S"},{"name":"Inoue T"},{"name":"Node K"},{"name":"PROLOGUE Study Investigators"}]},"description":{"en":"BACKGROUND: Experimental studies have suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors provide cardiovascular protective effects. We performed a randomized study to evaluate the effects of sitagliptin added on to the conventional therapy compared with conventional therapy alone (diet, exercise, and/or drugs, except for incretin-related agents) on the intima-media thickness (IMT) of the carotid artery, a surrogate marker for the evaluation of atherosclerotic cardiovascular disease, in people with type 2 diabetes mellitus (T2DM).METHODS AND FINDINGS: We used a multicenter PROBE (prospective, randomized, open label, blinded endpoint) design. Individuals aged 30 y with T2DM (6.2% HbA1c < 9.4%) were randomly allocated to receive either sitagliptin (25 to 100 mg/d) or conventional therapy. Carotid ultrasound was performed at participating medical centers, and all parameters were measured in a core laboratory. Of the 463 enrolled participants with T2DM, 442 were included in the primary analysis (sitagliptin group, 222; conventional therapy group, 220). Estimated mean (± standard error) common carotid artery IMT at 24 mo of follow-up in the sitagliptin and conventional therapy groups was 0.827 ± 0.007 mm and 0.837 ± 0.007 mm, respectively, with a mean difference of -0.009 mm (97.2% CI -0.028 to 0.011, p = 0.309). HbA1c level at 24 mo was significantly lower with sitagliptin than with conventional therapy (6.56% ± 0.05% versus 6.72% ± 0.05%, p = 0.008; group mean difference -0.159, 95% CI -0.278 to -0.041). Episodes of serious hypoglycemia were recorded only in the conventional therapy group, and the rate of other adverse events was not different between the two groups. As it was not a placebo-controlled trial and carotid IMT was measured as a surrogate marker of atherosclerosis, there were some limitations of interpretation.CONCLUSIONS: In the PROLOGUE study, there was no evidence that treatment with sitagliptin had an additional effect on the progression of carotid IMT in participants with T2DM beyond that achieved with conventional treatment.TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry UMIN000004490.","ja":"BACKGROUND: Experimental studies have suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors provide cardiovascular protective effects. We performed a randomized study to evaluate the effects of sitagliptin added on to the conventional therapy compared with conventional therapy alone (diet, exercise, and/or drugs, except for incretin-related agents) on the intima-media thickness (IMT) of the carotid artery, a surrogate marker for the evaluation of atherosclerotic cardiovascular disease, in people with type 2 diabetes mellitus (T2DM).METHODS AND FINDINGS: We used a multicenter PROBE (prospective, randomized, open label, blinded endpoint) design. Individuals aged 30 y with T2DM (6.2% HbA1c < 9.4%) were randomly allocated to receive either sitagliptin (25 to 100 mg/d) or conventional therapy. Carotid ultrasound was performed at participating medical centers, and all parameters were measured in a core laboratory. Of the 463 enrolled participants with T2DM, 442 were included in the primary analysis (sitagliptin group, 222; conventional therapy group, 220). Estimated mean (± standard error) common carotid artery IMT at 24 mo of follow-up in the sitagliptin and conventional therapy groups was 0.827 ± 0.007 mm and 0.837 ± 0.007 mm, respectively, with a mean difference of -0.009 mm (97.2% CI -0.028 to 0.011, p = 0.309). HbA1c level at 24 mo was significantly lower with sitagliptin than with conventional therapy (6.56% ± 0.05% versus 6.72% ± 0.05%, p = 0.008; group mean difference -0.159, 95% CI -0.278 to -0.041). Episodes of serious hypoglycemia were recorded only in the conventional therapy group, and the rate of other adverse events was not different between the two groups. As it was not a placebo-controlled trial and carotid IMT was measured as a surrogate marker of atherosclerosis, there were some limitations of interpretation.CONCLUSIONS: In the PROLOGUE study, there was no evidence that treatment with sitagliptin had an additional effect on the progression of carotid IMT in participants with T2DM beyond that achieved with conventional treatment.TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry UMIN000004490."},"publication_date":"2016-06-28","publication_name":{"en":"PLoS Medicine","ja":"PLoS Medicine"},"volume":"Vol.13","number":"No.6","starting_page":"e1002051","ending_page":"e1002051","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pmed.1002051"],"issn":["1549-1676"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114506","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27317093","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84975229374&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=313985","label":"url"}],"paper_title":{"en":"Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.","ja":"Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study."},"authors":{"en":[{"name":"Oyama Jun-Ichi"},{"name":"Tanaka Atsushi"},{"name":"Sato Yasunori"},{"name":"Tomiyama Hirofumi"},{"name":"Sata Masataka"},{"name":"Ishizu Tomoko"},{"name":"Taguchi Isao"},{"name":"Kuroyanagi Takanori"},{"name":"Teragawa Hiroki"},{"name":"Ishizaka Nobukazu"},{"name":"Kanzaki Yumiko"},{"name":"Ohishi Mitsuru"},{"name":"Eguchi Kazuo"},{"name":"Higashi Yukihito"},{"name":"Yamada Hirotsugu"},{"name":"Maemura Koji"},{"name":"Ako Junya"},{"name":"Bando K. Yasuko"},{"name":"Ueda Shinichiro"},{"name":"Inoue Teruo"},{"name":"Murohara Toyoaki"},{"name":"Node Koichi"}],"ja":[{"name":"Oyama Jun-Ichi"},{"name":"Tanaka Atsushi"},{"name":"Sato Yasunori"},{"name":"Tomiyama Hirofumi"},{"name":"佐田 政隆"},{"name":"Ishizu Tomoko"},{"name":"Taguchi Isao"},{"name":"Kuroyanagi Takanori"},{"name":"Teragawa Hiroki"},{"name":"Ishizaka Nobukazu"},{"name":"Kanzaki Yumiko"},{"name":"Ohishi Mitsuru"},{"name":"Eguchi Kazuo"},{"name":"Higashi Yukihito"},{"name":"山田 博胤"},{"name":"Maemura Koji"},{"name":"Ako Junya"},{"name":"Bando K. Yasuko"},{"name":"Ueda Shinichiro"},{"name":"Inoue Teruo"},{"name":"Murohara Toyoaki"},{"name":"Node Koichi"}]},"description":{"en":"BACKGROUND: Xanthine oxidase inhibitors are anti-hyperuricemic drugs that decrease serum uric acid levels by inhibiting its synthesis. Xanthine oxidase is also recognized as a pivotal enzyme in the production of oxidative stress. Excess oxidative stress induces endothelial dysfunction and inflammatory reactions in vascular systems, leading to atherosclerosis. Many experimental studies have suggested that xanthine oxidase inhibitors have anti-atherosclerotic effects by decreasing in vitro and in vivo oxidative stress. However, there is only limited evidence on the clinical implications of xanthine oxidase inhibitors on atherosclerotic cardiovascular disease in patients with hyperuricemia. We designed the PRIZE study to evaluate the effects of febuxostat on a surrogate marker of cardiovascular disease risk, ultrasonography-based intima-media thickness of the carotid artery in patients with hyperuricemia.METHODS: The study is a multicenter, prospective, randomized, open-label and blinded-endpoint evaluation (PROBE) design. A total of 500 patients with asymptomatic hyperuricemia (uric acid >7.0 mg/dL) and carotid intima-media thickness 1.1 mm will be randomized centrally to receive either febuxostat (10-60 mg/day) or non-pharmacological treatment. Randomization is carried out using the dynamic allocation method stratified according to age (<65, 65 year), gender, presence or absence of diabetes mellitus, serum uric acid (<8.0, 8.0 mg/dL), and carotid intima-media thickness (<1.3, 1.3 mm). In addition to administering the study drug, we will also direct lifestyle modification in all participants, including advice on control of body weight, sleep, exercise and healthy diet. Carotid intima-media thickness will be evaluated using ultrasonography performed by skilled technicians at a central laboratory. Follow-up will be continued for 24 months. The primary endpoint is percentage change in mean intima-media thickness of the common carotid artery 24 months after baseline, measured by carotid ultrasound imaging.CONCLUSIONS: PRIZE will be the first study to provide important data on the effects of febuxostat on atherosclerosis in patients with asymptomatic hyperuricemia. Trial Registration Unique trial Number, UMIN000012911 ( https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000015081&language=E ).","ja":"BACKGROUND: Xanthine oxidase inhibitors are anti-hyperuricemic drugs that decrease serum uric acid levels by inhibiting its synthesis. Xanthine oxidase is also recognized as a pivotal enzyme in the production of oxidative stress. Excess oxidative stress induces endothelial dysfunction and inflammatory reactions in vascular systems, leading to atherosclerosis. Many experimental studies have suggested that xanthine oxidase inhibitors have anti-atherosclerotic effects by decreasing in vitro and in vivo oxidative stress. However, there is only limited evidence on the clinical implications of xanthine oxidase inhibitors on atherosclerotic cardiovascular disease in patients with hyperuricemia. We designed the PRIZE study to evaluate the effects of febuxostat on a surrogate marker of cardiovascular disease risk, ultrasonography-based intima-media thickness of the carotid artery in patients with hyperuricemia.METHODS: The study is a multicenter, prospective, randomized, open-label and blinded-endpoint evaluation (PROBE) design. A total of 500 patients with asymptomatic hyperuricemia (uric acid >7.0 mg/dL) and carotid intima-media thickness 1.1 mm will be randomized centrally to receive either febuxostat (10-60 mg/day) or non-pharmacological treatment. Randomization is carried out using the dynamic allocation method stratified according to age (<65, 65 year), gender, presence or absence of diabetes mellitus, serum uric acid (<8.0, 8.0 mg/dL), and carotid intima-media thickness (<1.3, 1.3 mm). In addition to administering the study drug, we will also direct lifestyle modification in all participants, including advice on control of body weight, sleep, exercise and healthy diet. Carotid intima-media thickness will be evaluated using ultrasonography performed by skilled technicians at a central laboratory. Follow-up will be continued for 24 months. The primary endpoint is percentage change in mean intima-media thickness of the common carotid artery 24 months after baseline, measured by carotid ultrasound imaging.CONCLUSIONS: PRIZE will be the first study to provide important data on the effects of febuxostat on atherosclerosis in patients with asymptomatic hyperuricemia. Trial Registration Unique trial Number, UMIN000012911 ( https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000015081&language=E )."},"publication_date":"2016-06-18","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.15","number":"No.1","starting_page":"87","ending_page":"87","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-016-0409-2"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27416363","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=313163","label":"url"}],"paper_title":{"en":"The pathophysiological role of oxidized cholesterols in epicardial fat accumulation and cardiac dysfunction: A study in swine fed a high caloric diet with an inhibitor of intestinal cholesterol absorption, ezetimibe.","ja":"The pathophysiological role of oxidized cholesterols in epicardial fat accumulation and cardiac dysfunction: A study in swine fed a high caloric diet with an inhibitor of intestinal cholesterol absorption, ezetimibe."},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Okawa C"},{"name":"Yamada Hirotsugu"},{"name":"Yanagi S"},{"name":"Uematsu E"},{"name":"Sugasawa N"},{"name":"Kurobe Hirotsugu"},{"name":"Hirata Y"},{"name":"Kim-Kaneyama JR"},{"name":"Lei XF"},{"name":"Takao S"},{"name":"Tanaka Y"},{"name":"Fukuda Daiju"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Kitagawa Tetsuya"},{"name":"Masuzaki H"},{"name":"Sato M"},{"name":"Sata Masataka"}],"ja":[{"name":"島袋 充生"},{"name":"Okawa C"},{"name":"山田 博胤"},{"name":"Yanagi S"},{"name":"Uematsu E"},{"name":"Sugasawa N"},{"name":"黒部 裕嗣"},{"name":"Hirata Y"},{"name":"Kim-Kaneyama JR"},{"name":"Lei XF"},{"name":"Takao S"},{"name":"Tanaka Y"},{"name":"福田 大受"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"北川 哲也"},{"name":"Masuzaki H"},{"name":"Sato M"},{"name":"佐田 政隆"}]},"description":{"en":"Oxidized cholesterols (oxycholesterols) in food have been recognized as strong atherogenic components, but their tissue distributions and roles in cardiovascular diseases remain unclear. To investigate whether accumulation of oxycholesterols is linked to cardiac morphology and function, and whether reduction of oxycholesterols can improve cardiac performance, domestic male swine were randomized to a control diet (C), high caloric diet (HCD) or HCD+Ezetimibe, an inhibitor of intestinal cholesterol absorption, group (HCD+E) and evaluated for: (1) distribution of oxycholesterol components in serum and tissues, (2) levels of oxycholesterol-related enzymes, (3) paracardial and epicardial coronary fat thickness, and (4) cardiac performance. Ezetimibe treatment for 8weeks attenuated increases in oxycholesterols in the HCD group almost completely in liver, but reduced only levels of 4β-hydroxycholesterol in left ventricular (LV) myocardium. Ezetimibe treatment altered the expression of genes for cholesterol and fatty acid metabolism and decreased the expression of CYP3A46, which catabolizes cholesterol to 4β-hydroxycholesterol, strongly in liver. An increase in epicardial fat thickness and impaired cardiac performance in the HCD group were improved by ezetimibe treatment, and the improvement was closely related to the reduction in levels of 4β-hydroxycholesterol in LV myocardium. In conclusion, an increase in oxycholesterols in the HCD group was closely related to cardiac hypertrophy and dysfunction, as well as an increase in epicardial fat thickness. Ezetimibe may directly reduce oxycholesterol in liver and LV myocardium, and improve cardiac morphology and function.","ja":"Oxidized cholesterols (oxycholesterols) in food have been recognized as strong atherogenic components, but their tissue distributions and roles in cardiovascular diseases remain unclear. To investigate whether accumulation of oxycholesterols is linked to cardiac morphology and function, and whether reduction of oxycholesterols can improve cardiac performance, domestic male swine were randomized to a control diet (C), high caloric diet (HCD) or HCD+Ezetimibe, an inhibitor of intestinal cholesterol absorption, group (HCD+E) and evaluated for: (1) distribution of oxycholesterol components in serum and tissues, (2) levels of oxycholesterol-related enzymes, (3) paracardial and epicardial coronary fat thickness, and (4) cardiac performance. Ezetimibe treatment for 8weeks attenuated increases in oxycholesterols in the HCD group almost completely in liver, but reduced only levels of 4β-hydroxycholesterol in left ventricular (LV) myocardium. Ezetimibe treatment altered the expression of genes for cholesterol and fatty acid metabolism and decreased the expression of CYP3A46, which catabolizes cholesterol to 4β-hydroxycholesterol, strongly in liver. An increase in epicardial fat thickness and impaired cardiac performance in the HCD group were improved by ezetimibe treatment, and the improvement was closely related to the reduction in levels of 4β-hydroxycholesterol in LV myocardium. In conclusion, an increase in oxycholesterols in the HCD group was closely related to cardiac hypertrophy and dysfunction, as well as an increase in epicardial fat thickness. Ezetimibe may directly reduce oxycholesterol in liver and LV myocardium, and improve cardiac morphology and function."},"publication_date":"2016-05","publication_name":{"en":"The Journal of Nutritional Biochemistry","ja":"The Journal of Nutritional Biochemistry"},"volume":"Vol.35","starting_page":"66","ending_page":"73","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jnutbio.2016.05.010"],"issn":["1873-4847"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114505","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27188597","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=312429","label":"url"}],"paper_title":{"en":"Impact of individual metabolic risk components or its clustering on endothelial and smooth muscle cell function in men.","ja":"Impact of individual metabolic risk components or its clustering on endothelial and smooth muscle cell function in men."},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Higa N"},{"name":"Masuzaki H"},{"name":"Sata Masataka"},{"name":"Ueda S"}],"ja":[{"name":"島袋 充生"},{"name":"Higa N"},{"name":"Masuzaki H"},{"name":"佐田 政隆"},{"name":"Ueda S"}]},"description":{"en":"Impaired vasoreactivity is often observed in subjects with metabolic syndrome, a condition that includes the presence of a specific cluster of risk factors for obesity and cardiovascular disease. However, hierarchical causes in the impaired vasoreactivity have not been clarified. We evaluated the impact of individual metabolic risk components or its clustering under the condition of insulin resistance on endothelial and smooth muscle cell function. Vascular reactivity to acetylcholine (Ach), with or without nitric oxide synthase (NOS) inhibitor N (G)-monomethyl-L-arginine (L-NMMA), or sodium nitroprusside (SNP) by forearm venous occlusion plethysmography and insulin sensitivity index (M mg/kg/min) in euglycemic clamp were measured in men without (n = 18, control group) or with (n = 19, metabolic syndrome group) metabolic syndrome. (1) Ach-induced maximal forearm blood flow (maxFBF) was impaired in subjects with metabolic syndrome. In particular, the NOS-dependent component of Ach-induced maxFBF was selectively decreased, while the NOS-independent component remained relatively unchanged. (2) Ach-induced maxFBF and ∆Ach-induced maxFBF with L-NMMA were correlated with waist circumference, glucose, and triglycerides, and most strongly correlated with visceral fat area, adiponectin, and M. (3) Multivariate regression analysis indicated that individual metabolic risk components explained Ach-induced maxFBF by 4-21 %. Clustering of all metabolic risk components increased this to 35 %, and the presence of metabolic syndrome explained 30 %, indicating that defining metabolic syndrome can effectively predict impairment of endothelial dysfunction. Endothelial dysfunction was correlated with individual metabolic risk components, but more strongly with clustering of the components under a condition with low insulin sensitivity. We suggest that in subjects with metabolic syndrome, endothelial function is impaired by multiple cardiovascular risk factors exclusively when under the condition of insulin insensitivity and also that defining metabolic syndrome can effectively predict impairment of endothelial dysfunction.","ja":"Impaired vasoreactivity is often observed in subjects with metabolic syndrome, a condition that includes the presence of a specific cluster of risk factors for obesity and cardiovascular disease. However, hierarchical causes in the impaired vasoreactivity have not been clarified. We evaluated the impact of individual metabolic risk components or its clustering under the condition of insulin resistance on endothelial and smooth muscle cell function. Vascular reactivity to acetylcholine (Ach), with or without nitric oxide synthase (NOS) inhibitor N (G)-monomethyl-L-arginine (L-NMMA), or sodium nitroprusside (SNP) by forearm venous occlusion plethysmography and insulin sensitivity index (M mg/kg/min) in euglycemic clamp were measured in men without (n = 18, control group) or with (n = 19, metabolic syndrome group) metabolic syndrome. (1) Ach-induced maximal forearm blood flow (maxFBF) was impaired in subjects with metabolic syndrome. In particular, the NOS-dependent component of Ach-induced maxFBF was selectively decreased, while the NOS-independent component remained relatively unchanged. (2) Ach-induced maxFBF and ∆Ach-induced maxFBF with L-NMMA were correlated with waist circumference, glucose, and triglycerides, and most strongly correlated with visceral fat area, adiponectin, and M. (3) Multivariate regression analysis indicated that individual metabolic risk components explained Ach-induced maxFBF by 4-21 %. Clustering of all metabolic risk components increased this to 35 %, and the presence of metabolic syndrome explained 30 %, indicating that defining metabolic syndrome can effectively predict impairment of endothelial dysfunction. Endothelial dysfunction was correlated with individual metabolic risk components, but more strongly with clustering of the components under a condition with low insulin sensitivity. We suggest that in subjects with metabolic syndrome, endothelial function is impaired by multiple cardiovascular risk factors exclusively when under the condition of insulin insensitivity and also that defining metabolic syndrome can effectively predict impairment of endothelial dysfunction."},"publication_date":"2016-05-17","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.15","number":"No.1","starting_page":"77","ending_page":"77","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-016-0394-5"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26093930","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84931059223&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=291323","label":"url"}],"paper_title":{"en":"Noninvasive quantitative tissue characterization of carotid plaque using color-coded mapping based on ultrasound integrated backscatter.","ja":"Noninvasive quantitative tissue characterization of carotid plaque using color-coded mapping based on ultrasound integrated backscatter."},"authors":{"en":[{"name":"Bando Mika"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Fukuda Daiju"},{"name":"Amano Rie"},{"name":"Tamai Rina"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Satomi Junichiro"},{"name":"Nagahiro Shinji"},{"name":"Sata Masataka"}],"ja":[{"name":"坂東 美佳"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"福田 大受"},{"name":"Amano Rie"},{"name":"Tamai Rina"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"里見 淳一郎"},{"name":"永廣 信治"},{"name":"佐田 政隆"}]},"publication_date":"2016-05","publication_name":{"en":"JACC. Cardiovascular Imaging","ja":"JACC. Cardiovascular Imaging"},"volume":"Vol.9","number":"No.5","starting_page":"625","ending_page":"627","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jcmg.2015.02.017"],"issn":["1876-7591"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114504","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27044332","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=310419","label":"url"}],"paper_title":{"en":"Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.","ja":"Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial."},"authors":{"en":[{"name":"Tanaka A"},{"name":"Inoue T"},{"name":"Kitakaze M"},{"name":"Oyama J"},{"name":"Sata Masataka"},{"name":"Taguchi I"},{"name":"Shimizu W"},{"name":"Watada H"},{"name":"Ako J"},{"name":"Sakata Y"},{"name":"Anzai T"},{"name":"Uematsu M"},{"name":"Suzuki M"},{"name":"Eguchi K"},{"name":"Yamashina A"},{"name":"Saito Y"},{"name":"Sato Y"},{"name":"Ueda S"},{"name":"Murohara T"},{"name":"Node K"}],"ja":[{"name":"Tanaka A"},{"name":"Inoue T"},{"name":"Kitakaze M"},{"name":"Oyama J"},{"name":"佐田 政隆"},{"name":"Taguchi I"},{"name":"Shimizu W"},{"name":"Watada H"},{"name":"Ako J"},{"name":"Sakata Y"},{"name":"Anzai T"},{"name":"Uematsu M"},{"name":"Suzuki M"},{"name":"Eguchi K"},{"name":"Yamashina A"},{"name":"Saito Y"},{"name":"Sato Y"},{"name":"Ueda S"},{"name":"Murohara T"},{"name":"Node K"}]},"description":{"en":"Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence of therapeutic strategies in such patients is still lacking. A recent randomized, placebo-controlled trial in patients with type 2 diabetes with high cardiovascular risk demonstrated that the SGLT2 inhibitor, empagliflozin, reduced the incidence of hospitalization for heart failure. Because SGLT2 inhibitors cause a reduction in body weight and blood pressure in addition to improving glycemic control, they have the potential to exert beneficial effects on the clinical pathophysiology of heart failure. The aim of the ongoing CANDLE trial is to test the safety and non-inferiority of canagliflozin, another SGLT2 inhibitor, compared with glimepiride, a sulfonylurea agent, in patients with type 2 diabetes mellitus and chronic heart failure. A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6.5, ≥6.5 %), and left ventricular ejection fraction (<40, ≥40 %). After randomization, all the participants will be given the add-on study drug for 24 weeks in addition to their background therapy. The primary endpoint is the percentage change from baseline in NT-proBNP after 24 weeks of treatment. The key secondary endpoints after 24 weeks of treatment are the change from baseline in glycemic control, blood pressure, body weight, lipid profile, quality of life score related to heart failure, and cardiac and renal function. The CANDLE trial is the first to assess the safety and non-inferiority of canagliflozin in comparison with glimepiride in patients with type 2 diabetes with chronic heart failure. This trial has the potential to evaluate the clinical safety and efficacy of canagliflozin on heart failure. Trial registration Unique trial Number, UMIN000017669.","ja":"Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence of therapeutic strategies in such patients is still lacking. A recent randomized, placebo-controlled trial in patients with type 2 diabetes with high cardiovascular risk demonstrated that the SGLT2 inhibitor, empagliflozin, reduced the incidence of hospitalization for heart failure. Because SGLT2 inhibitors cause a reduction in body weight and blood pressure in addition to improving glycemic control, they have the potential to exert beneficial effects on the clinical pathophysiology of heart failure. The aim of the ongoing CANDLE trial is to test the safety and non-inferiority of canagliflozin, another SGLT2 inhibitor, compared with glimepiride, a sulfonylurea agent, in patients with type 2 diabetes mellitus and chronic heart failure. A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6.5, ≥6.5 %), and left ventricular ejection fraction (<40, ≥40 %). After randomization, all the participants will be given the add-on study drug for 24 weeks in addition to their background therapy. The primary endpoint is the percentage change from baseline in NT-proBNP after 24 weeks of treatment. The key secondary endpoints after 24 weeks of treatment are the change from baseline in glycemic control, blood pressure, body weight, lipid profile, quality of life score related to heart failure, and cardiac and renal function. The CANDLE trial is the first to assess the safety and non-inferiority of canagliflozin in comparison with glimepiride in patients with type 2 diabetes with chronic heart failure. This trial has the potential to evaluate the clinical safety and efficacy of canagliflozin on heart failure. Trial registration Unique trial Number, UMIN000017669."},"publication_date":"2016-04-04","publication_name":{"en":"Cardiovascular Diabetology","ja":"Cardiovascular Diabetology"},"volume":"Vol.15","number":"No.1","starting_page":"57","ending_page":"57","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12933-016-0381-x"],"issn":["1475-2840"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/110139","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26277250","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=298714","label":"url"}],"paper_title":{"en":"Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.","ja":"Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice."},"authors":{"en":[{"name":"Salim HM"},{"name":"Fukuda Daiju"},{"name":"Higashikuni Y"},{"name":"Tanaka K"},{"name":"Hirata Y"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Salim HM"},{"name":"福田 大受"},{"name":"Higashikuni Y"},{"name":"Tanaka K"},{"name":"Hirata Y"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Background; The dipeptidyl peptidase-4 (DPP-4) inhibitors have vasoprotective effects. This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina), suppresses atherogenesis in non-diabetic apolipoprotein-E deficient (ApoE-/-) mice and examined its effects on endothelial function. Methods and Results; Lina (10 mg/kg/day) was administered orally to ApoE-/- mice for 20 weeks. Lina reduced atherogenesis without the alteration of metabolic parameters including blood glucose level compared with the control (P<0.05). Results of immunohistochemistry and quantitative RT-PCR demonstrated that Lina significantly decreased inflammatory molecule expression and macrophage infiltration in atherosclerotic aorta. Lina administration to ApoE-/- mice for 9 weeks ameliorated endothelium-dependent vasodilation compared with non-treated mice. Plasma active glucagon-like peptide-1 (GLP-1) level was significantly higher in the treated group (P<0.05). Exendin-4 (Ex-4), a GLP-1 analogue, ameliorated endothelium-dependent vasodilation impaired by palmitic acid (PA) in wild-type mouse aortic segments. Ex-4 promoted phosphorylation of eNOSSer1177 and Akt which are abrogated by PA in human umbilical vein endothelial cells. In addition, Lina administration to ApoE-/- mice decreased oxidative stress as determined by urinary 8-OHdG secretion and NADPH oxidase subunit expression in the abdominal aorta.Conclusion; Lina inhibited atherogenesis in non-diabetic ApoE-/- mice. Amelioration of endothelial dysfunction associated with the reduction of oxidative stress by GLP-1 contributes to the atheroprotective effects of Lina.","ja":"Background; The dipeptidyl peptidase-4 (DPP-4) inhibitors have vasoprotective effects. This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina), suppresses atherogenesis in non-diabetic apolipoprotein-E deficient (ApoE-/-) mice and examined its effects on endothelial function. Methods and Results; Lina (10 mg/kg/day) was administered orally to ApoE-/- mice for 20 weeks. Lina reduced atherogenesis without the alteration of metabolic parameters including blood glucose level compared with the control (P<0.05). Results of immunohistochemistry and quantitative RT-PCR demonstrated that Lina significantly decreased inflammatory molecule expression and macrophage infiltration in atherosclerotic aorta. Lina administration to ApoE-/- mice for 9 weeks ameliorated endothelium-dependent vasodilation compared with non-treated mice. Plasma active glucagon-like peptide-1 (GLP-1) level was significantly higher in the treated group (P<0.05). Exendin-4 (Ex-4), a GLP-1 analogue, ameliorated endothelium-dependent vasodilation impaired by palmitic acid (PA) in wild-type mouse aortic segments. Ex-4 promoted phosphorylation of eNOSSer1177 and Akt which are abrogated by PA in human umbilical vein endothelial cells. In addition, Lina administration to ApoE-/- mice decreased oxidative stress as determined by urinary 8-OHdG secretion and NADPH oxidase subunit expression in the abdominal aorta.Conclusion; Lina inhibited atherogenesis in non-diabetic ApoE-/- mice. Amelioration of endothelial dysfunction associated with the reduction of oxidative stress by GLP-1 contributes to the atheroprotective effects of Lina."},"publication_date":"2016-04","publication_name":{"en":"Vascular Pharmacology","ja":"Vascular Pharmacology"},"volume":"Vol.79","starting_page":"16","ending_page":"23","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.vph.2015.08.011"],"issn":["1879-3649"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/110123","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27051864","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84986905526&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=310765","label":"url"}],"paper_title":{"en":"Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance.","ja":"Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance."},"authors":{"en":[{"name":"Nishimoto Sachiko"},{"name":"Fukuda Daiju"},{"name":"Higashikuni Yasutomi"},{"name":"Tanaka Kimie"},{"name":"Hirata Yoichiro"},{"name":"Murata Chie"},{"name":"Kim-Kaneyama Joo-Ri"},{"name":"Sato Fukiko"},{"name":"Bando Masahiro"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Hayashi Tetsuya"},{"name":"Imoto Issei"},{"name":"Sakaue Hiroshi"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"西本 幸子"},{"name":"福田 大受"},{"name":"Higashikuni Yasutomi"},{"name":"Tanaka Kimie"},{"name":"Hirata Yoichiro"},{"name":"村田 知慧"},{"name":"Kim-Kaneyama Joo-Ri"},{"name":"佐藤 蕗子"},{"name":"板東 正浩"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Hayashi Tetsuya"},{"name":"井本 逸勢"},{"name":"阪上 浩"},{"name":"Shimabukuro Michio"},{"name":"佐田 政隆"}]},"description":{"en":"Obesity stimulates chronic inflammation in adipose tissue, which is associated with insulin resistance, although the underlying mechanism remains largely unknown. Here we showed that obesity-related adipocyte degeneration causes release of cell-free DNA (cfDNA), which promotes macrophage accumulation in adipose tissue via Toll-like receptor 9 (TLR9), originally known as a sensor of exogenous DNA fragments. Fat-fed obese wild-type mice showed increased release of cfDNA, as determined by the concentrations of single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in plasma. cfDNA released from degenerated adipocytes promoted monocyte chemoattractant protein-1 (MCP-1) expression in wild-type macrophages, but not in TLR9-deficient (Tlr9 (-/-) ) macrophages. Fat-fed Tlr9 (-/-) mice demonstrated reduced macrophage accumulation and inflammation in adipose tissue and better insulin sensitivity compared with wild-type mice, whereas bone marrow reconstitution with wild-type bone marrow restored the attenuation of insulin resistance observed in fat-fed Tlr9 (-/-) mice. Administration of a TLR9 inhibitory oligonucleotide to fat-fed wild-type mice reduced the accumulation of macrophages in adipose tissue and improved insulin resistance. Furthermore, in humans, plasma ssDNA level was significantly higher in patients with computed tomography-determined visceral obesity and was associated with homeostasis model assessment of insulin resistance (HOMA-IR), which is the index of insulin resistance. Our study may provide a novel mechanism for the development of sterile inflammation in adipose tissue and a potential therapeutic target for insulin resistance.","ja":"Obesity stimulates chronic inflammation in adipose tissue, which is associated with insulin resistance, although the underlying mechanism remains largely unknown. Here we showed that obesity-related adipocyte degeneration causes release of cell-free DNA (cfDNA), which promotes macrophage accumulation in adipose tissue via Toll-like receptor 9 (TLR9), originally known as a sensor of exogenous DNA fragments. Fat-fed obese wild-type mice showed increased release of cfDNA, as determined by the concentrations of single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in plasma. cfDNA released from degenerated adipocytes promoted monocyte chemoattractant protein-1 (MCP-1) expression in wild-type macrophages, but not in TLR9-deficient (Tlr9 (-/-) ) macrophages. Fat-fed Tlr9 (-/-) mice demonstrated reduced macrophage accumulation and inflammation in adipose tissue and better insulin sensitivity compared with wild-type mice, whereas bone marrow reconstitution with wild-type bone marrow restored the attenuation of insulin resistance observed in fat-fed Tlr9 (-/-) mice. Administration of a TLR9 inhibitory oligonucleotide to fat-fed wild-type mice reduced the accumulation of macrophages in adipose tissue and improved insulin resistance. Furthermore, in humans, plasma ssDNA level was significantly higher in patients with computed tomography-determined visceral obesity and was associated with homeostasis model assessment of insulin resistance (HOMA-IR), which is the index of insulin resistance. Our study may provide a novel mechanism for the development of sterile inflammation in adipose tissue and a potential therapeutic target for insulin resistance."},"publication_date":"2016-03-25","publication_name":{"en":"Science Advances","ja":"Science Advances"},"volume":"Vol.2","number":"No.3","starting_page":"e1501332","ending_page":"e1501332","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1126/sciadv.1501332"],"issn":["2375-2548"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26936237","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84961625684&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=309329","label":"url"}],"paper_title":{"en":"Prognostic implications of non-invasive vascular function tests in high-risk atherosclerosis patients.","ja":"Prognostic implications of non-invasive vascular function tests in high-risk atherosclerosis patients."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Sato M"},{"name":"Yamada Hirotsugu"},{"name":"Saijo Y"},{"name":"Bando Mika"},{"name":"Hirata Y"},{"name":"Nishio S"},{"name":"Hayashi S"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Sato M"},{"name":"山田 博胤"},{"name":"Saijo Y"},{"name":"坂東 美佳"},{"name":"Hirata Y"},{"name":"Nishio S"},{"name":"Hayashi S"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: The aim of this study was to assess the role of clinically available vascular function tests as predictors of cardiovascular events and decline in kidney function.MethodsandResults:One hundred and fourteen patients who had at least 2 cardiovascular risk factors were recruited for vascular function assessment including ankle-brachial blood pressure index (ABI), brachial-ankle pulse wave velocity (baPWV), cardio-ankle vascular index (CAVI) and flow-mediated vasodilatation (%FMD). During a median period of 51 months, 35 patients reached the primary endpoint (29 cardiovascular events and 6 cardiac deaths), and 30 patients reached the secondary endpoint (decline in kidney function: defined as a 5% per year decline of estimated glomerular filtration rate). In sequential Cox models, a model on the basis of the Framingham risk score, hemoglobin, and high-sensitivity C-reactive protein (chi-squared, 16.6) was improved by the ABI (chi-squared: 21.5; P=0.047). The baPWV (hazard ratio: 1.42 per 1 SD increase; P=0.025) and the CAVI (hazard ratio: 1.52 per 1 SD increase; P=0.040) were associated with the secondary endpoint. The %FMD was only slightly associated with the primary and secondary endpoints.CONCLUSIONS: Both ABI and baPWV are significantly associated with future cardiovascular events in high-risk patients with cardiovascular disease. The predictive capabilities of these parameters are greater than that of other parameters in this cohort.","ja":"BACKGROUND: The aim of this study was to assess the role of clinically available vascular function tests as predictors of cardiovascular events and decline in kidney function.MethodsandResults:One hundred and fourteen patients who had at least 2 cardiovascular risk factors were recruited for vascular function assessment including ankle-brachial blood pressure index (ABI), brachial-ankle pulse wave velocity (baPWV), cardio-ankle vascular index (CAVI) and flow-mediated vasodilatation (%FMD). During a median period of 51 months, 35 patients reached the primary endpoint (29 cardiovascular events and 6 cardiac deaths), and 30 patients reached the secondary endpoint (decline in kidney function: defined as a 5% per year decline of estimated glomerular filtration rate). In sequential Cox models, a model on the basis of the Framingham risk score, hemoglobin, and high-sensitivity C-reactive protein (chi-squared, 16.6) was improved by the ABI (chi-squared: 21.5; P=0.047). The baPWV (hazard ratio: 1.42 per 1 SD increase; P=0.025) and the CAVI (hazard ratio: 1.52 per 1 SD increase; P=0.040) were associated with the secondary endpoint. The %FMD was only slightly associated with the primary and secondary endpoints.CONCLUSIONS: Both ABI and baPWV are significantly associated with future cardiovascular events in high-risk patients with cardiovascular disease. The predictive capabilities of these parameters are greater than that of other parameters in this cohort."},"publication_date":"2016-03-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.80","number":"No.4","starting_page":"1034","ending_page":"1040","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-15-1356"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26973275","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84961564419&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=309899","label":"url"}],"paper_title":{"en":"Inflammatory biomarkers and atherosclerosis.","ja":"Inflammatory biomarkers and atherosclerosis."},"authors":{"en":[{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"Atherosclerosis has been regarded as a form of chronic vascular inflammation. Numerous biomarkers associated with inflammation have been identified as novel targets to monitor atherosclerosis and cardiovascular risk. C-reactive protein (CRP) is one of the most actively studied and established inflammatory biomarkers for cardiovascular events. However, CRP response is triggered by many disorders unrelated to cardiovascular disease, which interferes with the clinical application. This review describes established and traditional inflammatory biomarkers including CRP as well as novel inflammatory biomarkers reflective of local atherosclerotic inflammation. In addition, we focus on the potential usefulness of inflammatory biomarkers in developing anti-atherosclerotic therapeutic approaches.","ja":"Atherosclerosis has been regarded as a form of chronic vascular inflammation. Numerous biomarkers associated with inflammation have been identified as novel targets to monitor atherosclerosis and cardiovascular risk. C-reactive protein (CRP) is one of the most actively studied and established inflammatory biomarkers for cardiovascular events. However, CRP response is triggered by many disorders unrelated to cardiovascular disease, which interferes with the clinical application. This review describes established and traditional inflammatory biomarkers including CRP as well as novel inflammatory biomarkers reflective of local atherosclerotic inflammation. In addition, we focus on the potential usefulness of inflammatory biomarkers in developing anti-atherosclerotic therapeutic approaches."},"publication_date":"2016-03-22","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.57","number":"No.2","starting_page":"134","ending_page":"139","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.15-346"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26987792","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84960969355&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320947","label":"url"}],"paper_title":{"en":"Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation.","ja":"Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation."},"authors":{"en":[{"name":"Soeki Takeshi"},{"name":"Matsuura Tomomi"},{"name":"Bando Sachiko"},{"name":"Tobiume Takeshi"},{"name":"Uematsu Etsuko"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"添木 武"},{"name":"松浦 朋美"},{"name":"Bando Sachiko"},{"name":"飛梅 威"},{"name":"Uematsu Etsuko"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: The underlying mechanism of atrial substrate remodeling in atrial fibrillation (AF) remains unknown. In this study, we investigated whether local and systemic levels of microRNA (miR) might be associated with the presence of AF and with left atrial (LA) substrate properties.METHODS: Blood from the periphery, pulmonary vein (PV), and left atrial appendage (LAA) was sampled from 30 patients with AF undergoing PV isolation, and from 10 control subjects with Wolff-Parkinson-White syndrome and without AF. We measured peripheral, PV, and LAA plasma levels of miR-1, -26, -133a, -328, and -590 by reverse transcription-polymerase chain reaction. LA global contact mapping during sinus rhythm was performed before PV isolation.RESULTS: Plasma levels of miR-328 were higher in patients with AF than in control subjects. Plasma miR-328 levels were significantly higher in the LAA than in the periphery and PV in patients with AF, but not in control subjects. Plasma miR-1 levels were also higher in the LAA than in the PV in AF patients. Interestingly, LAA plasma levels of miR-328 showed a positive correlation with the LA voltage zone index (area with voltage <0.5mV divided by total LA surface area) and a weak correlation with LA volume.CONCLUSION: Local production of miR-328 in the left atrium may be involved in the process of atrial remodeling in patients with AF.","ja":"BACKGROUND: The underlying mechanism of atrial substrate remodeling in atrial fibrillation (AF) remains unknown. In this study, we investigated whether local and systemic levels of microRNA (miR) might be associated with the presence of AF and with left atrial (LA) substrate properties.METHODS: Blood from the periphery, pulmonary vein (PV), and left atrial appendage (LAA) was sampled from 30 patients with AF undergoing PV isolation, and from 10 control subjects with Wolff-Parkinson-White syndrome and without AF. We measured peripheral, PV, and LAA plasma levels of miR-1, -26, -133a, -328, and -590 by reverse transcription-polymerase chain reaction. LA global contact mapping during sinus rhythm was performed before PV isolation.RESULTS: Plasma levels of miR-328 were higher in patients with AF than in control subjects. Plasma miR-328 levels were significantly higher in the LAA than in the periphery and PV in patients with AF, but not in control subjects. Plasma miR-1 levels were also higher in the LAA than in the PV in AF patients. Interestingly, LAA plasma levels of miR-328 showed a positive correlation with the LA voltage zone index (area with voltage <0.5mV divided by total LA surface area) and a weak correlation with LA volume.CONCLUSION: Local production of miR-328 in the left atrium may be involved in the process of atrial remodeling in patients with AF."},"publication_date":"2016-03-14","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.68","number":"No.6","starting_page":"472","ending_page":"477","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2015.12.007"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26903022","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=308374","label":"url"}],"paper_title":{"en":"Left Ventricular lipomatous hamartoma mimicking a calcified amorphous tumor.","ja":"Left Ventricular lipomatous hamartoma mimicking a calcified amorphous tumor."},"authors":{"en":[{"name":"Torii Yuta"},{"name":"Yamada Hirotsugu"},{"name":"Matsukuma Susumu"},{"name":"Nishio Susumu"},{"name":"Kusunose Kenya"},{"name":"Abe Miho"},{"name":"Sata Masataka"}],"ja":[{"name":"Torii Yuta"},{"name":"山田 博胤"},{"name":"Matsukuma Susumu"},{"name":"Nishio Susumu"},{"name":"楠瀬 賢也"},{"name":"Abe Miho"},{"name":"佐田 政隆"}]},"publication_date":"2016-02-23","publication_name":{"en":"Circulation","ja":"Circulation"},"volume":"Vol.133","number":"No.8","starting_page":"e408","ending_page":"e410","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/CIRCULATIONAHA.115.019252"],"issn":["1524-4539"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112369","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26919617","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=317618","label":"url"}],"paper_title":{"en":"Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.","ja":"Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs."},"authors":{"en":[{"name":"Hayakawa Yoshihiro"},{"name":"Kawada Manabu"},{"name":"Nishikawa Hiroyoshi"},{"name":"Ochiya Takahiro"},{"name":"Saya Hideyuki"},{"name":"Seimiya Hiroyuki"},{"name":"Yao Ryoji"},{"name":"Hayashi Masahiro"},{"name":"Kai Chieko"},{"name":"Matsuda Akira"},{"name":"Naoe Tomoki"},{"name":"Ohtsu Atsushi"},{"name":"Okazaki Taku"},{"name":"Saji Hideo"},{"name":"Sata Masataka"},{"name":"Sugimura Haruhiko"},{"name":"Sugiyama Yuichi"},{"name":"Toi Masakazu"},{"name":"Irimura Tatsuro"}],"ja":[{"name":"Hayakawa Yoshihiro"},{"name":"Kawada Manabu"},{"name":"Nishikawa Hiroyoshi"},{"name":"Ochiya Takahiro"},{"name":"Saya Hideyuki"},{"name":"Seimiya Hiroyuki"},{"name":"Yao Ryoji"},{"name":"Hayashi Masahiro"},{"name":"Kai Chieko"},{"name":"Matsuda Akira"},{"name":"Naoe Tomoki"},{"name":"Ohtsu Atsushi"},{"name":"岡崎 拓"},{"name":"Saji Hideo"},{"name":"佐田 政隆"},{"name":"Sugimura Haruhiko"},{"name":"Sugiyama Yuichi"},{"name":"Toi Masakazu"},{"name":"Irimura Tatsuro"}]},"description":{"en":"Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.","ja":"Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs."},"publication_date":"2016-02","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"Vol.107","number":"No.2","starting_page":"189","ending_page":"202","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/cas.12857"],"issn":["1349-7006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26781270","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84955469675&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=306349","label":"url"}],"paper_title":{"en":"Screening of coronary artery disease in diabetic patients: who and how? -reply-","ja":"Screening of coronary artery disease in diabetic patients: who and how? -reply-"},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Saito T"},{"name":"Masuzaki H"},{"name":"Sata Masataka"}],"ja":[{"name":"島袋 充生"},{"name":"Saito T"},{"name":"Masuzaki H"},{"name":"佐田 政隆"}]},"publication_date":"2016-01-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.80","number":"No.2","starting_page":"544","ending_page":"544","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-15-1377"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109653","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26667367","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84955453337&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305315","label":"url"}],"paper_title":{"en":"Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound.","ja":"Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound."},"authors":{"en":[{"name":"Niki Toshiyuki"},{"name":"Wakatsuki Tetsuzo"},{"name":"Yamaguchi Koji"},{"name":"Taketani Yoshio"},{"name":"Oeduka Hiroyasu"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"}],"ja":[{"name":"仁木 敏之"},{"name":"若槻 哲三"},{"name":"山口 浩司"},{"name":"竹谷 善雄"},{"name":"Oeduka Hiroyasu"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: The effects of eicosapentaenoic acid (EPA) on coronary artery disease have been previously reported; however, those of the addition of EPA to strong statins on coronary plaque components and local inflammatory cytokines are not known.METHODSANDRESULTS: A total of 95 patients who had been treated with strong statin for at least 6 months were randomized into 2 groups: an EPA group (additional treatment with EPA at 1,800 mg/day, n=48) or a control group (no additional treatment, n=47), for 6 months. The tissue characteristics of target coronary plaque in each patient were analyzed using IB-IVUS before and after treatment. We also measured plasma levels of inflammatory cytokines sampled in the coronary sinus (CS) and peripheral vein.A significant reduction in lipid volume (18.5±1.3 to 15.0±1.5 mm(3), P=0.007) and a significant increase in fibrous volume (22.9±0.8 to 25.6±1.1 mm(3), P=0.01) were observed in IB-IVUS image analyses in the EPA group, but no significant changes in the plaque components in the control group. CS levels of pentraxin 3 and monocyte chemoattractant protein-1 were lower after than before treatment with EPA (3.3±2.1 to 2.6±1.2 ng/ml, 120.4±26.2 to 110.2±26.8 pg/ml, P=0.015 and P=0.008, respectively); however, there were no significant changes in those inflammatory cytokines between pre- and post-treatment in the control group.CONCLUSIONS: The addition of EPA was associated with reduced lipid volume in coronary plaques and decreased inflammatory cytokines. (Circ J 2016; 80: 450-460).","ja":"BACKGROUND: The effects of eicosapentaenoic acid (EPA) on coronary artery disease have been previously reported; however, those of the addition of EPA to strong statins on coronary plaque components and local inflammatory cytokines are not known.METHODSANDRESULTS: A total of 95 patients who had been treated with strong statin for at least 6 months were randomized into 2 groups: an EPA group (additional treatment with EPA at 1,800 mg/day, n=48) or a control group (no additional treatment, n=47), for 6 months. The tissue characteristics of target coronary plaque in each patient were analyzed using IB-IVUS before and after treatment. We also measured plasma levels of inflammatory cytokines sampled in the coronary sinus (CS) and peripheral vein.A significant reduction in lipid volume (18.5±1.3 to 15.0±1.5 mm(3), P=0.007) and a significant increase in fibrous volume (22.9±0.8 to 25.6±1.1 mm(3), P=0.01) were observed in IB-IVUS image analyses in the EPA group, but no significant changes in the plaque components in the control group. CS levels of pentraxin 3 and monocyte chemoattractant protein-1 were lower after than before treatment with EPA (3.3±2.1 to 2.6±1.2 ng/ml, 120.4±26.2 to 110.2±26.8 pg/ml, P=0.015 and P=0.008, respectively); however, there were no significant changes in those inflammatory cytokines between pre- and post-treatment in the control group.CONCLUSIONS: The addition of EPA was associated with reduced lipid volume in coronary plaques and decreased inflammatory cytokines. (Circ J 2016; 80: 450-460)."},"publication_date":"2016-01-25","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.80","number":"No.2","starting_page":"450","ending_page":"460","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-15-0813"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26651451","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84949257248&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305569","label":"url"}],"paper_title":{"en":"Comparison of tricuspid annular plane systolic excursion in patients with atrial fibrillation vs sinus rhythm.","ja":"Comparison of tricuspid annular plane systolic excursion in patients with atrial fibrillation vs sinus rhythm."},"authors":{"en":[{"name":"Torii Yuta"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Amano Rie"},{"name":"Yamao Masami"},{"name":"Bando Mika"},{"name":"Hayashi Shuji"},{"name":"Sata Masataka"}],"ja":[{"name":"Torii Yuta"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Amano Rie"},{"name":"Yamao Masami"},{"name":"坂東 美佳"},{"name":"Hayashi Shuji"},{"name":"佐田 政隆"}]},"description":{"en":"Echocardiography now plays a central guiding role in the management of patients with atrial fibrillation (AF). However, the current guidelines mention little about the presence AF during the assessment of echocardiographic variables in the clinical setting. AF itself may impact on tricuspid annular plane systolic excursion (TAPSE) as a right ventricular systolic function compared with sinus rhythm (SR). The aim of this study was to compare and assess the echocardiographic parameters including TAPSE in patients with AF and SR. From January 1, 2013, to September 30, 2014, patients with AF without any cardiovascular disease were retrospectively evaluated using echocardiography. Age-, gender-, and left ventricular ejection fraction-matched patients with SR were selected from our database on the basis of a comprehensive history, physical examination, and echocardiographic findings. During the study period, we identified 239 patients with AF (74 ± 9 years; 65% men) and without any cardiac disease who underwent echocardiography. We also included 281 patients in the SR group (74 ± 8 years; 67% men). In all study subjects, TAPSE in AF was smaller than in SR regardless of age (17 ± 3 vs 20 ± 3 mm, p <0.001). In the stepwise multiple regression model, TAPSE was strongly associated with the presence of AF (standardized β = -0.362, p <0.001) and stroke volume index (standardized β = 0.173, p <0.001) after adjustment for age, gender, heart rate, left ventricular ejection fraction, and tricuspid regurgitant grade. In conclusions, patients with AF had lower TAPSE than those with SR regardless of age. When we assess TAPSE in the clinical setting, we must pay attention to the presence of AF.","ja":"Echocardiography now plays a central guiding role in the management of patients with atrial fibrillation (AF). However, the current guidelines mention little about the presence AF during the assessment of echocardiographic variables in the clinical setting. AF itself may impact on tricuspid annular plane systolic excursion (TAPSE) as a right ventricular systolic function compared with sinus rhythm (SR). The aim of this study was to compare and assess the echocardiographic parameters including TAPSE in patients with AF and SR. From January 1, 2013, to September 30, 2014, patients with AF without any cardiovascular disease were retrospectively evaluated using echocardiography. Age-, gender-, and left ventricular ejection fraction-matched patients with SR were selected from our database on the basis of a comprehensive history, physical examination, and echocardiographic findings. During the study period, we identified 239 patients with AF (74 ± 9 years; 65% men) and without any cardiac disease who underwent echocardiography. We also included 281 patients in the SR group (74 ± 8 years; 67% men). In all study subjects, TAPSE in AF was smaller than in SR regardless of age (17 ± 3 vs 20 ± 3 mm, p <0.001). In the stepwise multiple regression model, TAPSE was strongly associated with the presence of AF (standardized β = -0.362, p <0.001) and stroke volume index (standardized β = 0.173, p <0.001) after adjustment for age, gender, heart rate, left ventricular ejection fraction, and tricuspid regurgitant grade. In conclusions, patients with AF had lower TAPSE than those with SR regardless of age. When we assess TAPSE in the clinical setting, we must pay attention to the presence of AF."},"publication_date":"2016-01-16","publication_name":{"en":"The American Journal of Cardiology","ja":"The American Journal of Cardiology"},"volume":"Vol.117","number":"No.2","starting_page":"226","ending_page":"232","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.amjcard.2015.10.035"],"issn":["1879-1913"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26808990","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84958019532&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=306597","label":"url"}],"paper_title":{"en":"Vegetation in the coronary sinus that concealed the presence of a coronary arteriovenous fistula in a patient with infectious endocarditis.","ja":"Vegetation in the coronary sinus that concealed the presence of a coronary arteriovenous fistula in a patient with infectious endocarditis."},"authors":{"en":[{"name":"Takashima Akira"},{"name":"Yagi Shusuke"},{"name":"Yamaguchi Koji"},{"name":"Takagi Eri"},{"name":"Kanbara Tamotsu"},{"name":"Ogawa Hirohisa"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Tobiume Takeshi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Kitagawa Tetsuya"},{"name":"Sata Masataka"}],"ja":[{"name":"Takashima Akira"},{"name":"八木 秀介"},{"name":"山口 浩司"},{"name":"Takagi Eri"},{"name":"神原 保"},{"name":"小川 博久"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"飛梅 威"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"北川 哲也"},{"name":"佐田 政隆"}]},"publication_date":"2016-01-11","publication_name":{"en":"International Journal of Cardiology","ja":"International Journal of Cardiology"},"volume":"Vol.207","starting_page":"266","ending_page":"268","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijcard.2016.01.057"],"issn":["1874-1754"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26549390","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305846","label":"url"}],"paper_title":{"en":"Correlation between arteriosclerosis and periodontal condition assessed by lactoferrin and [alpha]1-antitrypsin levels in gingival crevicular fluid.","ja":"Correlation between arteriosclerosis and periodontal condition assessed by lactoferrin and [alpha]1-antitrypsin levels in gingival crevicular fluid."},"authors":{"en":[{"name":"Hayashi S"},{"name":"Yamada Hirotsugu"},{"name":"Fukui Makoto"},{"name":"Ito Hiro-O"},{"name":"Sata Masataka"}],"ja":[{"name":"Hayashi S"},{"name":"山田 博胤"},{"name":"福井 誠"},{"name":"伊藤 博夫"},{"name":"佐田 政隆"}]},"description":{"en":"Patients with periodontal disease exhibit exacerbated atherosclerosis, aortic stiffness, or vascular endothelial dysfunction. However, in a recent scientific statement, the American Heart Association noted that neither has periodontal disease been proven to cause atherosclerotic vascular disease nor has the treatment of periodontal disease been proven to prevent atherosclerotic vascular disease. Therefore, the aim of the present study was to examine the correlation between periodontal condition and arteriosclerosis in patients with coronary artery disease (CAD), which is usually accompanied by systemic arteriosclerosis.We measured levels of gingival crevicular fluid lactoferrin (GCF-Lf) and 1-antitrypsin (GCF-AT) in 72 patients (67 ± 8 years, 56 men) with CAD. Furthermore, we evaluated the maximum intima-media thickness (max IMT) and plaque score of the carotid arteries as well as brachial-ankle pulse wave velocity (baPWV) and flow-mediated dilation (FMD) of the brachial artery, each of which is a parameter for determining arteriosclerosis status. The average level of GCF-Lf was 0.29 ± 0.36 µg/mL and that of GCF-AT was 0.31 ± 0.66 µg/mL, with significant correlation between the two (r = 0.701, P < 0.001). No significant difference in GCF-Lf and GCF-AT levels was observed between patients with single-, double-, and triple-vessel CAD. There were no significant correlations between the arteriosclerosis parameters (ie, max IMT, plaque score, baPWV, and FMD) and GCF-Lf or GCF-AT.No correlation between the GCF biomarkers and the severity of arteriosclerosis was detected. This result may suggest that worsening of the periodontal condition assessed by GCF biomarkers is not a major potential risk factor for arteriosclerosis.","ja":"Patients with periodontal disease exhibit exacerbated atherosclerosis, aortic stiffness, or vascular endothelial dysfunction. However, in a recent scientific statement, the American Heart Association noted that neither has periodontal disease been proven to cause atherosclerotic vascular disease nor has the treatment of periodontal disease been proven to prevent atherosclerotic vascular disease. Therefore, the aim of the present study was to examine the correlation between periodontal condition and arteriosclerosis in patients with coronary artery disease (CAD), which is usually accompanied by systemic arteriosclerosis.We measured levels of gingival crevicular fluid lactoferrin (GCF-Lf) and 1-antitrypsin (GCF-AT) in 72 patients (67 ± 8 years, 56 men) with CAD. Furthermore, we evaluated the maximum intima-media thickness (max IMT) and plaque score of the carotid arteries as well as brachial-ankle pulse wave velocity (baPWV) and flow-mediated dilation (FMD) of the brachial artery, each of which is a parameter for determining arteriosclerosis status. The average level of GCF-Lf was 0.29 ± 0.36 µg/mL and that of GCF-AT was 0.31 ± 0.66 µg/mL, with significant correlation between the two (r = 0.701, P < 0.001). No significant difference in GCF-Lf and GCF-AT levels was observed between patients with single-, double-, and triple-vessel CAD. There were no significant correlations between the arteriosclerosis parameters (ie, max IMT, plaque score, baPWV, and FMD) and GCF-Lf or GCF-AT.No correlation between the GCF biomarkers and the severity of arteriosclerosis was detected. This result may suggest that worsening of the periodontal condition assessed by GCF biomarkers is not a major potential risk factor for arteriosclerosis."},"publication_date":"2015-12-02","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.56","number":"No.6","starting_page":"639","ending_page":"643","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.15-218"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26549399","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84948967619&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305074","label":"url"}],"paper_title":{"en":"Effect of a low-intensity pulsed ultrasound device, SX-1001, on clinical symptoms in buerger disease with limb ischemia.","ja":"Effect of a low-intensity pulsed ultrasound device, SX-1001, on clinical symptoms in buerger disease with limb ischemia."},"authors":{"en":[{"name":"Higashi Y"},{"name":"Azuma N"},{"name":"Takeishi Y"},{"name":"Minamino T"},{"name":"Kihara Y"},{"name":"Node K"},{"name":"Sata Masataka"},{"name":"Fukumoto Y"},{"name":"Origasa H"},{"name":"Matsuo H"},{"name":"Naritomi H"},{"name":"Fujita M"},{"name":"Shimizu W"}],"ja":[{"name":"Higashi Y"},{"name":"Azuma N"},{"name":"Takeishi Y"},{"name":"Minamino T"},{"name":"Kihara Y"},{"name":"Node K"},{"name":"佐田 政隆"},{"name":"Fukumoto Y"},{"name":"Origasa H"},{"name":"Matsuo H"},{"name":"Naritomi H"},{"name":"Fujita M"},{"name":"Shimizu W"}]},"description":{"en":"Buerger disease is a rare disease of unknown etiology and cannot be treated by bypass surgery or percutaneous re-endovascularization. Although the need for effective limb ischemia prevention strategies is increasingly being recognized, effective preventative strategies are insufficient. The aim of this study using a new pulsed ultrasound device, SX-1001, is to determine whether treatment using SX-1001 can mitigate rest pain and improve blood supply to ischemic legs in patients with Buerger disease. This study is a multicenter, double-blinded, parallel randomized clinical trial testing the efficacy and safety of SX-1001. Treatment using SX-1001 is expected to result in reduction of the visual analog scale score for pain in Buerger disease patients who have Fontaine stage III. A total of 44 patients from 20 hospitals in Japan will be enrolled. The primary endpoint of the trial is a change in rest pain intensity on the visual analog scale score from baseline to 24 weeks. This trial will be the first to show the safety and efficacy of low-intensity pulsed ultrasound using SX-1001 for clinical symptoms in patients with Buerger disease. Low-intensity pulsed ultrasound may be a new therapy for limb ischemia. Ethical approval has been obtained from each of the participating institutes. Study findings will be disseminated through peer-reviewed journals and at scientific conferences.This study is registered at UMIN Clinical Trial Registry (UMIN000014757).","ja":"Buerger disease is a rare disease of unknown etiology and cannot be treated by bypass surgery or percutaneous re-endovascularization. Although the need for effective limb ischemia prevention strategies is increasingly being recognized, effective preventative strategies are insufficient. The aim of this study using a new pulsed ultrasound device, SX-1001, is to determine whether treatment using SX-1001 can mitigate rest pain and improve blood supply to ischemic legs in patients with Buerger disease. This study is a multicenter, double-blinded, parallel randomized clinical trial testing the efficacy and safety of SX-1001. Treatment using SX-1001 is expected to result in reduction of the visual analog scale score for pain in Buerger disease patients who have Fontaine stage III. A total of 44 patients from 20 hospitals in Japan will be enrolled. The primary endpoint of the trial is a change in rest pain intensity on the visual analog scale score from baseline to 24 weeks. This trial will be the first to show the safety and efficacy of low-intensity pulsed ultrasound using SX-1001 for clinical symptoms in patients with Buerger disease. Low-intensity pulsed ultrasound may be a new therapy for limb ischemia. Ethical approval has been obtained from each of the participating institutes. Study findings will be disseminated through peer-reviewed journals and at scientific conferences.This study is registered at UMIN Clinical Trial Registry (UMIN000014757)."},"publication_date":"2015-12-02","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.56","number":"No.6","starting_page":"632","ending_page":"638","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.15-191"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26408320","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84949101634&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305930","label":"url"}],"paper_title":{"en":"Pulmonary embolism due to right atrial free-floating thrombus during echocardiographic examination: a case of a pulmonary saddle thrombus.","ja":"Pulmonary embolism due to right atrial free-floating thrombus during echocardiographic examination: a case of a pulmonary saddle thrombus."},"authors":{"en":[{"name":"Bando Mika"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Hayashi Shuji"},{"name":"Takagawa Yuriko"},{"name":"Saijo Yoshihito"},{"name":"Nishio Susumu"},{"name":"Ogasawara Kozue"},{"name":"Sata Masataka"}],"ja":[{"name":"坂東 美佳"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"Hayashi Shuji"},{"name":"Takagawa Yuriko"},{"name":"Saijo Yoshihito"},{"name":"Nishio Susumu"},{"name":"Ogasawara Kozue"},{"name":"佐田 政隆"}]},"description":{"en":"A 69-year-old female with polymyositis was referred to our hospital with a chief complaint of dyspnea. Transthoracic echocardiography showed right ventricular overloading. In addition to two-dimensional echocardiography, observation of the abnormal free-floating string-like mass by three-dimensional echocardiography provided superior visualization of the features of the mass which protruded into the right ventricle across the tricuspid valve during diastole. These findings enabled us to confirm the diagnosis of venous thrombus. The thrombus disappeared during the echocardiographic examination. Multidetector-row computed tomography showed a string-like thrombus across the bifurcation of the main pulmonary artery. Anticoagulation therapy was initiated with heparin and warfarin, and fondaparinux was started on the fourth day. Three-dimensional echocardiography was useful in characterizing the motion and extent of the thrombus.","ja":"A 69-year-old female with polymyositis was referred to our hospital with a chief complaint of dyspnea. Transthoracic echocardiography showed right ventricular overloading. In addition to two-dimensional echocardiography, observation of the abnormal free-floating string-like mass by three-dimensional echocardiography provided superior visualization of the features of the mass which protruded into the right ventricle across the tricuspid valve during diastole. These findings enabled us to confirm the diagnosis of venous thrombus. The thrombus disappeared during the echocardiographic examination. Multidetector-row computed tomography showed a string-like thrombus across the bifurcation of the main pulmonary artery. Anticoagulation therapy was initiated with heparin and warfarin, and fondaparinux was started on the fourth day. Three-dimensional echocardiography was useful in characterizing the motion and extent of the thrombus."},"publication_date":"2015-12","publication_name":{"en":"Journal of Echocardiography","ja":"Journal of Echocardiography"},"volume":"Vol.13","number":"No.4","starting_page":"145","ending_page":"147","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12574-015-0263-3"],"issn":["1880-344X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26427796","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84948111930&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305073","label":"url"}],"paper_title":{"en":"Epac1 Deficiency Attenuated Vascular Smooth Muscle Cell Migration and Neointimal Formation.","ja":"Epac1 Deficiency Attenuated Vascular Smooth Muscle Cell Migration and Neointimal Formation."},"authors":{"en":[{"name":"Kato Y"},{"name":"Yokoyama U"},{"name":"Yanai C"},{"name":"Ishige R"},{"name":"Kurotaki D"},{"name":"Umemura M"},{"name":"Fujita T"},{"name":"Kubota T"},{"name":"Okumura S"},{"name":"Sata Masataka"},{"name":"Tamura T"},{"name":"Ishikawa Y"}],"ja":[{"name":"Kato Y"},{"name":"Yokoyama U"},{"name":"Yanai C"},{"name":"Ishige R"},{"name":"Kurotaki D"},{"name":"Umemura M"},{"name":"Fujita T"},{"name":"Kubota T"},{"name":"Okumura S"},{"name":"佐田 政隆"},{"name":"Tamura T"},{"name":"Ishikawa Y"}]},"description":{"en":"OBJECTIVE: Vascular smooth muscle cell (SMC) migration causes neointima, which is related to vascular remodeling after mechanical injury and atherosclerosis development. We previously reported that an exchange protein activated by cAMP (Epac) 1 was upregulated in mouse arterial neointima and promoted SMC migration. In this study, we examined the molecular mechanisms of Epac1-induced SMC migration and the effect of Epac1 deficiency on vascular remodeling in vivo.APPROACH AND RESULTS: Platelet-derived growth factor-BB promoted a 2-fold increase in SMC migration in a primary culture of aortic SMCs obtained from Epac1+/+ mice (Epac1+/+-ASMCs), whereas there was only a 1.2-fold increase in Epac1-/--ASMCs. The degree of platelet-derived growth factor-BB-induced increase in intracellular Ca2+ was smaller in Fura2-labeled Epac1-/--ASMCs than in Epac1+/+-ASMCs. In Epac1+/+-ASMCs, an Epac-selective cAMP analog or platelet-derived growth factor-BB increased lamellipodia accompanied by cofilin dephosphorylation, which is induced by Ca2+ signaling, whereas these effects were rarely observed in Epac1-/--ASMCs. Furthermore, 4 weeks after femoral artery injury, prominent neointima were formed in Epac1+/+ mice, whereas neointima formation was significantly attenuated in Epac1-/- mice in which dephosphorylation of cofilin was inhibited. The chimeric mice generated by bone marrow cell transplantation from Epac1+/+ into Epac1-/- mice and vice versa demonstrated that the genetic background of vascular tissues, including SMCs rather than of bone marrow-derived cells affected Epac1-mediated neointima formation.CONCLUSIONS: These data suggest that Epac1 deficiency attenuates neointima formation through, at least in part, inhibition of SMC migration, in which a decrease in Ca2+ influx and a suppression of cofilin-mediated lamellipodia formation occur.","ja":"OBJECTIVE: Vascular smooth muscle cell (SMC) migration causes neointima, which is related to vascular remodeling after mechanical injury and atherosclerosis development. We previously reported that an exchange protein activated by cAMP (Epac) 1 was upregulated in mouse arterial neointima and promoted SMC migration. In this study, we examined the molecular mechanisms of Epac1-induced SMC migration and the effect of Epac1 deficiency on vascular remodeling in vivo.APPROACH AND RESULTS: Platelet-derived growth factor-BB promoted a 2-fold increase in SMC migration in a primary culture of aortic SMCs obtained from Epac1+/+ mice (Epac1+/+-ASMCs), whereas there was only a 1.2-fold increase in Epac1-/--ASMCs. The degree of platelet-derived growth factor-BB-induced increase in intracellular Ca2+ was smaller in Fura2-labeled Epac1-/--ASMCs than in Epac1+/+-ASMCs. In Epac1+/+-ASMCs, an Epac-selective cAMP analog or platelet-derived growth factor-BB increased lamellipodia accompanied by cofilin dephosphorylation, which is induced by Ca2+ signaling, whereas these effects were rarely observed in Epac1-/--ASMCs. Furthermore, 4 weeks after femoral artery injury, prominent neointima were formed in Epac1+/+ mice, whereas neointima formation was significantly attenuated in Epac1-/- mice in which dephosphorylation of cofilin was inhibited. The chimeric mice generated by bone marrow cell transplantation from Epac1+/+ into Epac1-/- mice and vice versa demonstrated that the genetic background of vascular tissues, including SMCs rather than of bone marrow-derived cells affected Epac1-mediated neointima formation.CONCLUSIONS: These data suggest that Epac1 deficiency attenuates neointima formation through, at least in part, inhibition of SMC migration, in which a decrease in Ca2+ influx and a suppression of cofilin-mediated lamellipodia formation occur."},"publication_date":"2015-12","publication_name":{"en":"Arteriosclerosis, Thrombosis, and Vascular Biology","ja":"Arteriosclerosis, Thrombosis, and Vascular Biology"},"volume":"Vol.35","number":"No.12","starting_page":"2617","ending_page":"2625","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/ATVBAHA.115.306534"],"issn":["1524-4636"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25797126","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84947031165&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=291325","label":"url"}],"paper_title":{"en":"3D transthoracic echocardiography provides accurate cross-sectional area of the RV outflow tract.","ja":"3D transthoracic echocardiography provides accurate cross-sectional area of the RV outflow tract."},"authors":{"en":[{"name":"Sawada Naoko"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Hayashi Shuji"},{"name":"Iwase Takashi"},{"name":"Sata Masataka"}],"ja":[{"name":"Sawada Naoko"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"Hayashi Shuji"},{"name":"岩瀬 俊"},{"name":"佐田 政隆"}]},"publication_date":"2015-11","publication_name":{"en":"JACC. Cardiovascular Imaging","ja":"JACC. Cardiovascular Imaging"},"volume":"Vol.8","number":"No.11","starting_page":"1343","ending_page":"1345","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jcmg.2014.12.018"],"issn":["1876-7591"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25028167","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84947493138&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=279812","label":"url"}],"paper_title":{"en":"Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension","ja":"Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension"},"authors":{"en":[{"name":"Hatano Masaru"},{"name":"Yamada Hidehiro"},{"name":"Fukuda Keiichi"},{"name":"Yoshioka Koichiro"},{"name":"Funauchi Masanori"},{"name":"Kuwana Masataka"},{"name":"Sata Masataka"},{"name":"Taniguchi Mutsugu"},{"name":"Nakanishi Norifumi"},{"name":"Saito Takefumi"},{"name":"Tsutomu Saji"},{"name":"Sasayama Shigetake"}],"ja":[{"name":"Hatano Masaru"},{"name":"Yamada Hidehiro"},{"name":"Fukuda Keiichi"},{"name":"Yoshioka Koichiro"},{"name":"Funauchi Masanori"},{"name":"Kuwana Masataka"},{"name":"佐田 政隆"},{"name":"Taniguchi Mutsugu"},{"name":"Nakanishi Norifumi"},{"name":"Saito Takefumi"},{"name":"Tsutomu Saji"},{"name":"Sasayama Shigetake"}]},"description":{"en":"Pulmonary arterial hypertension (PAH) trial has mostly enrolled patients with World Health Organization functional class (WHO FC) III or IV. However, PAH is rapidly progressive in nature even in patients with less severe forms at diagnosis. Following the recent studies in Western population, here we assessed the efficacy of bosentan in Japanese patients with WHO FCII PAH. In this open-label trial, bosentan 125 mg twice daily was administered for 12 weeks in 16 patients, and a hemodynamic evaluation was performed. Treatment was continued for a further 12 weeks, where the effect on exercise capacity was assessed in 13 patients. In 16 patients, mean pulmonary arterial pressure decreased from 40.4 ± 10.4 to 35.6 ± 12.6 mmHg (p = 0.018) and cardiac index increased from 2.54 ± 0.73 to 2.96 ± 0.82 L/min/m2 (p = 0.023). Thus, pulmonary vascular resistance decreased from 792 ± 565 to 598 ± 558 dyn·sec/cm5 (p = 0.006). In 13 patients followed up for 24 weeks, 6-min walking distance increased from baseline at Week 12 (p = 0.003) and Week 24 (p = 0.011). All patients were mildly symptomatic at baseline with dyspnea index (Borg scale) of 2.50 ± 1.58 and the specific activity scale (SAS) of 5.0 ± 1.4 METs. These values remained unchanged throughout the study. These results suggest that bosentan treatment was beneficial for Japanese patients with WHO FC II PAH and treatment should be started in the early stage of the disease.","ja":"Pulmonary arterial hypertension (PAH) trial has mostly enrolled patients with World Health Organization functional class (WHO FC) III or IV. However, PAH is rapidly progressive in nature even in patients with less severe forms at diagnosis. Following the recent studies in Western population, here we assessed the efficacy of bosentan in Japanese patients with WHO FCII PAH. In this open-label trial, bosentan 125 mg twice daily was administered for 12 weeks in 16 patients, and a hemodynamic evaluation was performed. Treatment was continued for a further 12 weeks, where the effect on exercise capacity was assessed in 13 patients. In 16 patients, mean pulmonary arterial pressure decreased from 40.4 ± 10.4 to 35.6 ± 12.6 mmHg (p = 0.018) and cardiac index increased from 2.54 ± 0.73 to 2.96 ± 0.82 L/min/m2 (p = 0.023). Thus, pulmonary vascular resistance decreased from 792 ± 565 to 598 ± 558 dyn·sec/cm5 (p = 0.006). In 13 patients followed up for 24 weeks, 6-min walking distance increased from baseline at Week 12 (p = 0.003) and Week 24 (p = 0.011). All patients were mildly symptomatic at baseline with dyspnea index (Borg scale) of 2.50 ± 1.58 and the specific activity scale (SAS) of 5.0 ± 1.4 METs. These values remained unchanged throughout the study. These results suggest that bosentan treatment was beneficial for Japanese patients with WHO FC II PAH and treatment should be started in the early stage of the disease."},"publication_date":"2015-11","publication_name":{"en":"Heart and Vessels","ja":"Heart and Vessels"},"volume":"Vol.30","number":"No.6","starting_page":"798","ending_page":"804","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s00380-014-0544-1"],"issn":["1615-2573"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26514181","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84945959581&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305291","label":"url"}],"paper_title":{"en":"Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome.","ja":"Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Aihara Ken-ichi"},{"name":"Fukuda Daiju"},{"name":"Takashima Akira"},{"name":"Bando Mika"},{"name":"Hara Tomoya"},{"name":"Nishimoto Sachiko"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"粟飯原 賢一"},{"name":"福田 大受"},{"name":"Takashima Akira"},{"name":"坂東 美佳"},{"name":"Hara Tomoya"},{"name":"Nishimoto Sachiko"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: The hospitalization rate for acute coronary syndrome (ACS) for people aged 50 has remained stable over the past decade. Increased serum levels of n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with a decreased incidence of cardiovascular events and mortality in older patients; however, it is currently unknown whether reduced serum levels of n-3 PUFAs is also a risk factor for ACS in patients aged 50 years.METHODS AND RESULTS: We retrospectively reviewed 102 (male/ female 73/29) Japanese ACS patients whose serum levels of EPA/arachidonic acid (AA) and DHA/AA were evaluated on admission. The EPA/AA ratio was the lowest in patients aged 50 compared to patients aged 51-74 and 75. Pearson correlation analysis showed that early ACS onset was associated with low EPA/AA and DHA/AA ratios, and multiple regression analysis determined that decreased ratios of EPA/AA and DHA/AA, and male sex, current smoker status, increased body mass index and triglyceride levels, independently correlated with early ACS onset. Conversely, low-density and high-density lipoproteins, glycated hemoglobin, and hypertension did not correlate with early ACS onset. Subgroup analyses of male patients revealed that decreased ratios of EPA/AA and DHA/AA independently correlated with early ACS onset.CONCLUSION: Decreased EPA/AA and DHA/AA ratios may be risk factors for early onset of ACS, suggesting that reduced EPA/AA and DHA/AA may represent targets for preventing ACS in Japanese young people.","ja":"BACKGROUND: The hospitalization rate for acute coronary syndrome (ACS) for people aged 50 has remained stable over the past decade. Increased serum levels of n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with a decreased incidence of cardiovascular events and mortality in older patients; however, it is currently unknown whether reduced serum levels of n-3 PUFAs is also a risk factor for ACS in patients aged 50 years.METHODS AND RESULTS: We retrospectively reviewed 102 (male/ female 73/29) Japanese ACS patients whose serum levels of EPA/arachidonic acid (AA) and DHA/AA were evaluated on admission. The EPA/AA ratio was the lowest in patients aged 50 compared to patients aged 51-74 and 75. Pearson correlation analysis showed that early ACS onset was associated with low EPA/AA and DHA/AA ratios, and multiple regression analysis determined that decreased ratios of EPA/AA and DHA/AA, and male sex, current smoker status, increased body mass index and triglyceride levels, independently correlated with early ACS onset. Conversely, low-density and high-density lipoproteins, glycated hemoglobin, and hypertension did not correlate with early ACS onset. Subgroup analyses of male patients revealed that decreased ratios of EPA/AA and DHA/AA independently correlated with early ACS onset.CONCLUSION: Decreased EPA/AA and DHA/AA ratios may be risk factors for early onset of ACS, suggesting that reduced EPA/AA and DHA/AA may represent targets for preventing ACS in Japanese young people."},"publication_date":"2015-10-29","publication_name":{"en":"Nutrition Journal","ja":"Nutrition Journal"},"volume":"Vol.14","number":"No.1","starting_page":"111","ending_page":"111","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12937-015-0102-4"],"issn":["1475-2891"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26399764","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=298713","label":"url"}],"paper_title":{"en":"Risk stratification of coronary artery disease in asymptomatic diabetic subjects using multidetector computed tomography","ja":"Risk stratification of coronary artery disease in asymptomatic diabetic subjects using multidetector computed tomography"},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Saito T"},{"name":"Higa T"},{"name":"Nakamura K"},{"name":"Masuzaki H"},{"name":"Sata Masataka"},{"name":"the Fukuoka diabetologists group"}],"ja":[{"name":"島袋 充生"},{"name":"Saito T"},{"name":"Higa T"},{"name":"Nakamura K"},{"name":"Masuzaki H"},{"name":"佐田 政隆"},{"name":"the Fukuoka diabetologists group"}]},"description":{"en":"BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) show a greater risk for coronary artery disease (CAD), but the risk stratification in asymptomatic CAD patients has not been established. This study investigated the prevalence and severity for asymptomatic CAD and predictors in T2DM patients.METHODSANDRESULTS: In a multiclinic group, diabetic patients (320 men, 186 women) without known symptoms suggestive of CAD were recruited for multidetector computed tomography (MDCT). Patients were categorized according to severity of coronary atherosclerosis: Grade 1 (normal findings), Grade 2 (mild atherosclerosis without significant stenosis), Grade 3 (moderate stenosis/atherosclerosis, 50-74% stenosis), Grade 4 (moderate stenosis/atherosclerosis, 75-89% stenosis), Grade 5 (severe stenosis/atherosclerosis, 90% stenosis). The trend for severity grade of CAD was slightly higher in men than women (P=0.054). For critical lesions (combined Grades 3-5), the prevalence was almost equal (men 44% vs. women 37%; P=0.113). Multivariate models showed that in men, HbA1c7.4%, dyslipidemia, duration of diabetes, retinopathy, and other type of cardiovascular diseases were predictors of critical lesions and in women, duration of diabetes and retinopathy were predictors.CONCLUSIONS: The prevalence and severity of asymptomatic CAD are comparably high in men and women with T2DM. Risk stratification by using MDCT might be useful to predict asymptomatic coronary lesions requiring coronary revascularization. (Circ J 2015; 79: 2422-2429).","ja":"BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) show a greater risk for coronary artery disease (CAD), but the risk stratification in asymptomatic CAD patients has not been established. This study investigated the prevalence and severity for asymptomatic CAD and predictors in T2DM patients.METHODSANDRESULTS: In a multiclinic group, diabetic patients (320 men, 186 women) without known symptoms suggestive of CAD were recruited for multidetector computed tomography (MDCT). Patients were categorized according to severity of coronary atherosclerosis: Grade 1 (normal findings), Grade 2 (mild atherosclerosis without significant stenosis), Grade 3 (moderate stenosis/atherosclerosis, 50-74% stenosis), Grade 4 (moderate stenosis/atherosclerosis, 75-89% stenosis), Grade 5 (severe stenosis/atherosclerosis, 90% stenosis). The trend for severity grade of CAD was slightly higher in men than women (P=0.054). For critical lesions (combined Grades 3-5), the prevalence was almost equal (men 44% vs. women 37%; P=0.113). Multivariate models showed that in men, HbA1c7.4%, dyslipidemia, duration of diabetes, retinopathy, and other type of cardiovascular diseases were predictors of critical lesions and in women, duration of diabetes and retinopathy were predictors.CONCLUSIONS: The prevalence and severity of asymptomatic CAD are comparably high in men and women with T2DM. Risk stratification by using MDCT might be useful to predict asymptomatic coronary lesions requiring coronary revascularization. (Circ J 2015; 79: 2422-2429)."},"publication_date":"2015-10-23","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.79","number":"No.11","starting_page":"2422","ending_page":"2429","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-15-0325"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109532","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26282945","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=299239","label":"url"}],"paper_title":{"en":"Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis.","ja":"Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis."},"authors":{"en":[{"name":"Bando S"},{"name":"Fukuda Daiju"},{"name":"Soeki Takeshi"},{"name":"Nishimoto S"},{"name":"Uematsu E"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Bando S"},{"name":"福田 大受"},{"name":"添木 武"},{"name":"Nishimoto S"},{"name":"Uematsu E"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"ObjectivesThe promotion of adipose tissue inflammation by lifestyle-related diseases such as obesity and diabetes accelerates atherogenesis; however, the underlying mechanisms remain incompletely understood. Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome contributes to chronic inflammation in adipose tissue. Here, we investigated the link between NLRP3 expression in subcutaneous adipose tissue (SAT) and the severity of coronary atherosclerosis.Methods and resultsSAT was obtained from 72 patients who underwent heart device implantation and coronary angiography. Expression of NLRP3 inflammasome-related molecules (NLRP3, IL-1 and IL-18) in SAT were evaluated by quantitative RT-PCR. Laboratory markers related to lifestyle-related diseases were measured. Patients with obesity, dyslipidemia (P < 0.05, respectively), diabetes or hyperuricemia (P < 0.01, respectively) had significantly higher expression of NLRP3. Multivariate analysis demonstrated that body mass index and serum level of uric acid were predictors of NLRP3 expression in SAT. The expression of NLRP3 in SAT correlated negatively with serum adiponectin level (r = 0.23, P < 0.05). Patients with coronary artery disease showed higher NLRP3 expression than patients without significant stenosis (P < 0.01). Furthermore, the expression of NLRP3 in SAT correlated positively with the severity of coronary atherosclerosis as determined by Gensini score (r = 0.47, P < 0.0001) or SYNTAX score (r = 0.55, P < 0.0001). Multiple regression analysis revealed that the expression of NLRP3 in SAT remains as an independent predictors for the severity of coronary atherosclerosis.ConclusionsThe expression of NLRP3 in SAT, which is affected by lifestyle-related diseases, is associated with the severity of coronary atherosclerosis. Our results suggest that NLRP3 inflammasome in SAT may have a role in atherogenesis.","ja":"ObjectivesThe promotion of adipose tissue inflammation by lifestyle-related diseases such as obesity and diabetes accelerates atherogenesis; however, the underlying mechanisms remain incompletely understood. Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome contributes to chronic inflammation in adipose tissue. Here, we investigated the link between NLRP3 expression in subcutaneous adipose tissue (SAT) and the severity of coronary atherosclerosis.Methods and resultsSAT was obtained from 72 patients who underwent heart device implantation and coronary angiography. Expression of NLRP3 inflammasome-related molecules (NLRP3, IL-1 and IL-18) in SAT were evaluated by quantitative RT-PCR. Laboratory markers related to lifestyle-related diseases were measured. Patients with obesity, dyslipidemia (P < 0.05, respectively), diabetes or hyperuricemia (P < 0.01, respectively) had significantly higher expression of NLRP3. Multivariate analysis demonstrated that body mass index and serum level of uric acid were predictors of NLRP3 expression in SAT. The expression of NLRP3 in SAT correlated negatively with serum adiponectin level (r = 0.23, P < 0.05). Patients with coronary artery disease showed higher NLRP3 expression than patients without significant stenosis (P < 0.01). Furthermore, the expression of NLRP3 in SAT correlated positively with the severity of coronary atherosclerosis as determined by Gensini score (r = 0.47, P < 0.0001) or SYNTAX score (r = 0.55, P < 0.0001). Multiple regression analysis revealed that the expression of NLRP3 in SAT remains as an independent predictors for the severity of coronary atherosclerosis.ConclusionsThe expression of NLRP3 in SAT, which is affected by lifestyle-related diseases, is associated with the severity of coronary atherosclerosis. Our results suggest that NLRP3 inflammasome in SAT may have a role in atherogenesis."},"publication_date":"2015-10","publication_name":{"en":"Atherosclerosis","ja":"Atherosclerosis"},"volume":"Vol.242","number":"No.2","starting_page":"407","ending_page":"414","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.atherosclerosis.2015.07.043"],"issn":["1879-1484"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26213347","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84943198660&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=296983","label":"url"}],"paper_title":{"en":"PPAR-gamma agonist attenuates inflammation in aortic aneurysm patients.","ja":"PPAR-gamma agonist attenuates inflammation in aortic aneurysm patients."},"authors":{"en":[{"name":"Motoki Tatsuo"},{"name":"Kurobe Hirotsugu"},{"name":"Hirata Yoichiro"},{"name":"Nakayama Taisuke"},{"name":"Kinoshita Hajime"},{"name":"Rocco A. Kevin"},{"name":"Sogabe Hitoshi"},{"name":"Hori Takaki"},{"name":"Sata Masataka"},{"name":"Kitagawa Tetsuya"}],"ja":[{"name":"元木 達夫"},{"name":"黒部 裕嗣"},{"name":"Hirata Yoichiro"},{"name":"Nakayama Taisuke"},{"name":"木下 肇"},{"name":"Rocco A. Kevin"},{"name":"Sogabe Hitoshi"},{"name":"堀 隆樹"},{"name":"佐田 政隆"},{"name":"北川 哲也"}]},"description":{"en":"Peroxisome proliferator-activated receptor (PPAR) -γ agonist, which is an anti-diabetes drug and reduces expression of tumor necrosis factor (TNF)-α, reported to have the effects for anti-inflammation in our body. In cardiovascular fields, this PPAR-γ agonist already reported to suppress progression of coronary atherosclerosis. Various cytokines, which is secreted from fat tissues around artery, promote atherosclerosis and/or aneurysmal changes in aorta/artery. Objective of our study is to clarify whether PPAR-γ agonist has anti-inflammatory effects in aorta of patients with aortic aneurysm (AA). The medical ethics committee in Tokushima University Hospital approved protocol for this study. Sixteen patients with AA (more than 5 cm in diameter, scheduled open surgery) were divided into two groups; one is PPAR-γ agonist administrating group [Formula: see text] n = 6, group P[Formula: see text], and another is the without group [Formula: see text] n = 10, group C[Formula: see text]. PPAR-γ agonist, whose dose was 15 mg/day, was administrated in the group P for more than 2 months before aneurysectomy and grafting (mean; 4.2 ± 3.4 months) (Supplemental Table 1). Biopsy specimens were obtained from abdominal subcutaneous fat, greater omentum, retroperitoneal periaortic fat and aneurysmal wall in surgical procedure. Blood examination also achieved before/after procedure. Harvested specimens were analyzed with histology (HE and EVG), immunohistochemistry (macrophage) and RT-PCR (adiponectin, MCP-1, TNF-α, CD68, matrix metalloprotease (MMP)-2, MMP-9). Macrophage infiltration in aortic wall and retroperitoneal periaortic fat among group P was significantly decreased compared to that among group C. Adiponectin expressions in both subcutaneous fat and retroperitoneal periaortic fat among the group P (adiponectin/β-actin) were significantly increased compared to those among the group C [subcutaneous fat; 16.8 ± 13.9 vs. 5.82 ± 2.94 (P = 0.04), retroperitoneal periaortic fat; 21.3 ± 24.1 vs. 2.12 ± 1.69 (P = 0.04)]. On the other hand, expressions of TNF-α, and MMP-9 in both aortic aneurysmal wall and retroperitoneal periaortic fat among group P were significantly decreased. [(Aortic aneurysmal wall; TNF-α; 0.45 ± 0.15 vs. 5.18 ± 3.49 (P = 0.02), MMP-9; 39.6 ± 69.0 vs. 721 ± 741 (P = 0.04)], [retroperitoneal periaortic fat; TNF-α; 1.14 ± 0.36 vs. 26.4 ± 25.0 (P = 0.048), MMP-9; 0.18 ± 0.21 vs. 50.0 ± 41.8 (P = 0.047)]. These data may indicate that PPAR-γ agonist become the way for preventing or delaying aortic aneurysm progression in patients. More studies will be needed to clarify this drug effects in detail.","ja":"Peroxisome proliferator-activated receptor (PPAR) -γ agonist, which is an anti-diabetes drug and reduces expression of tumor necrosis factor (TNF)-α, reported to have the effects for anti-inflammation in our body. In cardiovascular fields, this PPAR-γ agonist already reported to suppress progression of coronary atherosclerosis. Various cytokines, which is secreted from fat tissues around artery, promote atherosclerosis and/or aneurysmal changes in aorta/artery. Objective of our study is to clarify whether PPAR-γ agonist has anti-inflammatory effects in aorta of patients with aortic aneurysm (AA). The medical ethics committee in Tokushima University Hospital approved protocol for this study. Sixteen patients with AA (more than 5 cm in diameter, scheduled open surgery) were divided into two groups; one is PPAR-γ agonist administrating group [Formula: see text] n = 6, group P[Formula: see text], and another is the without group [Formula: see text] n = 10, group C[Formula: see text]. PPAR-γ agonist, whose dose was 15 mg/day, was administrated in the group P for more than 2 months before aneurysectomy and grafting (mean; 4.2 ± 3.4 months) (Supplemental Table 1). Biopsy specimens were obtained from abdominal subcutaneous fat, greater omentum, retroperitoneal periaortic fat and aneurysmal wall in surgical procedure. Blood examination also achieved before/after procedure. Harvested specimens were analyzed with histology (HE and EVG), immunohistochemistry (macrophage) and RT-PCR (adiponectin, MCP-1, TNF-α, CD68, matrix metalloprotease (MMP)-2, MMP-9). Macrophage infiltration in aortic wall and retroperitoneal periaortic fat among group P was significantly decreased compared to that among group C. Adiponectin expressions in both subcutaneous fat and retroperitoneal periaortic fat among the group P (adiponectin/β-actin) were significantly increased compared to those among the group C [subcutaneous fat; 16.8 ± 13.9 vs. 5.82 ± 2.94 (P = 0.04), retroperitoneal periaortic fat; 21.3 ± 24.1 vs. 2.12 ± 1.69 (P = 0.04)]. On the other hand, expressions of TNF-α, and MMP-9 in both aortic aneurysmal wall and retroperitoneal periaortic fat among group P were significantly decreased. [(Aortic aneurysmal wall; TNF-α; 0.45 ± 0.15 vs. 5.18 ± 3.49 (P = 0.02), MMP-9; 39.6 ± 69.0 vs. 721 ± 741 (P = 0.04)], [retroperitoneal periaortic fat; TNF-α; 1.14 ± 0.36 vs. 26.4 ± 25.0 (P = 0.048), MMP-9; 0.18 ± 0.21 vs. 50.0 ± 41.8 (P = 0.047)]. These data may indicate that PPAR-γ agonist become the way for preventing or delaying aortic aneurysm progression in patients. More studies will be needed to clarify this drug effects in detail."},"publication_date":"2015-10","publication_name":{"en":"General Thoracic and Cardiovascular Surgery","ja":"General Thoracic and Cardiovascular Surgery"},"volume":"Vol.63","number":"No.10","starting_page":"565","ending_page":"571","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s11748-015-0576-1"],"issn":["1863-6713"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109485","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25817329","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84941742835&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=291492","label":"url"}],"paper_title":{"en":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.","ja":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice."},"authors":{"en":[{"name":"Tomoya Hara"},{"name":"Fukuda Daiju"},{"name":"Kimie Tanaka"},{"name":"Yasutomi Higashikuni"},{"name":"Yoichiro Hirata"},{"name":"Yagi Shusuke"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"Tomoya Hara"},{"name":"福田 大受"},{"name":"Kimie Tanaka"},{"name":"Yasutomi Higashikuni"},{"name":"Yoichiro Hirata"},{"name":"八木 秀介"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"OBJECTIVE: Activated factor X (FXa) plays a key role in the coagulation cascade, whereas accumulating evidence suggests that it also contributes to the pathophysiology of chronic inflammation on the vasculature. In this study, we assessed the hypothesis that rivaroxaban (Riv), a direct FXa inhibitor, inhibits atherogenesis by reducing macrophage activation.METHODS AND RESULTS: Expression levels of PAR-1 and PAR-2, receptors for FXa, increased in the aorta of apolipoprotein E-deficient (ApoE(-/-)) mice compared with wild-type mice (P < 0.01, P < 0.05, respectively). Administration of Riv (5 mg/kg/day) for 20 weeks to 8-week-old ApoE(-/-) mice reduced atherosclerotic lesion progression in the aortic arch as determined by en-face Sudan IV staining compared with the non-treated group (P < 0.05) without alteration of plasma lipid levels and blood pressure. Histological analyses demonstrated that Riv significantly decreased lipid deposition, collagen loss, macrophage accumulation and matrix metallopeptidase-9 (MMP-9) expression in atherosclerotic plaques in the aortic root. Quantitative RT-PCR analyses using abdominal aorta revealed that Riv significantly reduced mRNA expression of inflammatory molecules, such as MMP-9, tumor necrosis factor- (TNF-). In vitro experiments using mouse peritoneal macrophages or murine macrophage cell line RAW264.7 demonstrated that FXa increased mRNA expression of inflammatory molecules (e.g., interleukin (IL)-1 and TNF-), which was blocked in the presence of Riv.CONCLUSIONS: Riv attenuates atherosclerotic plaque progression and destabilization in ApoE(-/-) mice, at least in part by inhibiting pro-inflammatory activation of macrophages. These results indicate that Riv may be particularly beneficial for the management of atherosclerotic diseases, in addition to its antithrombotic activity.","ja":"OBJECTIVE: Activated factor X (FXa) plays a key role in the coagulation cascade, whereas accumulating evidence suggests that it also contributes to the pathophysiology of chronic inflammation on the vasculature. In this study, we assessed the hypothesis that rivaroxaban (Riv), a direct FXa inhibitor, inhibits atherogenesis by reducing macrophage activation.METHODS AND RESULTS: Expression levels of PAR-1 and PAR-2, receptors for FXa, increased in the aorta of apolipoprotein E-deficient (ApoE(-/-)) mice compared with wild-type mice (P < 0.01, P < 0.05, respectively). Administration of Riv (5 mg/kg/day) for 20 weeks to 8-week-old ApoE(-/-) mice reduced atherosclerotic lesion progression in the aortic arch as determined by en-face Sudan IV staining compared with the non-treated group (P < 0.05) without alteration of plasma lipid levels and blood pressure. Histological analyses demonstrated that Riv significantly decreased lipid deposition, collagen loss, macrophage accumulation and matrix metallopeptidase-9 (MMP-9) expression in atherosclerotic plaques in the aortic root. Quantitative RT-PCR analyses using abdominal aorta revealed that Riv significantly reduced mRNA expression of inflammatory molecules, such as MMP-9, tumor necrosis factor- (TNF-). In vitro experiments using mouse peritoneal macrophages or murine macrophage cell line RAW264.7 demonstrated that FXa increased mRNA expression of inflammatory molecules (e.g., interleukin (IL)-1 and TNF-), which was blocked in the presence of Riv.CONCLUSIONS: Riv attenuates atherosclerotic plaque progression and destabilization in ApoE(-/-) mice, at least in part by inhibiting pro-inflammatory activation of macrophages. These results indicate that Riv may be particularly beneficial for the management of atherosclerotic diseases, in addition to its antithrombotic activity."},"publication_date":"2015-10","publication_name":{"en":"Atherosclerosis","ja":"Atherosclerosis"},"volume":"Vol.242","number":"No.2","starting_page":"639","ending_page":"646","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.atherosclerosis.2015.03.023"],"issn":["1879-1484"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25572021","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84939572949&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=291330","label":"url"}],"paper_title":{"en":"Echocardiographic screening for congenital heart disease in 8819 children: A report from local community events for children's healthcare.","ja":"Echocardiographic screening for congenital heart disease in 8819 children: A report from local community events for children's healthcare."},"authors":{"en":[{"name":"Nishio Susumu"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Yamao Masami"},{"name":"Hirata Yukina"},{"name":"Mori Kazuhiro"},{"name":"Matsuoka Suguru"},{"name":"Sata Masataka"}],"ja":[{"name":"Nishio Susumu"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"Yamao Masami"},{"name":"Hirata Yukina"},{"name":"森 一博"},{"name":"Matsuoka Suguru"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: We had the opportunity to perform echocardiographic screening of children at local community events for children's healthcare sponsored by the prefectural government. The aim of this study was to assess the utility of echocardiographic screening by measuring the prevalence of congenital heart disease (CHD) and abnormal findings in children without history of diagnosed CHD.METHODS: Subjects consisted of 8819 infants and preschool children (1 month to 6 years) who underwent echocardiographic examination at public events from 2001 to 2013. Children with known CHD were excluded.RESULTS: We performed echocardiographic screening on 752 (range: 464-993) children at each event. At a total of 12 events, subjects consisted of 3175 infants less than one year (36%), 2292 one-year-olds (26%), 1058 two-year-olds (12%), 794 three-year-olds (9%), and other children up to age six years. We identified echocardiographic abnormalities in 137 children (15.5/1000 subjects), and 89 children (10.1/1000 subjects) were diagnosed with CHD. The prevalence of an echocardiographic abnormality did not change over the 12-year period (Kendall's tau=-0.272, p=0.19).CONCLUSIONS: CHD which could not be identified by prenatal echocardiography and neonatal auscultation could be detected in a substantial number of young children by echocardiographic screening. Echocardiographic screening may be useful for early diagnosis of CHD. However, our study is based on cross-sectional data without follow-up. Larger prospective studies are needed to verify the utility of echocardiographic screening with follow-up data in this cohort.","ja":"BACKGROUND: We had the opportunity to perform echocardiographic screening of children at local community events for children's healthcare sponsored by the prefectural government. The aim of this study was to assess the utility of echocardiographic screening by measuring the prevalence of congenital heart disease (CHD) and abnormal findings in children without history of diagnosed CHD.METHODS: Subjects consisted of 8819 infants and preschool children (1 month to 6 years) who underwent echocardiographic examination at public events from 2001 to 2013. Children with known CHD were excluded.RESULTS: We performed echocardiographic screening on 752 (range: 464-993) children at each event. At a total of 12 events, subjects consisted of 3175 infants less than one year (36%), 2292 one-year-olds (26%), 1058 two-year-olds (12%), 794 three-year-olds (9%), and other children up to age six years. We identified echocardiographic abnormalities in 137 children (15.5/1000 subjects), and 89 children (10.1/1000 subjects) were diagnosed with CHD. The prevalence of an echocardiographic abnormality did not change over the 12-year period (Kendall's tau=-0.272, p=0.19).CONCLUSIONS: CHD which could not be identified by prenatal echocardiography and neonatal auscultation could be detected in a substantial number of young children by echocardiographic screening. Echocardiographic screening may be useful for early diagnosis of CHD. However, our study is based on cross-sectional data without follow-up. Larger prospective studies are needed to verify the utility of echocardiographic screening with follow-up data in this cohort."},"publication_date":"2015-10","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.66","number":"No.4","starting_page":"315","ending_page":"319","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2014.11.011"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25543526","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84944158077&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=289087","label":"url"}],"paper_title":{"en":"Arterial stiffness is increased in young women with endometriosis.","ja":"Arterial stiffness is increased in young women with endometriosis."},"authors":{"en":[{"name":"Tani Anna"},{"name":"Yamamoto S"},{"name":"Maegawa Masahiko"},{"name":"Kunimi Koutaro"},{"name":"Matsui Sumika"},{"name":"Keyama Kaoru"},{"name":"Katou Takeshi"},{"name":"Uemura Hirokazu"},{"name":"Kuwahara Akira"},{"name":"Matsuzaki Toshiya"},{"name":"Yasui Toshiyuki"},{"name":"Kamada M"},{"name":"Soeki Takeshi"},{"name":"Sata Masataka"},{"name":"Irahara Minoru"}],"ja":[{"name":"谷 杏奈"},{"name":"Yamamoto S"},{"name":"前川 正彦"},{"name":"國見 幸太郎"},{"name":"松井 寿美佳"},{"name":"毛山 薫"},{"name":"加藤 剛志"},{"name":"上村 浩一"},{"name":"桑原 章"},{"name":"松崎 利也"},{"name":"安井 敏之"},{"name":"Kamada M"},{"name":"添木 武"},{"name":"佐田 政隆"},{"name":"苛原 稔"}]},"description":{"en":"Endometriosis is a chronic gynaecological disorder that is accompanied by inflammation and oxidative stress. Atherosclerosis has a long subclinical progression in arteries of children and young adults decades before overt clinical manifestations of the disease. In this study, we determined arterial stiffness by measuring brachial-ankle pulse wave velocity (baPWV) in women with endometriosis to assess the presence of subclinical atherosclerosis. We also measured markers of inflammation and oxidative stress in women with endometriosis. baPWV in women with endometriosis aged over 30 years was significantly higher than that in women without endometriosis aged over 30 years (p < 0.05), but not in women aged less than 30. Serum high-sensitivity C-reactive protein level in women with endometriosis was significantly higher than that in controls (p < 0.05). Young women with endometriosis show significantly increased arterial stiffness, suggesting that women with endometriosis need to be cautious of the future onset of atherosclerosis.","ja":"Endometriosis is a chronic gynaecological disorder that is accompanied by inflammation and oxidative stress. Atherosclerosis has a long subclinical progression in arteries of children and young adults decades before overt clinical manifestations of the disease. In this study, we determined arterial stiffness by measuring brachial-ankle pulse wave velocity (baPWV) in women with endometriosis to assess the presence of subclinical atherosclerosis. We also measured markers of inflammation and oxidative stress in women with endometriosis. baPWV in women with endometriosis aged over 30 years was significantly higher than that in women without endometriosis aged over 30 years (p < 0.05), but not in women aged less than 30. Serum high-sensitivity C-reactive protein level in women with endometriosis was significantly higher than that in controls (p < 0.05). Young women with endometriosis show significantly increased arterial stiffness, suggesting that women with endometriosis need to be cautious of the future onset of atherosclerosis."},"publication_date":"2015-10","publication_name":{"en":"Journal of Obstetrics and Gynaecology","ja":"Journal of Obstetrics and Gynaecology"},"volume":"Vol.35","number":"No.7","starting_page":"711","ending_page":"715","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3109/01443615.2014.992871"],"issn":["1364-6893"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26133316","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84940380486&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=291618","label":"url"}],"paper_title":{"en":"Subclinical carotid atherosclerosis burden in Japanese: comparison between Okinawa and Nagano residents.","ja":"Subclinical carotid atherosclerosis burden in Japanese: comparison between Okinawa and Nagano residents."},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Hasegawa Yoshimasa"},{"name":"Higa Moritake"},{"name":"Amano Rie"},{"name":"Yamada Hirotsugu"},{"name":"Mizushima Shunsaku"},{"name":"Masuzaki Hiroaki"},{"name":"Sata Masataka"}],"ja":[{"name":"島袋 充生"},{"name":"Hasegawa Yoshimasa"},{"name":"Higa Moritake"},{"name":"Amano Rie"},{"name":"山田 博胤"},{"name":"Mizushima Shunsaku"},{"name":"Masuzaki Hiroaki"},{"name":"佐田 政隆"}]},"description":{"en":"AIM: The prevalence of overweight and a change in atherosclerotic lipid profiles may be linked to region-specific differences in atherosclerotic diseases. We evaluated whether the lipid phenotype could be linked to region- and sex-specific differences in the degree of atherosclerosis.METHODS: Non-diabetic subjects included Okinawa (n=1674) and Nagano (n=1392) residents aged 30-75 years who underwent carotid ultrasonography for the measurement of maximum intima-media thickness (max IMT).RESULTS: Average max IMT was higher in Okinawa men and women, and the increase in max IMT with age was enhanced in men. Multiple regression analysis showed that in addition to age and systolic blood pressure, low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol were IMT determinants only in men for both Okinawa and Nagano. Meanwhile, HDL-cholesterol was a determinant for Okinawa men and women, but not for Nagano men and women.CONCLUSIONS: This is the first report to show region- and sex-specific differences in the determinants for max IMT in a Japanese population. The evaluation of the relationship between lipid profile patterns and region- and sex-specific differences in carotid atherosclerosis burden may be required.","ja":"AIM: The prevalence of overweight and a change in atherosclerotic lipid profiles may be linked to region-specific differences in atherosclerotic diseases. We evaluated whether the lipid phenotype could be linked to region- and sex-specific differences in the degree of atherosclerosis.METHODS: Non-diabetic subjects included Okinawa (n=1674) and Nagano (n=1392) residents aged 30-75 years who underwent carotid ultrasonography for the measurement of maximum intima-media thickness (max IMT).RESULTS: Average max IMT was higher in Okinawa men and women, and the increase in max IMT with age was enhanced in men. Multiple regression analysis showed that in addition to age and systolic blood pressure, low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol were IMT determinants only in men for both Okinawa and Nagano. Meanwhile, HDL-cholesterol was a determinant for Okinawa men and women, but not for Nagano men and women.CONCLUSIONS: This is the first report to show region- and sex-specific differences in the determinants for max IMT in a Japanese population. The evaluation of the relationship between lipid profile patterns and region- and sex-specific differences in carotid atherosclerosis burden may be required."},"publication_date":"2015-08-26","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.22","number":"No.8","starting_page":"854","ending_page":"868","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.26674"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109714","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26275751","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84944180106&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=308508","label":"url"}],"paper_title":{"en":"Clinical Utility of Measuring Epicardial Adipose Tissue Thickness with Echocardiography Using a High-Frequency Linear Probe in Patients with Coronary Artery Disease.","ja":"Clinical Utility of Measuring Epicardial Adipose Tissue Thickness with Echocardiography Using a High-Frequency Linear Probe in Patients with Coronary Artery Disease."},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Iwase Takashi"},{"name":"Nishio Susumu"},{"name":"Hayashi Shuji"},{"name":"Bando Mika"},{"name":"Amano Rie"},{"name":"Yamaguchi Koji"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"Hirata Yukina"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"岩瀬 俊"},{"name":"Nishio Susumu"},{"name":"Hayashi Shuji"},{"name":"坂東 美佳"},{"name":"Amano Rie"},{"name":"山口 浩司"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"The relationship between epicardial adipose tissue (EAT) and coronary artery disease (CAD) has recently attracted a great deal of attention in the medical community. The objective of this study was to determine whether measuring EAT thickness in the anterior interventricular groove (AIG) using echocardiography is feasible and whether this index can be a marker of CAD. A total of 311 patients (mean age, 67 ± 11 years; 208 men) who underwent coronary angiography between December 2011 and December 2013 were prospectively enrolled. EAT-AIG thickness and EAT thickness on the free wall of the right ventricle (RV) were measured in systole using a high-frequency linear probe. Seventy-one patients who underwent multidetector-row computed tomography were enrolled to validate the method for measuring EAT thickness using echocardiography. Subjects were divided into two groups, those with and without significant coronary stenosis, on the basis of findings on coronary angiography (≥ 75% luminal narrowing). EAT-AIG thickness measured using echocardiography was validated by computed tomography. EAT-AIG thickness was strongly correlated with EAT volume (r = 0.714, P < .001). The CAD group had thicker EAT-AIG than the non-CAD group (8.3 ± 3.0 vs 6.3 ± 2.5 mm, P < .001). EAT-RV thickness was greater in the CAD group than in the non-CAD group (5.0 ± 2.1 vs 4.4 ± 2.3 mm, P = .009) as well. The area under the curve on receiver operating characteristic curve analysis of EAT-AIG thickness for predicting CAD was 0.704, which was higher than the EAT-RV thickness. Measuring EAT thickness using echocardiography with a high-frequency linear probe was validated with computed tomography. EAT-AIG was thicker in the CAD group than in the non-CAD group, as was EAT-RV thickness. This noninvasive index may have potential as a diagnostic marker for predicting coronary atherosclerosis.","ja":"The relationship between epicardial adipose tissue (EAT) and coronary artery disease (CAD) has recently attracted a great deal of attention in the medical community. The objective of this study was to determine whether measuring EAT thickness in the anterior interventricular groove (AIG) using echocardiography is feasible and whether this index can be a marker of CAD. A total of 311 patients (mean age, 67 ± 11 years; 208 men) who underwent coronary angiography between December 2011 and December 2013 were prospectively enrolled. EAT-AIG thickness and EAT thickness on the free wall of the right ventricle (RV) were measured in systole using a high-frequency linear probe. Seventy-one patients who underwent multidetector-row computed tomography were enrolled to validate the method for measuring EAT thickness using echocardiography. Subjects were divided into two groups, those with and without significant coronary stenosis, on the basis of findings on coronary angiography (≥ 75% luminal narrowing). EAT-AIG thickness measured using echocardiography was validated by computed tomography. EAT-AIG thickness was strongly correlated with EAT volume (r = 0.714, P < .001). The CAD group had thicker EAT-AIG than the non-CAD group (8.3 ± 3.0 vs 6.3 ± 2.5 mm, P < .001). EAT-RV thickness was greater in the CAD group than in the non-CAD group (5.0 ± 2.1 vs 4.4 ± 2.3 mm, P = .009) as well. The area under the curve on receiver operating characteristic curve analysis of EAT-AIG thickness for predicting CAD was 0.704, which was higher than the EAT-RV thickness. Measuring EAT thickness using echocardiography with a high-frequency linear probe was validated with computed tomography. EAT-AIG was thicker in the CAD group than in the non-CAD group, as was EAT-RV thickness. This noninvasive index may have potential as a diagnostic marker for predicting coronary atherosclerosis."},"publication_date":"2015-08-12","publication_name":{"en":"Journal of the American Society of Echocardiography","ja":"Journal of the American Society of Echocardiography"},"volume":"Vol.28","number":"No.10","starting_page":"1240","ending_page":"1246.e1","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.echo.2015.07.006"],"issn":["1097-6795"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115008","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26291496","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84939809758&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=300624","label":"url"}],"paper_title":{"en":"Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese.","ja":"Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese."},"authors":{"en":[{"name":"Tomiyama Hirofumi"},{"name":"Kohro Takahide"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"Sata Masataka"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"}],"ja":[{"name":"Tomiyama Hirofumi"},{"name":"Kohro Takahide"},{"name":"Higashi Yukihito"},{"name":"Takase Bonpei"},{"name":"Suzuki Toru"},{"name":"Ishizu Tomoko"},{"name":"Ueda Shinichiro"},{"name":"Yamazaki Tsutomu"},{"name":"Furumoto Tomoo"},{"name":"Kario Kazuomi"},{"name":"Inoue Teruo"},{"name":"Koba Shinji"},{"name":"Watanabe Kentaro"},{"name":"Takemoto Yasuhiko"},{"name":"Hano Takuzo"},{"name":"佐田 政隆"},{"name":"Ishibashi Yutaka"},{"name":"Node Koichi"},{"name":"Maemura Koji"},{"name":"Ohya Yusuke"},{"name":"Furukawa Taiji"},{"name":"Ito Hiroshi"},{"name":"Ikeda Hisao"},{"name":"Yamashina Akira"}]},"description":{"en":"AIMS: For the standardization of flow-mediated vasodilatation (FMD) assessment as a clinical tool, validation of its reliability across multiple institutions and the establishment of normal/reference values based on reliable data from multiple institutions are needed.METHODS AND RESULTS: In Study 1, assessment of FMD (scan recording and analysis) using an ultrasonographic semi-automatic measuring system (sFMD) was conducted at 18 participating institutions (sFMD-INST) (n = 981). All of the brachial arterial scans were also analyzed at a core laboratory (sFMD-COLB). After 111 subjects with inadequate sFMD recordings were excluded (n = 880), the correlation between the sFMD-INST and sFMD-COLB improved from R = 0.725 to R = 0.838 (p < 0.001). In Study 2, based on good-quality sFMD data obtained from 6660 subjects without cardiovascular disease (CVD) and 729 subjects with CVD from 27 institutions, reference values of sFMD are proposed by the Framingham risk score (FRS)-based risk categories and according to gender and age. The receiver-operating characteristic curve analysis revealed a significant power of sFMD values in reference ranges to discriminate between subjects with and without CVD (e.g., area under curve = 0.64 in the FRS-low risk group).CONCLUSIONS: When the analysis was limited to cases with clear sFMD recordings, the reliability of the sFMD assessment (scan and its analysis) conducted in individual institutions appeared to be acceptable. Reference sFMD values (lower cuff occlusion) for the Japanese population are proposed based on reliable data derived from multiple institutions, and the reference values may identify patients without advanced vascular damage.","ja":"AIMS: For the standardization of flow-mediated vasodilatation (FMD) assessment as a clinical tool, validation of its reliability across multiple institutions and the establishment of normal/reference values based on reliable data from multiple institutions are needed.METHODS AND RESULTS: In Study 1, assessment of FMD (scan recording and analysis) using an ultrasonographic semi-automatic measuring system (sFMD) was conducted at 18 participating institutions (sFMD-INST) (n = 981). All of the brachial arterial scans were also analyzed at a core laboratory (sFMD-COLB). After 111 subjects with inadequate sFMD recordings were excluded (n = 880), the correlation between the sFMD-INST and sFMD-COLB improved from R = 0.725 to R = 0.838 (p < 0.001). In Study 2, based on good-quality sFMD data obtained from 6660 subjects without cardiovascular disease (CVD) and 729 subjects with CVD from 27 institutions, reference values of sFMD are proposed by the Framingham risk score (FRS)-based risk categories and according to gender and age. The receiver-operating characteristic curve analysis revealed a significant power of sFMD values in reference ranges to discriminate between subjects with and without CVD (e.g., area under curve = 0.64 in the FRS-low risk group).CONCLUSIONS: When the analysis was limited to cases with clear sFMD recordings, the reliability of the sFMD assessment (scan and its analysis) conducted in individual institutions appeared to be acceptable. Reference sFMD values (lower cuff occlusion) for the Japanese population are proposed based on reliable data derived from multiple institutions, and the reference values may identify patients without advanced vascular damage."},"publication_date":"2015-08-05","publication_name":{"en":"Atherosclerosis","ja":"Atherosclerosis"},"volume":"Vol.242","number":"No.2","starting_page":"433","ending_page":"442","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.atherosclerosis.2015.08.001"],"issn":["1879-1484"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26301197","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84939780057&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=302708","label":"url"}],"paper_title":{"en":"Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus.","ja":"Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Aihara Ken-ichi"},{"name":"Akaike Masashi"},{"name":"Fukuda Daiju"},{"name":"Salim HM"},{"name":"Ishida Masayoshi"},{"name":"Matsuura Tomomi"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Matsumoto Toshio"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"粟飯原 賢一"},{"name":"赤池 雅史"},{"name":"福田 大受"},{"name":"Salim HM"},{"name":"石田 昌義"},{"name":"松浦 朋美"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"松本 俊夫"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.METHODS: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3±35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.RESULTS: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167±63 to 151±49 mg/dL (P<0.01), and from 7.5%±1.3% to 6.9%±0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.CONCLUSION: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.","ja":"BACKGROUND: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.METHODS: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3±35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.RESULTS: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167±63 to 151±49 mg/dL (P<0.01), and from 7.5%±1.3% to 6.9%±0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.CONCLUSION: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment."},"publication_date":"2015-08","publication_name":{"en":"Diabetes & Metabolism Journal","ja":"Diabetes & Metabolism Journal"},"volume":"Vol.39","number":"No.4","starting_page":"342","ending_page":"347","languages":["eng"],"referee":true,"identifiers":{"doi":["10.4093/dmj.2015.39.4.342"],"issn":["2233-6079"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26231083","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84939243774&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297338","label":"url"}],"paper_title":{"en":"Diverse contribution of bone marrow-derived late-outgrowth endothelial progenitor cells to vascular repair under pulmonary arterial hypertension and arterial neointimal formation.","ja":"Diverse contribution of bone marrow-derived late-outgrowth endothelial progenitor cells to vascular repair under pulmonary arterial hypertension and arterial neointimal formation."},"authors":{"en":[{"name":"Ikutomi Masayasu"},{"name":"Sahara Makoto"},{"name":"Nakajima Toshiaki"},{"name":"Minami Yoshiyasu"},{"name":"Morita Toshihiro"},{"name":"Hirata Yasunobu"},{"name":"Komuro Issei"},{"name":"Nakamura Fumitaka"},{"name":"Sata Masataka"}],"ja":[{"name":"Ikutomi Masayasu"},{"name":"Sahara Makoto"},{"name":"Nakajima Toshiaki"},{"name":"Minami Yoshiyasu"},{"name":"Morita Toshihiro"},{"name":"Hirata Yasunobu"},{"name":"Komuro Issei"},{"name":"Nakamura Fumitaka"},{"name":"佐田 政隆"}]},"description":{"en":"It is still controversial whether bone marrow (BM)-derived endothelial progenitor cells (EPCs) can contribute to vascular repair and prevent the progression of vascular diseases. We aimed to characterize BM-derived EPC subpopulations and to evaluate their therapeutic efficacies to repair injured vascular endothelium of systemic and pulmonary arteries. BM mononuclear cells of Fisher-344 rats were cultured under endothelial cell-conditions. Early EPCs appeared on days 3-6. Late-outgrowth and very late-outgrowth EPCs (LOCs and VLOCs) were defined as cells forming cobblestone colonies on days 9-14 and 17-21, respectively. Among EPC subpopulations, LOCs showed the highest angiogenic capability with enhanced proliferation potential and secretion of proangiogenic proteins. To investigate the therapeutic effects of these EPCs, Fisher-344 rats underwent wire-mediated endovascular injury in femoral artery (FA) and were concurrently injected intraperitoneally with 60mg/kg monocrotaline (MCT). Injured rats were then treated with six injections of one of three EPCs (1×10(6) per time). After 4weeks, transplanted LOCs, but not early EPCs or VLOCs, significantly attenuated neointimal lesion formation in injured FAs. Some of CD31(+) LOCs directly replaced the injured FA endothelium (replacement ratio: 11.7±7.0%). In contrast, any EPC treatment could neither replace MCT-injured endothelium of pulmonary arterioles nor prevent the progression of pulmonary arterial hypertension (PAH). LOCs modified protectively the expression profile of angiogenic and inflammatory genes in injured FAs, but not in MCT-injured lungs. BM-derived LOCs can contribute to vascular repair of injured systemic artery; however, even they cannot rescue injured pulmonary vasculature under MCT-induced PAH.","ja":"It is still controversial whether bone marrow (BM)-derived endothelial progenitor cells (EPCs) can contribute to vascular repair and prevent the progression of vascular diseases. We aimed to characterize BM-derived EPC subpopulations and to evaluate their therapeutic efficacies to repair injured vascular endothelium of systemic and pulmonary arteries. BM mononuclear cells of Fisher-344 rats were cultured under endothelial cell-conditions. Early EPCs appeared on days 3-6. Late-outgrowth and very late-outgrowth EPCs (LOCs and VLOCs) were defined as cells forming cobblestone colonies on days 9-14 and 17-21, respectively. Among EPC subpopulations, LOCs showed the highest angiogenic capability with enhanced proliferation potential and secretion of proangiogenic proteins. To investigate the therapeutic effects of these EPCs, Fisher-344 rats underwent wire-mediated endovascular injury in femoral artery (FA) and were concurrently injected intraperitoneally with 60mg/kg monocrotaline (MCT). Injured rats were then treated with six injections of one of three EPCs (1×10(6) per time). After 4weeks, transplanted LOCs, but not early EPCs or VLOCs, significantly attenuated neointimal lesion formation in injured FAs. Some of CD31(+) LOCs directly replaced the injured FA endothelium (replacement ratio: 11.7±7.0%). In contrast, any EPC treatment could neither replace MCT-injured endothelium of pulmonary arterioles nor prevent the progression of pulmonary arterial hypertension (PAH). LOCs modified protectively the expression profile of angiogenic and inflammatory genes in injured FAs, but not in MCT-injured lungs. BM-derived LOCs can contribute to vascular repair of injured systemic artery; however, even they cannot rescue injured pulmonary vasculature under MCT-induced PAH."},"publication_date":"2015-07-29","publication_name":{"en":"Journal of Molecular and Cellular Cardiology","ja":"Journal of Molecular and Cellular Cardiology"},"volume":"Vol.86","starting_page":"121","ending_page":"135","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.yjmcc.2015.07.019"],"issn":["1095-8584"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26205595","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84937681606&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297193","label":"url"}],"paper_title":{"en":"Prediction of Future Overt Pulmonary Hypertension by 6-Min Walk Stress Echocardiography in Patients With Connective Tissue Disease.","ja":"Prediction of Future Overt Pulmonary Hypertension by 6-Min Walk Stress Echocardiography in Patients With Connective Tissue Disease."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Hotsuchi Junko"},{"name":"Bando Mika"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Kishi Jun"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"發知 淳子"},{"name":"坂東 美佳"},{"name":"Nishio Susumu"},{"name":"Hirata Yukina"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"岸 潤"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Early detection of pulmonary hypertension (PH) in connective tissue disease (CTD) is crucial to ensuring that patients receive timely treatment for this progressive disease. Exercise stress tests have been used to screen patients in an attempt to identify early-stage PH. Recent studies have described abnormal mean pulmonary artery pressure (mPAP)-cardiac output (Q) responses as having the potential to assess the disease state.OBJECTIVES: This study hypothesized that pulmonary circulation pressure-flow relationships obtained by 6-min walk (6MW) stress echocardiography would better delineate differential progression of PH and predict development of PH during follow-up.METHODS: We prospectively performed 6MW stress echocardiographic studies in 78 CTD patients (age 58 ± 12 years; 9% male) at baseline and follow-up. All patients underwent yearly echocardiographic follow-up studies for up to 5 years.RESULTS: During a median period of 32 months (range: 15 to 62 months), 16 patients reached the clinical endpoint of development of PH and none died during follow-up. PH was confirmed by right heart catheterization in all 16 patients (mPAP 25 mm Hg and pulmonary capillary wedge pressure 15 mm Hg). In a Cox proportional-hazards survival model, 6MW distance (hazard ratio [HR]: 0.99; p = 0.010), early diastolic tricuspid annulus motion velocity (HR: 0.79; p = 0.025), and mPAP/Q by 6MW stress (HR: 1.10; p = 0.005) were associated with development of PH. In sequential Cox models, a model on the basis of 6MW distance (chi-square, 6.6) was improved by mPAP/Q (chi-square: 14.4; p = 0.019). Using a receiver-operating characteristic curve, we found that the best cutoff value of mPAP/Q for predicting development of pulmonary hypertension was >3.3 mm Hg/l/min.CONCLUSIONS: The 6MW stress echocardiography noninvasively provides an incremental prognostic value of PH development in CTD. This is a single-center prospective cohort study. Larger multicenter studies are warranted to confirm this result.","ja":"BACKGROUND: Early detection of pulmonary hypertension (PH) in connective tissue disease (CTD) is crucial to ensuring that patients receive timely treatment for this progressive disease. Exercise stress tests have been used to screen patients in an attempt to identify early-stage PH. Recent studies have described abnormal mean pulmonary artery pressure (mPAP)-cardiac output (Q) responses as having the potential to assess the disease state.OBJECTIVES: This study hypothesized that pulmonary circulation pressure-flow relationships obtained by 6-min walk (6MW) stress echocardiography would better delineate differential progression of PH and predict development of PH during follow-up.METHODS: We prospectively performed 6MW stress echocardiographic studies in 78 CTD patients (age 58 ± 12 years; 9% male) at baseline and follow-up. All patients underwent yearly echocardiographic follow-up studies for up to 5 years.RESULTS: During a median period of 32 months (range: 15 to 62 months), 16 patients reached the clinical endpoint of development of PH and none died during follow-up. PH was confirmed by right heart catheterization in all 16 patients (mPAP 25 mm Hg and pulmonary capillary wedge pressure 15 mm Hg). In a Cox proportional-hazards survival model, 6MW distance (hazard ratio [HR]: 0.99; p = 0.010), early diastolic tricuspid annulus motion velocity (HR: 0.79; p = 0.025), and mPAP/Q by 6MW stress (HR: 1.10; p = 0.005) were associated with development of PH. In sequential Cox models, a model on the basis of 6MW distance (chi-square, 6.6) was improved by mPAP/Q (chi-square: 14.4; p = 0.019). Using a receiver-operating characteristic curve, we found that the best cutoff value of mPAP/Q for predicting development of pulmonary hypertension was >3.3 mm Hg/l/min.CONCLUSIONS: The 6MW stress echocardiography noninvasively provides an incremental prognostic value of PH development in CTD. This is a single-center prospective cohort study. Larger multicenter studies are warranted to confirm this result."},"publication_date":"2015-07-28","publication_name":{"en":"Journal of the American College of Cardiology","ja":"Journal of the American College of Cardiology"},"volume":"Vol.66","number":"No.4","starting_page":"376","ending_page":"384","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jacc.2015.05.032"],"issn":["1558-3597"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109520","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26209244","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84937791819&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=296984","label":"url"}],"paper_title":{"en":"Comparison of carotid plaque tissue characteristics in patients with acute coronary syndrome or stable angina pectoris: assessment by iPlaque, transcutaneous carotid ultrasonography with integrated backscatter analysis.","ja":"Comparison of carotid plaque tissue characteristics in patients with acute coronary syndrome or stable angina pectoris: assessment by iPlaque, transcutaneous carotid ultrasonography with integrated backscatter analysis."},"authors":{"en":[{"name":"Bando Mika"},{"name":"Yamada Hirotsugu"},{"name":"Kusunose Kenya"},{"name":"Fukuda Daiju"},{"name":"Amano Rie"},{"name":"Tamai Rina"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"Yamaguchi Koji"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"坂東 美佳"},{"name":"山田 博胤"},{"name":"楠瀬 賢也"},{"name":"福田 大受"},{"name":"Amano Rie"},{"name":"Tamai Rina"},{"name":"Torii Yuta"},{"name":"Hirata Yukina"},{"name":"Nishio Susumu"},{"name":"山口 浩司"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: The association of the tissue characteristics of carotid plaques with coronary artery disease has attracted interest. The present study compared the tissue characteristics of carotid plaques in patients with acute coronary syndrome (ACS) with those in patients with stable angina pectoris (SAP) using the iPlaque system, which is based on ultrasound integrated backscatter.METHODS AND RESULTS: Carotid ultrasound examinations were performed in 26 patients with ACS, and 38 age- and gender-matched patients with SAP. Neither plaque area nor maximal intima-media thickness differed significantly between the two groups. However, the average integrated backscatter value within the plaque was greater in the ACS patients than in the SAP patients. iPlaque analysis revealed that the percentage blue area (lipid pool) was greater in the ACS patients than in the SAP patients (43.4±11.2 vs 18.3±10.3 %, p<0.0001), and that the percentage green area (fibrosis) was lower in the ACS than in the SAP patients (7.5±7.5 % vs 20.7±11.7 %, p<0.0001).CONCLUSIONS: The lipid component of carotid plaques is greater in ACS patients than in SAP patients. Our iPlaque system provides a useful and feasible method for the tissue characterization of carotid plaques in the clinical setting.","ja":"BACKGROUND: The association of the tissue characteristics of carotid plaques with coronary artery disease has attracted interest. The present study compared the tissue characteristics of carotid plaques in patients with acute coronary syndrome (ACS) with those in patients with stable angina pectoris (SAP) using the iPlaque system, which is based on ultrasound integrated backscatter.METHODS AND RESULTS: Carotid ultrasound examinations were performed in 26 patients with ACS, and 38 age- and gender-matched patients with SAP. Neither plaque area nor maximal intima-media thickness differed significantly between the two groups. However, the average integrated backscatter value within the plaque was greater in the ACS patients than in the SAP patients. iPlaque analysis revealed that the percentage blue area (lipid pool) was greater in the ACS patients than in the SAP patients (43.4±11.2 vs 18.3±10.3 %, p<0.0001), and that the percentage green area (fibrosis) was lower in the ACS than in the SAP patients (7.5±7.5 % vs 20.7±11.7 %, p<0.0001).CONCLUSIONS: The lipid component of carotid plaques is greater in ACS patients than in SAP patients. Our iPlaque system provides a useful and feasible method for the tissue characterization of carotid plaques in the clinical setting."},"publication_date":"2015-07-25","publication_name":{"en":"Cardiovascular Ultrasound","ja":"Cardiovascular Ultrasound"},"volume":"Vol.13","number":"No.1","starting_page":"34","ending_page":"34","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12947-015-0031-6"],"issn":["1476-7120"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109533","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25971408","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84937904061&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=292621","label":"url"}],"paper_title":{"en":"Impact of indoxyl sulfate, a uremic toxin, on non-culprit coronary plaque composition assessed by integrated backscatter intravascular ultrasound.","ja":"Impact of indoxyl sulfate, a uremic toxin, on non-culprit coronary plaque composition assessed by integrated backscatter intravascular ultrasound."},"authors":{"en":[{"name":"Yamazaki Hiromu"},{"name":"Yamaguchi Koji"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Niki Toshiyuki"},{"name":"Taketani Yoshio"},{"name":"Kitaoka Atsunori"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yagi Shusuke"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"Yamazaki Hiromu"},{"name":"山口 浩司"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"仁木 敏之"},{"name":"竹谷 善雄"},{"name":"Kitaoka Atsunori"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"八木 秀介"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Uremic toxin has emerged as an important determinant of cardiovascular risk. The aim of this study was to examine the relationship between serum uremic toxin and coronary plaque composition on integrated backscatter intravascular ultrasound (IB-IVUS).MethodsandResults:IB-IVUS was performed in 47 patients with planned treatment for angina pectoris. Non-culprit intermediate plaque analyzed in this study had to be >5 mm apart from the intervention site. 3-D IB-IVUS analysis was performed to determine percent lipid volume (LV) and fibrous volume (FV). We also measured serum uremic toxins (indoxyl sulfate [IS], asymmetric dimethylarginine [ADMA], and p-cresol [PC]). Glomerular filtration rate correlated with IS (r=-0.329, P=0.04), but did not correlate with ADMA or PC. Percent LV correlated with IS (r=0.365, P=0.02), but did not correlate with ADMA or PC. Percent FV also correlated with IS (r=-0.356, P=0.03), but did not correlate with ADMA or PC. On multivariate regression, only IS was associated with percent LV (r=0.359, P=0.04) and percent FV (r=-0.305, P=0.04) independently of potentially confounding coronary risk factors.CONCLUSIONS: Among the uremic toxins, serum IS might be a novel useful biomarker to detect and monitor lipid-rich coronary plaque on IB imaging. (Circ J 2015; 79: 1773-1779).","ja":"BACKGROUND: Uremic toxin has emerged as an important determinant of cardiovascular risk. The aim of this study was to examine the relationship between serum uremic toxin and coronary plaque composition on integrated backscatter intravascular ultrasound (IB-IVUS).MethodsandResults:IB-IVUS was performed in 47 patients with planned treatment for angina pectoris. Non-culprit intermediate plaque analyzed in this study had to be >5 mm apart from the intervention site. 3-D IB-IVUS analysis was performed to determine percent lipid volume (LV) and fibrous volume (FV). We also measured serum uremic toxins (indoxyl sulfate [IS], asymmetric dimethylarginine [ADMA], and p-cresol [PC]). Glomerular filtration rate correlated with IS (r=-0.329, P=0.04), but did not correlate with ADMA or PC. Percent LV correlated with IS (r=0.365, P=0.02), but did not correlate with ADMA or PC. Percent FV also correlated with IS (r=-0.356, P=0.03), but did not correlate with ADMA or PC. On multivariate regression, only IS was associated with percent LV (r=0.359, P=0.04) and percent FV (r=-0.305, P=0.04) independently of potentially confounding coronary risk factors.CONCLUSIONS: Among the uremic toxins, serum IS might be a novel useful biomarker to detect and monitor lipid-rich coronary plaque on IB imaging. (Circ J 2015; 79: 1773-1779)."},"publication_date":"2015-07-24","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.79","number":"No.8","starting_page":"1773","ending_page":"1779","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-15-0019"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25363348","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84937512721&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=287824","label":"url"}],"paper_title":{"en":"Optimal analysis of left atrial strain by speckle tracking echocardiography: P-wave versus R-wave trigger.","ja":"Optimal analysis of left atrial strain by speckle tracking echocardiography: P-wave versus R-wave trigger."},"authors":{"en":[{"name":"Hayashi S"},{"name":"Yamada Hirotsugu"},{"name":"Bando Mika"},{"name":"Saijo Y"},{"name":"Nishio S"},{"name":"Hirata Y"},{"name":"Klein AL"},{"name":"Sata Masataka"}],"ja":[{"name":"Hayashi S"},{"name":"山田 博胤"},{"name":"坂東 美佳"},{"name":"Saijo Y"},{"name":"Nishio S"},{"name":"Hirata Y"},{"name":"Klein AL"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Left atrial (LA) strain analysis using speckle tracking echocardiography is useful for assessing LA function. However, there is no established procedure for this method. Most investigators have determined the electrocardiographic R-wave peak as the starting point for LA strain analysis. To test our hypothesis that P-wave onset should be used as the starting point, we measured LA strain using 2 different starting points and compared the strain values with the corresponding LA volume indices obtained by three-dimensional (3D) echocardiography.METHODS: We enrolled 78 subjects (61 ± 17 years, 25 males) with and without various cardiac diseases in this study and assessed global longitudinal LA strain by two-dimensional speckle tracking strain echocardiography using EchoPac software. We used either R-wave peak or P-wave onset as the starting point for determining LA strains during the reservoir (Rres, Pres), conduit (Rcon, Pcon), and booster pump (Rpump, Ppump) phases. We determined the maximum, minimum, and preatrial contraction LA volumes, and calculated the LA total, passive, and active emptying fractions using 3D echocardiography.RESULTS: The correlation between Pres and LA total emptying fraction was better than the correlation between Rres and LA total emptying fraction (r = 0.458 vs. 0.308, P = 0.026). Pcon and Ppump exhibited better correlation with the corresponding 3D echocardiographic parameters than Rcon (r = 0.560 vs. 0.479, P = 0.133) and Rpump (r = 0.577 vs. 0.345, P = 0.003), respectively.CONCLUSIONS: LA strain in any phase should be analyzed using P-wave onset as the starting point rather than R-wave peak.","ja":"BACKGROUND: Left atrial (LA) strain analysis using speckle tracking echocardiography is useful for assessing LA function. However, there is no established procedure for this method. Most investigators have determined the electrocardiographic R-wave peak as the starting point for LA strain analysis. To test our hypothesis that P-wave onset should be used as the starting point, we measured LA strain using 2 different starting points and compared the strain values with the corresponding LA volume indices obtained by three-dimensional (3D) echocardiography.METHODS: We enrolled 78 subjects (61 ± 17 years, 25 males) with and without various cardiac diseases in this study and assessed global longitudinal LA strain by two-dimensional speckle tracking strain echocardiography using EchoPac software. We used either R-wave peak or P-wave onset as the starting point for determining LA strains during the reservoir (Rres, Pres), conduit (Rcon, Pcon), and booster pump (Rpump, Ppump) phases. We determined the maximum, minimum, and preatrial contraction LA volumes, and calculated the LA total, passive, and active emptying fractions using 3D echocardiography.RESULTS: The correlation between Pres and LA total emptying fraction was better than the correlation between Rres and LA total emptying fraction (r = 0.458 vs. 0.308, P = 0.026). Pcon and Ppump exhibited better correlation with the corresponding 3D echocardiographic parameters than Rcon (r = 0.560 vs. 0.479, P = 0.133) and Rpump (r = 0.577 vs. 0.345, P = 0.003), respectively.CONCLUSIONS: LA strain in any phase should be analyzed using P-wave onset as the starting point rather than R-wave peak."},"publication_date":"2015-07-20","publication_name":{"en":"Echocardiography","ja":"Echocardiography"},"volume":"Vol.32","number":"No.8","starting_page":"1241","ending_page":"1249","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/echo.12834"],"issn":["1540-8175"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26173061","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84940416779&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297343","label":"url"}],"paper_title":{"en":"Transdermal patch of bisoprolol for the treatment of hypertension complicated with aortic dissection.","ja":"Transdermal patch of bisoprolol for the treatment of hypertension complicated with aortic dissection."},"authors":{"en":[{"name":"Hara Tomoya"},{"name":"Yagi Shusuke"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"Hara Tomoya"},{"name":"八木 秀介"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"publication_date":"2015-06-30","publication_name":{"en":"International Journal of Cardiology","ja":"International Journal of Cardiology"},"volume":"Vol.198","starting_page":"220","ending_page":"221","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijcard.2015.06.112"],"issn":["1874-1754"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25891211","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84931043161&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=293894","label":"url"}],"paper_title":{"en":"Does echocardiographic epicardial adipose tissue thickness become a useful biomarker?","ja":"Does echocardiographic epicardial adipose tissue thickness become a useful biomarker?"},"authors":{"en":[{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2015-05","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.22","number":"No.6","starting_page":"555","ending_page":"556","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.ED015"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25877739","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84930074602&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=292622","label":"url"}],"paper_title":{"en":"Visualization of human coronary vasa vasorum in vivo.","ja":"Visualization of human coronary vasa vasorum in vivo."},"authors":{"en":[{"name":"Tanaka Kimie"},{"name":"Sata Masataka"}],"ja":[{"name":"Tanaka Kimie"},{"name":"佐田 政隆"}]},"publication_date":"2015-05","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.79","number":"No.6","starting_page":"1211","ending_page":"1212","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-15-0356"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26015466","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84936080389&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=292618","label":"url"}],"paper_title":{"en":"Serial imaging changes during treatment of immunoglobulin G4-related disease with multiple pseudotumors.","ja":"Serial imaging changes during treatment of immunoglobulin G4-related disease with multiple pseudotumors."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Hotsuchi Junko"},{"name":"Takagawa Y"},{"name":"Nishio S"},{"name":"Ise Takayuki"},{"name":"Tobiume Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"發知 淳子"},{"name":"Takagawa Y"},{"name":"Nishio S"},{"name":"伊勢 孝之"},{"name":"飛梅 威"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"佐田 政隆"}]},"publication_date":"2015-05-26","publication_name":{"en":"Circulation","ja":"Circulation"},"volume":"Vol.131","number":"No.21","starting_page":"1882","ending_page":"1883","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1161/CIRCULATIONAHA.115.015638"],"issn":["1524-4539"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/130005071052/","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25342567","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390282679408260352/","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84929412906&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=286316","label":"url"}],"paper_title":{"en":"Effects of docosahexaenoic acid on the endothelial function in patients with coronary artery disease.","ja":"Effects of docosahexaenoic acid on the endothelial function in patients with coronary artery disease."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Aihara Ken-ichi"},{"name":"Fukuda Daiju"},{"name":"Takashima Akira"},{"name":"Hara Tomoya"},{"name":"Hotsuchi Junko"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"粟飯原 賢一"},{"name":"福田 大受"},{"name":"髙島 啓"},{"name":"原 知也"},{"name":"發知 淳子"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"AIM: The consumption of n-3 polyunsaturated fatty acids (PUFA), including docosahexaenoic acid DHA), reduces the incidence of cardiovascular events, and reduced serum levels of n-3 PUFA may be associated with an increased risk of cardiovascular events. However, controversy remains regarding which components of PUFA are associated with the endothelial function in patients with coronary artery disease (CAD). We therefore examined the associations between the n-3 and n-6 PUFA levels and CAD.METHODS: We retrospectively reviewed 160 consecutive Japanese patients with CAD whose endothelial function was measured according to the percent change in flow-mediated dilation (FMD) and the serum levels of n-3 PUFA, including eicosapentaenoic acid (EPA) and DHA, and n-6 PUFA, including arachidonic acid (AA) and dihomo-gamma-linolenic acid (DHLA).RESULTS: A single regression analysis showed no relationships between the FMD and the serum levels of PUFA, including EPA, DHA, AA and DHLA. In contrast, a multiple regression analysis showed that the DHA level was a positive (P0.01) and age was a negative (P0.001) contributor to an increased FMD; however, sex, body mass index, systolic and diastolic blood pressure, current/past smoking and the levels of HbA1c, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, EPA, AA and DHLA did not significantly affect the outcome.CONCLUSIONS: The serum level of DHA is associated with the endothelial function evaluated according to the FMD in patients with CAD, thus suggesting that a low serum level of DHA may be a predictive biomarker for endothelial dysfunction.","ja":"AIM: The consumption of n-3 polyunsaturated fatty acids (PUFA), including docosahexaenoic acid DHA), reduces the incidence of cardiovascular events, and reduced serum levels of n-3 PUFA may be associated with an increased risk of cardiovascular events. However, controversy remains regarding which components of PUFA are associated with the endothelial function in patients with coronary artery disease (CAD). We therefore examined the associations between the n-3 and n-6 PUFA levels and CAD.METHODS: We retrospectively reviewed 160 consecutive Japanese patients with CAD whose endothelial function was measured according to the percent change in flow-mediated dilation (FMD) and the serum levels of n-3 PUFA, including eicosapentaenoic acid (EPA) and DHA, and n-6 PUFA, including arachidonic acid (AA) and dihomo-gamma-linolenic acid (DHLA).RESULTS: A single regression analysis showed no relationships between the FMD and the serum levels of PUFA, including EPA, DHA, AA and DHLA. In contrast, a multiple regression analysis showed that the DHA level was a positive (P0.01) and age was a negative (P0.001) contributor to an increased FMD; however, sex, body mass index, systolic and diastolic blood pressure, current/past smoking and the levels of HbA1c, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, EPA, AA and DHLA did not significantly affect the outcome.CONCLUSIONS: The serum level of DHA is associated with the endothelial function evaluated according to the FMD in patients with CAD, thus suggesting that a low serum level of DHA may be a predictive biomarker for endothelial dysfunction."},"publication_date":"2015-05-20","publication_name":{"en":"Journal of Atherosclerosis and Thrombosis","ja":"Journal of Atherosclerosis and Thrombosis"},"volume":"Vol.22","number":"No.5","starting_page":"447","ending_page":"454","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5551/jat.26914"],"issn":["1880-3873"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25902883","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=294720","label":"url"}],"paper_title":{"en":"Elevated concentration of interferon-inducible protein of 10 kD (IP-10) is associated with coronary atherosclerosis.","ja":"Elevated concentration of interferon-inducible protein of 10 kD (IP-10) is associated with coronary atherosclerosis."},"authors":{"en":[{"name":"Niki Toshiyuki"},{"name":"Soeki Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Taketani Yoshio"},{"name":"Yagi Shusuke"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"仁木 敏之"},{"name":"添木 武"},{"name":"山口 浩司"},{"name":"竹谷 善雄"},{"name":"八木 秀介"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Several studies have shown that various chemokines are more highly expressed in atherosclerotic plaques than in normal vessel walls. In the present study, we investigated the relationship between coronary atherosclerosis and noteworthy chemokines, including interferon-inducible protein of 10 kD (IP-10); monocyte chemoattractant protein 1 (MCP-1); regulated on activation, normal T-cell expressed and secreted (RANTES); and high-sensitivity C-reactive protein (hsCRP), an established marker of atherosclerotic disease. We studied 28 patients who underwent coronary angiography because of suspected coronary artery disease (CAD). CAD was defined as stenosis of more than 50% of the vessel diameter on coronary angiograms. Blood samples were obtained both from the aorta and the coronary sinus (CS) just before coronary angiography. Relative to CAD (-) patients, those who were CAD (+) tended to have higher plasma concentrations of IP-10 in the aorta, as well as significantly higher transcoronary concentration gradients of circulating IP-10. There were no significant differences between the two groups in aortic plasma concentrations or transcoronary concentration gradients of MCP-1, RANTES, and hsCRP. Furthermore, both the aortic plasma concentrations and transcoronary concentration gradients of IP-10 correlated with the Gensini score (r = 0.58 and r = 0.63, respectively, P < 0.01), while the plasma MCP-1, RANTES, and serum hsCRP concentrations did not. This study suggests that IP-10 is a good surrogate marker of coronary atherosclerosis.","ja":"Several studies have shown that various chemokines are more highly expressed in atherosclerotic plaques than in normal vessel walls. In the present study, we investigated the relationship between coronary atherosclerosis and noteworthy chemokines, including interferon-inducible protein of 10 kD (IP-10); monocyte chemoattractant protein 1 (MCP-1); regulated on activation, normal T-cell expressed and secreted (RANTES); and high-sensitivity C-reactive protein (hsCRP), an established marker of atherosclerotic disease. We studied 28 patients who underwent coronary angiography because of suspected coronary artery disease (CAD). CAD was defined as stenosis of more than 50% of the vessel diameter on coronary angiograms. Blood samples were obtained both from the aorta and the coronary sinus (CS) just before coronary angiography. Relative to CAD (-) patients, those who were CAD (+) tended to have higher plasma concentrations of IP-10 in the aorta, as well as significantly higher transcoronary concentration gradients of circulating IP-10. There were no significant differences between the two groups in aortic plasma concentrations or transcoronary concentration gradients of MCP-1, RANTES, and hsCRP. Furthermore, both the aortic plasma concentrations and transcoronary concentration gradients of IP-10 correlated with the Gensini score (r = 0.58 and r = 0.63, respectively, P < 0.01), while the plasma MCP-1, RANTES, and serum hsCRP concentrations did not. This study suggests that IP-10 is a good surrogate marker of coronary atherosclerosis."},"publication_date":"2015-05-13","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.56","number":"No.3","starting_page":"269","ending_page":"272","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.14-300"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25838182","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84929190302&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=292755","label":"url"}],"paper_title":{"en":"Angiogenic potential of early and late outgrowth endothelial progenitor cells is dependent on the time of emergence.","ja":"Angiogenic potential of early and late outgrowth endothelial progenitor cells is dependent on the time of emergence."},"authors":{"en":[{"name":"Minami Yoshiyasu"},{"name":"Nakajima Toshiaki"},{"name":"Ikutomi Masayasu"},{"name":"Morita Toshihiro"},{"name":"Komuro Issei"},{"name":"Sata Masataka"},{"name":"Sahara Makoto"}],"ja":[{"name":"Minami Yoshiyasu"},{"name":"Nakajima Toshiaki"},{"name":"Ikutomi Masayasu"},{"name":"Morita Toshihiro"},{"name":"Komuro Issei"},{"name":"佐田 政隆"},{"name":"Sahara Makoto"}]},"description":{"en":"BACKGROUND: Recent studies have suggested that late-outgrowth endothelial progenitor cells (EPCs) derived from human peripheral blood mononuclear cells (hPBMNCs) might have higher angiogenic potential than classically-defined early-outgrowth EPCs (EOCs). However, it still remains unclear which of \"so-called\" EPC subpopulations defined in a variety of ways has the highest angiogenic potential.METHODS AND RESULTS: We classified hPBMNC-derived EPC subpopulations by the time of their emergence in culture. EOCs were defined as attached cells on culture days 3-7. Late-outgrowth EPCs, defined as the cell forming colonies with cobblestone appearance since day 10, were further classified as follows: \"moderate\"-outgrowth EPCs (MOCs) emerging on days 10-16, \"late\"-outgrowth EPCs (LOCs) on days 17-23, and \"very late\"-outgrowth EPCs (VOCs) on days 24-30. Flow cytometry analyses showed the clear differences of hematopoietic/endothelial markers between EOC (CD31+VE-cadherin-CD34-CD14+CD45+) and LOC (CD31+VE-cadherin+CD34+CD14-CD45-). We found that LOCs had the highest proliferation and tube formation capabilities in vitro along with the highest expression of angiogenic genes including KDR and eNOS. To investigate the in vivo therapeutic efficacies, each EPC subpopulation was intravenously transplanted into immunocompromised mice (total 4×105 cells) after unilateral hindlimb ischemia surgery. The LOC-treated mice exhibited significantly-enhanced blood flow recovery (flow ratios of ischemic/non-ischemic leg: 0.99±0.02 [LOC group] versus 0.67±0.07 to 0.78±0.09 [other groups]; P<0.05) and augmented capillary collateral formation in ischemic leg, which were attributable to their direct engraftment into host angiogenic vessels (approximately 10%) and paracrine effects.CONCLUSION: hPBMNC-derived late-outgrowth EPCs emerging on culture days 17-23 are superior to other EPC subpopulations with regard to therapeutic angiogenic potential.","ja":"BACKGROUND: Recent studies have suggested that late-outgrowth endothelial progenitor cells (EPCs) derived from human peripheral blood mononuclear cells (hPBMNCs) might have higher angiogenic potential than classically-defined early-outgrowth EPCs (EOCs). However, it still remains unclear which of \"so-called\" EPC subpopulations defined in a variety of ways has the highest angiogenic potential.METHODS AND RESULTS: We classified hPBMNC-derived EPC subpopulations by the time of their emergence in culture. EOCs were defined as attached cells on culture days 3-7. Late-outgrowth EPCs, defined as the cell forming colonies with cobblestone appearance since day 10, were further classified as follows: \"moderate\"-outgrowth EPCs (MOCs) emerging on days 10-16, \"late\"-outgrowth EPCs (LOCs) on days 17-23, and \"very late\"-outgrowth EPCs (VOCs) on days 24-30. Flow cytometry analyses showed the clear differences of hematopoietic/endothelial markers between EOC (CD31+VE-cadherin-CD34-CD14+CD45+) and LOC (CD31+VE-cadherin+CD34+CD14-CD45-). We found that LOCs had the highest proliferation and tube formation capabilities in vitro along with the highest expression of angiogenic genes including KDR and eNOS. To investigate the in vivo therapeutic efficacies, each EPC subpopulation was intravenously transplanted into immunocompromised mice (total 4×105 cells) after unilateral hindlimb ischemia surgery. The LOC-treated mice exhibited significantly-enhanced blood flow recovery (flow ratios of ischemic/non-ischemic leg: 0.99±0.02 [LOC group] versus 0.67±0.07 to 0.78±0.09 [other groups]; P<0.05) and augmented capillary collateral formation in ischemic leg, which were attributable to their direct engraftment into host angiogenic vessels (approximately 10%) and paracrine effects.CONCLUSION: hPBMNC-derived late-outgrowth EPCs emerging on culture days 17-23 are superior to other EPC subpopulations with regard to therapeutic angiogenic potential."},"publication_date":"2015-05-01","publication_name":{"en":"International Journal of Cardiology","ja":"International Journal of Cardiology"},"volume":"Vol.186","starting_page":"305","ending_page":"314","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijcard.2015.03.166"],"issn":["1874-1754"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25483741","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84929093226&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=288831","label":"url"}],"paper_title":{"en":"Histopathological heterogeneity of in-stent restenosis in four coronary endarterectomy specimens.","ja":"Histopathological heterogeneity of in-stent restenosis in four coronary endarterectomy specimens."},"authors":{"en":[{"name":"Takashima A"},{"name":"Shimabukuro Michio"},{"name":"Tabata M"},{"name":"Fukuda Daiju"},{"name":"Uematsu E"},{"name":"Ishibashi-Ueda H"},{"name":"Takanashi S"},{"name":"Sata Masataka"}],"ja":[{"name":"Takashima A"},{"name":"島袋 充生"},{"name":"Tabata M"},{"name":"福田 大受"},{"name":"Uematsu E"},{"name":"Ishibashi-Ueda H"},{"name":"Takanashi S"},{"name":"佐田 政隆"}]},"description":{"en":"Here, we histopathologically compare four patients undergoing coronary artery bypass with coronary endarterectomy and onlay patch grafting for in-stent restenosis (ISR) after the implantation of a bare-metal stent (BMS), sirolimus-eluting stent (SES), or paclitaxel-eluting stent (PES) in an everolimus-eluting stent (EES). Heterogeneity of ISR was noted histopathologically. In ISR for BMS, restenosis is likely caused by so-called neoatherosclerosis that occurred which altered the healing process of BMS implantation. Two ISR cases for SES showed a histopathological heterogeneity: one showed nodular calcified thrombus around stent strut protruding into the lumen, and the other showed concentric neointima composed of CD68-positive foam cell proliferation. In the ISR lesion for PES in EES, infiltrations with foam cells macrophages, particularly numerous eosinophilic cell infiltrations, suggest a peristent strut hypersensitivity reaction. We found a remarkable histopathological heterogeneity of ISR. The study using coronary endarterectomy specimens can give us pivotal information about the histopathological heterogeneity of ISR.","ja":"Here, we histopathologically compare four patients undergoing coronary artery bypass with coronary endarterectomy and onlay patch grafting for in-stent restenosis (ISR) after the implantation of a bare-metal stent (BMS), sirolimus-eluting stent (SES), or paclitaxel-eluting stent (PES) in an everolimus-eluting stent (EES). Heterogeneity of ISR was noted histopathologically. In ISR for BMS, restenosis is likely caused by so-called neoatherosclerosis that occurred which altered the healing process of BMS implantation. Two ISR cases for SES showed a histopathological heterogeneity: one showed nodular calcified thrombus around stent strut protruding into the lumen, and the other showed concentric neointima composed of CD68-positive foam cell proliferation. In the ISR lesion for PES in EES, infiltrations with foam cells macrophages, particularly numerous eosinophilic cell infiltrations, suggest a peristent strut hypersensitivity reaction. We found a remarkable histopathological heterogeneity of ISR. The study using coronary endarterectomy specimens can give us pivotal information about the histopathological heterogeneity of ISR."},"publication_date":"2015-05","publication_name":{"en":"Cardiovascular Pathology","ja":"Cardiovascular Pathology"},"volume":"Vol.24","number":"No.3","starting_page":"194","ending_page":"197","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.carpath.2014.11.002"],"issn":["1879-1336"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25199979","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84929404966&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=285770","label":"url"}],"paper_title":{"en":"Tricuspid annular motion velocity as a differentiation index of hypertrophic cardiomyopathy from hypertensive heart disease.","ja":"Tricuspid annular motion velocity as a differentiation index of hypertrophic cardiomyopathy from hypertensive heart disease."},"authors":{"en":[{"name":"Hayashi S"},{"name":"Yamada Hiroshi"},{"name":"Nishio S"},{"name":"Hotsuchi Junko"},{"name":"Bando Mika"},{"name":"Takagawa Y"},{"name":"Saijo Y"},{"name":"Hirata Y"},{"name":"Sata Masataka"}],"ja":[{"name":"Hayashi S"},{"name":"山田 博司"},{"name":"Nishio S"},{"name":"發知 淳子"},{"name":"坂東 美佳"},{"name":"Takagawa Y"},{"name":"Saijo Y"},{"name":"Hirata Y"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Hypertensive heart disease (HHD) and hypertrophic cardiomyopathy (HCM) are the most frequently encountered entities presenting left ventricular hypertrophy in routine echocardiographic examination, and their differentiation is sometimes difficult. Abnormalities in right ventricular (RV) myocardium have been reported frequently in patients with HCM more than in those with HHD. We therefore hypothesized that tricuspid annular motion (TAM) velocity determined by pulsed tissue Doppler echocardiography can be used to detect RV dysfunction in HCM and discriminate these etiologies.METHODS: TAM velocities were compared among clinically stable patients with 60 HCM and 60 HHD patients as well as 60 age-matched healthy controls. Peak systolic, early diastolic (TAM-e'), and atrial systolic velocities were measured. RV myocardial performance index was measured by tissue Doppler method. To more accurately differentiate HCM from HHD, electrocardiographic findings and brain natriuretic peptide levels, which can both be examined simply and noninvasively, were investigated in addition to echocardiography.RESULTS: RV wall thickness of the HCM group was greater than the HHD group (p=0.092), while there was no significant difference in RV myocardial performance index between the HCM and HHD groups (p=0.606). TAM-e' was significantly lower in the HCM group than in HHD and control groups (p=0.001). To differentiate HCM from HHD, TAM-e' was a powerful predictor as per multivariate logistic regression analysis (hazard ratio, 0.665; p<0.001) of parameters other than those of left ventricular parameters, and the area under the receiver operating characteristic curve (AUC) was 0.686 and the best cut-off value was 8.0cm/s (62% sensitivity, 65% specificity). Multivariate logistic analysis revealed that electrocardiographic ST-T changes were the next most effective marker for differentiating HCM after TAM-e'. When TAM-e' and ST-T changes were combined, the AUC increased to 0.748.CONCLUSIONS: TAM-e' is a potentially useful index to differentiate HCM from HHD.","ja":"BACKGROUND: Hypertensive heart disease (HHD) and hypertrophic cardiomyopathy (HCM) are the most frequently encountered entities presenting left ventricular hypertrophy in routine echocardiographic examination, and their differentiation is sometimes difficult. Abnormalities in right ventricular (RV) myocardium have been reported frequently in patients with HCM more than in those with HHD. We therefore hypothesized that tricuspid annular motion (TAM) velocity determined by pulsed tissue Doppler echocardiography can be used to detect RV dysfunction in HCM and discriminate these etiologies.METHODS: TAM velocities were compared among clinically stable patients with 60 HCM and 60 HHD patients as well as 60 age-matched healthy controls. Peak systolic, early diastolic (TAM-e'), and atrial systolic velocities were measured. RV myocardial performance index was measured by tissue Doppler method. To more accurately differentiate HCM from HHD, electrocardiographic findings and brain natriuretic peptide levels, which can both be examined simply and noninvasively, were investigated in addition to echocardiography.RESULTS: RV wall thickness of the HCM group was greater than the HHD group (p=0.092), while there was no significant difference in RV myocardial performance index between the HCM and HHD groups (p=0.606). TAM-e' was significantly lower in the HCM group than in HHD and control groups (p=0.001). To differentiate HCM from HHD, TAM-e' was a powerful predictor as per multivariate logistic regression analysis (hazard ratio, 0.665; p<0.001) of parameters other than those of left ventricular parameters, and the area under the receiver operating characteristic curve (AUC) was 0.686 and the best cut-off value was 8.0cm/s (62% sensitivity, 65% specificity). Multivariate logistic analysis revealed that electrocardiographic ST-T changes were the next most effective marker for differentiating HCM after TAM-e'. When TAM-e' and ST-T changes were combined, the AUC increased to 0.748.CONCLUSIONS: TAM-e' is a potentially useful index to differentiate HCM from HHD."},"publication_date":"2015-05","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.65","number":"No.6","starting_page":"519","ending_page":"525","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2014.08.005"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25062786","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84928929859&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=280351","label":"url"}],"paper_title":{"en":"Age-and gender-specific changes of tricuspid annular motion velocities in normal hearts.","ja":"Age-and gender-specific changes of tricuspid annular motion velocities in normal hearts."},"authors":{"en":[{"name":"Hayashi S"},{"name":"Yamada Hirotsugu"},{"name":"Nishio S"},{"name":"Hotsuchi Junko"},{"name":"Bando Mika"},{"name":"Takagawa Y"},{"name":"Saijo Y"},{"name":"Hirata Y"},{"name":"Sata Masataka"}],"ja":[{"name":"Hayashi S"},{"name":"山田 博胤"},{"name":"Nishio S"},{"name":"發知 淳子"},{"name":"坂東 美佳"},{"name":"Takagawa Y"},{"name":"Saijo Y"},{"name":"Hirata Y"},{"name":"佐田 政隆"}]},"description":{"en":"Mitral annular motion (MAM) and tricuspid annular motion (TAM) velocities obtained by pulsed tissue Doppler echocardiography have been used to evaluate left ventricular (LV) and right ventricular (RV) functions. Although TAM velocity has been clinically applied for evaluating various cardiac diseases, the effects of age and gender remain unclear. Therefore, we aimed to determine the effects of age and gender on TAM velocity in normal hearts. We randomly selected 265 subjects (mean age, 59 years; range, 20-89 years) without abnormal clinical, electrocardiographic, and echocardiographic findings from a pool of subjects who had undergone transthoracic echocardiography. They were classified into four age groups: 20-39, 40-59, 60-79, and >80 years. Pulsed wave Doppler was applied to obtain MAM velocity of the lateral side and TAM velocity of the RV free wall side. The peak systolic (s'), early diastolic (e'), and atrial systolic (a') velocities of MAM and TAM were measured in all subjects. While MAM-s' (r=-0.267, p<0.001) correlated with age, TAM-s' did not (p=0.755). TAM-s' in any age groups had no significant gender differences. TAM-e' (r=-0.447, p<0.001) and MAM-e' (r=-0.724, p<0.001) correlated with age, respectively. In those aged 40-59 years, both TAM-e' (p=0.002) and MAM-e' (p=0.048) in females were significantly higher than those in males. The gender differences diminished in the ≥60 years age groups. There was no age-associated decline in TAM-s', while TAM-e' varied with age and gender as did MAM-e'. Although the same criteria for the TAM-s' can be used for identifying abnormal RV systolic function regardless of age and gender, age and gender differences must be considered when one utilizes the TAM-e' for the diagnosis or management of cardiovascular disease.","ja":"Mitral annular motion (MAM) and tricuspid annular motion (TAM) velocities obtained by pulsed tissue Doppler echocardiography have been used to evaluate left ventricular (LV) and right ventricular (RV) functions. Although TAM velocity has been clinically applied for evaluating various cardiac diseases, the effects of age and gender remain unclear. Therefore, we aimed to determine the effects of age and gender on TAM velocity in normal hearts. We randomly selected 265 subjects (mean age, 59 years; range, 20-89 years) without abnormal clinical, electrocardiographic, and echocardiographic findings from a pool of subjects who had undergone transthoracic echocardiography. They were classified into four age groups: 20-39, 40-59, 60-79, and >80 years. Pulsed wave Doppler was applied to obtain MAM velocity of the lateral side and TAM velocity of the RV free wall side. The peak systolic (s'), early diastolic (e'), and atrial systolic (a') velocities of MAM and TAM were measured in all subjects. While MAM-s' (r=-0.267, p<0.001) correlated with age, TAM-s' did not (p=0.755). TAM-s' in any age groups had no significant gender differences. TAM-e' (r=-0.447, p<0.001) and MAM-e' (r=-0.724, p<0.001) correlated with age, respectively. In those aged 40-59 years, both TAM-e' (p=0.002) and MAM-e' (p=0.048) in females were significantly higher than those in males. The gender differences diminished in the ≥60 years age groups. There was no age-associated decline in TAM-s', while TAM-e' varied with age and gender as did MAM-e'. Although the same criteria for the TAM-s' can be used for identifying abnormal RV systolic function regardless of age and gender, age and gender differences must be considered when one utilizes the TAM-e' for the diagnosis or management of cardiovascular disease."},"publication_date":"2015-05","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.65","number":"No.5","starting_page":"397","ending_page":"402","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2014.06.013"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25149094","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84930182808&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=284716","label":"url"}],"paper_title":{"en":"The role of pericardial fat: The good, the bad and the ugly.","ja":"The role of pericardial fat: The good, the bad and the ugly."},"authors":{"en":[{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"publication_date":"2015-01","publication_name":{"en":"Journal of Cardiology","ja":"Journal of Cardiology"},"volume":"Vol.65","number":"No.1","starting_page":"2","ending_page":"4","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jjcc.2014.07.004"],"issn":["1876-4738"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25519160","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390001205108464000/","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84928251309&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=288201","label":"url"}],"paper_title":{"en":"Plasma microRNA-100 is associated with coronary plaque vulnerability.","ja":"Plasma microRNA-100 is associated with coronary plaque vulnerability."},"authors":{"en":[{"name":"Soeki Takeshi"},{"name":"Yamaguchi Koji"},{"name":"Niki Toshiyuki"},{"name":"Uematsu E"},{"name":"Bando S"},{"name":"Matsuura T"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Hotsuchi Junko"},{"name":"Tobiume Takeshi"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Taketani Yoshio"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"添木 武"},{"name":"山口 浩司"},{"name":"仁木 敏之"},{"name":"Uematsu E"},{"name":"Bando S"},{"name":"Matsuura T"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"發知 淳子"},{"name":"飛梅 威"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"竹谷 善雄"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Although numerous studies have reported altered plasma levels of various microRNAs (miRNAs) in patients with cardiovascular disease, there are no data on the relationship between plasma miRNAs and vulnerable coronary plaque. In this study, we investigated whether plasma miRNAs might be a sensitive marker of coronary plaque vulnerability.MethodsandResults:Integrated backscatter intravascular ultrasound (IB-IVUS) was performed in 32 consecutive patients with angina pectoris who underwent percutaneous coronary intervention. Three-dimensional analysis of IB-IVUS was performed to determine the percentage of lipid volume (%LV) and fibrous volume (%FV). Circulating miRNAs were measured in EDTA-plasma simultaneously obtained from the aorta and the coronary sinus (CS). Muscle-enriched (miR-133a, miR-208a, miR-499), vascular-enriched (miR-92a, miR-100, miR-126, miR-127, miR-145), and myeloid cell-enriched miRNAs (miR-155, miR-223) were measured. Plasma miR-100 was higher in the CS than in the aorta, but there were no significant differences in the levels of other miRNAs between the aorta and CS. Plasma miR-100 in the aorta was positively correlated with %LV (r=0.48, P<0.01) and negatively correlated with %FV (r=-0.41, P<0.05). Importantly, transcoronary concentration gradient of circulating miR-100 was more strongly correlated with %LV (r=0.53, P<0.01) and %FV (r=-0.56, P<0.01).CONCLUSIONS: miR-100 might be released into the coronary circulation from vulnerable coronary plaques. This study provides insights into the role of miRNAs in coronary atherosclerotic disease. (Circ J 2015; 79: 413-418).","ja":"BACKGROUND: Although numerous studies have reported altered plasma levels of various microRNAs (miRNAs) in patients with cardiovascular disease, there are no data on the relationship between plasma miRNAs and vulnerable coronary plaque. In this study, we investigated whether plasma miRNAs might be a sensitive marker of coronary plaque vulnerability.MethodsandResults:Integrated backscatter intravascular ultrasound (IB-IVUS) was performed in 32 consecutive patients with angina pectoris who underwent percutaneous coronary intervention. Three-dimensional analysis of IB-IVUS was performed to determine the percentage of lipid volume (%LV) and fibrous volume (%FV). Circulating miRNAs were measured in EDTA-plasma simultaneously obtained from the aorta and the coronary sinus (CS). Muscle-enriched (miR-133a, miR-208a, miR-499), vascular-enriched (miR-92a, miR-100, miR-126, miR-127, miR-145), and myeloid cell-enriched miRNAs (miR-155, miR-223) were measured. Plasma miR-100 was higher in the CS than in the aorta, but there were no significant differences in the levels of other miRNAs between the aorta and CS. Plasma miR-100 in the aorta was positively correlated with %LV (r=0.48, P<0.01) and negatively correlated with %FV (r=-0.41, P<0.05). Importantly, transcoronary concentration gradient of circulating miR-100 was more strongly correlated with %LV (r=0.53, P<0.01) and %FV (r=-0.56, P<0.01).CONCLUSIONS: miR-100 might be released into the coronary circulation from vulnerable coronary plaques. This study provides insights into the role of miRNAs in coronary atherosclerotic disease. (Circ J 2015; 79: 413-418)."},"publication_date":"2015-01-23","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.79","number":"No.2","starting_page":"413","ending_page":"418","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-14-0958"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109367","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25742947","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=291321","label":"url"}],"paper_title":{"en":"Impact of supervised cardiac rehabilitation on urinary albumin excretion in patients with cardiovascular disease.","ja":"Impact of supervised cardiac rehabilitation on urinary albumin excretion in patients with cardiovascular disease."},"authors":{"en":[{"name":"Kimura S"},{"name":"Ueda Yuka"},{"name":"Ise Takayuki"},{"name":"Yagi Shusuke"},{"name":"Iwase Takashi"},{"name":"Nishikawa K"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Katoh Shinsuke"},{"name":"Akaike Masashi"},{"name":"Yasui Natsuo"},{"name":"Sata Masataka"}],"ja":[{"name":"Kimura S"},{"name":"上田 由佳"},{"name":"伊勢 孝之"},{"name":"八木 秀介"},{"name":"岩瀬 俊"},{"name":"Nishikawa K"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"加藤 真介"},{"name":"赤池 雅史"},{"name":"安井 夏生"},{"name":"佐田 政隆"}]},"description":{"en":"Urinary albumin excretion is a predictor of cardiovascular death. Cardiac rehabilitation (CR) with exercise training (ET) has been shown to improve exercise capacity and prognosis in patients with cardiovascular disease (CVD). However, it remains unclear whether CR reduces urinary albumin excretion in CVD patients. We performed a retrospective, observational study using data obtained from 98 male CVD patients without macroalbuminuria and estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m(2) who participated in CR with ET during hospitalization. Twenty-three patients continued supervised ET for 6 months (supervised group) and 75 patients quit supervised ET (non-supervised group). The supervised ET program consisted of 60 minutes of supervised sessions 1-3 times a week and 30-60 minutes of home exercise at least twice a week. Urinary albumin/creatinine ratio (ACR) was significantly decreased in the supervised group at 6 months after enrollment (43 ± 71 mg/g to 17 ± 20 mg/g creatinine, P < 0.05) but not in the non-supervised group. eGFR was unchanged in the supervised group but was significantly decreased in the non-supervised group (72 ± 18 mL/minute/1.73 m(2) to 67 ± 17 mL/minute/1.73 m(2), P < 0.001). The results of multiple regression analysis showed that only supervised ET was an independent contributor to ACR. CR with supervised ET decreased urinary albumin excretion without deterioration of renal function. These findings suggest that continuation of a supervised ET program is associated with reduction in the development of CVD and reduction in cardiovascular morbidity and mortality in CVD patients.","ja":"Urinary albumin excretion is a predictor of cardiovascular death. Cardiac rehabilitation (CR) with exercise training (ET) has been shown to improve exercise capacity and prognosis in patients with cardiovascular disease (CVD). However, it remains unclear whether CR reduces urinary albumin excretion in CVD patients. We performed a retrospective, observational study using data obtained from 98 male CVD patients without macroalbuminuria and estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m(2) who participated in CR with ET during hospitalization. Twenty-three patients continued supervised ET for 6 months (supervised group) and 75 patients quit supervised ET (non-supervised group). The supervised ET program consisted of 60 minutes of supervised sessions 1-3 times a week and 30-60 minutes of home exercise at least twice a week. Urinary albumin/creatinine ratio (ACR) was significantly decreased in the supervised group at 6 months after enrollment (43 ± 71 mg/g to 17 ± 20 mg/g creatinine, P < 0.05) but not in the non-supervised group. eGFR was unchanged in the supervised group but was significantly decreased in the non-supervised group (72 ± 18 mL/minute/1.73 m(2) to 67 ± 17 mL/minute/1.73 m(2), P < 0.001). The results of multiple regression analysis showed that only supervised ET was an independent contributor to ACR. CR with supervised ET decreased urinary albumin excretion without deterioration of renal function. These findings suggest that continuation of a supervised ET program is associated with reduction in the development of CVD and reduction in cardiovascular morbidity and mortality in CVD patients."},"publication_date":"2015-01-21","publication_name":{"en":"International Heart Journal","ja":"International Heart Journal"},"volume":"Vol.56","number":"No.1","starting_page":"105","ending_page":"109","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1536/ihj.14-161"],"issn":["1349-3299"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25624765","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84921260560&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=289160","label":"url"}],"paper_title":{"en":"Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension.","ja":"Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Takashima A"},{"name":"Mitsugi M"},{"name":"Wada T"},{"name":"Hotsuchi Junko"},{"name":"Aihara Ken-ichi"},{"name":"Hara T"},{"name":"Ishida Masayoshi"},{"name":"Fukuda Daiju"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Takashima A"},{"name":"Mitsugi M"},{"name":"Wada T"},{"name":"發知 淳子"},{"name":"粟飯原 賢一"},{"name":"Hara T"},{"name":"石田 昌義"},{"name":"福田 大受"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"Background: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.Methods: We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.Results: The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.Conclusion: The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension.","ja":"Background: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.Methods: We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.Results: The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.Conclusion: The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension."},"publication_date":"2015-01-12","publication_name":{"en":"Therapeutics and Clinical Risk Management","ja":"Therapeutics and Clinical Risk Management"},"volume":"Vol.11","starting_page":"83","ending_page":"88","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2147/TCRM.S72299"],"issn":["1176-6336"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25471307","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84926465688&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=288108","label":"url"}],"paper_title":{"en":"Serum concentration of eicosapentaenoic acid is associated with cognitive function in patients with coronary artery disease.","ja":"Serum concentration of eicosapentaenoic acid is associated with cognitive function in patients with coronary artery disease."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Hara T"},{"name":"Ueno R"},{"name":"Aihara Ken-ichi"},{"name":"Fukuda Daiju"},{"name":"Takashima A"},{"name":"Hotsuchi Junko"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Tobiume Takeshi"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Hara T"},{"name":"Ueno R"},{"name":"粟飯原 賢一"},{"name":"福田 大受"},{"name":"Takashima A"},{"name":"發知 淳子"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"飛梅 威"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Recent studies have shown that intake of n-3 polyunsaturated fatty acids (PUFAs) is associated with reduced risk of cognitive impairment and coronary artery disease (CAD); however, it is currently unknown whether reduced serum n-3 PUFA is associated with cognitive impairment in patients with CAD.METHODS: We retrospectively evaluated cognitive function with the mini-mental state examination (MMSE), serum levels of PUFAs (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], dihomogammalinolenic acid [DGLA], and arachidonic acid [AA]), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking), and parameters of cardiac function (left ventricular ejection fraction and brain natriuretic peptide levels) in 146 Japanese CAD patients. The associations between the MMSE scores and the other parameters were evaluated.RESULTS: Pearson correlation analysis showed that EPA (R =0.25, P <0.01), EPA/AA ratio (R =0.22, P =0.01), and left ventricular ejection fraction (R =0.15, P =0.04) were positively associated with MMSE score, and that age (R = -0.20, P <0.01) and brain natriuretic peptide levels (R = -0.28, P <0.01) were inversely associated with MMSE score. Multiple regression analysis showed that age (P <0.05) was negatively associated with MMSE score, while EPA (P <0.01) and EPA/AA ratio (P <0.05) were positively associated with MMSE score; however, sex; body mass index; left ventricular ejection fraction; levels of DHA, AA, and DGLA; DHA/AA ratio; brain natriuretic peptide; and presence of hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking were statistically excluded.CONCLUSIONS: Serum EPA concentration is associated with cognitive function in patients with CAD, suggesting that a low serum EPA level is a risk factor for cognitive impairment independent of cardiac function, including left ventricular ejection fraction. This correlation potentially lends further support to a role of dietary n-3 PUFAs in preventing the cognitive decline in CAD patients.","ja":"BACKGROUND: Recent studies have shown that intake of n-3 polyunsaturated fatty acids (PUFAs) is associated with reduced risk of cognitive impairment and coronary artery disease (CAD); however, it is currently unknown whether reduced serum n-3 PUFA is associated with cognitive impairment in patients with CAD.METHODS: We retrospectively evaluated cognitive function with the mini-mental state examination (MMSE), serum levels of PUFAs (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], dihomogammalinolenic acid [DGLA], and arachidonic acid [AA]), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking), and parameters of cardiac function (left ventricular ejection fraction and brain natriuretic peptide levels) in 146 Japanese CAD patients. The associations between the MMSE scores and the other parameters were evaluated.RESULTS: Pearson correlation analysis showed that EPA (R =0.25, P <0.01), EPA/AA ratio (R =0.22, P =0.01), and left ventricular ejection fraction (R =0.15, P =0.04) were positively associated with MMSE score, and that age (R = -0.20, P <0.01) and brain natriuretic peptide levels (R = -0.28, P <0.01) were inversely associated with MMSE score. Multiple regression analysis showed that age (P <0.05) was negatively associated with MMSE score, while EPA (P <0.01) and EPA/AA ratio (P <0.05) were positively associated with MMSE score; however, sex; body mass index; left ventricular ejection fraction; levels of DHA, AA, and DGLA; DHA/AA ratio; brain natriuretic peptide; and presence of hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking were statistically excluded.CONCLUSIONS: Serum EPA concentration is associated with cognitive function in patients with CAD, suggesting that a low serum EPA level is a risk factor for cognitive impairment independent of cardiac function, including left ventricular ejection fraction. This correlation potentially lends further support to a role of dietary n-3 PUFAs in preventing the cognitive decline in CAD patients."},"publication_date":"2014-12-04","publication_name":{"en":"Nutrition Journal","ja":"Nutrition Journal"},"volume":"Vol.13","number":"No.1","starting_page":"112","ending_page":"112","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/1475-2891-13-112"],"issn":["1475-2891"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25265271","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=286318","label":"url"}],"paper_title":{"en":"Effect of ghrelin on autonomic activity in healthy volunteers.","ja":"Effect of ghrelin on autonomic activity in healthy volunteers."},"authors":{"en":[{"name":"Soeki Takeshi"},{"name":"Koshiba Kunihiko"},{"name":"Niki Toshiyuki"},{"name":"Kusunose Kenya"},{"name":"Yamaguchi Koji"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Minakuchi Kazuo"},{"name":"Kishimoto I"},{"name":"Kangawa Kenji"},{"name":"Sata Masataka"}],"ja":[{"name":"添木 武"},{"name":"小柴 邦彦"},{"name":"仁木 敏之"},{"name":"楠瀬 賢也"},{"name":"山口 浩司"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"水口 和生"},{"name":"Kishimoto I"},{"name":"寒川 賢治"},{"name":"佐田 政隆"}]},"description":{"en":"Ghrelin is a novel growth hormone (GH)-releasing peptide originally isolated from the stomach. Recently, we have shown that ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. In the present study, we evaluated the effect of ghrelin on autonomic nerve activity in healthy human subjects. An intravenous bolus of human synthetic ghrelin (10g/kg) was administered to 10 healthy men (mean age, 33 years). Holter monitoring assessment was performed before and during 2h after the ghrelin therapy. The standard deviation of normal RR intervals (SDNN), square root of the mean of the sum of the squares of differences between adjacent RR intervals (rMSSD), high-frequency power (HF), and low-frequency power (LF) were analyzed. Blood samples were also obtained before and after the therapy. A single administration of ghrelin decreased both heart rate and blood pressure. Interestingly, ghrelin significantly decreased the LF and LF/HF ratio of heart rate variability and increased the SDNN, rMSSD, and HF. Ghrelin also elicited a marked increase in circulating GH, but not insulin-like growth factor-1. These data suggest that ghrelin might suppress cardiac sympathetic nerve activity and stimulate cardiac parasympathetic nerve activity.","ja":"Ghrelin is a novel growth hormone (GH)-releasing peptide originally isolated from the stomach. Recently, we have shown that ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. In the present study, we evaluated the effect of ghrelin on autonomic nerve activity in healthy human subjects. An intravenous bolus of human synthetic ghrelin (10g/kg) was administered to 10 healthy men (mean age, 33 years). Holter monitoring assessment was performed before and during 2h after the ghrelin therapy. The standard deviation of normal RR intervals (SDNN), square root of the mean of the sum of the squares of differences between adjacent RR intervals (rMSSD), high-frequency power (HF), and low-frequency power (LF) were analyzed. Blood samples were also obtained before and after the therapy. A single administration of ghrelin decreased both heart rate and blood pressure. Interestingly, ghrelin significantly decreased the LF and LF/HF ratio of heart rate variability and increased the SDNN, rMSSD, and HF. Ghrelin also elicited a marked increase in circulating GH, but not insulin-like growth factor-1. These data suggest that ghrelin might suppress cardiac sympathetic nerve activity and stimulate cardiac parasympathetic nerve activity."},"publication_date":"2014-12","publication_name":{"en":"Peptides","ja":"Peptides"},"volume":"Vol.62","starting_page":"1","ending_page":"5","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.peptides.2014.09.015"],"issn":["1873-5169"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25379946","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=287355","label":"url"}],"paper_title":{"en":"MicroRNA-378 regulates adiponectin expression in adipose tissue: A new plausible mechanism.","ja":"MicroRNA-378 regulates adiponectin expression in adipose tissue: A new plausible mechanism."},"authors":{"en":[{"name":"Ishida Masayoshi"},{"name":"Shimabukuro Michio"},{"name":"Yagi Shusuke"},{"name":"Nishimoto S"},{"name":"Kozuka C"},{"name":"Fukuda Daiju"},{"name":"Soeki Takeshi"},{"name":"Masuzaki H"},{"name":"Tsutsui M"},{"name":"Sata Masataka"}],"ja":[{"name":"石田 昌義"},{"name":"島袋 充生"},{"name":"八木 秀介"},{"name":"Nishimoto S"},{"name":"Kozuka C"},{"name":"福田 大受"},{"name":"添木 武"},{"name":"Masuzaki H"},{"name":"Tsutsui M"},{"name":"佐田 政隆"}]},"description":{"en":"AIMS: Mechanisms regulating adiponectin expression have not been fully clarified. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, are involved in biological processes, including obesity and insulin resistance. We evaluated whether the miRNA-378 pathway is involved in regulating adiponectin expression.METHODS AND RESULTS: First, we determined a putative target site for miRNA-378 in the 3 prime untranslated region (3'UTR) of the adiponectin gene by in silico analysis. The levels of adiponectin mRNA and protein were decreased in 3T3-L1 cells overexpressing the mimic of miRNA-378. Luminescence activity in HEK293T cells expressing a renilla-luciferase-adiponectin-3'UTR sequence was inhibited by overexpressing the mimic of miRNA-378, and the decrease was reversed by adding the inhibitor of miRNA-378. Moreover, we confirmed the inhibitory effects of the mimic were cancelled in a deleted mutant of the miR-378 3'-UTR binding site. Addition of tumor necrosis factor- (TNF) led a upregulation of miR-378 and downregulation of adiponectin at mRNA and protein levels in 3T3-L1 cells. Level of miR-378 was higher and mRNA level of adiponectin was lower in diabetic ob/ob mice than those of normal C57BL/6 mice and levels of miR378 and adiponectin were negatively well correlated (r=-0.624, p=0.004).CONCLUSIONS: We found that levels of miRNA-378 could modulate adiponectin expression via the 3'UTR sequence-binding site. Our findings warrant further investigations into the role of miRNAs in regulating the adiponectin expression.","ja":"AIMS: Mechanisms regulating adiponectin expression have not been fully clarified. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, are involved in biological processes, including obesity and insulin resistance. We evaluated whether the miRNA-378 pathway is involved in regulating adiponectin expression.METHODS AND RESULTS: First, we determined a putative target site for miRNA-378 in the 3 prime untranslated region (3'UTR) of the adiponectin gene by in silico analysis. The levels of adiponectin mRNA and protein were decreased in 3T3-L1 cells overexpressing the mimic of miRNA-378. Luminescence activity in HEK293T cells expressing a renilla-luciferase-adiponectin-3'UTR sequence was inhibited by overexpressing the mimic of miRNA-378, and the decrease was reversed by adding the inhibitor of miRNA-378. Moreover, we confirmed the inhibitory effects of the mimic were cancelled in a deleted mutant of the miR-378 3'-UTR binding site. Addition of tumor necrosis factor- (TNF) led a upregulation of miR-378 and downregulation of adiponectin at mRNA and protein levels in 3T3-L1 cells. Level of miR-378 was higher and mRNA level of adiponectin was lower in diabetic ob/ob mice than those of normal C57BL/6 mice and levels of miR378 and adiponectin were negatively well correlated (r=-0.624, p=0.004).CONCLUSIONS: We found that levels of miRNA-378 could modulate adiponectin expression via the 3'UTR sequence-binding site. Our findings warrant further investigations into the role of miRNAs in regulating the adiponectin expression."},"publication_date":"2014-11-07","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"Vol.9","number":"No.11","starting_page":"e111537","ending_page":"e111537","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0111537"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/130003382181/","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24189463","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390282680085613824/","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84891099318&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=279849","label":"url"}],"paper_title":{"en":"Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients.","ja":"Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients."},"authors":{"en":[{"name":"Yamaguchi Koji"},{"name":"Wakatsuki Tetsuzo"},{"name":"Soeki Takeshi"},{"name":"Niki Toshiyuki"},{"name":"Taketani Yoshio"},{"name":"Oeduka Hiroyasu"},{"name":"Kusunose Kenya"},{"name":"Ise Takayuki"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"山口 浩司"},{"name":"若槻 哲三"},{"name":"添木 武"},{"name":"仁木 敏之"},{"name":"竹谷 善雄"},{"name":"Oeduka Hiroyasu"},{"name":"楠瀬 賢也"},{"name":"伊勢 孝之"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"description":{"en":"Telmisartan has unique pleiotropic effects in addition to renin-angiotensin system (RAS)-inhibition effects. The aim of this study was to evaluate the effects of telmisartan on the coronary plaque component and local inflammatory cytokines. A total of 50 patients with hypertension were randomized to 2 groups: the telmisartan group (additional treatment with telmisartan 80mg/day, n=25) or the control group (additional treatment with other anti-hypertensive drugs except RAS blockers, n=25) for 6 months. Tissue characteristics of target coronary plaque were analyzed using integrated backscatter intravascular ultrasound (IB-IVUS) before and after treatment. Plasma levels of inflammatory cytokines sampled in the coronary sinus (CS) and peripheral vein were also measured. Significant increases in fibrous volume (51.2±10.4 to 58.3±7.7%, P=0.03) and reductions in lipid volume (38.4±12.4 to 32.8±9.7%, P=0.03) were observed on IB in the telmisartan group, while there were no significant changes in the plaque component in the control group. CS levels of inflammatory cytokines (matrix metalloproteinase [MMP]3, tumor necrosis factor-, high-sensitivity C-reactive protein and MMP9) were lower after than before treatment in the only telmisartan group (7.7±6.1 to 5.5±4.9ng/ml, 3.1±1.9 to 2.3±2.0pg/ml, 5.6±6.0 to 2.2±2.4mg/L, 36.1±39.3 to 19.9±27.5ng/ml, P=0.02, P=0.03, P=0.04, P=0.07, respectively). Decreased local inflammatory response and plaque stabilization on IB imaging were observed after 6 months of telmisartan treatment. These findings might be associated with local anti-inflammatory and anti-arteriosclerotic effects of telmisartan.","ja":"Telmisartan has unique pleiotropic effects in addition to renin-angiotensin system (RAS)-inhibition effects. The aim of this study was to evaluate the effects of telmisartan on the coronary plaque component and local inflammatory cytokines. A total of 50 patients with hypertension were randomized to 2 groups: the telmisartan group (additional treatment with telmisartan 80mg/day, n=25) or the control group (additional treatment with other anti-hypertensive drugs except RAS blockers, n=25) for 6 months. Tissue characteristics of target coronary plaque were analyzed using integrated backscatter intravascular ultrasound (IB-IVUS) before and after treatment. Plasma levels of inflammatory cytokines sampled in the coronary sinus (CS) and peripheral vein were also measured. Significant increases in fibrous volume (51.2±10.4 to 58.3±7.7%, P=0.03) and reductions in lipid volume (38.4±12.4 to 32.8±9.7%, P=0.03) were observed on IB in the telmisartan group, while there were no significant changes in the plaque component in the control group. CS levels of inflammatory cytokines (matrix metalloproteinase [MMP]3, tumor necrosis factor-, high-sensitivity C-reactive protein and MMP9) were lower after than before treatment in the only telmisartan group (7.7±6.1 to 5.5±4.9ng/ml, 3.1±1.9 to 2.3±2.0pg/ml, 5.6±6.0 to 2.2±2.4mg/L, 36.1±39.3 to 19.9±27.5ng/ml, P=0.02, P=0.03, P=0.04, P=0.07, respectively). Decreased local inflammatory response and plaque stabilization on IB imaging were observed after 6 months of telmisartan treatment. These findings might be associated with local anti-inflammatory and anti-arteriosclerotic effects of telmisartan."},"publication_date":"2014-11-01","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.78","number":"No.1","starting_page":"240","ending_page":"247","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-13-0741"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109368","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25241889","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=281256","label":"url"}],"paper_title":{"en":"Cardiac rehabilitation reduces serum levels of oxidized low-density lipoprotein.","ja":"Cardiac rehabilitation reduces serum levels of oxidized low-density lipoprotein."},"authors":{"en":[{"name":"Takashima A"},{"name":"Ise Takayuki"},{"name":"Yagi Shusuke"},{"name":"Iwase Takashi"},{"name":"Kimura S"},{"name":"Ueda Yuka"},{"name":"Nishikawa K"},{"name":"Ishii A"},{"name":"Niki Toshiyuki"},{"name":"Yamaguchi Koji"},{"name":"Taketani Yoshio"},{"name":"Yamada Hirotsugu"},{"name":"Soeki Takeshi"},{"name":"Wakatsuki Tetsuzo"},{"name":"Katoh Shinsuke"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"Takashima A"},{"name":"伊勢 孝之"},{"name":"八木 秀介"},{"name":"岩瀬 俊"},{"name":"Kimura S"},{"name":"上田 由佳"},{"name":"Nishikawa K"},{"name":"Ishii A"},{"name":"仁木 敏之"},{"name":"山口 浩司"},{"name":"竹谷 善雄"},{"name":"山田 博胤"},{"name":"添木 武"},{"name":"若槻 哲三"},{"name":"加藤 真介"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"BACKGROUND: Oxidized low-density lipoprotein (oxLDL) levels have been found to play an important role in the progression of atherosclerosis. However, methods for effectively reducing oxLDL levels have not been established. Comprehensive cardiac rehabilitation (CR) with exercise training prevents the progression of atherosclerosis, and might reduce oxLDL levels.MethodsandResults:We measured the serum levels of malondialdehyde-modified LDL (MDA-LDL), a marker of oxLDL, in 136 patients who were enrolled in a 6-month CR program. Peak oxygen consumption (VO2) and MDA-LDL levels were analyzed, before and 6 months after enrolment. In total, 67 patients completed the CR program (CR group) and 69 patients failed to complete the program (non-CR group). Peak VO2increased significantly in the CR group (P<0.01). The levels of MDA-LDL decreased significantly in the CR group (P<0.01) but not in the non-CR group. VO2(peak VO2after CR-peak VO2before CR) was negatively associated with MDA-LDL (MDA-LDL after CR-MDA-LDL before CR) (R(2)=0.11, P=0.01). Multiple regression analysis showed that continuing CR was an independent determining factor for lowering MDA-LDL levels.CONCLUSIONS: CR decreases oxLDL levels in patients with cardiovascular diseases. Moreover, CR may prevent cardiovascular events through an antioxidative effect. (Circ J 2014; 78: 2682-2687).","ja":"BACKGROUND: Oxidized low-density lipoprotein (oxLDL) levels have been found to play an important role in the progression of atherosclerosis. However, methods for effectively reducing oxLDL levels have not been established. Comprehensive cardiac rehabilitation (CR) with exercise training prevents the progression of atherosclerosis, and might reduce oxLDL levels.MethodsandResults:We measured the serum levels of malondialdehyde-modified LDL (MDA-LDL), a marker of oxLDL, in 136 patients who were enrolled in a 6-month CR program. Peak oxygen consumption (VO2) and MDA-LDL levels were analyzed, before and 6 months after enrolment. In total, 67 patients completed the CR program (CR group) and 69 patients failed to complete the program (non-CR group). Peak VO2increased significantly in the CR group (P<0.01). The levels of MDA-LDL decreased significantly in the CR group (P<0.01) but not in the non-CR group. VO2(peak VO2after CR-peak VO2before CR) was negatively associated with MDA-LDL (MDA-LDL after CR-MDA-LDL before CR) (R(2)=0.11, P=0.01). Multiple regression analysis showed that continuing CR was an independent determining factor for lowering MDA-LDL levels.CONCLUSIONS: CR decreases oxLDL levels in patients with cardiovascular diseases. Moreover, CR may prevent cardiovascular events through an antioxidative effect. (Circ J 2014; 78: 2682-2687)."},"publication_date":"2014-10-24","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"Vol.78","number":"No.11","starting_page":"2682","ending_page":"2687","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-14-0532"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/40020214800/","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1523388080096837504/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=285999","label":"url"}],"paper_title":{"en":"The treatment of atherosclerosis in the elderly","ja":"(特集 老化からみた循環器疾患)高齢者の動脈硬化治療"},"authors":{"en":[{"name":"田中 君枝"},{"name":"Sata Masataka"}],"ja":[{"name":"田中 君枝"},{"name":"佐田 政隆"}]},"publication_date":"2014-09-28","publication_name":{"en":"Cardioangiology","ja":"循環器内科"},"volume":"Vol.76","number":"No.3","starting_page":"289","ending_page":"295","languages":["jpn"],"referee":true,"identifiers":{"issn":["1884-2909"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/130004687654/","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25224192","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390282679850242944/","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84907454931&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=280349","label":"url"}],"paper_title":{"en":"Left main coronary artery compression syndrome with an incomplete atrioventricular septal defect presenting as angina induced by hyperthyroidism.","ja":"Left main coronary artery compression syndrome with an incomplete atrioventricular septal defect presenting as angina induced by hyperthyroidism."},"authors":{"en":[{"name":"Kusunose Kenya"},{"name":"Tomita N"},{"name":"Nishio S"},{"name":"Bando Mika"},{"name":"Hayashi S"},{"name":"Hotsuchi Junko"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Sata Masataka"}],"ja":[{"name":"楠瀬 賢也"},{"name":"Tomita N"},{"name":"Nishio S"},{"name":"坂東 美佳"},{"name":"Hayashi S"},{"name":"發知 淳子"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"佐田 政隆"}]},"description":{"en":"We herein report the case of a 29-year-old woman who was diagnosed with incomplete atrioventricular septal defect and extrinsic compression of the left main coronary artery (LMCA) with chest pain due to postpartum thyroiditis. She exhibited chest pain with ST elevation, and coronary computed tomography showed that the LMCA was compressed between the dilated pulmonary artery and aorta. After her hyperthyroidism was treated, her chest pain resolved. Surgical repair of endocardiosis and coronary bypass grafting were performed. On the one-year follow-up visit, the dilation of the pulmonary artery and right heart was decreased. It is important to consider the possibility of compression of the LMCA in patients presenting with pulmonary hypertension and chest pain.","ja":"We herein report the case of a 29-year-old woman who was diagnosed with incomplete atrioventricular septal defect and extrinsic compression of the left main coronary artery (LMCA) with chest pain due to postpartum thyroiditis. She exhibited chest pain with ST elevation, and coronary computed tomography showed that the LMCA was compressed between the dilated pulmonary artery and aorta. After her hyperthyroidism was treated, her chest pain resolved. Surgical repair of endocardiosis and coronary bypass grafting were performed. On the one-year follow-up visit, the dilation of the pulmonary artery and right heart was decreased. It is important to consider the possibility of compression of the LMCA in patients presenting with pulmonary hypertension and chest pain."},"publication_date":"2014-09-15","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"volume":"Vol.53","number":"No.18","starting_page":"2083","ending_page":"2085","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.53.2403"],"issn":["1349-7235"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23979265","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84929517476&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=270271","label":"url"}],"paper_title":{"en":"Pentraxin 3 is a local inflammatory marker in atrial fibrillation.","ja":"Pentraxin 3 is a local inflammatory marker in atrial fibrillation."},"authors":{"en":[{"name":"Soeki Takeshi"},{"name":"Bando S"},{"name":"Uematsu E"},{"name":"Matsuura T"},{"name":"Niki Toshiyuki"},{"name":"Ise Takayuki"},{"name":"Kusunose Kenya"},{"name":"Hotsuchi Junko"},{"name":"Ueda Yuka"},{"name":"Tomita N"},{"name":"Yamaguchi Koji"},{"name":"Yagi Shusuke"},{"name":"Fukuda Daiju"},{"name":"Taketani Yoshio"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Wakatsuki Tetsuzo"},{"name":"Shimabukuro Michio"},{"name":"Sata Masataka"}],"ja":[{"name":"添木 武"},{"name":"Bando S"},{"name":"Uematsu E"},{"name":"Matsuura T"},{"name":"仁木 敏之"},{"name":"伊勢 孝之"},{"name":"楠瀬 賢也"},{"name":"發知 淳子"},{"name":"上田 由佳"},{"name":"Tomita N"},{"name":"山口 浩司"},{"name":"八木 秀介"},{"name":"福田 大受"},{"name":"竹谷 善雄"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"若槻 哲三"},{"name":"島袋 充生"},{"name":"佐田 政隆"}]},"description":{"en":"Increasing evidence indicates that inflammation contributes to the pathogenesis of atrial fibrillation (AF). Pentraxin 3 (PTX3) is produced abundantly in local inflammatory lesions while C-reactive protein (CRP) is produced mainly in the liver. In this study, we investigated whether a local level of PTX3 might be a sensitive marker for the local inflammation of AF. Blood from the periphery and left atrial appendage (LAA) was sampled from 23 patients with AF undergoing pulmonary vein isolation, and from 10 control subjects with Wolff-Parkinson-White syndrome. We measured peripheral and LAA plasma concentrations of CRP, interleukin-6 (IL-6), tumor necrosis factor- (TNF-), and PTX3. Plasma PTX3 concentrations in both locations were higher in patients with AF than in control subjects. PTX3 concentrations were significantly higher in the LAA than the periphery in patients with AF (3.7 ± 1.4 vs 3.3 ± 1.2 ng/ml, P < 0.01), but not in control subjects (2.4 ± 0.5 vs 2.4 ± 0.5 ng/ml, not significant). Patients and controls showed no significant differences in CRP, IL-6, or TNF- concentrations between the periphery and LAA. Interestingly, there was a significant positive correlation between LAA plasma concentrations of PTX3 and left atrial volume (r = 0.55, P < 0.01). These data demonstrate that Local PTX3 production in the left atrium might reflect the local inflammation of AF.","ja":"Increasing evidence indicates that inflammation contributes to the pathogenesis of atrial fibrillation (AF). Pentraxin 3 (PTX3) is produced abundantly in local inflammatory lesions while C-reactive protein (CRP) is produced mainly in the liver. In this study, we investigated whether a local level of PTX3 might be a sensitive marker for the local inflammation of AF. Blood from the periphery and left atrial appendage (LAA) was sampled from 23 patients with AF undergoing pulmonary vein isolation, and from 10 control subjects with Wolff-Parkinson-White syndrome. We measured peripheral and LAA plasma concentrations of CRP, interleukin-6 (IL-6), tumor necrosis factor- (TNF-), and PTX3. Plasma PTX3 concentrations in both locations were higher in patients with AF than in control subjects. PTX3 concentrations were significantly higher in the LAA than the periphery in patients with AF (3.7 ± 1.4 vs 3.3 ± 1.2 ng/ml, P < 0.01), but not in control subjects (2.4 ± 0.5 vs 2.4 ± 0.5 ng/ml, not significant). Patients and controls showed no significant differences in CRP, IL-6, or TNF- concentrations between the periphery and LAA. Interestingly, there was a significant positive correlation between LAA plasma concentrations of PTX3 and left atrial volume (r = 0.55, P < 0.01). These data demonstrate that Local PTX3 production in the left atrium might reflect the local inflammation of AF."},"publication_date":"2014-09-01","publication_name":{"en":"Heart and Vessels","ja":"Heart and Vessels"},"volume":"Vol.29","number":"No.5","starting_page":"653","ending_page":"658","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s00380-013-0400-8"],"issn":["1615-2573"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=286366","label":"url"}],"paper_title":{"en":"Multimodality imaging of biatrial myxomas in an asymptomatic patient.","ja":"Multimodality imaging of biatrial myxomas in an asymptomatic patient."},"authors":{"en":[{"name":"Nishio S"},{"name":"Kusunose Kenya"},{"name":"Yamada Hirotsugu"},{"name":"Hotsuchi Junko"},{"name":"Hayashi S"},{"name":"Bando Mika"},{"name":"Saijo Y"},{"name":"Hirata Y"},{"name":"Abe M"},{"name":"Sata Masataka"}],"ja":[{"name":"Nishio S"},{"name":"楠瀬 賢也"},{"name":"山田 博胤"},{"name":"發知 淳子"},{"name":"Hayashi S"},{"name":"坂東 美佳"},{"name":"Saijo Y"},{"name":"Hirata Y"},{"name":"Abe M"},{"name":"佐田 政隆"}]},"description":{"en":"Myxomas are located in the left atrium in 7580% of cases and almost always present with signs and symptoms of a thromboembolic event. Biatrial myxomas are rare, and their incidence is generally less than 2.5% of all myxomas. We herein present a case of biatrial myxomas as an incidental finding by echocardiography where the patient underwent surgery. Echocardiography continues to be the initial imaging modality for intracardiac masses. Cardiac magnetic resonance provides superior tissue characterization, particularly important in differentiating a myxoma from a thrombus. Appropriate use of these non-invasive imaging modalities may lead to a correct diagnosis and good outcome.","ja":"Myxomas are located in the left atrium in 7580% of cases and almost always present with signs and symptoms of a thromboembolic event. Biatrial myxomas are rare, and their incidence is generally less than 2.5% of all myxomas. We herein present a case of biatrial myxomas as an incidental finding by echocardiography where the patient underwent surgery. Echocardiography continues to be the initial imaging modality for intracardiac masses. Cardiac magnetic resonance provides superior tissue characterization, particularly important in differentiating a myxoma from a thrombus. Appropriate use of these non-invasive imaging modalities may lead to a correct diagnosis and good outcome."},"publication_date":"2014-09","publication_name":{"en":"Journal of Cardiology Cases","ja":"Journal of Cardiology Cases"},"volume":"Vol.10","number":"No.3","starting_page":"85","ending_page":"87","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jccase.2014.03.009"],"issn":["1878-5409"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/130004822749/","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109593","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25264062","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390282679219954688/","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84907518768&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=276005","label":"url"}],"paper_title":{"en":"Utility of lower limb positive pressure test for diagnosis of diastolic heart failure: a case report.","ja":"Utility of lower limb positive pressure test for diagnosis of diastolic heart failure: a case report."},"authors":{"en":[{"name":"Hara T"},{"name":"Kishi-Tanaka K"},{"name":"Iwase Takashi"},{"name":"Yamada Hirotsugu"},{"name":"Akaike Masashi"},{"name":"Sata Masataka"}],"ja":[{"name":"Hara T"},{"name":"Kishi-Tanaka K"},{"name":"岩瀬 俊"},{"name":"山田 博胤"},{"name":"赤池 雅史"},{"name":"佐田 政隆"}]},"description":{"en":"A 70-year-old woman with dyspnea on exertion was admitted to our hospital. She had a history of apical hypertrophic cardiomyopathy (HCM) and repeated hospitalization for heart failure. Results of physical examination were normal except for leg edema. Echocardiography showed apical HCM with preserved LV systolic function (LVEF = 70%). Although dyspnea on exertion and leg edema improved rapidly with the use of diuretics, her symptoms soon worsened when daily activity was started again. In order to examine the effect of preload on hemodynamics, we performed a lower limb positive pressure test by compressing both legs using a household air leg massager. Echocardiography showed increases in mitral E velocity, E/A ratio and pulmonary venous D flow as well as decrease in stroke volume during the lower limb positive pressure test. Simultaneously-recorded pressure study also showed elevated LVEDP and increased v wave of pulmonary capillary wedge pressure. These results suggested that even a small increase in preload led to elevation of LVEDP and symptomatic worsening due to severe diastolic heart failure in the present case. The lower limb positive pressure test may be useful for assessing the effect of preload on hemodynamics in patients with diastolic heart failure.","ja":"A 70-year-old woman with dyspnea on exertion was admitted to our hospital. She had a history of apical hypertrophic cardiomyopathy (HCM) and repeated hospitalization for heart failure. Results of physical examination were normal except for leg edema. Echocardiography showed apical HCM with preserved LV systolic function (LVEF = 70%). Although dyspnea on exertion and leg edema improved rapidly with the use of diuretics, her symptoms soon worsened when daily activity was started again. In order to examine the effect of preload on hemodynamics, we performed a lower limb positive pressure test by compressing both legs using a household air leg massager. Echocardiography showed increases in mitral E velocity, E/A ratio and pulmonary venous D flow as well as decrease in stroke volume during the lower limb positive pressure test. Simultaneously-recorded pressure study also showed elevated LVEDP and increased v wave of pulmonary capillary wedge pressure. These results suggested that even a small increase in preload led to elevation of LVEDP and symptomatic worsening due to severe diastolic heart failure in the present case. The lower limb positive pressure test may be useful for assessing the effect of preload on hemodynamics in patients with diastolic heart failure."},"publication_date":"2014-08","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.61","number":"No.3-4","starting_page":"404","ending_page":"408","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.61.404"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=298716","label":"url"}],"paper_title":{"en":"Effects of ezetimibe on oxidized cholesterol components in epicardial fat and myocardium: a gas chromatography-mass spectrometry analysis","ja":"Effects of ezetimibe on oxidized cholesterol components in epicardial fat and myocardium: a gas chromatography-mass spectrometry analysis"},"authors":{"en":[{"name":"Shimabukuro Michio"},{"name":"Okawa C."},{"name":"Lei F. X."},{"name":"Kim-Kaneyama R. J."},{"name":"Yamada Hirotsugu"},{"name":"Kurobe Hirotsugu"},{"name":"Fukuda Daiju"},{"name":"Sato M."},{"name":"Kitagawa Tetsuya"},{"name":"Sata Masataka"}],"ja":[{"name":"島袋 充生"},{"name":"Okawa C."},{"name":"Lei F. X."},{"name":"Kim-Kaneyama R. J."},{"name":"山田 博胤"},{"name":"黒部 裕嗣"},{"name":"福田 大受"},{"name":"Sato M."},{"name":"北川 哲也"},{"name":"佐田 政隆"}]},"publication_date":"2014-08","publication_name":{"en":"Atherosclerosis","ja":"Atherosclerosis"},"volume":"Vol.235","number":"No.2","starting_page":"113","ending_page":"113","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.atherosclerosis.2014.05.307"],"issn":["0021-9150"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109588","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25264058","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84907500921&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=285923","label":"url"}],"paper_title":{"en":"Electrocardiographic and chronobiological features of paroxysmal AV block recorded by ambulatory electrocardiography.","ja":"Electrocardiographic and chronobiological features of paroxysmal AV block recorded by ambulatory electrocardiography."},"authors":{"en":[{"name":"Saito Ken"},{"name":"Takeda S"},{"name":"Saito Y"},{"name":"Kawamura M"},{"name":"Yoshikawa Y"},{"name":"Yano H"},{"name":"Sata Masataka"}],"ja":[{"name":"齋藤 憲"},{"name":"Takeda S"},{"name":"Saito Y"},{"name":"Kawamura M"},{"name":"Yoshikawa Y"},{"name":"Yano H"},{"name":"佐田 政隆"}]},"description":{"en":"The goal of this study was to investigate the electrocardiographic and chronobio-logical features of paroxysmal atrioventricular (AV) block (PAVB) using data from ambulatory electrocardiography (AECG). The study population consisted of five men and six women aged from 47 to 82 years of age. Main presenting symptoms were pre-syncope in five patients (45.5%) and syncope in three patients (27.3%). Organic cardiovascular diseases were seen in eight patients (72.7%), and AV conduction disturbances were seen in six patients (54.5%), such as right bundle branch block, first to second degree AV block on standard 12-lead electrocardiography. Incidence of PAVB events were 1-329 (37.9 ± 98.0) episodes/patient/day, and the maximum pause during Holter recordings was 3.3-12.4 (6.39 ± 3.09) seconds. This maximum pause caused by intrinsic AV block was longer than that of vagally mediated AV block (8.4 ± 3.2 sec vs 4.7 ± 1.0 sec, p<0.05). In chronobiological analysis, episodes of PAVB exhibited a circadian rhythm characterized by a peak between 2:00 am and 4:00 am and a trough between 0:00 pm and 2:00 pm. AECG is a useful tool to detect the maximum pause occurring during sleep and provides critical data necessary to prevent the sudden cardiac death caused by PAVB.","ja":"The goal of this study was to investigate the electrocardiographic and chronobio-logical features of paroxysmal atrioventricular (AV) block (PAVB) using data from ambulatory electrocardiography (AECG). The study population consisted of five men and six women aged from 47 to 82 years of age. Main presenting symptoms were pre-syncope in five patients (45.5%) and syncope in three patients (27.3%). Organic cardiovascular diseases were seen in eight patients (72.7%), and AV conduction disturbances were seen in six patients (54.5%), such as right bundle branch block, first to second degree AV block on standard 12-lead electrocardiography. Incidence of PAVB events were 1-329 (37.9 ± 98.0) episodes/patient/day, and the maximum pause during Holter recordings was 3.3-12.4 (6.39 ± 3.09) seconds. This maximum pause caused by intrinsic AV block was longer than that of vagally mediated AV block (8.4 ± 3.2 sec vs 4.7 ± 1.0 sec, p<0.05). In chronobiological analysis, episodes of PAVB exhibited a circadian rhythm characterized by a peak between 2:00 am and 4:00 am and a trough between 0:00 pm and 2:00 pm. AECG is a useful tool to detect the maximum pause occurring during sleep and provides critical data necessary to prevent the sudden cardiac death caused by PAVB."},"publication_date":"2014-08","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.61","number":"No.3, 4","starting_page":"380","ending_page":"387","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.61.380"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"5000074866","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84905378195&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=278032","label":"url"}],"paper_title":{"en":"Increase in serum triglyceride was associated with coronary plaque vulnerability in a patient with rheumatoid arthritis.","ja":"Increase in serum triglyceride was associated with coronary plaque vulnerability in a patient with rheumatoid arthritis."},"authors":{"en":[{"name":"Yagi Shusuke"},{"name":"Fujimura M"},{"name":"Akaike Masashi"},{"name":"Aihara Ken-ichi"},{"name":"Iwase Takashi"},{"name":"Tada M"},{"name":"Ueda Yuka"},{"name":"Ise Takayuki"},{"name":"Yamaguchi Koji"},{"name":"Wakatsuki Tetsuzo"},{"name":"Matsumoto Toshio"},{"name":"Sata Masataka"}],"ja":[{"name":"八木 秀介"},{"name":"Fujimura M"},{"name":"赤池 雅史"},{"name":"粟飯原 賢一"},{"name":"岩瀬 俊"},{"name":"Tada M"},{"name":"上田 由佳"},{"name":"伊勢 孝之"},{"name":"山口 浩司"},{"name":"若槻 哲三"},{"name":"松本 俊夫"},{"name":"佐田 政隆"}]},"description":{"en":"Rates of morbidity and mortality from cardiovascular disease are high in patients with rheumatoid arthritis (RA); however, the mechanisms and biomarkers that reflect coronary plaque vulnerability have not yet been established. We present a case of acute coronary syndrome (ACS) presumably caused by exacerbation of chronic inflammation of RA, in which an abrupt increase in serum triglyceride was seen on the day of onset of ACS but not during effort angina. This case suggests that RA patients with an abrupt increase in triglyceride need intensive care including anti-platelet and statin therapy for the prevention of coronary plaque rupture.